assay_id,src_id,description,assay_tissue,bao_format,src_assay_id,assay_organism,assay_category,curated_by,doc_id,assay_test_type,assay_type,assay_tax_id,assay_strain,assay_cell_type,assay_subcellular_fraction,tid
1,1,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,BAO_0000019,,,,Autocuration,11087,,B,,,,,12052
2,1,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,BAO_0000219,,,,Autocuration,684,,F,,,,,22226
3,1,,,BAO_0000019,,,,Autocuration,15453,,B,,,,,22226
4,1,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,BAO_0000249,,Bos taurus,,Autocuration,17841,,B,9913.0,,,,104729
5,1,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,BAO_0000219,,Homo sapiens,,Intermediate,17430,,F,9606.0,,143B,,80001
6,1,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,BAO_0000219,,Homo sapiens,,Intermediate,17430,,F,9606.0,,143B,,80001
7,1,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,BAO_0000219,,Mus musculus,,Intermediate,13799,,F,10090.0,,143B,,80001
8,1,In vitro cell cytotoxicity was determined against 143B cell line,,BAO_0000219,,Homo sapiens,,Expert,17774,,F,9606.0,,143B,,80001
9,1,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,BAO_0000219,,Homo sapiens,,Intermediate,3801,,F,9606.0,,143B,,80001
10,1,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,BAO_0000219,,Homo sapiens,,Intermediate,17430,,F,9606.0,,143B,,80001
11,1,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,BAO_0000219,,Homo sapiens,,Intermediate,17430,,F,9606.0,,143B,,80001
12,1,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,BAO_0000219,,Homo sapiens,,Expert,17774,,F,9606.0,,143B,,80001
13,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,BAO_0000218,,Staphylococcus aureus,,Intermediate,11324,,F,1280.0,,,,50185
14,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,BAO_0000218,,Staphylococcus aureus,,Intermediate,11324,,F,1280.0,,,,50185
15,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,BAO_0000218,,Staphylococcus aureus,,Intermediate,11324,,F,1280.0,,,,50185
16,1,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,BAO_0000218,,Staphylococcus aureus,,Intermediate,11324,,F,1280.0,,,,50185
17,1,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,BAO_0000357,,Rattus norvegicus,,Expert,11347,,A,10116.0,,,,100122
18,1,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,BAO_0000357,,,,Autocuration,16474,,B,,,,,12054
19,1,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,BAO_0000019,,,,Autocuration,10091,,B,,,,,12054
20,1,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,BAO_0000357,,,,Autocuration,16474,,B,,,,,12054
21,1,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,BAO_0000357,,,,Autocuration,16474,,B,,,,,12054
22,1,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,BAO_0000357,,,,Autocuration,16474,,B,,,,,12054
23,1,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,BAO_0000357,,,,Autocuration,16474,,B,,,,,12054
24,1,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,BAO_0000357,,,,Autocuration,16474,,B,,,,,12054
25,1,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,BAO_0000219,,,,Autocuration,14352,,B,,,,,22226
26,1,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,BAO_0000357,,Oryctolagus cuniculus,,Autocuration,5646,,B,9986.0,,,,12054
27,1,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,BAO_0000357,,Oryctolagus cuniculus,,Autocuration,5646,,B,9986.0,,,,12054
28,1,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,BAO_0000219,,,,Autocuration,10997,,B,,,,,12426
29,1,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,BAO_0000357,,soya bean,,Autocuration,6309,,B,3847.0,,,,12054
30,1,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,BAO_0000357,,Glycine max,,Autocuration,167,,B,3847.0,,,,12054
31,1,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,BAO_0000357,,Glycine max,,Autocuration,167,,B,3847.0,,,,12054
32,1,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,BAO_0000357,,Glycine max,,Autocuration,11087,,B,3847.0,,,,12054
33,1,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,BAO_0000357,,Glycine max,,Autocuration,11087,,B,3847.0,,,,12054
34,1,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,BAO_0000357,,Glycine max,,Autocuration,13622,,B,3847.0,,,,12054
35,1,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,BAO_0000357,,Glycine max,,Autocuration,13622,,B,3847.0,,,,12054
36,1,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,BAO_0000019,,Rattus norvegicus,,Autocuration,11347,,A,10116.0,,,,22226
37,1,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,BAO_0000019,,Escherichia coli,,Autocuration,5926,,B,562.0,,,,22226
38,1,Dissociation constant with dimeric 16S rRNA RNA construct B,,BAO_0000019,,,,Autocuration,4567,,B,,,,,22226
39,1,Dissociation constant towards 16S rRNA construct A,,BAO_0000225,,,,Intermediate,3782,,B,,,,,22222
40,1,Dissociation constant towards 16S rRNA construct B,,BAO_0000225,,,,Intermediate,3782,,B,,,,,22222
41,1,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,BAO_0000225,,Escherichia coli,,Expert,4466,,B,562.0,,,,100263
42,1,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,BAO_0000225,,Escherichia coli,,Expert,6592,,B,562.0,,,,100263
43,1,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,BAO_0000019,,,,Autocuration,898,,B,,,,,13053
44,1,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,BAO_0000019,,,,Autocuration,898,,B,,,,,13053
45,1,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,BAO_0000019,,Homo sapiens,,Autocuration,13163,,B,9606.0,,,,20001
46,1,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,BAO_0000019,,Homo sapiens,,Autocuration,13163,,B,9606.0,,,,20001
47,1,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,BAO_0000019,,Rattus norvegicus,,Expert,10691,,B,10116.0,,,,12971
48,1,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,BAO_0000019,,Rattus norvegicus,,Expert,10691,,B,10116.0,,,,12971
49,1,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,BAO_0000019,,Rattus norvegicus,,Expert,10691,,B,10116.0,,,,12971
50,1,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,BAO_0000019,,Rattus norvegicus,,Expert,10691,,B,10116.0,,,,12971
51,1,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,BAO_0000019,,,,Autocuration,898,,B,,,,,13053
52,1,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,BAO_0000357,,,,Autocuration,912,,B,,,,,11512
53,1,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,BAO_0000357,,,,Autocuration,912,,B,,,,,11512
54,1,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,BAO_0000357,,,,Autocuration,912,,B,,,,,11512
55,1,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,BAO_0000249,,Rattus norvegicus,,Autocuration,15103,,B,10116.0,,,Membranes,104740
56,1,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,BAO_0000219,,Homo sapiens,,Intermediate,5116,,F,9606.0,,1A9,,80002
57,1,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,BAO_0000219,,Rattus norvegicus,,Autocuration,14578,,F,10116.0,,Oocytes,,104835
58,1,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,BAO_0000219,,Rattus norvegicus,,Autocuration,14578,,F,10116.0,,Oocytes,,104821
59,1,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,BAO_0000219,,Rattus norvegicus,,Autocuration,14578,,F,10116.0,,Oocytes,,104848
60,1,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,BAO_0000219,,Homo sapiens,,Expert,4787,,F,9606.0,,1A9,,80002
61,1,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,BAO_0000219,,Homo sapiens,,Intermediate,4787,,F,9606.0,,1A9,,80002
62,1,Cytotoxic activity against human ovarian cancer (1A9) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,3547,,F,9606.0,,1A9,,80002
63,1,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,BAO_0000219,,Homo sapiens,,Intermediate,3547,,F,9606.0,,1A9,,80002
64,1,Effective dose of compound against replication of 1A9 cell line was evaluated,,BAO_0000219,,Homo sapiens,,Intermediate,6726,,F,9606.0,,1A9,,80002
65,1,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,BAO_0000219,,Homo sapiens,,Expert,3455,,F,9606.0,,1A9,,80002
66,1,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,BAO_0000219,,Homo sapiens,,Intermediate,5726,,F,9606.0,,1A9,,80002
67,1,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,BAO_0000219,,Homo sapiens,,Intermediate,5726,,F,9606.0,,1A9,,80002
68,1,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,5726,,F,9606.0,,1A9,,80002
69,1,Inhibitory activity against Taxol resistant 1A9 cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,3395,,F,9606.0,,1A9,,80002
70,1,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,BAO_0000219,,Homo sapiens,,Expert,3415,,F,9606.0,,1A9,,80002
71,1,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,BAO_0000219,,Homo sapiens,,Expert,3415,,F,9606.0,,1A9,,80002
72,1,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,BAO_0000219,,Homo sapiens,,Expert,17099,,F,9606.0,,1A9,,80002
73,1,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,17099,,F,9606.0,,1A9,,80002
74,1,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,17099,,F,9606.0,,1A9,,80002
75,1,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,17099,,F,9606.0,,1A9,,80002
76,1,Inhibitory concentration against Jurkat cells,,BAO_0000219,,Homo sapiens,,Intermediate,17721,,F,9606.0,,Jurkat,,81072
77,1,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,BAO_0000019,,,,Intermediate,1229,,F,,,,,22226
78,1,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,BAO_0000357,,Rattus norvegicus,,Expert,11347,,A,10116.0,,,,100121
79,1,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,BAO_0000357,,,,Expert,17117,,B,,,,,11231
80,1,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,BAO_0000357,,,,Expert,17117,,B,,,,,11231
81,1,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,BAO_0000357,,,,Expert,17117,,B,,,,,11231
82,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,BAO_0000251,,Candida albicans,,Autocuration,11375,,B,5476.0,,,Microsomes,11231
83,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,BAO_0000251,,Candida albicans,,Autocuration,11375,,B,5476.0,,,Microsomes,11231
84,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,BAO_0000251,,Saccharomyces cerevisiae,,Autocuration,11375,,B,4932.0,,,Microsomes,11231
85,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,BAO_0000251,,Saccharomyces cerevisiae,,Autocuration,11375,,B,4932.0,,,Microsomes,11231
86,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",Liver,BAO_0000251,,Sus scrofa,,Autocuration,11375,,B,9823.0,,,Microsomes,12083
87,1,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,BAO_0000019,,Rattus norvegicus,,Autocuration,791,,B,10116.0,,,,11231
88,1,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,BAO_0000019,,Rattus norvegicus,,Autocuration,791,,B,10116.0,,,,11231
89,1,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,BAO_0000019,,Rattus norvegicus,,Autocuration,791,,B,10116.0,,,,11231
90,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,11375,,B,10116.0,,,Microsomes,12083
91,1,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,11375,,B,10116.0,,,Microsomes,12083
92,1,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,153,,B,10116.0,,,Microsomes,12083
93,1,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,BAO_0000357,,,,Expert,8269,,B,,,,,11377
94,1,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,BAO_0000357,,,,Expert,8269,,B,,,,,11377
95,1,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,BAO_0000219,,Homo sapiens,,Expert,17653,,F,9606.0,,HepG2,,81020
96,1,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,BAO_0000219,,Homo sapiens,,Intermediate,14277,,F,9606.0,,HepG2,,81020
97,1,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,1717,,F,9606.0,,HepG2,,81020
98,1,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,BAO_0000219,,Homo sapiens,,Intermediate,14091,,F,9606.0,,HepG2,,81020
99,1,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,BAO_0000219,,Homo sapiens,,Intermediate,14091,,F,9606.0,,HepG2,,81020
100,1,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,BAO_0000218,,Hepatitis B virus,,Expert,17653,,F,10407.0,,,,50606
101,1,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,BAO_0000219,,Homo sapiens,,Intermediate,13105,,F,9606.0,,HepG2,,81020
102,1,Concentration required to inhibit 50% of 2.2.15 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,1717,,F,9606.0,,HepG2,,81020
103,1,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,BAO_0000219,,Homo sapiens,,Intermediate,13105,,A,9606.0,,HepG2,,81020
104,1,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,BAO_0000218,,Homo sapiens,,Intermediate,13600,,F,9606.0,,2.2.15,,50587
105,1,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,BAO_0000218,,Homo sapiens,,Intermediate,13467,,F,9606.0,,2.2.15,,50587
106,1,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,BAO_0000218,,Hepatitis B virus,,Expert,17477,,F,10407.0,,2.2.15,,50606
107,1,In vitro anti-HBV activity in 2.2.15 cells,,BAO_0000218,,Homo sapiens,,Intermediate,1593,,F,9606.0,,2.2.15,,50587
108,1,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,BAO_0000218,,Homo sapiens,,Intermediate,1593,,F,9606.0,,2.2.15,,50587
109,1,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,BAO_0000218,,Homo sapiens,,Intermediate,15089,,F,9606.0,,2.2.15,,50587
110,1,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,BAO_0000218,,Homo sapiens,,Intermediate,15089,,F,9606.0,,2.2.15,,50587
111,1,Cytotoxicity in 2.2.15 cells,,BAO_0000218,,Homo sapiens,,Intermediate,1593,,F,9606.0,,2.2.15,,50587
112,1,Cytotoxicity in 2.2.15 cells; Not determined,,BAO_0000218,,Homo sapiens,,Intermediate,1593,,F,9606.0,,2.2.15,,50587
113,1,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,BAO_0000218,,Homo sapiens,,Intermediate,13600,,F,9606.0,,2.2.15,,50587
114,1,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,BAO_0000218,,Homo sapiens,,Intermediate,13467,,F,9606.0,,2.2.15,,50587
115,1,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,BAO_0000218,,Homo sapiens,,Intermediate,13467,,F,9606.0,,2.2.15,,50587
116,1,Antiviral activity against HBV was determined in 2.215 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,14764,,F,9606.0,,HepG2,,81020
117,1,Inhibition of 20-HETE synthesis in human renal microsomes,,BAO_0000251,,Homo sapiens,,Autocuration,6531,,B,9606.0,,,Microsomes,22226
118,1,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,BAO_0000019,,,,Autocuration,17322,,B,,,,,22226
119,1,Inhibitory concentration against 2008 (ovarian) cells,,BAO_0000219,,Homo sapiens,,Intermediate,17072,,F,9606.0,,2008,,80612
120,1,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,16936,,F,9606.0,,2008,,80612
121,1,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,BAO_0000219,,Homo sapiens,,Intermediate,16936,,F,9606.0,,2008,,80612
122,1,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,BAO_0000219,,Homo sapiens,,Intermediate,17146,,F,9606.0,,2008,,80612
123,1,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,BAO_0000219,,Homo sapiens,,Intermediate,17146,,F,9606.0,,2008,,80612
124,1,In vitro inhibition of 2008/R ovarian cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,10797,,F,9606.0,,2008/R,,80613
125,1,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,BAO_0000219,,Homo sapiens,,Intermediate,10797,,F,9606.0,,2008/R,,80613
126,1,In vitro inhibition of 2008/S ovarian cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,10797,,F,9606.0,,2008/S,,80614
127,1,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,BAO_0000219,,Homo sapiens,,Intermediate,10797,,F,9606.0,,2008/S,,80614
128,1,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,BAO_0000220,,Homo sapiens,,Expert,4823,,B,9606.0,,,,100256
129,1,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,BAO_0000220,,Homo sapiens,,Intermediate,12912,,B,9606.0,,,,100256
130,1,Inhibition of chymotrypsin-like activity of 20S proteasome,,BAO_0000220,,,,Expert,2957,,B,,,,,100256
131,1,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,BAO_0000220,,,,Expert,2957,,B,,,,,100256
132,1,Inhibitory activity against 20S proteosome,,BAO_0000220,,,,Intermediate,3260,,B,,,,,100256
133,1,Compound was tested for inhibitory activity against tryptase,,BAO_0000019,,Homo sapiens,,Autocuration,3451,,B,9606.0,,,,22226
134,1,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,13885,,F,9606.0,,HepG2,,81020
135,1,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,13885,,F,9606.0,,HepG2,,81020
136,1,Compound was tested for the inhibition of Alpha-glucosidase,,BAO_0000019,,,,Autocuration,3676,,B,,,,,22226
137,1,Inhibitory concentration against human neutrophil elastase (HNE),,BAO_0000357,,,,Autocuration,6043,,B,,,,,235
138,1,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,Heart,BAO_0000218,,Rattus norvegicus,,Autocuration,11140,,F,10116.0,,,,22226
139,1,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,BAO_0000019,,,,Autocuration,10543,,F,,,,,19640
140,1,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,BAO_0000019,,,,Expert,10543,,F,,,,,19640
141,1,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,BAO_0000357,,,,Autocuration,10543,,B,,,,,19640
142,1,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,BAO_0000019,,,,Expert,10543,,F,,,,,19640
143,1,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,BAO_0000219,,Mus musculus,,Intermediate,11365,,F,10090.0,,P338,,80360
144,1,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,BAO_0000219,,Mus musculus,,Intermediate,11365,,F,10090.0,,P338,,80360
145,1,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,BAO_0000219,,Homo sapiens,,Intermediate,11803,,F,9606.0,,PBL,,80384
146,1,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,BAO_0000019,,Ovis aries,,Autocuration,11803,,F,9940.0,,,,22226
147,1,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,BAO_0000019,,Ovis aries,,Autocuration,11803,,F,9940.0,,,,22226
148,1,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,BAO_0000357,,,,Autocuration,12278,,B,,,,,191
149,1,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,BAO_0000019,,Homo sapiens,,Autocuration,8249,,F,9606.0,,,,22226
150,1,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,BAO_0000019,,Homo sapiens,,Autocuration,8249,,F,9606.0,,,,22226
151,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,BAO_0000219,,Homo sapiens,,Autocuration,8249,,F,9606.0,,CCRF-CEM,,22226
152,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,BAO_0000219,,Homo sapiens,,Autocuration,8249,,F,9606.0,,CCRF-CEM,,22226
153,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,BAO_0000219,,Homo sapiens,,Autocuration,8249,,F,9606.0,,CCRF-CEM,,22226
154,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,BAO_0000219,,Homo sapiens,,Autocuration,8249,,F,9606.0,,CCRF-CEM,,22226
155,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,BAO_0000019,,Homo sapiens,,Autocuration,8249,,F,9606.0,,,,22226
156,1,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,BAO_0000019,,Homo sapiens,,Autocuration,8249,,F,9606.0,,,,22226
157,1,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,BAO_0000249,,,,Autocuration,16992,,B,,,,,104290
158,1,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,BAO_0000218,,Streptococcus pyogenes,,Intermediate,10543,,F,1314.0,,,,50264
159,1,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,BAO_0000218,,Human herpesvirus 3,,Intermediate,17833,,F,10335.0,,,,50527
160,1,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,BAO_0000218,,vericilla zoster virus,,Expert,17290,,F,10335.0,,HEL,,50527
161,1,Antiviral activity against 07/1 strain of VZV; ND: No data,,BAO_0000218,,vericilla zoster virus,,Intermediate,17290,,F,10335.0,,,,50527
162,1,Antiviral activity against 07/1 strain of VZV; ND=No data,,BAO_0000218,,vericilla zoster virus,,Intermediate,17290,,F,10335.0,,,,50527
163,1,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,BAO_0000218,,escherichia cloac,,Intermediate,10932,,F,561.0,,,,50145
164,1,Ratio of Ki at A2 to Ki at A1 receptors,,BAO_0000019,,,,Autocuration,9707,,B,,,,,22226
165,1,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,BAO_0000249,,Candida albicans,,Expert,2346,,B,5476.0,,,,11143
166,1,"Inhibition of 1,3-beta-glucan synthase",,BAO_0000357,,Candida glabrata CBS 138,,Expert,2205,,B,284593.0,,,,18077
167,1,Inhibition of growth of 1-87 human tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,11900,,F,9606.0,,1-87 tumor cell line,,80609
168,1,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,BAO_0000219,,Rattus norvegicus,,Expert,14864,,B,10116.0,,,,12166
169,1,Inhibitory activity against soybean 1-lipoxygenase (SLO),,BAO_0000357,,Glycine max,,Autocuration,16474,,B,3847.0,,,,100171
170,1,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,BAO_0000357,,Glycine max,,Autocuration,16474,,B,3847.0,,,,100171
171,1,% inhibition against soybean 1-lipoxygenase (SLO),,BAO_0000357,,Glycine max,,Autocuration,16474,,B,3847.0,,,,100171
172,1,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,BAO_0000357,,Glycine max,,Autocuration,16474,,B,3847.0,,,,100171
173,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,BAO_0000357,,Glycine max,,Autocuration,3094,,B,3847.0,,,,100171
174,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,BAO_0000357,,Glycine max,,Autocuration,3094,,B,3847.0,,,,100171
175,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,BAO_0000357,,Glycine max,,Autocuration,3094,,B,3847.0,,,,100171
176,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,BAO_0000357,,Glycine max,,Autocuration,3094,,B,3847.0,,,,100171
177,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,BAO_0000357,,Glycine max,,Autocuration,3094,,B,3847.0,,,,100171
178,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,BAO_0000357,,Glycine max,,Autocuration,3094,,B,3847.0,,,,100171
179,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,BAO_0000357,,Glycine max,,Autocuration,3094,,B,3847.0,,,,100171
180,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,BAO_0000357,,Glycine max,,Autocuration,3094,,B,3847.0,,,,100171
181,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,BAO_0000357,,Glycine max,,Autocuration,3094,,B,3847.0,,,,100171
182,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,BAO_0000357,,Glycine max,,Autocuration,3094,,B,3847.0,,,,100171
183,1,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,BAO_0000357,,Glycine max,,Autocuration,3094,,B,3847.0,,,,100171
184,1,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,BAO_0000019,,Mus musculus,,Autocuration,10413,,B,10090.0,,,,22226
185,1,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,BAO_0000219,,Mus musculus,,Intermediate,16929,,F,10090.0,,C3H 10T1/2,,80049
186,1,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,BAO_0000019,,,,Intermediate,1229,,F,,,,,22226
187,1,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,BAO_0000357,,,,Autocuration,16587,,B,,,,,11489
188,1,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,BAO_0000357,,,,Autocuration,16587,,B,,,,,11862
189,1,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,BAO_0000357,,,,Autocuration,16587,,B,,,,,11862
190,1,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,BAO_0000357,,,,Autocuration,16587,,B,,,,,11489
191,1,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,BAO_0000357,,,,Autocuration,16587,,B,,,,,11862
192,1,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,BAO_0000019,,Bos taurus,,Expert,8058,,F,9913.0,,,,12347
193,1,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,BAO_0000357,,Rattus norvegicus,,Expert,9065,,B,10116.0,,,,100120
194,1,Inhibition of 11 beta-hydroxylase from rat adrenal gland,Adrenal gland,BAO_0000357,,Rattus norvegicus,,Expert,8865,,B,10116.0,,,,100120
195,1,Inhibition of rat adrenal 11-beta-hydroxylase,,BAO_0000357,,Rattus norvegicus,,Expert,9066,,B,10116.0,,,,100120
196,1,Inhibition of rat adrenal 11-beta-hydroxylase,,BAO_0000357,,Rattus norvegicus,,Expert,8394,,B,10116.0,,,,100120
197,1,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,BAO_0000357,,Rattus norvegicus,,Expert,8394,,B,10116.0,,,,100120
198,1,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,BAO_0000019,,,,Autocuration,6431,,B,,,,,10328
199,1,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,BAO_0000357,,,,Autocuration,6431,,B,,,,,11490
200,1,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,BAO_0000357,,,,Autocuration,6431,,B,,,,,11490
201,1,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,BAO_0000019,,,,Autocuration,9295,,F,,,,,11134
202,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,BAO_0000019,,,,Autocuration,10193,,B,,,,,12052
203,1,Compound was tested in vitro for inhibition of 12-LO human platelet,,BAO_0000019,,,,Autocuration,13622,,B,,,,,11134
204,1,Inhibitory concentration against human platelet 12-lipoxygenase,,BAO_0000019,,,,Autocuration,12079,,F,,,,,11134
205,1,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,BAO_0000019,,,,Autocuration,13622,,B,,,,,11134
206,1,Inhibitory concentration against human platelet 12-lipoxygenase,,BAO_0000019,,Homo sapiens,,Autocuration,12079,,F,9606.0,,,,11134
207,1,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,BAO_0000019,,,,Expert,13500,,B,,,,,11835
208,1,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,BAO_0000357,,,,Expert,13723,,B,,,,,11601
209,1,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,BAO_0000019,,,,Autocuration,16474,,B,,,,,11134
210,1,Inhibitory activity against human platelet 12-lipoxygenase,,BAO_0000019,,,,Autocuration,1630,,B,,,,,11134
211,1,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,BAO_0000019,,,,Autocuration,167,,B,,,,,11134
212,1,% inhibition against human platelet 12-lipoxygenase (12-HLO),,BAO_0000019,,,,Autocuration,16474,,B,,,,,11134
213,1,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,BAO_0000019,,,,Autocuration,167,,B,,,,,11134
214,1,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,BAO_0000019,,,,Autocuration,16474,,B,,,,,11134
215,1,Inhibitory activity towards porcine 12-lipoxygenase,,BAO_0000357,,,,Autocuration,10091,,B,,,,,11601
216,1,Tested for inhibition against porcine 12-LO,,BAO_0000357,,,,Autocuration,11966,,B,,,,,11601
217,1,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,BAO_0000019,,,,Autocuration,951,,B,,,,,12052
218,1,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,BAO_0000019,,,,Autocuration,10997,,B,,,,,12052
219,1,In vitro inhibition of rat platelet 12-lipoxygenase,,BAO_0000019,,,,Expert,10193,,B,,,,,12052
220,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,BAO_0000019,,,,Autocuration,10193,,B,,,,,12052
221,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,BAO_0000019,,,,Autocuration,10193,,B,,,,,12052
222,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,BAO_0000019,,,,Autocuration,10193,,B,,,,,12052
223,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,BAO_0000019,,,,Autocuration,10193,,B,,,,,12052
224,1,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,BAO_0000019,,,,Autocuration,10193,,B,,,,,12052
225,1,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,BAO_0000019,,,,Autocuration,11087,,B,,,,,12052
226,1,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,BAO_0000219,,Homo sapiens,,Intermediate,15569,,F,9606.0,,41M,,80007
227,1,In vitro antitumor activity against 41M cell line.,,BAO_0000219,,Homo sapiens,,Expert,12989,,F,9606.0,,41M,,80007
228,1,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,BAO_0000219,,Homo sapiens,,Intermediate,16745,,F,9606.0,,41M,,80007
229,1,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,BAO_0000219,,Homo sapiens,,Intermediate,15569,,F,9606.0,,41M,,80007
230,1,In vitro antitumor activity against 41McisR cell line.,,BAO_0000219,,Homo sapiens,,Expert,12989,,F,9606.0,,41M,,80007
231,1,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,BAO_0000219,,Homo sapiens,,Expert,12989,,F,9606.0,,41M,,80007
232,1,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,16745,,F,9606.0,,41M,,80007
233,1,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,BAO_0000357,,Homo sapiens,,Expert,6210,,B,9606.0,,,,84
234,1,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,BAO_0000357,,Homo sapiens,,Expert,6210,,B,9606.0,,,,68
235,1,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,BAO_0000357,,,,Expert,6226,,B,,,,,68
236,1,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,BAO_0000357,,,,Expert,17855,,B,,,,,10201
237,1,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,BAO_0000357,,,,Expert,17855,,B,,,,,10201
238,1,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,BAO_0000357,,,,Expert,17855,,B,,,,,10201
239,1,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,BAO_0000357,,,,Autocuration,10413,,B,,,,,12220
240,1,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,BAO_0000357,,Escherichia coli,,Autocuration,10413,,B,562.0,,,,11303
241,1,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,BAO_0000357,,Escherichia coli,,Autocuration,10413,,B,562.0,,,,11303
242,1,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,BAO_0000357,,Escherichia coli,,Autocuration,10413,,B,562.0,,,,11303
243,1,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,BAO_0000357,,,,Autocuration,10413,,B,,,,,12220
244,1,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,BAO_0000357,,,,Autocuration,10413,,B,,,,,12220
245,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,BAO_0000357,,Sus scrofa,,Autocuration,7587,,B,9823.0,,,,11303
246,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,BAO_0000019,,Sus scrofa,,Autocuration,7587,,B,9823.0,,,,11303
247,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,BAO_0000357,,Sus scrofa,,Autocuration,7587,,B,9823.0,,,,11303
248,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,BAO_0000357,,Sus scrofa,,Autocuration,7587,,B,9823.0,,,,11303
249,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,BAO_0000357,,Sus scrofa,,Autocuration,7587,,B,9823.0,,,,11303
250,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,BAO_0000019,,Sus scrofa,,Autocuration,7587,,B,9823.0,,,,11303
251,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,BAO_0000019,,Sus scrofa,,Autocuration,7587,,B,9823.0,,,,11303
252,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,BAO_0000019,,Sus scrofa,,Autocuration,7587,,B,9823.0,,,,11303
253,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,BAO_0000019,,Sus scrofa,,Autocuration,7587,,B,9823.0,,,,11303
254,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,BAO_0000019,,Sus scrofa,,Autocuration,7587,,B,9823.0,,,,11303
255,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,BAO_0000357,,Sus scrofa,,Autocuration,7587,,B,9823.0,,,,11303
256,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,BAO_0000019,,Sus scrofa,,Autocuration,7587,,B,9823.0,,,,11303
257,1,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,BAO_0000357,,,,Autocuration,7323,,B,,,,,11303
258,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,BAO_0000019,,Sus scrofa,,Autocuration,7587,,B,9823.0,,,,22226
259,1,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,BAO_0000019,,Sus scrofa,,Autocuration,7587,,B,9823.0,,,,22226
260,1,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,BAO_0000357,,Saccharomyces cerevisiae,,Expert,13750,,B,4932.0,,,,100249
261,1,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,BAO_0000019,,Rattus norvegicus,,Autocuration,7662,,B,10116.0,,,,22226
262,1,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,BAO_0000019,,Rattus norvegicus,,Autocuration,7662,,B,10116.0,,,,22226
263,1,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,BAO_0000019,,Rattus norvegicus,,Autocuration,7662,,B,10116.0,,,,22226
264,1,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,BAO_0000019,,,,Autocuration,12211,,F,,,,,104698
265,1,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,BAO_0000019,,,,Autocuration,12211,,F,,,,,104698
266,1,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,12211,,F,10141.0,,,,20033
267,1,Stimulatory activity of intragastric pressure was tested in the rat,,BAO_0000019,,,,Expert,12211,,F,,,,,10623
268,1,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,BAO_0000357,,,,Autocuration,15453,,B,,,,,121
269,1,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,BAO_0000218,,Rattus norvegicus,,Autocuration,11884,,F,10116.0,,,,22226
270,1,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,BAO_0000019,,,,Autocuration,7185,,F,,,,,12688
271,1,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,BAO_0000357,,Homo sapiens,,Expert,6876,,B,9606.0,,,,121
272,1,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,BAO_0000357,,Homo sapiens,,Expert,6876,,B,9606.0,,,,121
273,1,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,BAO_0000019,,,,Autocuration,11863,,F,,,,,12198
274,1,Inhibition constant of high-affinity 5-HT uptake,,BAO_0000357,,,,Autocuration,11863,,B,,,,,12198
275,1,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,BAO_0000019,,,,Autocuration,11863,,F,,,,,12198
276,1,Maximum rate was determined for high affinity transport of 5-HT,,BAO_0000019,,,,Autocuration,11863,,F,,,,,12198
277,1,Compound was tested for agonistic activity against 5-HT uptake,,BAO_0000019,,,,Autocuration,4639,,F,,,,,104714
278,1,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,BAO_0000019,,,,Expert,15796,,B,,,,,10577
279,1,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,BAO_0000357,,Bos taurus,,Expert,15796,,B,9913.0,,,,105
280,1,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,BAO_0000224,,Rattus norvegicus,,Autocuration,12801,,B,10116.0,,,,104744
281,1,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,BAO_0000224,,,,Autocuration,12801,,B,,,,,104744
282,1,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,BAO_0000249,,,,Autocuration,12120,,B,,,,Membranes,104744
283,1,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,BAO_0000249,,,,Autocuration,12120,,B,,,,Membranes,104744
284,1,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,BAO_0000019,,,,Autocuration,11963,,B,,,,,104744
285,1,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,BAO_0000019,,,,Autocuration,11701,,F,,,,,51
286,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,B,,,,,51
287,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,B,,,,,51
288,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,B,,,,,51
289,1,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,BAO_0000218,,,,Autocuration,16394,In vivo,F,,,,,10576
290,1,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,BAO_0000019,,Cavia porcellus,,Intermediate,11574,,F,10141.0,,,,105570
291,1,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,B,,,CHO,,279
292,1,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,15363,,B,,,,,107
293,1,Efficacy against 5-hydroxytryptamine 2A receptor,,BAO_0000019,,Rattus norvegicus,,Expert,15363,,F,10116.0,,,,12687
294,1,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,BAO_0000019,,,,Expert,15329,,F,,,,,12687
295,1,Relative potency towards 5-HT2A receptor of rat tail artery,,BAO_0000019,,,,Expert,15329,,F,,,,,12687
296,1,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,BAO_0000019,,,,Expert,15329,,F,,,,,12687
297,1,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,BAO_0000019,,,,Expert,15329,,F,,,,,12687
298,1,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,BAO_0000019,,,,Autocuration,15329,,F,,,,,12687
299,1,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,BAO_0000019,,,,Expert,15329,,F,,,,,12687
300,1,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,273,,F,10141.0,,,,20033
301,1,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,273,,F,10141.0,,,,20033
302,1,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,273,,F,10141.0,,,,20033
303,1,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,BAO_0000357,,,,Autocuration,12092,,B,,,,,10623
304,1,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,BAO_0000019,,Rattus norvegicus,,Expert,1317,,F,10116.0,,,,10623
305,1,Binding affinity against 5-hydroxytryptamine 4 receptor,,BAO_0000357,,,,Expert,12409,,B,,,,,168
306,1,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,BAO_0000019,,Gallus gallus,,Autocuration,11126,,B,9031.0,,,,22226
307,1,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,BAO_0000019,,Homo sapiens,,Autocuration,11126,,F,9606.0,,,,22226
308,1,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,BAO_0000019,,Homo sapiens,,Autocuration,11126,,F,9606.0,,,,22226
309,1,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,BAO_0000219,,Homo sapiens,,Autocuration,11126,,B,9606.0,,HL-60,,80156
310,1,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,BAO_0000019,,Homo sapiens,,Autocuration,11126,,B,9606.0,,,,22226
311,1,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,BAO_0000019,,Homo sapiens,,Autocuration,11126,,B,9606.0,,,,22226
312,1,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,BAO_0000219,,Homo sapiens,,Autocuration,17807,,B,9606.0,,Oocytes,,104703
313,1,Chymotryptic inhibitory activity against 26S proteasome,,BAO_0000220,,,,Intermediate,16575,,F,,,,,100256
314,1,Inhibitory activity against 26S proteasome degradation of IkB,,BAO_0000220,,,,Intermediate,15407,,B,,,,,100256
315,1,In vitro inhibition of 2780/DOX ovarian cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,10797,,F,9606.0,,A2780,,81034
316,1,In vitro inhibition of 2780/S ovarian cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,10797,,F,9606.0,,A2780,,81034
317,1,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,BAO_0000019,,Homo sapiens,,Autocuration,3469,,F,9606.0,,,,22226
318,1,Association constant for binding to AATT 28-mer AATT hairpin,,BAO_0000225,,,,Intermediate,16037,,B,,,,,22222
319,1,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,BAO_0000225,,,,Intermediate,16037,,B,,,,,22222
320,1,Reaction Rate Parameter for 28-mer AATT hairpin,,BAO_0000225,,,,Intermediate,16037,,B,,,,,22222
321,1,Reaction Rate Parameter for 28-mer AATT hairpin,,BAO_0000225,,,,Intermediate,16037,,B,,,,,22222
322,1,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,BAO_0000019,,Homo sapiens,,Autocuration,16524,,F,9606.0,,,,22226
323,1,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,BAO_0000019,,Homo sapiens,,Autocuration,16524,,F,9606.0,,,,22226
324,1,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,BAO_0000019,,Homo sapiens,,Autocuration,16524,,F,9606.0,,,,22226
325,1,Cytotoxicity against cell line 2SC/20 determined by MTT test,,BAO_0000019,,Cricetulus griseus,,Autocuration,16758,,F,10029.0,,,,22226
326,1,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,BAO_0000019,,Cricetulus griseus,,Autocuration,16758,,F,10029.0,,,,22226
327,1,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,BAO_0000019,,Cricetulus griseus,,Autocuration,16758,,F,10029.0,,,,22226
328,1,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,BAO_0000357,,,,Autocuration,14360,,B,,,,,241
329,1,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,BAO_0000357,,Homo sapiens,,Expert,14360,,B,9606.0,,,,241
330,1,Selectivity ratio of ID50 in liver and heart,,BAO_0000019,,Rattus norvegicus,,Autocuration,9964,,B,10116.0,,,,22226
331,1,"Selectivity, ratio of relative ID50 in liver and heart",,BAO_0000019,,,,Autocuration,9964,,B,,,,,12132
332,1,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,BAO_0000019,,,,Autocuration,9964,,B,,,,,12132
333,1,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,,,,Autocuration,9964,,B,,,,,12132
334,1,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,,,,Autocuration,9964,,B,,,,,12132
335,1,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,,,,Autocuration,9964,In vivo,B,,,,,12132
336,1,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,,,,Autocuration,9964,In vivo,F,,,,,12132
337,1,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,BAO_0000019,,,,Autocuration,9964,,B,,,,,22226
338,1,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,BAO_0000019,,,,Autocuration,9964,,B,,,,,12132
339,1,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,BAO_0000019,,Homo sapiens,,Autocuration,9964,,B,9606.0,,,,22226
340,1,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,BAO_0000019,,,,Autocuration,9964,,B,,,,,12132
341,1,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,BAO_0000019,,,,Autocuration,9964,,F,,,,,12132
342,1,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,BAO_0000019,,,,Autocuration,9964,,B,,,,,12132
343,1,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,BAO_0000218,,Rattus norvegicus,,Autocuration,9964,,B,10116.0,,,,22226
344,1,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,BAO_0000218,,,,Autocuration,9964,In vivo,B,,,,,12132
345,1,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,BAO_0000218,,,,Autocuration,9964,,B,,,,,12132
346,1,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,BAO_0000218,,Rattus norvegicus,,Autocuration,9964,,B,10116.0,,,,22226
347,1,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,BAO_0000019,,,,Autocuration,9964,,B,,,,,12132
348,1,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,BAO_0000019,,,,Autocuration,9964,,F,,,,,12132
349,1,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,BAO_0000019,,Rattus norvegicus,,Autocuration,3796,,B,10116.0,,,,22226
350,1,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,BAO_0000357,,Escherichia coli,,Autocuration,4251,,B,562.0,,,,19690
351,1,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,BAO_0000357,,Escherichia coli,,Autocuration,4251,,B,562.0,,,,19690
352,1,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,BAO_0000357,,Escherichia coli,,Autocuration,4251,,B,562.0,,,,19690
353,1,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,BAO_0000357,,Escherichia coli,,Autocuration,4251,,B,562.0,,,,19690
354,1,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,BAO_0000357,,,,Autocuration,166,,B,,,,,19690
355,1,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,BAO_0000357,,,,Autocuration,17861,,B,,,,,19690
356,1,Inhibition constant against 3-dehydroquinate synthase,,BAO_0000357,,,,Autocuration,166,,B,,,,,19690
357,1,Association rate constant against 3-dehydroquinate synthase,,BAO_0000357,,,,Autocuration,166,,B,,,,,19690
358,1,Rate constant against 3-dehydroquinate synthase,,BAO_0000357,,,,Autocuration,166,,B,,,,,19690
359,1,Inhibitory activity against fuc-TVII,,BAO_0000019,,,,Autocuration,3548,,B,,,,,22226
360,1,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,9877,,B,10116.0,,,Microsomes,12236
361,1,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,9877,,B,10116.0,,,Microsomes,12236
362,1,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,9877,,B,10116.0,,,Microsomes,12236
363,1,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,9877,,B,10116.0,,,Microsomes,12236
364,1,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,9877,,B,10116.0,,,Microsomes,12236
365,1,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,9877,,B,10116.0,,,Microsomes,12236
366,1,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,9877,,B,10116.0,,,Microsomes,12236
367,1,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,9877,,B,10116.0,,,Microsomes,12236
368,1,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,9877,,B,10116.0,,,Microsomes,12236
369,1,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,9877,,B,10116.0,,,Microsomes,12236
370,1,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,9877,,B,10116.0,,,Microsomes,12236
371,1,Inhibitory activity against 3-phosphoglycerate kinase.,,BAO_0000224,,,,Autocuration,3003,,B,,,,,104832
372,1,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,BAO_0000224,,,,Autocuration,3003,,B,,,,,104832
373,1,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,BAO_0000224,,,,Autocuration,3003,,B,,,,,104832
374,1,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,BAO_0000357,,Homo sapiens,,Expert,17185,,B,9606.0,,,,10612
375,1,Cytotoxicity on 3677 melanoma cells,,BAO_0000219,,Homo sapiens,,Intermediate,6072,,F,9606.0,,3677 melanoma cell line,,80616
376,1,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,BAO_0000219,,Homo sapiens,,Intermediate,6072,,F,9606.0,,3677 melanoma cell line,,80616
377,1,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,BAO_0000219,,Mus musculus,,Intermediate,5018,,F,10090.0,,MC-38,,80617
378,1,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,BAO_0000019,,Homo sapiens,,Intermediate,2852,,F,9606.0,,,,22226
379,1,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,BAO_0000218,,,,Autocuration,8663,,F,,,B16,,22226
380,1,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,BAO_0000218,,,,Autocuration,8663,,F,,,B16,,22226
381,1,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,BAO_0000019,,Human rhinovirus 14,,Expert,3245,,F,12131.0,,,,12464
382,1,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,BAO_0000218,,Human rhinovirus sp.,,Intermediate,3245,,F,169066.0,,,,50085
383,1,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,BAO_0000218,,human rhinovirus type 14,,Intermediate,3877,,F,169066.0,,,,50679
384,1,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,BAO_0000218,,human rhinovirus type 14,,Intermediate,3877,,F,169066.0,,,,50679
385,1,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,BAO_0000019,,Human rhinovirus 14,,Expert,5861,,F,12131.0,,,,12464
386,1,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,BAO_0000019,,Human rhinovirus 14,,Expert,5861,,F,12131.0,,,,12464
387,1,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,BAO_0000019,,Human rhinovirus 14,,Expert,5861,,F,12131.0,,,,12464
388,1,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,BAO_0000019,,Human rhinovirus 14,,Expert,5861,,F,12131.0,,,,12464
389,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,BAO_0000218,,Enterovirus,,Intermediate,13748,,F,12059.0,,,,50665
390,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,BAO_0000218,,Enterovirus,,Intermediate,13748,,F,12059.0,,,,50665
391,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,BAO_0000218,,Enterovirus,,Intermediate,13748,,F,12059.0,,,,50665
392,1,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,BAO_0000218,,Enterovirus,,Intermediate,13748,,F,12059.0,,,,50665
393,1,Inhibition of human rhinovirus 3C protease,,BAO_0000357,,Human rhinovirus B,,Expert,13748,,B,147712.0,,,,12464
394,1,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,BAO_0000019,,Homo sapiens,,Autocuration,17699,,B,9606.0,,,,22226
395,1,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,BAO_0000218,,Mus musculus,,Intermediate,7145,,F,10090.0,,3EM 37,,80619
396,1,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,BAO_0000218,,Mus musculus,,Intermediate,7145,,F,10090.0,,3EM 37,,80619
397,1,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,BAO_0000218,,Mus musculus,,Intermediate,7145,,F,10090.0,,3EM 37,,80619
398,1,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,BAO_0000218,,Mus musculus,,Intermediate,7145,,F,10090.0,,3EM 37,,80619
399,1,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,7145,,F,10090.0,,3EM 37,,80619
400,1,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,7145,,F,10090.0,,3EM 37,,80619
401,1,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,BAO_0000218,,Mus musculus,,Intermediate,5325,,F,10090.0,,3LL cell line,,80620
402,1,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,BAO_0000218,,Mus musculus,,Intermediate,5325,,F,10090.0,,3LL cell line,,80620
403,1,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,BAO_0000218,,Mus musculus,,Expert,5325,,F,10090.0,,3LL cell line,,80620
404,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
405,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
406,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
407,1,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
408,1,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
409,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
410,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
411,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
412,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
413,1,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
414,1,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
415,1,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
416,1,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
417,1,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
418,1,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
419,1,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
420,1,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
421,1,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
422,1,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
423,1,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
424,1,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
425,1,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
426,1,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
427,1,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
428,1,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
429,1,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,BAO_0000219,,Mus musculus,,Intermediate,16169,,F,10090.0,,3LL cell line,,80620
430,1,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,BAO_0000219,,Homo sapiens,,Intermediate,15547,,F,9606.0,,3LLD122,,80621
431,1,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,BAO_0000218,,,,Autocuration,8663,,F,,,,,22226
432,1,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,BAO_0000218,,,,Autocuration,8663,,F,,,,,22226
433,1,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,BAO_0000218,,,,Autocuration,8663,,F,,,,,22226
434,1,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,BAO_0000218,,,,Autocuration,8663,,F,,,,,22226
435,1,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,BAO_0000219,,Mus musculus,,Intermediate,4504,,F,10090.0,,NIH3T3,,80951
436,1,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,BAO_0000219,,Mus musculus,,Intermediate,4504,,F,10090.0,,NIH3T3,,80951
437,1,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,BAO_0000219,,,,Expert,12695,,F,,,NIH3T3,,11169
438,1,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,BAO_0000219,,Mus musculus,,Intermediate,12695,,F,10090.0,,NIH3T3,,80951
439,1,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,BAO_0000219,,Mus musculus,,Intermediate,12695,,F,10090.0,,NIH3T3,,80951
440,1,Effective dose against murine 3T3 fibroblasts cells,,BAO_0000219,,Mus musculus,,Expert,17642,,F,10090.0,,NIH3T3,,80951
441,1,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,BAO_0000219,,Mus musculus,,Expert,17642,,F,10090.0,,NIH3T3,,80951
442,1,Cytotoxic effect on 3T3 cells,,BAO_0000219,,Mus musculus,,Expert,12340,,F,10090.0,,NIH3T3,,80951
443,1,Cytotoxic effect on 3T3 cells,,BAO_0000219,,Mus musculus,,Expert,12340,,F,10090.0,,NIH3T3,,80951
444,1,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,BAO_0000219,,Mus musculus,,Intermediate,12716,,F,10090.0,,NIH3T3,,80951
445,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,BAO_0000219,,Mus musculus,,Intermediate,6277,,F,10090.0,,NIH3T3,,80951
446,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,BAO_0000219,,Mus musculus,,Intermediate,6277,,F,10090.0,,NIH3T3,,80951
447,1,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,BAO_0000219,,Mus musculus,,Expert,6277,,F,10090.0,,NIH3T3,,80951
448,1,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,BAO_0000219,,Mus musculus,,Expert,6277,,F,10090.0,,NIH3T3,,80951
449,1,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,BAO_0000219,,Mus musculus,,Intermediate,6277,,F,10090.0,,NIH3T3,,80951
450,1,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,BAO_0000219,,Mus musculus,,Expert,6277,,F,10090.0,,NIH3T3,,80951
451,1,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,BAO_0000219,,Mus musculus,,Expert,6277,,F,10090.0,,NIH3T3,,80951
452,1,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,BAO_0000219,,Mus musculus,,Intermediate,6277,,F,10090.0,,NIH3T3,,80951
453,1,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,BAO_0000218,,Mus musculus,,Expert,17780,,F,10090.0,,NIH3T3,,80951
454,1,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,BAO_0000219,,Mus musculus,,Autocuration,12751,,F,10090.0,,,,104860
455,1,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,BAO_0000219,,Mus musculus,,Expert,12380,,F,10090.0,,NIH3T3,,80951
456,1,Inhibitory activity against 3T3 cell line,,BAO_0000219,,Mus musculus,,Intermediate,14892,,F,10090.0,,NIH3T3,,80951
457,1,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,BAO_0000219,,Mus musculus,,Intermediate,12695,,F,10090.0,,NIH3T3,,80951
458,1,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,BAO_0000019,,,,Expert,12695,,F,,,,,11169
459,1,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,BAO_0000219,,Mus musculus,,Intermediate,12695,,F,10090.0,,NIH3T3,,80951
460,1,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,BAO_0000219,,Mus musculus,,Intermediate,12695,,F,10090.0,,NIH3T3,,80951
461,1,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,BAO_0000019,,,,Expert,12695,,F,,,,,11169
462,1,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,BAO_0000019,,,,Expert,12695,,F,,,,,11169
463,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,BAO_0000219,,Mus musculus,,Intermediate,6277,,F,10090.0,,NIH3T3,,80951
464,1,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,BAO_0000219,,Mus musculus,,Expert,6277,,F,10090.0,,NIH3T3,,80951
465,1,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,BAO_0000219,,Homo sapiens,,Expert,4959,,F,9606.0,,NIH3T3,,9
466,1,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,BAO_0000219,,Homo sapiens,,Expert,4959,,F,9606.0,,NIH3T3,,9
467,1,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,BAO_0000219,,Homo sapiens,,Expert,4959,,F,9606.0,,NIH3T3,,188
468,1,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,BAO_0000219,,Homo sapiens,,Expert,4959,,F,9606.0,,NIH3T3,,188
469,1,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,BAO_0000219,,Mus musculus,,Intermediate,12082,,F,10090.0,,NIH3T3,,80951
470,1,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,BAO_0000219,,Mus musculus,,Intermediate,12082,,F,10090.0,,NIH3T3,,80951
471,1,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,BAO_0000219,,Mus musculus,,Intermediate,12082,,F,10090.0,,NIH3T3,,80951
472,1,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,BAO_0000219,,Mus musculus,,Intermediate,12082,,F,10090.0,,NIH3T3,,80951
473,1,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,BAO_0000219,,Mus musculus,,Intermediate,2643,,F,10090.0,,NIH3T3,,80951
474,1,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,BAO_0000219,,Mus musculus,,Expert,11926,,F,10090.0,,NIH3T3,,80951
475,1,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,BAO_0000219,,Mus musculus,,Intermediate,15204,,A,10090.0,,NIH3T3,,80951
476,1,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,BAO_0000219,,Mus musculus,,Expert,15992,,F,10090.0,,NIH3T3,,80951
477,1,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,BAO_0000219,,Mus musculus,,Intermediate,16279,,F,10090.0,,NIH3T3,,80951
478,1,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,BAO_0000219,,Mus musculus,,Intermediate,16279,,F,10090.0,,NIH3T3,,80951
479,1,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,BAO_0000219,,Mus musculus,,Intermediate,16279,,F,10090.0,,NIH3T3,,80951
480,1,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,BAO_0000219,,Mus musculus,,Intermediate,16279,,F,10090.0,,NIH3T3,,80951
481,1,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,BAO_0000219,,Mus musculus,,Intermediate,16279,,F,10090.0,,NIH3T3,,80951
482,1,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,BAO_0000219,,Mus musculus,,Intermediate,16279,,F,10090.0,,NIH3T3,,80951
483,1,Inhibition of swiss 3T3 mouse fibroblast proliferation,,BAO_0000219,,Mus musculus,,Expert,12831,,F,10090.0,,NIH3T3,,80951
484,1,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,BAO_0000219,,Mus musculus,,Intermediate,13497,,F,10090.0,,NIH3T3,,80951
485,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,BAO_0000218,,,,Intermediate,13715,,F,,,3T3-L1,,80006
486,1,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,BAO_0000219,,Mus musculus,,Intermediate,13618,,F,10090.0,,3T3-L1,,80006
487,1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,BAO_0000219,,Mus musculus,,Intermediate,11902,,F,10090.0,,3T3-L1,,80006
488,1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,BAO_0000219,,Mus musculus,,Intermediate,11902,,F,10090.0,,3T3-L1,,80006
489,1,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,BAO_0000219,,Mus musculus,,Intermediate,11902,,F,10090.0,,3T3-L1,,80006
490,1,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,BAO_0000218,,Mus musculus,,Intermediate,14840,,F,10090.0,,3T3-L1,,80006
491,1,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,BAO_0000218,,Mus musculus,,Intermediate,14840,,F,10090.0,,3T3-L1,,80006
492,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,BAO_0000219,,,,Intermediate,13715,,F,,,3T3-L1,,80006
493,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,BAO_0000219,,,,Intermediate,13715,,F,,,3T3-L1,,80006
494,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,BAO_0000219,,,,Intermediate,13715,,F,,,3T3-L1,,80006
495,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,BAO_0000219,,,,Intermediate,13715,,F,,,3T3-L1,,80006
496,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,BAO_0000219,,,,Intermediate,13715,,F,,,3T3-L1,,80006
497,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,BAO_0000218,,,,Intermediate,13715,,F,,,3T3-L1,,80006
498,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,BAO_0000218,,,,Intermediate,13715,,F,,,3T3-L1,,80006
499,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,BAO_0000218,,,,Intermediate,13715,,F,,,3T3-L1,,80006
500,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,BAO_0000218,,,,Intermediate,13715,,F,,,3T3-L1,,80006
501,1,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,BAO_0000218,,,,Expert,13715,,F,,,3T3-L1,,80006
502,1,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,BAO_0000218,,,,Expert,13715,,F,,,3T3-L1,,80006
503,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,BAO_0000218,,,,Intermediate,13715,,F,,,3T3-L1,,80006
504,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,BAO_0000218,,,,Intermediate,13715,,F,,,3T3-L1,,80006
505,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,BAO_0000218,,,,Intermediate,13715,,F,,,3T3-L1,,80006
506,1,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,BAO_0000218,,,,Expert,13715,,F,,,3T3-L1,,80006
507,1,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,BAO_0000218,,,,Expert,13715,,F,,,3T3-L1,,80006
508,1,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,BAO_0000218,,,,Expert,13715,,F,,,3T3-L1,,80006
509,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,BAO_0000219,,,,Intermediate,13715,,F,,,3T3-L1,,80006
510,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,BAO_0000219,,,,Intermediate,13715,,F,,,3T3-L1,,80006
511,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,BAO_0000219,,,,Intermediate,13715,,F,,,3T3-L1,,80006
512,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,BAO_0000218,,,,Intermediate,13715,,F,,,3T3-L1,,80006
513,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,BAO_0000218,,,,Intermediate,13715,,F,,,3T3-L1,,80006
514,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,BAO_0000218,,,,Intermediate,13715,,F,,,3T3-L1,,80006
515,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,BAO_0000218,,,,Intermediate,13715,,F,,,3T3-L1,,80006
516,1,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,BAO_0000218,,,,Intermediate,13715,,F,,,3T3-L1,,80006
517,1,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,BAO_0000219,,,,Expert,6411,,F,,,3T3-L1,,11214
518,1,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,BAO_0000219,,Mus musculus,,Intermediate,6411,,F,10090.0,,3T3-L1,,80006
519,1,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,BAO_0000219,,,,Expert,6411,,F,,,3T3-L1,,11214
520,1,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,BAO_0000219,,Mus musculus,,Expert,3966,,F,10090.0,,3T3-L1,,80006
521,1,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,BAO_0000219,,Mus musculus,,Intermediate,3966,,F,10090.0,,3T3-L1,,80006
522,1,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,BAO_0000219,,Mus musculus,,Expert,15556,,F,10090.0,,3T3-L1,,80006
523,1,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,BAO_0000219,,Mus musculus,,Expert,5845,,F,10090.0,,3T3-L1,,80006
524,1,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,BAO_0000219,,Mus musculus,,Expert,14422,,F,10090.0,,3T3-L1,,80006
525,1,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,BAO_0000219,,Mus musculus,,Expert,5845,,F,10090.0,,3T3-L1,,80006
526,1,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,BAO_0000219,,Mus musculus,,Expert,14508,,F,10090.0,,3T3-L1,,80006
527,1,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,BAO_0000219,,Mus musculus,,Expert,14508,,F,10090.0,,3T3-L1,,80006
528,1,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,BAO_0000219,,Mus musculus,,Expert,14508,,F,10090.0,,3T3-L1,,80006
529,1,Inhibitory activity against rat fibroblast (3Y1) cell line,,BAO_0000219,,Rattus norvegicus,,Intermediate,6349,,F,10116.0,,3Y1 cell line,,80622
530,1,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,BAO_0000219,,Rattus norvegicus,,Expert,15899,,F,10116.0,,3Y1 cell line,,80622
531,1,Cytotoxicity in 3Y1 cells.,,BAO_0000219,,Rattus norvegicus,,Expert,15899,,F,10116.0,,3Y1 cell line,,80622
532,1,Cytostatic effect in 3Y1 cells.,,BAO_0000219,,Rattus norvegicus,,Expert,15899,,F,10116.0,,3Y1 cell line,,80622
533,1,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,BAO_0000219,,Rattus norvegicus,,Intermediate,15899,,F,10116.0,,3Y1 cell line,,80622
534,1,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,BAO_0000219,,Rattus norvegicus,,Expert,17038,,F,10116.0,,3Y1 cell line,,80622
535,1,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,BAO_0000019,,,,Autocuration,12421,,B,,,,,22226
536,1,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,BAO_0000019,,,,Autocuration,12947,,B,,,,,22226
537,1,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,BAO_0000019,,,,Autocuration,12947,,B,,,,,22226
538,1,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,BAO_0000019,,Sus scrofa,,Expert,4896,,B,9823.0,,,,11607
539,1,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,BAO_0000019,,,,Autocuration,6148,,B,,,,,11607
540,1,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,BAO_0000019,,,,Autocuration,16432,,B,,,,,11607
541,1,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,BAO_0000019,,,,Expert,4978,,B,,,,,11607
542,1,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,BAO_0000019,,,,Expert,4978,,B,,,,,11607
543,1,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,BAO_0000019,,,,Autocuration,3723,,B,,,,,11607
544,1,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,BAO_0000357,,,,Autocuration,3518,,B,,,,,11607
545,1,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,BAO_0000019,,,,Autocuration,4164,,B,,,,,11607
546,1,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,BAO_0000019,,,,Autocuration,3518,,B,,,,,11607
547,1,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,BAO_0000019,,Sus scrofa,,Expert,4164,,B,9823.0,,,,11607
548,1,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,BAO_0000019,,,,Autocuration,3518,,B,,,,,11607
549,1,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,BAO_0000357,,,,Autocuration,3518,,B,,,,,11607
550,1,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,BAO_0000019,,,,Autocuration,4978,,B,,,,,11607
551,1,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,BAO_0000019,,,,Autocuration,4978,,B,,,,,11607
552,1,Binding affinity against melatonin (MT1) receptor (pC1),,BAO_0000224,,,,Autocuration,6455,,B,,,,,104733
553,1,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,BAO_0000019,,,,Autocuration,2222,,B,,,,,22226
554,1,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,BAO_0000019,,,,Autocuration,13020,,B,,,,,22226
555,1,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,BAO_0000019,,,,Autocuration,13021,,B,,,,,22226
556,1,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,BAO_0000357,,,,Autocuration,14532,,B,,,,,10619
557,1,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,14118,,B,,,,,10619
558,1,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,Hippocampus,BAO_0000221,,,,Autocuration,11884,,B,,,,,51
559,1,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Expert,13969,,B,,,,,51
560,1,Binding affinity for 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Expert,13392,,B,,,,,51
561,1,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,BAO_0000019,,,,Expert,14430,,B,,,,,51
562,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,12248,,B,,,,,51
563,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,12249,,B,,,,,51
564,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,B,,,,,51
565,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,B,,,,,51
566,1,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,B,,,,,51
567,1,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,B,,,,,51
568,1,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,B,,,,,51
569,1,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,12249,,B,,,,,51
570,1,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",Hippocampus,BAO_0000221,,,,Autocuration,11799,,B,,,,,51
571,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,BAO_0000249,,Rattus norvegicus,,Expert,14331,,B,10116.0,,,Membranes,10576
572,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,Hippocampus,BAO_0000221,,Bos taurus,,Expert,11884,,B,9913.0,,,,51
573,1,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,Hippocampus,BAO_0000221,,,,Autocuration,14331,,B,,,,,51
574,1,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,11701,,B,,,,,51
575,1,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,Hippocampus,BAO_0000221,,,,Expert,11701,,B,,,,,51
576,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,12248,,B,,,,,51
577,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,BAO_0000219,,,,Autocuration,12248,,B,,,CHO,,51
578,1,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus,BAO_0000221,,,,Expert,12248,,B,,,,,51
579,1,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus,BAO_0000221,,,,Expert,12249,,B,,,,,51
580,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,BAO_0000219,,,,Autocuration,12248,,B,,,CHO,,51
581,1,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",Hippocampus,BAO_0000221,,,,Expert,11799,,B,,,,,51
582,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,BAO_0000357,,,,Autocuration,634,,B,,,,,51
583,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,B,,,,,51
584,1,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,B,,,,,51
585,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,B,,,,,51
586,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,B,,,,,51
587,1,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,9995,,B,,,,,51
588,1,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,Hippocampus,BAO_0000218,,,,Expert,12210,,B,,,,,51
589,1,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Expert,13311,,B,,,,,51
590,1,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,BAO_0000219,,Homo sapiens,,Expert,2331,,B,9606.0,,CHO,,51
591,1,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,BAO_0000019,,Cavia porcellus,,Autocuration,1375,,F,10141.0,,,,51
592,1,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,BAO_0000019,,Cavia porcellus,,Autocuration,1375,,F,10141.0,,,,51
593,1,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,Hippocampus,BAO_0000221,,Cavia porcellus,,Autocuration,11574,,F,10141.0,,,,51
594,1,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,12867,,B,10141.0,,,,51
595,1,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,12867,,B,10141.0,,,,51
596,1,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,12867,,B,10141.0,,,,51
597,1,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,12867,,B,10141.0,,,,51
598,1,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,12867,,B,10141.0,,,,51
599,1,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,12867,,B,10141.0,,,,51
600,1,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Cavia porcellus,,Autocuration,11574,,B,10141.0,,,,51
601,1,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Cavia porcellus,,Autocuration,13114,,B,10141.0,,,,51
602,1,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Cavia porcellus,,Autocuration,13181,,B,10141.0,,,,51
603,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Hippocampus,BAO_0000221,,Cavia porcellus,,Autocuration,10639,,B,10141.0,,,,106
604,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Hippocampus,BAO_0000221,,Cavia porcellus,,Autocuration,10639,,F,10141.0,,,,106
605,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,BAO_0000218,,Cricetulus griseus,,Autocuration,11883,,B,10029.0,,CHO,,11863
606,1,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,17785,,B,,,,,51
607,1,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,BAO_0000219,,,,Autocuration,1558,,F,,,HeLa,,51
608,1,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,BAO_0000219,,,,Autocuration,1558,,F,,,HeLa,,51
609,1,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,BAO_0000019,,,,Autocuration,15740,,F,,,,,51
610,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,BAO_0000219,,,,Autocuration,17624,,F,,,CHO,,51
611,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,BAO_0000219,,,,Expert,17624,,F,,,CHO,,51
612,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,BAO_0000219,,,,Autocuration,17624,,F,,,CHO,,51
613,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,BAO_0000219,,,,Autocuration,17624,,F,,,CHO,,51
614,1,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,BAO_0000219,,,,Expert,17624,,B,,,CHO,,51
615,1,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,BAO_0000219,,,,Expert,17624,,B,,,CHO,,51
616,1,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,BAO_0000219,,,,Autocuration,17624,,B,,,CHO,,51
617,1,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,BAO_0000219,,,,Autocuration,14256,,F,,,,,51
618,1,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,BAO_0000219,,Homo sapiens,,Expert,3445,,B,9606.0,,HeLa,,51
619,1,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,BAO_0000219,,Homo sapiens,,Expert,3445,,B,9606.0,,HeLa,,51
620,1,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000219,,Homo sapiens,,Expert,17200,,B,9606.0,,CHO,,51
621,1,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,BAO_0000219,,Homo sapiens,,Expert,17200,,B,9606.0,,CHO,,51
622,1,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,BAO_0000019,,,,Autocuration,15180,,F,,,,,51
623,1,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,BAO_0000019,,,,Autocuration,15180,,F,,,,,51
624,1,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,BAO_0000019,,,,Autocuration,16026,,F,,,,,51
625,1,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,BAO_0000219,,,,Autocuration,2759,,F,,,CHO,,51
626,1,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,BAO_0000219,,Homo sapiens,,Expert,2759,,F,9606.0,,CHO,,51
627,1,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,BAO_0000219,,,,Autocuration,2759,,F,,,CHO,,51
628,1,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,BAO_0000219,,Homo sapiens,,Expert,2759,,F,9606.0,,CHO,,51
629,1,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,BAO_0000219,,,,Autocuration,2759,,F,,,CHO,,51
630,1,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,BAO_0000219,,,,Autocuration,2759,,F,,,CHO,,51
631,1,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,BAO_0000219,,Homo sapiens,,Expert,2759,,F,9606.0,,CHO,,51
632,1,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,BAO_0000219,,,,Autocuration,2759,,F,,,CHO,,51
633,1,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,BAO_0000219,,Homo sapiens,,Expert,2759,,F,9606.0,,CHO,,51
634,1,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,BAO_0000019,,Homo sapiens,,Expert,3445,,F,9606.0,,,,51
635,1,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,BAO_0000019,,Homo sapiens,,Expert,5272,,F,9606.0,,,,51
636,1,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,BAO_0000019,,Homo sapiens,,Expert,5272,,F,9606.0,,,,51
637,1,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,BAO_0000019,,Homo sapiens,,Expert,5272,,F,9606.0,,,,51
638,1,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,BAO_0000219,,,,Autocuration,17624,,F,,,CHO,,51
639,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,BAO_0000219,,,,Autocuration,17624,,F,,,CHO,,51
640,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,BAO_0000219,,,,Autocuration,17624,,F,,,CHO,,51
641,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,BAO_0000219,,,,Expert,17624,,F,,,CHO,,51
642,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,BAO_0000219,,,,Autocuration,17624,,F,,,CHO,,51
643,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,BAO_0000219,,,,Autocuration,17624,,F,,,CHO,,51
644,1,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,BAO_0000219,,,,Autocuration,17624,,F,,,CHO,,51
645,1,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,BAO_0000219,,,,Autocuration,17624,,F,,,CHO,,51
646,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,BAO_0000219,,,,Expert,17624,,F,,,CHO,,51
647,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,BAO_0000219,,,,Autocuration,17624,,F,,,CHO,,51
648,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,BAO_0000219,,,,Autocuration,17624,,F,,,CHO,,51
649,1,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,BAO_0000219,,,,Autocuration,17624,,F,,,CHO,,51
650,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,,,,Autocuration,6563,,F,,,,,51
651,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,,,,Autocuration,6563,,F,,,,,51
652,1,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,BAO_0000019,,,,Autocuration,6563,,F,,,,,51
653,1,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,BAO_0000219,,,,Autocuration,17296,,F,,,HEK293,,51
654,1,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,BAO_0000019,,Homo sapiens,,Expert,6876,,F,9606.0,,,,51
655,1,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,BAO_0000019,,,,Expert,6876,,F,,,,,51
656,1,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,BAO_0000019,,Homo sapiens,,Expert,5272,,F,9606.0,,,,51
657,1,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,BAO_0000019,,Homo sapiens,,Expert,5272,,F,9606.0,,,,51
658,1,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,BAO_0000019,,,,Autocuration,5548,,F,,,,,51
659,1,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,BAO_0000019,,,,Expert,5548,,F,,,,,51
660,1,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,BAO_0000019,,,,Autocuration,5548,,F,,,,,51
661,1,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,BAO_0000019,,,,Autocuration,5548,,F,,,,,51
662,1,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,BAO_0000019,,,,Expert,5929,,F,,,,,51
663,1,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,BAO_0000019,,Homo sapiens,,Expert,5929,,F,9606.0,,,,51
664,1,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,BAO_0000019,,Homo sapiens,,Expert,5929,,F,9606.0,,,,51
665,1,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,BAO_0000019,,,,Autocuration,16245,,F,,,,,51
666,1,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,BAO_0000019,,,,Expert,5640,,F,,,,,51
667,1,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,BAO_0000019,,,,Autocuration,5640,,F,,,,,51
668,1,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,BAO_0000219,,,,Autocuration,14509,,F,,,CHO,,51
669,1,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,BAO_0000219,,,,Expert,14509,,F,,,CHO,,51
670,1,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,BAO_0000357,,,,Autocuration,15331,,B,,,,,51
671,1,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,BAO_0000357,,,,Autocuration,15331,,B,,,,,51
672,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,,,,Autocuration,6563,,F,,,,,51
673,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,BAO_0000019,,,,Autocuration,6563,,F,,,,,51
674,1,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,BAO_0000019,,,,Autocuration,6563,,F,,,,,51
675,1,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,BAO_0000019,,Homo sapiens,,Expert,6563,,F,9606.0,,,,51
676,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,,,,Autocuration,6563,,F,,,,,51
677,1,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,BAO_0000019,,Homo sapiens,,Expert,5272,,F,9606.0,,,,51
678,1,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,BAO_0000019,,Homo sapiens,,Expert,5272,,F,9606.0,,,,51
679,1,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,BAO_0000019,,Homo sapiens,,Expert,5272,,F,9606.0,,,,51
680,1,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,BAO_0000019,,Homo sapiens,,Expert,5272,,F,9606.0,,,,51
681,1,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,BAO_0000019,,Homo sapiens,,Expert,5272,,F,9606.0,,,,51
682,1,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,BAO_0000019,,Homo sapiens,,Expert,5272,,F,9606.0,,,,51
683,1,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,BAO_0000019,,Homo sapiens,,Expert,5272,,F,9606.0,,,,51
684,1,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,BAO_0000019,,Homo sapiens,,Expert,5272,,F,9606.0,,,,51
685,1,Inhibition of human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Homo sapiens,,Expert,16146,,B,9606.0,,,,51
686,1,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,BAO_0000219,,,,Autocuration,17624,,B,,,CHO,,51
687,1,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,BAO_0000219,,,,Expert,13706,,B,,,HEK293,,105
688,1,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,BAO_0000219,,,,Autocuration,15250,,B,,,CHO,,51
689,1,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,BAO_0000219,,,,Autocuration,17624,,F,,,CHO,,51
690,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,BAO_0000357,,,,Expert,6861,,B,,,,,51
691,1,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Homo sapiens,,Expert,17200,,B,9606.0,,,,51
692,1,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,BAO_0000219,,,,Autocuration,17624,,B,,,CHO,,51
693,1,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,BAO_0000219,,,,Autocuration,17624,,B,,,CHO,,51
694,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,F,10116.0,,,,22226
695,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,F,10116.0,,,,22226
696,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,F,10116.0,,,,22226
697,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,F,10116.0,,,,22226
698,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,F,10116.0,,,,22226
699,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,F,10116.0,,,,22226
700,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,F,10116.0,,,,22226
701,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,F,10116.0,,,,22226
702,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,F,10116.0,,,,22226
703,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,F,10116.0,,,,22226
704,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,F,10116.0,,,,22226
705,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,F,10116.0,,,,22226
706,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,F,10116.0,,,,22226
707,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,F,10116.0,,,,22226
708,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,F,10116.0,,,,22226
709,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,F,10116.0,,,,22226
710,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,F,10116.0,,,,22226
711,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,F,10116.0,,,,22226
712,1,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,BAO_0000218,,Rattus norvegicus,,Autocuration,12058,In vivo,F,10116.0,,,,22226
713,1,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,BAO_0000019,,,,Autocuration,11440,,B,,,,,105093
714,1,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,Hypothalamus,BAO_0000249,,,,Autocuration,6238,,B,,,,,11923
715,1,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,BAO_0000019,,,,Autocuration,10046,,B,,,,,10577
716,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,BAO_0000019,,,,Autocuration,10046,,B,,,,,10577
717,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,BAO_0000019,,,,Expert,10046,,B,,,,,10577
718,1,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,BAO_0000357,,,,Autocuration,167,,B,,,,,55
719,1,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,BAO_0000357,,,,Autocuration,167,,B,,,,,55
720,1,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,BAO_0000019,,,,Autocuration,11520,,F,,,,,12166
721,1,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,BAO_0000019,,,,Autocuration,11520,,F,,,,,12166
722,1,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,BAO_0000019,,,,Autocuration,11520,,F,,,,,12166
723,1,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,BAO_0000019,,,,Autocuration,11520,,F,,,,,12166
724,1,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,BAO_0000019,,Cavia porcellus,,Autocuration,135,,F,10141.0,,,,55
725,1,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,BAO_0000019,,Cavia porcellus,,Autocuration,135,,F,10141.0,,,,55
726,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,BAO_0000019,,Cavia porcellus,,Autocuration,11311,,B,10141.0,,,,55
727,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,BAO_0000357,,Cavia porcellus,,Autocuration,10193,,B,10141.0,,,,55
728,1,Inhibitory concentration against 5-lipoxygenase from human whole blood,,BAO_0000357,,Homo sapiens,,Expert,12281,,B,9606.0,,,,55
729,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,BAO_0000219,,,,Autocuration,11311,,B,,,,,55
730,1,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,BAO_0000218,,,,Autocuration,12576,,F,,,,,17087
731,1,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,BAO_0000357,,,,Autocuration,12281,,B,,,,,17087
732,1,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,BAO_0000218,,,,Autocuration,12576,,F,,,,,17087
733,1,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,BAO_0000019,,Sus scrofa,,Expert,11089,,B,9823.0,,,,55
734,1,In vitro inhibition of rat 5-Lipoxygenase,,BAO_0000357,,,,Expert,11006,,B,,,,,12166
735,1,Inhibitory activity against 5-Lipoxygenase,,BAO_0000357,,Rattus norvegicus,,Expert,11481,,B,10116.0,,,,12166
736,1,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,BAO_0000219,,,,Expert,10864,,B,,,RBL-1,,12166
737,1,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,BAO_0000219,,,,Autocuration,3595,,B,,,RBL-1,,12166
738,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,BAO_0000219,,,,Autocuration,11311,,B,,,RBL-1,,12166
739,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,BAO_0000019,,,,Autocuration,11311,,B,,,,,12166
740,1,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,BAO_0000219,,,,Autocuration,11311,,B,,,,,12166
741,1,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,BAO_0000357,,,,Autocuration,11006,,B,,,,,12166
742,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,BAO_0000219,,,,Autocuration,3595,,B,,,RBL-1,,12166
743,1,The compound was tested for inhibition of isolated 5-Lipoxygenase,,BAO_0000357,,,,Autocuration,11311,,B,,,,,12166
744,1,Ratio of IC50 against 5-LO and COX,,BAO_0000019,,Rattus norvegicus,,Autocuration,11481,,B,10116.0,,,,22226
745,1,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,BAO_0000357,,,,Autocuration,11006,,B,,,,,12166
746,1,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,BAO_0000357,,,,Autocuration,11006,,B,,,,,12166
747,1,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,BAO_0000219,,,,Autocuration,11311,,B,,,,,12166
748,1,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,BAO_0000019,,,,Autocuration,11006,,F,,,,,12166
749,1,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,Prostate gland,BAO_0000357,,,,Autocuration,4288,,B,,,,,120
750,1,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,BAO_0000019,,Columba livia,,Autocuration,7587,,B,8932.0,,,,22226
751,1,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,BAO_0000019,,Columba livia,,Autocuration,7587,,B,8932.0,,,,22226
752,1,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,BAO_0000019,,Columba livia,,Autocuration,7587,,B,8932.0,,,,22226
753,1,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,BAO_0000357,,,,Autocuration,11249,,B,,,,,10732
754,1,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,BAO_0000019,,Rattus norvegicus,,Expert,8003,,F,10116.0,,,,12198
755,1,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,BAO_0000019,,Rattus norvegicus,,Expert,8003,,F,10116.0,,,,12198
756,1,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,BAO_0000019,,Rattus norvegicus,,Expert,8003,,F,10116.0,,,,12198
757,1,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,Hippocampus,BAO_0000221,,,,Expert,12416,,B,,,,,10576
758,1,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,BAO_0000357,,,,Autocuration,16293,,B,,,,,51
759,1,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,13047,,B,9986.0,,,,22226
760,1,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,13047,,B,9986.0,,,,22226
761,1,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,13047,,B,9986.0,,,,22226
762,1,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,13047,,B,9986.0,,,,22226
763,1,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Hippocampus,BAO_0000221,,,,Autocuration,10085,,B,,,,,104744
764,1,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Hippocampus,BAO_0000221,,,,Autocuration,10085,,B,,,,,104744
765,1,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Hippocampus,BAO_0000221,,,,Autocuration,10085,,B,,,,,104744
766,1,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,BAO_0000249,,,,Autocuration,9841,,B,,,,Membranes,104744
767,1,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,BAO_0000249,,Rattus norvegicus,,Autocuration,8822,,B,10116.0,,,,104744
768,1,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,BAO_0000019,,Rattus norvegicus,,Autocuration,9806,,B,10116.0,,,,104744
769,1,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,BAO_0000019,,Rattus norvegicus,,Autocuration,9806,,B,10116.0,,,,104744
770,1,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,BAO_0000224,,,,Autocuration,8868,,B,,,,,104744
771,1,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,Hippocampus,BAO_0000221,,,,Autocuration,9036,,B,,,,,104744
772,1,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,11374,,B,,,,,104744
773,1,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,BAO_0000224,,,,Autocuration,10881,,B,,,,,104744
774,1,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,BAO_0000019,,,,Autocuration,8822,,B,,,,,104744
775,1,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,BAO_0000249,,Rattus norvegicus,,Autocuration,9806,,B,10116.0,,,,104744
776,1,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,BAO_0000019,,,,Autocuration,15463,,B,,,,,104744
777,1,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,BAO_0000019,,,,Autocuration,15463,,B,,,,,104744
778,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Brain,BAO_0000221,,,,Autocuration,14542,,B,,,,,104744
779,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Brain,BAO_0000221,,,,Autocuration,14542,,B,,,,,104744
780,1,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,BAO_0000019,,,,Autocuration,8569,,B,,,,,104744
781,1,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,BAO_0000224,,Rattus norvegicus,,Autocuration,10062,,B,10116.0,,,,104744
782,1,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,BAO_0000224,,,,Autocuration,4771,,B,,,,,104744
783,1,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,BAO_0000224,,,,Autocuration,10062,,B,,,,,104744
784,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,BAO_0000224,,,,Autocuration,10062,,B,,,,,104744
785,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,BAO_0000224,,,,Autocuration,10062,,B,,,,,104744
786,1,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,BAO_0000019,,,,Autocuration,15463,,B,,,,,104744
787,1,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,BAO_0000019,,,,Autocuration,15463,,B,,,,,104744
788,1,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,BAO_0000224,,,,Autocuration,9098,,B,,,,,104744
789,1,Affinity for 5-hydroxytryptamine 1 receptor,,BAO_0000019,,Rattus norvegicus,,Autocuration,3070,,B,10116.0,,,,22226
790,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,Brain,BAO_0000221,,,,Autocuration,14542,,B,,,,,104744
791,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Brain,BAO_0000221,,,,Autocuration,14542,,B,,,,,104744
792,1,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,BAO_0000224,,,,Autocuration,6398,,B,,,,,104744
793,1,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,Brain,BAO_0000221,,,,Autocuration,1344,,B,,,,,104744
794,1,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,BAO_0000019,,,,Autocuration,11963,,B,,,,,104744
795,1,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,BAO_0000019,,Rattus norvegicus,,Autocuration,8908,,B,10116.0,,,,22226
796,1,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,BAO_0000019,,,,Autocuration,9098,,B,,,,,104744
797,1,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,BAO_0000019,,Rattus norvegicus,,Autocuration,8841,,B,10116.0,,,,104744
798,1,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,BAO_0000019,,Rattus norvegicus,,Autocuration,8814,,B,10116.0,,,,22226
799,1,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,BAO_0000019,,,,Autocuration,11752,,B,,,,,104744
800,1,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,Brain,BAO_0000221,,,,Autocuration,11642,,B,,,,,104744
801,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,BAO_0000019,,,,Autocuration,11642,,B,,,,,104744
802,1,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,Brain,BAO_0000220,,,,Autocuration,9231,,B,,,,,104744
803,1,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,Brain,BAO_0000221,,,,Autocuration,11351,,B,,,,,104744
804,1,Compound was tested for binding affinity against 5-HT1 receptor,,BAO_0000019,,,,Autocuration,4639,,B,,,,,22226
805,1,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,BAO_0000019,,,,Autocuration,1205,,B,,,,,22226
806,1,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,BAO_0000357,,,,Expert,10025,,B,,,,,10576
807,1,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,BAO_0000249,,,,Autocuration,13241,,F,,,,,10576
808,1,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,BAO_0000218,,,,Autocuration,16245,In vivo,F,,,,,10576
809,1,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,BAO_0000218,,,,Autocuration,16245,In vivo,F,,,,,10576
810,1,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,BAO_0000019,,,,Autocuration,12438,,F,,,,,10576
811,1,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,BAO_0000218,,,,Autocuration,16245,In vivo,F,,,,,10576
812,1,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,BAO_0000218,,,,Autocuration,16245,In vivo,F,,,,,10576
813,1,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,BAO_0000019,,,,Autocuration,15740,,F,,,,,10576
814,1,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,BAO_0000219,,,,Autocuration,15535,,F,,,,,10576
815,1,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,BAO_0000219,,,,Expert,15535,,F,,,,,51
816,1,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,BAO_0000219,,,,Autocuration,15535,,F,,,,,10576
817,1,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,BAO_0000249,,,,Expert,9888,,B,,,,,10576
818,1,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,Hippocampus,BAO_0000221,,,,Autocuration,10085,,B,,,,,10576
819,1,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,Hippocampus,BAO_0000221,,,,Autocuration,10085,,B,,,,,10576
820,1,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,BAO_0000249,,,,Expert,17331,,B,,,,Membranes,10576
821,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,10845,,B,10116.0,,,,10576
822,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,10845,,B,10116.0,,,,10576
823,1,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,Hippocampus,BAO_0000221,,,,Expert,10845,,B,,,,,10576
824,1,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,10845,,B,10116.0,,,,10576
825,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,10845,,B,10116.0,,,,10576
826,1,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Expert,13730,,B,,,,,10576
827,1,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,BAO_0000249,,,,Expert,13508,,B,,,,,10576
828,1,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,Hippocampus,BAO_0000249,,,,Expert,13508,,B,,,,,10576
829,1,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,BAO_0000221,,,,Expert,12073,,B,,,,,10576
830,1,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,Hippocampus,BAO_0000221,,,,Autocuration,4671,,B,,,,,10576
831,1,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,Hippocampus,BAO_0000221,,,,Expert,13631,,B,,,,,10576
832,1,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,12438,,B,,,,,10576
833,1,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,BAO_0000019,,,,Autocuration,10483,,B,,,,,10576
834,1,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,Hippocampus,BAO_0000221,,,,Autocuration,10483,,B,,,,,10576
835,1,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,BAO_0000249,,,,Intermediate,12352,,B,,,,,10576
836,1,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,Hippocampus,BAO_0000249,,,,Autocuration,14732,,B,,,,,10576
837,1,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,BAO_0000019,,Rattus norvegicus,,Expert,11049,,B,10116.0,,,,10576
838,1,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,BAO_0000019,,Rattus norvegicus,,Expert,11049,,B,10116.0,,,,10576
839,1,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,BAO_0000249,,,,Expert,13657,,B,,,,,10576
840,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,BAO_0000019,,,,Autocuration,11473,,B,,,,,10576
841,1,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,BAO_0000249,,,,Autocuration,2014,,B,,,,,10576
842,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,BAO_0000221,,,,Expert,3086,,B,,,,,10576
843,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,BAO_0000019,,,,Expert,15854,,B,,,,,10576
844,1,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,Hippocampus,BAO_0000221,,,,Expert,10922,,B,,,,,10576
845,1,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,Hippocampus,BAO_0000221,,,,Expert,13346,,B,,,,,10576
846,1,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,BAO_0000357,,,,Expert,15311,,B,,,,,10576
847,1,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,Hippocampus,BAO_0000221,,,,Autocuration,10922,,B,,,,,10576
848,1,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,BAO_0000357,,,,Autocuration,10025,,B,,,,,10576
849,1,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,BAO_0000357,,,,Expert,10025,,B,,,,,10576
850,1,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,BAO_0000019,,,,Autocuration,9742,,B,,,,,10576
851,1,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,BAO_0000019,,,,Autocuration,9742,,F,,,,,10576
852,1,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,BAO_0000019,,,,Expert,12304,,B,,,,,10576
853,1,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,15789,,B,,,,,10576
854,1,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,BAO_0000019,,,,Autocuration,9912,,B,,,,,10576
855,1,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,BAO_0000019,,,,Autocuration,9912,,B,,,,,10576
856,1,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,BAO_0000019,,,,Autocuration,9912,,B,,,,,10576
857,1,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,BAO_0000019,,,,Expert,16693,,B,,,,,10576
858,1,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,BAO_0000357,,,,Expert,13276,,B,,,,,10576
859,1,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,Hippocampus,BAO_0000221,,,,Autocuration,12678,,B,,,,,10576
860,1,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,BAO_0000357,,,,Autocuration,11825,,B,,,,,10576
861,1,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,BAO_0000357,,,,Expert,12443,,B,,,,,10576
862,1,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Expert,13830,,B,,,,,10576
863,1,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,Hippocampus,BAO_0000249,,,,Expert,14286,,B,,,,,10576
864,1,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,14356,,B,10116.0,,,,10576
865,1,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,15306,,B,,,,,10576
866,1,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,BAO_0000357,,,,Expert,15306,,B,,,,,10576
867,1,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,BAO_0000249,,Rattus norvegicus,,Expert,16616,,F,10116.0,,,,10576
868,1,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",Hippocampus,BAO_0000221,,,,Autocuration,3651,,B,,,,,10576
869,1,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,14331,,F,,,,,10576
870,1,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,14331,,F,,,,,10576
871,1,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Rattus norvegicus,,Expert,14178,,B,10116.0,,,,10576
872,1,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,BAO_0000019,,Rattus norvegicus,,Expert,10639,,B,10116.0,,,,10576
873,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus,BAO_0000221,,,,Autocuration,12306,,B,,,,,10576
874,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,BAO_0000357,,Rattus norvegicus,,Expert,1348,,B,10116.0,,,,10576
875,1,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,13605,,B,,,,,10576
876,1,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,BAO_0000219,,,,Autocuration,17624,,B,,,CHO,,51
877,1,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,BAO_0000219,,,,Autocuration,17624,,F,,,CHO,,51
878,1,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,BAO_0000219,,,,Autocuration,17624,,F,,,CHO,,51
879,1,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,15267,,B,,,,,51
880,1,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,BAO_0000357,,,,Autocuration,16532,,B,,,,,51
881,1,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,BAO_0000019,,,,Autocuration,6563,,F,,,,,51
882,1,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,BAO_0000219,,,,Autocuration,4751,,B,,,CHO,,51
883,1,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,15463,,B,,,,,51
884,1,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,BAO_0000357,,,,Autocuration,3805,,B,,,,,51
885,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,5640,,B,,,,,51
886,1,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,BAO_0000357,,,,Autocuration,6563,,B,,,,,51
887,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,BAO_0000357,,,,Autocuration,5548,,B,,,,,51
888,1,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,6347,,B,,,,,51
889,1,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,BAO_0000219,,,,Autocuration,17296,,F,,,HEK293,,51
890,1,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,BAO_0000019,,,,Autocuration,13047,,B,,,,,51
891,1,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,BAO_0000357,,,,Autocuration,15740,,B,,,,,51
892,1,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,BAO_0000019,,,,Expert,5640,,F,,,,,51
893,1,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,BAO_0000019,,,,Autocuration,5640,,F,,,,,51
894,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,BAO_0000219,,,,Expert,17211,,B,,,HeLa,,51
895,1,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,BAO_0000219,,,,Autocuration,4751,,B,,,CHO,,51
896,1,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,BAO_0000357,,Homo sapiens,,Expert,6491,,B,9606.0,,,,51
897,1,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,BAO_0000357,,,,Autocuration,4707,,B,,,,,51
898,1,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Homo sapiens,,Expert,13910,,B,9606.0,,,,51
899,1,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,BAO_0000219,,,,Autocuration,16190,,B,,,HeLa,,51
900,1,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,16633,,B,,,,,51
901,1,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,BAO_0000219,,,,Autocuration,11898,,B,,,CHO,,51
902,1,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,BAO_0000219,,,,Autocuration,11898,,B,,,CHO,,51
903,1,Binding affinity against human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,14331,,B,,,,,51
904,1,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,BAO_0000219,,,,Expert,17624,,B,,,CHO,,51
905,1,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,BAO_0000219,,,,Autocuration,17624,,B,,,CHO,,51
906,1,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,3307,,B,,,,,51
907,1,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,BAO_0000219,,Homo sapiens,,Expert,6563,,B,9606.0,,CHO,,51
908,1,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,BAO_0000019,,,,Autocuration,14165,,B,,,,,51
909,1,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,,,,Autocuration,5732,,B,,,,,51
910,1,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,BAO_0000357,,,,Expert,13366,,B,,,,,51
911,1,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,17626,,B,,,,,51
912,1,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,BAO_0000219,,,,Expert,6588,,B,,,HeLa,,51
913,1,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,BAO_0000357,,,,Autocuration,16209,,B,,,,,51
914,1,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,15463,,B,,,,,51
915,1,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,15463,,B,,,,,51
916,1,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,BAO_0000357,,,,Autocuration,14770,,B,,,,,51
917,1,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,BAO_0000219,,,,Autocuration,16245,,B,,,Cell line,,51
918,1,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,BAO_0000019,,,,Autocuration,16245,,B,,,,,51
919,1,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,5548,,B,,,,,51
920,1,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Expert,5548,,B,,,,,51
921,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,5548,,B,,,,,51
922,1,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,BAO_0000357,,,,Expert,6876,,B,,,,,51
923,1,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,2598,,B,,,,,51
924,1,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,BAO_0000357,,,,Expert,17785,,B,,,,,51
925,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,6013,,B,,,,,51
926,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Expert,5929,,B,,,,,51
927,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,16633,,B,,,,,51
928,1,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,,,,Autocuration,1558,,B,,,,,51
929,1,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Expert,16026,,B,,,,,51
930,1,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,BAO_0000219,,,,Autocuration,12469,,B,,,,,51
931,1,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,BAO_0000357,,Homo sapiens,,Expert,15874,,B,9606.0,,,,51
932,1,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,BAO_0000357,,,,Autocuration,15874,,B,,,,,51
933,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,3935,,B,,,,,51
934,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,15818,,B,,,,,51
935,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,BAO_0000219,,,,Autocuration,13706,,B,,,CHO-K1,,51
936,1,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,BAO_0000219,,,,Expert,13729,,F,,,CHO-K1,,51
937,1,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,BAO_0000019,,,,Autocuration,15413,,B,,,,,51
938,1,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,BAO_0000019,,,,Autocuration,15413,,B,,,,,51
939,1,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,BAO_0000019,,,,Autocuration,15413,,B,,,,,51
940,1,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,BAO_0000019,,,,Autocuration,15413,,B,,,,,51
941,1,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,BAO_0000219,,Homo sapiens,,Expert,3445,,B,9606.0,,HeLa,,51
942,1,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,15740,,B,,,,,51
943,1,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,BAO_0000357,,,,Autocuration,15740,,B,,,,,51
944,1,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,17626,,B,,,,,51
945,1,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Homo sapiens,,Expert,4234,,B,9606.0,,,,51
946,1,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,BAO_0000357,,,,Expert,5640,,B,,,,,51
947,1,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,BAO_0000357,,Rattus norvegicus,,Expert,5272,,B,10116.0,,,,51
948,1,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,BAO_0000219,,,,Autocuration,4622,,B,,,CHO,,51
949,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,BAO_0000019,,,,Expert,17085,,B,,,,,51
950,1,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,BAO_0000357,,,,Autocuration,3025,,B,,,,,51
951,1,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Expert,15315,,B,,,,,51
952,1,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,BAO_0000357,,,,Autocuration,15267,,B,,,,,51
953,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,BAO_0000219,,,,Autocuration,17158,,B,,,HeLa,,51
954,1,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,BAO_0000219,,Homo sapiens,,Expert,14214,,B,9606.0,,HeLa,,51
955,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,17133,,B,,,,,51
956,1,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,BAO_0000357,,,,Autocuration,16532,,B,,,,,51
957,1,Affinity for 5-hydroxytryptamine 1A receptor subtype,,BAO_0000357,,Homo sapiens,,Expert,2391,,B,9606.0,,,,51
958,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,BAO_0000019,,,,Autocuration,14447,,B,,,,,51
959,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,BAO_0000019,,,,Autocuration,14447,,B,,,,,51
960,1,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,BAO_0000357,,,,Autocuration,15086,,B,,,,,51
961,1,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Homo sapiens,,Expert,13051,,B,9606.0,,,,51
962,1,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,BAO_0000019,,,,Autocuration,16026,,F,,,,,51
963,1,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,BAO_0000019,,,,Expert,17085,,B,,,,,51
964,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,17133,,B,,,,,51
965,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,BAO_0000357,,,,Autocuration,17133,,B,,,,,51
966,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,BAO_0000219,,,,Autocuration,17211,,B,,,HeLa,,51
967,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,BAO_0000219,,,,Autocuration,17211,,B,,,HeLa,,51
968,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,BAO_0000219,,,,Autocuration,17211,,B,,,HeLa,,51
969,1,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,BAO_0000219,,,,Autocuration,17211,,B,,,HeLa,,51
970,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,BAO_0000019,,,,Autocuration,16394,,F,,,,,51
971,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,BAO_0000019,,,,Autocuration,16394,,F,,,,,51
972,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,BAO_0000019,,,,Autocuration,16394,,F,,,,,51
973,1,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,BAO_0000218,,,,Autocuration,16394,In vivo,F,,,,,51
974,1,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,BAO_0000019,,,,Autocuration,16394,,B,,,,,51
975,1,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,BAO_0000019,,,,Autocuration,15740,,F,,,,,51
976,1,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,BAO_0000019,,,,Autocuration,15740,,F,,,,,51
977,1,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,15740,,B,,,,,51
978,1,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,BAO_0000219,,,,Autocuration,17296,,F,,,HEK293,,51
979,1,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,BAO_0000019,,,,Expert,5640,,F,,,,,51
980,1,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,BAO_0000019,,,,Autocuration,5640,,F,,,,,51
981,1,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,BAO_0000019,,,,Autocuration,5640,,F,,,,,51
982,1,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,BAO_0000019,,,,Autocuration,5640,,F,,,,,51
983,1,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,BAO_0000219,,,,Autocuration,2759,,F,,,CHO,,51
984,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,BAO_0000019,,,,Autocuration,16394,,F,,,,,51
985,1,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,BAO_0000019,,Homo sapiens,,Expert,16394,,F,9606.0,,,,51
986,1,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,BAO_0000019,,Homo sapiens,,Expert,3445,,F,9606.0,,,,51
987,1,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,BAO_0000219,,,,Expert,4316,,B,,,CHO,,51
988,1,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,BAO_0000019,,,,Expert,4316,,B,,,,,51
989,1,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,BAO_0000019,,Homo sapiens,,Expert,15180,,F,9606.0,,,,51
990,1,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,BAO_0000019,,Homo sapiens,,Expert,15180,,F,9606.0,,,,51
991,1,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,,,,Autocuration,15042,,F,,,,,51
992,1,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,,,,Autocuration,15042,,F,,,,,51
993,1,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000019,,,,Autocuration,15042,,F,,,,,51
994,1,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,,,,Autocuration,15042,,F,,,,,51
995,1,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,,,,Autocuration,15042,,F,,,,,51
996,1,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,BAO_0000019,,,,Autocuration,15042,,F,,,,,51
997,1,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000019,,,,Autocuration,15042,,F,,,,,51
998,1,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,BAO_0000219,,Homo sapiens,,Expert,15180,,F,9606.0,,HeLa,,51
999,1,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,BAO_0000219,,Homo sapiens,,Expert,15180,,F,9606.0,,HeLa,,51
1000,1,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,BAO_0000219,,Homo sapiens,,Expert,15180,,F,9606.0,,HeLa,,51
1001,1,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,BAO_0000019,,,,Autocuration,16245,,F,,,,,51
1002,1,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,BAO_0000019,,,,Autocuration,16026,,F,,,,,51
1003,1,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,BAO_0000219,,,,Autocuration,17296,,F,,,HEK293,,51
1004,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,BAO_0000219,,,,Autocuration,2759,,F,,,CHO,,51
1005,1,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,BAO_0000219,,,,Autocuration,2759,,F,,,CHO,,51
1006,1,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,BAO_0000219,,Homo sapiens,,Expert,2759,,F,9606.0,,CHO,,51
1007,1,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,BAO_0000219,,,,Autocuration,2759,,F,,,CHO,,51
1008,1,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,BAO_0000219,,,,Expert,15419,,F,,,,,51
1009,1,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,BAO_0000219,,,,Autocuration,15419,,F,,,,,51
1010,1,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,BAO_0000019,,,,Autocuration,16026,,F,,,,,51
1011,1,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,BAO_0000219,,,,Expert,1414,In vitro,B,,,,,51
1012,1,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,BAO_0000219,,,,Expert,1414,In vitro,B,,,,,51
1013,1,Binding activity radioligand.,,BAO_0000357,,,,Autocuration,12861,,B,,,,,51
1014,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,BAO_0000019,,,,Autocuration,12861,,B,,,,,51
1015,1,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,5104,,B,,,,,51
1016,1,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,5105,,B,,,,,51
1017,1,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,16312,,B,,,,,51
1018,1,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Homo sapiens,,Expert,15180,,B,9606.0,,,,51
1019,1,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,5033,,B,,,,,51
1020,1,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,BAO_0000219,,Homo sapiens,,Expert,16909,,B,9606.0,,CHO,,51
1021,1,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000019,,,,Autocuration,2590,,F,,,,,51
1022,1,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,BAO_0000019,,,,Autocuration,2590,,F,,,,,51
1023,1,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,BAO_0000019,,,,Expert,16394,,B,,,,,51
1024,1,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,BAO_0000219,,Homo sapiens,,Expert,4540,,B,9606.0,,HEK293,,51
1025,1,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,BAO_0000219,,,,Autocuration,17296,,B,,,HEK293,,51
1026,1,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,BAO_0000219,,,,Autocuration,17296,,B,,,HEK293,,51
1027,1,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,BAO_0000219,,,,Autocuration,15779,,B,,,HEK293,,51
1028,1,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,BAO_0000219,,,,Autocuration,15779,,B,,,HEK293,,51
1029,1,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,BAO_0000219,,,,Autocuration,15779,,B,,,HEK293,,51
1030,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,6166,,B,,,,,51
1031,1,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,BAO_0000219,,,,Autocuration,15779,,B,,,HEK293,,51
1032,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,BAO_0000219,,,,Autocuration,4199,,B,,,HEK293,,51
1033,1,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,BAO_0000219,,,,Autocuration,15316,,B,,,,,51
1034,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,14875,,B,,,,,51
1035,1,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,BAO_0000219,,,,Expert,14727,,B,,,HeLa,,51
1036,1,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,BAO_0000019,,,,Expert,14727,,B,,,,,51
1037,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,BAO_0000219,,,,Autocuration,15146,,B,,,HEK293,,51
1038,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,BAO_0000219,,,,Autocuration,5213,,B,,,HEK293,,51
1039,1,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,BAO_0000219,,,,Autocuration,16429,,B,,,,,51
1040,1,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,BAO_0000219,,Homo sapiens,,Expert,15042,,B,9606.0,,HeLa,,51
1041,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,BAO_0000219,,,,Autocuration,14818,,B,,,HEK293,,51
1042,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,BAO_0000219,,,,Autocuration,4829,,B,,,HEK293,,51
1043,1,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Expert,17200,,B,,,,,51
1044,1,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Homo sapiens,,Autocuration,13051,,B,9606.0,,,,51
1045,1,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,BAO_0000357,,,,Autocuration,5486,,B,,,,,106
1046,1,Binding affinity against 5-HT1D receptor,,BAO_0000357,,,,Autocuration,5254,,B,,,,,105
1047,1,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,5254,,B,,,,,105
1048,1,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,BAO_0000357,,,,Autocuration,15331,,B,,,,,107
1049,1,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,BAO_0000357,,Homo sapiens,,Autocuration,13506,,B,9606.0,,,,10576
1050,1,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,15267,,B,,,,,51
1051,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,BAO_0000218,,,,Autocuration,16616,In vivo,F,,,,,11863
1052,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,BAO_0000218,,,,Autocuration,16616,In vivo,F,,,,,11863
1053,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,BAO_0000218,,,,Autocuration,16616,In vivo,F,,,,,11863
1054,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,BAO_0000218,,Mus musculus,,Expert,16616,,F,10090.0,,,,11863
1055,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,BAO_0000218,,Mus musculus,,Expert,16616,,F,10090.0,,,,11863
1056,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,BAO_0000218,,Mus musculus,,Expert,16616,,F,10090.0,,,,11863
1057,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,BAO_0000218,,Mus musculus,,Expert,16616,,F,10090.0,,,,11863
1058,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,BAO_0000218,,Mus musculus,,Expert,16616,,F,10090.0,,,,11863
1059,1,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,BAO_0000218,,Mus musculus,,Expert,16616,,F,10090.0,,,,11863
1060,1,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,10297,,B,,,,,11863
1061,1,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,BAO_0000357,,,,Expert,13704,,B,,,,,11863
1062,1,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Hippocampus,BAO_0000221,,Mus musculus,,Expert,10297,,B,10090.0,,,,11863
1063,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,Hippocampus,BAO_0000221,,,,Autocuration,10297,,B,,,,,11863
1064,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Hippocampus,BAO_0000221,,Mus musculus,,Expert,10297,,B,10090.0,,,,11863
1065,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,Hippocampus,BAO_0000221,,,,Autocuration,10297,,B,,,,,11863
1066,1,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,BAO_0000357,,,,Autocuration,217,,B,,,,,11863
1067,1,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,Hippocampus,BAO_0000221,,Mus musculus,,Expert,10297,,B,10090.0,,,,11863
1068,1,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Sus scrofa,,Autocuration,4921,,B,9823.0,,,,51
1069,1,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,BAO_0000357,,Sus scrofa,,Autocuration,4921,,B,9823.0,,,,51
1070,1,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,BAO_0000019,,Sus scrofa,,Autocuration,4996,,B,9823.0,,,,51
1071,1,Compound was evaluated for the binding affinity at 5- HT1A receptor,,BAO_0000357,,Sus scrofa,,Autocuration,12918,,B,9823.0,,,,51
1072,1,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,BAO_0000019,,Sus scrofa,,Autocuration,5333,,B,9823.0,,,,51
1073,1,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,BAO_0000019,,Sus scrofa,,Autocuration,4437,,B,9823.0,,,,51
1074,1,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,BAO_0000019,,Sus scrofa,,Autocuration,1742,,B,9823.0,,,,51
1075,1,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Sus scrofa,,Expert,16688,,B,9823.0,,,,51
1076,1,Binding activity radioligand.,,BAO_0000357,,Sus scrofa,,Autocuration,12861,,B,9823.0,,,,51
1077,1,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,BAO_0000019,,Sus scrofa,,Expert,12861,,B,9823.0,,,,51
1078,1,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,BAO_0000019,,Sus scrofa,,Autocuration,12861,,B,9823.0,,,,51
1079,1,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,BAO_0000019,,,,Expert,12490,,B,,,,,10624
1080,1,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,BAO_0000019,,Sus scrofa,,Expert,11828,,B,9823.0,,,,51
1081,1,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,Hippocampus,BAO_0000221,,Sus scrofa,,Autocuration,11866,,B,9823.0,,,,51
1082,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,BAO_0000249,,Sus scrofa,,Autocuration,12827,,B,9823.0,,,,51
1083,1,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,BAO_0000019,,Sus scrofa,,Autocuration,12918,,B,9823.0,,,,51
1084,1,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,BAO_0000019,,Sus scrofa,,Expert,12919,,F,9823.0,,,,51
1085,1,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,13047,,B,9986.0,,,,51
1086,1,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,BAO_0000249,,Rattus norvegicus,,Expert,15796,,B,10116.0,,,,10576
1087,1,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,3651,,B,10116.0,,,,10576
1088,1,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,BAO_0000357,,,,Autocuration,188,,B,,,,,10576
1089,1,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,BAO_0000249,,Rattus norvegicus,,Expert,16616,,F,10116.0,,,Membranes,10576
1090,1,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Hippocampus,BAO_0000249,,Rattus norvegicus,,Expert,16616,,F,10116.0,,,Membranes,10576
1091,1,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus,BAO_0000221,,,,Autocuration,12306,,B,,,,,10576
1092,1,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,17167,,B,10116.0,,,,10576
1093,1,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,BAO_0000019,,,,Autocuration,14776,,B,,,,,10576
1094,1,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,BAO_0000357,,,,Expert,12158,,B,,,,,10576
1095,1,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,BAO_0000357,,,,Autocuration,13481,,B,,,,,10576
1096,1,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,BAO_0000219,,,,Autocuration,13427,In vitro,B,,,,,10576
1097,1,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,BAO_0000357,,,,Autocuration,10210,,B,,,,,10576
1098,1,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,BAO_0000249,,,,Autocuration,10205,,B,,,,Membranes,10576
1099,1,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,BAO_0000249,,,,Autocuration,10205,,B,,,,Membranes,10576
1100,1,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,BAO_0000249,,,,Expert,10205,,B,,,,Membranes,10576
1101,1,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,BAO_0000357,,Rattus norvegicus,,Expert,12280,,B,10116.0,,,,10576
1102,1,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Expert,17386,,B,,,,,10576
1103,1,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,BAO_0000357,,,,Expert,13654,,B,,,,,10576
1104,1,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,Hippocampus,BAO_0000221,,,,Autocuration,14423,,B,,,,,10576
1105,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,Hippocampus,BAO_0000221,,,,Autocuration,15412,,B,,,,,10576
1106,1,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,12073,,B,,,,,10576
1107,1,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Rattus norvegicus,,Expert,4101,,B,10116.0,,,,10576
1108,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,10062,,B,,,,,10576
1109,1,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,BAO_0000249,,,,Autocuration,6238,,B,,,,,10576
1110,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,16273,,B,,,,,10576
1111,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,BAO_0000357,,,,Autocuration,11139,,B,,,,,10576
1112,1,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,BAO_0000019,,,,Expert,16796,,B,,,,,10576
1113,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Brain,BAO_0000221,,Rattus norvegicus,,Expert,9548,,B,10116.0,,,,10576
1114,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Brain,BAO_0000221,,,,Autocuration,10381,,B,,,,,10576
1115,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,BAO_0000249,,,,Autocuration,13408,,B,,,,,10576
1116,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,13825,,B,10116.0,,,,10576
1117,1,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,Hippocampus,BAO_0000221,,,,Expert,11147,,B,,,,,10576
1118,1,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,BAO_0000249,,,,Autocuration,10552,,B,,,,,10576
1119,1,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Striatum,BAO_0000249,,,,Autocuration,10552,,B,,,,,10576
1120,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,BAO_0000249,,Rattus norvegicus,,Expert,17136,,B,10116.0,,,Membranes,10576
1121,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,BAO_0000249,,Rattus norvegicus,,Expert,5778,,B,10116.0,,,Membranes,10576
1122,1,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Hippocampus,BAO_0000221,,,,Autocuration,13481,,B,,,,,10576
1123,1,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,Hippocampus,BAO_0000221,,,,Autocuration,13481,,B,,,,,10576
1124,1,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,Hippocampus,BAO_0000221,,,,Intermediate,13630,,B,,,,,10576
1125,1,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,BAO_0000249,,,,Expert,16245,,B,,,,,10576
1126,1,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,Hippocampus,BAO_0000221,,,,Autocuration,14509,,B,,,,,10576
1127,1,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,Hippocampus,BAO_0000221,,,,Expert,14509,,B,,,,,10576
1128,1,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,Hippocampus,BAO_0000221,,,,Autocuration,14509,,B,,,,,10576
1129,1,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,Hippocampus,BAO_0000221,,,,Autocuration,14509,,B,,,,,10576
1130,1,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,BAO_0000019,,,,Expert,14256,,B,,,,,10576
1131,1,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,11139,,B,,,,,10576
1132,1,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,BAO_0000019,,Rattus norvegicus,,Expert,11047,,B,10116.0,,,,10576
1133,1,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,BAO_0000019,,Rattus norvegicus,,Expert,11047,,B,10116.0,,,,10576
1134,1,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,BAO_0000019,,Rattus norvegicus,,Expert,11047,,B,10116.0,,,,10576
1135,1,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,BAO_0000219,,Rattus norvegicus,,Expert,2395,,B,10116.0,,CHO-K1,,10576
1136,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,9699,,B,,,,,10576
1137,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,12028,,B,10116.0,,,,10576
1138,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,Hippocampus,BAO_0000221,,,,Autocuration,12028,,B,,,,,10576
1139,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,BAO_0000019,,,,Autocuration,5815,,B,,,,,10576
1140,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,BAO_0000019,,,,Expert,16616,,B,,,,,10576
1141,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,BAO_0000019,,,,Autocuration,5815,,B,,,,,10576
1142,1,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",Hippocampus,BAO_0000221,,,,Autocuration,2761,,B,,,,,10576
1143,1,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,BAO_0000357,,,,Expert,13133,,B,,,,,10576
1144,1,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,BAO_0000019,,,,Autocuration,10444,,B,,,,,10576
1145,1,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,BAO_0000357,,Rattus norvegicus,,Expert,13278,,B,10116.0,,,,10576
1146,1,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,BAO_0000357,,,,Autocuration,15874,,B,,,,,10576
1147,1,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Striatum,BAO_0000249,,,,Autocuration,10552,,B,,,,Membranes,10576
1148,1,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,BAO_0000357,,,,Autocuration,11130,,B,,,,,10576
1149,1,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,BAO_0000218,,,,Autocuration,11130,In vivo,B,,,,,10576
1150,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,Brain,BAO_0000221,,,,Autocuration,14542,,B,,,,,10576
1151,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Rattus norvegicus,,Expert,13670,,B,10116.0,,,,10576
1152,1,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,BAO_0000249,,,,Expert,9888,,B,,,,,10576
1153,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,BAO_0000249,,Rattus norvegicus,,Expert,3678,,B,10116.0,,,Membranes,10576
1154,1,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,Hippocampus,BAO_0000221,,,,Autocuration,11332,,B,,,,,10576
1155,1,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,Hippocampus,BAO_0000221,,,,Autocuration,11332,,B,,,,,10576
1156,1,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Expert,1185,,B,,,,,10576
1157,1,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,BAO_0000249,,,,Expert,2014,,B,,,,,10576
1158,1,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,1185,,B,,,,,10576
1159,1,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,BAO_0000019,,,,Expert,14429,,B,,,,,10576
1160,1,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,BAO_0000019,,,,Expert,16288,,B,,,,,10576
1161,1,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,BAO_0000019,,Rattus norvegicus,,Expert,5432,,B,10116.0,,,,10576
1162,1,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,BAO_0000019,,,,Autocuration,14429,,B,,,,,10576
1163,1,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,BAO_0000357,,,,Expert,13672,,B,,,,,10576
1164,1,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Hippocampus,BAO_0000221,,,,Expert,11296,,B,,,,,10576
1165,1,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,BAO_0000357,,,,Autocuration,11296,,B,,,,,10576
1166,1,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,BAO_0000219,,,,Expert,14749,,B,,,CHO,,10576
1167,1,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,BAO_0000019,,,,Expert,15086,,B,,,,,10576
1168,1,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,Hippocampus,BAO_0000221,,,,Autocuration,13462,,B,,,,,10576
1169,1,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,BAO_0000019,,,,Autocuration,15363,,B,,,,,10576
1170,1,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,BAO_0000019,,,,Autocuration,15363,,B,,,,,10576
1171,1,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,10796,,B,,,,,10576
1172,1,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,Brain,BAO_0000221,,,,Expert,12816,,B,,,,,10576
1173,1,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus,BAO_0000221,,,,Expert,13542,,B,,,,,10576
1174,1,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,BAO_0000019,,,,Expert,13308,,B,,,,,10576
1175,1,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,Hippocampus,BAO_0000221,,,,Expert,13541,,B,,,,,10576
1176,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,Hippocampus,BAO_0000221,,,,Autocuration,10058,,B,,,,,10576
1177,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,10058,,B,,,,,10576
1178,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,Hippocampus,BAO_0000221,,,,Autocuration,10058,,B,,,,,10576
1179,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,Hippocampus,BAO_0000221,,,,Autocuration,10058,,B,,,,,10576
1180,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,Hippocampus,BAO_0000221,,,,Autocuration,10058,,B,,,,,10576
1181,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,Hippocampus,BAO_0000221,,,,Autocuration,10058,,B,,,,,10576
1182,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,Hippocampus,BAO_0000221,,,,Autocuration,10058,,B,,,,,10576
1183,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,Hippocampus,BAO_0000221,,,,Autocuration,10058,,B,,,,,10576
1184,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,Hippocampus,BAO_0000221,,,,Autocuration,10058,,B,,,,,10576
1185,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,Hippocampus,BAO_0000221,,,,Autocuration,10058,,B,,,,,10576
1186,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,Hippocampus,BAO_0000221,,,,Autocuration,10058,,B,,,,,10576
1187,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,Hippocampus,BAO_0000221,,,,Autocuration,10058,,B,,,,,10576
1188,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,Hippocampus,BAO_0000221,,,,Autocuration,10058,,B,,,,,10576
1189,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,10058,,B,10116.0,,,,10576
1190,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,Hippocampus,BAO_0000221,,,,Autocuration,10058,,B,,,,,10576
1191,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,Hippocampus,BAO_0000221,,,,Autocuration,10058,,B,,,,,10576
1192,1,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,BAO_0000019,,,,Expert,12879,,B,,,,,10576
1193,1,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,BAO_0000019,,,,Expert,11964,,B,,,,,10576
1194,1,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,BAO_0000019,,,,Autocuration,11964,,B,,,,,10576
1195,1,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,BAO_0000019,,,,Autocuration,11964,,B,,,,,10576
1196,1,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Brain,BAO_0000221,,,,Expert,9548,,B,,,,,10576
1197,1,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,BAO_0000019,,,,Expert,9098,,B,,,,,10576
1198,1,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,BAO_0000019,,,,Autocuration,9098,,B,,,,,10576
1199,1,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,BAO_0000019,,,,Autocuration,9098,,B,,,,,10576
1200,1,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,BAO_0000219,,,,Expert,13248,,B,,,CHO,,10576
1201,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,BAO_0000249,,,,Expert,3147,,B,,,,,10576
1202,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,BAO_0000019,,,,Expert,13949,,B,,,,,10576
1203,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,BAO_0000218,,,,Autocuration,11883,,B,,,CHO,,10576
1204,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,BAO_0000218,,,,Autocuration,11883,,B,,,,,10576
1205,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,BAO_0000357,,Rattus norvegicus,,Expert,11883,,B,10116.0,,,,10576
1206,1,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,BAO_0000249,,,,Expert,15535,,B,,,,Membranes,10576
1207,1,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,BAO_0000249,,,,Autocuration,15535,,B,,,,,10576
1208,1,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,BAO_0000249,,,,Autocuration,15535,,B,,,,,10576
1209,1,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,BAO_0000219,,Homo sapiens,,Expert,16372,,B,9606.0,,CHO,,51
1210,1,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,BAO_0000249,,,,Expert,14608,,B,,,,,10576
1211,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,4795,,B,10116.0,,,,10576
1212,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,13863,,B,,,,,10576
1213,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,BAO_0000357,,,,Autocuration,13863,,B,,,,,10576
1214,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,BAO_0000357,,,,Autocuration,13863,,B,,,,,10576
1215,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,BAO_0000357,,,,Autocuration,13863,,B,,,,,10576
1216,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,BAO_0000357,,,,Autocuration,13863,,B,,,,,10576
1217,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,BAO_0000357,,,,Autocuration,13863,,B,,,,,10576
1218,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,BAO_0000357,,,,Autocuration,13863,,B,,,,,10576
1219,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,BAO_0000357,,,,Autocuration,13863,,B,,,,,10576
1220,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,BAO_0000357,,,,Autocuration,13863,,B,,,,,10576
1221,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,BAO_0000357,,,,Autocuration,13863,,B,,,,,10576
1222,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,BAO_0000357,,,,Autocuration,13863,,B,,,,,10576
1223,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,BAO_0000357,,,,Autocuration,13863,,B,,,,,10576
1224,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,BAO_0000357,,,,Autocuration,13863,,B,,,,,10576
1225,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,BAO_0000357,,,,Autocuration,13863,,B,,,,,10576
1226,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,BAO_0000357,,,,Autocuration,13863,,B,,,,,10576
1227,1,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,BAO_0000019,,,,Autocuration,9742,,B,,,,,10576
1228,1,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,12073,,B,,,,,10576
1229,1,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,BAO_0000357,,,,Autocuration,4101,,B,,,,,10576
1230,1,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,BAO_0000019,,,,Autocuration,15360,,B,,,,,10576
1231,1,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus,BAO_0000221,,,,Autocuration,11576,,B,,,,,10576
1232,1,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,BAO_0000019,,,,Expert,5834,,B,,,,,10576
1233,1,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,BAO_0000219,,Rattus norvegicus,,Expert,2395,,B,10116.0,,CHO-K1,,10576
1234,1,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,BAO_0000019,,,,Autocuration,1375,,B,,,,,10576
1235,1,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,BAO_0000019,,,,Autocuration,1375,,B,,,,,10576
1236,1,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,BAO_0000357,,,,Autocuration,3967,,B,,,,,10576
1237,1,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,BAO_0000357,,,,Expert,12884,,B,,,,,10576
1238,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,BAO_0000357,,,,Expert,2343,,B,,,,,10576
1239,1,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,BAO_0000019,,,,Autocuration,11511,,B,,,,,10576
1240,1,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,BAO_0000019,,Rattus norvegicus,,Expert,11511,,B,10116.0,,,,10576
1241,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,BAO_0000218,,,,Autocuration,16394,In vivo,F,,,,,10576
1242,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,BAO_0000218,,,,Autocuration,16394,In vivo,F,,,,,10576
1243,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,BAO_0000218,,,,Autocuration,16394,In vivo,F,,,,,10576
1244,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,BAO_0000218,,,,Autocuration,16394,In vivo,F,,,,,10576
1245,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,BAO_0000218,,,,Autocuration,16394,In vivo,F,,,,,10576
1246,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,BAO_0000218,,,,Autocuration,16394,In vivo,F,,,,,10576
1247,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,BAO_0000218,,,,Autocuration,16394,In vivo,F,,,,,10576
1248,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,BAO_0000218,,,,Autocuration,16394,In vivo,F,,,,,10576
1249,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,BAO_0000218,,,,Autocuration,16394,In vivo,F,,,,,10576
1250,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,BAO_0000218,,,,Autocuration,16394,In vivo,F,,,,,10576
1251,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,BAO_0000218,,,,Autocuration,16394,In vivo,F,,,,,10576
1252,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,BAO_0000218,,,,Autocuration,16394,In vivo,F,,,,,10576
1253,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,BAO_0000218,,,,Autocuration,16394,In vivo,F,,,,,10576
1254,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,BAO_0000218,,,,Autocuration,16394,In vivo,F,,,,,10576
1255,1,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,BAO_0000218,,,,Autocuration,16394,In vivo,F,,,,,10576
1256,1,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,BAO_0000249,,Rattus norvegicus,,Expert,16616,,F,10116.0,,,Membranes,10576
1257,1,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,BAO_0000019,,,,Autocuration,16796,,B,,,,,10576
1258,1,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,BAO_0000019,,,,Autocuration,16796,,B,,,,,10576
1259,1,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,BAO_0000357,,,,Autocuration,15629,,B,,,,,10576
1260,1,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,BAO_0000249,,,,Autocuration,13241,,F,,,,,10576
1261,1,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,BAO_0000221,,,,Expert,12073,,B,,,,,10576
1262,1,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,Hippocampus,BAO_0000249,,,,Autocuration,14286,,B,,,,,10576
1263,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,Brain,BAO_0000221,,,,Autocuration,14542,,B,,,,,10576
1264,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,F,,,,,10576
1265,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,F,,,,,10576
1266,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,F,,,,,10576
1267,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,BAO_0000019,,,,Autocuration,13630,,F,,,,,10576
1268,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,BAO_0000019,,,,Expert,13630,,F,,,,,10576
1269,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,F,,,,,10576
1270,1,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,BAO_0000019,,Rattus norvegicus,,Expert,13630,,F,10116.0,,,,10576
1271,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,F,,,,,10576
1272,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,BAO_0000019,,,,Expert,13630,,F,,,,,10576
1273,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,F,,,,,10576
1274,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,BAO_0000019,,,,Expert,13630,,F,,,,,10576
1275,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,F,,,,,10576
1276,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,BAO_0000019,,,,Expert,13630,,F,,,,,10576
1277,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,F,,,,,10576
1278,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,F,,,,,10576
1279,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,F,,,,,10576
1280,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,BAO_0000019,,,,Expert,13630,,F,,,,,10576
1281,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,BAO_0000019,,,,Expert,13630,,F,,,,,10576
1282,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,BAO_0000019,,,,Autocuration,13630,,F,,,,,10576
1283,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,BAO_0000019,,,,Expert,13630,,F,,,,,10576
1284,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,F,,,,,10576
1285,1,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,BAO_0000019,,,,Autocuration,13630,,F,,,,,10576
1286,1,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,F,,,,,10576
1287,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,BAO_0000019,,,,Autocuration,13630,,F,,,,,10576
1288,1,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,Hippocampus,BAO_0000221,,,,Autocuration,9783,,B,,,,,10576
1289,1,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,Hippocampus,BAO_0000221,,,,Expert,9783,,B,,,,,10576
1290,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,BAO_0000249,,Rattus norvegicus,,Expert,14331,,B,10116.0,,,Membranes,10576
1291,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,Hippocampus,BAO_0000221,,,,Expert,15260,,B,,,,,10576
1292,1,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,Hippocampus,BAO_0000221,,,,Autocuration,15260,,B,,,,,10576
1293,1,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,Hippocampus,BAO_0000221,,,,Autocuration,15260,,B,,,,,10576
1294,1,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,BAO_0000249,,Rattus norvegicus,,Expert,16616,,F,10116.0,,,,10576
1295,1,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,BAO_0000357,,,,Autocuration,15629,,B,,,,,10576
1296,1,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,BAO_0000019,,,,Autocuration,15086,,B,,,,,10576
1297,1,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,BAO_0000019,,,,Expert,5717,,F,,,,,10576
1298,1,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,BAO_0000357,,,,Autocuration,12652,,B,,,,,10576
1299,1,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,Hippocampus,BAO_0000221,,,,Autocuration,14608,,B,,,,,10576
1300,1,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus,BAO_0000221,,,,Autocuration,12306,,B,,,,,10576
1301,1,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus,BAO_0000221,,,,Autocuration,12306,,B,,,,,10576
1302,1,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Rattus norvegicus,,Expert,15247,,B,10116.0,,,,10576
1303,1,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,Hippocampus,BAO_0000221,,,,Expert,17529,,B,,,,,10576
1304,1,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,14826,,B,,,,,10576
1305,1,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,14826,,B,,,,,10576
1306,1,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus,BAO_0000221,,,,Autocuration,13241,,B,,,,,10576
1307,1,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,Hippocampus,BAO_0000221,,,,Autocuration,14093,,B,,,,,10576
1308,1,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,Hippocampus,BAO_0000221,,,,Autocuration,14093,,B,,,,,10576
1309,1,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,Brain,BAO_0000221,,,,Autocuration,14442,,B,,,,,10576
1310,1,Affinity for 5-hydroxytryptamine 1A receptor site,,BAO_0000357,,,,Autocuration,9919,,B,,,,,10576
1311,1,Affinity for 5-hydroxytryptamine 1A receptor site,,BAO_0000357,,,,Autocuration,9919,,B,,,,,10576
1312,1,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,Hippocampus,BAO_0000221,,,,Autocuration,11440,,B,,,,,10576
1313,1,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,BAO_0000357,,,,Autocuration,11257,,B,,,,,10576
1314,1,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,BAO_0000357,,,,Expert,10330,,B,,,,,10576
1315,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,17331,,B,10116.0,,,,10576
1316,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,BAO_0000249,,,,Expert,16567,,B,,,,,10576
1317,1,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,BAO_0000019,,Rattus norvegicus,,Expert,12058,,B,10116.0,,,,10576
1318,1,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,Hippocampus,BAO_0000221,,,,Autocuration,9699,,B,,,,,10576
1319,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,BAO_0000357,,,,Autocuration,9547,,B,,,,,10576
1320,1,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,BAO_0000357,,,,Autocuration,10330,,B,,,,,10576
1321,1,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,14331,,B,,,,,10576
1322,1,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,BAO_0000019,,Rattus norvegicus,,Expert,14060,,B,10116.0,,,,10576
1323,1,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,Hippocampus,BAO_0000221,,,,Autocuration,14744,,B,,,,,10576
1324,1,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,BAO_0000357,,,,Autocuration,13506,,B,,,,,10576
1325,1,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Brain,BAO_0000221,,,,Expert,10862,,B,,,,,10576
1326,1,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Brain,BAO_0000221,,,,Expert,10862,,B,,,,,10576
1327,1,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,BAO_0000357,,,,Expert,10062,,B,,,,,10576
1328,1,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,BAO_0000357,,,,Autocuration,12073,,B,,,,,10576
1329,1,GTPgammaS radioligand binding assay,,BAO_0000357,,,,Autocuration,14875,,B,,,,,106
1330,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,BAO_0000357,,,,Autocuration,2391,,B,,,,,106
1331,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,BAO_0000019,,,,Autocuration,2391,,F,,,,,106
1332,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,BAO_0000019,,,,Autocuration,2391,,F,,,,,106
1333,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,2391,,B,,,,,106
1334,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,BAO_0000357,,,,Autocuration,2391,,B,,,,,106
1335,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,BAO_0000019,,,,Autocuration,2391,,F,,,,,106
1336,1,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,BAO_0000219,,,,Expert,17211,,B,,,HeLa,,106
1337,1,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,BAO_0000219,,,,Autocuration,17211,,B,,,HeLa,,106
1338,1,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,BAO_0000357,,Homo sapiens,,Expert,6491,,B,9606.0,,,,106
1339,1,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,,,,Autocuration,16190,,B,,,CHO,,106
1340,1,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,BAO_0000019,,,,Autocuration,14165,,B,,,,,106
1341,1,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,BAO_0000019,,,,Autocuration,14165,,B,,,,,106
1342,1,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,,Homo sapiens,,Expert,4234,,B,9606.0,,,,106
1343,1,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,BAO_0000219,,,,Expert,6328,,B,,,,,106
1344,1,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,BAO_0000357,,,,Autocuration,14770,,B,,,,,106
1345,1,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,BAO_0000357,,,,Autocuration,2598,,B,,,,,106
1346,1,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Expert,6897,,B,,,,,106
1347,1,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,6897,,B,,,,,106
1348,1,Binding affinity towards 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,6013,,B,,,,,106
1349,1,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Expert,5843,,B,,,,,106
1350,1,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,BAO_0000357,,,,Expert,14454,,B,,,,,106
1351,1,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,BAO_0000357,,,,Autocuration,16209,,B,,,,,106
1352,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,3935,,B,,,,,106
1353,1,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,BAO_0000219,,,,Expert,13729,,F,,,CHO-K1,,106
1354,1,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,BAO_0000019,,,,Expert,14251,,F,,,,,106
1355,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,BAO_0000019,,,,Expert,17085,,B,,,,,106
1356,1,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,BAO_0000357,,,,Autocuration,3025,,B,,,,,106
1357,1,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Expert,15315,,B,,,,,106
1358,1,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,BAO_0000219,,Homo sapiens,,Expert,14214,,B,9606.0,,,,106
1359,1,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,BAO_0000357,,Homo sapiens,,Expert,3804,,B,9606.0,,,,106
1360,1,Affinity for 5-hydroxytryptamine 1B receptor subtype,,BAO_0000357,,Homo sapiens,,Expert,2391,,B,9606.0,,,,106
1361,1,Binding affinity for human 5-hydroxytryptamine 1B receptor,,BAO_0000357,,Homo sapiens,,Expert,4175,,B,9606.0,,,,106
1362,1,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,BAO_0000219,,,,Autocuration,17296,,B,,,CHO,,106
1363,1,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,BAO_0000019,,,,Expert,17085,,B,,,,,106
1364,1,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,BAO_0000219,,,,Autocuration,17211,,B,,,HeLa,,106
1365,1,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,BAO_0000219,,,,Autocuration,17211,,B,,,HeLa,,106
1366,1,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,BAO_0000219,,,,Autocuration,17211,,B,,,HeLa,,106
1367,1,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,BAO_0000357,,Homo sapiens,,Expert,15926,,B,9606.0,,,,106
1368,1,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,BAO_0000219,,,,Autocuration,16312,,B,,,CHO-K1,,106
1369,1,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,BAO_0000357,,,,Expert,5843,,B,,,,,106
1370,1,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,5843,,B,,,,,106
1371,1,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,BAO_0000219,,,,Expert,16312,,B,,,CHO-K1,,106
1372,1,Binding activity against human 5-hydroxytryptamine 1B receptor,,BAO_0000357,,Homo sapiens,,Expert,15926,,B,9606.0,,,,106
1373,1,Binding activity against human 5-hydroxytryptamine 1B receptor,,BAO_0000357,,Homo sapiens,,Expert,15926,,B,9606.0,,,,106
1374,1,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,,Homo sapiens,,Expert,4540,,B,9606.0,,CHO,,106
1375,1,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,BAO_0000357,,,,Autocuration,6166,,B,,,,,106
1376,1,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,BAO_0000219,,,,Autocuration,17296,,B,,,CHO,,106
1377,1,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,BAO_0000219,,,,Autocuration,17296,,B,,,CHO,,106
1378,1,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,BAO_0000219,,,,Autocuration,17296,,B,,,CHO,,106
1379,1,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,,,,Autocuration,15779,,B,,,CHO,,106
1380,1,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,,,,Autocuration,15779,,B,,,CHO,,106
1381,1,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,BAO_0000219,,,,Autocuration,15779,,B,,,CHO,,106
1382,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,BAO_0000219,,,,Autocuration,4199,,B,,,CHO,,106
1383,1,Binding affinity for human 5-hydroxytryptamine 1B receptor,,BAO_0000357,,Homo sapiens,,Expert,14875,,B,9606.0,,,,106
1384,1,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,BAO_0000219,,,,Autocuration,15146,,B,,,CHO,,106
1385,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,BAO_0000357,,,,Autocuration,5213,,B,,,,,106
1386,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,BAO_0000219,,,,Autocuration,14818,,B,,,CHO,,106
1387,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,BAO_0000219,,,,Autocuration,4829,,B,,,CHO,,106
1388,1,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,BAO_0000019,,,,Expert,14454,,F,,,,,106
1389,1,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,BAO_0000019,,,,Expert,14454,,F,,,,,106
1390,1,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,BAO_0000219,,,,Autocuration,14875,,F,,,CHO,,106
1391,1,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,BAO_0000219,,,,Autocuration,14875,,F,,,CHO,,106
1392,1,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,BAO_0000019,,,,Autocuration,15250,,F,,,,,105
1393,1,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,BAO_0000219,,,,Autocuration,15250,,B,,,CHO,,105
1394,1,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,15086,,B,,,,,17105
1395,1,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,3025,,F,9986.0,,,,106
1396,1,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,14998,,B,9986.0,,,,106
1397,1,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,BAO_0000019,,Oryctolagus cuniculus,,Intermediate,14998,,B,9986.0,,,,106
1398,1,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,14998,,B,9986.0,,,,106
1399,1,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,BAO_0000357,,,,Expert,13969,,B,,,,,10577
1400,1,Binding affinity for 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Intermediate,13392,,B,,,,,10577
1401,1,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,Striatum,BAO_0000019,,Rattus norvegicus,,Expert,3651,,B,10116.0,,,,10577
1402,1,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,BAO_0000357,,,,Expert,10025,,B,,,,,10577
1403,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,BAO_0000357,,,,Autocuration,13863,,B,,,,,10576
1404,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,BAO_0000357,,,,Autocuration,13863,,B,,,,,10576
1405,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,BAO_0000357,,,,Autocuration,13863,,B,,,,,10576
1406,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,BAO_0000357,,,,Autocuration,13863,,B,,,,,10576
1407,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,BAO_0000357,,,,Autocuration,13863,,B,,,,,10576
1408,1,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,BAO_0000357,,,,Autocuration,13863,,B,,,,,10576
1409,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,Hippocampus,BAO_0000249,,,,Autocuration,4622,,B,,,,,10576
1410,1,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,BAO_0000019,,,,Intermediate,14911,,B,,,,,10576
1411,1,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,Hippocampus,BAO_0000221,,,,Autocuration,12678,,B,,,,,10576
1412,1,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,Hippocampus,BAO_0000221,,,,Expert,12678,,B,,,,,10576
1413,1,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Hippocampus,BAO_0000221,,,,Expert,14235,,B,,,,,10576
1414,1,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,Hippocampus,BAO_0000221,,,,Expert,14949,,B,,,,,10576
1415,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,Hippocampus,BAO_0000221,,,,Expert,14949,,B,,,,,10576
1416,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,Hippocampus,BAO_0000221,,,,Expert,14949,,B,,,,,10576
1417,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,Hippocampus,BAO_0000221,,,,Expert,14949,,B,,,,,10576
1418,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,Hippocampus,BAO_0000221,,,,Expert,14949,,B,,,,,10576
1419,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,BAO_0000249,,,,Expert,16118,,B,,,,,10576
1420,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,BAO_0000249,,,,Autocuration,3268,,B,,,,,10576
1421,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,BAO_0000249,,,,Autocuration,3268,,B,,,,,10576
1422,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,BAO_0000357,,,,Expert,16117,,B,,,,,10576
1423,1,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,Hippocampus,BAO_0000221,,,,Expert,9783,,B,,,,,10576
1424,1,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,Hippocampus,BAO_0000221,,,,Autocuration,9783,,B,,,,,10576
1425,1,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,14356,,B,10116.0,,,,10576
1426,1,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,BAO_0000019,,,,Autocuration,15740,,F,,,,,10576
1427,1,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus,BAO_0000221,,,,Autocuration,12306,,B,,,,,10576
1428,1,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,13348,,B,10116.0,,,,10576
1429,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,BAO_0000249,,,,Autocuration,10394,,B,,,,,10576
1430,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,Hippocampus,BAO_0000221,,,,Autocuration,15260,,B,,,,,10576
1431,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Hippocampus,BAO_0000221,,,,Expert,10046,,B,,,,,10576
1432,1,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,Hippocampus,BAO_0000221,,,,Intermediate,15260,,F,,,,,10576
1433,1,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,12851,,B,,,,,10576
1434,1,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,2148,,B,10116.0,,,,10576
1435,1,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,BAO_0000357,,,,Expert,13134,,B,,,,,10576
1436,1,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,BAO_0000019,,,,Autocuration,12462,,B,,,,,10576
1437,1,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,BAO_0000019,,,,Expert,12462,,B,,,,,10576
1438,1,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,BAO_0000219,,,,Autocuration,12462,,B,,,CHO,,10576
1439,1,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Expert,11933,,B,,,,,10576
1440,1,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,BAO_0000357,,,,Autocuration,11933,,B,,,,,10576
1441,1,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,403,,B,10116.0,,,,10576
1442,1,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,15538,,B,,,,,10576
1443,1,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,Hippocampus,BAO_0000221,,,,Autocuration,15538,,B,,,,,10576
1444,1,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,Hippocampus,BAO_0000221,,,,Autocuration,15538,,B,,,,,10576
1445,1,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,BAO_0000019,,,,Intermediate,12464,,B,,,,,10576
1446,1,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,BAO_0000357,,,,Expert,1455,,B,,,,,10576
1447,1,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,BAO_0000357,,,,Autocuration,12652,,B,,,,,10576
1448,1,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,Hippocampus,BAO_0000221,,,,Autocuration,12639,,B,,,,,10576
1449,1,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,BAO_0000249,,,,Expert,13949,,B,,,,,10576
1450,1,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,BAO_0000357,,Rattus norvegicus,,Expert,12463,,B,10116.0,,,,10576
1451,1,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,Hippocampus,BAO_0000221,,,,Expert,14829,,B,,,,,10576
1452,1,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,Hippocampus,BAO_0000221,,,,Autocuration,14829,,B,,,,,10576
1453,1,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,BAO_0000357,,,,Autocuration,12092,,B,,,,,10576
1454,1,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,BAO_0000249,,,,Autocuration,403,,B,,,,,10576
1455,1,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,BAO_0000249,,,,Autocuration,403,,B,,,,,10576
1456,1,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,BAO_0000357,,,,Expert,3967,,B,,,,,10576
1457,1,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,BAO_0000019,,Rattus norvegicus,,Expert,12771,,B,10116.0,,,,10576
1458,1,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,BAO_0000019,,,,Autocuration,15086,,B,,,,,10576
1459,1,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,14909,,B,,,,,10576
1460,1,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,BAO_0000221,,,,Expert,14949,,B,,,,,10576
1461,1,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,2309,,B,10116.0,,,,10576
1462,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Expert,4170,,B,,,,,10576
1463,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,11642,,B,10116.0,,,,10576
1464,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,11642,,B,,,,,10576
1465,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,Hippocampus,BAO_0000221,,,,Autocuration,12953,,B,,,,,10576
1466,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,Hippocampus,BAO_0000221,,,,Autocuration,12953,,B,,,,,10576
1467,1,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,Hippocampus,BAO_0000221,,,,Expert,12953,,B,,,,,10576
1468,1,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,BAO_0000219,,,,Expert,12903,,B,,,CHO,,10576
1469,1,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Expert,12536,,B,,,,,10576
1470,1,The inhibition activity of 5-HT1A at 1 uM,,BAO_0000357,,,,Autocuration,10058,,B,,,,,10576
1471,1,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,BAO_0000219,,,,Expert,12902,,B,,,CHO-K1,,10576
1472,1,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,BAO_0000249,,,,Expert,14057,,B,,,,,10576
1473,1,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,BAO_0000357,,,,Autocuration,11296,,B,,,,,10576
1474,1,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,11296,,B,,,,,10576
1475,1,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Hippocampus,BAO_0000221,,,,Expert,11296,,B,,,,,10576
1476,1,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,BAO_0000249,,Rattus norvegicus,,Expert,16616,,F,10116.0,,,Membranes,10576
1477,1,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Hippocampus,BAO_0000249,,Rattus norvegicus,,Expert,16616,,F,10116.0,,,Membranes,10576
1478,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,BAO_0000019,,,,Autocuration,16567,,B,,,,,10576
1479,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,BAO_0000019,,,,Autocuration,16567,,B,,,,,10576
1480,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,BAO_0000019,,,,Autocuration,16567,,B,,,,,10576
1481,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,BAO_0000019,,,,Autocuration,16567,,B,,,,,10576
1482,1,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,BAO_0000249,,,,Autocuration,17136,,B,,,,,10576
1483,1,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,BAO_0000249,,,,Autocuration,17136,,B,,,,,10576
1484,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,BAO_0000019,,Rattus norvegicus,,Expert,16616,,B,10116.0,,,,10576
1485,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,Hippocampus,BAO_0000221,,,,Autocuration,17331,,B,,,,,10576
1486,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,Hippocampus,BAO_0000221,,,,Autocuration,17331,,B,,,,,10576
1487,1,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,17167,,B,10116.0,,,,10576
1488,1,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,BAO_0000019,,,,Autocuration,15740,,F,,,,,10576
1489,1,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,BAO_0000019,,,,Autocuration,15740,,F,,,,,10576
1490,1,Ratio of binding affinity to 5-HT 1A and D2 receptor,,BAO_0000357,,,,Autocuration,4671,,B,,,,,10576
1491,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,Hippocampus,BAO_0000221,,,,Autocuration,10058,,B,,,,,10576
1492,1,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,Hippocampus,BAO_0000221,,,,Autocuration,10058,,B,,,,,10576
1493,1,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,Hippocampus,BAO_0000221,,,,Autocuration,10058,,B,,,,,10576
1494,1,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,12073,,B,,,,,10576
1495,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,BAO_0000249,,,,Autocuration,2759,,B,,,,,10576
1496,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,BAO_0000249,,,,Autocuration,2759,,F,,,,,10576
1497,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,BAO_0000249,,,,Autocuration,2759,,B,,,,,10576
1498,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,BAO_0000249,,,,Autocuration,2759,,F,,,,,10576
1499,1,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,BAO_0000249,,,,Autocuration,2759,,F,,,,,10576
1500,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Brain,BAO_0000249,,,,Autocuration,9737,,B,,,,,10576
1501,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,BAO_0000019,,,,Autocuration,9737,,B,,,,,10576
1502,1,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,BAO_0000019,,,,Expert,5717,,F,,,,,10576
1503,1,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,12253,,B,,,,,10576
1504,1,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,BAO_0000019,,,,Autocuration,14025,,B,,,,,10576
1505,1,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,BAO_0000249,,,,Expert,10425,,B,,,,,10576
1506,1,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,BAO_0000019,,,,Autocuration,14998,,B,,,,,10576
1507,1,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,Hippocampus,BAO_0000221,,,,Autocuration,13694,,B,,,,,10576
1508,1,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,Hippocampus,BAO_0000221,,,,Autocuration,13694,,B,,,,,10576
1509,1,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,,,,Autocuration,4342,,B,,,,,10576
1510,1,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Rattus norvegicus,,Expert,12936,,B,10116.0,,,,10576
1511,1,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,BAO_0000019,,Rattus norvegicus,,Expert,13144,,B,10116.0,,,,10576
1512,1,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,BAO_0000019,,,,Expert,13343,,B,,,,,10576
1513,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,BAO_0000357,,,,Expert,12132,,B,,,,,10576
1514,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,BAO_0000019,,,,Expert,15419,,B,,,,,10576
1515,1,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,1479,,B,,,,,10576
1516,1,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,BAO_0000019,,,,Expert,14287,,B,,,,,10576
1517,1,Binding affinity at 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Expert,13116,,B,,,,,10576
1518,1,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,BAO_0000249,,Rattus norvegicus,,Expert,2759,,B,10116.0,,,Membranes,10576
1519,1,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,BAO_0000249,,,,Autocuration,2759,,B,,,,,10576
1520,1,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,BAO_0000019,,,,Expert,14748,,B,,,,,10576
1521,1,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,BAO_0000019,,,,Autocuration,12304,,B,,,,,10576
1522,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,12409,,B,10116.0,,,,10576
1523,1,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,12409,,B,10116.0,,,,10576
1524,1,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,Hippocampus,BAO_0000221,,,,Autocuration,13267,,B,,,,,10576
1525,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,BAO_0000357,,,,Autocuration,15194,,B,,,,,10576
1526,1,pKi value against rat 5-hydroxytryptamine 1A receptor.,,BAO_0000357,,,,Expert,14256,,B,,,,,10576
1527,1,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,BAO_0000019,,,,Autocuration,16567,,B,,,,,10576
1528,1,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,BAO_0000019,,,,Autocuration,15740,,F,,,,,10576
1529,1,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,BAO_0000357,,Rattus norvegicus,,Expert,13278,,B,10116.0,,,,12687
1530,1,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,BAO_0000249,,,,Expert,1970,,B,,,,Membranes,10626
1531,1,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,Brain,BAO_0000221,,,,Autocuration,10034,,B,,,,,10576
1532,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,BAO_0000019,,Rattus norvegicus,,Autocuration,13348,,B,10116.0,,,,51
1533,1,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,BAO_0000019,,,,Autocuration,13630,,F,,,,,10576
1534,1,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Brain,BAO_0000221,,,,Autocuration,10862,,B,,,,,10576
1535,1,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,BAO_0000019,,,,Autocuration,12058,,B,,,,,10576
1536,1,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,4639,,B,,,,,51
1537,1,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,BAO_0000357,,,,Expert,15453,,B,,,,,51
1538,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Expert,4820,,B,,,,,51
1539,1,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,1089,,B,,,,,51
1540,1,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,BAO_0000249,,,,Autocuration,386,,B,,,,Brain membranes,51
1541,1,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,BAO_0000357,,,,Autocuration,6011,,B,,,,,51
1542,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,5014,,B,,,,,51
1543,1,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Expert,4402,,B,,,,,51
1544,1,Binding affinity towards 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Expert,17066,,B,,,,,51
1545,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,BAO_0000357,,,,Autocuration,17515,,B,,,,,51
1546,1,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,2474,,B,,,,,51
1547,1,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,,,,Autocuration,4775,,B,,,,,51
1548,1,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,BAO_0000357,,Homo sapiens,,Expert,14294,,B,9606.0,,,,51
1549,1,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,BAO_0000357,,Homo sapiens,,Expert,14294,,B,9606.0,,,,51
1550,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,BAO_0000219,,,,Autocuration,12249,,B,,,CHO,,51
1551,1,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,BAO_0000219,,,,Expert,11376,,B,,,,,51
1552,1,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,BAO_0000218,,,,Autocuration,2474,In vivo,B,,,,,51
1553,1,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,13311,,B,,,,,51
1554,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,,,,Autocuration,4373,,B,,,,,51
1555,1,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,BAO_0000357,,,,Expert,1633,,B,,,,,51
1556,1,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,,,,Autocuration,11866,,B,,,,,51
1557,1,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,BAO_0000357,,,,Autocuration,4373,,B,,,,,51
1558,1,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,4687,,B,,,,,51
1559,1,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,16946,,B,,,,,11863
1560,1,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,BAO_0000357,,,,Autocuration,13291,,B,,,,,11863
1561,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,14159,,B,,,,,11863
1562,1,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,BAO_0000357,,,,Autocuration,10812,,B,,,,,11863
1563,1,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,BAO_0000219,,Mus musculus,,Expert,3032,,B,10090.0,,CHO,,11863
1564,1,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,16655,,B,,,,,11863
1565,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,BAO_0000357,,,,Autocuration,14532,,B,,,,,11863
1566,1,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,13944,,B,,,,,11863
1567,1,Binding affinity against serotonergic 5-HT1a receptor,,BAO_0000357,,,,Autocuration,13033,,B,,,,,11863
1568,1,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,10321,,B,,,,,11863
1569,1,Binding affinity for 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Mus musculus,,Expert,2968,,B,10090.0,,,,11863
1570,1,Binding affinity at 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,13964,,B,,,,,11863
1571,1,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,BAO_0000357,,,,Autocuration,15527,,B,,,,,11863
1572,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,BAO_0000219,,,,Autocuration,12248,,B,,,CHO,,11863
1573,1,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,BAO_0000219,,,,Autocuration,12249,,B,,,CHO,,11863
1574,1,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,15120,,B,,,,,11863
1575,1,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,13313,,B,,,,,11863
1576,1,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,BAO_0000218,,,,Autocuration,2613,,B,,,,,11863
1577,1,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,BAO_0000357,,,,Autocuration,16700,,B,,,,,11863
1578,1,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,2201,,B,,,,,11863
1579,1,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,Mus musculus,,Expert,1274,,B,10090.0,,,,11863
1580,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,BAO_0000357,,,,Autocuration,1317,,B,,,,,11863
1581,1,Tested against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,12146,,B,,,,,11863
1582,1,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,14059,,B,,,,,11863
1583,1,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,BAO_0000019,,Oryctolagus cuniculus,,Expert,14025,,B,9986.0,,,,106
1584,1,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,14025,,B,9986.0,,,,106
1585,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,BAO_0000219,,Gorilla gorilla,,Intermediate,14447,,B,9593.0,,HEK293,,105571
1586,1,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,BAO_0000218,,Cavia porcellus,,Autocuration,3025,In vivo,F,10141.0,,,,106
1587,1,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,BAO_0000218,,Cavia porcellus,,Autocuration,3025,In vivo,F,10141.0,,,,106
1588,1,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,BAO_0000019,,Cavia porcellus,,Autocuration,15329,,F,10141.0,,,,106
1589,1,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,BAO_0000019,,Cavia porcellus,,Autocuration,15329,,F,10141.0,,,,106
1590,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,BAO_0000019,,Cavia porcellus,,Autocuration,15847,,F,10141.0,,,,106
1591,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,BAO_0000019,,Cavia porcellus,,Autocuration,15847,,F,10141.0,,,,106
1592,1,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,BAO_0000019,,,,Autocuration,14165,,F,,,,,106
1593,1,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,BAO_0000019,,,,Autocuration,14214,,F,,,,,106
1594,1,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,BAO_0000019,,,,Autocuration,14214,,F,,,,,106
1595,1,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,BAO_0000019,,Homo sapiens,,Expert,14214,,F,9606.0,,,,106
1596,1,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,BAO_0000219,,Homo sapiens,,Expert,13729,,F,9606.0,,CHO-K1,,106
1597,1,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,BAO_0000219,,,,Autocuration,3025,,F,,,CHO,,106
1598,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,2391,,B,,,,,106
1599,1,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,BAO_0000019,,,,Autocuration,2391,,F,,,,,106
1600,1,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,BAO_0000219,,,,Expert,14956,,F,,,CHO,,106
1601,1,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,BAO_0000219,,,,Autocuration,2598,,F,,,CHO,,106
1602,1,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,BAO_0000219,,,,Autocuration,2598,,F,,,CHO,,106
1603,1,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,BAO_0000219,,,,Autocuration,2598,,F,,,CHO,,106
1604,1,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,BAO_0000219,,,,Autocuration,2598,,F,,,CHO,,106
1605,1,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,BAO_0000019,,,,Expert,14956,,F,,,,,106
1606,1,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,BAO_0000019,,,,Autocuration,14956,,F,,,,,106
1607,1,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,BAO_0000357,,Homo sapiens,,Expert,14214,,B,9606.0,,,,106
1608,1,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,BAO_0000219,,,,Expert,3463,,B,,,CHO,,106
1609,1,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,BAO_0000357,,,,Autocuration,15331,,B,,,,,106
1610,1,Binding affinity against 5-hydroxytryptamine 1B receptor,,BAO_0000357,,Homo sapiens,,Expert,16146,,B,9606.0,,,,106
1611,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,BAO_0000219,,Homo sapiens,,Expert,14159,,B,9606.0,,CHO,,106
1612,1,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,BAO_0000219,,,,Expert,14158,,B,,,CHO,,106
1613,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,14159,,B,,,,,106
1614,1,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,BAO_0000219,,,,Expert,15250,,B,,,CHO,,106
1615,1,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,BAO_0000219,,,,Expert,15250,,B,,,CHO,,106
1616,1,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,BAO_0000219,,,,Expert,15331,,B,,,CHO,,106
1617,1,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,BAO_0000219,,,,Expert,15332,,B,,,CHO,,106
1618,1,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,BAO_0000219,,,,Expert,14956,,B,,,CHO,,106
1619,1,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,BAO_0000357,,,,Autocuration,3805,,B,,,,,106
1620,1,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,BAO_0000357,,,,Autocuration,14875,,B,,,,,106
1621,1,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,14454,,F,9986.0,,,,105
1622,1,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,BAO_0000019,,Oryctolagus cuniculus,,Expert,14454,,F,9986.0,,,,105
1623,1,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,BAO_0000357,,,,Autocuration,16288,,B,,,,,105
1624,1,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,BAO_0000357,,,,Autocuration,16288,,B,,,,,105
1625,1,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,16312,,B,,,,,105
1626,1,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,BAO_0000357,,Bos taurus,,Expert,1348,,B,9913.0,,,,105
1627,1,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,BAO_0000357,,Bos taurus,,Autocuration,5834,,B,9913.0,,,,105
1628,1,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Striatum,BAO_0000019,,Bos taurus,,Autocuration,13366,,B,9913.0,,,,105
1629,1,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,BAO_0000357,,Bos taurus,,Expert,1414,,B,9913.0,,,,105
1630,1,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,BAO_0000019,,Bos taurus,,Autocuration,14998,,B,9913.0,,,,105
1631,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,BAO_0000357,,Bos taurus,,Autocuration,11473,,B,9913.0,,,,105
1632,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,BAO_0000357,,Bos taurus,,Autocuration,11473,,B,9913.0,,,,105
1633,1,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,BAO_0000357,,Bos taurus,,Autocuration,10639,,B,9913.0,,,,105
1634,1,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,BAO_0000357,,Bos taurus,,Autocuration,10639,,B,9913.0,,,,105
1635,1,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,BAO_0000357,,Bos taurus,,Autocuration,1375,,B,9913.0,,,,105
1636,1,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,BAO_0000357,,Bos taurus,,Autocuration,1375,,B,9913.0,,,,105
1637,1,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,BAO_0000357,,Bos taurus,,Autocuration,16532,,B,9913.0,,,,105
1638,1,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,BAO_0000357,,Bos taurus,,Autocuration,11147,,B,9913.0,,,,105
1639,1,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Striatum,BAO_0000019,,Bos taurus,,Autocuration,13366,,B,9913.0,,,,105
1640,1,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,BAO_0000019,,Bos taurus,,Autocuration,10444,,B,9913.0,,,,105
1641,1,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,BAO_0000357,,Bos taurus,,Autocuration,16532,,B,9913.0,,,,105
1642,1,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,BAO_0000357,,Bos taurus,,Autocuration,16532,,B,9913.0,,,,105
1643,1,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,BAO_0000249,,Bos taurus,,Autocuration,12827,,B,9913.0,,,,105
1644,1,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,BAO_0000249,,Bos taurus,,Autocuration,12827,,B,9913.0,,,,105
1645,1,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,BAO_0000019,,Bos taurus,,Expert,12919,,F,9913.0,,,,105
1646,1,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,BAO_0000019,,Bos taurus,,Autocuration,14025,,B,9913.0,,,,105
1647,1,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,BAO_0000019,,Bos taurus,,Expert,12919,,F,9913.0,,,,105
1648,1,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,BAO_0000019,,Bos taurus,,Expert,12919,,F,9913.0,,,,105
1649,1,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,BAO_0000019,,Bos taurus,,Expert,12919,,F,9913.0,,,,105
1650,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,BAO_0000219,,Gorilla gorilla,,Autocuration,14447,,B,9593.0,,HEK293,,105
1651,1,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,BAO_0000019,,Cavia porcellus,,Intermediate,1375,,B,10141.0,,,,105570
1652,1,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,BAO_0000019,,Cavia porcellus,,Intermediate,1375,,B,10141.0,,,,105570
1653,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,BAO_0000019,,Cavia porcellus,,Intermediate,12409,,F,10141.0,,,,105570
1654,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,BAO_0000019,,Cavia porcellus,,Intermediate,12409,,F,10141.0,,,,105570
1655,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,BAO_0000019,,Cavia porcellus,,Intermediate,12409,,F,10141.0,,,,105570
1656,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,BAO_0000019,,Cavia porcellus,,Intermediate,12409,,F,10141.0,,,,105570
1657,1,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,BAO_0000019,,Cavia porcellus,,Intermediate,12409,,F,10141.0,,,,105570
1658,1,Binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,,Cavia porcellus,,Intermediate,11574,,B,10141.0,,,,105570
1659,1,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,BAO_0000357,,Cavia porcellus,,Intermediate,1558,,B,10141.0,,,,105570
1660,1,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,BAO_0000218,,Cavia porcellus,,Intermediate,12409,,F,10141.0,,,,105570
1661,1,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,BAO_0000218,,Cavia porcellus,,Intermediate,12409,,F,10141.0,,,,105570
1662,1,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,BAO_0000218,,Cavia porcellus,,Intermediate,12409,,F,10141.0,,,,105570
1663,1,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,BAO_0000218,,Cavia porcellus,,Intermediate,12409,,F,10141.0,,,,105570
1664,1,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,BAO_0000019,,Cavia porcellus,,Intermediate,12253,,B,10141.0,,,,105570
1665,1,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,BAO_0000357,,Cavia porcellus,,Intermediate,12936,,B,10141.0,,,,105570
1666,1,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,BAO_0000019,,Cavia porcellus,,Autocuration,13181,,B,10141.0,,,,105
1667,1,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,Striatum,BAO_0000357,,Cavia porcellus,,Intermediate,12409,,B,10141.0,,,,105570
1668,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,BAO_0000357,,Cavia porcellus,,Intermediate,10639,,B,10141.0,,,,105570
1669,1,Binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,5254,,B,,,,,51
1670,1,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,,,,Autocuration,13051,,B,,,,,106
1671,1,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,BAO_0000019,,,,Expert,3463,,F,,,,,105
1672,1,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,BAO_0000019,,,,Autocuration,15315,,F,,,,,105
1673,1,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,BAO_0000019,,,,Autocuration,6011,,F,,,,,105
1674,1,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,BAO_0000219,,Homo sapiens,,Expert,14159,,F,9606.0,,CHO,,105
1675,1,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,BAO_0000219,,,,Autocuration,14159,,F,,,CHO,,105
1676,1,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,BAO_0000219,,,,Expert,15250,,B,,,CHO,,105
1677,1,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,BAO_0000219,,,,Autocuration,15250,,B,,,CHO,,105
1678,1,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,BAO_0000219,,,,Expert,15331,,F,,,CHO,,105
1679,1,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,BAO_0000219,,Homo sapiens,,Expert,15332,,F,9606.0,,CHO,,105
1680,1,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,BAO_0000219,,,,Expert,15332,,F,,,CHO,,105
1681,1,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,BAO_0000219,,,,Autocuration,3294,,F,,,CHO,,105
1682,1,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,BAO_0000219,,,,Expert,14158,,F,,,CHO,,105
1683,1,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,BAO_0000219,,,,Expert,14956,,F,,,CHO,,105
1684,1,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,BAO_0000019,,,,Autocuration,12469,,F,,,,,105
1685,1,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,BAO_0000219,,,,Expert,3463,,F,,,CHO,,105
1686,1,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,BAO_0000219,,Homo sapiens,,Expert,15250,,F,9606.0,,CHO,,105
1687,1,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,BAO_0000219,,Homo sapiens,,Expert,15250,,F,9606.0,,CHO,,105
1688,1,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,BAO_0000019,,,,Expert,14956,,F,,,,,105
1689,1,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,BAO_0000019,,,,Autocuration,14159,,F,,,,,105
1690,1,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,BAO_0000019,,Homo sapiens,,Expert,14159,,F,9606.0,,,,105
1691,1,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,BAO_0000219,,Homo sapiens,,Expert,14499,,F,9606.0,,CHO,,105
1692,1,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,BAO_0000019,,,,Autocuration,15315,,F,,,,,105
1693,1,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,BAO_0000219,,,,Autocuration,3294,In vitro,B,,,,,105
1694,1,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,BAO_0000219,,,,Expert,3463,,B,,,CHO,,105
1695,1,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,BAO_0000357,,,,Autocuration,15331,,B,,,,,105
1696,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,BAO_0000219,,Homo sapiens,,Expert,14159,,B,9606.0,,CHO,,105
1697,1,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,BAO_0000219,,,,Expert,14158,,B,,,CHO,,105
1698,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,14159,,B,,,,,105
1699,1,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,BAO_0000219,,,,Expert,15250,,B,,,CHO,,105
1700,1,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,BAO_0000219,,,,Expert,15250,,B,,,CHO,,105
1701,1,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,BAO_0000219,,,,Expert,15331,,B,,,CHO,,105
1702,1,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,BAO_0000219,,Homo sapiens,,Expert,15332,,B,9606.0,,CHO,,105
1703,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,BAO_0000219,,Homo sapiens,,Expert,14499,,B,9606.0,,CHO,,105
1704,1,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,BAO_0000219,,,,Expert,15332,,B,,,CHO,,105
1705,1,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,BAO_0000219,,,,Expert,14956,,B,,,CHO,,105
1706,1,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,BAO_0000357,,,,Autocuration,3805,,B,,,,,105
1707,1,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,BAO_0000219,,Homo sapiens,,Expert,6011,,B,9606.0,,CHO,,105
1708,1,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,,,,Autocuration,16190,,B,,,CHO,,105
1709,1,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,BAO_0000019,,,,Autocuration,14165,,B,,,,,105
1710,1,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,,Homo sapiens,,Expert,4234,,B,9606.0,,,,105
1711,1,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,BAO_0000357,,,,Autocuration,15527,,B,,,,,105
1712,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,BAO_0000219,,,,Expert,6328,,B,,,,,105
1713,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,16209,,B,,,,,105
1714,1,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,BAO_0000357,,,,Autocuration,14770,,B,,,,,105
1715,1,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,BAO_0000357,,,,Autocuration,2598,,B,,,,,105
1716,1,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Expert,6897,,B,,,,,105
1717,1,Binding affinity towards 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,6013,,B,,,,,105
1718,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Expert,5843,,B,,,,,105
1719,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,BAO_0000357,,,,Expert,14454,,B,,,,,105
1720,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,BAO_0000357,,,,Autocuration,14454,,B,,,,,105
1721,1,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,BAO_0000357,,,,Autocuration,14454,,B,,,,,105
1722,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,15818,,B,,,,,105
1723,1,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,BAO_0000219,,,,Expert,13729,,F,,,CHO-K1,,105
1724,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,BAO_0000219,,Homo sapiens,,Expert,6011,In vitro,B,9606.0,,,,105
1725,1,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,BAO_0000357,,Homo sapiens,,Expert,4234,,B,9606.0,,,,105
1726,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,BAO_0000019,,,,Expert,17085,,B,,,,,105
1727,1,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,BAO_0000357,,,,Autocuration,3025,,B,,,,,105
1728,1,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Expert,15315,,B,,,,,105
1729,1,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,BAO_0000219,,Homo sapiens,,Expert,14214,,B,9606.0,,,,105
1730,1,Binding affinity for human 5-hydroxytryptamine 1D receptor,,BAO_0000357,,Homo sapiens,,Expert,3804,,B,9606.0,,,,105
1731,1,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,BAO_0000357,,,,Autocuration,16700,,B,,,,,105
1732,1,Affinity for 5-hydroxytryptamine 1D receptor subtype,,BAO_0000357,,Homo sapiens,,Expert,2391,,B,9606.0,,,,105
1733,1,Binding affinity for human 5-hydroxytryptamine 1D receptor,,BAO_0000357,,Homo sapiens,,Expert,4175,,B,9606.0,,,,105
1734,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,BAO_0000019,,,,Autocuration,17085,,B,,,,,105
1735,1,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,BAO_0000019,,,,Expert,17085,,B,,,,,105
1736,1,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,BAO_0000357,,Homo sapiens,,Expert,15926,,B,9606.0,,,,105
1737,1,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,BAO_0000219,,,,Autocuration,16312,,B,,,CHO-K1,,105
1738,1,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,BAO_0000219,,,,Autocuration,16312,,B,,,CHO-K1,,105
1739,1,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,BAO_0000219,,,,Autocuration,14956,,B,,,CHO,,104802
1740,1,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,BAO_0000019,,,,Autocuration,3294,,F,,,,,105
1741,1,Binding activity radioligand.,,BAO_0000357,,,,Autocuration,12861,,B,,,,,105
1742,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,BAO_0000019,,,,Autocuration,12861,,B,,,,,105
1743,1,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,BAO_0000219,,,,Expert,16312,,B,,,CHO-K1,,105
1744,1,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,5104,,B,,,,,105
1745,1,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,5105,,B,,,,,105
1746,1,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,14499,,B,,,,,105
1747,1,Binding activity against human 5-hydroxytryptamine 1D receptor,,BAO_0000357,,Homo sapiens,,Expert,15926,,B,9606.0,,,,105
1748,1,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,,Homo sapiens,,Expert,4540,,B,9606.0,,CHO,,105
1749,1,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,B,,,CHO,,105
1750,1,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,B,,,CHO,,105
1751,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,6166,,B,,,,,105
1752,1,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,B,,,CHO,,105
1753,1,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,BAO_0000219,,,,Autocuration,15779,,B,,,CHO,,105
1754,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,BAO_0000219,,,,Autocuration,17451,,B,,,HEK293,,105
1755,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,BAO_0000219,,,,Autocuration,17451,,B,,,HEK293,,105
1756,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,BAO_0000219,,,,Autocuration,17451,,B,,,HEK293,,105
1757,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,BAO_0000219,,,,Autocuration,4199,,B,,,CHO,,105
1758,1,Binding affinity for human 5-hydroxytryptamine 1D receptor,,BAO_0000357,,Homo sapiens,,Expert,14875,,B,9606.0,,,,105
1759,1,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,BAO_0000219,,,,Autocuration,15146,,B,,,CHO,,105
1760,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,BAO_0000357,,,,Autocuration,5213,,B,,,,,105
1761,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,BAO_0000219,,,,Autocuration,14818,,B,,,CHO,,105
1762,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,BAO_0000219,,,,Autocuration,4829,,B,,,CHO,,105
1763,1,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,BAO_0000019,,,,Expert,14454,,F,,,,,105
1764,1,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,BAO_0000019,,,,Expert,14454,,F,,,,,105
1765,1,Binding affinity against 5-HT2C receptor,,BAO_0000357,,,,Autocuration,5254,,B,,,,,108
1766,1,Binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,5254,,B,,,,,108
1767,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,BAO_0000357,,,,Autocuration,10639,,B,,,,,10577
1768,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,BAO_0000019,,,,Autocuration,10639,,F,,,,,10577
1769,1,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,BAO_0000019,,,,Expert,12352,,B,,,,,10577
1770,1,Binding affinity towards 5-HT1B was determined,,BAO_0000357,,,,Autocuration,9098,,B,,,,,10577
1771,1,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,BAO_0000019,,,,Expert,14430,,B,,,,,10577
1772,1,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,BAO_0000019,,,,Expert,13657,,B,,,,,10577
1773,1,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,BAO_0000019,,,,Autocuration,13657,,B,,,,,10577
1774,1,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,BAO_0000019,,,,Expert,15854,,B,,,,,10577
1775,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,BAO_0000019,,Rattus norvegicus,,Expert,10639,,B,10116.0,,,,10577
1776,1,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,BAO_0000357,,,,Autocuration,10025,,B,,,,,10577
1777,1,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,BAO_0000357,,,,Autocuration,10025,,B,,,,,10577
1778,1,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,BAO_0000249,,,,Autocuration,14286,,B,,,,,10577
1779,1,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,Striatum,BAO_0000019,,,,Autocuration,3651,,B,,,,,10577
1780,1,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,BAO_0000357,,Rattus norvegicus,,Expert,14178,,B,10116.0,,,,10577
1781,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,BAO_0000019,,,,Autocuration,10639,,B,,,,,10577
1782,1,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,Striatum,BAO_0000019,,,,Autocuration,13605,,B,,,,,10577
1783,1,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,Striatum,BAO_0000019,,,,Autocuration,5834,,B,,,,,10577
1784,1,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,Striatum,BAO_0000357,,,,Autocuration,10922,,B,,,,,10577
1785,1,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,BAO_0000249,,,,Autocuration,14286,,B,,,,,10577
1786,1,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,BAO_0000357,,,,Autocuration,11825,,B,,,,,10577
1787,1,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,Striatum,BAO_0000019,,,,Autocuration,14826,,B,,,,,10577
1788,1,Binding affinity against 5-HT1B serotonin receptor in rat striatum,Striatum,BAO_0000019,,,,Autocuration,9699,,B,,,,,10577
1789,1,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,BAO_0000019,,,,Autocuration,14423,,B,,,,,10577
1790,1,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,BAO_0000357,,,,Expert,10062,,B,,,,,10577
1791,1,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,10062,,B,,,,,10577
1792,1,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,BAO_0000357,,Rattus norvegicus,,Expert,12280,,B,10116.0,,,,10577
1793,1,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,Striatum,BAO_0000357,,,,Autocuration,15412,,B,,,,,10577
1794,1,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,Striatum,BAO_0000357,,,,Autocuration,15412,,B,,,,,10577
1795,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,10062,,B,,,,,10577
1796,1,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,11147,,B,,,,,10577
1797,1,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,BAO_0000019,,,,Autocuration,9547,,B,,,,,10577
1798,1,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,BAO_0000019,,,,Autocuration,10444,,B,,,,,10577
1799,1,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,Striatum,BAO_0000019,,,,Autocuration,12469,,B,,,,,10577
1800,1,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,BAO_0000019,,,,Expert,9098,,B,,,,,10577
1801,1,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,BAO_0000019,,,,Autocuration,9098,,B,,,,,10577
1802,1,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,9699,,B,,,,,10577
1803,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,BAO_0000249,,,,Autocuration,10394,,B,,,,,10577
1804,1,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,BAO_0000357,,,,Autocuration,12092,,B,,,,,10577
1805,1,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,BAO_0000357,,,,Autocuration,16700,,B,,,,,10577
1806,1,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,BAO_0000249,,Rattus norvegicus,,Expert,403,,B,10116.0,,,,10577
1807,1,Binding affinity towards 5-hydroxytryptamine 1B receptor,,BAO_0000357,,Rattus norvegicus,,Expert,12771,,B,10116.0,,,,10577
1808,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,BAO_0000019,,,,Autocuration,11642,,B,,,,,10577
1809,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,12953,,B,,,,,10577
1810,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,BAO_0000357,,,,Autocuration,12953,,B,,,,,10577
1811,1,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,Striatum,BAO_0000019,,,,Expert,12953,,B,,,,,10577
1812,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,BAO_0000357,,,,Autocuration,12953,,B,,,,,10577
1813,1,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Brain,BAO_0000249,,,,Autocuration,9737,,B,,,,,10577
1814,1,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,BAO_0000019,,,,Autocuration,9737,,B,,,,,10577
1815,1,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Brain,BAO_0000249,,,,Autocuration,9737,,B,,,,,10577
1816,1,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,BAO_0000357,,,,Autocuration,12827,,B,,,,,10577
1817,1,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,5033,,B,,,,,10577
1818,1,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,BAO_0000019,,Rattus norvegicus,,Expert,9786,,B,10116.0,,,,10577
1819,1,Binding affinity at 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Expert,13116,,B,,,,,10577
1820,1,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,BAO_0000019,,,,Autocuration,16429,,B,,,,,10577
1821,1,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,BAO_0000249,,Rattus norvegicus,,Expert,12409,,B,10116.0,,,,10577
1822,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,15194,,B,,,,,10577
1823,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,BAO_0000357,,,,Autocuration,15194,,B,,,,,10577
1824,1,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,BAO_0000019,,,,Autocuration,5486,,B,,,,,104686
1825,1,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,4639,,B,,,,,106
1826,1,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,BAO_0000249,,,,Autocuration,386,,B,,,,Brain membranes,106
1827,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,BAO_0000357,,,,Autocuration,2474,,B,,,,,106
1828,1,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,BAO_0000357,,,,Autocuration,6011,,B,,,,,106
1829,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,5014,,B,,,,,106
1830,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,BAO_0000357,,,,Autocuration,17515,,B,,,,,106
1831,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,BAO_0000357,,,,Autocuration,4373,,B,,,,,106
1832,1,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,BAO_0000357,,,,Expert,1633,,B,,,,,106
1833,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,BAO_0000357,,,,Autocuration,1633,,B,,,,,106
1834,1,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,BAO_0000357,,,,Autocuration,4373,,B,,,,,106
1835,1,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,4687,,B,,,,,106
1836,1,Binding affinity against 5-hydroxytryptamine 1B receptor,,BAO_0000357,,,,Autocuration,11574,,B,,,,,106
1837,1,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,10321,,B,,,,,106
1838,1,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,BAO_0000357,,,,Autocuration,15527,,B,,,,,106
1839,1,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,BAO_0000357,,,,Autocuration,17200,,B,,,,,106
1840,1,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,BAO_0000224,,,,Autocuration,14423,,B,,,,,104802
1841,1,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,BAO_0000357,,Bos taurus,,Autocuration,5834,,B,9913.0,,,,108
1842,1,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,BAO_0000357,,Sus scrofa,,Autocuration,11473,,B,9823.0,,,,108
1843,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,BAO_0000357,,Sus scrofa,,Autocuration,11473,,B,9823.0,,,,108
1844,1,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,BAO_0000357,,Sus scrofa,,Autocuration,10639,,B,9823.0,,,,108
1845,1,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,BAO_0000357,,Sus scrofa,,Autocuration,10639,,B,9823.0,,,,108
1846,1,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,BAO_0000357,,Sus scrofa,,Autocuration,14331,,B,9823.0,,,,108
1847,1,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,BAO_0000357,,Sus scrofa,,Autocuration,10796,,B,9823.0,,,,108
1848,1,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,BAO_0000357,,Sus scrofa,,Expert,9098,,B,9823.0,,,,108
1849,1,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,BAO_0000357,,Sus scrofa,,Expert,14331,,B,9823.0,,,,108
1850,1,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,BAO_0000019,,Sus scrofa,,Expert,11828,,B,9823.0,,,,108
1851,1,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,BAO_0000357,,Sus scrofa,,Autocuration,11866,,B,9823.0,,,,108
1852,1,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,13047,,B,9986.0,,,,108
1853,1,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,BAO_0000357,,Rattus norvegicus,,Autocuration,188,,B,10116.0,,,,12689
1854,1,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,BAO_0000357,,Rattus norvegicus,,Autocuration,11825,,B,10116.0,,,,12689
1855,1,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,BAO_0000357,,Rattus norvegicus,,Autocuration,11825,,B,10116.0,,,,12689
1856,1,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,BAO_0000019,,Rattus norvegicus,,Expert,11624,,B,10116.0,,,,12689
1857,1,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,BAO_0000357,,Rattus norvegicus,,Autocuration,11139,,B,10116.0,,,,12689
1858,1,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,BAO_0000357,,Rattus norvegicus,,Autocuration,11147,,B,10116.0,,,,12689
1859,1,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,BAO_0000019,,Rattus norvegicus,,Autocuration,10444,,B,10116.0,,,,12689
1860,1,Binding affinity against 5-hydroxytryptamine 1C receptor,,BAO_0000357,,Rattus norvegicus,,Expert,11624,,B,10116.0,,,,12689
1861,1,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,BAO_0000019,,Rattus norvegicus,,Autocuration,11662,,B,10116.0,,,,12689
1862,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,BAO_0000019,,Rattus norvegicus,,Autocuration,11662,,B,10116.0,,,,12689
1863,1,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,BAO_0000019,,Rattus norvegicus,,Expert,11662,,B,10116.0,,,,12689
1864,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,BAO_0000019,,Rattus norvegicus,,Autocuration,11662,,B,10116.0,,,,12689
1865,1,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,BAO_0000357,,Rattus norvegicus,,Autocuration,9098,,B,10116.0,,,,12689
1866,1,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,BAO_0000249,,Rattus norvegicus,,Autocuration,10394,,B,10116.0,,,,12689
1867,1,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,BAO_0000357,,,,Expert,11933,,B,,,,,12689
1868,1,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,BAO_0000357,,Rattus norvegicus,,Autocuration,12092,,B,10116.0,,,,12689
1869,1,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,BAO_0000019,,Rattus norvegicus,,Autocuration,12253,,B,10116.0,,,,12689
1870,1,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,BAO_0000219,,Rattus norvegicus,,Autocuration,12253,,B,10116.0,,HEK293,,12689
1871,1,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,BAO_0000357,,,,Autocuration,1558,,B,,,,,108
1872,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,BAO_0000357,,,,Autocuration,2474,,B,,,,,108
1873,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,BAO_0000357,,,,Autocuration,2474,,B,,,,,108
1874,1,Binding affinity against 5-hydroxytryptamine 1C receptor,,BAO_0000357,,,,Autocuration,11574,,B,,,,,12689
1875,1,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,BAO_0000357,,,,Autocuration,1558,,B,,,,,12689
1876,1,Binding affinity against 5-hydroxytryptamine 1C receptor,,BAO_0000357,,,,Autocuration,13944,,B,,,,,12689
1877,1,Binding affinity against serotonergic 5-HT1c receptor,,BAO_0000357,,,,Autocuration,13033,,B,,,,,12689
1878,1,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,BAO_0000357,,,,Autocuration,10321,,B,,,,,12689
1879,1,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,BAO_0000357,,,,Autocuration,11866,,B,,,,,12689
1880,1,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,14454,,B,9986.0,,,,105
1881,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,BAO_0000224,,,,Autocuration,11574,,B,,,,,104686
1882,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,BAO_0000224,,,,Autocuration,11574,,B,,,,,104686
1883,1,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,BAO_0000019,,,,Autocuration,13631,,B,,,,,104686
1884,1,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,BAO_0000019,,Rattus norvegicus,,Autocuration,9630,,B,10116.0,,,,104686
1885,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,BAO_0000249,,Rattus norvegicus,,Autocuration,8822,,B,10116.0,,,,104686
1886,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,Brain,BAO_0000221,,Rattus norvegicus,,Autocuration,9064,,B,10116.0,,,,104686
1887,1,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,BAO_0000224,,,,Autocuration,8868,,B,,,,,104686
1888,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,BAO_0000224,,,,Autocuration,9064,,B,,,,,104686
1889,1,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,BAO_0000019,,,,Autocuration,9806,,B,,,,,104686
1890,1,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,,,,Autocuration,9098,,B,,,,,104686
1891,1,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,BAO_0000224,,,,Autocuration,8868,,B,,,,,104686
1892,1,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,BAO_0000224,,,,Autocuration,12765,,B,,,,,104686
1893,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,,,,Autocuration,11049,,B,,,,,104686
1894,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,,,,Autocuration,11049,,B,,,,,104686
1895,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,BAO_0000019,,,,Autocuration,11049,,B,,,,,104686
1896,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,BAO_0000019,,,,Autocuration,11049,,B,,,,,104686
1897,1,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,,,,Autocuration,11049,,B,,,,,104686
1898,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,BAO_0000019,,,,Autocuration,11473,,B,,,,,104686
1899,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,BAO_0000019,,,,Autocuration,11473,,B,,,,,104686
1900,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,BAO_0000019,,,,Autocuration,3086,,B,,,,,104686
1901,1,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,,,,Autocuration,11049,,B,,,,,104686
1902,1,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,BAO_0000019,,,,Autocuration,11049,,B,,,,,104686
1903,1,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,BAO_0000019,,,,Autocuration,10639,,B,,,,,104686
1904,1,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,BAO_0000019,,,,Autocuration,10922,,B,,,,,104686
1905,1,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Brain,BAO_0000221,,Rattus norvegicus,,Autocuration,9064,,B,10116.0,,,,104686
1906,1,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,Brain,BAO_0000221,,,,Autocuration,10748,,B,,,,,104686
1907,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,BAO_0000249,,,,Autocuration,11614,,B,,,,Membranes,104686
1908,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,BAO_0000249,,,,Autocuration,11615,,B,,,,Membranes,104686
1909,1,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,11615,,B,,,,,104686
1910,1,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,BAO_0000249,,,,Autocuration,11614,,B,,,,Membranes,104686
1911,1,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,BAO_0000224,,,,Autocuration,11702,,B,,,,,104686
1912,1,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,BAO_0000224,,,,Autocuration,11702,,B,,,,,104686
1913,1,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,BAO_0000224,,Rattus norvegicus,,Autocuration,11702,,B,10116.0,,,,104686
1914,1,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,BAO_0000224,,,,Autocuration,11702,,B,,,,,104686
1915,1,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,BAO_0000019,,,,Autocuration,13346,,B,,,,,104686
1916,1,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,10025,,B,,,,,104686
1917,1,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,BAO_0000224,,,,Autocuration,10025,,B,,,,,104686
1918,1,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,BAO_0000224,,,,Autocuration,10025,,B,,,,,104686
1919,1,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,BAO_0000224,,,,Autocuration,9036,,B,,,,,104686
1920,1,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,BAO_0000224,,,,Autocuration,9036,,B,,,,,104686
1921,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,BAO_0000019,,,,Autocuration,9161,,B,,,,,104686
1922,1,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,BAO_0000019,,,,Autocuration,12304,,B,,,,,104686
1923,1,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,BAO_0000224,,,,Autocuration,13276,,B,,,,,104686
1924,1,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,BAO_0000224,,,,Autocuration,11825,,B,,,,,104686
1925,1,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,BAO_0000224,,,,Autocuration,12443,,B,,,,,104686
1926,1,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,13830,,B,,,,,104686
1927,1,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,BAO_0000249,,,,Autocuration,9592,,B,,,,Membranes,104686
1928,1,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,BAO_0000249,,,,Autocuration,9592,,B,,,,Membranes,104686
1929,1,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,BAO_0000224,,,,Autocuration,10881,,B,,,,,104686
1930,1,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,BAO_0000019,,,,Autocuration,13605,,B,,,,,104686
1931,1,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,BAO_0000224,,Rattus norvegicus,,Autocuration,11624,,B,10116.0,,,,104686
1932,1,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,BAO_0000224,,,,Autocuration,4101,,B,,,,,104686
1933,1,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,BAO_0000224,,,,Autocuration,4101,,B,,,,,104686
1934,1,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,BAO_0000019,,,,Autocuration,15360,,B,,,,,104686
1935,1,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,BAO_0000019,,,,Autocuration,11576,,B,,,,,104686
1936,1,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,BAO_0000019,,,,Autocuration,5834,,B,,,,,104686
1937,1,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,BAO_0000219,,Rattus norvegicus,,Autocuration,2395,,B,10116.0,,CHO-K1,,104686
1938,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,BAO_0000249,,,,Autocuration,11965,,B,,,,Membranes,104686
1939,1,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,BAO_0000224,,,,Autocuration,3967,,B,,,,,104686
1940,1,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,BAO_0000249,,,,Autocuration,11130,,B,,,,Brain membranes,104686
1941,1,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,BAO_0000219,,,,Autocuration,13427,In vitro,B,,,,,104686
1942,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,9443,,B,,,,,104686
1943,1,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,BAO_0000224,,,,Autocuration,9443,,B,,,,,104686
1944,1,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,BAO_0000224,,,,Autocuration,11825,,B,,,,,104686
1945,1,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,BAO_0000249,,,,Autocuration,12120,,B,,,,Membranes,104686
1946,1,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,BAO_0000249,,,,Autocuration,12120,,B,,,,Membranes,104686
1947,1,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,Thoracic aorta,BAO_0000019,,,,Autocuration,11963,,F,,,,,104686
1948,1,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,BAO_0000019,,,,Autocuration,9069,,B,,,,,104686
1949,1,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,BAO_0000224,,,,Autocuration,8868,,B,,,,,104686
1950,1,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,BAO_0000357,,,,Autocuration,17200,,B,,,,,10624
1951,1,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,BAO_0000357,,,,Autocuration,17200,,B,,,,,10624
1952,1,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,BAO_0000357,,,,Expert,13969,,B,,,,,17106
1953,1,Binding affinity for 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Expert,13392,,B,,,,,17106
1954,1,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,BAO_0000249,,,,Autocuration,1742,,B,,,,,17106
1955,1,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,BAO_0000249,,,,Autocuration,1742,,B,,,,,17106
1956,1,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,Striatum,BAO_0000357,,,,Autocuration,14331,,B,,,,,17106
1957,1,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,BAO_0000019,,,,Autocuration,12861,,F,,,,,17106
1958,1,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,BAO_0000019,,,,Expert,12861,,B,,,,,17106
1959,1,Binding activity radioligand.,,BAO_0000357,,,,Autocuration,12861,,B,,,,,17106
1960,1,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,BAO_0000019,,,,Autocuration,12861,,B,,,,,17106
1961,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,BAO_0000019,,,,Expert,12861,,B,,,,,17106
1962,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,BAO_0000019,,,,Autocuration,12861,,B,,,,,17106
1963,1,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,BAO_0000249,,,,Autocuration,675,,B,,,,,17106
1964,1,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,BAO_0000019,,,,Expert,12490,,B,,,,,17106
1965,1,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,BAO_0000249,,,,Expert,11828,,B,,,,,17106
1966,1,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,BAO_0000357,,,,Autocuration,11866,,B,,,,,17106
1967,1,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,BAO_0000357,,Sus scrofa,,Autocuration,773,,B,9823.0,,,,105
1968,1,The compound was tested for intrinsic activity against 5-HT1D receptor,,BAO_0000357,,Oryctolagus cuniculus,,Expert,13047,,B,9986.0,,,,105
1969,1,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,13047,,B,9986.0,,,,105
1970,1,The compound was tested for binding affinity against 5-HT1D receptor,,BAO_0000357,,Oryctolagus cuniculus,,Expert,13047,,B,9986.0,,,,105
1971,1,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,BAO_0000357,,,,Autocuration,188,,B,,,,,10578
1972,1,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,BAO_0000019,,,,Autocuration,10639,,F,,,,,10578
1973,1,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,BAO_0000019,,,,Autocuration,12438,,F,,,,,10578
1974,1,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,12438,,B,,,,,10578
1975,1,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,BAO_0000019,,,,Expert,15854,,B,,,,,10578
1976,1,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,BAO_0000249,,,,Autocuration,10394,,B,,,,,10578
1977,1,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,BAO_0000357,,,,Autocuration,12092,,B,,,,,10578
1978,1,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,BAO_0000019,,,,Expert,3389,,B,,,,,10578
1979,1,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,BAO_0000357,,,,Autocuration,6011,,B,,,,,105
1980,1,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,4639,,B,,,,,105
1981,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,2474,,B,,,,,105
1982,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,5014,,B,,,,,105
1983,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,BAO_0000357,,,,Autocuration,17515,,B,,,,,105
1984,1,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,BAO_0000357,,,,Autocuration,11866,,B,,,,,105
1985,1,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,4687,,B,,,,,105
1986,1,Tested against 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,12146,,B,,,,,105
1987,1,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,10321,,B,,,,,105
1988,1,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,BAO_0000219,,,,Autocuration,13267,,B,,,HEK293,,105
1989,1,Binding affinity against 5-Hydroxytryptamine 1D receptor,,BAO_0000357,,Homo sapiens,,Expert,1274,,B,9606.0,,,,105
1990,1,,,BAO_0000357,,,,Autocuration,15250,,B,,,,,105
1991,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,BAO_0000219,,,,Autocuration,13706,,B,,,CHO-K1,,106
1992,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,BAO_0000219,,,,Autocuration,13706,,B,,,CHO-K1,,105
1993,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,BAO_0000219,,,,Autocuration,13706,,B,,,HEK293,,105
1994,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,BAO_0000219,,,,Autocuration,13706,,B,,,HEK293,,105
1995,1,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,BAO_0000019,,,,Autocuration,13047,,B,,,,,105
1996,1,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,BAO_0000357,,,,Autocuration,13366,,B,,,,,105
1997,1,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,BAO_0000357,,,,Expert,13366,,B,,,,,105
1998,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,BAO_0000357,,,,Autocuration,1558,,B,,,,,105
1999,1,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,BAO_0000219,,,,Expert,12902,,B,,,CHO-K1,,105
2000,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,BAO_0000219,,,,Autocuration,13706,,B,,,CHO-K1,,105
2001,1,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,BAO_0000019,,,,Autocuration,13706,,F,,,,,105
2002,1,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,BAO_0000019,,,,Autocuration,13706,,F,,,,,105
2003,1,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,BAO_0000019,,,,Autocuration,14251,,F,,,,,105
2004,1,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,BAO_0000019,,,,Autocuration,14251,,F,,,,,105
2005,1,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,BAO_0000019,,,,Autocuration,14251,,F,,,,,105
2006,1,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,13313,,B,,,,,105
2007,1,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,13313,,B,,,,,105
2008,1,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,,,,Autocuration,13366,,B,,,,,105
2009,1,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,,,,Expert,13051,,B,,,,,105
2010,1,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,BAO_0000219,,,,Expert,12903,,B,,,CHO,,105
2011,1,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,BAO_0000219,,Homo sapiens,,Autocuration,12469,,B,9606.0,,,,105
2012,1,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,BAO_0000357,,,,Autocuration,5619,,B,,,,,17106
2013,1,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,13047,,B,9986.0,,,,105
2014,1,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,,,,Autocuration,16633,,B,,,,,105
2015,1,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,,,,Autocuration,16633,,B,,,,,105
2016,1,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,,,,Autocuration,16633,,B,,,,,105
2017,1,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,16633,,B,,,,,105
2018,1,Affinity against 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,,,,Autocuration,3269,,B,,,,,105
2019,1,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,BAO_0000357,,,,Expert,12409,,B,,,,,105
2020,1,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,BAO_0000019,,,,Autocuration,13706,,F,,,,,106
2021,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,BAO_0000219,,,,Autocuration,13706,,B,,,HEK293,,106
2022,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,BAO_0000219,,,,Autocuration,13706,,B,,,HEK293,,106
2023,1,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,BAO_0000219,,,,Autocuration,12903,,B,,,CHO,,106
2024,1,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,BAO_0000019,,,,Autocuration,13047,,B,,,,,106
2025,1,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,,,,Expert,13366,,B,,,,,106
2026,1,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,,,,Expert,13366,,B,,,,,106
2027,1,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,,,,Expert,13366,,B,,,,,106
2028,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,13366,,B,,,,,106
2029,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,BAO_0000357,,,,Autocuration,13366,,B,,,,,106
2030,1,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,BAO_0000219,,,,Autocuration,12469,,B,,,CHO,,106
2031,1,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,BAO_0000219,,,,Autocuration,13706,,B,,,CHO-K1,,106
2032,1,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,BAO_0000219,,,,Autocuration,13706,,B,,,CHO-K1,,106
2033,1,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,BAO_0000019,,,,Autocuration,13706,,F,,,,,106
2034,1,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,BAO_0000219,,,,Expert,12902,,B,,,CHO-K1,,106
2035,1,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,,,,Expert,13051,,B,,,,,105
2036,1,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,BAO_0000219,,,,Expert,12903,,B,,,CHO,,106
2037,1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,BAO_0000219,,,,Autocuration,1558,,F,,,CHO-K1,,105
2038,1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,BAO_0000219,,,,Autocuration,1558,,F,,,CHO-K1,,105
2039,1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,BAO_0000219,,,,Autocuration,1558,,F,,,CHO-K1,,105
2040,1,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,BAO_0000219,,,,Autocuration,1558,,F,,,CHO-K1,,105
2041,1,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,BAO_0000357,,,,Autocuration,1558,,B,,,,,105
2042,1,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,13047,,B,9986.0,,,,106
2043,1,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,BAO_0000357,,,,Autocuration,13313,,B,,,,,105
2044,1,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,13313,,B,,,,,105
2045,1,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,BAO_0000357,,,,Expert,12409,,B,,,,,105
2046,1,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,BAO_0000219,,,,Autocuration,15250,,B,,,CHO,,10618
2047,1,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,BAO_0000357,,Homo sapiens,,Expert,1348,,B,9606.0,,,,10618
2048,1,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,BAO_0000357,,,,Autocuration,1348,,B,,,,,10618
2049,1,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,BAO_0000357,,Homo sapiens,,Expert,4234,,B,9606.0,,,,10618
2050,1,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,16209,,B,,,,,10618
2051,1,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,BAO_0000019,,,,Autocuration,10444,,B,,,,,10618
2052,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,BAO_0000357,,,,Autocuration,3935,,B,,,,,10618
2053,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,BAO_0000357,,,,Autocuration,15818,,B,,,,,10618
2054,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,BAO_0000019,,,,Autocuration,17085,,B,,,,,10618
2055,1,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,BAO_0000219,,Homo sapiens,,Expert,12936,,B,9606.0,,CHO,,10618
2056,1,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,BAO_0000357,,,,Autocuration,6166,,B,,,,,10618
2057,1,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,B,,,CHO,,10618
2058,1,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,B,,,CHO,,10618
2059,1,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,BAO_0000219,,,,Autocuration,15779,,B,,,CHO,,10618
2060,1,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,BAO_0000357,,,,Autocuration,13181,,B,,,,,10618
2061,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,BAO_0000219,,,,Autocuration,4199,,B,,,CHO,,10618
2062,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,BAO_0000357,,,,Autocuration,14875,,B,,,,,10618
2063,1,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,BAO_0000219,,,,Autocuration,15146,,B,,,CHO,,10618
2064,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,BAO_0000357,,,,Autocuration,5213,,B,,,,,10618
2065,1,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,12146,,B,,,,,10618
2066,1,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,BAO_0000219,,,,Autocuration,13267,,B,,,CHO,,10618
2067,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,BAO_0000219,,,,Autocuration,14818,,B,,,CHO,,10618
2068,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,BAO_0000219,,,,Autocuration,4829,,B,,,CHO,,10618
2069,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,BAO_0000357,,,,Autocuration,4373,,B,,,,,10618
2070,1,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,BAO_0000357,,,,Autocuration,4373,,B,,,,,10618
2071,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,BAO_0000357,,,,Autocuration,14159,,B,,,,,10618
2072,1,Binding affinity towards 5-hydroxytryptamine 1E receptor,,BAO_0000357,,,,Autocuration,16633,,B,,,,,10618
2073,1,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,BAO_0000019,,,,Autocuration,17085,,F,,,,,279
2074,1,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,BAO_0000019,,,,Expert,17085,,F,,,,,279
2075,1,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,BAO_0000019,,,,Autocuration,16209,,F,,,,,279
2076,1,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,BAO_0000019,,,,Autocuration,16209,,F,,,,,279
2077,1,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,BAO_0000019,,,,Expert,17085,,F,,,,,279
2078,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,BAO_0000357,,,,Autocuration,14159,,B,,,,,279
2079,1,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,BAO_0000219,,,,Autocuration,15250,,B,,,CHO,,279
2080,1,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,BAO_0000357,,,,Autocuration,3805,,B,,,,,279
2081,1,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,BAO_0000219,,,,Autocuration,16190,,B,,,CHO,,279
2082,1,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,BAO_0000357,,,,Autocuration,16190,,B,,,,,279
2083,1,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,BAO_0000357,,,,Autocuration,16209,,B,,,,,279
2084,1,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,BAO_0000357,,,,Autocuration,16209,,B,,,,,279
2085,1,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,BAO_0000357,,,,Autocuration,16209,,B,,,,,279
2086,1,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,BAO_0000357,,,,Autocuration,6866,,B,,,,,279
2087,1,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,BAO_0000019,,,,Expert,17085,,B,,,,,279
2088,1,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,BAO_0000357,,,,Autocuration,16312,,B,,,,,279
2089,1,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,BAO_0000357,,,,Autocuration,6166,,B,,,,,279
2090,1,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,B,,,CHO,,279
2091,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,BAO_0000219,,,,Autocuration,4199,,B,,,CHO,,279
2092,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,BAO_0000357,,,,Autocuration,14875,,B,,,,,279
2093,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,BAO_0000219,,,,Autocuration,15146,,B,,,CHO,,279
2094,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,BAO_0000357,,,,Autocuration,5213,,B,,,,,279
2095,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,BAO_0000219,,,,Autocuration,14818,,B,,,CHO,,279
2096,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,BAO_0000219,,,,Autocuration,4829,,B,,,CHO,,279
2097,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,BAO_0000219,,,,Autocuration,4829,,B,,,CHO,,279
2098,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,BAO_0000357,,,,Autocuration,4373,,B,,,,,279
2099,1,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,BAO_0000357,,,,Autocuration,4373,,B,,,,,279
2100,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,BAO_0000357,,,,Autocuration,5014,,B,,,,,279
2101,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,BAO_0000019,,,,Autocuration,11662,,B,,,,,104686
2102,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,BAO_0000019,,,,Autocuration,11662,,B,,,,,104686
2103,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,BAO_0000019,,,,Autocuration,11662,,B,,,,,104686
2104,1,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,BAO_0000019,,,,Autocuration,14093,,B,,,,,12687
2105,1,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,BAO_0000218,,,,Autocuration,11200,In vivo,F,,,,,104686
2106,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,,,,Autocuration,11200,,F,,,,,104686
2107,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,BAO_0000019,,,,Intermediate,12352,,B,,,,,17005
2108,1,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,BAO_0000019,,Bos taurus,,Autocuration,13657,,B,9913.0,,,,22226
2109,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,BAO_0000019,,Bos taurus,,Autocuration,14331,,B,9913.0,,,,22226
2110,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,BAO_0000019,,Bos taurus,,Autocuration,14331,,B,9913.0,,,,22226
2111,1,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,BAO_0000019,,,,Autocuration,14331,,B,,,,,22226
2112,1,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,BAO_0000019,,Cavia porcellus,,Autocuration,12685,,B,10141.0,,,,104784
2113,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,BAO_0000019,,Cavia porcellus,,Autocuration,14389,,B,10141.0,,,,104784
2114,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,BAO_0000019,,Cavia porcellus,,Autocuration,14386,,B,10141.0,,,,104784
2115,1,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,,,,Autocuration,5732,,B,,,,,104784
2116,1,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,,,,Autocuration,16293,,B,,,,,104784
2117,1,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,2078,,B,,,,,104784
2118,1,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,BAO_0000357,,,,Autocuration,5486,,B,,,,,10209
2119,1,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,BAO_0000218,,,,Autocuration,11820,In vivo,B,,,,,104826
2120,1,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,BAO_0000019,,,,Autocuration,10297,,B,,,,,104826
2121,1,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,BAO_0000224,,,,Autocuration,13704,,B,,,,,104826
2122,1,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,BAO_0000019,,Mus musculus,,Autocuration,10297,,B,10090.0,,,,104826
2123,1,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,BAO_0000218,,,,Autocuration,11820,In vivo,B,,,,,104826
2124,1,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,BAO_0000019,,Mus musculus,,Autocuration,10297,,B,10090.0,,,,104826
2125,1,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,11555,,B,,,,,104826
2126,1,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,BAO_0000224,,,,Autocuration,11555,,B,,,,,104826
2127,1,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,BAO_0000224,,,,Autocuration,11555,,B,,,,,104826
2128,1,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,BAO_0000019,,Mus musculus,,Autocuration,10297,,B,10090.0,,,,104826
2129,1,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,BAO_0000224,,Sus scrofa,,Autocuration,16688,,B,9823.0,,,,104784
2130,1,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,BAO_0000224,,Sus scrofa,,Autocuration,16688,,B,9823.0,,,,104784
2131,1,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,BAO_0000221,,,,Autocuration,5333,,B,,,,,22226
2132,1,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,BAO_0000221,,,,Autocuration,4437,,B,,,,,22226
2133,1,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,BAO_0000357,,Sus scrofa,,Autocuration,5033,,B,9823.0,,,,17005
2134,1,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,BAO_0000019,,,,Autocuration,15267,,B,,,,,104686
2135,1,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,BAO_0000019,,,,Autocuration,15267,,B,,,,,104686
2136,1,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,BAO_0000019,,,,Autocuration,11820,,B,,,,,104826
2137,1,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,9069,,B,,,,,104686
2138,1,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,BAO_0000019,,Rattus norvegicus,,Autocuration,9162,,B,10116.0,,,,104686
2139,1,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,BAO_0000019,,,,Autocuration,9162,,B,,,,,104686
2140,1,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,BAO_0000019,,,,Autocuration,9162,,B,,,,,104686
2141,1,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,BAO_0000019,,,,Autocuration,10428,,F,,,,,104686
2142,1,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,BAO_0000019,,,,Autocuration,9628,,B,,,,,104686
2143,1,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,12704,,B,,,,,104686
2144,1,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,BAO_0000224,,Rattus norvegicus,,Autocuration,15453,,B,10116.0,,,,104686
2145,1,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,BAO_0000224,,,,Autocuration,188,,B,,,,,104686
2146,1,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,BAO_0000224,,,,Autocuration,10349,,B,,,,,104686
2147,1,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,BAO_0000224,,,,Autocuration,10349,,B,,,,,104686
2148,1,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,BAO_0000224,,,,Autocuration,8868,,B,,,,,104686
2149,1,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,BAO_0000224,,,,Autocuration,10025,,B,,,,,104686
2150,1,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,BAO_0000224,,,,Autocuration,10025,,B,,,,,104686
2151,1,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,BAO_0000224,,,,Autocuration,11702,,B,,,,,104686
2152,1,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,11702,,B,,,,,104686
2153,1,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,BAO_0000224,,,,Autocuration,11702,,B,,,,,104686
2154,1,Compound was tested for the inhibition of quipazine induced head twitches in rats,,BAO_0000019,,,,Autocuration,11702,,F,,,,,104686
2155,1,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,BAO_0000019,,,,Autocuration,11702,,F,,,,,104686
2156,1,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,Hippocampus,BAO_0000221,,,,Autocuration,10085,,B,,,,,104686
2157,1,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,Hippocampus,BAO_0000221,,,,Autocuration,10085,,B,,,,,104686
2158,1,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,Brain,BAO_0000221,,Rattus norvegicus,,Autocuration,9630,,B,10116.0,,,,104686
2159,1,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,BAO_0000019,,,,Autocuration,11070,,B,,,,,104686
2160,1,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,BAO_0000249,,,,Autocuration,9841,,B,,,,Membranes,104686
2161,1,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,BAO_0000249,,,,Autocuration,9841,,B,,,,Membranes,104686
2162,1,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,BAO_0000019,,,,Autocuration,13291,,B,,,,,104686
2163,1,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,BAO_0000019,,,,Autocuration,10590,,F,,,,,104686
2164,1,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Brain,BAO_0000221,,Rattus norvegicus,,Autocuration,9064,,B,10116.0,,,,104686
2165,1,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,BAO_0000249,,Rattus norvegicus,,Autocuration,12268,,B,10116.0,,,Membranes,104686
2166,1,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,Brain,BAO_0000221,,,,Autocuration,13508,,B,,,,,104686
2167,1,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,BAO_0000019,,,,Autocuration,11279,,F,,,,,104686
2168,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,BAO_0000019,,,,Autocuration,11200,,F,,,,,104686
2169,1,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,,,,Autocuration,11200,,F,,,,,104686
2170,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,BAO_0000019,,,,Autocuration,11200,,F,,,,,104686
2171,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,BAO_0000019,,,,Autocuration,11200,,F,,,,,104686
2172,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,,,,Autocuration,11200,,F,,,,,104686
2173,1,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,Brain,BAO_0000220,,,,Autocuration,9231,,B,,,,,104686
2174,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,BAO_0000019,,,,Autocuration,9737,,B,,,,,104686
2175,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Brain,BAO_0000249,,,,Autocuration,9737,,B,,,,,104686
2176,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,BAO_0000019,,,,Autocuration,9737,,B,,,,,104686
2177,1,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,BAO_0000019,,,,Autocuration,9737,,B,,,,,104686
2178,1,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,BAO_0000019,,Rattus norvegicus,,Autocuration,11828,,B,10116.0,,,,104686
2179,1,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,BAO_0000019,,,,Autocuration,12253,,B,,,,,104686
2180,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,BAO_0000019,,,,Autocuration,12253,,B,,,,,104686
2181,1,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,BAO_0000019,,,,Autocuration,11279,,F,,,,,104686
2182,1,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,BAO_0000019,,,,Autocuration,11866,,B,,,,,104686
2183,1,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,BAO_0000224,,Rattus norvegicus,,Autocuration,14424,,B,10116.0,,,,104686
2184,1,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,BAO_0000019,,Rattus norvegicus,,Autocuration,15180,,B,10116.0,,,,104686
2185,1,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,BAO_0000019,,Rattus norvegicus,,Autocuration,15180,,B,10116.0,,,,104686
2186,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,BAO_0000019,,Rattus norvegicus,,Autocuration,9786,,B,10116.0,,,,104686
2187,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,BAO_0000224,,,,Autocuration,12132,,B,,,,,104686
2188,1,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,BAO_0000249,,,,Autocuration,5486,,B,,,,,104686
2189,1,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,BAO_0000019,,,,Autocuration,15316,,B,,,,,104686
2190,1,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,BAO_0000019,,,,Autocuration,16429,,B,,,,,104686
2191,1,pKi value for 5-hydroxytryptamine 2 receptor binding site,,BAO_0000224,,,,Autocuration,14617,,B,,,,,104686
2192,1,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,Brain,BAO_0000221,,,,Autocuration,11351,,B,,,,,104686
2193,1,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,BAO_0000019,,,,Autocuration,11279,,F,,,,,104686
2194,1,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,,,,Autocuration,9523,,B,,,,,105075
2195,1,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,,,,Autocuration,9523,,B,,,,,105075
2196,1,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,,,,Autocuration,9523,,B,,,,,105075
2197,1,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,,,,Autocuration,9523,,B,,,,,105075
2198,1,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,,,,Autocuration,9523,,B,,,,,105075
2199,1,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,BAO_0000019,,,,Autocuration,9523,,B,,,,,105075
2200,1,Hill coefficient of compound was determined,,BAO_0000224,,,,Autocuration,9523,,B,,,,,105075
2201,1,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,BAO_0000019,,,,Autocuration,4771,,B,,,,,22226
2202,1,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,BAO_0000019,,Rattus norvegicus,,Autocuration,5033,,B,10116.0,,,,104686
2203,1,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,BAO_0000019,,,,Expert,10845,,B,,,,,12687
2204,1,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,BAO_0000019,,,,Expert,10845,,B,,,,,12687
2205,1,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,BAO_0000357,,,,Autocuration,16288,,B,,,,,12687
2206,1,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,BAO_0000019,,,,Autocuration,16288,,B,,,,,12687
2207,1,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,BAO_0000019,,,,Autocuration,16190,,B,,,,,12687
2208,1,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,BAO_0000224,,Rattus norvegicus,,Autocuration,12463,,B,10116.0,,,,104686
2209,1,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,BAO_0000224,,,,Autocuration,9699,,B,,,,,104686
2210,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,BAO_0000224,,,,Autocuration,9699,,B,,,,,104686
2211,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,BAO_0000019,,,,Autocuration,11662,,B,,,,,104686
2212,1,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,1205,,B,,,,,104784
2213,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,BAO_0000219,,,,Autocuration,11376,,B,,,,,22226
2214,1,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,BAO_0000219,,,,Autocuration,11376,,B,,,,,104784
2215,1,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,4639,,B,,,,,104784
2216,1,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,2222,,B,,,,,104784
2217,1,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,1558,,B,,,,,104784
2218,1,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,1089,,B,,,,,104784
2219,1,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,BAO_0000249,,,,Autocuration,386,,B,,,,Brain membranes,104784
2220,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,BAO_0000224,,,,Autocuration,2474,,B,,,,,104784
2221,1,Binding affinity towards 5-HT2 receptor,,BAO_0000224,,,,Autocuration,17066,,B,,,,,104784
2222,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,959,,B,,,,,104784
2223,1,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,BAO_0000224,,,,Autocuration,6398,,B,,,,,104784
2224,1,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,BAO_0000224,,,,Autocuration,11889,,B,,,,,104686
2225,1,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,4221,,B,,,,,104784
2226,1,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,BAO_0000224,,,,Autocuration,11026,,B,,,,,104784
2227,1,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,,,,Autocuration,11866,,B,,,,,104784
2228,1,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,4221,,B,,,,,104784
2229,1,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000019,,,,Autocuration,13950,,B,,,,,22226
2230,1,5-hydroxytryptamine 2 receptor binding affinity,,BAO_0000224,,,,Autocuration,1263,,B,,,,,104784
2231,1,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,BAO_0000357,,,,Autocuration,13291,,B,,,,,17005
2232,1,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,BAO_0000357,,,,Autocuration,10812,,B,,,,,17005
2233,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,BAO_0000224,,,,Autocuration,13020,,B,,,,,104784
2234,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,BAO_0000224,,,,Autocuration,13021,,B,,,,,104784
2235,1,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,BAO_0000224,,,,Autocuration,13020,,B,,,,,104784
2236,1,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,BAO_0000357,,,,Autocuration,14532,,B,,,,,17005
2237,1,Binding affinity against 5-hydroxytryptamine 2 receptor,,BAO_0000357,,,,Autocuration,13944,,B,,,,,17005
2238,1,Binding affinity against 5-hydroxytryptamine 2 receptor,,BAO_0000357,,,,Autocuration,14331,,B,,,,,17005
2239,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,BAO_0000357,,,,Autocuration,14118,,B,,,,,17005
2240,1,Binding affinity against serotonergic 5-HT2 receptor,,BAO_0000357,,,,Autocuration,13033,,B,,,,,17005
2241,1,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,BAO_0000357,,,,Autocuration,10321,,B,,,,,17005
2242,1,Compound was evaluated for the binding affinity at 5- HT2 receptor,,BAO_0000357,,,,Autocuration,12918,,B,,,,,17005
2243,1,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,BAO_0000357,,,,Autocuration,15120,,B,,,,,17005
2244,1,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,BAO_0000218,,,,Autocuration,2613,,B,,,,,17005
2245,1,Inhibitory activity against cloned human 5-HT2 receptor,,BAO_0000224,,Homo sapiens,,Autocuration,13378,,B,9606.0,,,,104784
2246,1,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,BAO_0000219,,Homo sapiens,,Autocuration,2331,,B,9606.0,,CHO,,104784
2247,1,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,BAO_0000219,,Homo sapiens,,Autocuration,2331,,B,9606.0,,CHO,,104784
2248,1,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,BAO_0000219,,Homo sapiens,,Autocuration,2331,,B,9606.0,,CHO,,104784
2249,1,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,BAO_0000219,,Homo sapiens,,Autocuration,2331,,B,9606.0,,CHO,,104784
2250,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,4170,,B,,,,,104784
2251,1,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,BAO_0000224,,,,Autocuration,15453,,B,,,,,104784
2252,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000357,,,,Autocuration,1479,,B,,,,,17005
2253,1,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,BAO_0000224,,,,Autocuration,11139,,B,,,,,104686
2254,1,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,BAO_0000357,,,,Expert,13969,,B,,,,,17005
2255,1,Binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Expert,13392,,B,,,,,17005
2256,1,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,BAO_0000019,,,,Expert,14430,,B,,,,,17005
2257,1,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,BAO_0000357,,Cavia porcellus,,Autocuration,13181,,B,10141.0,,,,107
2258,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,,,,Autocuration,17200,,B,,,,,51
2259,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,,,,Autocuration,17200,,B,,,,,107
2260,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,,,,Autocuration,17200,,B,,,,,51
2261,1,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,BAO_0000357,,,,Autocuration,13463,,B,,,,,107
2262,1,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,BAO_0000219,,,,Autocuration,6347,,B,,,CHO,,107
2263,1,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,BAO_0000219,,Homo sapiens,,Expert,6857,,F,9606.0,,CHO,,107
2264,1,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,BAO_0000219,,,,Autocuration,4176,,F,,,,,107
2265,1,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,BAO_0000219,,,,Autocuration,4176,,F,,,,,107
2266,1,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,BAO_0000219,,,,Autocuration,4176,,F,,,,,107
2267,1,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,BAO_0000219,,,,Autocuration,6347,,B,,,CHO,,107
2268,1,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,BAO_0000219,,,,Autocuration,6347,,B,,,CHO,,107
2269,1,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,BAO_0000357,,,,Autocuration,15331,,B,,,,,107
2270,1,Inhibition of human 5-hydroxytryptamine 2A receptor,,BAO_0000357,,Homo sapiens,,Expert,16146,,B,9606.0,,,,107
2271,1,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,BAO_0000219,,,,Autocuration,15250,,B,,,CHO,,107
2272,1,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,BAO_0000219,,,,Expert,13631,,B,,,,,107
2273,1,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,BAO_0000357,,,,Autocuration,3805,,B,,,,,107
2274,1,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,BAO_0000219,,,,Autocuration,4011,,B,,,CHO,,107
2275,1,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,BAO_0000219,,,,Expert,4012,,B,,,CHO,,107
2276,1,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,BAO_0000219,,,,Expert,6366,,B,,,L929,,107
2277,1,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,BAO_0000219,,,,Expert,15949,,B,,,CHO,,107
2278,1,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,BAO_0000019,,,,Autocuration,14093,,F,,,,,107
2279,1,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,BAO_0000019,,,,Autocuration,13481,,F,,,,,107
2280,1,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,BAO_0000219,,,,Autocuration,6347,,B,,,CHO,,107
2281,1,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,BAO_0000219,,,,Autocuration,6347,,B,,,CHO,,107
2282,1,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,BAO_0000019,,,,Autocuration,14093,,F,,,,,107
2283,1,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,BAO_0000019,,,,Autocuration,14093,,F,,,,,107
2284,1,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000019,,,,Autocuration,13481,,F,,,,,107
2285,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,BAO_0000357,,,,Autocuration,14442,,B,,,,,107
2286,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,,,,Autocuration,14442,,B,,,,,107
2287,1,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,BAO_0000357,,,,Autocuration,14755,,B,,,,,107
2288,1,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,BAO_0000357,,,,Autocuration,16441,,B,,,,,107
2289,1,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,BAO_0000357,,,,Autocuration,14744,,B,,,,,107
2290,1,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,BAO_0000219,,,,Expert,16659,,B,,,CHO,,107
2291,1,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,3307,,B,,,,,107
2292,1,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,BAO_0000019,,Homo sapiens,,Expert,6857,,B,9606.0,,,,107
2293,1,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,BAO_0000357,,,,Expert,5635,,B,,,,,107
2294,1,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,BAO_0000357,,Homo sapiens,,Expert,4234,,B,9606.0,,,,107
2295,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,BAO_0000357,,,,Autocuration,15527,,B,,,,,107
2296,1,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,BAO_0000219,,,,Expert,6588,,B,,,CHO,,107
2297,1,Binding affinity towards human 5-HT2A receptor in BEK cells,,BAO_0000219,,,,Expert,13631,,B,,,,,107
2298,1,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,17723,,B,,,,,107
2299,1,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,BAO_0000357,,,,Autocuration,14770,,B,,,,,107
2300,1,Binding affinity for human 5-hydroxytryptamine 2A receptor,,BAO_0000357,,Homo sapiens,,Expert,16293,,B,9606.0,,,,107
2301,1,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,BAO_0000357,,,,Autocuration,16209,,B,,,,,107
2302,1,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,BAO_0000219,,,,Autocuration,12469,,B,,,,,107
2303,1,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,15363,,B,,,,,107
2304,1,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,15363,,B,,,,,107
2305,1,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,BAO_0000019,,,,Expert,16441,,B,,,,,107
2306,1,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,BAO_0000357,,,,Autocuration,8,,B,,,,,107
2307,1,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,BAO_0000219,,,,Autocuration,4176,,B,,,HEK293,,107
2308,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,BAO_0000019,,,,Autocuration,17085,,B,,,,,107
2309,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,,,,Autocuration,17200,,B,,,,,107
2310,1,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,BAO_0000357,,Homo sapiens,,Expert,17200,,B,9606.0,,,,107
2311,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,BAO_0000219,,Homo sapiens,,Expert,4013,,B,9606.0,,CHO,,107
2312,1,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,5088,,B,,,,,107
2313,1,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,BAO_0000357,,Homo sapiens,,Expert,5088,,B,9606.0,,,,107
2314,1,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,BAO_0000357,,,,Autocuration,5088,,B,,,,,107
2315,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,BAO_0000357,,Homo sapiens,,Expert,5088,,B,9606.0,,,,107
2316,1,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,5088,,B,,,,,107
2317,1,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,BAO_0000357,,,,Autocuration,5088,,B,,,,,107
2318,1,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,BAO_0000019,,,,Autocuration,9786,,B,,,,,104686
2319,1,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,BAO_0000019,,Rattus norvegicus,,Autocuration,9205,,B,10116.0,,,,104686
2320,1,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,BAO_0000224,,,,Autocuration,11257,,B,,,,,104686
2321,1,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,BAO_0000019,,,,Autocuration,9362,,B,,,,,104686
2322,1,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,BAO_0000019,,,,Autocuration,9362,,B,,,,,104686
2323,1,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,BAO_0000224,,,,Autocuration,10590,,B,,,,,104686
2324,1,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,BAO_0000019,,,,Autocuration,10468,,B,,,,,104686
2325,1,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,BAO_0000019,,,,Autocuration,13050,,B,,,,,104686
2326,1,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,BAO_0000019,,,,Autocuration,11624,,B,,,,,104686
2327,1,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,BAO_0000019,,,,Autocuration,10468,,B,,,,,104686
2328,1,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,BAO_0000224,,,,Autocuration,10330,,B,,,,,104686
2329,1,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,BAO_0000224,,,,Autocuration,10062,,B,,,,,104686
2330,1,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,11642,,B,,,,,104686
2331,1,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,10062,,B,,,,,104686
2332,1,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,BAO_0000219,,,,Autocuration,13427,In vitro,B,,,,,104686
2333,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,BAO_0000224,,Rattus norvegicus,,Autocuration,12280,,B,10116.0,,,,104686
2334,1,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,BAO_0000224,,Rattus norvegicus,,Autocuration,4101,,B,10116.0,,,,104686
2335,1,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,10062,,B,,,,,104686
2336,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,BAO_0000224,,,,Autocuration,11147,,B,,,,,104686
2337,1,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,BAO_0000219,,Rattus norvegicus,,Autocuration,2395,,B,10116.0,,CHO-K1,,104686
2338,1,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,BAO_0000219,,Rattus norvegicus,,Autocuration,2395,,B,10116.0,,CHO-K1,,104686
2339,1,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,BAO_0000019,,Rattus norvegicus,,Autocuration,9098,,B,10116.0,,,,104686
2340,1,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,BAO_0000019,,,,Autocuration,9098,,B,,,,,104686
2341,1,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,BAO_0000019,,Rattus norvegicus,,Autocuration,9098,,B,10116.0,,,,104686
2342,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,9443,,B,,,,,104686
2343,1,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,BAO_0000224,,,,Autocuration,9443,,B,,,,,104686
2344,1,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,BAO_0000019,,,,Autocuration,9699,,B,,,,,104686
2345,1,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,BAO_0000019,,,,Autocuration,9699,,B,,,,,104686
2346,1,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,BAO_0000224,,,,Autocuration,9098,,B,,,,,104686
2347,1,Affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,,Rattus norvegicus,,Autocuration,3070,,B,10116.0,,,,104686
2348,1,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,BAO_0000224,,,,Autocuration,9547,,B,,,,,104686
2349,1,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,BAO_0000019,,,,Autocuration,10444,,B,,,,,104686
2350,1,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,BAO_0000019,,,,Autocuration,14617,,B,,,,,104686
2351,1,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,BAO_0000019,,,,Autocuration,14617,,B,,,,,104686
2352,1,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,BAO_0000224,,,,Autocuration,11130,,B,,,,,104686
2353,1,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,BAO_0000218,,,,Autocuration,11130,In vivo,B,,,,,104686
2354,1,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,Brain,BAO_0000221,,,,Autocuration,14542,,B,,,,,104686
2355,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,BAO_0000224,,,,Autocuration,2797,,B,,,,,104686
2356,1,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,BAO_0000019,,,,Autocuration,11332,,B,,,,,104686
2357,1,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,BAO_0000019,,,,Autocuration,11332,,B,,,,,104686
2358,1,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,Frontal cortex,BAO_0000019,,,,Autocuration,10752,,B,,,,,104686
2359,1,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,1185,,B,,,,,104686
2360,1,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,1185,,B,,,,,104686
2361,1,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,BAO_0000224,,Rattus norvegicus,,Autocuration,11624,,B,10116.0,,,,104686
2362,1,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,BAO_0000019,,,,Autocuration,1344,,B,,,,,104686
2363,1,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,Striatum,BAO_0000019,,Rattus norvegicus,,Autocuration,15453,,B,10116.0,,,,104686
2364,1,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,BAO_0000019,,,,Autocuration,11662,,B,,,,,104686
2365,1,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,BAO_0000019,,,,Autocuration,11662,,B,,,,,104686
2366,1,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,10796,,B,,,,,104686
2367,1,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,9069,,B,,,,,104686
2368,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,BAO_0000019,,Rattus norvegicus,,Autocuration,8814,,B,10116.0,,,,104686
2369,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,BAO_0000019,,Rattus norvegicus,,Autocuration,8908,,B,10116.0,,,,104686
2370,1,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,BAO_0000019,,,,Autocuration,9098,,B,,,,,104686
2371,1,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,BAO_0000019,,,,Autocuration,9098,,B,,,,,104686
2372,1,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,BAO_0000019,,,,Autocuration,9098,,B,,,,,104686
2373,1,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,BAO_0000019,,,,Autocuration,9098,,B,,,,,104686
2374,1,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,BAO_0000249,,,,Autocuration,9098,,B,,,,,104686
2375,1,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,BAO_0000019,,,,Autocuration,9098,,B,,,,,104686
2376,1,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,BAO_0000019,,,,Autocuration,9098,,B,,,,,104686
2377,1,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,BAO_0000019,,,,Autocuration,9161,,B,,,,,104686
2378,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,BAO_0000019,,,,Autocuration,9161,,B,,,,,104686
2379,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,BAO_0000019,,,,Autocuration,9161,,B,,,,,104686
2380,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,BAO_0000019,,,,Autocuration,9161,,B,,,,,104686
2381,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,BAO_0000019,,,,Autocuration,9161,,B,,,,,104686
2382,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,BAO_0000019,,,,Autocuration,9161,,B,,,,,104686
2383,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,BAO_0000019,,,,Autocuration,9161,,B,,,,,104686
2384,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,BAO_0000019,,,,Autocuration,9161,,B,,,,,104686
2385,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,BAO_0000019,,,,Autocuration,9161,,B,,,,,104686
2386,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,BAO_0000019,,,,Autocuration,9161,,B,,,,,104686
2387,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,BAO_0000019,,,,Autocuration,9161,,B,,,,,104686
2388,1,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,BAO_0000019,,,,Autocuration,9161,,B,,,,,104686
2389,1,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,BAO_0000019,,,,Autocuration,12094,,B,,,,,104686
2390,1,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,BAO_0000249,,,,Autocuration,12018,,B,,,,,104686
2391,1,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,BAO_0000249,,,,Autocuration,10394,,B,,,,,104686
2392,1,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,15260,,B,,,,,104686
2393,1,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,BAO_0000224,,Rattus norvegicus,,Autocuration,11624,,B,10116.0,,,,104686
2394,1,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,13654,,B,,,,,104686
2395,1,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,BAO_0000019,,,,Autocuration,9541,,B,,,,,104686
2396,1,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,BAO_0000224,,,,Autocuration,11933,,B,,,,,104686
2397,1,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,BAO_0000019,,,,Autocuration,15538,,B,,,,,104686
2398,1,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,BAO_0000019,,,,Autocuration,15538,,B,,,,,104686
2399,1,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,BAO_0000019,,,,Autocuration,15538,,B,,,,,104686
2400,1,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,BAO_0000019,,,,Autocuration,8841,,B,,,,,104686
2401,1,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,BAO_0000224,,,,Autocuration,1455,,B,,,,,104686
2402,1,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,BAO_0000224,,,,Autocuration,1455,,B,,,,,104686
2403,1,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,BAO_0000019,,,,Autocuration,11752,,B,,,,,104686
2404,1,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,Brain,BAO_0000221,,,,Autocuration,11642,,B,,,,,104686
2405,1,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,BAO_0000224,,,,Autocuration,12092,,B,,,,,104686
2406,1,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,BAO_0000224,,,,Autocuration,3967,,B,,,,,104686
2407,1,Binding affinity towards 5-hydroxytryptamine 2 receptor,,BAO_0000224,,Rattus norvegicus,,Autocuration,12771,,B,10116.0,,,,104686
2408,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,BAO_0000019,,,,Autocuration,11642,,B,,,,,104686
2409,1,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,BAO_0000224,,,,Autocuration,11628,,B,,,,,104686
2410,1,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,BAO_0000224,,,,Autocuration,13654,,B,,,,,104686
2411,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,,,,Autocuration,11200,,F,,,,,104686
2412,1,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,BAO_0000019,,,,Autocuration,11200,,F,,,,,104686
2413,1,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,BAO_0000218,,,,Autocuration,11200,In vivo,F,,,,,104686
2414,1,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,BAO_0000218,,,,Autocuration,11200,In vivo,F,,,,,104686
2415,1,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,BAO_0000218,,,,Autocuration,11200,In vivo,F,,,,,104686
2416,1,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,BAO_0000218,,,,Autocuration,11200,In vivo,F,,,,,104686
2417,1,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,Brain,BAO_0000221,,,,Expert,15436,,B,,,,,12687
2418,1,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,BAO_0000019,,Rattus norvegicus,,Expert,15436,,B,10116.0,,,,12687
2419,1,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,BAO_0000019,,,,Autocuration,14025,,B,,,,,12687
2420,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,,,,Autocuration,4342,,B,,,,,12687
2421,1,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,BAO_0000019,,Rattus norvegicus,,Expert,13735,,B,10116.0,,,,12687
2422,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,BAO_0000357,,Rattus norvegicus,,Expert,5816,,B,10116.0,,,,12687
2423,1,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,BAO_0000019,,,,Expert,14287,,B,,,,,12687
2424,1,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,BAO_0000357,,,,Autocuration,15738,,B,,,,,12687
2425,1,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,,Rattus norvegicus,,Expert,15738,,B,10116.0,,,,12687
2426,1,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,BAO_0000019,,,,Autocuration,15026,,B,,,,,12687
2427,1,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,BAO_0000019,,,,Expert,16647,,B,,,,,12687
2428,1,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,BAO_0000019,,,,Autocuration,16647,,B,,,,,12687
2429,1,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,BAO_0000019,,Rattus norvegicus,,Expert,13345,,B,10116.0,,,,12687
2430,1,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,BAO_0000249,,,,Autocuration,1543,,B,,,,Membranes,12687
2431,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,BAO_0000019,,,,Autocuration,12444,,B,,,,,12687
2432,1,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,BAO_0000019,,,,Expert,16404,,B,,,,,12687
2433,1,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,BAO_0000219,,,,Autocuration,16404,,B,,,CHO,,12687
2434,1,Kinetic inhibition constant evaluated by measuring serotonergic activity,,BAO_0000357,,,,Expert,15577,,B,,,,,12687
2435,1,Serotonergic activity of the compound.,,BAO_0000357,,,,Autocuration,15577,,B,,,,,12687
2436,1,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,BAO_0000249,,,,Autocuration,2495,,B,,,,,12687
2437,1,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,BAO_0000019,,Rattus norvegicus,,Expert,15042,,B,10116.0,,,,12687
2438,1,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,BAO_0000249,,,,Expert,15026,,B,,,,,12687
2439,1,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,BAO_0000019,,Rattus norvegicus,,Expert,12919,,F,10116.0,,,,12687
2440,1,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,BAO_0000019,,Rattus norvegicus,,Expert,12919,,F,10116.0,,,,12687
2441,1,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,BAO_0000019,,Rattus norvegicus,,Expert,12919,,F,10116.0,,,,12687
2442,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,,,,Autocuration,15194,,B,,,,,12687
2443,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,BAO_0000357,,,,Autocuration,15194,,B,,,,,12687
2444,1,Binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Expert,4820,,B,,,,,107
2445,1,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,BAO_0000357,,,,Autocuration,6736,,B,,,,,107
2446,1,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,BAO_0000357,,,,Autocuration,5163,,B,,,,,107
2447,1,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,BAO_0000357,,,,Autocuration,5163,,B,,,,,107
2448,1,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,BAO_0000357,,,,Autocuration,6011,,B,,,,,107
2449,1,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,BAO_0000357,,Homo sapiens,,Expert,14294,,B,9606.0,,,,107
2450,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,5014,,B,,,,,107
2451,1,Binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Expert,17066,,B,,,,,107
2452,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,BAO_0000357,,,,Autocuration,17515,,B,,,,,107
2453,1,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Expert,6736,,B,,,,,107
2454,1,Affinity for 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Expert,5163,,B,,,,,107
2455,1,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,BAO_0000219,,,,Expert,16911,,B,,,NIH3T3,,107
2456,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,BAO_0000357,,,,Expert,6841,,B,,,,,107
2457,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,BAO_0000357,,,,Expert,6119,,B,,,,,107
2458,1,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,3962,,B,,,,,107
2459,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,,,,Autocuration,4373,,B,,,,,107
2460,1,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,,,,Autocuration,4373,,B,,,,,107
2461,1,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,BAO_0000019,,,,Autocuration,3962,,F,,,,,107
2462,1,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,BAO_0000357,,,,Expert,1633,,B,,,,,107
2463,1,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,,,,Autocuration,4373,,B,,,,,107
2464,1,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Expert,6576,,B,,,,,107
2465,1,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,4687,,B,,,,,107
2466,1,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,16946,,B,,,,,107
2467,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,14159,,B,,,,,107
2468,1,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,BAO_0000219,,Mus musculus,,Expert,3032,,B,10090.0,,CHO,,107
2469,1,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,16655,,B,,,,,107
2470,1,Binding affinity at 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,13964,,B,,,,,107
2471,1,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Expert,16989,,B,,,,,107
2472,1,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,BAO_0000357,,,,Autocuration,16117,,B,,,,,107
2473,1,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,BAO_0000357,,,,Autocuration,16700,,B,,,,,107
2474,1,Affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,3269,,B,,,,,107
2475,1,Binding affinity against 5-Hydroxytryptamine 2A receptor,,BAO_0000357,,Homo sapiens,,Expert,1274,,B,9606.0,,,,107
2476,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,BAO_0000357,,,,Autocuration,1317,,B,,,,,107
2477,1,Tested against 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,12146,,B,,,,,107
2478,1,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,BAO_0000224,,,,Autocuration,12652,,B,,,,,105075
2479,1,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,BAO_0000224,,,,Autocuration,12652,,B,,,,,105075
2480,1,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,BAO_0000224,,,,Autocuration,12652,,B,,,,,105075
2481,1,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,BAO_0000224,,,,Autocuration,12652,,B,,,,,105075
2482,1,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,BAO_0000357,,,,Autocuration,16647,,B,,,,,107
2483,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,BAO_0000219,,Homo sapiens,,Expert,15851,,B,9606.0,,HEK293,,227
2484,1,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,BAO_0000219,,Homo sapiens,,Expert,6857,,F,9606.0,,CHO,,227
2485,1,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,BAO_0000357,,,,Autocuration,3805,,B,,,,,227
2486,1,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,BAO_0000357,,Homo sapiens,,Expert,6491,,B,9606.0,,,,227
2487,1,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,BAO_0000019,,,,Autocuration,14093,,F,,,,,227
2488,1,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,BAO_0000019,,,,Autocuration,13481,,F,,,,,227
2489,1,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,BAO_0000019,,,,Autocuration,14093,,F,,,,,227
2490,1,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,BAO_0000019,,,,Autocuration,14093,,F,,,,,227
2491,1,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,BAO_0000019,,,,Autocuration,14093,,F,,,,,227
2492,1,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,BAO_0000019,,,,Autocuration,13481,,F,,,,,227
2493,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,BAO_0000357,,,,Autocuration,14442,,B,,,,,227
2494,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,BAO_0000357,,,,Autocuration,14442,,B,,,,,227
2495,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,BAO_0000357,,,,Autocuration,14442,,B,,,,,227
2496,1,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,12369,,B,,,,,107
2497,1,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,BAO_0000357,,,,Expert,12369,,B,,,,,107
2498,1,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,BAO_0000357,,,,Expert,12369,,B,,,,,107
2499,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,BAO_0000019,,,,Autocuration,14447,,B,,,,,107
2500,1,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,BAO_0000019,,,,Autocuration,14447,,B,,,,,107
2501,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,BAO_0000219,,,,Autocuration,17451,,B,,,NIH3T3,,107
2502,1,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,BAO_0000219,,,,Autocuration,6857,,F,,,CHO,,107
2503,1,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,BAO_0000219,,Homo sapiens,,Expert,6857,,F,9606.0,,CHO,,107
2504,1,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,BAO_0000224,,,,Autocuration,5635,,B,,,,,104817
2505,1,Binding activity radioligand.,,BAO_0000357,,,,Autocuration,12861,,B,,,,,107
2506,1,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,BAO_0000019,,,,Autocuration,12861,,B,,,,,107
2507,1,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,BAO_0000219,,,,Autocuration,5105,,B,,,L929,,107
2508,1,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,BAO_0000219,,,,Expert,5104,,B,,,L929,,107
2509,1,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,BAO_0000219,,,,Expert,5105,,B,,,L929,,107
2510,1,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,BAO_0000219,,,,Autocuration,5105,,B,,,L929,,107
2511,1,Binding affinity against 5-HT2A receptor,,BAO_0000357,,,,Autocuration,5254,,B,,,,,107
2512,1,Binding affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,5254,,B,,,,,107
2513,1,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,BAO_0000219,,,,Autocuration,13267,,B,,,HEK293,,107
2514,1,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,BAO_0000219,,,,Autocuration,13267,,B,,,HEK293,,107
2515,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,BAO_0000219,,Homo sapiens,,Expert,14157,,B,9606.0,,HEK293,,107
2516,1,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,BAO_0000219,,Homo sapiens,,Expert,12936,,B,9606.0,,HEK293,,107
2517,1,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,BAO_0000357,,,,Expert,14068,,B,,,,,107
2518,1,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,BAO_0000219,,Homo sapiens,,Expert,12936,,B,9606.0,,HEK293,,107
2519,1,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,BAO_0000219,,Homo sapiens,,Expert,12936,,B,9606.0,,HEK293,,107
2520,1,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,BAO_0000219,,Homo sapiens,,Expert,4540,,B,9606.0,,HEK293,,107
2521,1,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,BAO_0000357,,,,Expert,6166,,B,,,,,107
2522,1,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,BAO_0000219,,,,Autocuration,17296,,B,,,HEK293,,107
2523,1,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,BAO_0000219,,,,Autocuration,17296,,B,,,HEK293,,107
2524,1,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,BAO_0000219,,,,Autocuration,17296,,B,,,HEK293,,107
2525,1,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,BAO_0000219,,Homo sapiens,,Expert,15779,,B,9606.0,,HEK293,,107
2526,1,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,BAO_0000219,,,,Expert,14391,,B,,,HEK293,,107
2527,1,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,BAO_0000219,,,,Expert,15851,,B,,,HEK293,,107
2528,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,BAO_0000219,,Homo sapiens,,Expert,15851,,B,9606.0,,HEK293,,107
2529,1,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,BAO_0000219,,,,Expert,3832,,B,,,HEK293,,107
2530,1,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,BAO_0000219,,,,Expert,3833,,B,,,HEK293,,107
2531,1,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,BAO_0000219,,Homo sapiens,,Expert,12936,,B,9606.0,,HEK293,,107
2532,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,BAO_0000219,,,,Autocuration,17451,,B,,,NIH3T3,,107
2533,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,BAO_0000219,,,,Autocuration,17451,,B,,,NIH3T3,,107
2534,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,BAO_0000219,,,,Autocuration,17451,,B,,,NIH3T3,,107
2535,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,BAO_0000219,,,,Autocuration,4199,,B,,,HEK293,,107
2536,1,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,BAO_0000219,,,,Autocuration,1883,,B,,,CHO-K1,,107
2537,1,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,BAO_0000219,,,,Expert,1883,,B,,,CHO-K1,,107
2538,1,Binding affinity for human 5-hydroxytryptamine 2A receptor,,BAO_0000357,,Homo sapiens,,Expert,14875,,B,9606.0,,,,107
2539,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,BAO_0000219,,,,Autocuration,15146,,B,,,HEK293,,107
2540,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,BAO_0000219,,,,Autocuration,5213,,B,,,HEK293,,107
2541,1,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,BAO_0000219,,Homo sapiens,,Expert,16404,,B,9606.0,,CHO,,107
2542,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,BAO_0000219,,,,Autocuration,14818,,B,,,HEK293,,107
2543,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,BAO_0000219,,,,Autocuration,4829,,B,,,HEK293,,107
2544,1,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,BAO_0000219,,,,Autocuration,12652,,F,,,NIH3T3,,10620
2545,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,BAO_0000219,,,,Expert,4682,,B,,,NIH3T3,,107
2546,1,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,BAO_0000019,,,,Autocuration,12652,,F,,,,,10620
2547,1,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,4921,,B,,,,,10621
2548,1,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,BAO_0000357,,,,Autocuration,4921,,B,,,,,10621
2549,1,Binding affinity against rabbit aorta 5-HT2A receptor,,BAO_0000357,,Oryctolagus cuniculus,,Autocuration,16312,,B,9986.0,,,,107
2550,1,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,BAO_0000357,,Oryctolagus cuniculus,,Expert,14998,,B,9986.0,,,,107
2551,1,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,BAO_0000357,,Oryctolagus cuniculus,,Expert,14025,,B,9986.0,,,,107
2552,1,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,13047,,B,9986.0,,,,107
2553,1,The compound was tested for binding affinity against 5-HT2A receptor,,BAO_0000357,,Oryctolagus cuniculus,,Expert,13047,,B,9986.0,,,,107
2554,1,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,BAO_0000219,,,,Autocuration,1883,,B,,,CHO-K1,,10576
2555,1,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,BAO_0000019,,,,Autocuration,13463,,B,,,,,12687
2556,1,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,BAO_0000019,,,,Autocuration,13463,,B,,,,,12687
2557,1,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,Stomach,BAO_0000019,,,,Autocuration,13463,,B,,,,,12687
2558,1,Binding affinity for 5-HT 2A in rat stomach fundus,Stomach,BAO_0000019,,Rattus norvegicus,,Expert,13463,,B,10116.0,,,,12687
2559,1,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,BAO_0000019,,,,Autocuration,13463,,B,,,,,12687
2560,1,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,BAO_0000219,,,,Expert,16326,,B,,,NIH3T3,,12687
2561,1,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,BAO_0000019,,,,Autocuration,14093,,F,,,,,12687
2562,1,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,BAO_0000019,,,,Autocuration,14093,,F,,,,,12687
2563,1,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,15740,,B,,,,,12687
2564,1,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,BAO_0000357,,,,Autocuration,16633,,B,,,,,12687
2565,1,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,BAO_0000019,,Rattus norvegicus,,Expert,17200,,F,10116.0,,,,12687
2566,1,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,17133,,B,,,,,12687
2567,1,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,17133,,B,,,,,12687
2568,1,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,17133,,B,,,,,12687
2569,1,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,BAO_0000219,,,,Autocuration,17200,,F,,,,,12687
2570,1,Efficacy at 5-hydroxytryptamine 2A receptor,,BAO_0000019,,,,Autocuration,15363,,F,,,,,12687
2571,1,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,BAO_0000357,,,,Autocuration,17200,,B,,,,,12687
2572,1,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,BAO_0000357,,Rattus norvegicus,,Expert,17200,,B,10116.0,,,,12687
2573,1,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,BAO_0000357,,Rattus norvegicus,,Expert,17200,,B,10116.0,,,,12687
2574,1,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,BAO_0000219,,Rattus norvegicus,,Expert,17200,,F,10116.0,,,,12687
2575,1,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,BAO_0000219,,,,Autocuration,17200,,F,,,,,12687
2576,1,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,BAO_0000019,,,,Autocuration,17211,,B,,,,,12687
2577,1,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,BAO_0000019,,,,Expert,17331,,B,,,,,12687
2578,1,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,BAO_0000249,,,,Expert,13565,,B,,,,,12687
2579,1,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,BAO_0000357,,,,Expert,13730,,B,,,,,12687
2580,1,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,BAO_0000019,,,,Expert,12416,,B,,,,,12687
2581,1,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,15295,,B,,,,,12687
2582,1,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,BAO_0000019,,,,Autocuration,1742,,B,,,,,12687
2583,1,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,15295,,B,,,,,12687
2584,1,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,BAO_0000019,,,,Expert,14970,,B,,,,,12687
2585,1,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,BAO_0000019,,,,Expert,16693,,B,,,,,12687
2586,1,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,BAO_0000019,,Rattus norvegicus,,Expert,14776,,B,10116.0,,,,12687
2587,1,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,,,,Autocuration,14286,,B,,,,,12687
2588,1,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,BAO_0000019,,Rattus norvegicus,,Expert,17200,,B,10116.0,,,,12687
2589,1,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,BAO_0000357,,,,Expert,15306,,B,,,,,12687
2590,1,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,BAO_0000357,,Rattus norvegicus,,Expert,14178,,B,10116.0,,,,12687
2591,1,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,BAO_0000019,,Rattus norvegicus,,Expert,14229,,B,10116.0,,,,12687
2592,1,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,BAO_0000357,,,,Expert,12884,,B,,,,,12687
2593,1,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,BAO_0000357,,,,Expert,13149,,B,,,,,12687
2594,1,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,BAO_0000019,,Rattus norvegicus,,Expert,15295,,B,10116.0,,,,12687
2595,1,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,BAO_0000357,,,,Autocuration,15740,,B,,,,,12687
2596,1,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,BAO_0000019,,,,Autocuration,15185,,B,,,,,12687
2597,1,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,BAO_0000019,,,,Autocuration,15185,,B,,,,,12687
2598,1,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,BAO_0000019,,,,Expert,17529,,B,,,,,12687
2599,1,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,BAO_0000019,,,,Autocuration,14826,,B,,,,,12687
2600,1,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,BAO_0000019,,,,Expert,17211,,B,,,,,12687
2601,1,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,BAO_0000019,,,,Autocuration,14826,,B,,,,,12687
2602,1,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,BAO_0000019,,,,Autocuration,14093,,B,,,,,12687
2603,1,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,BAO_0000019,,,,Autocuration,14093,,B,,,,,12687
2604,1,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,BAO_0000219,,,,Expert,13246,,B,,,NIH3T3,,12687
2605,1,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,BAO_0000357,,,,Expert,13246,,B,,,,,12687
2606,1,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,BAO_0000019,,Rattus norvegicus,,Expert,15436,,B,10116.0,,,,12687
2607,1,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,BAO_0000019,,Rattus norvegicus,,Expert,15436,,B,10116.0,,,,12687
2608,1,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,Brain,BAO_0000221,,,,Autocuration,14442,,B,,,,,12687
2609,1,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Expert,12457,,B,,,,,12687
2610,1,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,BAO_0000219,,,,Expert,12457,,B,,,NIH3T3,,12687
2611,1,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,BAO_0000221,,,,Autocuration,14755,,F,,,,,12687
2612,1,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,BAO_0000357,,,,Autocuration,4707,,B,,,,,12687
2613,1,Binding affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Expert,13297,,B,,,,,12687
2614,1,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,BAO_0000019,,,,Expert,17331,,B,,,,,12687
2615,1,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,BAO_0000019,,,,Autocuration,4664,,B,,,,,12687
2616,1,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,BAO_0000357,,,,Autocuration,16633,,B,,,,,12687
2617,1,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,BAO_0000219,,Rattus norvegicus,,Expert,4664,,B,10116.0,,NIH3T3,,12687
2618,1,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,BAO_0000357,,,,Expert,16133,,B,,,,,12687
2619,1,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,,,,Expert,16133,,B,,,,,12687
2620,1,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,BAO_0000019,,Rattus norvegicus,,Expert,14060,,B,10116.0,,,,12687
2621,1,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,BAO_0000357,,,,Expert,16326,,B,,,,,12687
2622,1,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,BAO_0000219,,,,Expert,16659,,B,,,CHO,,12687
2623,1,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,BAO_0000019,,,,Autocuration,14776,,B,,,,,12687
2624,1,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,BAO_0000357,,,,Autocuration,13481,,B,,,,,12687
2625,1,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,17386,,B,,,,,12687
2626,1,Binding affinity for 5-hydroxytryptamine 2A receptor,,BAO_0000357,,Rattus norvegicus,,Expert,6611,,B,10116.0,,,,12687
2627,1,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,BAO_0000019,,,,Autocuration,14423,,B,,,,,12687
2628,1,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,BAO_0000019,,,,Autocuration,15412,,B,,,,,12687
2629,1,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,BAO_0000019,,,,Autocuration,15412,,B,,,,,12687
2630,1,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,BAO_0000019,,,,Autocuration,6238,,B,,,,,12687
2631,1,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,BAO_0000357,,,,Expert,6648,,B,,,,,12687
2632,1,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,BAO_0000357,,,,Expert,5667,,B,,,,,12687
2633,1,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,BAO_0000357,,Rattus norvegicus,,Expert,6611,,B,10116.0,,,,12687
2634,1,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,,,,Autocuration,13481,,B,,,,,12687
2635,1,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,BAO_0000357,,,,Autocuration,13481,,B,,,,,12687
2636,1,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,BAO_0000219,,,,Expert,15558,,B,,,NIH3T3,,12687
2637,1,Binding affinity towards 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,6013,,B,,,,,12687
2638,1,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,BAO_0000357,,,,Autocuration,16633,,B,,,,,12687
2639,1,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,BAO_0000357,,,,Autocuration,6013,,B,,,,,12687
2640,1,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,BAO_0000357,,Rattus norvegicus,,Expert,6013,,B,10116.0,,,,12687
2641,1,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,BAO_0000357,,,,Autocuration,6013,,B,,,,,12687
2642,1,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,BAO_0000357,,,,Expert,6013,,B,,,,,12687
2643,1,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,BAO_0000357,,,,Autocuration,6013,,B,,,,,12687
2644,1,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,BAO_0000357,,,,Autocuration,6013,,B,,,,,12687
2645,1,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,16293,,B,,,,,12687
2646,1,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,BAO_0000219,,,,Expert,17175,,B,,,NIH3T3,,12687
2647,1,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,BAO_0000357,,Rattus norvegicus,,Expert,13278,,B,10116.0,,,,12687
2648,1,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,Caudate-putamen,BAO_0000019,,,,Autocuration,3682,,B,,,,,12687
2649,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,BAO_0000357,,,,Autocuration,2014,,B,,,,,12687
2650,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,BAO_0000357,,,,Autocuration,2014,,B,,,,,12687
2651,1,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,BAO_0000357,,,,Autocuration,4932,,B,,,,,12687
2652,1,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,BAO_0000019,,,,Autocuration,4932,,B,,,,,12687
2653,1,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,3935,,B,,,,,12687
2654,1,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,Hippocampus,BAO_0000221,,Rattus norvegicus,,Expert,5432,,B,10116.0,,,,12687
2655,1,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,15818,,B,,,,,12687
2656,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,BAO_0000357,,,,Autocuration,13672,,B,,,,,12687
2657,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,BAO_0000357,,,,Autocuration,13672,,B,,,,,12687
2658,1,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,BAO_0000219,,,,Expert,14749,,B,,,NIH3T3,,12687
2659,1,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,BAO_0000019,,,,Autocuration,13462,,B,,,,,12687
2660,1,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,15740,,B,,,,,12687
2661,1,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,BAO_0000019,,,,Expert,16647,,B,,,,,12687
2662,1,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,Brain,BAO_0000221,,,,Autocuration,13345,,B,,,,,12687
2663,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,,,,Autocuration,16740,,B,,,,,12687
2664,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,,,,Autocuration,16740,,B,,,,,12687
2665,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,BAO_0000019,,Rattus norvegicus,,Expert,15535,,B,10116.0,,,,12687
2666,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,,,,Expert,16740,,B,,,,,12687
2667,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,,,,Autocuration,16740,,B,,,,,12687
2668,1,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,BAO_0000249,,,,Autocuration,16740,,B,,,,,12687
2669,1,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,BAO_0000019,,Rattus norvegicus,,Expert,4795,,B,10116.0,,,,12687
2670,1,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,BAO_0000019,,,,Expert,8,,B,,,,,12687
2671,1,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,BAO_0000019,,,,Autocuration,8,,B,,,,,12687
2672,1,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,BAO_0000019,,Rattus norvegicus,,Expert,17200,,B,10116.0,,,,12687
2673,1,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,BAO_0000019,,Rattus norvegicus,,Expert,2148,,B,10116.0,,,,12687
2674,1,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,BAO_0000224,,Rattus norvegicus,,Expert,13345,,B,10116.0,,,,105102
2675,1,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,BAO_0000357,,,,Autocuration,5088,,B,,,,,12687
2676,1,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,BAO_0000357,,,,Autocuration,5088,,B,,,,,12687
2677,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,BAO_0000357,,,,Autocuration,17133,,B,,,,,12687
2678,1,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,BAO_0000357,,Rattus norvegicus,,Expert,17133,,B,10116.0,,,,12687
2679,1,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,BAO_0000357,,,,Autocuration,16532,,B,,,,,12687
2680,1,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,BAO_0000357,,,,Autocuration,15086,,B,,,,,12687
2681,1,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,BAO_0000019,,Rattus norvegicus,,Expert,2309,,B,10116.0,,,,12687
2682,1,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,BAO_0000019,,,,Expert,12953,,B,,,,,12687
2683,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,BAO_0000019,,,,Autocuration,12953,,B,,,,,12687
2684,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,BAO_0000019,,,,Autocuration,12953,,B,,,,,12687
2685,1,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,BAO_0000219,,,,Autocuration,16659,,B,,,CHO,,12687
2686,1,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,BAO_0000019,,,,Autocuration,16740,,B,,,,,12687
2687,1,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,BAO_0000019,,,,Autocuration,16740,,B,,,,,12687
2688,1,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,BAO_0000357,,,,Autocuration,17133,,B,,,,,12687
2689,1,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,BAO_0000019,,,,Autocuration,17211,,B,,,,,12687
2690,1,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,BAO_0000019,,,,Autocuration,17331,,B,,,,,12687
2691,1,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,BAO_0000218,,,,Autocuration,16633,,B,,,,,12687
2692,1,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,BAO_0000218,,,,Autocuration,16633,,B,,,,,12687
2693,1,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,BAO_0000218,,,,Autocuration,16633,,B,,,,,12687
2694,1,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,BAO_0000357,,,,Expert,15026,,B,,,,,12687
2695,1,Ratio of pKi of 5-HT2A to that of D2 receptor,,BAO_0000357,,,,Expert,15026,,B,,,,,12687
2696,1,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,BAO_0000224,,,,Expert,16404,,B,,,,,105093
2697,1,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,BAO_0000224,,,,Expert,16404,,B,,,,,105093
2698,1,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,BAO_0000224,,,,Expert,16404,,B,,,,,105075
2699,1,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,BAO_0000357,,,,Autocuration,16404,,B,,,,,12687
2700,1,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,BAO_0000357,,,,Expert,16326,,B,,,,,12687
2701,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,BAO_0000019,,,,Autocuration,15847,,F,,,,,12687
2702,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,BAO_0000019,,,,Autocuration,15847,,F,,,,,12687
2703,1,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,BAO_0000019,,,,Autocuration,15329,,F,,,,,12687
2704,1,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,Thoracic aorta,BAO_0000019,,,,Expert,16404,,F,,,,,12687
2705,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,Thoracic aorta,BAO_0000019,,,,Expert,16404,,F,,,,,12687
2706,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,Thoracic aorta,BAO_0000019,,,,Autocuration,16404,,F,,,,,12687
2707,1,Binding activity radioligand.,,BAO_0000357,,,,Autocuration,12861,,B,,,,,12687
2708,1,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,BAO_0000019,,,,Expert,12861,,B,,,,,12687
2709,1,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,BAO_0000019,,,,Autocuration,12861,,B,,,,,12687
2710,1,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,BAO_0000019,,,,Expert,12490,,B,,,,,12687
2711,1,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,BAO_0000219,,,,Autocuration,12827,,B,,,N1E-115,,12687
2712,1,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,BAO_0000219,,,,Autocuration,12827,,B,,,N1E-115,,12687
2713,1,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,BAO_0000019,,,,Autocuration,12918,,B,,,,,12687
2714,1,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,BAO_0000019,,Rattus norvegicus,,Expert,12919,,F,10116.0,,,,12687
2715,1,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,17723,,B,,,,,108
2716,1,Binding affinity towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,6013,,B,,,,,108
2717,1,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,16293,,B,,,,,108
2718,1,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,BAO_0000019,,,,Expert,3857,,B,,,,,108
2719,1,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,BAO_0000019,,,,Expert,3857,,B,,,,,108
2720,1,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,BAO_0000019,,,,Expert,3857,,B,,,,,108
2721,1,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,15363,,B,,,,,108
2722,1,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,15363,,B,,,,,108
2723,1,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,BAO_0000019,,,,Expert,16441,,B,,,,,108
2724,1,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,BAO_0000019,,,,Expert,16441,,B,,,,,108
2725,1,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,BAO_0000219,,,,Autocuration,4176,,B,,,HEK293,,108
2726,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,BAO_0000019,,,,Autocuration,17085,,B,,,,,108
2727,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,BAO_0000357,,Homo sapiens,,Expert,17200,,B,9606.0,,,,108
2728,1,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,BAO_0000357,,,,Expert,5088,,B,,,,,108
2729,1,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,BAO_0000357,,,,Autocuration,5088,,B,,,,,108
2730,1,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000357,,,,Autocuration,5088,,B,,,,,108
2731,1,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,5088,,B,,,,,108
2732,1,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,BAO_0000219,,,,Autocuration,16659,,B,,,CHO,,108
2733,1,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,BAO_0000219,,,,Autocuration,16659,,B,,,CHO,,108
2734,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,BAO_0000219,,,,Autocuration,17451,,B,,,NIH3T3,,108
2735,1,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,BAO_0000219,,Homo sapiens,,Expert,6857,,F,9606.0,,CHO,,108
2736,1,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,BAO_0000019,,,,Expert,3857,,B,,,,,108
2737,1,Binding activity radioligand.,,BAO_0000357,,,,Autocuration,12861,,B,,,,,108
2738,1,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,BAO_0000019,,,,Autocuration,12861,,B,,,,,108
2739,1,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,BAO_0000219,,,,Expert,5104,,B,,,CHO,,108
2740,1,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,BAO_0000219,,,,Expert,5105,,B,,,CHO,,108
2741,1,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,BAO_0000219,,,,Autocuration,5105,,B,,,CHO,,108
2742,1,Binding affinity against 5-HT2C receptor,,BAO_0000357,,,,Autocuration,5254,,B,,,,,108
2743,1,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,BAO_0000219,,,,Autocuration,13267,,B,,,HEK293,,108
2744,1,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,BAO_0000219,,Homo sapiens,,Expert,14157,,B,9606.0,,HEK293,,108
2745,1,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,BAO_0000219,,Homo sapiens,,Expert,12936,,B,9606.0,,HEK293,,108
2746,1,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,BAO_0000357,,,,Expert,14068,,B,,,,,108
2747,1,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,BAO_0000219,,Homo sapiens,,Expert,12936,,B,9606.0,,HEK293,,108
2748,1,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,BAO_0000219,,Homo sapiens,,Expert,4540,,B,9606.0,,HEK293,,108
2749,1,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,BAO_0000219,,Homo sapiens,,Expert,4540,,B,9606.0,,HEK293,,108
2750,1,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,BAO_0000357,,,,Autocuration,6166,,B,,,,,108
2751,1,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,BAO_0000219,,,,Autocuration,17296,,B,,,HEK293,,108
2752,1,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,BAO_0000219,,,,Autocuration,17296,,B,,,HEK293,,108
2753,1,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,BAO_0000219,,,,Autocuration,15779,,B,,,HEK293,,108
2754,1,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,BAO_0000219,,,,Autocuration,15779,,B,,,HEK293,,108
2755,1,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,BAO_0000219,,,,Expert,14391,,B,,,HEK293,,108
2756,1,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,BAO_0000219,,,,Autocuration,15779,,B,,,HEK293,,108
2757,1,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,BAO_0000219,,,,Expert,15851,,B,,,HEK293,,108
2758,1,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,BAO_0000219,,Homo sapiens,,Expert,15851,,B,9606.0,,HEK293,,108
2759,1,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,BAO_0000219,,,,Autocuration,15779,,B,,,HEK293,,108
2760,1,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,BAO_0000219,,,,Expert,3832,,B,,,HEK293,,108
2761,1,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,BAO_0000219,,,,Expert,3833,,B,,,HEK293,,108
2762,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,BAO_0000219,,,,Autocuration,17451,,B,,,NIH3T3,,108
2763,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,BAO_0000219,,,,Autocuration,4199,,B,,,HEK293,,108
2764,1,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,BAO_0000219,,,,Expert,1883,,B,,,CHO-K1,,108
2765,1,Binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,,Homo sapiens,,Expert,4321,,B,9606.0,,,,108
2766,1,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,14875,,B,,,,,108
2767,1,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,BAO_0000219,,,,Autocuration,15146,,B,,,HEK293,,108
2768,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,BAO_0000219,,,,Autocuration,5213,,B,,,HEK293,,108
2769,1,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,BAO_0000219,,,,Autocuration,16404,,B,,,HeLa,,108
2770,1,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,BAO_0000019,,,,Autocuration,13267,,F,,,,,108
2771,1,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,Hippocampus,BAO_0000221,,,,Autocuration,13267,,F,,,,,108
2772,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,BAO_0000219,,,,Autocuration,14818,,B,,,HEK293,,108
2773,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,BAO_0000219,,,,Autocuration,4829,,B,,,HEK293,,108
2774,1,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,BAO_0000357,,,,Autocuration,13463,,B,,,,,11864
2775,1,Binding affinity analysed on 5-HT 2C in rat stomach fundus,Stomach,BAO_0000019,,,,Autocuration,13463,,B,,,,,11864
2776,1,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,Stomach,BAO_0000019,,,,Autocuration,13463,,B,,,,,11864
2777,1,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,BAO_0000219,,,,Autocuration,12652,,F,,,A9,,11864
2778,1,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,BAO_0000219,,,,Autocuration,4682,,B,,,NIH3T3,,11864
2779,1,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,BAO_0000219,,,,Autocuration,4682,,B,,,NIH3T3,,11864
2780,1,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,BAO_0000219,,,,Autocuration,4682,,B,,,NIH3T3,,11864
2781,1,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,BAO_0000019,,,,Autocuration,12652,,F,,,,,11864
2782,1,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,Stomach,BAO_0000019,,Mus musculus,,Autocuration,13463,,B,10090.0,,,,12689
2783,1,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,Stomach,BAO_0000019,,Rattus norvegicus,,Expert,13463,,B,10116.0,,,,12689
2784,1,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,BAO_0000357,,,,Expert,13969,,B,,,,,108
2785,1,Binding affinity for 5-hydroxytryptamine 2C receptor,,BAO_0000357,,Sus scrofa,,Expert,13392,,B,9823.0,,,,108
2786,1,Binding affinity towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Expert,13392,,B,,,,,108
2787,1,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,BAO_0000019,,,,Expert,14430,,B,,,,,108
2788,1,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,BAO_0000019,,,,Autocuration,1742,,B,,,,,108
2789,1,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,BAO_0000249,,,,Autocuration,14286,,B,,,,,108
2790,1,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,5619,,B,,,,,108
2791,1,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,15086,,B,,,,,108
2792,1,Binding activity radioligand.,,BAO_0000357,,,,Autocuration,12861,,B,,,,,108
2793,1,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,BAO_0000019,,,,Expert,12861,,B,,,,,108
2794,1,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,BAO_0000019,,,,Autocuration,12861,,B,,,,,108
2795,1,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,BAO_0000249,,,,Autocuration,12827,,B,,,,,108
2796,1,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,BAO_0000249,,,,Autocuration,12827,,B,,,,,108
2797,1,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,BAO_0000019,,Sus scrofa,,Expert,12919,,F,9823.0,,,,108
2798,1,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,BAO_0000019,,Sus scrofa,,Expert,12919,,F,9823.0,,,,108
2799,1,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,BAO_0000357,,Sus scrofa,,Autocuration,16429,,B,9823.0,,,,108
2800,1,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,BAO_0000019,,Sus scrofa,,Autocuration,773,,B,9823.0,,,,108
2801,1,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,BAO_0000357,,Sus scrofa,,Autocuration,5033,,B,9823.0,,,,108
2802,1,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,BAO_0000019,,,,Autocuration,12861,,B,,,,,12687
2803,1,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,BAO_0000019,,,,Autocuration,14093,,F,,,,,12689
2804,1,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,BAO_0000357,,,,Expert,14970,,B,,,,,12689
2805,1,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,BAO_0000357,,,,Autocuration,14970,,B,,,,,12689
2806,1,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,BAO_0000357,,,,Autocuration,14970,,B,,,,,12689
2807,1,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,BAO_0000357,,Rattus norvegicus,,Expert,14178,,B,10116.0,,,,12689
2808,1,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,BAO_0000357,,Rattus norvegicus,,Expert,14178,,B,10116.0,,,,12689
2809,1,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,BAO_0000249,,Rattus norvegicus,,Expert,14229,,B,10116.0,,,Brain membranes,12689
2810,1,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,BAO_0000357,,,,Autocuration,16532,,B,,,,,12689
2811,1,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,BAO_0000019,,,,Autocuration,14826,,B,,,,,12689
2812,1,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,BAO_0000019,,,,Autocuration,17211,,B,,,,,12689
2813,1,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,BAO_0000219,,,,Expert,17211,In vitro,B,,,,,12689
2814,1,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,BAO_0000219,,,,Expert,13246,,B,,,NIH3T3,,12689
2815,1,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,BAO_0000357,,,,Expert,13246,,B,,,,,12689
2816,1,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Expert,12457,,B,,,,,12689
2817,1,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,BAO_0000219,,,,Expert,12457,,B,,,NIH3T3,,12689
2818,1,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,BAO_0000357,,,,Autocuration,4707,,B,,,,,12689
2819,1,Binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Expert,13297,,B,,,,,12689
2820,1,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,BAO_0000357,,,,Autocuration,16633,,B,,,,,12689
2821,1,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000357,,,,Expert,16133,,B,,,,,12689
2822,1,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,BAO_0000357,,,,Expert,16326,,B,,,,,12689
2823,1,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,BAO_0000019,,,,Autocuration,14423,,B,,,,,12689
2824,1,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,BAO_0000019,,,,Autocuration,15412,,B,,,,,12689
2825,1,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,BAO_0000019,,,,Autocuration,15412,,B,,,,,12689
2826,1,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,BAO_0000219,,,,Expert,15558,,B,,,A9,,12689
2827,1,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,BAO_0000357,,,,Autocuration,16633,,B,,,,,12689
2828,1,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,BAO_0000357,,,,Expert,6013,,B,,,,,12689
2829,1,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,BAO_0000219,,,,Expert,17175,In vitro,B,,,,,12689
2830,1,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,BAO_0000219,,,,Autocuration,12469,,B,,,,,12689
2831,1,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,Caudate-putamen,BAO_0000019,,,,Autocuration,3682,,B,,,,,12689
2832,1,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,BAO_0000357,,,,Autocuration,4932,,B,,,,,12689
2833,1,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,BAO_0000019,,,,Autocuration,4932,,B,,,,,12689
2834,1,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,3935,,B,,,,,12689
2835,1,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,15818,,B,,,,,12689
2836,1,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,15818,,B,,,,,12689
2837,1,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,BAO_0000219,,,,Expert,14749,,B,,,,,12689
2838,1,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,15740,,B,,,,,12689
2839,1,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,BAO_0000357,,Rattus norvegicus,,Expert,17133,,B,10116.0,,,,12689
2840,1,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,BAO_0000357,,,,Autocuration,16532,,B,,,,,12689
2841,1,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,12369,,B,,,,,12689
2842,1,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,BAO_0000219,,,,Expert,12369,,B,,,,,12689
2843,1,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,BAO_0000019,,Rattus norvegicus,,Expert,2309,,B,10116.0,,,,12689
2844,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,12953,,B,,,,,12689
2845,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,BAO_0000019,,,,Autocuration,12953,,B,,,,,12689
2846,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,BAO_0000357,,,,Autocuration,12953,,B,,,,,12689
2847,1,Binding affinity for 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Expert,12953,,B,,,,,12689
2848,1,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,BAO_0000357,,,,Autocuration,17133,,B,,,,,12689
2849,1,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,BAO_0000019,,,,Autocuration,17211,,B,,,,,12689
2850,1,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,BAO_0000019,,,,Autocuration,17211,,B,,,,,12689
2851,1,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,BAO_0000019,,,,Autocuration,14025,,B,,,,,12689
2852,1,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,BAO_0000019,,,,Autocuration,14998,,B,,,,,12689
2853,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,BAO_0000357,,,,Autocuration,4342,,B,,,,,12689
2854,1,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,BAO_0000019,,Rattus norvegicus,,Expert,13735,,B,10116.0,,,,12689
2855,1,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,13181,,B,,,,,12689
2856,1,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,BAO_0000219,,,,Autocuration,1883,,B,,,CHO-K1,,12689
2857,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000357,,,,Autocuration,15194,,B,,,,,12689
2858,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,BAO_0000357,,,,Autocuration,15194,,B,,,,,12689
2859,1,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,BAO_0000019,,,,Autocuration,14579,,F,,,,,12689
2860,1,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,4639,,B,,,,,108
2861,1,Binding affinity towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Expert,4820,,B,,,,,108
2862,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,BAO_0000357,,,,Autocuration,14442,,B,,,,,227
2863,1,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,BAO_0000357,,,,Autocuration,14755,,B,,,,,227
2864,1,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,BAO_0000357,,,,Autocuration,14744,,B,,,,,227
2865,1,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,BAO_0000019,,Homo sapiens,,Expert,6857,,B,9606.0,,,,227
2866,1,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,16209,,B,,,,,227
2867,1,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,BAO_0000357,,,,Autocuration,15363,,B,,,,,227
2868,1,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,BAO_0000357,,,,Autocuration,15363,,B,,,,,227
2869,1,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,BAO_0000357,,,,Autocuration,15363,,B,,,,,227
2870,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,BAO_0000019,,,,Autocuration,17085,,B,,,,,227
2871,1,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,BAO_0000357,,Homo sapiens,,Expert,17200,,B,9606.0,,,,227
2872,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,BAO_0000219,,Homo sapiens,,Expert,15851,,B,9606.0,,HEK293,,227
2873,1,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,BAO_0000219,,Homo sapiens,,Expert,15851,,B,9606.0,,HEK293,,227
2874,1,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,BAO_0000219,,Homo sapiens,,Expert,6857,,F,9606.0,,CHO,,227
2875,1,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,BAO_0000219,,Homo sapiens,,Expert,6857,,F,9606.0,,CHO,,227
2876,1,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,BAO_0000219,,,,Autocuration,15779,,B,,,HEK293,,227
2877,1,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,BAO_0000219,,,,Expert,15851,,B,,,HEK293,,227
2878,1,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,BAO_0000219,,,,Autocuration,15779,,B,,,HEK293,,227
2879,1,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,BAO_0000219,,Homo sapiens,,Expert,14157,,B,9606.0,,HEK293,,227
2880,1,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,BAO_0000219,,Homo sapiens,,Expert,4540,,B,9606.0,,HEK293,,227
2881,1,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,BAO_0000357,,,,Autocuration,6166,,B,,,,,227
2882,1,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,B,,,HEK293,,227
2883,1,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,BAO_0000219,,,,Expert,14391,,B,,,HEK293,,227
2884,1,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,BAO_0000219,,,,Expert,3832,,B,,,HEK293,,227
2885,1,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,BAO_0000219,,,,Expert,3833,,B,,,HEK293,,227
2886,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,BAO_0000219,,Homo sapiens,,Expert,15851,,B,9606.0,,HEK293,,227
2887,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,BAO_0000219,,Homo sapiens,,Expert,15851,,B,9606.0,,HEK293,,227
2888,1,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,BAO_0000219,,,,Autocuration,4199,,B,,,HEK293,,227
2889,1,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,BAO_0000219,,,,Expert,1883,,B,,,CHO-K1,,227
2890,1,Binding affinity against 5-hydroxytryptamine 2B receptor,,BAO_0000357,,,,Expert,4321,,B,,,,,227
2891,1,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,BAO_0000219,,,,Autocuration,15146,,B,,,HEK293,,227
2892,1,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,BAO_0000219,,,,Autocuration,5213,,B,,,HEK293,,227
2893,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,BAO_0000219,,,,Autocuration,14818,,B,,,HEK293,,227
2894,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,BAO_0000219,,,,Autocuration,4829,,B,,,HEK293,,227
2895,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,BAO_0000219,,,,Autocuration,4829,,B,,,HEK293,,227
2896,1,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,14025,,B,9986.0,,,,227
2897,1,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,Stomach,BAO_0000019,,,,Expert,13463,,B,,,,,12688
2898,1,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,Stomach,BAO_0000357,,,,Expert,7259,,B,,,,,12688
2899,1,Affinity against serotonergic receptor in the isolated rat stomach fundus,Stomach,BAO_0000357,,,,Autocuration,7259,,B,,,,,12688
2900,1,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,Stomach,BAO_0000019,,Rattus norvegicus,,Expert,7185,,F,10116.0,,,,12688
2901,1,Antagonistic against 5-hydroxytryptamine 2B receptor,,BAO_0000019,,Rattus norvegicus,,Expert,7185,,F,10116.0,,,,12688
2902,1,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,Stomach,BAO_0000019,,,,Autocuration,13267,,F,,,,,12688
2903,1,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,Stomach,BAO_0000357,,Rattus norvegicus,,Expert,13735,,B,10116.0,,,,12688
2904,1,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,BAO_0000019,,,,Autocuration,15738,,F,,,,,12688
2905,1,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,BAO_0000019,,,,Autocuration,15738,,F,,,,,12688
2906,1,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,BAO_0000019,,,,Autocuration,15738,,F,,,,,12688
2907,1,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Stomach,BAO_0000357,,Rattus norvegicus,,Expert,12936,,B,10116.0,,,,12688
2908,1,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Stomach,BAO_0000357,,Rattus norvegicus,,Expert,12936,,B,10116.0,,,,12688
2909,1,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Stomach,BAO_0000357,,Rattus norvegicus,,Expert,12936,,B,10116.0,,,,12688
2910,1,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Stomach,BAO_0000357,,Rattus norvegicus,,Expert,12936,,B,10116.0,,,,12688
2911,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Stomach,BAO_0000019,,,,Autocuration,16404,,F,,,,,12688
2912,1,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Stomach,BAO_0000019,,,,Expert,16404,,F,,,,,12688
2913,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,Stomach,BAO_0000019,,,,Autocuration,16404,,F,,,,,12688
2914,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,Stomach,BAO_0000019,,,,Autocuration,16404,,F,,,,,12688
2915,1,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,Stomach,BAO_0000019,,Rattus norvegicus,,Expert,16404,,F,10116.0,,,,12688
2916,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,Thoracic aorta,BAO_0000019,,,,Autocuration,16404,,F,,,,,12688
2917,1,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,BAO_0000357,,,,Autocuration,7483,,B,,,,,12688
2918,1,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,BAO_0000357,,,,Expert,7483,,B,,,,,12688
2919,1,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,BAO_0000357,,,,Autocuration,7483,,B,,,,,12688
2920,1,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,BAO_0000357,,,,Autocuration,7483,,B,,,,,12688
2922,1,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Stomach,BAO_0000019,,Rattus norvegicus,,Autocuration,16404,,F,10116.0,,,,12688
2923,1,Binding affinity against 5-hydroxytryptamine 1A receptor,,BAO_0000357,,,,Autocuration,6347,,B,,,,,227
2924,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,BAO_0000357,,,,Autocuration,4373,,B,,,,,227
2925,1,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,BAO_0000357,,,,Autocuration,4373,,B,,,,,227
2926,1,Evaluated for the binding affinity to 5-HT 2B receptor,,BAO_0000357,,,,Autocuration,4687,,B,,,,,227
2927,1,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,BAO_0000357,,,,Autocuration,16946,,B,,,,,227
2928,1,Binding affinities against 5-hydroxytryptamine 2B receptor,,BAO_0000357,,,,Autocuration,16633,,B,,,,,227
2929,1,Binding affinities towards 5-hydroxytryptamine 2B receptor,,BAO_0000357,,,,Autocuration,16633,,B,,,,,227
2930,1,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,BAO_0000357,,,,Autocuration,16633,,B,,,,,227
2931,1,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,BAO_0000357,,,,Expert,15026,,B,,,,,108
2932,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,BAO_0000357,,Bos taurus,,Autocuration,15738,,B,9913.0,,,,108
2933,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,BAO_0000357,,Bos taurus,,Autocuration,15738,,B,9913.0,,,,108
2934,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,BAO_0000357,,Bos taurus,,Autocuration,15738,,B,9913.0,,,,108
2935,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,BAO_0000357,,Bos taurus,,Autocuration,15738,,B,9913.0,,,,108
2936,1,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,BAO_0000357,,Bos taurus,,Expert,16404,,B,9913.0,,,,108
2937,1,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,BAO_0000357,,Bos taurus,,Expert,15026,,B,9913.0,,,,108
2938,1,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,BAO_0000357,,Bos taurus,,Autocuration,15738,,B,9913.0,,,,108
2939,1,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,BAO_0000019,,Cavia porcellus,,Autocuration,16312,,B,10141.0,,,,108
2940,1,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,Striatum,BAO_0000357,,Cavia porcellus,,Intermediate,5486,,B,10141.0,,,,20033
2941,1,Binding affinity against 5-HT1A receptor,,BAO_0000357,,,,Autocuration,5254,,B,,,,,51
2942,1,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,BAO_0000219,,,,Expert,3857,,F,,,CHO,,108
2943,1,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,BAO_0000219,,Homo sapiens,,Expert,6857,,F,9606.0,,CHO,,108
2944,1,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,BAO_0000219,,,,Autocuration,4176,,F,,,,,108
2945,1,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,BAO_0000219,,,,Autocuration,6347,,B,,,CHO,,108
2946,1,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,BAO_0000219,,,,Autocuration,6347,,B,,,CHO,,108
2947,1,Inhibition of human 5-hydroxytryptamine 2C receptor,,BAO_0000357,,Homo sapiens,,Expert,16146,,B,9606.0,,,,108
2948,1,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,BAO_0000357,,,,Autocuration,3805,,B,,,,,108
2949,1,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,BAO_0000019,,,,Autocuration,3857,,B,,,,,108
2950,1,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,5635,,B,,,,,108
2951,1,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,BAO_0000357,,,,Autocuration,5635,,B,,,,,108
2952,1,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,BAO_0000357,,,,Autocuration,5635,,B,,,,,108
2953,1,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,BAO_0000219,,,,Expert,4012,,B,,,CHO,,108
2954,1,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,BAO_0000219,,,,Expert,6366,,B,,,CHO,,108
2955,1,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,BAO_0000219,,,,Expert,15949,,B,,,CHO,,108
2956,1,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,BAO_0000219,,,,Autocuration,17211,,B,,,CHO,,108
2957,1,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,BAO_0000357,,Homo sapiens,,Expert,6491,,B,9606.0,,,,108
2958,1,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,BAO_0000019,,,,Autocuration,14093,,F,,,,,108
2959,1,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,BAO_0000019,,,,Autocuration,13481,,F,,,,,108
2960,1,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,BAO_0000219,,Rattus norvegicus,,Expert,6347,,B,10116.0,,CHO,,108
2961,1,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,BAO_0000019,,,,Autocuration,14093,,F,,,,,108
2962,1,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,BAO_0000019,,,,Autocuration,14093,,F,,,,,108
2963,1,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000019,,,,Autocuration,13481,,F,,,,,108
2964,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,BAO_0000357,,,,Autocuration,14442,,B,,,,,108
2965,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,BAO_0000357,,,,Autocuration,14442,,B,,,,,108
2966,1,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,BAO_0000357,,,,Autocuration,14442,,B,,,,,108
2967,1,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,BAO_0000357,,,,Autocuration,14755,,B,,,,,108
2968,1,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,BAO_0000357,,,,Autocuration,14744,,B,,,,,108
2969,1,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,BAO_0000219,,,,Expert,16659,,B,,,CHO,,108
2970,1,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,BAO_0000019,,Homo sapiens,,Expert,6857,,B,9606.0,,,,108
2971,1,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,BAO_0000357,,,,Expert,5635,,B,,,,,108
2972,1,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,BAO_0000357,,Homo sapiens,,Expert,4234,,B,9606.0,,,,108
2973,1,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,BAO_0000357,,,,Autocuration,16209,,B,,,,,108
2974,1,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,BAO_0000249,,Rattus norvegicus,,Autocuration,5778,,B,10116.0,,,Membranes,104698
2975,1,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,BAO_0000223,,,,Autocuration,5094,,B,,,,,104698
2976,1,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,BAO_0000019,,Rattus norvegicus,,Autocuration,809,,B,10116.0,,,,104698
2977,1,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,BAO_0000019,,,,Autocuration,1578,,B,,,,,104698
2978,1,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,BAO_0000019,,,,Autocuration,809,,B,,,,,104698
2979,1,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,BAO_0000219,,,,Autocuration,12469,,B,,,,,104698
2980,1,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,BAO_0000019,,,,Autocuration,14290,,B,,,,,104698
2981,1,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,BAO_0000019,,,,Autocuration,14290,,B,,,,,104698
2982,1,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,BAO_0000223,,,,Autocuration,10609,,B,,,,,104698
2983,1,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,BAO_0000223,,,,Autocuration,10609,,B,,,,,104698
2984,1,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,BAO_0000223,,,,Autocuration,10609,,B,,,,,104698
2985,1,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,BAO_0000249,,,,Autocuration,15253,,B,,,,,104698
2986,1,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,BAO_0000249,,,,Autocuration,15253,,B,,,,,104698
2987,1,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,BAO_0000249,,,,Autocuration,11683,,B,,,,Membranes,104698
2988,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,12092,,B,,,,,104698
2989,1,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,BAO_0000019,,,,Autocuration,1946,,B,,,,,104698
2990,1,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,BAO_0000223,,,,Autocuration,11623,,B,,,,,104698
2991,1,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,BAO_0000223,,,,Autocuration,11623,,B,,,,,104698
2992,1,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,BAO_0000019,,,,Autocuration,14788,,B,,,,,104698
2993,1,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,BAO_0000019,,Rattus norvegicus,,Autocuration,5432,,B,10116.0,,,,104698
2994,1,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,BAO_0000249,,,,Autocuration,14826,,B,,,,,104698
2995,1,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,2222,,B,,,,,104698
2996,1,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,BAO_0000019,,,,Autocuration,11963,,B,,,,,104698
2997,1,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,BAO_0000019,,,,Autocuration,14145,,B,,,,,104698
2998,1,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,BAO_0000019,,,,Autocuration,17819,,B,,,,,104698
2999,1,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,BAO_0000249,,,,Autocuration,10394,,B,,,,,104698
3000,1,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,BAO_0000249,,,,Autocuration,10394,,B,,,,,104698
3001,1,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,BAO_0000019,,,,Autocuration,15034,,B,,,,,104698
3002,1,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,BAO_0000019,,,,Autocuration,691,,B,,,,,104698
3003,1,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,BAO_0000249,,,,Autocuration,12092,,B,,,,Membranes,104698
3004,1,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,BAO_0000223,,Rattus norvegicus,,Autocuration,11752,,B,10116.0,,,,104698
3005,1,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,Brain,BAO_0000221,,,,Autocuration,11752,,B,,,,,104698
3006,1,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,BAO_0000019,,,,Autocuration,301,,B,,,,,104698
3007,1,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,BAO_0000223,,,,Autocuration,16532,,B,,,,,104698
3008,1,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,BAO_0000223,,,,Autocuration,16532,,B,,,,,104698
3009,1,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,BAO_0000223,,,,Autocuration,12092,,B,,,,,104698
3010,1,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,BAO_0000223,,,,Autocuration,11684,,B,,,,,104698
3011,1,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,BAO_0000223,,,,Autocuration,11684,,B,,,,,104698
3012,1,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,BAO_0000019,,,,Autocuration,12953,,B,,,,,104698
3013,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,BAO_0000019,,,,Autocuration,12953,,B,,,,,104698
3014,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,BAO_0000223,,,,Autocuration,12953,,B,,,,,104698
3015,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,BAO_0000019,,,,Autocuration,12861,,B,,,,,104698
3016,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3017,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3018,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3019,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3020,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3021,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3022,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3023,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3024,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3025,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3026,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3027,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3028,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3029,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3030,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3031,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3032,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3033,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3034,1,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,BAO_0000019,,,,Autocuration,10609,,F,,,,,104698
3035,1,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,BAO_0000019,,,,Autocuration,12861,,B,,,,,104698
3036,1,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,BAO_0000019,,Rattus norvegicus,,Autocuration,12861,,B,10116.0,,,,104698
3037,1,Binding activity radioligand.,,BAO_0000223,,,,Autocuration,12861,,B,,,,,104698
3038,1,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,BAO_0000249,,,,Autocuration,10728,,B,,,,Brain membranes,104698
3039,1,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,BAO_0000249,,,,Autocuration,10728,,B,,,,Brain membranes,104698
3040,1,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,BAO_0000357,,,,Autocuration,5163,,B,,,,,108
3041,1,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,BAO_0000357,,,,Autocuration,5163,,B,,,,,108
3042,1,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,BAO_0000357,,,,Autocuration,6011,,B,,,,,108
3043,1,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,5014,,B,,,,,108
3044,1,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,5635,,B,,,,,108
3045,1,Affinity for 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Expert,5163,,B,,,,,108
3046,1,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,BAO_0000357,,,,Autocuration,6841,,B,,,,,108
3047,1,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,BAO_0000357,,,,Expert,6119,,B,,,,,108
3048,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,BAO_0000357,,,,Autocuration,4373,,B,,,,,108
3049,1,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,BAO_0000357,,,,Autocuration,1633,,B,,,,,108
3050,1,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,BAO_0000357,,,,Expert,1633,,B,,,,,108
3051,1,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,BAO_0000357,,,,Autocuration,4373,,B,,,,,108
3052,1,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Expert,6576,,B,,,,,108
3053,1,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,4687,,B,,,,,108
3054,1,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,BAO_0000357,,,,Autocuration,12146,,B,,,,,108
3055,1,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,BAO_0000357,,,,Autocuration,12146,,B,,,,,108
3056,1,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,16946,,B,,,,,108
3057,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,14159,,B,,,,,108
3058,1,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,BAO_0000357,,,,Autocuration,16700,,B,,,,,108
3059,1,Affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Autocuration,3269,,B,,,,,108
3060,1,Binding affinity against 5-hydroxytryptamine 2C receptor,,BAO_0000357,,Homo sapiens,,Expert,1274,,B,9606.0,,,,108
3061,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,BAO_0000357,,,,Autocuration,1317,,B,,,,,108
3062,1,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,BAO_0000357,,Bos taurus,,Autocuration,5834,,B,9913.0,,,,144
3063,1,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,BAO_0000357,,Bos taurus,,Autocuration,11147,,B,9913.0,,,,144
3064,1,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,BAO_0000019,,Cavia porcellus,,Expert,14145,,F,10141.0,,,,104714
3065,1,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,10561,,B,10141.0,,,,104714
3066,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,BAO_0000019,,Cavia porcellus,,Autocuration,15847,,F,10141.0,,,,104714
3067,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,BAO_0000019,,Cavia porcellus,,Autocuration,15847,,F,10141.0,,,,104714
3068,1,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,10561,,B,10141.0,,,,104714
3069,1,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,11454,,B,10141.0,,,,104714
3070,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,F,10141.0,,,,104714
3071,1,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,F,10141.0,,,,104714
3072,1,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,F,10141.0,,,,104714
3073,1,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,F,10141.0,,,,104714
3074,1,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,F,10141.0,,,,104714
3075,1,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,F,10141.0,,,,104714
3076,1,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,15253,,F,10141.0,,,,104714
3077,1,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,15253,,F,10141.0,,,,104714
3078,1,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,11963,,F,10141.0,,,,104714
3079,1,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,1946,,B,10141.0,,,,104714
3080,1,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,1946,,B,10141.0,,,,104714
3081,1,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,BAO_0000223,,Cavia porcellus,,Autocuration,12045,,B,10141.0,,,,104714
3082,1,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,1559,,B,10141.0,,,,104714
3083,1,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,273,,F,10141.0,,,,104714
3084,1,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,273,,F,10141.0,,,,104714
3085,1,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,188,,F,10141.0,,,,104714
3086,1,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,12919,,F,10141.0,,,,104714
3087,1,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,12918,,F,10141.0,,,,104714
3088,1,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,1559,,B,10141.0,,,,104714
3089,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,273,,F,10141.0,,,,104714
3090,1,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,1559,,B,10141.0,,,,104714
3091,1,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,1559,,B,10141.0,,,,104714
3092,1,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,1559,,B,10141.0,,,,104714
3093,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,14424,,B,10141.0,,,,104714
3094,1,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,BAO_0000019,,Cavia porcellus,,Autocuration,13181,,B,10141.0,,,,22226
3095,1,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,BAO_0000357,,,,Autocuration,5486,,B,,,,,51
3096,1,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,BAO_0000223,,Homo sapiens,,Expert,6491,,B,9606.0,,,,104714
3097,1,Binding affinity towards 5-HT3 receptor,,BAO_0000223,,,,Autocuration,6013,,B,,,,,104714
3098,1,Binding activity radioligand.,,BAO_0000223,,,,Autocuration,12861,,B,,,,,104714
3099,1,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,BAO_0000019,,,,Autocuration,12861,,B,,,,,104714
3100,1,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,5104,,B,,,,,104714
3101,1,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,5105,,B,,,,,104714
3102,1,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,BAO_0000223,,,,Autocuration,5104,,B,,,,,104714
3103,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,BAO_0000019,,,,Autocuration,3935,,B,,,,,22226
3104,1,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,BAO_0000219,,,,Expert,13657,,B,,,NG108-15,,105030
3105,1,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,BAO_0000218,,,,Autocuration,10369,In vivo,B,,,,,105030
3106,1,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,BAO_0000019,,,,Autocuration,10369,,B,,,,,105030
3107,1,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,BAO_0000224,,,,Autocuration,12918,,B,,,,,105030
3108,1,Compound was evaluated for the binding affinity at 5- HT3 receptor,,BAO_0000224,,,,Autocuration,12918,,B,,,,,105030
3109,1,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,BAO_0000019,,,,Autocuration,10369,,B,,,,,105030
3110,1,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,BAO_0000019,,,,Autocuration,773,,B,,,,,105030
3111,1,5-hydroxytryptamine 3 receptor agonism in mouse,,BAO_0000218,,,,Autocuration,12918,,F,,,,,105030
3112,1,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,BAO_0000219,,,,Autocuration,10561,,B,,,,,105030
3113,1,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,BAO_0000019,,,,Autocuration,12827,,B,,,,,105030
3114,1,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,BAO_0000019,,,,Autocuration,12827,,B,,,,,105030
3115,1,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,BAO_0000224,,,,Autocuration,12918,,B,,,,,105030
3116,1,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,BAO_0000219,,,,Autocuration,273,,B,,,,,105030
3117,1,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,BAO_0000219,,,,Autocuration,273,,B,,,,,105030
3118,1,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,BAO_0000224,,,,Autocuration,10561,,B,,,,,105030
3119,1,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,BAO_0000219,,,,Autocuration,5033,In vitro,B,,,,,105030
3120,1,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,BAO_0000219,,,,Autocuration,16429,,B,,,N1E-115,,105030
3121,1,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,BAO_0000019,,,,Autocuration,10322,,B,,,,,11765
3122,1,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,BAO_0000219,,,,Autocuration,14331,,B,,,,,11765
3123,1,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,BAO_0000357,,Mus musculus,,Autocuration,13462,,B,10090.0,,,,10630
3124,1,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,BAO_0000019,,,,Autocuration,12861,,B,,,,,17106
3125,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,BAO_0000357,,Sus scrofa,,Autocuration,15086,,B,9823.0,,,,144
3126,1,Binding activity radioligand.,,BAO_0000357,,Sus scrofa,,Autocuration,12861,,B,9823.0,,,,144
3127,1,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,BAO_0000223,,Oryctolagus cuniculus,,Autocuration,10561,,B,9986.0,,,,104714
3128,1,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,BAO_0000223,,Oryctolagus cuniculus,,Autocuration,10561,,B,9986.0,,,,104714
3129,1,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,BAO_0000223,,Oryctolagus cuniculus,,Autocuration,10561,,B,9986.0,,,,104714
3130,1,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,10561,,B,9986.0,,,,104714
3131,1,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,273,,F,9986.0,,,,104714
3132,1,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,273,,F,9986.0,,,,104714
3133,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Ileum,BAO_0000221,,Oryctolagus cuniculus,,Autocuration,273,,F,9986.0,,,,104714
3134,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,273,,F,9986.0,,,,104714
3135,1,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,273,,F,9986.0,,,,104714
3136,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,273,,F,9986.0,,,,104714
3137,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,273,,F,9986.0,,,,104714
3138,1,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,,Oryctolagus cuniculus,,Autocuration,13047,,B,9986.0,,CHO,,104714
3139,1,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,BAO_0000019,,Rattus norvegicus,,Autocuration,1650,,B,10116.0,,,,104698
3140,1,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,BAO_0000019,,,,Autocuration,16288,,B,,,,,12020
3141,1,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,BAO_0000357,,,,Autocuration,16288,,B,,,,,12020
3142,1,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,BAO_0000019,,Rattus norvegicus,,Autocuration,10254,,B,10116.0,,,,104698
3143,1,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,BAO_0000019,,,,Autocuration,14532,,B,,,,,104698
3144,1,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",Heart,BAO_0000218,,,,Autocuration,13392,In vivo,F,,,,,104698
3145,1,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",Heart,BAO_0000019,,,,Autocuration,13392,,F,,,,,104698
3146,1,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",Heart,BAO_0000019,,,,Autocuration,13392,,F,,,,,104698
3147,1,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",Heart,BAO_0000019,,,,Autocuration,13392,,F,,,,,104698
3148,1,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",Heart,BAO_0000019,,,,Autocuration,13392,,F,,,,,104698
3149,1,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,BAO_0000019,,,,Autocuration,13392,,F,,,,,104698
3150,1,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,BAO_0000019,,,,Autocuration,13392,,F,,,,,104698
3151,1,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,BAO_0000019,,,,Autocuration,13392,,F,,,,,104698
3152,1,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,BAO_0000019,,,,Autocuration,13392,,F,,,,,104698
3153,1,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,BAO_0000218,,Rattus norvegicus,,Autocuration,1089,In vivo,F,10116.0,,,,104698
3154,1,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,BAO_0000218,,,,Autocuration,1089,In vivo,F,,,,,104698
3155,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,Rattus norvegicus,,Autocuration,11454,In vivo,F,10116.0,,,,104698
3156,1,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,BAO_0000019,,Rattus norvegicus,,Autocuration,11454,,F,10116.0,,,,104698
3157,1,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,BAO_0000218,,Rattus norvegicus,,Autocuration,12205,In vivo,F,10116.0,,,,104698
3158,1,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,BAO_0000019,,Rattus norvegicus,,Autocuration,1089,,F,10116.0,,,,104698
3159,1,Binding affinity towards 5-HT3 receptor in rat was evaluated,,BAO_0000019,,,,Autocuration,5094,,B,,,,,104698
3160,1,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,BAO_0000019,,Rattus norvegicus,,Autocuration,2622,,B,10116.0,,,,104698
3161,1,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,245,,B,,,,,104698
3162,1,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,BAO_0000019,,,,Autocuration,14788,,B,,,,,104698
3163,1,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,BAO_0000019,,,,Autocuration,14788,,B,,,,,104698
3164,1,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,BAO_0000249,,,,Autocuration,3020,,B,,,,,104698
3165,1,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,BAO_0000019,,,,Autocuration,1742,,B,,,,,104698
3166,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,Brain,BAO_0000249,,,,Autocuration,17394,,B,,,,,104698
3167,1,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,Brain,BAO_0000221,,,,Autocuration,17394,,B,,,,,104698
3168,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,BAO_0000249,,,,Autocuration,17394,,B,,,,,104698
3169,1,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,BAO_0000249,,,,Autocuration,14286,,B,,,,,104698
3170,1,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,BAO_0000019,,,,Autocuration,14178,,B,,,,,104698
3171,1,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,BAO_0000019,,Rattus norvegicus,,Autocuration,14178,,B,10116.0,,,,104698
3172,1,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,BAO_0000019,,Rattus norvegicus,,Autocuration,14178,,B,10116.0,,,,104698
3173,1,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,BAO_0000223,,Rattus norvegicus,,Autocuration,14178,,B,10116.0,,,,104698
3174,1,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,BAO_0000019,,,,Autocuration,15034,,B,,,,,104698
3175,1,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,BAO_0000249,,,,Autocuration,1089,,B,,,,Membranes,104698
3176,1,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,BAO_0000019,,Rattus norvegicus,,Autocuration,1089,,B,10116.0,,,,104698
3177,1,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,BAO_0000223,,,,Autocuration,16532,,B,,,,,104698
3178,1,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,BAO_0000223,,Rattus norvegicus,,Autocuration,12801,,B,10116.0,,,,104698
3179,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,BAO_0000219,,,,Autocuration,15194,,B,,,NG108-15,,104698
3180,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,BAO_0000219,,,,Autocuration,15194,,B,,,NG108-15,,104698
3181,1,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,BAO_0000019,,,,Autocuration,15194,,B,,,,,104698
3182,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,BAO_0000019,,,,Autocuration,15194,,B,,,,,104698
3183,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,BAO_0000019,,,,Autocuration,15194,,B,,,,,104698
3184,1,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,BAO_0000019,,,,Autocuration,15194,,B,,,,,104698
3185,1,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,BAO_0000019,,,,Autocuration,10610,,F,,,,,104698
3186,1,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,BAO_0000019,,Rattus norvegicus,,Autocuration,10355,,F,10116.0,,,,104698
3187,1,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,BAO_0000019,,,,Autocuration,691,,F,,,,,104698
3188,1,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,BAO_0000218,,,,Autocuration,10611,,F,,,,,104698
3189,1,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,BAO_0000218,,,,Autocuration,12801,In vivo,F,,,,,104698
3190,1,Inhibition of 5-HT evoked reflex bradycardia in rat.,,BAO_0000218,,,,Autocuration,10609,,F,,,,,104698
3191,1,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3192,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3193,1,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3194,1,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,Rattus norvegicus,,Autocuration,11454,In vivo,F,10116.0,,,,104698
3195,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3196,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3197,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3198,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3199,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3200,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3201,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3202,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3203,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3204,1,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3205,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3206,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3207,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3208,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3209,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3210,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3211,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3212,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3213,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3214,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3215,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3216,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3217,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3218,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3219,1,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,BAO_0000218,,,,Autocuration,11454,In vivo,F,,,,,104698
3220,1,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,BAO_0000218,,,,Autocuration,670,,F,,,,,104698
3221,1,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,BAO_0000218,,,,Autocuration,670,,F,,,,,104698
3222,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,BAO_0000218,,,,Autocuration,10321,In vivo,F,,,,,104698
3223,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,BAO_0000218,,,,Autocuration,10321,In vivo,F,,,,,104698
3224,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,BAO_0000218,,,,Autocuration,10321,In vivo,F,,,,,104698
3225,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,BAO_0000218,,,,Autocuration,10321,In vivo,F,,,,,104698
3226,1,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,BAO_0000218,,,,Autocuration,10321,In vivo,F,,,,,104698
3227,1,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,BAO_0000218,,,,Autocuration,10322,In vivo,F,,,,,104698
3228,1,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,BAO_0000019,,,,Autocuration,15412,,F,,,,,104698
3229,1,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,BAO_0000019,,,,Autocuration,15412,,F,,,,,104698
3230,1,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,BAO_0000223,,Rattus norvegicus,,Autocuration,15412,,B,10116.0,,,,104698
3231,1,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,BAO_0000019,,,,Autocuration,15412,,F,,,,,104698
3232,1,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,Hippocampus,BAO_0000221,,,,Intermediate,15412,,B,,,,,104698
3233,1,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,BAO_0000019,,Rattus norvegicus,,Autocuration,15412,,B,10116.0,,,,104698
3234,1,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,BAO_0000019,,Rattus norvegicus,,Autocuration,17394,,B,10116.0,,,,104698
3235,1,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,12457,,B,,,,,104698
3236,1,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,BAO_0000019,,,,Autocuration,12457,,B,,,,,104698
3237,1,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,BAO_0000019,,,,Autocuration,12205,,B,,,,,104698
3238,1,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,BAO_0000019,,,,Autocuration,14532,,B,,,,,104698
3239,1,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,BAO_0000019,,,,Autocuration,1122,,B,,,,,104698
3240,1,Binding affinity towards 5-HT3 receptor in rat was evaluated,,BAO_0000019,,,,Autocuration,5094,,B,,,,,104698
3241,1,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,809,,F,10141.0,,,,20033
3242,1,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,809,,F,10141.0,,,,20033
3243,1,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,14290,,F,10141.0,,,,20033
3244,1,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,14290,,F,10141.0,,,,20033
3245,1,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,14290,,F,10141.0,,,,20033
3246,1,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,14290,,F,10141.0,,,,20033
3247,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,14290,,F,10141.0,,,,20033
3248,1,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,13961,,F,10141.0,,,,20033
3249,1,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,13961,,F,10141.0,,,,20033
3250,1,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,809,,F,10141.0,,,,20033
3251,1,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,809,,F,10141.0,,,,20033
3252,1,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,809,,F,10141.0,,,,20033
3253,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,14290,,F,10141.0,,,,20033
3254,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,14290,,F,10141.0,,,,20033
3255,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,14290,,F,10141.0,,,,20033
3256,1,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,14290,,F,10141.0,,,,20033
3257,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,14290,,F,10141.0,,,,20033
3258,1,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,14290,,F,10141.0,,,,20033
3259,1,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,BAO_0000357,,Cavia porcellus,,Intermediate,15034,,B,10141.0,,,,20033
3260,1,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Striatum,BAO_0000249,,Cavia porcellus,,Intermediate,5094,,B,10141.0,,,,20033
3261,1,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Striatum,BAO_0000249,,Cavia porcellus,,Intermediate,5094,,B,10141.0,,,,20033
3262,1,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,Striatum,BAO_0000357,,Cavia porcellus,,Intermediate,5399,,B,10141.0,,,,20033
3263,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,Striatum,BAO_0000357,,Cavia porcellus,,Intermediate,17394,,B,10141.0,,,,20033
3264,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Striatum,BAO_0000357,,Cavia porcellus,,Intermediate,17394,,B,10141.0,,,,20033
3265,1,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Striatum,BAO_0000357,,Cavia porcellus,,Intermediate,17394,,B,10141.0,,,,20033
3266,1,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,13961,,F,10141.0,,,,20033
3267,1,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,13961,,F,10141.0,,,,20033
3268,1,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,13961,,F,10141.0,,,,20033
3269,1,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,BAO_0000357,,Cavia porcellus,,Intermediate,16946,,B,10141.0,,,,20033
3270,1,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,BAO_0000357,,Cavia porcellus,,Intermediate,16946,,B,10141.0,,,,20033
3271,1,Agonistic activity against 5-hydroxytryptamine 4 receptor,,BAO_0000019,,Cavia porcellus,,Intermediate,15034,,F,10141.0,,,,20033
3272,1,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,BAO_0000019,,Cavia porcellus,,Intermediate,15034,,F,10141.0,,,,20033
3273,1,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,BAO_0000019,,Cavia porcellus,,Intermediate,12918,,F,10141.0,,,,20033
3274,1,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,BAO_0000357,,Cavia porcellus,,Intermediate,16946,,B,10141.0,,,,20033
3275,1,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,Striatum,BAO_0000357,,Cavia porcellus,,Intermediate,17394,,B,10141.0,,,,20033
3276,1,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,Striatum,BAO_0000357,,Cavia porcellus,,Intermediate,15034,,B,10141.0,,,,20033
3277,1,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Striatum,BAO_0000249,,Cavia porcellus,,Intermediate,5094,,B,10141.0,,,,20033
3278,1,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Striatum,BAO_0000249,,Cavia porcellus,,Intermediate,5094,,B,10141.0,,,,20033
3279,1,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,17358,,B,10141.0,,,,20033
3280,1,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,BAO_0000357,,Cavia porcellus,,Expert,12953,,B,10141.0,,,,20033
3281,1,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,BAO_0000357,,Cavia porcellus,,Intermediate,12953,,B,10141.0,,,,20033
3282,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,BAO_0000357,,Cavia porcellus,,Intermediate,12953,,B,10141.0,,,,20033
3283,1,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,BAO_0000357,,Cavia porcellus,,Intermediate,12953,,B,10141.0,,,,20033
3284,1,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,273,,F,10141.0,,,,20033
3285,1,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,12918,,F,10141.0,,,,20033
3286,1,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,12919,,F,10141.0,,,,20033
3287,1,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,273,,F,10141.0,,,,20033
3288,1,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,273,,F,10141.0,,,,20033
3289,1,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,BAO_0000357,,Cavia porcellus,,Intermediate,13181,,B,10141.0,,,,20033
3290,1,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,BAO_0000357,,Cavia porcellus,,Autocuration,13181,,B,10141.0,,,,168
3291,1,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,BAO_0000019,,Cavia porcellus,,Intermediate,15034,,F,10141.0,,,,20033
3292,1,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,BAO_0000357,,Cavia porcellus,,Intermediate,5033,,B,10141.0,,,,20033
3293,1,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,BAO_0000019,,Cavia porcellus,,Intermediate,1980,,B,10141.0,,,,20033
3294,1,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,BAO_0000219,,Cavia porcellus,,Autocuration,13181,,B,10141.0,,HEK293,,168
3295,1,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,BAO_0000019,,Cavia porcellus,,Intermediate,14287,,B,10141.0,,,,20033
3296,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,BAO_0000357,,Cavia porcellus,,Intermediate,1317,,B,10141.0,,,,20033
3297,1,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,BAO_0000357,,Cavia porcellus,,Intermediate,15316,,B,10141.0,,,,20033
3298,1,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,Striatum,BAO_0000357,,Cavia porcellus,,Intermediate,16429,,B,10141.0,,,,20033
3299,1,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,Hippocampus,BAO_0000221,,Cavia porcellus,,Intermediate,14818,,B,10141.0,,,,20033
3300,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,BAO_0000357,,Cavia porcellus,,Intermediate,15194,,B,10141.0,,,,20033
3301,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,BAO_0000357,,Cavia porcellus,,Intermediate,15194,,B,10141.0,,,,20033
3302,1,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,13961,,F,10141.0,,,,20033
3303,1,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,BAO_0000357,,,,Autocuration,5486,,B,,,,,108
3304,1,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,16209,,B,,,,,168
3305,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,BAO_0000019,,,,Autocuration,17085,,B,,,,,168
3306,1,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,BAO_0000219,,,,Autocuration,4199,,B,,,HeLa,,168
3307,1,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,BAO_0000357,,,,Autocuration,15146,,B,,,,,168
3308,1,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,BAO_0000357,,,,Autocuration,5213,,B,,,,,168
3309,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,BAO_0000219,,,,Autocuration,4829,,B,,,HeLa,,168
3310,1,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,BAO_0000357,,,,Autocuration,17358,,B,,,,,10622
3311,1,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,BAO_0000357,,,,Autocuration,17358,,B,,,,,10622
3312,1,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,BAO_0000219,,,,Autocuration,16946,,B,,,,,10622
3313,1,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,BAO_0000357,,,,Autocuration,17358,,B,,,,,10622
3314,1,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,Cardiac atrium,BAO_0000019,,,,Autocuration,268,,F,,,,,11249
3315,1,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,Cardiac atrium,BAO_0000019,,,,Autocuration,268,,F,,,,,11249
3316,1,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,BAO_0000357,,,,Autocuration,15086,,B,,,,,11249
3317,1,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,Hippocampus,BAO_0000221,,,,Autocuration,14875,,B,,,,,11249
3318,1,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,Hippocampus,BAO_0000221,,Sus scrofa,,Autocuration,13267,,B,9823.0,,,,168
3319,1,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,13047,,B,9986.0,,,,168
3320,1,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,BAO_0000357,,Rattus norvegicus,,Expert,1650,,B,10116.0,,,,10623
3321,1,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,BAO_0000019,,,,Autocuration,567,,F,,,,,10623
3322,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,BAO_0000357,,,,Autocuration,17358,,B,,,,,10623
3323,1,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,BAO_0000357,,,,Autocuration,188,,B,,,,,10623
3324,1,lntrinsic activity relative to 5-HT receptor,,BAO_0000019,,,,Autocuration,670,,F,,,,,10623
3325,1,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,BAO_0000019,,,,Autocuration,204,,F,,,,,10623
3326,1,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,BAO_0000019,,,,Expert,1946,,F,,,,,10623
3327,1,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,BAO_0000019,,,,Autocuration,6398,,F,,,,,10623
3328,1,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,BAO_0000019,,,,Autocuration,6398,,F,,,,,10623
3329,1,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,BAO_0000019,,,,Autocuration,17358,,F,,,,,10623
3330,1,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,BAO_0000019,,,,Autocuration,6398,,F,,,,,10623
3331,1,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,BAO_0000357,,,,Expert,11752,,B,,,,,10623
3332,1,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,BAO_0000019,,,,Autocuration,809,,F,,,,,10623
3333,1,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,BAO_0000357,,Rattus norvegicus,,Expert,14178,,B,10116.0,,,,10623
3334,1,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,BAO_0000357,,,,Autocuration,567,,B,,,,,10623
3335,1,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,BAO_0000357,,,,Autocuration,1946,,B,,,,,10623
3336,1,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,BAO_0000357,,,,Autocuration,1946,,B,,,,,10623
3337,1,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,BAO_0000019,,Rattus norvegicus,,Expert,13961,,B,10116.0,,,,10623
3338,1,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,Striatum,BAO_0000249,,,,Autocuration,6238,,B,,,,,10623
3339,1,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,BAO_0000249,,,,Autocuration,14290,,B,,,,,10623
3340,1,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,BAO_0000249,,,,Expert,14290,,B,,,,,10623
3341,1,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,Striatum,BAO_0000019,,Rattus norvegicus,,Expert,809,,B,10116.0,,,,10623
3342,1,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,Striatum,BAO_0000019,,,,Autocuration,1578,,B,,,,,10623
3343,1,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,Striatum,BAO_0000249,,,,Expert,16709,,B,,,,,10623
3344,1,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,Striatum,BAO_0000019,,,,Expert,1946,,B,,,,,10623
3345,1,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,Striatum,BAO_0000249,,,,Expert,15253,,B,,,,,10623
3346,1,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,Striatum,BAO_0000249,,,,Expert,4535,,B,,,,,10623
3347,1,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,BAO_0000249,,,,Expert,13961,,B,,,,,10623
3348,1,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,Brain,BAO_0000221,,,,Autocuration,17358,,F,,,,,10623
3349,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,BAO_0000019,,,,Autocuration,15847,,F,,,,,10623
3350,1,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,BAO_0000019,,,,Autocuration,15847,,F,,,,,10623
3351,1,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,BAO_0000019,,,,Autocuration,670,,F,,,,,10623
3352,1,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,BAO_0000019,,,,Autocuration,670,,F,,,,,10623
3353,1,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,BAO_0000019,,,,Autocuration,1317,,F,,,,,10623
3354,1,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,BAO_0000357,,Rattus norvegicus,,Expert,12936,,B,10116.0,,,,10623
3355,1,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,Striatum,BAO_0000249,,,,Expert,4535,,B,,,,,10623
3356,1,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,BAO_0000019,,Rattus norvegicus,,Expert,14424,,F,10116.0,,,,10623
3357,1,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,BAO_0000019,,,,Expert,14424,,F,,,,,10623
3358,1,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,BAO_0000019,,,,Expert,14424,,F,,,,,10623
3359,1,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,BAO_0000019,,Rattus norvegicus,,Expert,14424,,F,10116.0,,,,10623
3360,1,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,BAO_0000019,,,,Autocuration,14424,,F,,,,,10623
3361,1,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,BAO_0000019,,,,Expert,14424,,F,,,,,10623
3362,1,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,BAO_0000218,,,,Expert,14424,,F,,,,,10623
3363,1,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,BAO_0000019,,,,Autocuration,14424,,F,,,,,10623
3364,1,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,BAO_0000019,,Rattus norvegicus,,Autocuration,1980,,F,10116.0,,,,168
3365,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,BAO_0000019,,,,Autocuration,4639,,F,,,,,168
3366,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,BAO_0000357,,,,Autocuration,17358,,B,,,,,168
3367,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,BAO_0000357,,,,Autocuration,17358,,B,,,,,168
3368,1,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,BAO_0000357,,,,Autocuration,17358,,B,,,,,168
3369,1,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,BAO_0000357,,,,Autocuration,1558,,B,,,,,168
3370,1,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,BAO_0000019,,,,Autocuration,17358,,F,,,,,168
3371,1,In vitro binding affinity towards 5-HT4 receptor was determined,,BAO_0000357,,,,Autocuration,16117,,B,,,,,168
3372,1,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,BAO_0000019,,,,Autocuration,17358,,F,,,,,168
3373,1,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,BAO_0000019,,,,Autocuration,17358,,F,,,,,168
3374,1,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,BAO_0000357,,,,Autocuration,17358,,B,,,,,168
3375,1,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,BAO_0000357,,,,Autocuration,17358,,B,,,,,168
3376,1,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,BAO_0000357,,,,Autocuration,17358,,B,,,,,168
3377,1,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,BAO_0000357,,,,Autocuration,17358,,B,,,,,168
3378,1,Binding affinity against 5-Hydroxytryptamine 4 receptor,,BAO_0000357,,,,Expert,1274,,B,,,,,168
3379,1,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,BAO_0000249,,,,Autocuration,10728,,B,,,,Brain membranes,104698
3380,1,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,BAO_0000249,,,,Autocuration,11695,,B,,,,Brain membranes,104698
3381,1,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,BAO_0000249,,,,Autocuration,11695,,B,,,,Brain membranes,104698
3382,1,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,BAO_0000019,,,,Autocuration,12490,,B,,,,,104698
3383,1,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,BAO_0000019,,Rattus norvegicus,,Autocuration,11828,,B,10116.0,,,,104698
3384,1,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,Hippocampus,BAO_0000221,,,,Autocuration,12253,,B,,,,,104698
3385,1,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,BAO_0000019,,,,Autocuration,10561,,B,,,,,104698
3386,1,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,BAO_0000019,,,,Autocuration,10561,,B,,,,,104698
3387,1,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,BAO_0000019,,,,Autocuration,14432,,F,,,,,104698
3388,1,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,BAO_0000223,,Rattus norvegicus,,Autocuration,12936,,B,10116.0,,,,104698
3389,1,Binding affinity against 5-Hydroxytryptamine 3 receptor,,BAO_0000223,,Rattus norvegicus,,Autocuration,1274,,B,10116.0,,,,104698
3390,1,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,BAO_0000019,,,,Autocuration,1980,,B,,,,,104698
3391,1,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,BAO_0000249,,,,Autocuration,670,,B,,,,,104698
3392,1,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,BAO_0000019,,Rattus norvegicus,,Autocuration,968,,B,10116.0,,,,104698
3393,1,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,BAO_0000019,,,,Autocuration,14287,,B,,,,,104698
3394,1,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,BAO_0000019,,,,Autocuration,567,,B,,,,,104698
3395,1,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,BAO_0000019,,,,Autocuration,13267,,B,,,,,104698
3396,1,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,BAO_0000249,,,,Autocuration,14826,,B,,,,,104698
3397,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,BAO_0000223,,,,Autocuration,15194,,B,,,,,104698
3398,1,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,BAO_0000223,,,,Autocuration,15194,,B,,,,,104698
3399,1,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,BAO_0000223,,Rattus norvegicus,,Autocuration,10394,,B,10116.0,,,,104698
3400,1,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,BAO_0000249,,,,Expert,13657,,B,,,,,10576
3401,1,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,Brain,BAO_0000221,,,,Autocuration,1879,,F,,,,,12020
3402,1,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,BAO_0000019,,,,Autocuration,1879,,F,,,,,12020
3403,1,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,BAO_0000019,,,,Autocuration,1879,,F,,,,,12020
3404,1,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,BAO_0000218,,,,Autocuration,204,In vivo,F,,,,,12020
3405,1,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,BAO_0000019,,,,Autocuration,1879,,B,,,,,12020
3406,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,,,,Autocuration,1879,,B,,,,,12020
3407,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,BAO_0000019,,,,Autocuration,1879,,B,,,,,12020
3408,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,BAO_0000019,,,,Autocuration,1879,,B,,,,,12020
3409,1,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,BAO_0000019,,,,Autocuration,10641,,B,,,,,104698
3410,1,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,BAO_0000019,,,,Autocuration,773,,B,,,,,12020
3411,1,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,BAO_0000249,,,,Autocuration,11952,,B,,,,,104698
3412,1,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,BAO_0000019,,Rattus norvegicus,,Autocuration,14145,,F,10116.0,,,,12020
3413,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,,,,Expert,17066,,B,,,,,144
3414,1,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,BAO_0000223,,,,Autocuration,6398,,B,,,,,104714
3415,1,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,BAO_0000019,,,,Autocuration,10321,,B,,,,,22226
3416,1,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,BAO_0000019,,,,Autocuration,511,,F,,,,,104714
3417,1,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,4639,,B,,,,,104714
3418,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,4639,,B,,,,,104714
3419,1,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,F,10141.0,,,,104714
3420,1,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,F,10141.0,,,,104714
3421,1,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,F,10141.0,,,,104714
3422,1,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,1558,,B,,,,,104714
3423,1,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,BAO_0000019,,,,Autocuration,268,,F,,,,,104714
3424,1,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,BAO_0000223,,,,Autocuration,2474,,B,,,,,104714
3425,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,BAO_0000019,,,,Autocuration,5067,,F,,,,,104714
3426,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,BAO_0000019,,,,Autocuration,5067,,F,,,,,104714
3427,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,BAO_0000019,,,,Autocuration,5067,,F,,,,,104714
3428,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,BAO_0000223,,,,Autocuration,5067,,B,,,,,104714
3429,1,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,BAO_0000019,,,,Autocuration,5067,,F,,,,,104714
3430,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,BAO_0000019,,,,Autocuration,5067,,F,,,,,104714
3431,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,BAO_0000019,,,,Autocuration,5067,,F,,,,,104714
3432,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,BAO_0000223,,,,Autocuration,5067,,B,,,,,104714
3433,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,BAO_0000223,,,,Autocuration,5067,,B,,,,,104714
3434,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,BAO_0000019,,,,Autocuration,5067,,F,,,,,104714
3435,1,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,BAO_0000223,,,,Autocuration,5067,,B,,,,,104714
3436,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,5067,,B,,,,,104714
3437,1,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,BAO_0000219,,,,Autocuration,14331,,B,,,,,104714
3438,1,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,BAO_0000223,,,,Autocuration,5067,,B,,,,,104714
3439,1,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,BAO_0000219,,,,Autocuration,6179,,B,,,NG108-15,,104714
3440,1,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,BAO_0000019,,,,Autocuration,4265,,B,,,,,104714
3441,1,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,BAO_0000219,,,,Autocuration,4265,,B,,,NG108-15,,104714
3442,1,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,BAO_0000223,,,,Autocuration,17358,,B,,,,,104714
3443,1,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,BAO_0000223,,,,Autocuration,17358,,B,,,,,104714
3444,1,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,BAO_0000219,,,,Autocuration,13628,In vitro,B,,,,,104714
3445,1,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,BAO_0000223,,,,Autocuration,4612,,B,,,,,104714
3446,1,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,BAO_0000019,,,,Autocuration,17358,,F,,,,,104714
3447,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,F,10141.0,,,,104714
3448,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,F,10141.0,,,,104714
3449,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,F,10141.0,,,,104714
3450,1,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,F,10141.0,,,,104714
3451,1,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,BAO_0000223,,,,Autocuration,511,,B,,,,,104714
3452,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,1479,,B,,,,,104714
3453,1,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,BAO_0000223,,,,Autocuration,1317,,B,,,,,104714
3454,1,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,BAO_0000223,,,,Autocuration,12146,,B,,,,,104714
3455,1,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,BAO_0000223,,,,Autocuration,12146,,B,,,,,104714
3456,1,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,BAO_0000223,,,,Autocuration,13969,,B,,,,,104714
3457,1,Binding affinity for 5-hydroxytryptamine 2C receptor,,BAO_0000357,,,,Expert,13392,,B,,,,,108
3458,1,Binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,13392,,B,,,,,104698
3459,1,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,BAO_0000357,,,,Autocuration,14159,,B,,,,,144
3460,1,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,,,,Autocuration,1558,,B,,,,,144
3461,1,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,BAO_0000357,,,,Autocuration,16655,,B,,,,,144
3462,1,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,BAO_0000223,,,,Autocuration,13020,,B,,,,,104714
3463,1,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,BAO_0000223,,,,Autocuration,13021,,B,,,,,104714
3464,1,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,BAO_0000223,,,,Autocuration,13020,,B,,,,,104714
3465,1,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,BAO_0000019,,,,Autocuration,10321,,B,,,,,144
3466,1,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,,,,Autocuration,15818,,B,,,,,144
3467,1,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,BAO_0000357,,,,Autocuration,15818,,B,,,,,144
3468,1,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,BAO_0000357,,,,Autocuration,17358,,B,,,,,144
3469,1,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,BAO_0000357,,,,Autocuration,2222,,B,,,,,144
3470,1,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,BAO_0000019,,,,Autocuration,10322,,B,,,,,144
3471,1,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,BAO_0000357,,,,Autocuration,16117,,B,,,,,144
3472,1,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,BAO_0000357,,,,Autocuration,17200,,B,,,,,144
3473,1,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,BAO_0000019,,,,Autocuration,17358,,F,,,,,144
3474,1,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,BAO_0000357,,,,Autocuration,16700,,B,,,,,144
3475,1,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,BAO_0000019,,,,Autocuration,1980,,B,,,,,144
3476,1,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,BAO_0000019,,,,Autocuration,1980,,B,,,,,144
3477,1,Binding affinity against the 5-hydroxytryptamine 3 receptor,,BAO_0000223,,,,Autocuration,12409,,B,,,,,104714
3478,1,Binding affinity against human 5-hydroxytryptamine 3A receptor,,BAO_0000357,,,,Autocuration,4365,,B,,,,,144
3479,1,Percent efficacy against 5-hydroxytryptamine 3A receptor,,BAO_0000019,,,,Autocuration,4365,,F,,,,,144
3480,1,Binding affinity against human 5-hydroxytryptamine 3A receptor,,BAO_0000357,,,,Autocuration,4365,,B,,,,,144
3481,1,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,BAO_0000219,,Rattus norvegicus,,Expert,6769,,F,10116.0,,Oocytes,,12020
3482,1,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,BAO_0000219,,Rattus norvegicus,,Expert,6769,,F,10116.0,,Oocytes,,12020
3483,1,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,BAO_0000219,,Rattus norvegicus,,Expert,6769,,F,10116.0,,Oocytes,,12020
3484,1,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,809,,F,10141.0,,,,20033
3485,1,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,809,,F,10141.0,,,,20033
3486,1,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,BAO_0000019,,Cavia porcellus,,Intermediate,14290,,F,10141.0,,,,20033
3487,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,17358,,B,10141.0,,,,20033
3488,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,BAO_0000357,,Cavia porcellus,,Intermediate,17358,,B,10141.0,,,,20033
3489,1,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,Ileum,BAO_0000221,,Cavia porcellus,,Intermediate,17358,,B,10141.0,,,,20033
3490,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,Ileum,BAO_0000221,,,,Autocuration,17386,,B,,,,,10209
3491,1,Affinity against 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Autocuration,3269,,B,,,,,10209
3492,1,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,BAO_0000224,,Cavia porcellus,,Autocuration,7721,,B,10141.0,,,,104841
3493,1,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,BAO_0000224,,Cavia porcellus,,Autocuration,7721,,B,10141.0,,,,104841
3494,1,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,Ileum,BAO_0000221,,Cavia porcellus,,Autocuration,9117,,B,10141.0,,,,104841
3495,1,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,BAO_0000224,,Cavia porcellus,,Autocuration,7721,,B,10141.0,,,,104841
3496,1,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,BAO_0000224,,Cavia porcellus,,Autocuration,7721,,B,10141.0,,,,104841
3497,1,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,BAO_0000019,,Cavia porcellus,,Autocuration,15796,,F,10141.0,,,,104841
3498,1,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,BAO_0000019,,Cavia porcellus,,Autocuration,15796,,F,10141.0,,,,104841
3499,1,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,Cardiac atrium,BAO_0000219,,Homo sapiens,,Expert,15650,,B,9606.0,,,,168
3500,1,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,Cardiac atrium,BAO_0000219,,Homo sapiens,,Expert,15650,,B,9606.0,,,,168
3501,1,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,BAO_0000019,,Homo sapiens,,Autocuration,6866,,F,9606.0,,,,104841
3502,1,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",Cardiac atrium,BAO_0000219,,Homo sapiens,,Expert,15650,,F,9606.0,,,,168
3503,1,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,BAO_0000019,,Mus musculus,,Autocuration,10063,,B,10090.0,,,,22226
3504,1,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,BAO_0000019,,Mus musculus,,Autocuration,12665,,B,10090.0,,,,22226
3505,1,5-hydroxytryptamine receptor binding affinity was determined in rats,,BAO_0000019,,,,Autocuration,7504,,B,,,,,104705
3506,1,Binding affinity at rat 5-hydroxytryptamine receptor.,,BAO_0000224,,,,Autocuration,7504,,B,,,,,104705
3507,1,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,BAO_0000019,,,,Autocuration,7038,,B,,,,,104705
3508,1,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,BAO_0000224,,,,Autocuration,7626,,B,,,,,104705
3509,1,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,BAO_0000224,,,,Autocuration,7626,,B,,,,,104705
3510,1,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,Stomach,BAO_0000019,,,,Autocuration,7185,,F,,,,,104705
3511,1,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,Stomach,BAO_0000019,,,,Autocuration,7185,,F,,,,,104705
3512,1,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,BAO_0000019,,,,Autocuration,7185,,F,,,,,104705
3513,1,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,BAO_0000224,,,,Autocuration,6960,,B,,,,,104705
3514,1,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,BAO_0000224,,,,Autocuration,6960,,B,,,,,104705
3515,1,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,Hippocampus,BAO_0000221,,,,Autocuration,12416,,B,,,,,10576
3516,1,Binding affinity for rat 5-hydroxytryptamine transporter.,,BAO_0000357,,,,Expert,15753,,B,,,,,12198
3517,1,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,BAO_0000019,,,,Autocuration,8062,,B,,,,,104705
3518,1,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,BAO_0000019,,Rattus norvegicus,,Autocuration,9036,,B,10116.0,,,,104705
3519,1,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,BAO_0000224,,Rattus norvegicus,,Autocuration,15067,,B,10116.0,,,,104705
3520,1,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,Brain,BAO_0000019,,Rattus norvegicus,,Expert,15753,,F,10116.0,,,,12198
3521,1,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,Cerebellum,BAO_0000221,,Rattus norvegicus,,Expert,15753,,F,10116.0,,,,12198
3522,1,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,BAO_0000019,,Rattus norvegicus,,Autocuration,15295,,B,10116.0,,,,104705
3523,1,Percent binding affinity against 5-hydroxytryptamine receptor,,BAO_0000224,,Rattus norvegicus,,Autocuration,6347,,B,10116.0,,,,104705
3524,1,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,BAO_0000019,,,,Autocuration,6763,,B,,,,,22226
3525,1,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,BAO_0000224,,Rattus norvegicus,,Autocuration,12092,,B,10116.0,,,,104705
3526,1,Affinity against 5-hydroxytryptamine receptor was determined,,BAO_0000224,,Rattus norvegicus,,Autocuration,1579,,B,10116.0,,,,104705
3527,1,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Stomach,BAO_0000019,,Rattus norvegicus,,Autocuration,1579,,B,10116.0,,,,104705
3528,1,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,BAO_0000219,,Homo sapiens,,Expert,5963,In vitro,B,9606.0,,,,121
3529,1,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,BAO_0000219,,Homo sapiens,,Expert,5963,In vitro,B,9606.0,,,,121
3530,1,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,BAO_0000357,,,,Autocuration,5030,,B,,,,,18065
3531,1,Inhibition of 5-hydroxytryptamine reuptake,,BAO_0000357,,,,Expert,15796,,B,,,,,121
3532,1,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,BAO_0000019,,,,Autocuration,15413,,F,,,,,18065
3533,1,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,BAO_0000019,,,,Autocuration,15413,,F,,,,,18065
3534,1,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,BAO_0000019,,,,Autocuration,15413,,F,,,,,18065
3535,1,Tested for 5-hydroxytryptamine receptor uptake,,BAO_0000019,,,,Autocuration,12409,,F,,,,,18065
3536,1,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,BAO_0000219,,Homo sapiens,,Expert,16909,,B,9606.0,,CHO,,51
3537,1,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,BAO_0000019,,Homo sapiens,,Expert,16909,,F,9606.0,,,,51
3538,1,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,BAO_0000249,,Homo sapiens,,Autocuration,15629,,B,9606.0,,,,10576
3539,1,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,BAO_0000357,,,,Autocuration,15629,,B,,,,,10576
3540,1,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,BAO_0000249,,,,Expert,15629,,B,,,,,10576
3541,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,Striatum,BAO_0000019,,,,Autocuration,10034,,F,,,,,10825
3542,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,Striatum,BAO_0000019,,,,Autocuration,10034,,F,,,,,10825
3543,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,Striatum,BAO_0000019,,,,Autocuration,10034,,F,,,,,10825
3544,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,Striatum,BAO_0000019,,,,Autocuration,10034,,F,,,,,10825
3545,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,Striatum,BAO_0000019,,,,Autocuration,10034,,F,,,,,10825
3546,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,Striatum,BAO_0000019,,,,Autocuration,10034,,F,,,,,10825
3547,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,Striatum,BAO_0000019,,,,Autocuration,10034,,F,,,,,10825
3548,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,Striatum,BAO_0000019,,,,Autocuration,10034,,F,,,,,10825
3549,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,Striatum,BAO_0000019,,,,Autocuration,10034,,F,,,,,10825
3550,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,Striatum,BAO_0000019,,,,Autocuration,10034,,F,,,,,10825
3551,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,Striatum,BAO_0000019,,,,Autocuration,10034,,F,,,,,10825
3552,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,Limbic system,BAO_0000019,,,,Autocuration,10034,,F,,,,,10825
3553,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,Limbic system,BAO_0000019,,,,Autocuration,10034,,F,,,,,10825
3554,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,Limbic system,BAO_0000019,,,,Autocuration,10034,,F,,,,,10825
3555,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,Limbic system,BAO_0000019,,,,Autocuration,10034,,F,,,,,10825
3556,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,Limbic system,BAO_0000019,,,,Autocuration,10034,,F,,,,,10825
3557,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,Limbic system,BAO_0000019,,,,Autocuration,10034,,F,,,,,10825
3558,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,Limbic system,BAO_0000019,,,,Autocuration,10034,,F,,,,,10825
3559,1,Binding affinity against 5-hydroxytryptamine 4 receptor,,BAO_0000357,,,,Expert,1274,,B,,,,,168
3560,1,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,BAO_0000019,,,,Autocuration,17358,,F,,,,,168
3561,1,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,BAO_0000357,,,,Autocuration,14532,,B,,,,,168
3562,1,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,BAO_0000357,,,,Expert,16989,,B,,,,,168
3563,1,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,BAO_0000357,,,,Autocuration,17200,,B,,,,,168
3564,1,Binding affinity towards 5-hydroxytryptamine 4 receptor,,BAO_0000357,,,,Autocuration,15779,,B,,,,,168
3565,1,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,BAO_0000357,,,,Autocuration,15779,,B,,,,,168
3566,1,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,BAO_0000357,,,,Autocuration,15779,,B,,,,,168
3567,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,BAO_0000219,,,,Autocuration,15650,,B,,,COS-7,,168
3568,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,BAO_0000219,,,,Autocuration,15650,,B,,,COS-7,,168
3569,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,BAO_0000219,,,,Autocuration,15650,,B,,,COS-7,,168
3570,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,BAO_0000219,,,,Autocuration,15650,,B,,,COS-7,,168
3571,1,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,BAO_0000219,,,,Autocuration,17046,,B,,,C6,,168
3572,1,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,BAO_0000219,,,,Expert,17046,,B,,,C6,,168
3573,1,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,BAO_0000219,,,,Expert,15650,,B,,,C6,,168
3574,1,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,BAO_0000219,,,,Expert,17046,,B,,,C6,,168
3575,1,Binding affinity towards 5-hydroxytryptamine 5 receptor,,BAO_0000357,,,,Expert,17066,,B,,,,,10624
3576,1,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,BAO_0000357,,,,Autocuration,17200,,B,,,,,105
3577,1,Binding affinity against 5-hydroxytryptamine 5A receptor,,BAO_0000357,,Homo sapiens,,Expert,16146,,B,9606.0,,,,10624
3578,1,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,BAO_0000219,,,,Autocuration,15250,,B,,,CHO,,10624
3579,1,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,BAO_0000357,,Homo sapiens,,Expert,6491,,B,9606.0,,,,10624
3580,1,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,BAO_0000357,,Homo sapiens,,Expert,17066,,B,9606.0,,,,10624
3581,1,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,BAO_0000357,,Homo sapiens,,Expert,17066,,B,9606.0,,,,10624
3582,1,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,BAO_0000357,,Homo sapiens,,Expert,4234,,B,9606.0,,,,10624
3583,1,Binding affinity towards 5-HT5A receptor,,BAO_0000357,,,,Autocuration,6013,,B,,,,,10624
3584,1,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,BAO_0000357,,,,Expert,17175,,B,,,,,10624
3585,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,BAO_0000357,,,,Autocuration,15818,,B,,,,,10624
3586,1,Binding affinity towards cloned human 5-HT5A receptor was determined,,BAO_0000357,,,,Autocuration,6166,,B,,,,,10624
3587,1,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,BAO_0000219,,,,Autocuration,15779,,B,,,HEK293,,10624
3588,1,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,BAO_0000219,,,,Autocuration,15779,,B,,,HEK293,,10624
3589,1,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,BAO_0000219,,,,Autocuration,5213,,B,,,HEK293,,10624
3590,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,BAO_0000357,,Mus musculus,,Expert,17066,,B,10090.0,,,,10625
3591,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,BAO_0000357,,Mus musculus,,Expert,17066,,B,10090.0,,,,10625
3592,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,BAO_0000357,,Mus musculus,,Expert,17066,,B,10090.0,,,,10625
3593,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,BAO_0000357,,Mus musculus,,Expert,17066,,B,10090.0,,,,10625
3594,1,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,BAO_0000357,,Mus musculus,,Expert,17066,,B,10090.0,,,,10625
3595,1,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,BAO_0000357,,,,Expert,17175,,B,,,,,10625
3596,1,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,BAO_0000219,,,,Autocuration,16190,,B,,,HEK293,,10576
3597,1,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,BAO_0000219,,,,Autocuration,16190,,B,,,HEK293,,10626
3598,1,Binding affinity towards 5-HT5a receptor,,BAO_0000357,,,,Expert,4820,,B,,,,,10624
3599,1,Binding affinity towards 5-hydroxytryptamine 5A receptor,,BAO_0000357,,Homo sapiens,,Expert,17066,,B,9606.0,,,,10624
3600,1,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,BAO_0000357,,,,Expert,17066,,B,,,,,10624
3601,1,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,BAO_0000357,,,,Expert,17175,,B,,,,,10624
3602,1,Binding affinities against 5-hydroxytryptamine 5A receptor,,BAO_0000357,,,,Autocuration,16633,,B,,,,,10624
3603,1,Binding affinities towards 5-hydroxytryptamine 5A receptor,,BAO_0000357,,,,Autocuration,16633,,B,,,,,10624
3604,1,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,BAO_0000357,,,,Autocuration,16700,,B,,,,,10624
3605,1,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,BAO_0000019,,Cavia porcellus,,Autocuration,4639,,F,10141.0,,,,104714
3606,1,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,BAO_0000223,,,,Autocuration,5486,,B,,,,,104714
3607,1,Inhibition of human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,Homo sapiens,,Expert,16146,,B,9606.0,,,,10627
3608,1,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,BAO_0000357,,Homo sapiens,,Expert,17273,,B,9606.0,,,,10627
3609,1,Inhibition against human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Autocuration,17687,,B,,,,,10627
3610,1,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,BAO_0000357,,Homo sapiens,,Expert,6491,,B,9606.0,,,,10627
3611,1,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,BAO_0000219,,,,Expert,16190,,B,,,HeLa,,10627
3612,1,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,Homo sapiens,,Expert,17066,,B,9606.0,,,,10627
3613,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,Homo sapiens,,Expert,17066,,B,9606.0,,,,10627
3614,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,BAO_0000357,,Homo sapiens,,Expert,17066,,B,9606.0,,,,10627
3615,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,BAO_0000357,,Homo sapiens,,Expert,17066,,B,9606.0,,,,10627
3616,1,Binding affinity against 5-hydroxytryptamine 6 receptor,,BAO_0000357,,Homo sapiens,,Expert,3555,,B,9606.0,,,,10627
3617,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Expert,5808,,B,,,,,10627
3618,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Autocuration,6013,,B,,,,,10627
3619,1,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,BAO_0000219,,,,Expert,15818,,B,,,HEK293,,10627
3620,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,BAO_0000357,,,,Autocuration,16209,,B,,,,,10627
3621,1,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,BAO_0000219,,,,Expert,3935,,B,,,HEK293,,10627
3622,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Autocuration,15818,,B,,,,,10627
3623,1,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,BAO_0000219,,Homo sapiens,,Expert,3805,,B,9606.0,,HEK293,,10627
3624,1,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,BAO_0000019,,,,Expert,16441,,B,,,,,10627
3625,1,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,BAO_0000019,,,,Expert,16441,,B,,,,,10627
3626,1,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,BAO_0000219,,,,Expert,6786,,B,,,COS-7,,10627
3627,1,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,Homo sapiens,,Expert,4234,,B,9606.0,,,,10627
3628,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,BAO_0000019,,,,Autocuration,17085,,B,,,,,10627
3629,1,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,BAO_0000357,,,,Autocuration,17200,,B,,,,,10627
3630,1,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,BAO_0000219,,,,Autocuration,17451,,B,,,HEK293,,10627
3631,1,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,BAO_0000019,,,,Autocuration,3935,,F,,,,,10627
3632,1,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Autocuration,5033,,B,,,,,10627
3633,1,Binding affinity against human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Expert,4540,,B,,,,,10627
3634,1,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,BAO_0000219,,Homo sapiens,,Expert,4540,,B,9606.0,,HeLa,,10627
3635,1,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,BAO_0000219,,Homo sapiens,,Expert,4540,,B,9606.0,,HeLa,,10627
3636,1,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,BAO_0000219,,,,Autocuration,17296,,B,,,HeLa,,10627
3637,1,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,BAO_0000219,,,,Autocuration,17296,,B,,,HeLa,,10627
3638,1,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,BAO_0000219,,,,Autocuration,17296,,B,,,HeLa,,10627
3639,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,BAO_0000219,,,,Autocuration,15779,,B,,,CHO,,10627
3640,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,BAO_0000219,,,,Autocuration,15779,,B,,,HEK293,,10627
3641,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,BAO_0000219,,,,Autocuration,15779,,B,,,HEK293,,10627
3642,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,BAO_0000219,,,,Autocuration,15779,,B,,,HEK293,,10627
3643,1,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,BAO_0000219,,,,Autocuration,15779,,B,,,HeLa,,10627
3644,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Autocuration,6166,,B,,,,,10627
3645,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,BAO_0000219,,,,Autocuration,17451,,B,,,HeLa,,10627
3646,1,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Autocuration,15316,,B,,,,,10627
3647,1,Binding affinity against human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Expert,4199,,B,,,,,10627
3648,1,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,BAO_0000219,,,,Expert,15146,,B,,,HeLa,,10627
3649,1,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,BAO_0000357,,,,Autocuration,5213,,B,,,,,10627
3650,1,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,BAO_0000219,,,,Autocuration,16429,,B,,,,,10627
3651,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,BAO_0000219,,,,Autocuration,14818,,B,,,HeLa,,10627
3652,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,BAO_0000219,,,,Autocuration,4829,,B,,,HeLa,,10627
3653,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,BAO_0000219,,,,Autocuration,4829,,B,,,HeLa,,10627
3654,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,BAO_0000219,,,,Autocuration,4829,,B,,,HeLa,,10627
3655,1,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,BAO_0000219,,,,Autocuration,15250,,B,,,CHO,,10628
3656,1,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,BAO_0000019,,,,Autocuration,14423,,B,,,,,10628
3657,1,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Autocuration,15086,,B,,,,,10628
3658,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,BAO_0000357,,,,Autocuration,4342,,B,,,,,10628
3659,1,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,BAO_0000219,,Homo sapiens,,Autocuration,16190,,B,9606.0,,HeLa,,10627
3660,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Expert,4820,,B,,,,,10627
3661,1,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,BAO_0000357,,,,Autocuration,4639,,B,,,,,10627
3662,1,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,BAO_0000019,,Homo sapiens,,Expert,17066,,F,9606.0,,,,10627
3663,1,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,BAO_0000357,,,,Autocuration,6011,,B,,,,,10627
3664,1,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Expert,17066,,B,,,,,10627
3665,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,BAO_0000357,,,,Autocuration,17515,,B,,,,,10627
3666,1,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Autocuration,5014,,B,,,,,10627
3667,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,BAO_0000357,,,,Autocuration,4373,,B,,,,,10627
3668,1,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,BAO_0000019,,,,Expert,17066,,F,,,,,10627
3669,1,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,BAO_0000019,,,,Expert,17066,,F,,,,,10627
3670,1,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,BAO_0000357,,,,Autocuration,4373,,B,,,,,10627
3671,1,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Autocuration,4687,,B,,,,,10627
3672,1,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,BAO_0000357,,,,Autocuration,16946,,B,,,,,10627
3673,1,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,BAO_0000357,,,,Autocuration,16946,,B,,,,,10627
3674,1,Binding affinities against 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Autocuration,16633,,B,,,,,10627
3675,1,Binding affinities towards 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Autocuration,16633,,B,,,,,10627
3676,1,Binding affinity towards 5-hydroxytryptamine 6 receptor,,BAO_0000357,,Homo sapiens,,Expert,17066,,B,9606.0,,,,10627
3677,1,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,BAO_0000357,,,,Autocuration,16700,,B,,,,,10627
3678,1,Affinity against 5-hydroxytryptamine 6 receptor,,BAO_0000357,,,,Autocuration,3269,,B,,,,,10627
3679,1,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,BAO_0000357,,,,Autocuration,5486,,B,,,,,10627
3680,1,Inhibition of human 5-hydroxytryptamine 7 receptor,,BAO_0000357,,Homo sapiens,,Expert,16146,,B,9606.0,,,,10209
3681,1,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,BAO_0000219,,,,Autocuration,5014,,B,,,HEK293,,10209
3682,1,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Autocuration,15463,,B,,,,,10209
3683,1,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,BAO_0000357,,,,Autocuration,3805,,B,,,,,10209
3684,1,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,BAO_0000219,,,,Expert,5014,,B,,,HEK293,,10209
3685,1,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,BAO_0000357,,Homo sapiens,,Expert,6491,,B,9606.0,,,,10209
3686,1,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,BAO_0000219,,,,Autocuration,16190,,B,,,CHO,,10209
3687,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,BAO_0000357,,Homo sapiens,,Expert,17066,,B,9606.0,,,,10209
3688,1,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,BAO_0000357,,Homo sapiens,,Expert,17066,,B,9606.0,,,,10209
3689,1,Binding affinity against 5-hydroxytryptamine 7 receptor,,BAO_0000357,,Homo sapiens,,Expert,3555,,B,9606.0,,,,10209
3690,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,BAO_0000219,,,,Expert,6588,,B,,,CHO,,10209
3691,1,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,BAO_0000357,,,,Autocuration,15463,,B,,,,,10209
3692,1,Binding affinity towards 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Autocuration,6013,,B,,,,,10209
3693,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,16209,,B,,,,,10209
3694,1,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Autocuration,3935,,B,,,,,10209
3695,1,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Autocuration,15818,,B,,,,,10209
3696,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,BAO_0000219,,,,Expert,5014,,B,,,HEK293,,10209
3697,1,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,BAO_0000019,,,,Expert,16441,,B,,,,,10209
3698,1,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,BAO_0000019,,,,Expert,16441,,B,,,,,10209
3699,1,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,BAO_0000357,,Homo sapiens,,Expert,4234,,B,9606.0,,,,10209
3700,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,BAO_0000019,,,,Autocuration,17085,,B,,,,,10209
3701,1,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,BAO_0000357,,,,Autocuration,17200,,B,,,,,10209
3702,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,BAO_0000219,,,,Autocuration,17451,,B,,,CHO,,10209
3703,1,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,BAO_0000019,,,,Autocuration,17085,,B,,,,,10209
3704,1,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Autocuration,5104,,B,,,,,10209
3705,1,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,BAO_0000357,,,,Autocuration,5104,,B,,,,,10209
3706,1,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,BAO_0000219,,Homo sapiens,,Expert,5033,,B,9606.0,,COS-7,,10209
3707,1,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,BAO_0000219,,,,Autocuration,5486,,B,,,COS-7,,10209
3708,1,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,BAO_0000219,,Homo sapiens,,Expert,4540,,B,9606.0,,HEK293,,10209
3709,1,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,BAO_0000357,,,,Expert,6166,,B,,,,,10209
3710,1,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,BAO_0000219,,,,Expert,17342,,B,,,HEK293,,10209
3711,1,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,BAO_0000357,,,,Expert,17342,,B,,,,,10209
3712,1,Binding affinity against 5-hydroxytryptamine 7 human receptors,,BAO_0000357,,,,Autocuration,17296,,B,,,,,10209
3713,1,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,BAO_0000219,,,,Expert,16429,,B,,,,,10209
3714,1,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,B,,,HEK293,,10209
3715,1,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,B,,,HEK293,,10209
3716,1,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,B,,,HEK293,,10209
3717,1,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,B,,,HEK293,,10209
3718,1,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,BAO_0000219,,,,Autocuration,15779,,B,,,HEK293,,10209
3719,1,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,BAO_0000219,,,,Autocuration,17451,,B,,,CHO,,10209
3720,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,BAO_0000219,,,,Autocuration,4199,,B,,,HEK293,,10209
3721,1,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,BAO_0000219,,,,Expert,4199,,B,,,HEK293,,10209
3722,1,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,BAO_0000219,,,,Autocuration,4199,,B,,,HEK293,,10209
3723,1,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,BAO_0000219,,,,Intermediate,3680,,B,,,HEK293,,10209
3724,1,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,BAO_0000357,,,,Intermediate,3680,,B,,,,,10209
3725,1,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,BAO_0000219,,,,Autocuration,15316,,B,,,COS-7,,10209
3726,1,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,BAO_0000219,,,,Autocuration,15146,,B,,,HEK293,,10209
3727,1,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,BAO_0000219,,,,Expert,5213,,B,,,HEK293,,10209
3728,1,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,BAO_0000219,,,,Autocuration,5213,,B,,,HEK293,,10209
3729,1,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,BAO_0000219,,Homo sapiens,,Expert,14818,,B,9606.0,,HEK293,,10209
3730,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,BAO_0000219,,,,Autocuration,14818,,B,,,HEK293,,10209
3731,1,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,BAO_0000219,,,,Autocuration,14818,,B,,,HEK293,,10209
3732,1,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,BAO_0000219,,,,Autocuration,4829,,B,,,HEK293,,10209
3733,1,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,BAO_0000357,,Homo sapiens,,Autocuration,17200,,B,9606.0,,,,10209
3734,1,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,BAO_0000357,,Mus musculus,,Expert,17066,,B,10090.0,,,,10022
3735,1,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,14025,,B,9986.0,,,,10209
3736,1,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,BAO_0000219,,,,Autocuration,15250,,B,,,CHO,,11923
3737,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,BAO_0000219,,,,Autocuration,16372,,B,,,CHO,,11923
3738,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,BAO_0000219,,,,Autocuration,16372,,B,,,CHO,,11923
3739,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,BAO_0000219,,,,Autocuration,16372,,B,,,CHO,,11923
3740,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,BAO_0000219,,,,Autocuration,16372,,B,,,CHO,,11923
3741,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,BAO_0000219,,,,Autocuration,16372,,B,,,CHO,,11923
3742,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,BAO_0000219,,,,Autocuration,16372,,B,,,CHO,,11923
3743,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,BAO_0000219,,,,Autocuration,16372,,B,,,CHO,,11923
3744,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,BAO_0000219,,,,Autocuration,16372,,B,,,CHO,,11923
3745,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,BAO_0000219,,,,Autocuration,16372,,B,,,CHO,,11923
3746,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,BAO_0000219,,,,Autocuration,16372,,B,,,CHO,,11923
3747,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,BAO_0000219,,,,Autocuration,16372,,B,,,CHO,,11923
3748,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,BAO_0000219,,,,Autocuration,16372,,B,,,CHO,,11923
3749,1,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Expert,17066,,B,,,,,11923
3750,1,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,BAO_0000357,,Rattus norvegicus,,Expert,17066,,B,10116.0,,,,11923
3751,1,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Expert,17386,,B,,,,,11923
3752,1,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,BAO_0000019,,,,Autocuration,14423,,B,,,,,11923
3753,1,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,BAO_0000357,,Rattus norvegicus,,Expert,15874,,B,10116.0,,,,11923
3754,1,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,BAO_0000357,,Rattus norvegicus,,Expert,15874,,B,10116.0,,,,11923
3755,1,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,BAO_0000219,,Rattus norvegicus,,Expert,16372,,B,10116.0,,CHO,,11923
3756,1,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,4622,,B,,,,,11923
3757,1,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Autocuration,15086,,B,,,,,11923
3758,1,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,BAO_0000219,,,,Autocuration,16372,,B,,,CHO,,11923
3759,1,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,BAO_0000219,,,,Autocuration,16372,,B,,,CHO,,11923
3760,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,BAO_0000219,,,,Autocuration,16372,,B,,,CHO,,11923
3761,1,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,BAO_0000219,,,,Autocuration,16372,,B,,,CHO,,11923
3762,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,Ileum,BAO_0000221,,,,Autocuration,17386,,F,,,,,11923
3763,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,Ileum,BAO_0000221,,,,Autocuration,17386,,F,,,,,11923
3764,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,Ileum,BAO_0000221,,,,Autocuration,17386,,F,,,,,11923
3765,1,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,BAO_0000249,,Rattus norvegicus,,Expert,5831,,B,10116.0,,,Membranes,11923
3766,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,BAO_0000357,,,,Autocuration,4342,,B,,,,,11923
3767,1,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,BAO_0000357,,,,Expert,17319,,B,,,,,11923
3768,1,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,Hypothalamus,BAO_0000019,,,,Expert,17342,,B,,,,,11923
3769,1,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,BAO_0000357,,,,Autocuration,17342,,B,,,,,11923
3770,1,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,Hypothalamus,BAO_0000249,,,,Expert,3680,,B,,,,,11923
3771,1,Binding affinity towards 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Expert,3680,,B,,,,,11923
3772,1,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,BAO_0000219,,Rattus norvegicus,,Expert,17319,,F,10116.0,,HEK293,,11923
3773,1,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,BAO_0000219,,Rattus norvegicus,,Expert,17319,,F,10116.0,,HEK293,,11923
3774,1,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,BAO_0000219,,Rattus norvegicus,,Autocuration,17319,,F,10116.0,,HEK293,,11923
3775,1,Binding affinity towards 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Expert,4820,,B,,,,,10209
3776,1,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,BAO_0000357,,,,Autocuration,4639,,B,,,,,10209
3777,1,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,BAO_0000357,,,,Autocuration,6011,,B,,,,,10209
3778,1,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,BAO_0000357,,Homo sapiens,,Expert,17066,,B,9606.0,,,,10209
3779,1,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Expert,17066,,B,,,,,10209
3780,1,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,BAO_0000357,,,,Autocuration,17515,,B,,,,,10209
3781,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,BAO_0000357,,,,Autocuration,4373,,B,,,,,10209
3782,1,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,BAO_0000019,,,,Expert,17066,,F,,,,,10209
3783,1,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,BAO_0000357,,,,Autocuration,4373,,B,,,,,10209
3784,1,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,BAO_0000357,,,,Autocuration,4373,,B,,,,,10209
3785,1,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Autocuration,4687,,B,,,,,10209
3786,1,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Expert,17342,,B,,,,,10209
3787,1,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,BAO_0000357,,,,Autocuration,16946,,B,,,,,10209
3788,1,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,BAO_0000357,,,,Autocuration,16946,,B,,,,,10209
3789,1,Binding affinities against 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Autocuration,16633,,B,,,,,10209
3790,1,Binding affinities towards 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Autocuration,16633,,B,,,,,10209
3791,1,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,BAO_0000357,,,,Expert,17066,,B,,,,,10209
3792,1,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,BAO_0000357,,,,Autocuration,16700,,B,,,,,10209
3793,1,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,Ileum,BAO_0000221,,,,Autocuration,17386,,B,,,,,10209
3794,1,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,BAO_0000019,,,,Autocuration,14080,,F,,,,,55
3795,1,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,BAO_0000019,,Homo sapiens,,Expert,14080,,F,9606.0,,,,55
3796,1,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,BAO_0000357,,,,Autocuration,409,,B,,,,,55
3797,1,In vitro inhibition of human recombinant lipoxygenase enzyme,,BAO_0000357,,,,Autocuration,409,,B,,,,,55
3798,1,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,BAO_0000357,,,,Autocuration,409,,B,,,,,55
3799,1,Inhibition of 5-lipoxygenase in human whole blood.,Blood,BAO_0000357,,,,Expert,11090,,B,,,,,55
3800,1,Inhibition of 5-lipoxygenase in human whole blood.,Blood,BAO_0000357,,,,Expert,11090,,B,,,,,55
3801,1,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,BAO_0000357,,,,Autocuration,948,,B,,,,,55
3802,1,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,BAO_0000357,,,,Autocuration,948,,B,,,,,55
3803,1,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,BAO_0000219,,,,Expert,13622,,F,,,,,55
3804,1,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,Blood,BAO_0000019,,,,Autocuration,13622,,F,,,,,55
3805,1,In vitro inhibition of 5-lipoxygenase from human polymorphs,,BAO_0000357,,,,Autocuration,9637,,B,,,,,55
3806,1,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,BAO_0000357,,,,Autocuration,11320,,B,,,,,55
3807,1,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,BAO_0000357,,,,Expert,11320,,B,,,,,55
3808,1,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,BAO_0000357,,,,Autocuration,6838,,B,,,,,55
3809,1,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),Blood,BAO_0000357,,Homo sapiens,,Expert,17667,,B,9606.0,,,,55
3810,1,In vitro potency against human 5-Lipoxygenase,,BAO_0000357,,,,Autocuration,12703,,B,,,,,55
3811,1,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,BAO_0000019,,Homo sapiens,,Expert,14312,,F,9606.0,,,,55
3812,1,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,Blood,BAO_0000019,,,,Autocuration,14312,,F,,,,,55
3813,1,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,BAO_0000019,,,,Autocuration,5364,,F,,,,,55
3814,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,BAO_0000219,,,,Autocuration,951,,B,,,,,55
3815,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,BAO_0000219,,,,Autocuration,951,,B,,,,,55
3816,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,BAO_0000219,,,,Autocuration,951,,B,,,,,55
3817,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,BAO_0000219,,,,Autocuration,951,,B,,,,,55
3818,1,Inhibition of human 5-lipoxygenase in human cells,,BAO_0000219,,,,Autocuration,12365,,B,,,,,55
3819,1,Inhibition of human neutrophil 5-lipoxygenase,,BAO_0000357,,,,Expert,10603,,B,,,,,55
3820,1,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,BAO_0000019,,,,Autocuration,10501,,B,,,,,55
3821,1,Inhibition of 5-lipoxygenase from human whole blood,Blood,BAO_0000357,,,,Expert,12281,,B,,,,,55
3822,1,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,BAO_0000357,,,,Autocuration,2567,,B,,,,,55
3823,1,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,BAO_0000219,,,,Autocuration,2567,,B,,,,,55
3824,1,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,BAO_0000357,,,,Expert,10193,,B,,,,,55
3825,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,BAO_0000357,,,,Autocuration,10193,,B,,,,,55
3826,1,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,BAO_0000357,,,,Expert,13623,,B,,,,,55
3827,1,Tested against 5-lipoxygenase,,BAO_0000357,,,,Autocuration,12780,,B,,,,,55
3828,1,Tested for activity against 5-Lipoxygenase (5-LO),,BAO_0000357,,,,Autocuration,12780,,B,,,,,55
3829,1,Tested for activity against 5-lipoxygenase,,BAO_0000357,,,,Autocuration,12780,,B,,,,,55
3830,1,Tested for inhibition of 5-HPETE production by human 5-LO,,BAO_0000357,,,,Autocuration,11966,,B,,,,,55
3831,1,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,BAO_0000019,,,,Autocuration,5364,,F,,,,,55
3832,1,Inhibition of Human 5-lipoxygenase,,BAO_0000357,,,,Expert,13165,,B,,,,,55
3833,1,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,BAO_0000019,,,,Autocuration,5364,,B,,,,,55
3834,1,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,BAO_0000219,,,,Autocuration,11311,,B,,,,,55
3835,1,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,BAO_0000219,,,,Autocuration,11311,,B,,,,,55
3836,1,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,BAO_0000019,,,,Autocuration,14863,,B,,,,,55
3837,1,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,BAO_0000019,,,,Autocuration,14863,,B,,,,,55
3838,1,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),Blood,BAO_0000357,,,,Autocuration,11087,,B,,,,,55
3839,1,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,BAO_0000357,,,,Autocuration,455,,B,,,,,55
3840,1,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,BAO_0000357,,,,Autocuration,13183,,B,,,,,55
3841,1,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,BAO_0000019,,,,Expert,10319,,B,,,,,55
3842,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,BAO_0000357,,,,Autocuration,10193,,B,,,,,55
3843,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,BAO_0000219,,,,Autocuration,951,,B,,,,,55
3844,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,BAO_0000219,,,,Autocuration,951,,B,,,,,55
3845,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,BAO_0000219,,,,Autocuration,951,,B,,,,,55
3846,1,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,BAO_0000219,,,,Autocuration,951,,B,,,,,55
3847,1,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,BAO_0000357,,,,Expert,9859,,B,,,,,55
3848,1,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,BAO_0000357,,,,Expert,9859,,B,,,,,55
3849,1,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,BAO_0000357,,,,Autocuration,9859,,B,,,,,55
3850,1,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,BAO_0000357,,,,Autocuration,2567,,B,,,,,55
3851,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,BAO_0000357,,,,Autocuration,10193,,B,,,,,55
3852,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,BAO_0000357,,,,Autocuration,10193,,B,,,,,55
3853,1,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,BAO_0000019,,,,Autocuration,949,,B,,,,,55
3854,1,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,BAO_0000019,,,,Autocuration,949,,B,,,,,55
3855,1,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,BAO_0000357,,,,Expert,10603,,B,,,,,55
3856,1,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,BAO_0000357,,,,Expert,10603,,B,,,,,55
3857,1,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,BAO_0000019,,,,Autocuration,10603,,F,,,,,55
3858,1,Inhibition of lipoxygenase at the concentration of 0.1 uM,,BAO_0000357,,,,Expert,10603,,B,,,,,55
3859,1,Inhibition of lipoxygenase at the concentration of 1 uM,,BAO_0000357,,,,Expert,10603,,B,,,,,55
3860,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,BAO_0000357,,,,Autocuration,10193,,B,,,,,55
3861,1,Inhibition of 5-Lipoxygenase (5-LOX),,BAO_0000357,,Homo sapiens,,Expert,14580,,B,9606.0,,,,55
3862,1,Inhibition of 5-lipoxygenase in mouse macrophages.,,BAO_0000357,,,,Expert,11090,,B,,,,,17087
3863,1,Inhibition of 5-lipoxygenase in mouse macrophages.,,BAO_0000357,,,,Expert,11090,,B,,,,,17087
3864,1,Inhibitory activity against lipoxygenase-2 in mice,,BAO_0000357,,,,Autocuration,6339,,B,,,,,17087
3865,1,Inhibitory activity against murine lipoxygenase-2.,,BAO_0000357,,,,Expert,6339,,B,,,,,17087
3866,1,Inhibition of 5-lipoxygenase from mouse macrophage,,BAO_0000357,,Mus musculus,,Expert,12281,,B,10090.0,,,,17087
3867,1,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,BAO_0000357,,,,Autocuration,11311,,B,,,,,17087
3868,1,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,BAO_0000019,,Sus scrofa,,Autocuration,11089,,B,9823.0,,,,55
3869,1,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,BAO_0000019,,Sus scrofa,,Autocuration,10091,,B,9823.0,,,,55
3870,1,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,14352,,B,9986.0,,,,55
3871,1,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,BAO_0000019,,Rattus norvegicus,,Expert,13329,,B,10116.0,,,,12166
3872,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,BAO_0000019,,,,Autocuration,13329,,B,,,,,12166
3873,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,BAO_0000019,,,,Autocuration,13329,,B,,,,,12166
3874,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,BAO_0000019,,,,Autocuration,13329,,B,,,,,12166
3875,1,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,BAO_0000019,,,,Expert,13329,,B,,,,,12166
3876,1,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,BAO_0000019,,,,Expert,13329,,B,,,,,12166
3877,1,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,BAO_0000019,,,,Autocuration,13329,,B,,,,,12166
3878,1,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,BAO_0000019,,,,Autocuration,11311,,B,,,,,12166
3879,1,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,BAO_0000019,,,,Autocuration,11311,,B,,,,,12166
3880,1,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,BAO_0000219,,,,Autocuration,105,,B,,,RBL-1,,12166
3881,1,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,BAO_0000219,,,,Autocuration,105,,B,,,RBL-1,,12166
3882,1,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,BAO_0000357,,,,Autocuration,9138,,B,,,,,12166
3883,1,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,BAO_0000357,,,,Autocuration,9138,,B,,,,,12166
3884,1,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,BAO_0000357,,,,Autocuration,9138,,B,,,,,12166
3885,1,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,BAO_0000357,,,,Autocuration,14427,,B,,,,,12166
3886,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,BAO_0000019,,,,Autocuration,13329,,B,,,,,12166
3887,1,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,BAO_0000019,,,,Autocuration,13329,,B,,,,,12166
3888,1,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,BAO_0000219,,Rattus norvegicus,,Expert,14427,,B,10116.0,,RBL-2H3,,12166
3889,1,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,BAO_0000357,,,,Autocuration,14427,,B,,,,,12166
3890,1,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,BAO_0000357,,,,Autocuration,14427,,B,,,,,12166
3891,1,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,BAO_0000219,,,,Expert,10293,,B,,,RBL-1,,12166
3892,1,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,BAO_0000219,,Rattus norvegicus,,Expert,338,,B,10116.0,,RBL-1,,12166
3893,1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,BAO_0000357,,,,Autocuration,303,,B,,,,,12166
3894,1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,BAO_0000219,,,,Autocuration,303,,B,,,RBL-1,,12166
3895,1,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,BAO_0000219,,,,Expert,9247,,B,,,RBL-1,,12166
3896,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,BAO_0000219,,,,Autocuration,9247,,B,,,RBL-1,,12166
3897,1,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,BAO_0000219,,,,Autocuration,137,,B,,,RBL-1,,12166
3898,1,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,BAO_0000357,,,,Expert,11481,,B,,,,,12166
3899,1,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,BAO_0000357,,,,Expert,11481,,B,,,,,12166
3900,1,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,BAO_0000357,,,,Expert,9029,,B,,,,,12166
3901,1,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,BAO_0000019,,,,Autocuration,1701,,B,,,,,12166
3902,1,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,BAO_0000019,,,,Autocuration,1701,,B,,,,,12166
3903,1,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,BAO_0000019,,,,Autocuration,1701,,B,,,,,12166
3904,1,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,BAO_0000019,,,,Autocuration,1701,,B,,,,,12166
3905,1,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,BAO_0000219,,,,Expert,13358,,F,,,RBL-1,,12166
3906,1,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,BAO_0000219,,,,Expert,1175,,B,,,RBL-1,,12166
3907,1,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,BAO_0000219,,,,Expert,8797,,B,,,RBL-1,,12166
3908,1,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,BAO_0000019,,,,Autocuration,8797,,B,,,,,12166
3909,1,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,BAO_0000357,,Rattus norvegicus,,Expert,577,,B,10116.0,,,,12166
3910,1,In vitro inhibitory activity against RBL-1 5-LO,,BAO_0000219,,,,Expert,9295,,B,,,RBL-1,,12166
3911,1,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,BAO_0000219,,,,Autocuration,9295,,B,,,RBL-1,,12166
3912,1,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,BAO_0000219,,,,Autocuration,9295,,B,,,RBL-1,,12166
3913,1,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,BAO_0000218,,,,Autocuration,9295,,B,,,,,12166
3914,1,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,BAO_0000357,,,,Autocuration,9295,,B,,,,,12166
3915,1,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,BAO_0000218,,,,Autocuration,216,,B,,,,,12166
3916,1,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,BAO_0000219,,,,Autocuration,11090,,B,,,RBL-1,,12166
3917,1,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,Blood,BAO_0000019,,,,Autocuration,11090,,B,,,,,12166
3918,1,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,BAO_0000357,,,,Expert,10091,,B,,,,,12166
3919,1,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,BAO_0000019,,,,Autocuration,10274,,F,,,,,12166
3920,1,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,BAO_0000219,,,,Autocuration,13622,,F,,,,,12166
3921,1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,BAO_0000219,,,,Expert,12118,,B,,,RBL-1,,12166
3922,1,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,BAO_0000357,,,,Expert,12576,,B,,,,,12166
3923,1,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,BAO_0000219,,,,Expert,9546,,B,,,RBL-1,,12166
3924,1,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,BAO_0000219,,,,Autocuration,9521,,B,,,RBL-1,,12166
3925,1,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,BAO_0000219,,,,Expert,10626,,B,,,RBL-1,,12166
3926,1,In vitro inhibition of RBL-1 5-lipoxygenase,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
3927,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
3928,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
3929,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
3930,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
3931,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
3932,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
3933,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
3934,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
3935,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
3936,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
3937,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
3938,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
3939,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
3940,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
3941,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
3942,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
3943,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
3944,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
3945,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
3946,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
3947,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
3948,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
3949,1,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
3950,1,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,BAO_0000019,,,,Expert,9401,,B,,,,,12166
3951,1,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,BAO_0000019,,,,Autocuration,10325,,B,,,,,12166
3952,1,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,BAO_0000219,,,,Expert,1556,,F,,,RBL-2H3,,12166
3953,1,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,BAO_0000219,,,,Expert,1556,,F,,,RBL-2H3,,12166
3954,1,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,BAO_0000219,,Rattus norvegicus,,Expert,961,,B,10116.0,,RBL-1,,12166
3955,1,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,BAO_0000019,,,,Autocuration,6838,,B,,,,,12166
3956,1,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,BAO_0000019,,,,Expert,10325,,B,,,,,12166
3957,1,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,BAO_0000219,,Rattus norvegicus,,Expert,9209,,B,10116.0,,RBL-1,,12166
3958,1,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,BAO_0000219,,,,Expert,11520,,B,,,RBL-1,,12166
3959,1,In vitro inhibitory activity against 5-lipoxygenase was determined,,BAO_0000357,,,,Autocuration,137,,B,,,,,12166
3960,1,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,BAO_0000219,,,,Autocuration,4717,,B,,,RBL-1,,12166
3961,1,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,BAO_0000219,,,,Expert,10636,,B,,,RBL-1,,12166
3962,1,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,BAO_0000019,,Rattus norvegicus,,Expert,14312,,F,10116.0,,,,12166
3963,1,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,BAO_0000219,,,,Autocuration,1203,,B,,,RBL-1,,12166
3964,1,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,BAO_0000019,,,,Autocuration,1203,,B,,,,,12166
3965,1,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,BAO_0000219,,,,Expert,13622,,B,,,RBL-1,,12166
3966,1,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,BAO_0000357,,,,Autocuration,9793,,B,,,,,12166
3967,1,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,BAO_0000219,,Rattus norvegicus,,Expert,1143,,B,10116.0,,RBL-1,,12166
3968,1,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,BAO_0000219,,Rattus norvegicus,,Expert,11854,,B,10116.0,,RBL-1,,12166
3969,1,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,BAO_0000219,,,,Autocuration,3595,,B,,,RBL-1,,12166
3970,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,BAO_0000219,,,,Autocuration,3595,,B,,,RBL-1,,12166
3971,1,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,BAO_0000219,,Rattus norvegicus,,Expert,10501,,B,10116.0,,RBL-1,,12166
3972,1,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,BAO_0000219,,,,Expert,12526,,B,,,RBL-1,,12166
3973,1,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,Limbic system,BAO_0000019,,,,Autocuration,10034,,F,,,,,10825
3974,1,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,Limbic system,BAO_0000019,,,,Autocuration,10034,,F,,,,,10825
3975,1,Approximate dose levels for a half maximal reduction of 5-HTP levels,,BAO_0000019,,,,Autocuration,10034,,F,,,,,10825
3976,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Hippocampus,BAO_0000221,,,,Autocuration,10046,,B,,,,,10576
3977,1,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Hippocampus,BAO_0000221,,,,Autocuration,10046,,B,,,,,10576
3978,1,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,BAO_0000019,,,,Autocuration,10046,,B,,,,,10577
3979,1,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,Blood,BAO_0000019,,Canis lupus familiaris,,Autocuration,12079,,F,9615.0,,,,55
3980,1,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,Blood,BAO_0000019,,,,Autocuration,12079,,F,,,,,55
3981,1,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,BAO_0000219,,,,Autocuration,11311,,B,,,,,12166
3982,1,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,BAO_0000219,,,,Expert,12338,,B,,,,,17140
3983,1,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,BAO_0000219,,,,Expert,12143,,B,,,,,17140
3984,1,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,BAO_0000219,,,,Autocuration,12143,,B,,,,,17140
3985,1,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,BAO_0000219,,,,Expert,12143,,B,,,,,17140
3986,1,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,BAO_0000219,,,,Autocuration,12143,,B,,,,,17140
3987,1,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,BAO_0000357,,,,Expert,12365,,B,,,,,17140
3988,1,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,BAO_0000357,,,,Expert,13500,,B,,,,,17140
3989,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
3990,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
3991,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
3992,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
3993,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
3994,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
3995,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
3996,1,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
3997,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
3998,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
3999,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4000,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4001,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4002,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4003,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4004,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4005,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4006,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4007,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4008,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4009,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4010,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4011,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4012,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4013,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4014,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4015,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4016,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4017,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4018,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4019,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4020,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4021,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4022,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4023,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4024,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4025,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4026,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4027,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4028,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4029,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4030,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4031,1,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4032,1,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4033,1,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4034,1,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Canis lupus familiaris,,Autocuration,12832,In vivo,F,9615.0,,,,55
4035,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,BAO_0000218,,Canis lupus familiaris,,Autocuration,3595,,B,9615.0,,,,55
4036,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,BAO_0000218,,Canis lupus familiaris,,Autocuration,3595,,B,9615.0,,,,55
4037,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,BAO_0000218,,Canis lupus familiaris,,Autocuration,3595,,B,9615.0,,,,55
4038,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,BAO_0000218,,Canis lupus familiaris,,Autocuration,3595,,B,9615.0,,,,55
4039,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,BAO_0000218,,Canis lupus familiaris,,Autocuration,3595,,B,9615.0,,,,55
4040,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,BAO_0000218,,Canis lupus familiaris,,Autocuration,3595,,B,9615.0,,,,55
4041,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,BAO_0000218,,Canis lupus familiaris,,Autocuration,3595,,B,9615.0,,,,55
4042,1,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,BAO_0000218,,Canis lupus familiaris,,Autocuration,3595,,B,9615.0,,,,55
4043,1,Ability to inhibit 5-lipoxygenase in guinea pig,,BAO_0000357,,Cavia porcellus,,Autocuration,9203,,B,10141.0,,,,55
4044,1,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,BAO_0000357,,Cavia porcellus,,Expert,82,,B,10141.0,,,,55
4045,1,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,BAO_0000357,,Cavia porcellus,,Autocuration,11090,,B,10141.0,,,,55
4046,1,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",Blood,BAO_0000218,,Cavia porcellus,,Autocuration,12832,,B,10141.0,,,,55
4047,1,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,BAO_0000357,,Cavia porcellus,,Autocuration,1065,,B,10141.0,,,,55
4048,1,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,BAO_0000357,,Cavia porcellus,,Autocuration,1065,,B,10141.0,,,,55
4049,1,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,BAO_0000019,,Cavia porcellus,,Expert,12832,,B,10141.0,,,,55
4050,1,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,BAO_0000019,,Cavia porcellus,,Expert,12832,,B,10141.0,,,,55
4051,1,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,BAO_0000019,,Cavia porcellus,,Autocuration,12832,,B,10141.0,,,,55
4052,1,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,BAO_0000019,,Cavia porcellus,,Autocuration,10504,,B,10141.0,,,,55
4053,1,Inhibitory activity against 5-lipoxygenase,,BAO_0000357,,Cavia porcellus,,Autocuration,7788,,B,10141.0,,,,55
4054,1,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,BAO_0000357,,Cavia porcellus,,Autocuration,10001,,B,10141.0,,,,55
4055,1,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,BAO_0000357,,Cavia porcellus,,Autocuration,10193,,B,10141.0,,,,55
4056,1,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,BAO_0000357,,Cavia porcellus,,Autocuration,13243,,B,10141.0,,,,55
4057,1,Inhibitory activity uM,,BAO_0000357,,Cavia porcellus,,Autocuration,13243,,B,10141.0,,,,55
4058,1,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,BAO_0000219,,Cavia porcellus,,Autocuration,969,,B,10141.0,,,,55
4059,1,Inhibitory activity against 5-lipoxygenase at 10 uM,,BAO_0000357,,Cavia porcellus,,Autocuration,10001,,B,10141.0,,,,55
4060,1,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,BAO_0000357,,Cavia porcellus,,Autocuration,7788,,B,10141.0,,,,55
4061,1,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,BAO_0000357,,Cavia porcellus,,Autocuration,10001,,B,10141.0,,,,55
4062,1,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,BAO_0000357,,Cavia porcellus,,Autocuration,10193,,B,10141.0,,,,55
4063,1,Inhibitory activity uM,,BAO_0000357,,Cavia porcellus,,Autocuration,13243,,B,10141.0,,,,55
4064,1,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,BAO_0000357,,Cavia porcellus,,Autocuration,13243,,B,10141.0,,,,55
4065,1,Inhibitory activity uM,,BAO_0000357,,Cavia porcellus,,Expert,13243,,B,10141.0,,,,55
4066,1,Inhibitory activity uM,,BAO_0000019,,Cavia porcellus,,Autocuration,13243,,F,10141.0,,,,55
4067,1,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,BAO_0000019,,Cavia porcellus,,Autocuration,10504,,B,10141.0,,,,55
4068,1,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,BAO_0000357,,Cavia porcellus,,Autocuration,7788,,B,10141.0,,,,55
4069,1,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,Ileum,BAO_0000221,,Cavia porcellus,,Expert,10546,,F,10141.0,,,,55
4070,1,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,BAO_0000357,,,,Autocuration,13183,,B,,,,,55
4071,1,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,BAO_0000357,,,,Autocuration,13183,,B,,,,,55
4072,1,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,BAO_0000357,,,,Autocuration,2578,,B,,,,,55
4073,1,In vitro inhibition of human 5-Lipoxygenase.,,BAO_0000357,,,,Expert,12780,,B,,,,,55
4074,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4075,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4076,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4077,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4078,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4079,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4080,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4081,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4082,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4083,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4084,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4085,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4086,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4087,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4088,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4089,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4090,1,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4091,1,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4092,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4093,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4094,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4095,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4096,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4097,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4098,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4099,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4100,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4101,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4102,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4103,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4104,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4105,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4106,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4107,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4108,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4109,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4110,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4111,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4112,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4113,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4114,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4115,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4116,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4117,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4118,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4119,1,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4120,1,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4121,1,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4122,1,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4123,1,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4124,1,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4125,1,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4126,1,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4127,1,In vitro inhibition of 7226/S myeloma cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,10797,,F,9606.0,,RPMI-8226,,80433
4128,1,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,BAO_0000219,,Homo sapiens,,Intermediate,6881,,F,9606.0,,BEL-7404 tumor cell line,,80698
4129,1,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,BAO_0000219,,Homo sapiens,,Intermediate,3838,,F,9606.0,,786-0,,80640
4130,1,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,BAO_0000219,,Homo sapiens,,Intermediate,3838,,F,9606.0,,786-0,,80640
4131,1,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,BAO_0000219,,Cricetulus griseus,,Expert,12981,,F,10029.0,,V79,,81264
4132,1,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,BAO_0000219,,Cricetulus griseus,,Expert,12981,,F,10029.0,,V79,,81264
4133,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,BAO_0000219,,Rattus norvegicus,,Intermediate,7653,,F,10116.0,,7800C1 cell line,,80635
4134,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,BAO_0000219,,Rattus norvegicus,,Intermediate,7653,,F,10116.0,,7800C1 cell line,,80635
4135,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,BAO_0000219,,Rattus norvegicus,,Intermediate,7653,,F,10116.0,,7800C1 cell line,,80635
4136,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,BAO_0000219,,Rattus norvegicus,,Intermediate,7653,,F,10116.0,,7800C1 cell line,,80635
4137,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,BAO_0000219,,Rattus norvegicus,,Intermediate,7653,,F,10116.0,,7800C1 cell line,,80635
4138,1,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,BAO_0000219,,Rattus norvegicus,,Intermediate,7653,,F,10116.0,,7800C1 cell line,,80635
4139,1,In vitro antitumor activity against renal 786-0 tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,17229,,F,9606.0,,786-0,,80640
4140,1,Cytotoxic activity against 786-0 Renal cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,12858,,F,9606.0,,786-0,,80640
4141,1,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,BAO_0000219,,Homo sapiens,,Intermediate,16325,,F,9606.0,,786-0,,80640
4142,1,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,BAO_0000219,,Homo sapiens,,Intermediate,16325,,F,9606.0,,786-0,,80640
4143,1,In vitro antitumor activity against human renal 786-0 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,5858,,F,9606.0,,786-0,,80640
4144,1,Inhibition of Renal cancer in 786-0 cancer cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,16325,,F,9606.0,,786-0,,80640
4145,1,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,BAO_0000219,,Homo sapiens,,Intermediate,14696,,F,9606.0,,786-0,,80640
4146,1,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,BAO_0000219,,Homo sapiens,,Intermediate,3786,,F,9606.0,,786-0,,80640
4147,1,inhibition of the growth of renal cancer(786-0) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,14696,,F,9606.0,,786-0,,80640
4148,1,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,BAO_0000219,,Homo sapiens,,Intermediate,14769,,F,9606.0,,786-0,,80640
4149,1,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,15354,,F,9606.0,,786-0,,80640
4150,1,The IC50 value was measured on 786-0 cell line in ovarian tumor,,BAO_0000219,,Homo sapiens,,Intermediate,14255,,F,9606.0,,786-0,,80640
4151,1,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,BAO_0000219,,Homo sapiens,,Intermediate,14255,,F,9606.0,,786-0,,80640
4152,1,The IC50 value was measured on 786-0 cell line in renal tumor type.,,BAO_0000219,,Homo sapiens,,Intermediate,14255,,F,9606.0,,786-0,,80640
4153,1,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,BAO_0000219,,Homo sapiens,,Intermediate,14696,,F,9606.0,,786-0,,80640
4154,1,Tested for cytotoxic activity against renal cancer 786-0 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,12016,,F,9606.0,,786-0,,80640
4155,1,Compound was tested for growth inhibitory activity against 786-0 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2597,,F,9606.0,,786-0,,80640
4156,1,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,BAO_0000219,,,,Autocuration,12526,,B,,,RBL-1,,12166
4157,1,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,BAO_0000219,,,,Autocuration,12526,,B,,,RBL-1,,12166
4158,1,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,BAO_0000019,,,,Autocuration,14799,,B,,,,,12166
4159,1,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,BAO_0000219,,,,Expert,3595,,B,,,RBL-1,,12166
4160,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,BAO_0000219,,,,Expert,3595,,B,,,RBL-1,,12166
4161,1,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,BAO_0000357,,,,Autocuration,12767,,B,,,,,12166
4162,1,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,BAO_0000219,,,,Autocuration,10997,,B,,,,,12166
4163,1,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,BAO_0000219,,,,Autocuration,11388,,B,,,RBL-1,,12166
4164,1,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,BAO_0000357,,,,Autocuration,167,,B,,,,,12166
4165,1,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,BAO_0000357,,,,Autocuration,167,,B,,,,,12166
4166,1,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,BAO_0000357,,,,Expert,13744,,B,,,,,12166
4167,1,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,BAO_0000357,,,,Autocuration,1630,,B,,,,,12166
4168,1,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,BAO_0000357,,,,Autocuration,1630,,B,,,,,12166
4169,1,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,BAO_0000019,,Rattus norvegicus,,Expert,969,,B,10116.0,,,,12166
4170,1,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,BAO_0000219,,,,Autocuration,13621,,B,,,RBL-1,,12166
4171,1,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,BAO_0000357,,,,Autocuration,10089,,B,,,,,12166
4172,1,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,BAO_0000357,,,,Expert,10193,,B,,,,,12166
4173,1,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,BAO_0000357,,,,Autocuration,11966,,B,,,,,12166
4174,1,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,BAO_0000019,,,,Autocuration,12251,,B,,,,,12166
4175,1,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,BAO_0000219,,,,Autocuration,211,,B,,,RBL-1,,12166
4176,1,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,BAO_0000019,,,,Expert,12251,,F,,,,,12166
4177,1,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,BAO_0000219,,,,Autocuration,12495,,B,,,RBL-1,,12166
4178,1,Tested for its inhibitory activity against 5-lipoxygenase,,BAO_0000357,,,,Autocuration,414,,B,,,,,12166
4179,1,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,BAO_0000357,,,,Autocuration,414,,B,,,,,12166
4180,1,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,BAO_0000019,,,,Expert,10325,,B,,,,,12166
4181,1,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,BAO_0000019,,,,Expert,11966,,B,,,,,12166
4182,1,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,BAO_0000219,,,,Expert,165,,B,,,RBL-1,,12166
4183,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,BAO_0000219,,,,Autocuration,165,,B,,,RBL-1,,12166
4184,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,BAO_0000219,,,,Autocuration,165,,B,,,RBL-1,,12166
4185,1,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,BAO_0000219,,,,Expert,165,,B,,,RBL-1,,12166
4186,1,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,BAO_0000218,,,,Autocuration,11311,,B,,,,,12166
4187,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,BAO_0000219,,,,Autocuration,11311,,B,,,RBL-1,,12166
4188,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,BAO_0000219,,,,Autocuration,11311,,B,,,RBL-1,,12166
4189,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,BAO_0000219,,,,Autocuration,11311,,B,,,,,12166
4190,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,BAO_0000219,,,,Autocuration,11311,,B,,,,,12166
4191,1,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,BAO_0000218,,,,Autocuration,11311,In vivo,B,,,,,12166
4192,1,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,BAO_0000219,,,,Autocuration,11311,,F,,,RBL-2H3,,12166
4193,1,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,BAO_0000219,,,,Autocuration,11311,,F,,,RBL-2H3,,12166
4194,1,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,BAO_0000019,,,,Autocuration,11311,,B,,,,,12166
4195,1,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,BAO_0000019,,,,Autocuration,11732,,B,,,,,12166
4196,1,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,BAO_0000019,,,,Expert,11732,,B,,,,,12166
4197,1,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,BAO_0000019,,,,Expert,11087,,B,,,,,12166
4198,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,BAO_0000019,,,,Autocuration,11087,,B,,,,,12166
4199,1,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,BAO_0000219,,,,Autocuration,11087,,B,,,RBL-1,,12166
4200,1,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,BAO_0000357,,Rattus norvegicus,,Expert,11087,,B,10116.0,,,,12166
4201,1,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,BAO_0000219,,,,Autocuration,496,,B,,,RBL-1,,12166
4202,1,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,BAO_0000219,,,,Expert,13986,,F,,,RBL-1,,12166
4203,1,Compound was evaluated for the inhibition of 5-lipoxygenase,,BAO_0000357,,,,Autocuration,11520,,B,,,,,12166
4204,1,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,BAO_0000219,,,,Autocuration,10293,,B,,,RBL-1,,12166
4205,1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,BAO_0000219,,,,Autocuration,303,,B,,,RBL-1,,12166
4206,1,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,BAO_0000219,,,,Autocuration,303,,B,,,RBL-1,,12166
4207,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,BAO_0000219,,,,Autocuration,9247,,B,,,RBL-1,,12166
4208,1,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,BAO_0000219,,Rattus norvegicus,,Expert,9247,,B,10116.0,,RBL-1,,12166
4209,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,BAO_0000219,,,,Autocuration,9247,,B,,,RBL-1,,12166
4210,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,BAO_0000219,,,,Autocuration,9247,,B,,,RBL-1,,12166
4211,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,BAO_0000219,,,,Autocuration,9247,,B,,,RBL-1,,12166
4212,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,BAO_0000219,,,,Autocuration,9247,,B,,,RBL-1,,12166
4213,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,BAO_0000219,,,,Autocuration,9247,,B,,,RBL-1,,12166
4214,1,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,BAO_0000219,,,,Autocuration,9247,,B,,,RBL-1,,12166
4215,1,Inhibitory activity against 5-lipoxygenase at 10 uM,,BAO_0000357,,Rattus norvegicus,,Expert,11481,,B,10116.0,,,,12166
4216,1,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,BAO_0000357,,,,Autocuration,105,,B,,,,,12166
4217,1,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,BAO_0000357,,,,Expert,9029,,B,,,,,12166
4218,1,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,BAO_0000219,,,,Expert,1175,,B,,,RBL-1,,12166
4219,1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,BAO_0000219,,,,Autocuration,12118,,B,,,RBL-1,,12166
4220,1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,BAO_0000219,,,,Autocuration,12118,,B,,,RBL-1,,12166
4221,1,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,BAO_0000219,,,,Autocuration,12118,,B,,,RBL-1,,12166
4222,1,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,BAO_0000219,,,,Autocuration,9225,,B,,,RBL-1,,12166
4223,1,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,BAO_0000019,,,,Autocuration,9401,,B,,,,,12166
4224,1,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,BAO_0000357,,,,Autocuration,137,,B,,,,,12166
4225,1,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,BAO_0000357,,,,Autocuration,137,,B,,,,,12166
4226,1,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,BAO_0000219,,,,Autocuration,4717,,B,,,RBL-1,,12166
4227,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,BAO_0000219,,,,Autocuration,3595,,B,,,RBL-1,,12166
4228,1,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,BAO_0000219,,,,Autocuration,10501,,B,,,RBL-1,,12166
4229,1,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,BAO_0000219,,,,Autocuration,10501,,B,,,RBL-1,,12166
4230,1,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,BAO_0000219,,,,Autocuration,10501,,B,,,RBL-1,,12166
4231,1,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,BAO_0000219,,,,Autocuration,12526,,B,,,RBL-1,,12166
4232,1,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,BAO_0000219,,Rattus norvegicus,,Expert,14799,,B,10116.0,,RBL-1,,12166
4233,1,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,BAO_0000019,,,,Autocuration,14799,,B,,,,,12166
4234,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,BAO_0000219,,,,Autocuration,3595,,B,,,RBL-1,,12166
4235,1,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,BAO_0000219,,,,Expert,3595,,B,,,RBL-1,,12166
4236,1,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,BAO_0000219,,,,Autocuration,12526,,B,,,RBL-1,,12166
4237,1,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,BAO_0000219,,,,Autocuration,12526,,B,,,RBL-1,,12166
4238,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,BAO_0000019,,,,Autocuration,10193,,B,,,,,12166
4239,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,BAO_0000019,,,,Autocuration,10193,,B,,,,,12166
4240,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,BAO_0000019,,,,Autocuration,10193,,B,,,,,12166
4241,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,BAO_0000019,,,,Autocuration,10193,,B,,,,,12166
4242,1,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,BAO_0000357,,,,Expert,9138,,B,,,,,12166
4243,1,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,BAO_0000357,,,,Autocuration,9138,,B,,,,,12166
4244,1,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,BAO_0000019,,,,Autocuration,11966,,B,,,,,12166
4245,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,BAO_0000219,,,,Autocuration,165,,B,,,RBL-1,,12166
4246,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,BAO_0000219,,,,Autocuration,165,,B,,,RBL-1,,12166
4247,1,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,BAO_0000219,,,,Autocuration,11311,,B,,,RBL-2H3,,12166
4248,1,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,BAO_0000219,,,,Autocuration,11311,,B,,,RBL-2H3,,12166
4249,1,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,BAO_0000219,,,,Autocuration,11311,,F,,,RBL-2H3,,12166
4250,1,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,BAO_0000019,,,,Autocuration,11311,,F,,,,,12166
4251,1,The compound was tested for inhibition of isolated 5-lipoxygenase,,BAO_0000357,,,,Autocuration,11311,,B,,,,,12166
4252,1,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,BAO_0000219,,,,Autocuration,11311,,F,,,RBL-2H3,,12166
4253,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,BAO_0000019,,,,Autocuration,11087,,B,,,,,12166
4254,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,BAO_0000019,,,,Autocuration,11087,,B,,,,,12166
4255,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,BAO_0000019,,,,Autocuration,11087,,B,,,,,12166
4256,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,BAO_0000019,,,,Autocuration,11087,,B,,,,,12166
4257,1,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,BAO_0000019,,,,Autocuration,11087,,B,,,,,12166
4258,1,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,BAO_0000219,,,,Autocuration,496,,B,,,RBL-1,,12166
4259,1,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,BAO_0000219,,,,Autocuration,496,,B,,,RBL-1,,12166
4260,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,BAO_0000219,,,,Autocuration,13986,,F,,,RBL-1,,12166
4261,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,BAO_0000219,,,,Autocuration,13986,,F,,,RBL-1,,12166
4262,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,BAO_0000219,,,,Autocuration,13986,,F,,,RBL-1,,12166
4263,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,BAO_0000219,,,,Autocuration,13986,,F,,,RBL-1,,12166
4264,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,BAO_0000219,,,,Autocuration,13986,,F,,,RBL-1,,12166
4265,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,BAO_0000219,,,,Autocuration,13986,,F,,,RBL-1,,12166
4266,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,BAO_0000219,,,,Autocuration,13986,,F,,,RBL-1,,12166
4267,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,BAO_0000219,,,,Autocuration,13986,,F,,,RBL-1,,12166
4268,1,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,BAO_0000219,,,,Autocuration,13986,,F,,,RBL-1,,12166
4269,1,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,BAO_0000019,,Rattus norvegicus,,Expert,13986,,F,10116.0,,,,12166
4270,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,BAO_0000357,,,,Autocuration,10193,,B,,,,,12166
4271,1,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,BAO_0000357,,,,Autocuration,9295,,B,,,,,12166
4272,1,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,BAO_0000219,,,,Autocuration,4717,,B,,,RBL-1,,12166
4273,1,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,BAO_0000219,,,,Autocuration,4717,,B,,,RBL-1,,12166
4274,1,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,BAO_0000219,,,,Autocuration,11854,,B,,,RBL-1,,12166
4275,1,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,BAO_0000219,,,,Autocuration,11854,,B,,,RBL-1,,12166
4276,1,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,BAO_0000219,,,,Autocuration,11854,,B,,,RBL-1,,12166
4277,1,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,BAO_0000019,,,,Autocuration,10193,,B,,,,,12166
4278,1,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,BAO_0000219,,,,Autocuration,9295,,B,,,RBL-1,,12166
4279,1,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,BAO_0000219,,,,Autocuration,9295,,B,,,RBL-1,,12166
4280,1,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,BAO_0000219,,,,Autocuration,9295,,B,,,RBL-1,,12166
4281,1,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,BAO_0000219,,,,Autocuration,9295,,B,,,RBL-1,,12166
4282,1,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,BAO_0000219,,,,Autocuration,165,,B,,,RBL-1,,12166
4283,1,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,BAO_0000219,,,,Autocuration,11311,,B,,,,,12166
4284,1,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,BAO_0000219,,Homo sapiens,,Expert,10489,,B,9606.0,,RBL-1,,12166
4285,1,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,BAO_0000219,,Rattus norvegicus,,Expert,10489,,B,10116.0,,RBL-1,,12166
4286,1,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,BAO_0000219,,Rattus norvegicus,,Expert,10489,,B,10116.0,,RBL-1,,12166
4287,1,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,BAO_0000019,,Rattus norvegicus,,Autocuration,14799,,B,10116.0,,,,12166
4288,1,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,BAO_0000357,,Glycine max,,Autocuration,9295,,B,3847.0,,,,12054
4289,1,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,BAO_0000019,,,,Autocuration,16811,,B,,,,,22226
4290,1,In vitro inhibition of 5-Lipoxygenase; Inactive.,,BAO_0000357,,,,Expert,168,,B,,,,,55
4291,1,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,BAO_0000357,,,,Autocuration,6309,,B,,,,,55
4292,1,Inhibitory concentration against 5-lipoxygenase; No inhibition,,BAO_0000357,,,,Autocuration,6309,,B,,,,,55
4293,1,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,BAO_0000219,,,,Autocuration,3092,,B,,,RBL-1,,55
4294,1,Inhibitory activity against 5-lipoxygenase.,,BAO_0000357,,,,Expert,168,,B,,,,,55
4295,1,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,BAO_0000357,,,,Autocuration,168,,B,,,,,55
4296,1,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,BAO_0000357,,,,Autocuration,168,,B,,,,,55
4297,1,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,BAO_0000357,,,,Autocuration,168,,B,,,,,55
4298,1,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,BAO_0000019,,,,Expert,12338,,F,,,,,55
4299,1,Tested for the inhibitory activity against 5-lipoxygenase,,BAO_0000357,,,,Autocuration,4501,,B,,,,,55
4300,1,Compound was tested for its inhibitory activity against 5-lipoxygenase,,BAO_0000357,,,,Autocuration,1132,,B,,,,,55
4301,1,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,BAO_0000357,,,,Autocuration,2117,,B,,,,,55
4302,1,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,BAO_0000357,,,,Autocuration,168,,B,,,,,55
4303,1,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,BAO_0000357,,,,Autocuration,168,,B,,,,,55
4304,1,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,BAO_0000219,,,,Autocuration,13575,,B,,,RBL-1,,12166
4305,1,,,BAO_0000357,,,,Autocuration,11089,,B,,,,,12166
4306,1,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,BAO_0000357,,,,Autocuration,216,,B,,,,,10102
4307,1,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,BAO_0000019,,,,Autocuration,13165,,B,,,,,10102
4308,1,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,BAO_0000357,,,,Autocuration,3278,,B,,,,,10102
4309,1,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,BAO_0000357,,,,Expert,3278,,B,,,,,10102
4310,1,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,BAO_0000357,,,,Autocuration,11966,,B,,,,,10102
4311,1,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,BAO_0000357,,,,Autocuration,175,,B,,,,,10102
4312,1,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,BAO_0000357,,,,Autocuration,175,,B,,,,,10102
4313,1,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,BAO_0000357,,,,Autocuration,13449,,B,,,,,10102
4314,1,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,BAO_0000019,,,,Autocuration,12014,,B,,,,,11238
4315,1,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,BAO_0000019,,,,Autocuration,12014,,B,,,,,11238
4316,1,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,BAO_0000019,,,,Autocuration,12014,,B,,,,,11238
4317,1,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,BAO_0000220,,,,Intermediate,99,,B,,,,,100284
4318,1,The dark toxicity against 543 human galactophore carcinoma cells,,BAO_0000019,,Homo sapiens,,Autocuration,4349,,F,9606.0,,,,22226
4319,1,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,BAO_0000219,,Homo sapiens,,Expert,4071,,F,9606.0,,Panel (56 tumour cell lines),,80623
4320,1,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,BAO_0000219,,Homo sapiens,,Expert,17589,,F,9606.0,,5637,,80008
4321,1,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,BAO_0000219,,Homo sapiens,,Intermediate,15002,,F,9606.0,,5637,,80008
4322,1,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,BAO_0000219,,Homo sapiens,,Intermediate,13958,,F,9606.0,,5637,,80008
4323,1,Growth inhibition against human 5637 cell lines,,BAO_0000219,,Homo sapiens,,Expert,17589,,F,9606.0,,5637,,80008
4324,1,Antitumor activity against human bladder carcinoma 5637 cells.,,BAO_0000219,,Homo sapiens,,Expert,16748,,F,9606.0,,5637,,80008
4325,1,Antitumor activity against human bladder carcinoma 5637 cells,,BAO_0000219,,Homo sapiens,,Intermediate,16747,,F,9606.0,,5637,,80008
4326,1,Antitumor activity against human bladder carcinoma 5637 cells,,BAO_0000219,,Homo sapiens,,Intermediate,16747,,F,9606.0,,5637,,80008
4327,1,In vitro inhibition of bovine trypsin(Trp).,,BAO_0000357,,Bos taurus,,Expert,15285,,B,9913.0,,,,10443
4328,1,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,BAO_0000219,,Cercopithecidae,,Expert,3726,,B,9527.0,,CV-1,,240
4329,1,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,BAO_0000357,,,,Autocuration,5033,,B,,,,,10577
4330,1,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,BAO_0000019,,,,Autocuration,11756,,F,,,,,104698
4331,1,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,BAO_0000218,,,,Autocuration,11953,In vivo,F,,,,,22226
4332,1,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,BAO_0000357,,Cavia porcellus,,Intermediate,5033,,B,10141.0,,,,20033
4333,1,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,BAO_0000251,,Rattus norvegicus,,Expert,11347,,A,10116.0,,,Microsomes,17045
4334,1,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,BAO_0000251,,Rattus norvegicus,,Expert,11347,,A,10116.0,,,Microsomes,17045
4335,1,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,BAO_0000019,,,,Intermediate,1229,,F,,,,,22226
4336,1,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,BAO_0000019,,,,Intermediate,1229,,F,,,,,22226
4337,1,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,BAO_0000019,,Trypanosoma brucei,,Expert,17588,,B,5691.0,,,,11938
4338,1,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,BAO_0000019,,Trypanosoma brucei,,Autocuration,17588,,B,5691.0,,,,11938
4339,1,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,BAO_0000019,,Ovis aries,,Expert,17588,,B,9940.0,,,,11938
4340,1,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,BAO_0000019,,Ovis aries,,Autocuration,17588,,B,9940.0,,,,11938
4341,1,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,BAO_0000357,,,,Autocuration,16485,,B,,,,,11938
4342,1,Average inhibitory concentration against 60 human cell lines was reported,,BAO_0000019,,Homo sapiens,,Intermediate,4337,,F,9606.0,,,,22226
4343,1,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,BAO_0000019,,Homo sapiens,,Expert,4112,,F,9606.0,,,,22226
4344,1,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,BAO_0000219,,Homo sapiens,,Intermediate,16160,,F,9606.0,,Panel NCI-60 (60 carcinoma cell lines),,80315
4345,1,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,BAO_0000219,,Homo sapiens,,Intermediate,16160,,F,9606.0,,Panel NCI-60 (60 carcinoma cell lines),,80315
4346,1,In vitro mean growth inhibitory activity against 60-cell panel,,BAO_0000219,,,,Expert,17376,,F,,,Panel NCI-60 (60 carcinoma cell lines),,80315
4347,1,In vitro mean growth lethal concentration against 60-cell panel,,BAO_0000219,,,,Expert,17376,,F,,,Panel NCI-60 (60 carcinoma cell lines),,80315
4348,1,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,BAO_0000219,,,,Expert,17376,,F,,,Panel NCI-60 (60 carcinoma cell lines),,80315
4349,1,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,BAO_0000219,,,,Expert,17376,,F,,,Panel NCI-60 (60 carcinoma cell lines),,80315
4350,1,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,BAO_0000019,,,,Autocuration,3241,,F,,,,,104775
4351,1,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,BAO_0000019,,,,Autocuration,3241,,F,,,,,104775
4352,1,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,BAO_0000357,,,,Expert,3725,,B,,,,,275
4353,1,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,BAO_0000218,,Plasmodium falciparum,,Expert,10805,,F,5833.0,,,,50425
4354,1,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,BAO_0000218,,Plasmodium falciparum,,Expert,10805,,F,5833.0,,,,50425
4355,1,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,BAO_0000218,,Plasmodium falciparum,,Expert,10805,,F,5833.0,,,,50425
4356,1,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,BAO_0000218,,Plasmodium falciparum,,Expert,10805,,F,5833.0,,,,50425
4357,1,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,BAO_0000218,,Plasmodium falciparum,,Intermediate,10805,,F,5833.0,,,,50425
4358,1,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,BAO_0000218,,Mus musculus,,Intermediate,10144,,F,10090.0,,6C3HED,,80628
4359,1,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,BAO_0000218,,Mus musculus,,Intermediate,10144,,F,10090.0,,6C3HED,,80628
4360,1,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,BAO_0000218,,Mus musculus,,Intermediate,10144,,F,10090.0,,6C3HED,,80628
4361,1,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,BAO_0000218,,Mus musculus,,Intermediate,10144,,F,10090.0,,6C3HED,,80628
4362,1,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,BAO_0000218,,Mus musculus,,Intermediate,10144,,F,10090.0,,6C3HED,,80628
4363,1,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,BAO_0000218,,Mus musculus,,Intermediate,10144,,F,10090.0,,6C3HED,,80628
4364,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,,BAO_0000218,,Mus musculus,,Autocuration,10685,In vivo,F,10090.0,,,,22224
4365,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,,BAO_0000218,,Mus musculus,,Autocuration,10685,In vivo,F,10090.0,,,,22224
4366,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),,BAO_0000218,,Mus musculus,,Autocuration,10685,In vivo,F,10090.0,,,,22224
4367,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,,BAO_0000218,,Mus musculus,,Autocuration,10685,In vivo,F,10090.0,,,,22224
4368,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,,BAO_0000218,,Mus musculus,,Autocuration,10685,In vivo,F,10090.0,,,,22224
4369,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,,BAO_0000218,,Mus musculus,,Autocuration,10685,In vivo,F,10090.0,,,,22224
4370,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,,BAO_0000218,,Mus musculus,,Autocuration,10685,In vivo,F,10090.0,,,,22224
4371,1,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",,BAO_0000218,,Mus musculus,,Autocuration,10685,In vivo,F,10090.0,,,,22224
4372,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),,BAO_0000218,,Mus musculus,,Autocuration,10685,In vivo,F,10090.0,,,,22224
4373,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),,BAO_0000218,,Mus musculus,,Autocuration,10685,In vivo,F,10090.0,,,,22224
4374,1,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,,BAO_0000218,,Mus musculus,,Autocuration,10685,In vivo,F,10090.0,,,,22224
4375,1,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,BAO_0000218,,Mus musculus,,Autocuration,10144,,F,10090.0,,,,22224
4376,1,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,BAO_0000218,,Mus musculus,,Autocuration,10144,,F,10090.0,,,,22224
4377,1,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,BAO_0000218,,Mus musculus,,Autocuration,10144,,F,10090.0,,,,22224
4378,1,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,BAO_0000218,,Mus musculus,,Autocuration,10144,,F,10090.0,,,,22224
4379,1,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,BAO_0000218,,Mus musculus,,Autocuration,10685,,F,10090.0,,,,22224
4380,1,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,BAO_0000218,,Mus musculus,,Autocuration,10685,,F,10090.0,,,,22224
4381,1,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,BAO_0000218,,Mus musculus,,Autocuration,10685,,F,10090.0,,,,22224
4382,1,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,BAO_0000218,,Mus musculus,,Autocuration,10685,,F,10090.0,,,,22224
4383,1,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,BAO_0000218,,Mus musculus,,Autocuration,10685,,A,10090.0,,,,22224
4384,1,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,BAO_0000218,,Mus musculus,,Autocuration,10685,,A,10090.0,,,,22224
4385,1,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,BAO_0000218,,Mus musculus,,Autocuration,10685,,A,10090.0,,,,22224
4386,1,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,BAO_0000218,,Mus musculus,,Autocuration,10685,,A,10090.0,,,,22224
4387,1,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,BAO_0000218,,Mus musculus,,Intermediate,8831,,F,10090.0,,6C3HED,,80628
4388,1,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,BAO_0000218,,,,Autocuration,11704,In vivo,F,,,,,22224
4389,1,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,BAO_0000218,,Mus musculus,,Intermediate,11704,,A,10090.0,,,,50594
4390,1,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,,BAO_0000218,,Mus musculus,,Intermediate,10685,In vivo,F,10090.0,,6C3HED,,80628
4391,1,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,,BAO_0000218,,Mus musculus,,Intermediate,10685,In vivo,F,10090.0,,6C3HED,,80628
4392,1,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,BAO_0000218,,Mus musculus,,Expert,11368,,F,10090.0,,6C3HED,,80628
4393,1,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,BAO_0000218,,Mus musculus,,Intermediate,11368,,F,10090.0,,6C3HED,,80628
4394,1,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,BAO_0000218,,Mus musculus,,Expert,11368,,F,10090.0,,6C3HED,,80628
4395,1,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,BAO_0000019,,Staphylococcus aureus,,Autocuration,17763,,B,1280.0,,,,22226
4396,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4397,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4398,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4399,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4400,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4401,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4402,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4403,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4404,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4405,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4406,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4407,1,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Liver,BAO_0000251,,Rattus norvegicus,,Autocuration,7411,,B,10116.0,,,Microsomes,22226
4408,1,The apparent total plasma clearance in monkey,Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,347,In vivo,A,9527.0,,,,22224
4409,1,Compound was evaluated for Hepatic clearance in monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,3341,In vivo,A,9527.0,,,,22224
4410,1,Lower clearance in monkey (i.v.) at 0.5 mpk,,BAO_0000218,,Cercopithecidae,,Autocuration,17853,In vivo,A,9527.0,,,,22224
4411,1,Plasma clearance in rhesus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,4514,In vivo,A,9527.0,,,,22224
4412,1,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,6062,In vivo,A,9527.0,,,,22224
4413,1,Plasma clearance of compound was determined in monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,6821,In vivo,A,9527.0,,,,22224
4414,1,Plasma clearance was calculated in rhesus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,6057,In vivo,A,9527.0,,,,22224
4415,1,Plasma clearance in rhesus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,5145,In vivo,A,9527.0,,,,22224
4416,1,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,,Cercopithecidae,,Autocuration,6641,In vivo,A,9527.0,,,,22224
4417,1,Plasma clearance was evaluated in rhesus,,BAO_0000218,,Cercopithecidae,,Autocuration,5472,In vivo,A,9527.0,,,,22224
4418,1,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,,BAO_0000218,,Cercopithecidae,,Autocuration,4257,In vivo,A,9527.0,,,,22224
4419,1,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,BAO_0000218,,Cercopithecidae,,Autocuration,5546,In vivo,A,9527.0,,,,22224
4420,1,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,BAO_0000218,,Cercopithecidae,,Autocuration,5334,In vivo,A,9527.0,,,,22224
4421,1,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,BAO_0000218,,Cercopithecidae,,Autocuration,5334,In vivo,A,9527.0,,,,22224
4422,1,Cmax 24 hr after 2 mg/kg oral administration in monkeys,,BAO_0000218,,Cercopithecidae,,Autocuration,17509,In vivo,A,9527.0,,,,22224
4423,1,Cmax in monkey after administration of 1 mg/kg iv,,BAO_0000218,,Cercopithecidae,,Autocuration,6535,In vivo,A,9527.0,,,,22224
4424,1,Cmax was determine after peroral administration at 10 mpk in Rhesus,,BAO_0000218,,Cercopithecidae,,Autocuration,5668,In vivo,A,9527.0,,,,22224
4425,1,Cmax in cynomolgus monkey by iv administration,,BAO_0000218,,Cercopithecidae,,Autocuration,5922,In vivo,A,9527.0,,,,22224
4426,1,Cmax in cynomolgus monkey by po administration,,BAO_0000218,,Cercopithecidae,,Autocuration,5922,In vivo,A,9527.0,,,,22224
4427,1,Cmax value evaluated in monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,6078,In vivo,A,9527.0,,,,22224
4428,1,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,2661,In vivo,A,9527.0,,,,22224
4429,1,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,3249,In vivo,A,9527.0,,,,22224
4430,1,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,3249,In vivo,A,9527.0,,,,22224
4431,1,Maximal plasma concentration in squirrel monkeys,Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,5553,In vivo,A,9527.0,,,,22224
4432,1,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,,Cercopithecidae,,Autocuration,1916,In vivo,A,9527.0,,,,22224
4433,1,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,6227,In vivo,A,9527.0,,,,22224
4434,1,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,BAO_0000218,,Cercopithecidae,,Autocuration,4809,In vivo,A,9527.0,,,,22224
4435,1,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,A,9527.0,,,,22224
4436,1,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,A,9527.0,,,,22224
4437,1,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,A,9527.0,,,,22224
4438,1,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,A,9527.0,,,,22224
4439,1,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,6221,In vivo,A,9527.0,,,,22224
4440,1,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,BAO_0000218,,Cercopithecidae,,Autocuration,167,,A,9527.0,,,,22224
4441,1,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,BAO_0000218,,Cercopithecidae,,Autocuration,167,,A,9527.0,,,,22224
4442,1,Absolute bioavailability was evaluated in monkey,,BAO_0000218,,monkey,,Autocuration,4257,In vivo,A,9443.0,,,,22224
4443,1,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,,BAO_0000218,,monkey,,Autocuration,6221,In vivo,A,9443.0,,,,22224
4444,1,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,,BAO_0000218,,monkey,,Autocuration,17667,In vivo,A,9443.0,,,,22224
4445,1,Bioavailability of compound was determined in rhesus monkey,,BAO_0000218,,Macaca mulatta,,Autocuration,17267,In vivo,A,9544.0,,,,22224
4446,1,Bioavailability determined after oral administration in marmoset,,BAO_0000218,,marmosets,,Autocuration,4256,In vivo,A,38020.0,,,,22224
4447,1,Oral bioavailability in cynomolgus monkey,,BAO_0000218,,Macaca fascicularis,,Autocuration,4256,In vivo,A,9541.0,,,,22224
4448,1,Bioavailability in monkey (p.o.) at 2.0 mpk,,BAO_0000218,,monkey,,Autocuration,17853,In vivo,A,9443.0,,,,22224
4449,1,Bioavailability was evaluated after oral administration in monkey,,BAO_0000218,,monkey,,Autocuration,16365,In vivo,A,9443.0,,,,22224
4450,1,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,,Macaca fascicularis,,Autocuration,1916,In vivo,A,9541.0,,,,22224
4451,1,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,BAO_0000218,,Macaca mulatta,,Autocuration,5334,In vivo,A,9544.0,,,,22224
4452,1,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,BAO_0000218,,Macaca mulatta,,Autocuration,5334,In vivo,A,9544.0,,,,22224
4453,1,Bioavailability of the compound was determined in monkey,,BAO_0000218,,monkey,,Autocuration,17592,In vivo,A,9443.0,,,,22224
4454,1,Bioavailability in squirrel monkey (dose 5 mg/kg),,BAO_0000218,,Saimiri sciureus,,Autocuration,1399,In vivo,A,9521.0,,,,22224
4455,1,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),,BAO_0000218,,monkey,,Autocuration,4809,In vivo,A,9443.0,,,,22224
4456,1,Oral bioavailability in monkey,,BAO_0000218,,monkey,,Autocuration,3341,In vivo,A,9443.0,,,,22224
4457,1,Compound was tested for bioavailability in squirrel monkey,,BAO_0000218,,Saimiri sciureus,,Autocuration,64,In vivo,A,9521.0,,,,22224
4458,1,Oral bioavailability in Rhesus monkey,,BAO_0000218,,Macaca mulatta,,Autocuration,5005,In vivo,A,9544.0,,,,22224
4459,1,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),,BAO_0000218,,Macaca mulatta,,Autocuration,5005,In vivo,A,9544.0,,,,22224
4460,1,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,,BAO_0000218,,Macaca fascicularis,,Autocuration,5237,In vivo,A,9541.0,,,,22224
4461,1,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,,BAO_0000218,,Macaca fascicularis,,Autocuration,5237,In vivo,A,9541.0,,,,22224
4462,1,Oral bioavailability in monkey (dose 5 mg/kg),,BAO_0000218,,monkey,,Autocuration,5302,In vivo,A,9443.0,,,,22224
4463,1,Oral bioavailability of compound at 5 mg/kg in monkey,,BAO_0000218,,monkey,,Autocuration,17667,In vivo,A,9443.0,,,,22224
4464,1,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6161,In vivo,A,9615.0,,,,50588
4465,1,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6161,In vivo,A,9615.0,,,,50588
4466,1,Plasma half life determined,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,3854,,A,9615.0,,,,50588
4467,1,Plasma half life in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,993,,A,9615.0,,,,50588
4468,1,Plasma half-life in Beagle dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,4514,,A,9615.0,,,,50588
4469,1,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5334,In vivo,A,9615.0,,,,50588
4470,1,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5334,In vivo,A,9615.0,,,,50588
4471,1,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1466,In vivo,A,9615.0,,,,50588
4472,1,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1466,In vivo,A,9615.0,,,,50588
4473,1,Tested for the half life period in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5313,,A,9615.0,,,,50588
4474,1,Tested for the half life period in dog at dosage of 10 mpk,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5313,In vivo,A,9615.0,,,,50588
4475,1,The compound was tested for half life in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3880,,A,9615.0,,,,50588
4476,1,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,3639,,A,9615.0,,,,50588
4477,1,The half life was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3880,,A,9615.0,,,,50588
4478,1,The plasma half-life in dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,3918,,A,9615.0,,,,50588
4479,1,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,,A,9615.0,,,,50588
4480,1,Half life in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17796,,A,9615.0,,,,50588
4481,1,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5983,In vivo,A,9615.0,,,,50588
4482,1,tmax upon peroral administration of 10.0 mg/Kg dose in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1466,In vivo,A,9615.0,,,,50588
4483,1,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16456,In vivo,A,9615.0,,,,50588
4484,1,Cmax in ferrets after 30 mg/kg oral dose,,BAO_0000218,,Mustela putorius furo,,Expert,6113,In vivo,A,9669.0,,,,50506
4485,1,Emesis in ferrets at 30 mg/kg oral dose,,BAO_0000218,,Mustela putorius furo,,Expert,6113,In vivo,F,9669.0,,,,50506
4486,1,Bioavailability in cynomolgus monkey,,BAO_0000218,,Macaca fascicularis,,Autocuration,17796,In vivo,A,9541.0,,,,22224
4487,1,Volume of distribution in cynomolgus,,BAO_0000218,,Macaca fascicularis,,Intermediate,17796,In vivo,A,9541.0,,,,100710
4488,1,AUC tested in guinea pig when 3 mg/kg dose was given perorally,Plasma,BAO_0000218,,Cavia porcellus,,Autocuration,5308,,A,10141.0,,,,22224
4489,1,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,BAO_0000218,,Cavia porcellus,,Autocuration,4877,,A,10141.0,,,,22224
4490,1,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,BAO_0000218,,Cavia porcellus,,Autocuration,4876,,A,10141.0,,,,22224
4491,1,AUC in guinea pig after 3mg/kg oral dose,Plasma,BAO_0000218,,Cavia porcellus,,Autocuration,4878,In vivo,A,10141.0,,,,22224
4492,1,Bioavailability in guinea pig was tested,,BAO_0000218,,Cavia porcellus,,Autocuration,5308,In vivo,A,10141.0,,,,22224
4493,1,Tested for oral bioavailability in guinea pig at 5 mg/kg,,BAO_0000218,,Cavia porcellus,,Autocuration,4877,In vivo,A,10141.0,,,,22224
4494,1,Tested for the oral bioavailability of the compound,,BAO_0000218,,Cavia porcellus,,Autocuration,4876,In vivo,A,10141.0,,,,22224
4495,1,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,,BAO_0000218,,Cavia porcellus,,Autocuration,4876,In vivo,A,10141.0,,,,22224
4496,1,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,,BAO_0000218,,Cavia porcellus,,Autocuration,5308,In vivo,A,10141.0,,,,22224
4497,1,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,Lung,BAO_0000218,,Cavia porcellus,,Autocuration,4877,In vivo,A,10141.0,,,,22224
4498,1,Cmax in guinea pig after 3mg/kg oral dose,,BAO_0000218,,Cavia porcellus,,Autocuration,4878,In vivo,A,10141.0,,,,22224
4499,1,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,Blood,BAO_0000019,,Cavia porcellus,,Autocuration,5689,,A,10141.0,,,,22224
4500,1,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,Brain,BAO_0000019,,Cavia porcellus,,Autocuration,5689,,A,10141.0,,,,22224
4501,1,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,,Cavia porcellus,,Autocuration,5689,,A,10141.0,,,,22224
4502,1,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,Intestine,BAO_0000019,,Cavia porcellus,,Autocuration,5689,,A,10141.0,,,,22224
4503,1,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,Kidney,BAO_0000019,,Cavia porcellus,,Autocuration,5689,,A,10141.0,,,,22224
4504,1,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,Liver,BAO_0000019,,Cavia porcellus,,Autocuration,5689,,A,10141.0,,,,22224
4505,1,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,BAO_0000019,,Cavia porcellus,,Autocuration,5689,,A,10141.0,,,,22224
4506,1,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,Spleen,BAO_0000019,,Cavia porcellus,,Autocuration,5689,,A,10141.0,,,,22224
4507,1,Elimination T1/2 in Guinea pig (PO dose),,BAO_0000218,,Cavia porcellus,,Autocuration,14465,In vivo,A,10141.0,,,,22224
4508,1,Partition coefficient was measured as -log (counts per min ),,BAO_0000019,,Cavia porcellus,,Autocuration,5689,,A,10141.0,,,,22224
4509,1,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,,BAO_0000218,,Cavia porcellus,,Autocuration,611,In vivo,A,10141.0,,,,22224
4510,1,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,,BAO_0000218,,Cavia porcellus,,Autocuration,611,In vivo,A,10141.0,,,,22224
4511,1,Elimination T1/2 in Guinea pig (PO dose),,BAO_0000218,,Cavia porcellus,,Autocuration,14465,In vivo,A,10141.0,,,,22224
4512,1,"Tested for the half life period of the compound, intravenously",,BAO_0000218,,Cavia porcellus,,Autocuration,4876,In vivo,A,10141.0,,,,22224
4513,1,Half-life was measured,,BAO_0000019,,Cavia porcellus,,Autocuration,5689,,A,10141.0,,,,22224
4514,1,The time required for onset of inotropy after addition of a single dose of delta F75,,BAO_0000019,,Cavia porcellus,,Autocuration,7515,,A,10141.0,,,,22224
4515,1,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,,BAO_0000218,,Cavia porcellus,,Autocuration,17667,In vivo,A,10141.0,,,,22224
4516,1,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,,BAO_0000218,,Cavia porcellus,,Autocuration,17667,In vivo,A,10141.0,,,,22224
4517,1,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,BAO_0000218,,Cricetulus griseus,,Autocuration,4727,In vivo,A,10029.0,,,,22224
4518,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
4519,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
4520,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
4521,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
4522,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
4523,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
4524,1,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
4525,1,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,Blood,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4526,1,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,Blood,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4527,1,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,Blood,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4528,1,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,Bone,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4529,1,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,Bone,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4530,1,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,Bone,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4531,1,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,Brain,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4532,1,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,Brain,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4533,1,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,Brain,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4534,1,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4535,1,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4536,1,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4537,1,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,Intestine,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4538,1,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,Intestine,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4539,1,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,Intestine,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4540,1,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4541,1,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4542,1,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4543,1,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4544,1,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4545,1,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4546,1,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4547,1,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4548,1,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4549,1,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4550,1,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4551,1,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4552,1,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4553,1,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4554,1,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4555,1,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,Stomach,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4556,1,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,Stomach,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4557,1,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,Stomach,BAO_0000218,,Mus musculus,,Intermediate,3655,In vivo,A,10090.0,,,,50594
4558,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,A,10090.0,,,,50594
4559,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,F,10090.0,,,,50594
4560,1,MRT value at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,A,10090.0,,,,50594
4561,1,MRT value at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,A,10090.0,,,,50594
4562,1,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,A,10090.0,,,,50594
4563,1,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,F,10090.0,,,,50594
4564,1,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,BAO_0000219,,Homo sapiens,,Intermediate,3830,,F,9606.0,,A2780,,81034
4565,1,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,BAO_0000219,,Homo sapiens,,Intermediate,3829,,F,9606.0,,A2780,,81034
4566,1,Compound was evaluated for cytotoxicity against A2780 cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,2040,,F,9606.0,,A2780,,81034
4567,1,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,BAO_0000219,,Homo sapiens,,Intermediate,15684,,F,9606.0,,A2780,,81034
4568,1,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,BAO_0000219,,Homo sapiens,,Intermediate,15684,,F,9606.0,,A2780,,81034
4569,1,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,BAO_0000219,,Homo sapiens,,Intermediate,15684,,F,9606.0,,A2780,,81034
4570,1,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,BAO_0000219,,Homo sapiens,,Intermediate,15684,,F,9606.0,,A2780,,81034
4571,1,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,BAO_0000219,,Homo sapiens,,Intermediate,15684,,F,9606.0,,A2780,,81034
4572,1,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,BAO_0000219,,Homo sapiens,,Intermediate,15684,,F,9606.0,,A2780,,81034
4573,1,Compound was evaluated for cytotoxicity against A2780 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2859,,F,9606.0,,A2780,,81034
4574,1,In vitro inhibitory activity against human tumor cell line A2780,,BAO_0000219,,Homo sapiens,,Intermediate,5618,,F,9606.0,,A2780,,81034
4575,1,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,BAO_0000219,,Homo sapiens,,Intermediate,15684,,F,9606.0,,A2780,,81034
4576,1,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,BAO_0000219,,Homo sapiens,,Intermediate,15684,,F,9606.0,,A2780,,81034
4577,1,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,BAO_0000219,,Homo sapiens,,Intermediate,15684,,F,9606.0,,A2780,,81034
4578,1,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,BAO_0000219,,Homo sapiens,,Intermediate,15684,,F,9606.0,,A2780,,81034
4579,1,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,2113,,F,9606.0,,A2780,,81034
4580,1,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,2113,,F,9606.0,,A2780,,81034
4581,1,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,BAO_0000219,,Homo sapiens,,Intermediate,16745,,F,9606.0,,A2780,,81034
4582,1,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,BAO_0000218,,Homo sapiens,,Expert,16597,,F,9606.0,,A2780,,81034
4583,1,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,BAO_0000219,,Homo sapiens,,Intermediate,15684,,F,9606.0,,A2780,,81034
4584,1,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,BAO_0000219,,Homo sapiens,,Intermediate,15684,,F,9606.0,,A2780,,81034
4585,1,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,2040,,F,9606.0,,A2780,,81034
4586,1,Relative resistance factor in A2780 cisplatin-resistant line,,BAO_0000219,,Homo sapiens,,Intermediate,2040,,F,9606.0,,A2780,,81034
4587,1,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,BAO_0000219,,Homo sapiens,,Intermediate,16165,,F,9606.0,,A2780,,81034
4588,1,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,BAO_0000219,,Homo sapiens,,Intermediate,16165,,F,9606.0,,A2780,,81034
4589,1,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,BAO_0000218,,Homo sapiens,,Expert,16597,,F,9606.0,,A2780,,81034
4590,1,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,BAO_0000218,,Homo sapiens,,Expert,16597,,F,9606.0,,A2780,,81034
4591,1,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,BAO_0000219,,Homo sapiens,,Intermediate,3992,,F,9606.0,,A2780,,81034
4592,1,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,BAO_0000219,,Homo sapiens,,Intermediate,10553,,F,9606.0,,A2780,,81034
4593,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,BAO_0000219,,Homo sapiens,,Intermediate,15608,,F,9606.0,,A2780,,81034
4594,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,BAO_0000219,,Homo sapiens,,Intermediate,15608,,F,9606.0,,A2780,,81034
4595,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,BAO_0000219,,Homo sapiens,,Intermediate,15608,,F,9606.0,,A2780,,81034
4596,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,BAO_0000219,,Homo sapiens,,Intermediate,15608,,F,9606.0,,A2780,,81034
4597,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,BAO_0000219,,Homo sapiens,,Intermediate,15608,,F,9606.0,,A2780,,81034
4598,1,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,BAO_0000219,,Homo sapiens,,Intermediate,15608,,F,9606.0,,A2780,,81034
4599,1,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,BAO_0000219,,Homo sapiens,,Intermediate,15569,,F,9606.0,,A2780,,81034
4600,1,Antiproliferative effect of compound on A2780/DX cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17420,,F,9606.0,,A2780,,81034
4601,1,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,BAO_0000219,,Homo sapiens,,Intermediate,17420,,F,9606.0,,A2780,,81034
4602,1,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,BAO_0000219,,Homo sapiens,,Intermediate,15099,,F,9606.0,,A2780,,81034
4603,1,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,BAO_0000219,,Homo sapiens,,Intermediate,15099,,F,9606.0,,A2780,,81034
4604,1,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,17672,,F,9606.0,,A2780,,81034
4605,1,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,17672,,F,9606.0,,A2780,,81034
4606,1,In vitro cytotoxicity against A2780ADR cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17270,,F,9606.0,,A2780,,81034
4607,1,In vitro cytotoxicity against A2780CIS cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17270,,F,9606.0,,A2780,,81034
4608,1,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,BAO_0000219,,Homo sapiens,,Intermediate,5574,,F,9606.0,,A2780,,81034
4609,1,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,2113,,F,9606.0,,A2780,,81034
4610,1,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,BAO_0000219,,Homo sapiens,,Intermediate,16913,,F,9606.0,,A2780,,81034
4611,1,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,BAO_0000219,,Homo sapiens,,Intermediate,16913,,F,9606.0,,A2780,,81034
4612,1,Oral bioavailability of compound in rhesus macaques,,BAO_0000218,,Macaca mulatta,,Autocuration,17839,In vivo,A,9544.0,,,,22224
4613,1,Oral bioavailability in monkey,,BAO_0000218,,monkey,,Autocuration,6821,In vivo,A,9443.0,,,,22224
4614,1,Oral bioavailability evaluated in monkey,,BAO_0000218,,monkey,,Autocuration,6078,In vivo,A,9443.0,,,,22224
4615,1,Oral bioavailability in monkey (dose 1 mg/kg p.o.),,BAO_0000218,,monkey,,Autocuration,6535,In vivo,A,9443.0,,,,22224
4616,1,Oral bioavailability in Rhesus monkey,,BAO_0000218,,Macaca mulatta,,Autocuration,4449,In vivo,A,9544.0,,,,22224
4617,1,Oral bioavailability was calculated in rhesus monkey,,BAO_0000218,,Macaca mulatta,,Autocuration,6057,In vivo,A,9544.0,,,,22224
4618,1,Oral bioavailability in cynomolgus monkey,,BAO_0000218,,Macaca fascicularis,,Autocuration,5922,In vivo,A,9541.0,,,,22224
4619,1,Oral bioavailability in monkey,,BAO_0000218,,monkey,,Autocuration,5940,In vivo,A,9443.0,,,,22224
4620,1,Oral bioavailability in monkey,,BAO_0000218,,monkey,,Autocuration,6265,In vivo,A,9443.0,,,,22224
4621,1,Oral bioavailability in monkey (dose 1 mg/kg),,BAO_0000218,,monkey,,Autocuration,6265,In vivo,A,9443.0,,,,22224
4622,1,Oral bioavailability in monkey (dose 5 mg/kg),,BAO_0000218,,monkey,,Autocuration,6265,In vivo,A,9443.0,,,,22224
4623,1,Oral bioavailability in monkey,,BAO_0000218,,monkey,,Autocuration,5940,In vivo,A,9443.0,,,,22224
4624,1,Oral bioavailability in monkey,,BAO_0000218,,monkey,,Autocuration,5940,In vivo,A,9443.0,,,,22224
4625,1,Oral bioavailability in rhesus monkey,,BAO_0000218,,Macaca mulatta,,Autocuration,4514,In vivo,A,9544.0,,,,22224
4626,1,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,,BAO_0000218,,Macaca mulatta,,Autocuration,5546,In vivo,A,9544.0,,,,22224
4627,1,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,,BAO_0000218,,Saimiri sciureus,,Autocuration,5553,In vivo,A,9521.0,,,,22224
4628,1,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,,monkey,,Autocuration,6641,In vivo,A,9443.0,,,,22224
4629,1,Oral bioavailability in Rhesus monkey,,BAO_0000218,,Macaca mulatta,,Autocuration,5472,In vivo,A,9544.0,,,,22224
4630,1,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),,BAO_0000218,,Macaca mulatta,,Autocuration,5668,In vivo,A,9544.0,,,,22224
4631,1,Oral bioavailability in monkey at 10 mg/kg of the compound,,BAO_0000218,,monkey,,Autocuration,5711,In vivo,A,9443.0,,,,22224
4632,1,Bioavailability in Rhesus monkey,,BAO_0000218,,Macaca mulatta,,Autocuration,5145,In vivo,A,9544.0,,,,22224
4633,1,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,,Cercopithecidae,,Autocuration,3443,,A,9527.0,,,,22224
4634,1,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,,Cercopithecidae,,Autocuration,3443,,A,9527.0,,,,22224
4635,1,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,3249,In vivo,A,9527.0,,,,22224
4636,1,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,3249,In vivo,A,9527.0,,,,22224
4637,1,Mean residence time was determined after intravenous administration in cynomolgus monkeys,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,A,9527.0,,,,22224
4638,1,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,A,9527.0,,,,22224
4639,1,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,A,9527.0,,,,22224
4640,1,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,BAO_0000218,,Cercopithecidae,,Autocuration,4809,In vivo,A,9527.0,,,,22224
4641,1,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),,BAO_0000218,,Cercopithecidae,,Autocuration,4809,In vivo,A,9527.0,,,,22224
4642,1,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,BAO_0000251,,Cercopithecidae,,Autocuration,14294,,A,9527.0,,,Microsomes,22224
4643,1,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,BAO_0000251,,Cercopithecidae,,Autocuration,14294,,A,9527.0,,,Microsomes,22224
4644,1,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,BAO_0000251,,Cercopithecidae,,Autocuration,14294,,A,9527.0,,,Microsomes,22224
4645,1,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,BAO_0000251,,Cercopithecidae,,Autocuration,14294,,A,9527.0,,,Microsomes,22224
4646,1,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,,Cercopithecidae,,Autocuration,3443,In vivo,A,9527.0,,,,22224
4647,1,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,,Cercopithecidae,,Autocuration,3443,In vivo,A,9527.0,,,,22224
4648,1,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,A,9527.0,,,,22224
4649,1,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,,Cercopithecidae,,Autocuration,3443,,A,9527.0,,,,22224
4650,1,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,,Cercopithecidae,,Autocuration,3443,,A,9527.0,,,,22224
4651,1,Elimination Half-life of compound was determined in monkey,,BAO_0000019,,Cercopithecidae,,Autocuration,6821,,A,9527.0,,,,22224
4652,1,Half life of compound was determined in rhesus monkey,,BAO_0000019,,Cercopithecidae,,Autocuration,17267,,A,9527.0,,,,22224
4653,1,Half life in monkey plasma,Plasma,BAO_0000366,,Cercopithecidae,,Autocuration,5819,,A,9527.0,,,,22224
4654,1,Half life in monkey plasma; Not detected,Plasma,BAO_0000366,,Cercopithecidae,,Autocuration,5819,,A,9527.0,,,,22224
4655,1,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,,Cercopithecidae,,Autocuration,1916,In vivo,A,9527.0,,,,22224
4656,1,Half-life 24 hr after 2 mg/kg iv administration in monkeys,,BAO_0000218,,Cercopithecidae,,Autocuration,17509,In vivo,A,9527.0,,,,22224
4657,1,Terminal half life of the compound.,,BAO_0000019,,Cercopithecidae,,Autocuration,1399,,A,9527.0,,,,22224
4658,1,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,,Cercopithecidae,,Autocuration,1916,In vivo,A,9527.0,,,,22224
4659,1,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,BAO_0000218,,Cercopithecidae,,Autocuration,4809,In vivo,A,9527.0,,,,22224
4660,1,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,BAO_0000218,,Cercopithecidae,,Autocuration,5546,,A,9527.0,,,,22224
4661,1,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Urine,BAO_0000218,,Cercopithecidae,,Autocuration,3443,,A,9527.0,,,,22224
4662,1,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Urine,BAO_0000218,,Cercopithecidae,,Autocuration,3443,,A,9527.0,,,,22224
4663,1,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,,BAO_0000218,,Cercopithecidae,,Autocuration,4257,In vivo,A,9527.0,,,,22224
4664,1,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,,BAO_0000218,,Cercopithecidae,,Autocuration,6221,In vivo,A,9527.0,,,,22224
4665,1,Volume of distribution was evaluated in rhesus,,BAO_0000218,,Cercopithecidae,,Autocuration,5472,In vivo,A,9527.0,,,,22224
4666,1,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,BAO_0000218,,Cricetulus griseus,,Autocuration,4727,In vivo,A,10029.0,,,,22224
4667,1,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,,BAO_0000218,,Cricetulus griseus,,Autocuration,4727,In vivo,A,10029.0,,,,22224
4668,1,Bioavailability in hamster was determined,,BAO_0000218,,Cricetulus griseus,,Autocuration,4727,In vivo,A,10029.0,,,,22224
4669,1,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,,BAO_0000218,,Cricetulus griseus,,Autocuration,4727,In vivo,A,10029.0,,,,22224
4670,1,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,,BAO_0000218,,Cricetulus griseus,,Autocuration,4727,In vivo,A,10029.0,,,,22224
4671,1,Half life of compound was determined in hamster blood,Blood,BAO_0000221,,Cricetulus griseus,,Autocuration,4727,,A,10029.0,,,,22224
4672,1,Michaelis-Menten constant of the compound.,,BAO_0000019,,Sus scrofa,,Autocuration,1452,,A,9823.0,,,,22224
4673,1,Vmax value was measured at 0 uM concentration of silyl ether.,,BAO_0000019,,Sus scrofa,,Autocuration,1452,,A,9823.0,,,,22224
4674,1,Vmax value was measured at 10 uM concentration of silyl ether.,,BAO_0000019,,Sus scrofa,,Autocuration,1452,,A,9823.0,,,,22224
4675,1,Vmax value was measured at 5 uM concentration of silyl ether.,,BAO_0000019,,Sus scrofa,,Autocuration,1452,,A,9823.0,,,,22224
4676,1,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,BAO_0000357,,Homo sapiens,,Expert,11706,,B,9606.0,,,,235
4677,1,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,BAO_0000218,,Homo sapiens,,Autocuration,1916,,A,9606.0,,,,22224
4678,1,Compound was evaluated for area under the curve expressed as (h*ug/ml),,BAO_0000019,,Homo sapiens,,Autocuration,17791,,A,9606.0,,,,22224
4679,1,Active metabolite of ifosfamide determined in humans; A-Active,,BAO_0000019,,Homo sapiens,,Autocuration,7766,,A,9606.0,,,,22224
4680,1,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,BAO_0000019,,Homo sapiens,,Autocuration,6567,,A,9606.0,,,,22224
4681,1,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,BAO_0000019,,Homo sapiens,,Autocuration,6567,,A,9606.0,,,,22224
4682,1,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,BAO_0000019,,Homo sapiens,,Autocuration,6567,,A,9606.0,,,,22224
4683,1,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,BAO_0000019,,Homo sapiens,,Autocuration,6567,,A,9606.0,,,,22224
4684,1,Compound was evaluated for oral bioavailability in human,,BAO_0000218,,Homo sapiens,,Autocuration,17791,,A,9606.0,,,,22224
4685,1,Metabolite of ifosfamide determined in urine; NF-Not found,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,A,9606.0,,,,22224
4686,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,BAO_0000019,,Homo sapiens,,Autocuration,6852,,A,9606.0,,,,22224
4687,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,BAO_0000019,,Homo sapiens,,Autocuration,6852,,A,9606.0,,,,22224
4688,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,BAO_0000019,,Homo sapiens,,Autocuration,6852,,A,9606.0,,,,22224
4689,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,BAO_0000019,,Homo sapiens,,Autocuration,6852,,A,9606.0,,,,22224
4690,1,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,BAO_0000019,,Homo sapiens,,Autocuration,6852,,A,9606.0,,,,22224
4691,1,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,BAO_0000019,,Homo sapiens,,Autocuration,6852,,A,9606.0,,,,22224
4692,1,Percent of compound in healthy individuals (Group D),,BAO_0000019,,Homo sapiens,,Autocuration,6852,,A,9606.0,,,,22224
4693,1,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Autocuration,4397,,A,9606.0,,,Microsomes,22224
4694,1,Binding towards human plasma protein at 10 uM,,BAO_0000019,,Homo sapiens,,Autocuration,17409,,A,9606.0,,,,22224
4695,1,Binding towards human plasma protein at 100 uM,,BAO_0000019,,Homo sapiens,,Autocuration,17409,,A,9606.0,,,,22224
4696,1,Human plasma protein binding activity was determined,,BAO_0000019,,Homo sapiens,,Autocuration,17176,,A,9606.0,,,,22224
4697,1,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,BAO_0000019,,Homo sapiens,,Autocuration,15444,,A,9606.0,,,,22224
4698,1,Percent binding of compound towards human plasma protein was determined,,BAO_0000019,,Homo sapiens,,Autocuration,17267,,A,9606.0,,,,22224
4699,1,Plasma clearance in human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Autocuration,5944,In vitro,A,9606.0,,,Microsomes,22224
4700,1,In vitro intrinsic clearance in human liver microsome,Liver,BAO_0000251,,Homo sapiens,,Autocuration,5668,In vitro,A,9606.0,,,Microsomes,22224
4701,1,In vitro intrinsic clearance in human liver microsome,Liver,BAO_0000251,,Homo sapiens,,Autocuration,5669,In vitro,A,9606.0,,,Microsomes,22224
4702,1,In vitro microsome metabolism clearance in human was determined,,BAO_0000251,,Homo sapiens,,Autocuration,5041,In vitro,A,9606.0,,,Microsomes,22224
4703,1,In vitro microsome metabolism clearance in human was determined; High,,BAO_0000251,,Homo sapiens,,Autocuration,5041,In vitro,A,9606.0,,,Microsomes,22224
4704,1,In vitro microsome metabolism clearance in human was determined; ND denotes no data,,BAO_0000251,,Homo sapiens,,Autocuration,5041,In vitro,A,9606.0,,,Microsomes,22224
4705,1,Pharmacokinetic property (clearance) in human liver microsome,Liver,BAO_0000251,,Homo sapiens,,Autocuration,5676,In vitro,A,9606.0,,,Microsomes,22224
4706,1,Plasma clearance in human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Autocuration,5944,In vitro,A,9606.0,,,Microsomes,22224
4707,1,In vitro clearance in human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Autocuration,17538,In vitro,A,9606.0,,,Microsomes,22224
4708,1,Intrinsic clearance in human liver microsomes was determined,Liver,BAO_0000251,,Homo sapiens,,Autocuration,6331,In vitro,A,9606.0,,,Microsomes,22224
4709,1,Intrinsic clearance in human liver microsomes was determined,Liver,BAO_0000251,,Homo sapiens,,Autocuration,5948,In vitro,A,9606.0,,,Microsomes,22224
4710,1,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,,BAO_0000218,,Homo sapiens,,Autocuration,5965,In vivo,A,9606.0,,,,22224
4711,1,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,,BAO_0000218,,Homo sapiens,,Autocuration,1916,In vivo,A,9606.0,,,,22224
4712,1,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,BAO_0000218,,Homo sapiens,,Autocuration,5965,,A,9606.0,,,,22224
4713,1,Stability in human plasma 2 hr after incubation expressed as percent concentration,,BAO_0000019,,Homo sapiens,,Autocuration,1299,,A,9606.0,,,,22224
4714,1,Stability in human plasma 4 hr after incubation expressed as percent concentration,,BAO_0000019,,Homo sapiens,,Autocuration,1299,,A,9606.0,,,,22224
4715,1,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,A,9606.0,,,,22224
4716,1,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,A,9606.0,,,,22224
4717,1,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,A,9606.0,,,,22224
4718,1,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,A,9606.0,,,,22224
4719,1,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,F,10090.0,,,,50594
4720,1,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,F,10090.0,,,,50594
4721,1,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,F,10090.0,,,,50594
4722,1,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,F,10090.0,,,,50594
4723,1,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,BAO_0000218,,Mus musculus,,Intermediate,14294,,A,10090.0,,,,50594
4724,1,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,BAO_0000218,,Mus musculus,,Intermediate,14294,,A,10090.0,,,,50594
4725,1,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,BAO_0000218,,Mus musculus,,Intermediate,14294,,A,10090.0,,,,50594
4726,1,In vitro metabolic potential in mouse liver microsomes,Liver,BAO_0000218,,Mus musculus,,Intermediate,6251,,A,10090.0,,,,50594
4727,1,Ability of compound to bind to plasma protein was evaluated in HSA cells,,BAO_0000218,,Mus musculus,,Intermediate,17582,,A,10090.0,,,,50594
4728,1,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),Adrenal gland,BAO_0000218,,Mus musculus,,Intermediate,17811,,A,10090.0,,,,50594
4729,1,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,Brain,BAO_0000218,,Mus musculus,,Intermediate,17811,,A,10090.0,,,,50594
4730,1,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,Brain,BAO_0000218,,Mus musculus,,Intermediate,17811,,A,10090.0,,,,50594
4731,1,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,BAO_0000218,,Mus musculus,,Intermediate,17811,,A,10090.0,,,,50594
4732,1,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),Kidney,BAO_0000218,,Mus musculus,,Intermediate,17811,,A,10090.0,,,,50594
4733,1,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,BAO_0000218,,Mus musculus,,Intermediate,17811,,A,10090.0,,,,50594
4734,1,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,5288,,A,10090.0,,,,50594
4735,1,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,Serum,BAO_0000218,,Mus musculus,,Intermediate,2717,,A,10090.0,,,,50594
4736,1,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,Serum,BAO_0000218,,Mus musculus,,Intermediate,2717,,A,10090.0,,,,50594
4737,1,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,Serum,BAO_0000218,,Mus musculus,,Intermediate,2717,,A,10090.0,,,,50594
4738,1,Half life of compound was determined in plasma of mice at 24 mg/Kg,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17753,In vivo,A,10090.0,,,,50594
4739,1,Half life of compound was determined in plasma of mice at 40 mg/Kg,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17753,In vivo,A,10090.0,,,,50594
4740,1,Half life of compound was determined in plasma of mice at 5 mg/Kg,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17753,In vivo,A,10090.0,,,,50594
4741,1,Half life after intraperitoneal administration in mice at 18 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,F,10090.0,,,,50594
4742,1,Half life after intraperitoneal administration in mice at 23 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,F,10090.0,,,,50594
4743,1,Half life after intraperitoneal administration in mice at 25 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,F,10090.0,,,,50594
4744,1,Half life after intraperitoneal administration in mice at 26 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,F,10090.0,,,,50594
4745,1,Half life after intravenous administration in mice at 23 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,F,10090.0,,,,50594
4746,1,Half life after intravenous administration in mice at 24 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,A,10090.0,,,,50594
4747,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,A,10090.0,,,,50594
4748,1,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,,BAO_0000218,,Mus musculus,,Intermediate,2675,In vivo,A,10090.0,,,,50594
4749,1,Maximum time required to reach Cp max was evaluated in mice after oral administration,,BAO_0000218,,Mus musculus,,Intermediate,2675,In vivo,A,10090.0,,,,50594
4750,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,A,10090.0,,,,50594
4751,1,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",,BAO_0000218,,Mus musculus,,Intermediate,4890,In vivo,A,10090.0,,,,50594
4752,1,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,429,In vivo,A,10090.0,,,,50594
4753,1,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,Blood,BAO_0000218,,Mus musculus,,Intermediate,17837,In vivo,A,10090.0,,,,50594
4754,1,Half life at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,A,10090.0,,,,50594
4755,1,Half life at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,A,10090.0,,,,50594
4756,1,Half life in ob/ob mice,,BAO_0000218,,Mus musculus,,Intermediate,6619,,A,10090.0,,,,50594
4757,1,Half-life at a single subcutaneous administration of 40 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,4066,In vivo,A,10090.0,,,,50594
4758,1,Half-life was measured in mouse,,BAO_0000218,,Mus musculus,,Intermediate,4239,,A,10090.0,,,,50594
4759,1,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,5969,In vivo,A,10090.0,,,,50594
4760,1,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,BAO_0000218,,Mus musculus,,Intermediate,8999,,A,10090.0,,,,50594
4761,1,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,BAO_0000218,,Mus musculus,,Intermediate,8999,,A,10090.0,,,,50594
4762,1,T2 in brain of mice at the oral dose of 50 mg/kg,Brain,BAO_0000218,,Mus musculus,,Intermediate,17641,,A,10090.0,,,,50594
4763,1,T2 in kidney of mice at the oral dose of 50 mg/kg,Kidney,BAO_0000218,,Mus musculus,,Intermediate,17641,,A,10090.0,,,,50594
4764,1,T2 in liver of mice at the oral dose of 50 mg/kg,Liver,BAO_0000218,,Mus musculus,,Intermediate,17641,,A,10090.0,,,,50594
4765,1,T2 in lungs of mice at the oral dose of 50 mg/kg,Lung,BAO_0000218,,Mus musculus,,Intermediate,17641,,A,10090.0,,,,50594
4766,1,T2 in spleen of mice at the oral dose of 50 mg/kg,Spleen,BAO_0000218,,Mus musculus,,Intermediate,17641,,A,10090.0,,,,50594
4767,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,A,10090.0,,,,50594
4768,1,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",,BAO_0000218,,Mus musculus,,Intermediate,4890,In vivo,A,10090.0,,,,50594
4769,1,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,429,In vivo,A,10090.0,,,,50594
4770,1,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,,BAO_0000218,,Mus musculus,,Intermediate,429,In vivo,A,10090.0,,,,50594
4771,1,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,5969,In vivo,A,10090.0,,,,50594
4772,1,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,BAO_0000219,,Homo sapiens,,Intermediate,16913,,F,9606.0,,A2780,,81034
4773,1,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,BAO_0000219,,Homo sapiens,,Intermediate,16913,,F,9606.0,,A2780,,81034
4774,1,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,BAO_0000219,,Homo sapiens,,Intermediate,16913,,F,9606.0,,A2780,,81034
4775,1,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,BAO_0000219,,Homo sapiens,,Intermediate,16913,,F,9606.0,,A2780,,81034
4776,1,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,BAO_0000219,,Homo sapiens,,Intermediate,16913,,F,9606.0,,A2780,,81034
4777,1,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,BAO_0000219,,Homo sapiens,,Intermediate,16913,,F,9606.0,,A2780,,81034
4778,1,In vitro cytotoxicity against A2780TAX cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17270,,F,9606.0,,A2780,,81034
4779,1,In vitro inhibitory activity against human tumor cell line A2780cis,,BAO_0000219,,Homo sapiens,,Intermediate,5618,,F,9606.0,,A2780cisR,,80017
4780,1,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,BAO_0000219,,Homo sapiens,,Expert,17777,,F,9606.0,,A2780,,81034
4781,1,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,BAO_0000219,,Homo sapiens,,Intermediate,16112,,F,9606.0,,A2780cisR,,80017
4782,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,BAO_0000219,,Homo sapiens,,Intermediate,15748,,F,9606.0,,A2780cisR,,80017
4783,1,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,BAO_0000219,,Homo sapiens,,Intermediate,6633,,F,9606.0,,A2780,,81034
4784,1,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,BAO_0000219,,Homo sapiens,,Intermediate,16930,,F,9606.0,,A2780,,81034
4785,1,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17496,,F,9606.0,,A2780,,81034
4786,1,In vitro antitumor activity against A2780cisR cell line.,,BAO_0000219,,Homo sapiens,,Expert,12989,,F,9606.0,,A2780,,81034
4787,1,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,BAO_0000219,,Homo sapiens,,Intermediate,4840,,F,9606.0,,A2780,,81034
4788,1,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,BAO_0000219,,Homo sapiens,,Expert,12989,,F,9606.0,,A2780,,81034
4789,1,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,16745,,F,9606.0,,A2780cisR,,80017
4790,1,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,16597,,F,9606.0,,A2780,,81034
4791,1,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,BAO_0000019,,Rattus norvegicus,,Expert,16547,,B,10116.0,,,,11736
4792,1,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,BAO_0000019,,,,Expert,16547,,F,,,,,11736
4793,1,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,BAO_0000019,,Rattus norvegicus,,Expert,16547,,F,10116.0,,,,11736
4794,1,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,BAO_0000219,,Homo sapiens,,Expert,15856,,F,9606.0,,HEK293,,278
4795,1,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,BAO_0000219,,Homo sapiens,,Expert,15856,,F,9606.0,,HEK293,,278
4796,1,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,BAO_0000019,,Mus musculus,,Expert,16547,,B,10090.0,,,,11831
4797,1,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,BAO_0000019,,,,Expert,16547,,F,,,,,11831
4798,1,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,BAO_0000019,,Mus musculus,,Expert,16547,,F,10090.0,,,,11831
4799,1,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,BAO_0000357,,,,Expert,17402,,B,,,,,280
4800,1,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,BAO_0000219,,Homo sapiens,,Autocuration,11746,,F,9606.0,,T-cells,,22226
4801,1,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,BAO_0000219,,Homo sapiens,,Autocuration,11746,,F,9606.0,,T-cells,,22226
4802,1,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,BAO_0000219,,Homo sapiens,,Intermediate,5455,,F,9606.0,,A-375,,80018
4803,1,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,2068,,F,9606.0,,A-375,,80018
4804,1,In vitro antitumor activity against A375cell line extracted form melanoma,,BAO_0000219,,Homo sapiens,,Intermediate,2683,,F,9606.0,,A-375,,80018
4805,1,Inhibition of cell growth in (A375) melan cell line,,BAO_0000219,,Homo sapiens,,Expert,15313,,F,9606.0,,A-375,,80018
4806,1,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,BAO_0000219,,Homo sapiens,,Intermediate,13739,,F,9606.0,,A-375,,80018
4807,1,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,BAO_0000219,,Homo sapiens,,Intermediate,13739,,F,9606.0,,A-375,,80018
4808,1,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,BAO_0000219,,Homo sapiens,,Intermediate,14750,,F,9606.0,,A-375,,80018
4809,1,Antiproliferative activity measured against A427 human lung carcinoma,,BAO_0000219,,Homo sapiens,,Intermediate,14777,,F,9606.0,,A-427,,80019
4810,1,Antiproliferative activity measured against A427 human lung carcinoma,,BAO_0000219,,Homo sapiens,,Intermediate,14777,,F,9606.0,,A-427,,80019
4811,1,Cytotoxicity against lung carcinoma A427 tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,17672,,F,9606.0,,A-427,,80019
4812,1,Inhibition of large cell lung carcinoma (A427),,BAO_0000219,,Homo sapiens,,Intermediate,14368,,F,9606.0,,A-427,,80019
4813,1,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,BAO_0000219,,Homo sapiens,,Intermediate,14368,,F,9606.0,,A-427,,80019
4814,1,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,BAO_0000219,,Homo sapiens,,Intermediate,13866,,F,9606.0,,A-427,,80019
4815,1,Inhibitory concentration in human lung carcinoma A427 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2545,,F,9606.0,,A-427,,80019
4816,1,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2545,,F,9606.0,,A-427,,80019
4817,1,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,6062,In vivo,A,9527.0,,,,22224
4818,1,Tested for volume of distribution upon iv administration to african green monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,4578,In vivo,A,9527.0,,,,22224
4819,1,Volume of distribution in monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,17592,In vivo,A,9527.0,,,,22224
4820,1,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,BAO_0000218,,Macaca mulatta,,Autocuration,5005,In vivo,A,9544.0,,,,22224
4821,1,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,BAO_0000218,,Macaca mulatta,,Autocuration,5005,In vivo,A,9544.0,,,,22224
4822,1,Pharmacokinetic property(Vdss) in cynomolgus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,5922,In vivo,A,9527.0,,,,22224
4823,1,The distribution volume after intravenous administration in cynomolgus monkeys,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,A,9527.0,,,,22224
4824,1,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,A,9527.0,,,,22224
4825,1,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,A,9527.0,,,,22224
4826,1,Volume displacement was calculated in rhesus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,6057,In vivo,A,9527.0,,,,22224
4827,1,Volume of distribution in steady state was determined in rhesus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,5145,In vivo,A,9527.0,,,,22224
4828,1,Volume of distribution of compound was determined in monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,6821,In vivo,A,9527.0,,,,22224
4829,1,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,BAO_0000218,,Cercopithecidae,,Autocuration,5334,In vivo,A,9527.0,,,,22224
4830,1,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,BAO_0000218,,Cercopithecidae,,Autocuration,5334,In vivo,A,9527.0,,,,22224
4831,1,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,,Cercopithecidae,,Autocuration,6641,In vivo,A,9527.0,,,,22224
4832,1,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,2661,In vivo,A,9527.0,,,,22224
4833,1,Volume distribution in monkey after administration of 1 mg/kg iv,,BAO_0000218,,Cercopithecidae,,Autocuration,6535,In vivo,A,9527.0,,,,22224
4834,1,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,BAO_0000218,,Cercopithecidae,,Autocuration,4809,In vivo,A,9527.0,,,,22224
4835,1,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,6062,In vivo,A,9527.0,,,,22224
4836,1,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,,Cercopithecidae,,Autocuration,3443,In vivo,A,9527.0,,,,22224
4837,1,Oral systemic bioavailability upon iv administration to african green monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,4578,In vivo,A,9527.0,,,,22224
4838,1,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,BAO_0000218,,Cercopithecidae,,Autocuration,4809,In vivo,A,9527.0,,,,22224
4839,1,Baboon plasma free fraction. ,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,A,9527.0,,,,22224
4840,1,Area under the curve was calculated in rhesus monkey after iv administration,,BAO_0000218,,Cercopithecidae,,Autocuration,6057,,A,9527.0,,,,22224
4841,1,Area under the curve was calculated in rhesus monkey after peroral administration,,BAO_0000019,,Cercopithecidae,,Autocuration,6057,,A,9527.0,,,,22224
4842,1,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,BAO_0000019,,Cercopithecidae,,Autocuration,17853,,A,9527.0,,,,22224
4843,1,Half life period in monkey after 5 mg/kg dose,,BAO_0000218,,Cercopithecidae,,Autocuration,5302,In vivo,A,9527.0,,,,22224
4844,1,Half-life was determined in monkey after 3 mg/kg of i.v. dose,,BAO_0000218,,Cercopithecidae,,Autocuration,4257,In vivo,A,9527.0,,,,22224
4845,1,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,,BAO_0000218,,Cercopithecidae,,Autocuration,4257,In vivo,A,9527.0,,,,22224
4846,1,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,13501,In vivo,A,9527.0,,,,22224
4847,1,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,5394,In vivo,A,9527.0,,,,22224
4848,1,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,2661,In vivo,A,9527.0,,,,22224
4849,1,Compound was evaluated for terminal half life in monkey,,BAO_0000019,,Cercopithecidae,,Autocuration,3341,,A,9527.0,,,,22224
4850,1,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,3045,In vivo,A,9527.0,,,,22224
4851,1,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Plasma,BAO_0000218,,Macaca mulatta,,Autocuration,5005,In vivo,A,9544.0,,,,22224
4852,1,Half life of compound was determined in squirrel monkey,,BAO_0000019,,Cercopithecidae,,Autocuration,4847,,A,9527.0,,,,22224
4853,1,Half life after iv administration in cynomolgus monkey,,BAO_0000218,,Macaca fascicularis,,Autocuration,4256,In vivo,A,9541.0,,,,22224
4854,1,Half life in monkey plasma after administration of 1 mg/kg iv,Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,6535,In vivo,A,9527.0,,,,22224
4855,1,Half life was calculated in rhesus monkey,,BAO_0000019,,Cercopithecidae,,Autocuration,6057,,A,9527.0,,,,22224
4856,1,Half life in monkey,,BAO_0000019,,Cercopithecidae,,Autocuration,17592,,A,9527.0,,,,22224
4857,1,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,,Cercopithecidae,,Autocuration,6641,In vivo,A,9527.0,,,,22224
4858,1,Half life was evaluated in rhesus,,BAO_0000019,,Cercopithecidae,,Autocuration,5472,,A,9527.0,,,,22224
4859,1,Half life period after oral administration (2.5 mg/kg) in monkey was determined,,BAO_0000218,,Cercopithecidae,,Autocuration,6221,In vivo,A,9527.0,,,,22224
4860,1,Half life period was determine after peroral administration at 10 mpk in Rhesus,,BAO_0000218,,Cercopithecidae,,Autocuration,5668,In vivo,A,9527.0,,,,22224
4861,1,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,BAO_0000218,,Cercopithecidae,,Autocuration,4809,In vivo,A,9527.0,,,,22224
4862,1,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,BAO_0000218,,Cercopithecidae,,Autocuration,5546,In vivo,A,9527.0,,,,22224
4863,1,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,5553,In vivo,A,9527.0,,,,22224
4864,1,Half-life was calculated in monkey,,BAO_0000019,,Cercopithecidae,,Autocuration,6078,,A,9527.0,,,,22224
4865,1,Half-life in Squirrel monkey,,BAO_0000019,,Cercopithecidae,,Autocuration,5147,,A,9527.0,,,,22224
4866,1,Half-life in rhesus monkey,,BAO_0000019,,Cercopithecidae,,Autocuration,5145,,A,9527.0,,,,22224
4867,1,Half-life was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,6062,In vivo,A,9527.0,,,,22224
4868,1,Half-life period after intravenous administration in cynomolgus monkeys,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,A,9527.0,,,,22224
4869,1,Half-life period after oral administration in cynomolgus monkeys,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,A,9527.0,,,,22224
4870,1,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,A,9527.0,,,,22224
4871,1,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,A,9606.0,,,,22224
4872,1,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,A,9606.0,,,,22224
4873,1,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,A,9606.0,,,,22224
4874,1,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,A,9606.0,,,,22224
4875,1,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,A,9606.0,,,,22224
4876,1,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,A,9606.0,,,,22224
4877,1,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,A,9606.0,,,,22224
4878,1,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,A,9606.0,,,,22224
4879,1,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,,BAO_0000218,,Homo sapiens,,Autocuration,1916,In vivo,A,9606.0,,,,22224
4880,1,Oral bioavailability in human,,BAO_0000218,,Homo sapiens,,Autocuration,16643,In vivo,A,9606.0,,,,22224
4881,1,Compound was tested for human plasma protein binding,,BAO_0000019,,Homo sapiens,,Autocuration,17248,,A,9606.0,,,,22224
4882,1,Compound was tested for human plasma protein binding; Not determined,,BAO_0000019,,Homo sapiens,,Autocuration,17248,,A,9606.0,,,,22224
4883,1,Protein binding activity of compound in human plasma; % Free,,BAO_0000019,,Homo sapiens,,Autocuration,6241,,A,9606.0,,,,22224
4884,1,Unbound fraction (plasma),,BAO_0000019,,Homo sapiens,,Autocuration,17716,,A,9606.0,,,,22224
4885,1,Half life for the hydrolysis of compound in human blood serum,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,17605,,A,9606.0,,,,22224
4886,1,Half life period in human plasma using phosphate buffer (0.08 M),Plasma,BAO_0000366,,Homo sapiens,,Autocuration,17625,,A,9606.0,,,,22224
4887,1,Half life period in human plasma using phosphate buffer (0.1 M),Plasma,BAO_0000366,,Homo sapiens,,Autocuration,17625,,A,9606.0,,,,22224
4888,1,Half-life in human plasma was determined,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,17747,,A,9606.0,,,,22224
4889,1,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,BAO_0000019,,Homo sapiens,,Autocuration,15613,,A,9606.0,,,,22224
4890,1,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,BAO_0000019,,Homo sapiens,,Autocuration,354,,A,9606.0,,,,22224
4891,1,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,BAO_0000019,,Homo sapiens,,Autocuration,3741,,A,9606.0,,,,22224
4892,1,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,BAO_0000019,,Homo sapiens,,Autocuration,3741,,A,9606.0,,,,22224
4893,1,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,BAO_0000019,,Homo sapiens,,Autocuration,3741,,A,9606.0,,,,22224
4894,1,Partition coefficient (logP),,BAO_0000019,,Homo sapiens,,Autocuration,17599,,A,9606.0,,,,22224
4895,1,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,BAO_0000019,,Homo sapiens,,Autocuration,5486,,A,9606.0,,,,22224
4896,1,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,BAO_0000251,,Homo sapiens,,Autocuration,5600,,A,9606.0,,,Microsomes,22224
4897,1,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,BAO_0000019,,Homo sapiens,,Autocuration,14294,,A,9606.0,,,,22224
4898,1,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,BAO_0000019,,Homo sapiens,,Autocuration,14294,,A,9606.0,,,,22224
4899,1,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,BAO_0000019,,Homo sapiens,,Autocuration,14294,,A,9606.0,,,,22224
4900,1,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,BAO_0000251,,Homo sapiens,,Autocuration,14294,,A,9606.0,,,Microsomes,22224
4901,1,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,BAO_0000251,,Homo sapiens,,Autocuration,14294,,A,9606.0,,,Microsomes,22224
4902,1,Metabolism of compound in human microsomes; Trace,,BAO_0000251,,Homo sapiens,,Autocuration,14294,,A,9606.0,,,Microsomes,22224
4903,1,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Autocuration,6260,,A,9606.0,,,Microsomes,22224
4904,1,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,BAO_0000251,,Homo sapiens,,Autocuration,6187,,A,9606.0,,,Microsomes,22224
4905,1,In vitro metabolic potential in human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Autocuration,6251,,A,9606.0,,,Microsomes,22224
4906,1,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,BAO_0000019,,Homo sapiens,,Autocuration,3246,,A,9606.0,,,,22224
4907,1,Tested for human plasma protein binding of the compound; Not tested,,BAO_0000019,,Homo sapiens,,Autocuration,17313,,A,9606.0,,,,22224
4908,1,Compound was tested for percent protein binding (PB) in human,,BAO_0000019,,Homo sapiens,,Autocuration,6227,,A,9606.0,,,,22224
4909,1,Protein binding in human plasma,Plasma,BAO_0000019,,Homo sapiens,,Autocuration,5530,,A,9606.0,,,,22224
4910,1,Permeability coefficient (B to A) in Caco-2 cell,,BAO_0000019,,Homo sapiens,,Autocuration,6108,,A,9606.0,,,,22224
4911,1,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,BAO_0000019,,Homo sapiens,,Autocuration,6108,,A,9606.0,,,,22224
4912,1,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,BAO_0000019,,Homo sapiens,,Autocuration,2774,,A,9606.0,,,,22224
4913,1,In vitro rate of absorption observed as Caco-2 permeability in humans,,BAO_0000019,,Homo sapiens,,Autocuration,16643,,A,9606.0,,,,22224
4914,1,Cellular permeability of compound was determined in Caco-2 cells; High,,BAO_0000219,,Homo sapiens,,Autocuration,17582,,A,9606.0,,Caco-2,,22224
4915,1,Permeability in Caco-2 cells of compound,,BAO_0000219,,Homo sapiens,,Autocuration,6838,,A,9606.0,,Caco-2,,22224
4916,1,Permeability coefficient (A to B) in Caco-2 cell,,BAO_0000019,,Homo sapiens,,Autocuration,6108,,A,9606.0,,,,22224
4917,1,Permeability coefficient (B to A) in Caco-2 cell,,BAO_0000019,,Homo sapiens,,Autocuration,6108,,A,9606.0,,,,22224
4918,1,Permeability coefficient (Papp) (Caco-2 cell monolayer),,BAO_0000019,,Homo sapiens,,Autocuration,6108,,A,9606.0,,,,22224
4919,1,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,BAO_0000019,,Homo sapiens,,Autocuration,2146,,A,9606.0,,,,22224
4920,1,Compound was tested for protein binding in human plasma,,BAO_0000019,,Homo sapiens,,Autocuration,4514,,A,9606.0,,,,22224
4921,1,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,BAO_0000019,,Homo sapiens,,Autocuration,6108,,A,9606.0,,,,22224
4922,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,A,9606.0,,,,22224
4923,1,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,5969,In vivo,A,10090.0,,,,50594
4924,1,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,BAO_0000218,,Mus musculus,,Intermediate,3277,In vivo,A,10090.0,,,,50594
4925,1,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,,BAO_0000218,,Mus musculus,,Intermediate,3802,In vivo,A,10090.0,,,,50594
4926,1,Time taken to reach maximum concentration in plasma upon oral administration in mouse,Plasma,BAO_0000218,,Mus musculus,,Intermediate,2862,In vivo,A,10090.0,,,,50594
4927,1,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Plasma,BAO_0000218,,Mus musculus,,Intermediate,6348,In vivo,A,10090.0,,,,50594
4928,1,Tmax after intraperitoneal administration in mice at 23 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,F,10090.0,,,,50594
4929,1,Tmax after oral administration at 30 mg/kg in ICR mouse,,BAO_0000218,,Mus musculus,,Intermediate,5781,In vivo,A,10090.0,,,,50594
4930,1,Tmax after peroral administration in mice at 2.4 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,A,10090.0,,,,50594
4931,1,Tmax at a single subcutaneous administration of 40 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,4066,In vivo,A,10090.0,,,,50594
4932,1,Tmax in brain of mice at the oral dose of 50 mg/kg,Brain,BAO_0000218,,Mus musculus,,Intermediate,17641,In vivo,A,10090.0,,,,50594
4933,1,Tmax in kidney of mice at the oral dose of 50 mg/kg,Kidney,BAO_0000218,,Mus musculus,,Intermediate,17641,In vivo,A,10090.0,,,,50594
4934,1,Tmax in liver of mice at the oral dose of 50 mg/kg,Liver,BAO_0000218,,Mus musculus,,Intermediate,17641,In vivo,A,10090.0,,,,50594
4935,1,Tmax in lungs of mice at the oral dose of 50 mg/kg,Lung,BAO_0000218,,Mus musculus,,Intermediate,17641,In vivo,A,10090.0,,,,50594
4936,1,Tmax in mice at 18 uM/kg i.p. administration,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,F,10090.0,,,,50594
4937,1,Tmax in mice at 23 uM/kg i.v. administration,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,F,10090.0,,,,50594
4938,1,Tmax in mice at 25 uM/kg i.p. administration,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,F,10090.0,,,,50594
4939,1,Tmax in mice at 26 uM/kg i.p. administration,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,F,10090.0,,,,50594
4940,1,Tmax in spleen of mice at the oral dose of 50 mg/kg,Spleen,BAO_0000218,,Mus musculus,,Intermediate,17641,In vivo,A,10090.0,,,,50594
4941,1,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,A,10090.0,,,,50594
4942,1,Tmax value at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,A,10090.0,,,,50594
4943,1,Tmax value in IRC mice,,BAO_0000218,,Mus musculus,,Intermediate,5951,,A,10090.0,,,,50594
4944,1,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,BAO_0000218,,Mus musculus,,Intermediate,5506,In vivo,A,10090.0,,,,50594
4945,1,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,BAO_0000218,,Mus musculus,,Intermediate,5506,In vivo,A,10090.0,,,,50594
4946,1,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),Urine,BAO_0000218,,Mus musculus,,Intermediate,429,,A,10090.0,,,,50594
4947,1,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),Urine,BAO_0000218,,Mus musculus,,Intermediate,429,,A,10090.0,,,,50594
4948,1,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),Urine,BAO_0000218,,Mus musculus,,Intermediate,4066,,A,10090.0,,,,50594
4949,1,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,17734,,A,10090.0,,,,50594
4950,1,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,17734,,A,10090.0,,,,50594
4951,1,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,6062,In vivo,A,10090.0,,,,50594
4952,1,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,5969,In vivo,A,10090.0,,,,50594
4953,1,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,5969,In vivo,A,10090.0,,,,50594
4954,1,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,BAO_0000218,,Mus musculus,,Intermediate,5969,In vivo,A,10090.0,,,,50594
4955,1,Vd in mice,,BAO_0000218,,Mus musculus,,Intermediate,5980,In vivo,A,10090.0,,,,50594
4956,1,Volume of distribution in mouse,,BAO_0000218,,Mus musculus,,Intermediate,17592,In vivo,A,10090.0,,,,50594
4957,1,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,BAO_0000218,,Mus musculus,,Intermediate,6348,In vivo,A,10090.0,,,,50594
4958,1,Volume of distribution of compound in plasma was determined at 24 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,In vivo,A,10090.0,,,,50594
4959,1,Volume of distribution of compound in plasma was determined at 40 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,In vivo,A,10090.0,,,,50594
4960,1,Volume of distribution of compound in plasma was determined at 5 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,In vivo,A,10090.0,,,,50594
4961,1,Pharmacokinetic property (vdss) was measured in mouse,,BAO_0000218,,Mus musculus,,Intermediate,4239,In vivo,A,10090.0,,,,50594
4962,1,Value distribution upon iv administration in mouse,,BAO_0000218,,Mus musculus,,Intermediate,2862,In vivo,A,10090.0,,,,50594
4963,1,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,17734,In vivo,A,10090.0,,,,50594
4964,1,Volume of distribution was evaluated in mice after intravenous administration,,BAO_0000218,,Mus musculus,,Intermediate,2675,In vivo,A,10090.0,,,,50594
4965,1,Volume of distribution was evaluated in mice after oral administration,,BAO_0000218,,Mus musculus,,Intermediate,2675,In vivo,A,10090.0,,,,50594
4966,1,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,17837,In vivo,A,10090.0,,,,50594
4967,1,Steady state volume of distribution was determined in mice,,BAO_0000218,,Mus musculus,,Intermediate,5727,In vivo,A,10090.0,,,,50594
4968,1,Volume distribution (steady state) of compound was determined in mouse,,BAO_0000218,,Mus musculus,,Intermediate,17852,In vivo,A,10090.0,,,,50594
4969,1,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,A,10090.0,,,,50594
4970,1,Vss value at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,A,10090.0,,,,50594
4971,1,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,6062,In vivo,A,10090.0,,,,50594
4972,1,Biodistribution of compound (oxidized form) in in kidney tissue,Kidney,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
4973,1,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,Blood,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
4974,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Blood,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
4975,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Blood,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
4976,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,BAO_0000219,,Homo sapiens,,Intermediate,10708,,F,9606.0,,A-427,,80019
4977,1,Inhibition of A431 human squamous cell carcinoma cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,16597,,F,9606.0,,A-431,,80852
4978,1,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,BAO_0000219,,Homo sapiens,,Expert,16062,,F,9606.0,,A-431,,80852
4979,1,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,BAO_0000219,,Homo sapiens,,Expert,16062,,F,9606.0,,A-431,,80852
4980,1,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,BAO_0000219,,Homo sapiens,,Expert,16958,,F,9606.0,,A-431,,80852
4981,1,Inhibition of A431 human carcinoma cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,6700,,F,9606.0,,A-431,,80852
4982,1,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,BAO_0000219,,Homo sapiens,,Expert,17226,,F,9606.0,,A-431,,80852
4983,1,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,BAO_0000219,,Homo sapiens,,Intermediate,6828,,F,9606.0,,A-431,,80852
4984,1,In vitro cytotoxicity against epidermoid carcinoma cell line,,BAO_0000219,,Homo sapiens,,Intermediate,12314,,F,9606.0,,A-431,,80852
4985,1,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,BAO_0000218,,Homo sapiens,,Expert,13412,,F,9606.0,,A-431,,9
4986,1,Antiproliferative activity of compound was measured on human tumor cell line A431.,,BAO_0000219,,Homo sapiens,,Intermediate,13299,,F,9606.0,,A-431,,80852
4987,1,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,BAO_0000219,,Homo sapiens,,Intermediate,17420,,F,9606.0,,A-431,,80852
4988,1,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,BAO_0000219,,Homo sapiens,,Intermediate,13678,,F,9606.0,,A-431,,80852
4989,1,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,BAO_0000219,,,,Expert,14171,,F,,,A-431,,9
4990,1,Tested for antiproliferative activity against human A431 cells,,BAO_0000219,,Homo sapiens,,Expert,6333,,F,9606.0,,A-431,,80852
4991,1,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,BAO_0000219,,Homo sapiens,,Expert,2356,,F,9606.0,,A-431,,9
4992,1,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,BAO_0000219,,Homo sapiens,,Expert,15578,,F,9606.0,,A-431,,80852
4993,1,Inhibition of A431 cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,5126,,F,9606.0,,A-431,,80852
4994,1,Cytotoxic effect on A431 human epidermoid carcinoma cells,,BAO_0000219,,Homo sapiens,,Expert,6844,,F,9606.0,,A-431,,80852
4995,1,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,BAO_0000219,,Homo sapiens,,Expert,6844,,F,9606.0,,A-431,,80852
4996,1,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4925,,F,9606.0,,A-431,,80852
4997,1,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,BAO_0000219,,Homo sapiens,,Intermediate,4925,,F,9606.0,,A-431,,80852
4998,1,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,13978,,F,9606.0,,A-431,,80852
4999,1,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,BAO_0000219,,Homo sapiens,,Intermediate,16786,,F,9606.0,,A-431,,80852
5000,1,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,BAO_0000219,,,,Expert,13412,,F,,,A-431,,9
5001,1,In vivo antiproliferative activity against A431 cell line,,BAO_0000218,,Homo sapiens,,Intermediate,17824,,F,9606.0,,A-431,,80852
5002,1,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,BAO_0000219,,Homo sapiens,,Expert,12751,,F,9606.0,,A-431,,9
5003,1,Inhibition of A431 human epidermoid carcinoma cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,12380,,F,9606.0,,A-431,,80852
5004,1,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,BAO_0000219,,Homo sapiens,,Expert,4959,,F,9606.0,,A-431,,9
5005,1,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,BAO_0000219,,Homo sapiens,,Intermediate,6333,,F,9606.0,,A-431,,80852
5006,1,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,BAO_0000219,,Homo sapiens,,Intermediate,6333,,F,9606.0,,A-431,,80852
5007,1,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,BAO_0000219,,Homo sapiens,,Intermediate,6333,,F,9606.0,,A-431,,80852
5008,1,Inhibition of EGFR overexpressing A431 cell proliferation,,BAO_0000019,,Homo sapiens,,Expert,5296,,F,9606.0,,,,9
5009,1,Inhibition of A431 cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,12624,,F,9606.0,,A-431,,80852
5010,1,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,BAO_0000219,,Homo sapiens,,Expert,14926,,F,9606.0,,A-431,,9
5011,1,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,BAO_0000219,,Homo sapiens,,Expert,14926,,F,9606.0,,A-431,,9
5012,1,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,BAO_0000219,,,,Expert,14926,,F,,,A-431,,9
5013,1,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,15144,,F,9606.0,,A-431,,80852
5014,1,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,15144,,F,9606.0,,A-431,,80852
5015,1,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,BAO_0000219,,Homo sapiens,,Intermediate,5245,,F,9606.0,,A-431,,80852
5016,1,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,BAO_0000219,,Homo sapiens,,Intermediate,5245,,F,9606.0,,A-431,,80852
5017,1,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,BAO_0000219,,Homo sapiens,,Intermediate,5245,,F,9606.0,,A-431,,80852
5018,1,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,BAO_0000219,,Homo sapiens,,Intermediate,5245,,F,9606.0,,A-431,,80852
5019,1,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,BAO_0000219,,Homo sapiens,,Intermediate,5245,,F,9606.0,,A-431,,80852
5020,1,Half-life period in cynomolgus monkey,,BAO_0000019,,Cercopithecidae,,Autocuration,5922,,A,9527.0,,,,22224
5021,1,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",Plasma,BAO_0000366,,Cercopithecidae,,Autocuration,1116,In vitro,A,9527.0,,,,22224
5022,1,Longer half-life in monkey (i.v.) at 0.5 mpk,,BAO_0000218,,Cercopithecidae,,Autocuration,17853,In vivo,A,9527.0,,,,22224
5023,1,Plasma half life in monkey,Plasma,BAO_0000366,,Cercopithecidae,,Autocuration,993,,A,9527.0,,,,22224
5024,1,Plasma half-life in rhesus monkey,Plasma,BAO_0000366,,Cercopithecidae,,Autocuration,4514,,A,9527.0,,,,22224
5025,1,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,5334,In vivo,A,9527.0,,,,22224
5026,1,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,5334,In vivo,A,9527.0,,,,22224
5027,1,Tested for half life upon iv administration to african green monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,4578,In vivo,A,9527.0,,,,22224
5028,1,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,2661,In vivo,A,9527.0,,,,22224
5029,1,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,A,9527.0,,,,22224
5030,1,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,A,9527.0,,,,22224
5031,1,The time for peak concentration value after oral administration in cynomolgus monkeys,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,A,9527.0,,,,22224
5032,1,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,A,9527.0,,,,22224
5033,1,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,A,9527.0,,,,22224
5034,1,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,A,9527.0,,,,22224
5035,1,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,A,9527.0,,,,22224
5036,1,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,A,9527.0,,,,22224
5037,1,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,A,9527.0,,,,22224
5038,1,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,A,9527.0,,,,22224
5039,1,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,A,9527.0,,,,22224
5040,1,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,A,9527.0,,,,22224
5041,1,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,A,9527.0,,,,22224
5042,1,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,A,9527.0,,,,22224
5043,1,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,A,9527.0,,,,22224
5044,1,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,A,9527.0,,,,22224
5045,1,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,A,9527.0,,,,22224
5046,1,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,A,9527.0,,,,22224
5047,1,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,BAO_0000019,,Cercopithecidae,,Autocuration,11271,,A,9527.0,,,,22224
5048,1,Bioavailability in rat (cannulated) (dose 2 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,5809,In vivo,A,10116.0,,,,50597
5049,1,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17720,In vivo,A,10116.0,,,,50597
5050,1,AUC value in rat after IV administration at a dose of 10 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3546,,A,10116.0,,,,50597
5051,1,AUC value in rat after oral administration at a dose of 10 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3546,,A,10116.0,,,,50597
5052,1,Cmax value in rat after oral administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,3546,In vivo,A,10116.0,,,,50597
5053,1,Bioavailability in rat after oral administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,3546,In vivo,A,10116.0,,,,50597
5054,1,Tmax value in rat after oral administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,3546,In vivo,A,10116.0,,,,50597
5055,1,Vc value in rat after IV administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,3546,,A,10116.0,,,,50597
5056,1,Half life period in rat after IV administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,3546,In vivo,A,10116.0,,,,50597
5057,1,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,BAO_0000019,,Papio hamadryas,,Autocuration,10625,,A,9557.0,,,,22224
5058,1,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,BAO_0000019,,Papio hamadryas,,Autocuration,10625,,A,9557.0,,,,22224
5059,1,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,BAO_0000019,,Papio hamadryas,,Autocuration,10625,,A,9557.0,,,,22224
5060,1,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,BAO_0000019,,Papio hamadryas,,Autocuration,10625,,A,9557.0,,,,22224
5061,1,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,BAO_0000019,,Papio hamadryas,,Autocuration,10625,,A,9557.0,,,,22224
5062,1,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,BAO_0000019,,Papio hamadryas,,Autocuration,10625,,A,9557.0,,,,22224
5063,1,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,BAO_0000019,,Papio hamadryas,,Autocuration,10625,,A,9557.0,,,,22224
5064,1,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,BAO_0000019,,Papio hamadryas,,Autocuration,10625,,A,9557.0,,,,22224
5065,1,Area under curve after 1 mpk peroral administration to beagles,,BAO_0000019,,beagle,,Autocuration,3510,,A,9615.0,,,,22224
5066,1,Area under curve after 2 mpk peroral administration to beagles,,BAO_0000019,,beagle,,Autocuration,3510,,A,9615.0,,,,22224
5067,1,Cmax value after 1 mpk peroral administration to beagles,,BAO_0000218,,beagle,,Autocuration,3510,In vivo,A,9615.0,,,,22224
5068,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,A,9606.0,,,,22224
5069,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,A,9606.0,,,,22224
5070,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,A,9606.0,,,,22224
5071,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,A,9606.0,,,,22224
5072,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,A,9606.0,,,,22224
5073,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,A,9606.0,,,,22224
5074,1,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,Urine,BAO_0000019,,Homo sapiens,,Autocuration,7766,,A,9606.0,,,,22224
5075,1,Metabolic stability observed at 30 min after administration in human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Autocuration,16643,,A,9606.0,,,Microsomes,22224
5076,1,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,BAO_0000019,,Homo sapiens,,Autocuration,6852,,A,9606.0,,,,22224
5077,1,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,BAO_0000019,,Homo sapiens,,Autocuration,6852,,A,9606.0,,,,22224
5078,1,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,BAO_0000019,,Homo sapiens,,Autocuration,6852,,A,9606.0,,,,22224
5079,1,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",Liver,BAO_0000251,,Homo sapiens,,Autocuration,6567,,A,9606.0,,,Microsomes,22224
5080,1,Metabolic stability (% remaining at 30 mins) in human S9.,,BAO_0000019,,Homo sapiens,,Autocuration,6570,,A,9606.0,,,,22224
5081,1,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,BAO_0000019,,Homo sapiens,,Autocuration,6570,,A,9606.0,,,,22224
5082,1,Percent parent compound remaining after 20 min incubation with human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Autocuration,5237,,A,9606.0,,,Microsomes,22224
5083,1,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,Liver,BAO_0000251,,Homo sapiens,,Autocuration,5237,,A,9606.0,,,Microsomes,22224
5084,1,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,Liver,BAO_0000251,,Homo sapiens,,Autocuration,5237,,A,9606.0,,,Microsomes,22224
5085,1,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,BAO_0000218,,Homo sapiens,,Autocuration,5202,,A,9606.0,,,,22224
5086,1,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,BAO_0000019,,Homo sapiens,,Autocuration,5481,,A,9606.0,,,,22224
5087,1,Percent remaining in human plasma after incubation for 60 min at 37 C.,,BAO_0000019,,Homo sapiens,,Autocuration,5481,,A,9606.0,,,,22224
5088,1,The percent remaining in human plasma after 30 min was determined,,BAO_0000019,,Homo sapiens,,Autocuration,3956,,A,9606.0,,,,22224
5089,1,Conversion rate of the prodrug in human plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,5074,,A,9606.0,,,,22224
5090,1,Conversion rate of the prodrug in human plasma; ND means no data,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,5074,,A,9606.0,,,,22224
5091,1,Half life of compound was determined in human blood,Blood,BAO_0000221,,Homo sapiens,,Autocuration,4727,,A,9606.0,,,,22224
5092,1,Half life of compound was determined in man with once daily dosing,,BAO_0000019,,Homo sapiens,,Autocuration,5965,,A,9606.0,,,,22224
5093,1,Half life in human microsomes,,BAO_0000251,,Homo sapiens,,Autocuration,5732,In vitro,A,9606.0,,,Microsomes,22224
5094,1,Half life in human plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,5819,,A,9606.0,,,,22224
5095,1,Half life in human plasma; Not detected,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,5819,,A,9606.0,,,,22224
5096,1,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,,BAO_0000218,,Homo sapiens,,Autocuration,1916,In vivo,A,9606.0,,,,22224
5097,1,Half-life for oxidative metabolic stability was determined using rat liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Autocuration,6597,In vitro,A,9606.0,,,Microsomes,22224
5098,1,Half-life in human plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,5229,,A,9606.0,,,,22224
5099,1,Half-life of the parent prodrug in plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,5229,,A,9606.0,,,,22224
5100,1,In vitro half life in human plasma was determined,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,2192,In vitro,A,9606.0,,,,22224
5101,1,The compound was tested In Vitro for half life in human liver microsomes.,Liver,BAO_0000251,,Homo sapiens,,Autocuration,3032,In vitro,A,9606.0,,,Microsomes,22224
5102,1,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,,BAO_0000218,,Homo sapiens,,Autocuration,1916,In vivo,A,9606.0,,,,22224
5103,1,Observed volume of distribution,,BAO_0000218,,Homo sapiens,,Autocuration,17716,In vivo,A,9606.0,,,,22224
5104,1,Oral bioavailability in human,,BAO_0000218,,Homo sapiens,,Autocuration,15778,In vivo,A,9606.0,,,,22224
5105,1,Tested for human plasma protein binding of the compound,,BAO_0000019,,Homo sapiens,,Autocuration,17313,,A,9606.0,,,,22224
5106,1,"First order rate constant, k was determined in human plasma",,BAO_0000019,,Homo sapiens,,Autocuration,4231,,A,9606.0,,,,22224
5107,1,Observed rate constant in 80% human plasma at 37 degree Centigrade,,BAO_0000019,,Homo sapiens,,Autocuration,4755,,A,9606.0,,,,22224
5108,1,Observed rate constant in 80% human plasma at 37 degree Centigrade,,BAO_0000019,,Homo sapiens,,Autocuration,4755,,A,9606.0,,,,22224
5109,1,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Autocuration,16907,,A,9606.0,,,Microsomes,22224
5110,1,The compound was tested for the plasma binding in human,,BAO_0000019,,Homo sapiens,,Autocuration,10839,,A,9606.0,,,,22224
5111,1,Plasma protein binding (human),,BAO_0000019,,Homo sapiens,,Autocuration,10839,,A,9606.0,,,,22224
5112,1,Compound was evaluated for half-life in human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Autocuration,3199,In vitro,A,9606.0,,,Microsomes,22224
5113,1,Half life measured in vitro for its stability in human blood,Blood,BAO_0000221,,Homo sapiens,,Autocuration,1345,In vitro,A,9606.0,,,,22224
5114,1,Half life in human serum,Serum,BAO_0000019,,Homo sapiens,,Autocuration,4297,,A,9606.0,,,,22224
5115,1,Half life in human serum; ND=not determined,Serum,BAO_0000019,,Homo sapiens,,Autocuration,4297,,A,9606.0,,,,22224
5116,1,Half life were determined in CEM-SS cell extract in decomposition step 1,,BAO_0000019,,Homo sapiens,,Autocuration,4297,,A,9606.0,,,,22224
5117,1,Half life were determined in CEM-SS cell extract in decomposition step 2,,BAO_0000019,,Homo sapiens,,Autocuration,4297,,A,9606.0,,,,22224
5118,1,Half life of the in human plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,4231,,A,9606.0,,,,22224
5119,1,Half life period in human hepatic S9 fraction was determined,,BAO_0000220,,Homo sapiens,,Autocuration,5633,In vitro,A,9606.0,,,S9,22224
5120,1,Half life period in human liver microsome was determined,Liver,BAO_0000251,,Homo sapiens,,Autocuration,5633,In vitro,A,9606.0,,,Microsomes,22224
5121,1,Half life period was determined; 6-7,,BAO_0000019,,Homo sapiens,,Autocuration,17791,,A,9606.0,,,,22224
5122,1,Half life period was evaluated in human,,BAO_0000019,,Homo sapiens,,Autocuration,17791,,A,9606.0,,,,22224
5123,1,Half life time in human plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,3160,,A,9606.0,,,,22224
5124,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Brain,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5125,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Heart,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5126,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Heart,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5127,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Kidney,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5128,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Kidney,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5129,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Kidney,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5130,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Liver,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5131,1,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,Liver,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5132,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Liver,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5133,1,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,Spleen,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5134,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Spleen,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5135,1,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Spleen,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5136,1,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Brain,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5137,1,Biodistribution of compound (oxidized form) in blood tissue,Blood,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5138,1,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Blood,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5139,1,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Blood,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5140,1,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Blood,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5141,1,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Blood,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5142,1,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Blood,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5143,1,Biodistribution of compound (oxidized form) in brain tissue of mice,Brain,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5144,1,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Brain,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5145,1,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Brain,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5146,1,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Brain,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5147,1,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Brain,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5148,1,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",Brain,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5149,1,Biodistribution of compound (oxidized form) in heart tissue of mice,Heart,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5150,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Heart,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5151,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Heart,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5152,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Heart,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5153,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Heart,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5154,1,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Heart,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5155,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Kidney,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5156,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Kidney,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5157,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Kidney,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5158,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Kidney,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5159,1,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Kidney,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5160,1,Biodistribution of compound (oxidized form) in liver tissue,Liver,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5161,1,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Liver,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5162,1,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Liver,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
5163,1,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,BAO_0000219,,Homo sapiens,,Intermediate,5245,,F,9606.0,,A-431,,80852
5164,1,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,BAO_0000219,,Homo sapiens,,Intermediate,5245,,F,9606.0,,A-431,,80852
5165,1,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,BAO_0000218,,,,Expert,16289,,F,,,A-431,,80852
5166,1,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,BAO_0000218,,,,Expert,16289,,F,,,A-431,,80852
5167,1,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,BAO_0000219,,Homo sapiens,,Expert,16093,,F,9606.0,,A-431,,9
5168,1,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,BAO_0000219,,Homo sapiens,,Intermediate,16825,,F,9606.0,,A-431,,80852
5169,1,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,BAO_0000219,,Homo sapiens,,Intermediate,4848,,F,9606.0,,A-431,,80852
5170,1,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,BAO_0000219,,Homo sapiens,,Expert,14827,,F,9606.0,,A-431,,9
5171,1,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,BAO_0000219,,Homo sapiens,,Expert,14827,,F,9606.0,,A-431,,9
5172,1,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,BAO_0000218,,,,Expert,16289,,F,,,A-431,,80852
5173,1,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,BAO_0000218,,,,Expert,16289,,F,,,A-431,,80852
5174,1,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,BAO_0000218,,,,Expert,16289,,F,,,A-431,,80852
5175,1,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,BAO_0000218,,,,Expert,16289,,F,,,A-431,,80852
5176,1,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,BAO_0000218,,,,Expert,16289,,F,,,A-431,,80852
5177,1,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,BAO_0000219,,Homo sapiens,,Expert,16289,,F,9606.0,,A-431,,9
5178,1,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,BAO_0000219,,,,Expert,16289,,F,,,A-431,,9
5179,1,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,BAO_0000218,,,,Expert,16289,,F,,,A-431,,80852
5180,1,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,BAO_0000218,,,,Expert,16289,,F,,,A-431,,80852
5181,1,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,BAO_0000218,,,,Expert,16289,,F,,,A-431,,80852
5182,1,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,BAO_0000218,,Mus musculus,,Expert,14555,,F,10090.0,,A-431,,80852
5183,1,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,BAO_0000218,,Mus musculus,,Expert,14555,,F,10090.0,,A-431,,80852
5184,1,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,BAO_0000218,,Mus musculus,,Expert,14555,,F,10090.0,,A-431,,80852
5185,1,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,BAO_0000218,,Mus musculus,,Expert,14555,,F,10090.0,,A-431,,80852
5186,1,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,BAO_0000219,,Homo sapiens,,Expert,1937,,F,9606.0,,A-431,,80852
5187,1,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,13739,,F,9606.0,,A-431,,80852
5188,1,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,BAO_0000219,,Homo sapiens,,Intermediate,3558,,F,9606.0,,A-431,,80852
5189,1,Dose giving a 50% decrease in the living cell number (A437 cells),,BAO_0000219,,Homo sapiens,,Intermediate,3558,,F,9606.0,,A-431,,80852
5190,1,In vitro inhibitory concentration against proliferation of A459 cell line.,,BAO_0000219,,Homo sapiens,,Expert,17686,,F,9606.0,,A549,,80682
5191,1,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,BAO_0000219,,Homo sapiens,,Intermediate,5305,,F,9606.0,,A549,,80682
5192,1,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,BAO_0000219,,Homo sapiens,,Intermediate,3614,,F,9606.0,,A549,,80682
5193,1,In vitro antitumor activity against renal A498 tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,17229,,F,9606.0,,A498,,80021
5194,1,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,BAO_0000219,,Homo sapiens,,Intermediate,15935,,F,9606.0,,A498,,80021
5195,1,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,BAO_0000219,,Homo sapiens,,Intermediate,15935,,F,9606.0,,A498,,80021
5196,1,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,BAO_0000219,,Homo sapiens,,Intermediate,15560,,F,9606.0,,A498,,80021
5197,1,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,13891,,F,9606.0,,A498,,80021
5198,1,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,BAO_0000219,,Homo sapiens,,Intermediate,13891,,F,9606.0,,A498,,80021
5199,1,Cytotoxicity on kidney carcinoma (A-498) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,13788,,F,9606.0,,A498,,80021
5200,1,Compound was evaluated against Human cell line renal A498,,BAO_0000219,,Homo sapiens,,Intermediate,15403,,F,9606.0,,A498,,80021
5201,1,Compound was tested for inhibition of A498 human renal cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,1009,,F,9606.0,,A498,,80021
5202,1,Growth inhibitory activity against A498 human cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,1043,,F,9606.0,,A498,,80021
5203,1,In vitro antitumor activity against human renal A498 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,5858,,F,9606.0,,A498,,80021
5204,1,In vitro cytotoxic activity against renal (A498) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,5958,,F,9606.0,,A498,,80021
5205,1,In vitro cytotoxic activity against human renal cancer (A498) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,5506,,F,9606.0,,A498,,80021
5206,1,Tested for cytostatic activity against renal A498 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,12781,,F,9606.0,,A498,,80021
5207,1,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,14399,,F,9606.0,,A498,,80021
5208,1,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,BAO_0000219,,Homo sapiens,,Expert,5958,,F,9606.0,,A498,,80021
5209,1,Cmax value after 2 mpk peroral administration to beagles,,BAO_0000218,,beagle,,Autocuration,3510,In vivo,A,9615.0,,,,22224
5210,1,Bioavailability,,BAO_0000218,,Canis lupus familiaris,,Autocuration,3510,In vivo,A,9615.0,beagle,,,22224
5211,1,Bioavailability after 1 mpk peroral administration to beagles,,BAO_0000218,,Canis lupus familiaris,,Autocuration,3510,In vivo,A,9615.0,beagle,,,22224
5212,1,Bioavailability after 2 mpk peroral administration to beagles,,BAO_0000218,,Canis lupus familiaris,,Autocuration,3510,In vivo,A,9615.0,beagle,,,22224
5213,1,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,BAO_0000019,,Bos taurus,,Autocuration,3085,,A,9913.0,,,,22224
5214,1,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,BAO_0000019,,Bos taurus,,Autocuration,3085,,A,9913.0,,,,22224
5215,1,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,BAO_0000019,,Bos taurus,,Autocuration,3085,,A,9913.0,,,,22224
5216,1,Solubility against bovine alpha-chymotrypsin,,BAO_0000019,,Bos taurus,,Autocuration,9372,,A,9913.0,,,,22224
5217,1,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,BAO_0000019,,Bos taurus,,Autocuration,3085,,A,9913.0,,,,22224
5218,1,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,BAO_0000019,,Bos taurus,,Autocuration,3085,,A,9913.0,,,,22224
5219,1,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,Spleen,BAO_0000221,,Bos taurus,,Autocuration,1469,,A,9913.0,,,,22224
5220,1,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,BAO_0000019,,Bos taurus,,Autocuration,4297,,A,9913.0,,,,22224
5221,1,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,BAO_0000019,,Bos taurus,,Autocuration,4297,,A,9913.0,,,,22224
5222,1,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,BAO_0000019,,Bos taurus,,Autocuration,17585,,A,9913.0,,,,22224
5223,1,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,Spleen,BAO_0000221,,Bos taurus,,Autocuration,1336,,A,9913.0,,,,22224
5224,1,Half life in presence of 2 mg/mL BSA at pH 8.8,,BAO_0000019,,Bos taurus,,Autocuration,3085,,A,9913.0,,,,22224
5225,1,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,BAO_0000019,,Bos taurus,,Autocuration,2857,,A,9913.0,,,,22224
5226,1,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,BAO_0000019,,Bos taurus,,Autocuration,2857,,A,9913.0,,,,22224
5227,1,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,BAO_0000019,,Bos taurus,,Autocuration,2857,,A,9913.0,,,,22224
5228,1,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,BAO_0000019,,Bos taurus,,Autocuration,1540,,A,9913.0,,,,22224
5229,1,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6316,,A,9615.0,,,,50588
5230,1,AUC after administration at 100 mg/kg/day in dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17594,,A,9615.0,,,,50588
5231,1,AUC in dog at 0-24 hr by peroral administration at 3 mpk,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,4953,,A,9615.0,,,,50588
5232,1,AUC value after 15 mg/kg iv dose in Dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,,A,9615.0,,,,50588
5233,1,AUC value after 30 mg/kg po dose in Dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,,A,9615.0,,,,50588
5234,1,AUC value after administration of 4 mg/Kg oral dose in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,2959,,A,9615.0,,,,50588
5235,1,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17594,,A,9615.0,,,,50588
5236,1,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5356,,A,9615.0,,,,50588
5237,1,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16807,,A,9615.0,,,,50588
5238,1,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4527,,A,9615.0,,,,50588
5239,1,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4527,,A,9615.0,,,,50588
5240,1,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15660,,A,9615.0,,,,50588
5241,1,Area under curve determined in dogs after oral administration of 10 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15660,,A,9615.0,,,,50588
5242,1,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5802,,A,9615.0,,,,50588
5243,1,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Expert,3598,,A,9615.0,,,,50588
5244,1,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Expert,3598,,A,9615.0,,,,50588
5245,1,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5944,,A,9615.0,,,,50588
5246,1,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5944,,A,9615.0,,,,50588
5247,1,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5944,,A,9615.0,,,,50588
5248,1,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5944,,A,9615.0,,,,50588
5249,1,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4186,,A,9615.0,,,,50588
5250,1,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5007,,A,9615.0,,,,50588
5251,1,Area under curve was determine after peroral administration at 10 mpk in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,,A,9615.0,,,,50588
5252,1,Area under curve was determine after peroral administration at 5 mpk in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,,A,9615.0,,,,50588
5253,1,Area under curve was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5006,,A,9615.0,,,,50588
5254,1,Area under curve in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5006,,A,9615.0,,,,50588
5255,1,Area under curve in dogs at 10 mg/kg dose fo oral administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3771,,A,9615.0,,,,50588
5256,1,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,BAO_0000218,,Canis lupus familiaris,,Intermediate,3771,,A,9615.0,,,,50588
5257,1,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3771,,A,9615.0,,,,50588
5258,1,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1916,,A,9615.0,,,,50588
5259,1,Area under curve value in dog at a dose of 5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5302,,A,9615.0,,,,50588
5260,1,Area under curve was determined after 0.1 mg/kg iv administration in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5600,,A,9615.0,,,,50588
5261,1,Area under curve was determined after 0.3 mg/kg po administration in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5600,,A,9615.0,,,,50588
5262,1,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17764,,A,9615.0,,,,50588
5263,1,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4368,,A,9615.0,,,,50588
5264,1,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,BAO_0000019,,Homo sapiens,,Autocuration,5318,,A,9606.0,,,,22224
5265,1,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,BAO_0000019,,Homo sapiens,,Autocuration,5318,,A,9606.0,,,,22224
5266,1,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,BAO_0000019,,Homo sapiens,,Autocuration,5318,,A,9606.0,,,,22224
5267,1,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,BAO_0000019,,Homo sapiens,,Autocuration,5318,,A,9606.0,,,,22224
5268,1,Time taken to reduce 50% of the concentration of compound in blood plasma,Blood,BAO_0000221,,Homo sapiens,,Autocuration,14518,,A,9606.0,,,,22224
5269,1,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Plasma,BAO_0000366,,Homo sapiens,,Autocuration,2209,,A,9606.0,,,,22224
5270,1,Half life in human plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,6787,,A,9606.0,,,,22224
5271,1,Half life in human plasma was reported,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,4898,,A,9606.0,,,,22224
5272,1,Half life in human serum,Serum,BAO_0000019,,Homo sapiens,,Autocuration,6072,,A,9606.0,,,,22224
5273,1,Half life upon exposure to human plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,16907,,A,9606.0,,,,22224
5274,1,t1/2 in human microsomes,,BAO_0000251,,Homo sapiens,,Autocuration,5656,In vitro,A,9606.0,,,Microsomes,22224
5275,1,Half life period in 80% human plasma at 37 degree Centigrade,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,4755,,A,9606.0,,,,22224
5276,1,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),Zone of skin,BAO_0000221,,Homo sapiens,,Autocuration,17503,,A,9606.0,,,,22224
5277,1,Half-life measured in in vitro Cathepsin B assay in human plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,12357,In vitro,A,9606.0,,,,22224
5278,1,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,BAO_0000019,,Homo sapiens,,Autocuration,3076,,A,9606.0,,,,22224
5279,1,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,Liver,BAO_0000251,,Homo sapiens,,Autocuration,6410,In vitro,A,9606.0,,,Microsomes,22224
5280,1,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",Plasma,BAO_0000366,,Homo sapiens,,Autocuration,3741,,A,9606.0,,,,22224
5281,1,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",Plasma,BAO_0000366,,Homo sapiens,,Autocuration,3741,,A,9606.0,,,,22224
5282,1,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",Plasma,BAO_0000366,,Homo sapiens,,Autocuration,3741,,A,9606.0,,,,22224
5283,1,Half-life in the CEM cell extracts,,BAO_0000019,,Homo sapiens,,Autocuration,1540,,A,9606.0,,,,22224
5284,1,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,2905,,A,9606.0,,,,22224
5285,1,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,2905,,A,9606.0,,,,22224
5286,1,Half-life was determined,,BAO_0000019,,Homo sapiens,,Autocuration,5523,,A,9606.0,,,,22224
5287,1,Half-life (human blood stability),Blood,BAO_0000221,,Homo sapiens,,Autocuration,1499,,A,9606.0,,,,22224
5288,1,Half-life (human blood stability); no data,Blood,BAO_0000221,,Homo sapiens,,Autocuration,1499,,A,9606.0,,,,22224
5289,1,Half-life in human plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,17065,,A,9606.0,,,,22224
5290,1,CYP3A4 metabolism half-life (t1/2),,BAO_0000019,,Homo sapiens,,Autocuration,6861,,A,9606.0,,,,22224
5291,1,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),Blood,BAO_0000221,,Homo sapiens,,Autocuration,1499,,A,9606.0,,,,22224
5292,1,In vitro half life in human plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,530,In vitro,A,9606.0,,,,22224
5293,1,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",Plasma,BAO_0000366,,Homo sapiens,,Autocuration,1116,In vitro,A,9606.0,,,,22224
5294,1,In vitro hydrolysis in human plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,6695,In vitro,A,9606.0,,,,22224
5295,1,In vitro hydrolysis in human plasma; no data,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,6695,In vitro,A,9606.0,,,,22224
5296,1,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,Liver,BAO_0000251,,Homo sapiens,,Autocuration,10,In vitro,A,9606.0,,,Microsomes,22224
5297,1,Plasma half life in human,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,993,,A,9606.0,,,,22224
5298,1,Stability after incubation with human plasma (at 37 degree C),Plasma,BAO_0000366,,Homo sapiens,,Autocuration,15429,,A,9606.0,,,,22224
5299,1,T1/2 was evaluated in human plasma,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,1675,,A,9606.0,,,,22224
5300,1,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Plasma,BAO_0000366,,Homo sapiens,,Autocuration,2209,,A,9606.0,,,,22224
5301,1,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",Plasma,BAO_0000366,,Homo sapiens,,Autocuration,2209,,A,9606.0,,,,22224
5302,1,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,BAO_0000019,,Homo sapiens,,Autocuration,5318,,A,9606.0,,,,22224
5303,1,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,,BAO_0000019,,Homo sapiens,,Autocuration,2412,In vitro,A,9606.0,,,,22224
5304,1,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,,BAO_0000019,,Homo sapiens,,Autocuration,2412,In vitro,A,9606.0,,,,22224
5305,1,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,2906,,A,9606.0,,,,22224
5306,1,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,2906,,A,9606.0,,,,22224
5307,1,Time taken for 50% to be consumed by serum PON1 was determined,,BAO_0000019,,Homo sapiens,,Autocuration,5495,,A,9606.0,,,,22224
5308,1,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,BAO_0000019,,Homo sapiens,,Autocuration,5495,,A,9606.0,,,,22224
5309,1,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Autocuration,4397,,A,9606.0,,,Microsomes,22224
5310,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,A,10095.0,,,,22224
5311,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,A,10095.0,,,,22224
5312,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,A,10095.0,,,,22224
5313,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,A,10095.0,,,,22224
5314,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,A,10095.0,,,,22224
5315,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,A,10095.0,,,,22224
5316,1,Compound tested for growth inhibition of renal cancer cell line 786-0,,BAO_0000219,,Homo sapiens,,Intermediate,6058,,F,9606.0,,786-0,,80640
5317,1,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17708,,F,9606.0,,786-0,,80640
5318,1,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,BAO_0000219,,Homo sapiens,,Expert,14017,,F,9606.0,,786-0,,80640
5319,1,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,BAO_0000219,,Homo sapiens,,Intermediate,16818,,F,9606.0,,786-0,,80640
5320,1,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,BAO_0000219,,Homo sapiens,,Intermediate,16818,,F,9606.0,,786-0,,80640
5321,1,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,BAO_0000219,,Homo sapiens,,Intermediate,16818,,F,9606.0,,786-0,,80640
5322,1,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,BAO_0000219,,Homo sapiens,,Intermediate,11970,,F,9606.0,,786-0,,80640
5323,1,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,BAO_0000219,,Homo sapiens,,Intermediate,12400,,F,9606.0,,786-0,,80640
5324,1,Cytotoxic effect on renal cancer line 786-0,,BAO_0000219,,Homo sapiens,,Expert,12888,,F,9606.0,,786-0,,80640
5325,1,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,BAO_0000219,,Homo sapiens,,Intermediate,15300,,F,9606.0,,786-0,,80640
5326,1,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,BAO_0000219,,Homo sapiens,,Intermediate,14769,,F,9606.0,,786-0,,80640
5327,1,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,BAO_0000219,,Homo sapiens,,Intermediate,15895,,F,9606.0,,786-0,,80640
5328,1,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17376,,F,9606.0,,786-0,,80640
5329,1,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,BAO_0000219,,Homo sapiens,,Intermediate,14882,,F,9606.0,,786-0,,80640
5330,1,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,BAO_0000219,,Homo sapiens,,Intermediate,14882,,F,9606.0,,786-0,,80640
5331,1,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,BAO_0000219,,Homo sapiens,,Intermediate,15176,,F,9606.0,,786-0,,80640
5332,1,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,BAO_0000219,,Homo sapiens,,Intermediate,12696,,F,9606.0,,786-0,,80640
5333,1,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,BAO_0000219,,Homo sapiens,,Intermediate,2496,,F,9606.0,,786-0,,80640
5334,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,BAO_0000219,,Homo sapiens,,Intermediate,11831,,F,9606.0,,791T cell line,,80641
5335,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,BAO_0000219,,Homo sapiens,,Intermediate,11831,,F,9606.0,,791T cell line,,80641
5336,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,BAO_0000219,,Homo sapiens,,Intermediate,11831,,F,9606.0,,791T cell line,,80641
5337,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,BAO_0000219,,Homo sapiens,,Intermediate,11831,,F,9606.0,,791T cell line,,80641
5338,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,BAO_0000219,,Homo sapiens,,Intermediate,11831,,F,9606.0,,791T cell line,,80641
5339,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,BAO_0000219,,Homo sapiens,,Intermediate,11831,,F,9606.0,,791T cell line,,80641
5340,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,BAO_0000219,,Homo sapiens,,Intermediate,11831,,F,9606.0,,791T cell line,,80641
5341,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,BAO_0000219,,Homo sapiens,,Intermediate,11831,,F,9606.0,,791T cell line,,80641
5342,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,BAO_0000219,,Homo sapiens,,Intermediate,11831,,F,9606.0,,791T cell line,,80641
5343,1,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,BAO_0000219,,Homo sapiens,,Intermediate,11831,,F,9606.0,,791T cell line,,80641
5344,1,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,12782,,F,9606.0,,786-0,,80640
5345,1,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,BAO_0000019,,,,Intermediate,1229,,F,,,,,22226
5346,1,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,BAO_0000219,,Homo sapiens,,Expert,15313,,F,9606.0,,RPMI-8226,,80433
5347,1,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,BAO_0000219,,Homo sapiens,,Expert,15313,,F,9606.0,,RPMI-8226,,80433
5348,1,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,BAO_0000219,,Homo sapiens,,Intermediate,11544,,F,9606.0,,RPMI-8226,,80433
5349,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5350,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5351,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5352,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5353,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5354,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5355,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5356,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5357,1,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5358,1,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,BAO_0000219,,Homo sapiens,,Intermediate,14769,,F,9606.0,,A498,,80021
5359,1,Compound was tested for the growth inhibition of A498 renal tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,15354,,F,9606.0,,A498,,80021
5360,1,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,BAO_0000219,,Homo sapiens,,Intermediate,17445,,F,9606.0,,A498,,80021
5361,1,In vitro inhibitory concentration against renal cancer cell line A498,,BAO_0000219,,Homo sapiens,,Intermediate,4337,,F,9606.0,,A498,,80021
5362,1,Cytotoxicity against A 498 tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,15277,,F,9606.0,,A498,,80021
5363,1,In vitro antitumor activity against A498 human cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4812,,F,9606.0,,A498,,80021
5364,1,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,BAO_0000219,,Homo sapiens,,Intermediate,4812,,F,9606.0,,A498,,80021
5365,1,Inhibitory dose required against A498 human tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,4995,,F,9606.0,,A498,,80021
5366,1,Anticancer activity against one renal cancer (A498 cell line),,BAO_0000219,,Homo sapiens,,Intermediate,5847,,F,9606.0,,A498,,80021
5367,1,In vitro cytotoxicity against melanoma A498 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,6557,,F,9606.0,,A498,,80021
5368,1,Compound was tested for growth inhibitory activity against A498 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2597,,F,9606.0,,A498,,80021
5369,1,Compound tested for growth inhibition of renal cancer cell line A498,,BAO_0000219,,Homo sapiens,,Intermediate,6058,,F,9606.0,,A498,,80021
5370,1,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17708,,F,9606.0,,A498,,80021
5371,1,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,BAO_0000219,,Homo sapiens,,Intermediate,15176,,F,9606.0,,A498,,80021
5372,1,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,BAO_0000219,,Homo sapiens,,Intermediate,15300,,F,9606.0,,A498,,80021
5373,1,Tested for cytotoxicity against A498 cell lines in renal cancer,,BAO_0000219,,Homo sapiens,,Intermediate,11970,,F,9606.0,,A498,,80021
5374,1,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,BAO_0000219,,Homo sapiens,,Intermediate,12400,,F,9606.0,,A498,,80021
5375,1,Cytotoxic effect on renal cancer lines A498,,BAO_0000219,,Homo sapiens,,Expert,12888,,F,9606.0,,A498,,80021
5376,1,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,BAO_0000219,,Homo sapiens,,Intermediate,3030,,F,9606.0,,A498,,80021
5377,1,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,BAO_0000219,,Homo sapiens,,Intermediate,14769,,F,9606.0,,A498,,80021
5378,1,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17376,,F,9606.0,,A498,,80021
5379,1,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,16558,,F,9606.0,,A498,,80021
5380,1,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,BAO_0000219,,Homo sapiens,,Intermediate,5194,,F,9606.0,,A498,,80021
5381,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,BAO_0000219,,Homo sapiens,,Intermediate,10708,,F,9606.0,,A498,,80021
5382,1,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,BAO_0000219,,Homo sapiens,,Expert,16880,,F,9606.0,,A549,,80682
5383,1,Antitumor activity against A549 human lung carcinoma cell line,,BAO_0000219,,Homo sapiens,,Intermediate,10196,,F,9606.0,,A549,,80682
5384,1,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,BAO_0000219,,Homo sapiens,,Intermediate,10196,,F,9606.0,,A549,,80682
5385,1,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,BAO_0000219,,Homo sapiens,,Intermediate,10196,,F,9606.0,,A549,,80682
5386,1,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,BAO_0000219,,Homo sapiens,,Intermediate,12083,,F,9606.0,,A549,,80682
5387,1,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,BAO_0000219,,Homo sapiens,,Expert,16464,,F,9606.0,,A549,,80682
5388,1,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,BAO_0000219,,Homo sapiens,,Intermediate,16464,,F,9606.0,,A549,,80682
5389,1,In vitro cytotoxic activity against human lung A549 cell line,,BAO_0000219,,Homo sapiens,,Expert,16470,,F,9606.0,,A549,,80682
5390,1,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,BAO_0000219,,Homo sapiens,,Intermediate,16470,,F,9606.0,,A549,,80682
5391,1,In vitro cytotoxic activity against human lung A549 cell line),,BAO_0000219,,Homo sapiens,,Intermediate,16470,,F,9606.0,,A549,,80682
5392,1,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,BAO_0000219,,Homo sapiens,,Intermediate,16470,,F,9606.0,,A549,,80682
5393,1,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,BAO_0000219,,Homo sapiens,,Expert,16582,,F,9606.0,,A549,,80682
5394,1,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,BAO_0000219,,Homo sapiens,,Intermediate,15935,,F,9606.0,,A549,,80682
5395,1,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,BAO_0000219,,Homo sapiens,,Intermediate,15935,,F,9606.0,,A549,,80682
5396,1,Inhibition of A549 human lung carcinoma cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,16597,,F,9606.0,,A549,,80682
5397,1,Inhibitory activity against A549 lung adenocarcinoma cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17376,,F,9606.0,,A549,,80682
5398,1,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,16496,,F,9606.0,,A549,,80682
5399,1,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,16152,,F,9606.0,,A549,,80682
5400,1,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,16152,,F,9606.0,,A549,,80682
5401,1,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,BAO_0000219,,Homo sapiens,,Intermediate,16464,,F,9606.0,,A549,,80682
5402,1,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2288,,F,9606.0,,A549,,80682
5403,1,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,17350,,F,9606.0,,A549,,80682
5404,1,Inhibition of A549 cancer cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,4090,,F,9606.0,,A549,,80682
5405,1,Inhibition of A549 cancer cell proliferation (Not tested),,BAO_0000219,,Homo sapiens,,Expert,4090,,F,9606.0,,A549,,80682
5406,1,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,17350,,F,9606.0,,A549,,80682
5407,1,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,BAO_0000219,,Homo sapiens,,Intermediate,4197,,F,9606.0,,A549,,80682
5408,1,Antiproliferative potency determined as inhibitory concentration against A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17072,,F,9606.0,,A549,,80682
5409,1,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,BAO_0000219,,Homo sapiens,,Intermediate,17072,,F,9606.0,,A549,,80682
5410,1,Cytotoxicity against Renal cell lines A549 was determined,,BAO_0000219,,Homo sapiens,,Intermediate,5194,,F,9606.0,,A549,,80682
5411,1,Area under curve was determined in dog after a 3 mg/kg of oral dose,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4257,,A,9615.0,,,,50588
5412,1,Area under curve was determined in dog after oral administration at 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6123,,A,9615.0,,,,50588
5413,1,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1337,,A,9615.0,,,,50588
5414,1,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1337,,A,9615.0,,,,50588
5415,1,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,BAO_0000218,,Canis lupus familiaris,,Intermediate,8833,,A,9615.0,,,,50588
5416,1,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,BAO_0000218,,Canis lupus familiaris,,Intermediate,8833,,A,9615.0,,,,50588
5417,1,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,BAO_0000218,,Canis lupus familiaris,,Intermediate,8833,,A,9615.0,,,,50588
5418,1,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,BAO_0000218,,Canis lupus familiaris,,Intermediate,8833,,A,9615.0,,,,50588
5419,1,Area under plasma concentration time curve in dog upon oral administration,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17657,,A,9615.0,,,,50588
5420,1,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17650,,A,9615.0,,,,50588
5421,1,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1977,,A,9615.0,,,,50588
5422,1,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1977,,A,9615.0,,,,50588
5423,1,Area under the curve for the compound was obtained when tested in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3132,,A,9615.0,,,,50588
5424,1,Area under the curve at a dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5473,,A,9615.0,,,,50588
5425,1,Area under the curve at a dose of 1 mg/kg (oral),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5474,,A,9615.0,,,,50588
5426,1,Area under the curve at i.v. dose of 0.2 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5474,,A,9615.0,,,,50588
5427,1,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6062,,A,9615.0,,,,50588
5428,1,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4709,,A,9615.0,,,,50588
5429,1,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2652,,A,9615.0,,,,50588
5430,1,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2652,,A,9615.0,,,,50588
5431,1,Compound was evaluated for area under the curve in dog blood.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2877,,A,9615.0,,,,50588
5432,1,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5444,,A,9615.0,,,,50588
5433,1,AUC in dog after oral dose (1 mg/kg),Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5130,,A,9615.0,,,,50588
5434,1,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6265,,A,9615.0,,,,50588
5435,1,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,BAO_0000218,,Canis lupus familiaris,,Intermediate,4657,,A,9615.0,,,,50588
5436,1,Pharmacokinetic parameter AUC after intravenous administration to dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16367,,A,9615.0,,,,50588
5437,1,Pharmacokinetic parameter AUC after oral administration to dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16367,,A,9615.0,,,,50588
5438,1,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9579,,A,9615.0,,,,50588
5439,1,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9579,,A,9615.0,,,,50588
5440,1,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5983,,A,9615.0,,,,50588
5441,1,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6241,,A,9615.0,,,,50588
5442,1,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,BAO_0000218,,Canis lupus familiaris,,Intermediate,5313,,A,9615.0,,,,50588
5443,1,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,BAO_0000218,,Canis lupus familiaris,,Intermediate,5313,,A,9615.0,,,,50588
5444,1,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6642,,A,9615.0,,,,50588
5445,1,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6642,,A,9615.0,,,,50588
5446,1,Oral AUCN in dog (dosed at 0.5 mpk iv ),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6641,,A,9615.0,,,,50588
5447,1,Oral AUCN in dog (dosed at 0.5 mpk iv ),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6642,,A,9615.0,,,,50588
5448,1,Compound was evaluated for oral bioavailability in dog; 90-100,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17791,,A,9615.0,,,,50588
5449,1,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17655,,A,9615.0,,,,50588
5450,1,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17655,,A,9615.0,,,,50588
5451,1,PAPP (membrane permeability) in dog kidney cell monolayer assay,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6596,,A,9615.0,,,,50588
5452,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3880,,A,9615.0,,,,50588
5453,1,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16367,,A,9615.0,,,,50588
5454,1,Plasma protein binding towards dog plasma at 10 uM,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17409,,A,9615.0,,,,50588
5455,1,Plasma protein binding towards dog plasma at 100 uM,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17409,,A,9615.0,,,,50588
5456,1,Bioavailability in dog (dose 4 mg/kg p.o.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,2959,In vivo,A,9615.0,,,,50588
5457,1,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13501,In vivo,A,9615.0,,,,50588
5458,1,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4527,In vivo,A,9615.0,,,,50588
5459,1,Bioavailability in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15145,In vivo,A,9615.0,,,,50588
5460,1,Bioavailability,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4219,In vivo,A,9615.0,,,,50588
5461,1,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,17538,In vivo,A,9615.0,,,,50588
5462,1,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17538,In vivo,A,9615.0,,,,50588
5463,1,Bioavailability in dog (dose 10.0 mg/kg p.o.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,1466,In vivo,A,9615.0,,,,50588
5464,1,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17650,In vivo,A,9615.0,,,,50588
5465,1,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3132,In vivo,A,9615.0,,,,50588
5466,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,A,10095.0,,,,22224
5467,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,Liver,BAO_0000218,,Mus sp.,,Autocuration,2413,,A,10095.0,,,,22224
5468,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,Liver,BAO_0000218,,Mus sp.,,Autocuration,2413,,A,10095.0,,,,22224
5469,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,Liver,BAO_0000218,,Mus sp.,,Autocuration,2413,,A,10095.0,,,,22224
5470,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,A,10095.0,,,,22224
5471,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,A,10095.0,,,,22224
5472,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,Muscle tissue,BAO_0000218,,Mus sp.,,Autocuration,2413,,A,10095.0,,,,22224
5473,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,Muscle tissue,BAO_0000218,,Mus sp.,,Autocuration,2413,,A,10095.0,,,,22224
5474,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,Muscle tissue,BAO_0000218,,Mus sp.,,Autocuration,2413,,A,10095.0,,,,22224
5475,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,Spleen,BAO_0000218,,Mus sp.,,Autocuration,2413,,A,10095.0,,,,22224
5476,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,Spleen,BAO_0000218,,Mus sp.,,Autocuration,2413,,A,10095.0,,,,22224
5477,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,A,10095.0,,,,22224
5478,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,A,10095.0,,,,22224
5479,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,A,10095.0,,,,22224
5480,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,A,10095.0,,,,22224
5481,1,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,BAO_0000218,,Mus sp.,,Autocuration,2413,,A,10095.0,,,,22224
5482,1,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,BAO_0000019,,Cercopithecidae,,Autocuration,17827,,A,9527.0,,,,22224
5483,1,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Cerebellum,BAO_0000019,,Cercopithecidae,,Autocuration,17827,,A,9527.0,,,,22224
5484,1,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Frontal cortex,BAO_0000019,,Cercopithecidae,,Autocuration,17827,,A,9527.0,,,,22224
5485,1,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,BAO_0000019,,Cercopithecidae,,Autocuration,17827,,A,9527.0,,,,22224
5486,1,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),Striatum,BAO_0000019,,Cercopithecidae,,Autocuration,17827,,A,9527.0,,,,22224
5487,1,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,BAO_0000019,,Cercopithecidae,,Autocuration,17827,,A,9527.0,,,,22224
5488,1,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Cerebellum,BAO_0000019,,Cercopithecidae,,Autocuration,17827,,A,9527.0,,,,22224
5489,1,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Frontal cortex,BAO_0000019,,Cercopithecidae,,Autocuration,17827,,A,9527.0,,,,22224
5490,1,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,BAO_0000019,,Cercopithecidae,,Autocuration,17827,,A,9527.0,,,,22224
5491,1,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),Striatum,BAO_0000019,,Cercopithecidae,,Autocuration,17827,,A,9527.0,,,,22224
5492,1,Compound was evaluated for oral bioavailability in rats,,BAO_0000218,,Cercopithecidae,,Autocuration,17791,,A,9527.0,,,,22224
5493,1,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,17667,In vivo,A,9527.0,,,,22224
5494,1,Half life period was evaluated in monkey,,BAO_0000019,,Cercopithecidae,,Autocuration,17791,,A,9527.0,,,,22224
5495,1,Half-life in rhesus monkeys by intravenous administration of dose,,BAO_0000218,,Cercopithecidae,,Autocuration,110,In vivo,A,9527.0,,,,22224
5496,1,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,Plasma,BAO_0000218,,Mus musculus,,Intermediate,5781,,A,10090.0,,,,50594
5497,1,AUC after intraperitoneal administration of 100 mg/kg in mice,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17734,,A,10090.0,,,,50594
5498,1,AUC value was determined after oral administration,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17718,,A,10090.0,,,,50594
5499,1,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,BAO_0000218,,Mus musculus,,Intermediate,4573,,A,10090.0,,,,50594
5500,1,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,BAO_0000218,,Mus musculus,,Intermediate,3277,,A,10090.0,,,,50594
5501,1,Area under curve by ioral administration in mouse,,BAO_0000218,,Mus musculus,,Intermediate,2862,,A,10090.0,,,,50594
5502,1,Area under curve by iv administration in mouse,,BAO_0000218,,Mus musculus,,Intermediate,2862,,A,10090.0,,,,50594
5503,1,Area under curve at 0-8 hr in IRC mice after peroral administration,,BAO_0000218,,Mus musculus,,Intermediate,5951,,A,10090.0,,,,50594
5504,1,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,17729,,A,10090.0,,,,50594
5505,1,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,17728,,A,10090.0,,,,50594
5506,1,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,17728,,A,10090.0,,,,50594
5507,1,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,17729,,A,10090.0,,,,50594
5508,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5509,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5510,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5511,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5512,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5513,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5514,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5515,1,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5516,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5517,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5518,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5519,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5520,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5521,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5522,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5523,1,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,BAO_0000219,,Homo sapiens,,Intermediate,9424,,F,9606.0,,RPMI-8226,,80433
5524,1,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,BAO_0000219,,Homo sapiens,,Expert,9424,,F,9606.0,,RPMI-8226,,80433
5525,1,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,BAO_0000219,,Homo sapiens,,Intermediate,11544,,F,9606.0,,RPMI-8226,,80433
5526,1,Cytotoxicity of compound against 8226/DOX1V cells,,BAO_0000219,,Homo sapiens,,Intermediate,17378,,F,9606.0,,RPMI-8226,,80433
5527,1,Cytotoxicity of compound against 8226/S cells,,BAO_0000219,,Homo sapiens,,Intermediate,17378,,F,9606.0,,RPMI-8226,,80433
5528,1,Inhibitory concentration against 8226 myeloma cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17079,,F,9606.0,,RPMI-8226,,80433
5529,1,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17079,,F,9606.0,,RPMI-8226,,80433
5530,1,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,BAO_0000219,,Homo sapiens,,Intermediate,13466,,F,9606.0,,833K,,80647
5531,1,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,BAO_0000219,,Homo sapiens,,Intermediate,13466,,F,9606.0,,833K,,80647
5532,1,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,BAO_0000219,,Homo sapiens,,Expert,2392,,F,9606.0,,833K,,80647
5533,1,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,BAO_0000219,,Homo sapiens,,Intermediate,2392,,F,9606.0,,833K,,80647
5534,1,Inhibitory activity against caspase-1,,BAO_0000019,,,,Autocuration,6608,,B,,,,,22226
5535,1,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,BAO_0000357,,Enterococcus faecalis,,Autocuration,10199,,B,1351.0,,,,45
5536,1,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,17749,,F,9606.0,,8701-BC,,80648
5537,1,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,BAO_0000219,,Homo sapiens,,Intermediate,17749,,F,9606.0,,8701-BC,,80648
5538,1,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,BAO_0000019,,,,Intermediate,1229,,F,,,,,22226
5539,1,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,BAO_0000019,,,,Intermediate,1229,,F,,,,,22226
5540,1,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,BAO_0000019,,,,Intermediate,1229,,F,,,,,22226
5541,1,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,BAO_0000019,,,,Autocuration,6390,,B,,,,,22226
5542,1,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,BAO_0000019,,Streptococcus pyogenes,,Autocuration,16219,,F,1314.0,,,,22226
5543,1,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,BAO_0000019,,Streptococcus pyogenes,,Autocuration,16219,,F,1314.0,,,,22226
5544,1,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,BAO_0000357,,,,Autocuration,17043,,B,,,,,11922
5545,1,Tested for in vitro cytotoxic potency of compound in 9KB assay,,BAO_0000219,,Homo sapiens,,Intermediate,6929,,F,9606.0,,KB ,,81115
5546,1,Tested for in vitro cytotoxic potency of compound in 9KB assay,,BAO_0000219,,Homo sapiens,,Intermediate,6929,,A,9606.0,,KB ,,81115
5547,1,In vitro cytotoxicity of compound was tested against 9KB cells.,,BAO_0000219,,Homo sapiens,,Autocuration,7083,,F,9606.0,,,,22226
5548,1,Cytotoxic concentration against 9L cells was determined on day 3,,BAO_0000219,,Rattus norvegicus,,Intermediate,12446,,F,10116.0,,9L,,80653
5549,1,Tested in vitro for anticancer activity against 9L cells,,BAO_0000219,,Rattus norvegicus,,Expert,15345,,F,10116.0,,9L,,80653
5550,1,Tested in vitro for anticancer activity against 9L cells; Not determined,,BAO_0000219,,Rattus norvegicus,,Expert,15345,,F,10116.0,,9L,,80653
5551,1,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,BAO_0000219,,Homo sapiens,,Intermediate,6301,,F,9606.0,,A549,,80682
5552,1,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,BAO_0000219,,Homo sapiens,,Intermediate,4833,,F,9606.0,,A549,,80682
5553,1,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,BAO_0000219,,Homo sapiens,,Intermediate,4833,,F,9606.0,,A549,,80682
5554,1,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,BAO_0000219,,Homo sapiens,,Intermediate,4833,,F,9606.0,,A549,,80682
5555,1,Cytotoxicity against human lung carcinoma A549 cell line,,BAO_0000219,,Homo sapiens,,Expert,13330,,F,9606.0,,A549,,80682
5556,1,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,BAO_0000219,,Homo sapiens,,Expert,17517,,F,9606.0,,A549,,25
5557,1,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,BAO_0000219,,Homo sapiens,,Expert,17517,,F,9606.0,,A549,,25
5558,1,"In vitro growth inhibition of A549, lung carcinoma",,BAO_0000219,,Homo sapiens,,Intermediate,14425,,F,9606.0,,A549,,80682
5559,1,"In vitro growth inhibition of A549, lung carcinoma.",,BAO_0000219,,Homo sapiens,,Intermediate,14425,,F,9606.0,,A549,,80682
5560,1,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,BAO_0000219,,Homo sapiens,,Expert,5228,,F,9606.0,,A549,,80682
5561,1,Cytotoxic activity against human lung cancer A549 cell line was determined,,BAO_0000219,,Homo sapiens,,Intermediate,5351,,F,9606.0,,A549,,80682
5562,1,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,BAO_0000219,,Homo sapiens,,Expert,12198,,F,9606.0,,A549,,80682
5563,1,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,13891,,F,9606.0,,A549,,80682
5564,1,Cytotoxicity in A549 (human carcinoma) cell line.,,BAO_0000219,,Homo sapiens,,Expert,5677,,F,9606.0,,A549,,80682
5565,1,Cytotoxicity on lung carcinoma (A-549) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,13788,,F,9606.0,,A549,,80682
5566,1,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,BAO_0000219,,Homo sapiens,,Expert,13384,,F,9606.0,,A549,,80682
5567,1,Effective dose of compound against replication of A549 cell line was evaluated,,BAO_0000219,,Homo sapiens,,Intermediate,6726,,F,9606.0,,A549,,80682
5568,1,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,BAO_0000219,,Homo sapiens,,Expert,3455,,F,9606.0,,A549,,80682
5569,1,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,BAO_0000219,,Homo sapiens,,Intermediate,5726,,F,9606.0,,A549,,80682
5570,1,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,BAO_0000219,,Homo sapiens,,Intermediate,5726,,F,9606.0,,A549,,80682
5571,1,The compound was evaluated for antiproliferative activity against A549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,3936,,F,9606.0,,A549,,80682
5572,1,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,BAO_0000219,,Homo sapiens,,Intermediate,14991,,F,9606.0,,A549,,80682
5573,1,Concentration required for growth inhibition of human lung carcinoma cell line A549,,BAO_0000219,,Homo sapiens,,Intermediate,5243,,F,9606.0,,A549,,80682
5574,1,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,12858,,F,9606.0,,A549,,80682
5575,1,Growth inhibition against A549 cell line was evaluated,,BAO_0000219,,Homo sapiens,,Intermediate,6776,,F,9606.0,,A549,,80682
5576,1,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,16558,,F,9606.0,,A549,,80682
5577,1,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,BAO_0000219,,Homo sapiens,,Expert,4583,,F,9606.0,,A549,,80682
5578,1,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,BAO_0000219,,Homo sapiens,,Intermediate,13514,,F,9606.0,,A549,,80682
5579,1,Chemosensitivity against DT-diaphorase rich A549 cell lines,,BAO_0000219,,Homo sapiens,,Expert,15166,,F,9606.0,,A549,,80682
5580,1,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,BAO_0000219,,Homo sapiens,,Intermediate,13873,,F,9606.0,,A549,,80682
5581,1,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,BAO_0000219,,Homo sapiens,,Expert,6447,,F,9606.0,,A549,,80682
5582,1,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,2068,,F,9606.0,,A549,,80682
5583,1,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,BAO_0000219,,Homo sapiens,,Expert,1863,,F,9606.0,,A549,,80682
5584,1,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,BAO_0000219,,Homo sapiens,,Intermediate,13873,,F,9606.0,,A549,,80682
5585,1,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,BAO_0000219,,Homo sapiens,,Intermediate,13873,,F,9606.0,,A549,,80682
5586,1,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,BAO_0000219,,Homo sapiens,,Expert,13873,,F,9606.0,,A549,,80682
5587,1,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,BAO_0000219,,Homo sapiens,,Intermediate,579,,F,9606.0,,A549,,80682
5588,1,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,BAO_0000219,,Homo sapiens,,Intermediate,579,,F,9606.0,,A549,,80682
5589,1,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,BAO_0000219,,Homo sapiens,,Intermediate,4584,,F,9606.0,,A549,,80682
5590,1,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,BAO_0000219,,Homo sapiens,,Expert,5421,,F,9606.0,,A549,,80682
5591,1,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,BAO_0000219,,Homo sapiens,,Intermediate,5421,,F,9606.0,,A549,,80682
5592,1,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,BAO_0000219,,Homo sapiens,,Intermediate,5421,,F,9606.0,,A549,,80682
5593,1,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,BAO_0000219,,Homo sapiens,,Intermediate,5421,,F,9606.0,,A549,,80682
5594,1,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,BAO_0000219,,Homo sapiens,,Intermediate,14188,,F,9606.0,,A549,,80682
5595,1,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,BAO_0000219,,Homo sapiens,,Intermediate,14188,,F,9606.0,,A549,,80682
5596,1,Compound was tested for the growth inhibition of A549 lung tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,15354,,F,9606.0,,A549,,80682
5597,1,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,BAO_0000219,,Homo sapiens,,Expert,14253,,F,9606.0,,A549,,80682
5598,1,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,BAO_0000219,,Homo sapiens,,Intermediate,13873,,F,9606.0,,A549,,80682
5599,1,Oral bioavailability in dog (conscious),,BAO_0000218,,Canis lupus familiaris,,Intermediate,3043,In vivo,A,9615.0,,,,50588
5600,1,Compound was evaluated for the oral bioavailability after oral administration in dog.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3045,In vivo,A,9615.0,,,,50588
5601,1,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3022,In vivo,A,9615.0,,,,50588
5602,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4453,In vivo,A,9615.0,,,,50588
5603,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1696,In vivo,A,9615.0,,,,50588
5604,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5045,In vivo,A,9615.0,,,,50588
5605,1,Oral bioavailability in dog (fasted),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5356,In vivo,A,9615.0,,,,50588
5606,1,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17764,In vivo,A,9615.0,,,,50588
5607,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6448,In vivo,A,9615.0,,,,50588
5608,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1475,In vivo,A,9615.0,,,,50588
5609,1,Percent bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3788,In vivo,A,9615.0,,,,50588
5610,1,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3639,In vivo,A,9615.0,,,,50588
5611,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13397,In vivo,A,9615.0,,,,50588
5612,1,The compound was evaluated for bioavailability in dogs; 34-44,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2137,In vivo,A,9615.0,,,,50588
5613,1,Bioavailability in dog (dose 4 mg/kg p.o.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,2959,In vivo,A,9615.0,,,,50588
5614,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6448,In vivo,A,9615.0,,,,50588
5615,1,8 hour trough Blood level in dog was measured after administration of compound,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6084,,A,9615.0,,,,50588
5616,1,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,3639,In vivo,A,9615.0,,,,50588
5617,1,C24 after oral administration at 5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6316,,A,9615.0,,,,50588
5618,1,Clearance after oral and iv dosing in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5238,,A,9615.0,,,,50588
5619,1,Clearance of the drug was measured in the plasma of dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17796,,A,9615.0,,,,50588
5620,1,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2652,,A,9615.0,,,,50588
5621,1,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5654,In vivo,A,9615.0,,,,50588
5622,1,Clearance of compound was determined in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6621,In vivo,A,9615.0,,,,50588
5623,1,Clearance on i.v. administration of 2 mg/kg was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6505,In vivo,A,9615.0,,,,50588
5624,1,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5802,In vivo,A,9615.0,,,,50588
5625,1,Plasma clearance in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17267,In vivo,A,9615.0,,,,50588
5626,1,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4521,In vivo,A,9615.0,,,,50588
5627,1,Plasma clearance in dog after administration of 0.25 mg/kg iv,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6535,In vivo,A,9615.0,,,,50588
5628,1,Plasma clearance in dog after administration of 1 mg/kg iv,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6535,In vivo,A,9615.0,,,,50588
5629,1,Plasma clearance in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6535,In vivo,A,9615.0,,,,50588
5630,1,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5542,In vivo,A,9615.0,,,,50588
5631,1,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5199,In vivo,A,9615.0,,,,50588
5632,1,Plasma clearance after 15 mg/kg iv dose in Dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,In vivo,A,9615.0,,,,50588
5633,1,Plasma clearance after 30 mg/kg po dose in Dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,In vivo,A,9615.0,,,,50588
5634,1,Plasma administration to dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16367,In vivo,A,9615.0,,,,50588
5635,1,Plasma clearance was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5505,In vivo,A,9615.0,,,,50588
5636,1,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6215,In vivo,A,9615.0,,,,50588
5637,1,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1466,In vivo,A,9615.0,,,,50588
5638,1,Intrinsic clearance in human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Intermediate,5007,In vitro,A,9606.0,,,Microsomes,102164
5639,1,Intrinsic clearance in human liver microsomes,Liver,BAO_0000251,,Homo sapiens,,Intermediate,5007,In vitro,A,9606.0,,,Microsomes,102164
5640,1,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,A,9615.0,,,,50588
5641,1,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,A,9615.0,,,,50588
5642,1,Clearance in dog (dose 1 mg/kg i.v.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,A,9615.0,,,,50588
5643,1,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6221,In vivo,A,9615.0,,,,50588
5644,1,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5007,In vivo,A,9615.0,,,,50588
5645,1,Plasma clearance after peroral administration at 10 mpk in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,In vivo,A,9615.0,,,,50588
5646,1,Plasma clearance after peroral administration at 5 mpk in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,In vivo,A,9615.0,,,,50588
5647,1,Plasma clearance after peroral administration at 5 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,In vivo,A,9615.0,,,,50588
5648,1,Plasma clearance was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15660,In vivo,A,9615.0,,,,50588
5649,1,Plasma clearance was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15660,In vivo,A,9615.0,,,,50588
5650,1,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5983,In vivo,A,9615.0,,,,50588
5651,1,Total clearance was determined after 0.1 mg/kg iv administration in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5600,In vivo,A,9615.0,,,,50588
5652,1,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17764,In vivo,A,9615.0,,,,50588
5653,1,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6039,In vivo,A,9615.0,,,,50588
5654,1,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6039,In vivo,A,9615.0,,,,50588
5655,1,Clearance after peroral administration of 0.2 mg/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6039,In vivo,A,9615.0,,,,50588
5656,1,Clearance by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4368,In vivo,A,9615.0,,,,50588
5657,1,Clearance by iv administration in dogs at a dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4305,In vivo,A,9615.0,,,,50588
5658,1,Clearance value was evaluated in dog plasma,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,1918,In vivo,A,9615.0,,,,50588
5659,1,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6005,In vivo,A,9615.0,,,,50588
5660,1,Compound was tested for plasma clearance in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,4839,In vivo,A,9615.0,,,,50588
5661,1,Pharmacokinetic property (Plasma clearance) was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4239,In vivo,A,9615.0,,,,50588
5662,1,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,17729,,A,10090.0,,,,50594
5663,1,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,17728,,A,10090.0,,,,50594
5664,1,Area under curve value in mouse at a dose of 10 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,5302,,A,10090.0,,,,50594
5665,1,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,BAO_0000218,,Mus musculus,,Intermediate,5506,,A,10090.0,,,,50594
5666,1,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,BAO_0000218,,Mus musculus,,Intermediate,5506,,A,10090.0,,,,50594
5667,1,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,,F,10090.0,,,,50594
5668,1,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,,F,10090.0,,,,50594
5669,1,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,,F,10090.0,,,,50594
5670,1,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,,F,10090.0,,,,50594
5671,1,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,,A,10090.0,,,,50594
5672,1,Area under curve was determined for the compound at 24 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,,A,10090.0,,,,50594
5673,1,Area under curve was determined for the compound at 40 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,,A,10090.0,,,,50594
5674,1,Area under curve was determined for the compound at 5 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,,A,10090.0,,,,50594
5675,1,Area under the curve for the compound is obtained at dose 25 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,3132,,A,10090.0,,,,50594
5676,1,Area under the curve for the compound was obtained when tested in mouse,,BAO_0000218,,Mus musculus,,Intermediate,3132,,A,10090.0,,,,50594
5677,1,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,17837,,A,10090.0,,,,50594
5678,1,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,17837,,A,10090.0,,,,50594
5679,1,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,6062,,A,10090.0,,,,50594
5680,1,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,4066,,A,10090.0,,,,50594
5681,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,BAO_0000218,,Mus musculus,,Intermediate,16597,,A,10090.0,,,,50594
5682,1,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,14239,,A,10090.0,,,,50594
5683,1,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,14239,,A,10090.0,,,,50594
5684,1,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,BAO_0000218,,Mus musculus,,Intermediate,4890,,A,10090.0,,,,50594
5685,1,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,BAO_0000218,,Mus musculus,,Intermediate,429,,A,10090.0,,,,50594
5686,1,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,BAO_0000218,,Mus musculus,,Intermediate,429,,A,10090.0,,,,50594
5687,1,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,5969,,A,10090.0,,,,50594
5688,1,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,5969,,A,10090.0,,,,50594
5689,1,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,BAO_0000218,,Mus musculus,,Intermediate,5969,,A,10090.0,,,,50594
5690,1,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,BAO_0000218,,Mus musculus,,Intermediate,6091,,A,10090.0,,,,50594
5691,1,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,BAO_0000218,,Mus musculus,,Intermediate,6091,,A,10090.0,,,,50594
5692,1,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,6091,,A,10090.0,,,,50594
5693,1,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,BAO_0000218,,Mus musculus,,Intermediate,6091,,A,10090.0,,,,50594
5694,1,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,6178,,A,10090.0,,,,50594
5695,1,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,6178,,A,10090.0,,,,50594
5696,1,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,BAO_0000218,,Mus musculus,,Intermediate,6619,,A,10090.0,,,,50594
5697,1,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,BAO_0000218,,Mus musculus,,Intermediate,6619,,A,10090.0,,,,50594
5698,1,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,BAO_0000218,,Mus musculus,,Intermediate,3760,,A,10090.0,,,,50594
5699,1,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,BAO_0000218,,Mus musculus,,Intermediate,3760,,A,10090.0,,,,50594
5700,1,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,BAO_0000218,,Mus musculus,,Intermediate,3760,,A,10090.0,,,,50594
5701,1,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,BAO_0000218,,Mus musculus,,Intermediate,3760,,A,10090.0,,,,50594
5702,1,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,BAO_0000218,,Mus musculus,,Intermediate,3192,,A,10090.0,,,,50594
5703,1,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,BAO_0000218,,Mus musculus,,Intermediate,3192,,A,10090.0,,,,50594
5704,1,Area under the curve was evaluated in mice after intravenous administration,,BAO_0000218,,Mus musculus,,Intermediate,2675,,A,10090.0,,,,50594
5705,1,Area under the curve was evaluated in mice after oral administration,,BAO_0000218,,Mus musculus,,Intermediate,2675,,A,10090.0,,,,50594
5706,1,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,Plasma,BAO_0000218,,Mus musculus,,Intermediate,16597,,A,10090.0,,,,50594
5707,1,AUC total value at a dose of 10 mg/kg peroral administration in mice.,Plasma,BAO_0000218,,Mus musculus,,Intermediate,16597,,A,10090.0,,,,50594
5708,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,BAO_0000218,,Mus musculus,,Intermediate,16597,,A,10090.0,,,,50594
5709,1,AUMC after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,17734,,A,10090.0,,,,50594
5710,1,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,Blood,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5711,1,The compound was tested in vitro for anticancer activity against 9L cells,,BAO_0000219,,,,Intermediate,15345,,F,,,9L,,80653
5712,1,Anti proliferation activity determined; Weak effect,,BAO_0000019,,Rattus norvegicus,,Autocuration,2181,,F,10116.0,,,,22226
5713,1,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,BAO_0000219,,Rattus norvegicus,,Autocuration,2181,,F,10116.0,,,,22226
5714,1,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,BAO_0000219,,Rattus norvegicus,,Autocuration,2181,,F,10116.0,,,,22226
5715,1,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,BAO_0000219,,Rattus norvegicus,,Autocuration,2181,,F,10116.0,,,,22226
5716,1,The cytotoxic activity was in vitro tested by 9PS assay method,,BAO_0000019,,Mus musculus,,Autocuration,10486,,F,10090.0,,,,22226
5717,1,The cytotoxic activity was in vitro tested by 9PS assay method.,,BAO_0000019,,Mus musculus,,Autocuration,10486,,F,10090.0,,,,22226
5718,1,Partition coefficient (logD6.5),,BAO_0000019,,,,Autocuration,15508,,A,,,,,22224
5719,1,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,BAO_0000219,,Homo sapiens,,Expert,5242,,F,9606.0,,A2780,,81034
5720,1,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,BAO_0000219,,Homo sapiens,,Intermediate,16167,,F,9606.0,,A-375,,80018
5721,1,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,BAO_0000219,,Homo sapiens,,Expert,4782,,F,9606.0,,A-431,,80852
5722,1,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,BAO_0000219,,Homo sapiens,,Expert,16093,,F,9606.0,,A-431,,9
5723,1,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2596,,F,9606.0,,A498,,80021
5724,1,in vitro cytotoxicity against A 498 cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2596,,F,9606.0,,A498,,80021
5725,1,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,BAO_0000219,,Homo sapiens,,Intermediate,3239,,F,9606.0,,A498,,80021
5726,1,Cytotoxic activity against A 498 renal cancer cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,1847,,F,9606.0,,A498,,80021
5727,1,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,BAO_0000219,,Homo sapiens,,Intermediate,10553,,F,9606.0,,A498,,80021
5728,1,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,BAO_0000019,,Staphylococcus aureus,,Autocuration,16219,,F,1280.0,,,,22226
5729,1,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,BAO_0000019,,Staphylococcus aureus,,Autocuration,16219,,F,1280.0,,,,22226
5730,1,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,BAO_0000019,,Staphylococcus aureus,,Autocuration,16219,,F,1280.0,,,,22226
5731,1,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,BAO_0000019,,Staphylococcus aureus,,Autocuration,16219,,F,1280.0,,,,22226
5732,1,Inhibitory concentration required against A 549 lung cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4782,,F,9606.0,,A549,,80682
5733,1,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,BAO_0000219,,Homo sapiens,,Intermediate,11805,,F,9606.0,,A549,,80682
5734,1,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,BAO_0000219,,Homo sapiens,,Intermediate,11805,,F,9606.0,,A549,,80682
5735,1,In vitro cytotoxicity against lung cancer A 549 cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,2007,,F,9606.0,,A549,,80682
5736,1,Compound was tested for its cytotoxicity against A 549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4594,,F,9606.0,,A549,,80682
5737,1,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,BAO_0000219,,Homo sapiens,,Expert,6018,,F,9606.0,,A549,,80682
5738,1,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,BAO_0000219,,Homo sapiens,,Intermediate,6018,,F,9606.0,,A549,,80682
5739,1,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,BAO_0000219,,Homo sapiens,,Expert,3599,,F,9606.0,,A549,,80682
5740,1,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,BAO_0000219,,Homo sapiens,,Intermediate,2551,,F,9606.0,,A549,,80682
5741,1,In vitro inhibition of A549 (human lung cancer) cell growth.,,BAO_0000219,,Homo sapiens,,Expert,16132,,F,9606.0,,A549,,80682
5742,1,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,BAO_0000219,,Homo sapiens,,Intermediate,16132,,F,9606.0,,A549,,80682
5743,1,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,BAO_0000219,,Homo sapiens,,Expert,2551,,F,9606.0,,A549,,80682
5744,1,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,BAO_0000219,,Homo sapiens,,Expert,2551,,F,9606.0,,A549,,80682
5745,1,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,BAO_0000218,,,,Autocuration,11913,,F,,,,,22226
5746,1,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,BAO_0000218,,,,Autocuration,12621,In vivo,F,,,,,104694
5747,1,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,BAO_0000218,,,,Autocuration,12621,In vivo,F,,,,,104694
5748,1,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,BAO_0000218,,,,Autocuration,12621,In vivo,F,,,,,104694
5749,1,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,BAO_0000218,,,,Autocuration,12621,In vivo,F,,,,,104694
5750,1,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,BAO_0000218,,,,Autocuration,12621,In vivo,F,,,,,104694
5751,1,Inhibition of A-498 human Renal cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,3600,,F,9606.0,,A498,,80021
5752,1,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,BAO_0000019,,Rattus norvegicus,,Autocuration,1796,,F,10116.0,,,,22226
5753,1,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,BAO_0000019,,Rattus norvegicus,,Autocuration,1796,,F,10116.0,,,,22226
5754,1,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,BAO_0000019,,Rattus norvegicus,,Autocuration,1796,,F,10116.0,,,,22226
5755,1,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,BAO_0000219,,Homo sapiens,,Expert,16464,,F,9606.0,,A 172,,80012
5756,1,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,BAO_0000219,,Homo sapiens,,Intermediate,16464,,F,9606.0,,A 172,,80012
5757,1,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,BAO_0000219,,Homo sapiens,,Intermediate,16464,,F,9606.0,,A 172,,80012
5758,1,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,BAO_0000219,,Homo sapiens,,Expert,13617,,F,9606.0,,A549,,80682
5759,1,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,BAO_0000219,,Homo sapiens,,Intermediate,4584,,F,9606.0,,A549,,80682
5760,1,Cytotoxic activity evaluated against A549 tumor cells,,BAO_0000219,,Homo sapiens,,Expert,13799,,F,9606.0,,A549,,80682
5761,1,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,16726,,F,9606.0,,A549,,80682
5762,1,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,BAO_0000219,,Homo sapiens,,Intermediate,16109,,F,9606.0,,A549,,80682
5763,1,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,BAO_0000219,,Homo sapiens,,Intermediate,16109,,F,9606.0,,A549,,80682
5764,1,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,BAO_0000219,,Homo sapiens,,Intermediate,15474,,F,9606.0,,A549,,80682
5765,1,Cytotoxicity of compound against A549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,6851,,F,9606.0,,A549,,80682
5766,1,Cytotoxicity against human lung cell carcinoma A549 cell line,,BAO_0000219,,Homo sapiens,,Expert,17534,,F,9606.0,,A549,,80682
5767,1,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,2621,,F,9606.0,,A549,,80682
5768,1,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,830,,F,9606.0,,A549,,80682
5769,1,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,BAO_0000219,,Homo sapiens,,Intermediate,14255,,F,9606.0,,A549,,80682
5770,1,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,BAO_0000219,,Homo sapiens,,Intermediate,14255,,F,9606.0,,A549,,80682
5771,1,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,BAO_0000219,,Homo sapiens,,Intermediate,1590,,F,9606.0,,A549,,80682
5772,1,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,BAO_0000219,,Homo sapiens,,Expert,6146,,F,9606.0,,A549,,80682
5773,1,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,BAO_0000219,,Homo sapiens,,Expert,17427,,F,9606.0,,A549,,80682
5774,1,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,BAO_0000219,,Homo sapiens,,Intermediate,5280,,F,9606.0,,A549,,80682
5775,1,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,BAO_0000219,,Homo sapiens,,Intermediate,16786,,F,9606.0,,A549,,80682
5776,1,In vitro cytotoxicity against A549 (human lung cancer),,BAO_0000219,,Homo sapiens,,Intermediate,5895,,F,9606.0,,A549,,80682
5777,1,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,BAO_0000219,,Homo sapiens,,Expert,14297,,F,9606.0,,A549,,80682
5778,1,In vivo antiproliferative activity against A549 cell line,,BAO_0000218,,Homo sapiens,,Intermediate,17824,,F,9606.0,,A549,,80682
5779,1,Inhibition of non-small-cell lung adenocarcinoma (A549),,BAO_0000219,,Homo sapiens,,Intermediate,14368,,F,9606.0,,A549,,80682
5780,1,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,BAO_0000219,,Homo sapiens,,Intermediate,14368,,F,9606.0,,A549,,80682
5781,1,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,BAO_0000219,,Homo sapiens,,Intermediate,14254,,F,9606.0,,A549,,80682
5782,1,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,BAO_0000219,,Homo sapiens,,Intermediate,15897,,F,9606.0,,A549,,80682
5783,1,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,BAO_0000219,,Homo sapiens,,Intermediate,13866,,F,9606.0,,A549,,80682
5784,1,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,BAO_0000219,,Homo sapiens,,Intermediate,13370,,F,9606.0,,A549,,80682
5785,1,Inhibitory activity against A549 lung cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4862,,F,9606.0,,A549,,80682
5786,1,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4862,,F,9606.0,,A549,,80682
5787,1,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,BAO_0000219,,Homo sapiens,,Intermediate,4862,,F,9606.0,,A549,,80682
5788,1,Inhibitory concentration against A549 (lung cancer) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,15970,,F,9606.0,,A549,,80682
5789,1,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,BAO_0000219,,Homo sapiens,,Expert,17713,,F,9606.0,,A549,,80682
5790,1,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4833,,F,9606.0,,A549,,80682
5791,1,Activity against A549 cancer cell line.,,BAO_0000219,,Homo sapiens,,Expert,13736,,F,9606.0,,A549,,80682
5792,1,The compound was evaluated for cytotoxicity against A549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4312,,F,9606.0,,A549,,80682
5793,1,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,BAO_0000219,,Homo sapiens,,Intermediate,5421,,F,9606.0,,A549,,80682
5794,1,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,BAO_0000219,,Homo sapiens,,Intermediate,5421,,F,9606.0,,A549,,80682
5795,1,Growth inhibitory activity was measured for human A549 tumor cell line.,,BAO_0000219,,Homo sapiens,,Intermediate,14717,,F,9606.0,,A549,,80682
5796,1,Inhibitory activity against A549 lung cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4634,,F,9606.0,,A549,,80682
5797,1,Inhibitory activity against A549 cell line; inactive,,BAO_0000219,,Homo sapiens,,Intermediate,1149,,F,9606.0,,A549,,80682
5798,1,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,BAO_0000219,,Homo sapiens,,Expert,5421,,F,9606.0,,A549,,80682
5799,1,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,BAO_0000219,,Homo sapiens,,Expert,5421,,F,9606.0,,A549,,80682
5800,1,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,BAO_0000219,,Homo sapiens,,Intermediate,5421,,F,9606.0,,A549,,80682
5801,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,BAO_0000219,,Homo sapiens,,Intermediate,3320,,F,9606.0,,A549,,80682
5802,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,BAO_0000219,,Homo sapiens,,Intermediate,3320,,F,9606.0,,A549,,80682
5803,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,BAO_0000219,,Homo sapiens,,Intermediate,3320,,F,9606.0,,A549,,80682
5804,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,BAO_0000219,,Homo sapiens,,Intermediate,3320,,F,9606.0,,A549,,80682
5805,1,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,BAO_0000219,,Homo sapiens,,Intermediate,3320,,F,9606.0,,A549,,80682
5806,1,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,5726,,F,9606.0,,A549,,80682
5807,1,Plasma clearance (in vivo) in mongrel dogs was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17800,In vivo,A,9615.0,,,,50588
5808,1,Plasma clearance was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5985,In vivo,A,9615.0,,,,50588
5809,1,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5530,In vivo,A,9615.0,,,,50588
5810,1,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5530,In vivo,A,9615.0,,,,50588
5811,1,Tested for plasma clearance in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,4839,In vivo,A,9615.0,,,,50588
5812,1,The compound was tested for clearance in dog plasma.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3639,In vivo,A,9615.0,,,,50588
5813,1,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",,BAO_0000218,,Canis lupus familiaris,,Intermediate,4838,In vivo,A,9615.0,,,,50588
5814,1,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4137,In vivo,A,9615.0,,,,50588
5815,1,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5017,In vivo,A,9615.0,,,,50588
5816,1,In vitro clearance in dog liver microsomes,Liver,BAO_0000218,,Canis lupus familiaris,,Intermediate,17538,In vitro,A,9615.0,,,Microsomes,50588
5817,1,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6161,In vivo,A,9615.0,,,,50588
5818,1,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6161,In vivo,A,9615.0,,,,50588
5819,1,Plasma clearance in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1696,In vivo,A,9615.0,,,,50588
5820,1,Clearance rate in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6762,In vivo,A,9615.0,,,,50588
5821,1,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5932,In vivo,A,9615.0,,,,50588
5822,1,Clearance in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6305,In vivo,A,9615.0,,,,50588
5823,1,Plasma clearance in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4942,In vivo,A,9615.0,,,,50588
5824,1,Plasma clearance was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4219,In vivo,A,9615.0,,,,50588
5825,1,Lower clearance in dog (i.v.) at 0.5 mpk,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17853,In vivo,A,9615.0,,,,50588
5826,1,Plasma clearance in Beagle dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4514,In vivo,A,9615.0,,,,50588
5827,1,Plasma clearance (Clp) in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6448,In vivo,A,9615.0,,,,50588
5828,1,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,In vivo,A,9615.0,,,,50588
5829,1,Plasma clearance (pharmacokinetic parameter) in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,In vivo,A,9615.0,,,,50588
5830,1,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6062,In vivo,A,9615.0,,,,50588
5831,1,Plasma clearance of compound was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6821,In vivo,A,9615.0,,,,50588
5832,1,Plasma clearance after intravenous administration of 1 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4709,In vivo,A,9615.0,,,,50588
5833,1,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4521,In vivo,A,9615.0,,,,50588
5834,1,Plasma clearance in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5374,In vivo,A,9615.0,,,,50588
5835,1,Plasma clearance was calculated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6057,In vivo,A,9615.0,,,,50588
5836,1,Plasma clearance at the dose of 2 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4727,In vivo,A,9615.0,,,,50588
5837,1,Plasma clearance in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5145,In vivo,A,9615.0,,,,50588
5838,1,Plasma clearance in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17657,In vivo,A,9615.0,,,,50588
5839,1,Plasma clearance in dog; Unable to calculate,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17657,In vivo,A,9615.0,,,,50588
5840,1,Plasma clearance in rhesus monkey,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5145,In vivo,A,9615.0,,,,50588
5841,1,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6642,In vivo,A,9615.0,,,,50588
5842,1,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6641,In vivo,A,9615.0,,,,50588
5843,1,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6642,In vivo,A,9615.0,,,,50588
5844,1,Plasma clearance was evaluated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5472,In vivo,A,9615.0,,,,50588
5845,1,Plasma clearance was evaluated in dog; Not tested,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5472,In vivo,A,9615.0,,,,50588
5846,1,Plasma clearance was evaluated in rhesus,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5472,In vivo,A,9615.0,,,,50588
5847,1,Plasma clearance was evaluated in rhesus; Not tested,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5472,In vivo,A,9615.0,,,,50588
5848,1,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4257,In vivo,A,9615.0,,,,50588
5849,1,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6679,In vivo,A,9615.0,,,,50588
5850,1,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5546,In vivo,A,9615.0,,,,50588
5851,1,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6348,In vivo,A,9615.0,,,,50588
5852,1,Clearance value at a dose of 0.2 mg/kg i.v.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5474,In vivo,A,9615.0,,,,50588
5853,1,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6316,In vivo,A,9615.0,,,,50588
5854,1,Cmax after oral dose of compound at 3 mg/kg in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17594,In vivo,A,9615.0,,,,50588
5855,1,Cmax after single intravenous bolus of 1 mg/kg in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17594,In vivo,A,9615.0,,,,50588
5856,1,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5802,In vivo,A,9615.0,,,,50588
5857,1,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6535,In vivo,A,9615.0,,,,50588
5858,1,Cmax in dog after administration of 1 mg/kg iv,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6535,In vivo,A,9615.0,,,,50588
5859,1,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,1466,In vivo,A,9615.0,,,,50588
5860,1,Cmax on p.o. administration of 10 mg/kg was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6505,In vivo,A,9615.0,,,,50588
5861,1,Cmax was determine after peroral administration at 10 mpk in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,In vivo,A,9615.0,,,,50588
5862,1,Cmax was determine after peroral administration at 5 mpk in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,In vivo,A,9615.0,,,,50588
5863,1,Cmax was determine after peroral administration at 5 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,In vivo,A,9615.0,,,,50588
5864,1,Cmax after 0.3 mg/kg po administration in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5600,In vivo,A,9615.0,,,,50588
5865,1,Cmax after peroral administration in dogs at 2.4 uM/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17764,In vivo,A,9615.0,,,,50588
5866,1,Cmax in dog after oral administration at 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6123,In vivo,A,9615.0,,,,50588
5867,1,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6123,In vivo,A,9615.0,,,,50588
5868,1,Cmax upon oral administration in male Beagle dog at 10 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6757,In vivo,A,9615.0,,,,50588
5869,1,Cmax value after 15 mg/kg iv dose in Dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,In vivo,A,9615.0,,,,50588
5870,1,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Blood,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5871,1,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Blood,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5872,1,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Bone,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5873,1,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Bone,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5874,1,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Bone,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5875,1,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5876,1,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5877,1,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5878,1,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Heart,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5879,1,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Heart,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5880,1,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Heart,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5881,1,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Kidney,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5882,1,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Kidney,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5883,1,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Kidney,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5884,1,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intestine,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5885,1,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intestine,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5886,1,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intestine,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5887,1,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Liver,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5888,1,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Liver,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5889,1,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Liver,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5890,1,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Lung,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5891,1,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Lung,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5892,1,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Lung,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5893,1,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5894,1,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5895,1,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5896,1,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5897,1,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5898,1,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5899,1,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intestine,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5900,1,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intestine,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5901,1,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intestine,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5902,1,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Spleen,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5903,1,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Spleen,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5904,1,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Spleen,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5905,1,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Stomach,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5906,1,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Stomach,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
5907,1,Cytotoxicity against A-172 human tumor cell lines,,BAO_0000219,,Homo sapiens,,Expert,2036,,F,9606.0,,A 172,,80012
5908,1,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2357,,F,9606.0,,A 172,,80012
5909,1,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,BAO_0000219,,Homo sapiens,,Intermediate,1457,,F,9606.0,,A204,,80014
5910,1,Tested for antiproliferative activity against A-2780 tumoral cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4379,,F,9606.0,,A2780,,81034
5911,1,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,BAO_0000219,,Homo sapiens,,Intermediate,1093,,F,9606.0,,A-375,,80018
5912,1,Tested in vitro against A-375 cell line human melanoma,,BAO_0000219,,Homo sapiens,,Intermediate,12152,,F,9606.0,,A-375,,80018
5913,1,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,BAO_0000219,,Homo sapiens,,Expert,16464,,F,9606.0,,A-427,,80019
5914,1,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,BAO_0000219,,Homo sapiens,,Intermediate,16464,,F,9606.0,,A-427,,80019
5915,1,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,BAO_0000219,,Homo sapiens,,Expert,16582,,F,9606.0,,A-427,,80019
5916,1,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,BAO_0000219,,Homo sapiens,,Intermediate,16464,,F,9606.0,,A-427,,80019
5917,1,Antitumor activity on A-427 lung carcinoma cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,10413,,F,9606.0,,A-427,,80019
5918,1,Cytotoxic activity against human A-427 lung tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,6418,,F,9606.0,,A-427,,80019
5919,1,In vitro antitumor effects against human A-427 cell lines.,,BAO_0000219,,Homo sapiens,,Expert,17134,,F,9606.0,,A-427,,80019
5920,1,In vitro inhibition of A-427 (human lung cancer) cell growth.,,BAO_0000219,,Homo sapiens,,Expert,16132,,F,9606.0,,A-427,,80019
5921,1,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,BAO_0000219,,Homo sapiens,,Intermediate,16132,,F,9606.0,,A-427,,80019
5922,1,Cytotoxic activity of compound against A-427 lung human tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,16780,,F,9606.0,,A-427,,80019
5923,1,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,BAO_0000219,,Homo sapiens,,Expert,4085,,F,9606.0,,A-431,,80852
5924,1,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,1276,,F,9606.0,,A498,,80021
5925,1,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,BAO_0000219,,Homo sapiens,,Expert,3498,,F,9606.0,,A498,,80021
5926,1,Cytotoxicity against human kidney carcinoma A-498cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,1169,,F,9606.0,,A498,,80021
5927,1,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4450,,F,9606.0,,A498,,80021
5928,1,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,BAO_0000219,,Homo sapiens,,Intermediate,3311,,F,9606.0,,A498,,80021
5929,1,Antitumor cytotoxic activity against A-498 cell line was determined,,BAO_0000219,,Homo sapiens,,Intermediate,4461,,F,9606.0,,A498,,80021
5930,1,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,BAO_0000219,,Homo sapiens,,Intermediate,3311,,F,9606.0,,A498,,80021
5931,1,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,BAO_0000219,,Homo sapiens,,Intermediate,3311,,F,9606.0,,A498,,80021
5932,1,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,BAO_0000219,,Homo sapiens,,Intermediate,1457,,F,9606.0,,A498,,80021
5933,1,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,3664,,F,9606.0,,A498,,80021
5934,1,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,BAO_0000219,,Homo sapiens,,Intermediate,15895,,F,9606.0,,A498,,80021
5935,1,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,11843,,F,9606.0,,A549,,80682
5936,1,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,11843,,F,9606.0,,A549,,80682
5937,1,In vitro antiproliferative activity against human A-549 NSCL cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17705,,F,9606.0,,A549,,80682
5938,1,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,BAO_0000219,,Homo sapiens,,Intermediate,17705,,F,9606.0,,A549,,80682
5939,1,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,4369,,F,9606.0,,A549,,80682
5940,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,4369,,F,9606.0,,A549,,80682
5941,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,BAO_0000219,,Homo sapiens,,Intermediate,4369,,F,9606.0,,A549,,80682
5942,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,4369,,F,9606.0,,A549,,80682
5943,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,BAO_0000219,,Homo sapiens,,Intermediate,4369,,F,9606.0,,A549,,80682
5944,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,BAO_0000219,,Homo sapiens,,Intermediate,4369,,F,9606.0,,A549,,80682
5945,1,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,BAO_0000219,,Homo sapiens,,Intermediate,4369,,F,9606.0,,A549,,80682
5946,1,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,BAO_0000219,,Homo sapiens,,Expert,4787,,F,9606.0,,A549,,80682
5947,1,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,BAO_0000219,,Homo sapiens,,Intermediate,4787,,F,9606.0,,A549,,80682
5948,1,Cytotoxic activity against A-549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,6513,,F,9606.0,,A549,,80682
5949,1,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,BAO_0000219,,Homo sapiens,,Intermediate,6690,,F,9606.0,,A549,,80682
5950,1,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,BAO_0000219,,Homo sapiens,,Intermediate,6690,,F,9606.0,,A549,,80682
5951,1,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,BAO_0000219,,Homo sapiens,,Expert,12263,,F,9606.0,,A549,,80682
5952,1,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,BAO_0000219,,Homo sapiens,,Intermediate,1054,,F,9606.0,,A549,,80682
5953,1,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,BAO_0000219,,Homo sapiens,,Intermediate,1359,,F,9606.0,,A549,,80682
5954,1,Cytotoxic activity against human lung carcinoma (A-549) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,3547,,F,9606.0,,A549,,80682
5955,1,Cytotoxic activity towards A-549 cells,,BAO_0000219,,Homo sapiens,,Expert,5771,,F,9606.0,,A549,,80682
5956,1,"In vitro percent inhibition of A549, lung carcinoma.",,BAO_0000219,,Homo sapiens,,Intermediate,14425,,F,9606.0,,A549,,80682
5957,1,"In vitro percent inhibition of A549, lung carcinoma",,BAO_0000219,,Homo sapiens,,Intermediate,14425,,F,9606.0,,A549,,80682
5958,1,"In vitro percent inhibition of A549, lung carcinoma.",,BAO_0000219,,Homo sapiens,,Intermediate,14425,,F,9606.0,,A549,,80682
5959,1,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,BAO_0000219,,Homo sapiens,,Intermediate,14425,,F,9606.0,,A549,,80682
5960,1,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,BAO_0000219,,Homo sapiens,,Intermediate,5280,,F,9606.0,,A549,,80682
5961,1,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,BAO_0000219,,Homo sapiens,,Intermediate,15176,,F,9606.0,,A549,,80682
5962,1,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,BAO_0000219,,Homo sapiens,,Intermediate,15300,,F,9606.0,,A549,,80682
5963,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,BAO_0000218,,Homo sapiens,,Intermediate,17824,,F,9606.0,,A549,,80682
5964,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,BAO_0000218,,Homo sapiens,,Intermediate,17824,,F,9606.0,,A549,,80682
5965,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,BAO_0000218,,Homo sapiens,,Intermediate,17824,,F,9606.0,,A549,,80682
5966,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,BAO_0000218,,Homo sapiens,,Intermediate,17824,,F,9606.0,,A549,,80682
5967,1,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,BAO_0000218,,Homo sapiens,,Intermediate,17824,,F,9606.0,,A549,,80682
5968,1,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,BAO_0000219,,Homo sapiens,,Intermediate,17824,,F,9606.0,,A549,,80682
5969,1,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,BAO_0000218,,Homo sapiens,,Intermediate,17528,,F,9606.0,,A549,,80682
5970,1,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,BAO_0000219,,Homo sapiens,,Expert,6870,,F,9606.0,,A549,,80682
5971,1,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,BAO_0000219,,Homo sapiens,,Intermediate,6870,,F,9606.0,,A549,,80682
5972,1,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,BAO_0000219,,Homo sapiens,,Intermediate,6870,,F,9606.0,,A549,,80682
5973,1,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,BAO_0000219,,Homo sapiens,,Intermediate,6870,,F,9606.0,,A549,,80682
5974,1,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,BAO_0000219,,Homo sapiens,,Intermediate,16726,,F,9606.0,,A549,,80682
5975,1,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,BAO_0000219,,Homo sapiens,,Intermediate,6170,,F,9606.0,,A549,,80682
5976,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,BAO_0000219,,Homo sapiens,,Expert,6583,,F,9606.0,,A549,,80682
5977,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,BAO_0000219,,Homo sapiens,,Expert,6583,,F,9606.0,,A549,,80682
5978,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,BAO_0000219,,Homo sapiens,,Expert,6583,,F,9606.0,,A549,,80682
5979,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,BAO_0000219,,Homo sapiens,,Expert,6583,,F,9606.0,,A549,,80682
5980,1,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,BAO_0000219,,Homo sapiens,,Expert,6583,,F,9606.0,,A549,,80682
5981,1,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17321,,F,9606.0,,A549,,80682
5982,1,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,BAO_0000219,,Homo sapiens,,Expert,17528,,F,9606.0,,A549,,80682
5983,1,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,BAO_0000219,,Homo sapiens,,Expert,12888,,F,9606.0,,A549,,80682
5984,1,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4312,,F,9606.0,,A549,,80682
5985,1,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4312,,F,9606.0,,A549,,80682
5986,1,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,BAO_0000219,,Homo sapiens,,Intermediate,4312,,F,9606.0,,A549,,80682
5987,1,In vitro antiproliferative activity against A549 cell line,,BAO_0000219,,Mus musculus,,Intermediate,17737,,F,10090.0,,A549,,80682
5988,1,Synergism with indomethacin in A549 cells,,BAO_0000219,,,,Intermediate,6630,,F,,,A549,,80682
5989,1,Synergism with tolmetin in A549 cells,,BAO_0000219,,,,Intermediate,6630,,F,,,A549,,80682
5990,1,Synergism with sulindac in A549 cells,,BAO_0000219,,,,Intermediate,6630,,F,,,A549,,80682
5991,1,Antagonism of indomethacin in A549 cells,,BAO_0000219,,,,Intermediate,6630,,F,,,A549,,80682
5992,1,Antagonism of sulindac in A549 cells,,BAO_0000219,,,,Intermediate,6630,,F,,,A549,,80682
5993,1,Antagonism of tolmetin in A549 cells,,BAO_0000219,,,,Intermediate,6630,,F,,,A549,,80682
5994,1,Synergism with indomethacin in A549 cells,,BAO_0000219,,,,Intermediate,6630,,F,,,A549,,80682
5995,1,Synergism with sulindac in A549 cells,,BAO_0000219,,,,Intermediate,6630,,F,,,A549,,80682
5996,1,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,BAO_0000219,,,,Intermediate,6630,,F,,,A549,,80682
5997,1,Cmax value after 30 mg/kg po dose in Dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,In vivo,A,9615.0,,,,50588
5998,1,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5944,In vivo,A,9615.0,,,,50588
5999,1,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5944,In vivo,A,9615.0,,,,50588
6000,1,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5944,In vivo,A,9615.0,,,,50588
6001,1,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5944,In vivo,A,9615.0,,,,50588
6002,1,Cmax value after administration of 4 mg/Kg oral dose in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2959,In vivo,A,9615.0,,,,50588
6003,1,Cmax value in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6241,In vivo,A,9615.0,,,,50588
6004,1,Cmax value in dogs after oral administration at 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6241,In vivo,A,9615.0,,,,50588
6005,1,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2652,In vivo,A,9615.0,,,,50588
6006,1,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,1806,In vivo,A,9615.0,,,,50588
6007,1,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,1806,In vivo,A,9615.0,,,,50588
6008,1,Concentration maxima after oral dosing in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1021,In vivo,A,9615.0,,,,50588
6009,1,Concentration maxima after oral dosing in dogs; not available,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1021,In vivo,A,9615.0,,,,50588
6010,1,Concentration maxima after oral dosing in dogs; not available,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1021,In vivo,A,9615.0,,,,50588
6011,1,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5444,In vivo,A,9615.0,,,,50588
6012,1,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5444,In vivo,A,9615.0,,,,50588
6013,1,In vivo maximal concentration was calculated at 1 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5444,In vivo,A,9615.0,,,,50588
6014,1,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5444,In vivo,A,9615.0,,,,50588
6015,1,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5444,In vivo,A,9615.0,,,,50588
6016,1,Cmax in dog plasma after oral dose (1 mg/kg),Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5130,In vivo,A,9615.0,,,,50588
6017,1,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,3249,In vivo,A,9615.0,,,,50588
6018,1,Maximal plasma concentration at a dose of 1 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5473,In vivo,A,9615.0,,,,50588
6019,1,Maximal plasma concentration at a dose of 1 mg/kg (oral),Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5474,In vivo,A,9615.0,,,,50588
6020,1,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,4657,In vivo,A,9615.0,,,,50588
6021,1,Maximum concentration of compound in dog was evaluated.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3031,In vivo,A,9615.0,,,,50588
6022,1,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4527,In vivo,A,9615.0,,,,50588
6023,1,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4186,In vivo,A,9615.0,,,,50588
6024,1,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5007,In vivo,A,9615.0,,,,50588
6025,1,Maximum concentration obtained in dog plasma was determined,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,3132,In vivo,A,9615.0,,,,50588
6026,1,Maximum concentration was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5006,In vivo,A,9615.0,,,,50588
6027,1,Maximum concentration at the dose of 2 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4727,In vivo,A,9615.0,,,,50588
6028,1,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1916,In vivo,A,9615.0,,,,50588
6029,1,Maximum concentration was evaluated in dog plasma,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,1918,In vivo,A,9615.0,,,,50588
6030,1,Maximum concentration was evaluated after 75 min after administration in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3045,In vivo,A,9615.0,,,,50588
6031,1,Maximum plasma concentration determined in dog after oral administration of 17b,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,9579,In vivo,A,9615.0,,,,50588
6032,1,Maximum plasma concentration determined in dog after oral administration of 2b,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,9579,In vivo,A,9615.0,,,,50588
6033,1,Maximum plasma concentration in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,933,In vivo,A,9615.0,,,,50588
6034,1,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17839,In vivo,A,9615.0,,,,50588
6035,1,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17839,In vivo,A,9615.0,,,,50588
6036,1,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17839,In vivo,A,9615.0,,,,50588
6037,1,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17839,In vivo,A,9615.0,,,,50588
6038,1,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6348,In vivo,A,9615.0,,,,50588
6039,1,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,16367,In vivo,A,9615.0,,,,50588
6040,1,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,1337,In vivo,A,9615.0,,,,50588
6041,1,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,1337,In vivo,A,9615.0,,,,50588
6042,1,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5199,In vivo,A,9615.0,,,,50588
6043,1,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17650,In vivo,A,9615.0,,,,50588
6044,1,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6679,In vivo,A,9615.0,,,,50588
6045,1,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5356,In vivo,A,9615.0,,,,50588
6046,1,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5356,In vivo,A,9615.0,,,,50588
6047,1,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,In vivo,A,9615.0,,,,50588
6048,1,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,In vivo,A,9615.0,,,,50588
6049,1,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,In vivo,A,9615.0,,,,50588
6050,1,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,In vivo,A,9615.0,,,,50588
6051,1,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Expert,3598,In vivo,A,9615.0,,,,50588
6052,1,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4368,In vivo,A,9615.0,,,,50588
6053,1,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6265,In vivo,A,9615.0,,,,50588
6054,1,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Stomach,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
6055,1,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Urine,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
6056,1,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,Urine,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
6057,1,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,Urine,BAO_0000218,,Mus musculus,,Intermediate,7767,In vivo,A,10090.0,,,,50594
6058,1,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,BAO_0000218,,Mus musculus,,Intermediate,17811,,A,10090.0,,,,50594
6059,1,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,BAO_0000218,,Mus musculus,,Intermediate,17811,,A,10090.0,,,,50594
6060,1,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,BAO_0000218,,Mus musculus,,Intermediate,17827,,A,10090.0,,,,50594
6061,1,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Blood,BAO_0000218,,Mus musculus,,Intermediate,17827,,A,10090.0,,,,50594
6062,1,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,BAO_0000218,,Mus musculus,,Intermediate,17827,,A,10090.0,,,,50594
6063,1,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,BAO_0000218,,Mus musculus,,Intermediate,17827,,A,10090.0,,,,50594
6064,1,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,BAO_0000218,,Mus musculus,,Intermediate,17827,,A,10090.0,,,,50594
6065,1,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Blood,BAO_0000218,,Mus musculus,,Intermediate,17827,,A,10090.0,,,,50594
6066,1,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),Blood,BAO_0000218,,Mus musculus,,Intermediate,17827,,A,10090.0,,,,50594
6067,1,Compound was evaluated for washout rate in mice (Radiolabeled compound),,BAO_0000218,,Mus musculus,,Intermediate,17827,,A,10090.0,,,,50594
6068,1,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,BAO_0000218,,Mus musculus,,Intermediate,17827,,A,10090.0,,,,50594
6069,1,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,BAO_0000218,,Mus musculus,,Intermediate,17827,,A,10090.0,,,,50594
6070,1,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,BAO_0000218,,Mus musculus,,Intermediate,17827,,A,10090.0,,,,50594
6071,1,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,BAO_0000218,,Mus musculus,,Intermediate,17827,,A,10090.0,,,,50594
6072,1,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,BAO_0000218,,Mus musculus,,Intermediate,17257,,A,10090.0,,,,50594
6073,1,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,BAO_0000218,,Mus musculus,,Intermediate,17257,,A,10090.0,,,,50594
6074,1,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,BAO_0000218,,Mus musculus,,Intermediate,17257,,A,10090.0,,,,50594
6075,1,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,BAO_0000218,,Mus musculus,,Intermediate,17257,,A,10090.0,,,,50594
6076,1,Time at maximum activity in mice (Radiolabeled compound),,BAO_0000218,,Mus musculus,,Intermediate,17827,,A,10090.0,,,,50594
6077,1,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,BAO_0000218,,Mus musculus,,Intermediate,3760,,A,10090.0,,,,50594
6078,1,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,BAO_0000218,,Mus musculus,,Intermediate,3760,,A,10090.0,,,,50594
6079,1,Binding towards mouse plasma protein at 10 uM,,BAO_0000218,,Mus musculus,,Intermediate,17409,,A,10090.0,,,,50594
6080,1,Binding towards mouse plasma protein at 100 uM,,BAO_0000218,,Mus musculus,,Intermediate,17409,,A,10090.0,,,,50594
6081,1,Bioavailability was evaluated in mice after intravenous administration,,BAO_0000218,,Mus musculus,,Intermediate,2675,In vivo,A,10090.0,,,,50594
6082,1,Bioavailability was evaluated in mice after oral administration,,BAO_0000218,,Mus musculus,,Intermediate,2675,In vivo,A,10090.0,,,,50594
6083,1,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,,BAO_0000218,,Mus musculus,,Intermediate,3132,In vivo,A,10090.0,,,,50594
6084,1,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,3132,In vivo,A,10090.0,,,,50594
6085,1,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,A,10090.0,,,,50594
6086,1,Oral bioavailability in mouse,,BAO_0000218,,Mus musculus,,Intermediate,2862,In vivo,A,10090.0,,,,50594
6087,1,Oral bioavailability after intravenous administration in mice at 24 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,A,10090.0,,,,50594
6088,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Brain,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6089,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Brain,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6090,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Brain,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6091,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Brain,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6092,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Brain,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6093,1,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Brain,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6094,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Heart,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6095,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Heart,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6096,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Heart,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6097,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Heart,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6098,1,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,BAO_0000219,,Homo sapiens,,Intermediate,1276,,F,9606.0,,A549,,80682
6099,1,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,BAO_0000219,,Homo sapiens,,Expert,3498,,F,9606.0,,A549,,80682
6100,1,Cytotoxicity against human lung carcinoma A-549 cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,1169,,F,9606.0,,A549,,80682
6101,1,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4450,,F,9606.0,,A549,,80682
6102,1,In vitro cytotoxicity against human lung carcinoma cell line A-549,,BAO_0000219,,Homo sapiens,,Intermediate,358,,F,9606.0,,A549,,80682
6103,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,BAO_0000219,,Homo sapiens,,Intermediate,358,,F,9606.0,,A549,,80682
6104,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,BAO_0000219,,Homo sapiens,,Intermediate,358,,F,9606.0,,A549,,80682
6105,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,BAO_0000219,,Homo sapiens,,Intermediate,358,,F,9606.0,,A549,,80682
6106,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,BAO_0000219,,Homo sapiens,,Intermediate,358,,F,9606.0,,A549,,80682
6107,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,BAO_0000219,,Homo sapiens,,Intermediate,358,,F,9606.0,,A549,,80682
6108,1,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,BAO_0000219,,Homo sapiens,,Intermediate,358,,F,9606.0,,A549,,80682
6109,1,In vitro cytotoxicity against A-549 human lung cancer cells,,BAO_0000219,,Homo sapiens,,Intermediate,15167,,F,9606.0,,A549,,80682
6110,1,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4139,,F,9606.0,,A549,,80682
6111,1,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,833,,F,9606.0,,A549,,80682
6112,1,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,BAO_0000219,,Homo sapiens,,Expert,15718,,F,9606.0,,A549,,80682
6113,1,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,BAO_0000219,,Homo sapiens,,Intermediate,12373,,F,9606.0,,A549,,80682
6114,1,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,BAO_0000219,,Homo sapiens,,Intermediate,637,,F,9606.0,,A549,,80682
6115,1,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,BAO_0000219,,Homo sapiens,,Expert,14867,,F,9606.0,,A549,,80682
6116,1,Antitumor cytotoxic activity against A-549 cell line was determined,,BAO_0000219,,Homo sapiens,,Intermediate,4461,,F,9606.0,,A549,,80682
6117,1,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,BAO_0000219,,Homo sapiens,,Intermediate,5406,,F,9606.0,,A549,,80682
6118,1,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4457,,F,9606.0,,A549,,80682
6119,1,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,BAO_0000219,,Homo sapiens,,Expert,1386,,F,9606.0,,A549,,80682
6120,1,Antitumoral activity was assayed against A-549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,3265,,F,9606.0,,A549,,80682
6121,1,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,BAO_0000219,,Homo sapiens,,Intermediate,2359,,F,9606.0,,A549,,80682
6122,1,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4457,,F,9606.0,,A549,,80682
6123,1,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,BAO_0000219,,Homo sapiens,,Expert,12454,,F,9606.0,,A549,,80682
6124,1,Compound was tested for inhibition of cell growth of A-549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,1481,,F,9606.0,,A549,,80682
6125,1,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,BAO_0000219,,Homo sapiens,,Intermediate,1750,,F,9606.0,,A549,,80682
6126,1,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,BAO_0000219,,Homo sapiens,,Intermediate,5065,,F,9606.0,,A549,,80682
6127,1,In vitro cytotoxicity against A549-human lung carcinoma cells.,,BAO_0000219,,Homo sapiens,,Expert,808,,F,9606.0,,A549,,80682
6128,1,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,BAO_0000219,,Homo sapiens,,Expert,16364,,F,9606.0,,A549,,80682
6129,1,Cytotoxic activity against A-549 cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,1847,,F,9606.0,,A549,,80682
6130,1,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,BAO_0000219,,Homo sapiens,,Expert,1747,,F,9606.0,,A549,,80682
6131,1,Cytotoxicity against human A549 non small cell lung cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,1003,,F,9606.0,,A549,,80682
6132,1,Inhibition of cell growth in (A-549) lung cell line,,BAO_0000219,,Homo sapiens,,Expert,15313,,F,9606.0,,A549,,80682
6133,1,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,3122,,F,9606.0,,A549,,80682
6134,1,In vitro antitumor activity against A-549 tumor cells.,,BAO_0000219,,Homo sapiens,,Intermediate,16049,,F,9606.0,,A549,,80682
6135,1,In vitro antitumor effects against human A-549 cell lines.,,BAO_0000219,,Homo sapiens,,Expert,17134,,F,9606.0,,A549,,80682
6136,1,In vitro cytotoxic activity of compound against A-549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,6406,,F,9606.0,,A549,,80682
6137,1,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,627,,F,9606.0,,A549,,80682
6138,1,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,BAO_0000219,,Homo sapiens,,Intermediate,12307,,F,9606.0,,A549,,80682
6139,1,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,BAO_0000219,,Homo sapiens,,Intermediate,17861,,F,9606.0,,A549,,80682
6140,1,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,BAO_0000219,,Homo sapiens,,Expert,6682,,F,9606.0,,A549,,80682
6141,1,Inhibitory concentration of compound against A-549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,6663,,F,9606.0,,A549,,80682
6142,1,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,BAO_0000219,,Homo sapiens,,Intermediate,2454,,F,9606.0,,A549,,80682
6143,1,cytotoxic activity against leukemia (A-549) cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,14709,,F,9606.0,,A549,,80682
6144,1,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,BAO_0000219,,Homo sapiens,,Expert,15718,,F,9606.0,,A549,,80682
6145,1,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,15718,,F,9606.0,,A549,,80682
6146,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,BAO_0000219,,Homo sapiens,,Intermediate,17130,,F,9606.0,,A549,,80682
6147,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,BAO_0000219,,Homo sapiens,,Intermediate,17130,,F,9606.0,,A549,,80682
6148,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,BAO_0000219,,Homo sapiens,,Intermediate,17130,,F,9606.0,,A549,,80682
6149,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,BAO_0000219,,Homo sapiens,,Intermediate,17130,,F,9606.0,,A549,,80682
6150,1,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,BAO_0000219,,,,Intermediate,6630,,F,,,A549,,80682
6151,1,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,BAO_0000219,,Homo sapiens,,Intermediate,16726,,F,9606.0,,A549,,80682
6152,1,Cytotoxicity against A549 cells; No cytotoxicity,,BAO_0000219,,Homo sapiens,,Intermediate,17846,,F,9606.0,,A549,,80682
6153,1,Cytotoxicity against human lung carcinoma (A549) cell lines,,BAO_0000219,,Homo sapiens,,Expert,3415,,F,9606.0,,A549,,80682
6154,1,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,BAO_0000219,,Homo sapiens,,Expert,3415,,F,9606.0,,A549,,80682
6155,1,In vitro anticancer activity against human lung (A549) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,5609,,F,9606.0,,A549,,80682
6156,1,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,F,9606.0,,A549,,80682
6157,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,F,9606.0,,A549,,80682
6158,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,F,9606.0,,A549,,80682
6159,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,F,9606.0,,A549,,80682
6160,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,F,9606.0,,A549,,80682
6161,1,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,F,9606.0,,A549,,80682
6162,1,Inhibition of A549 human lung tumor cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,16295,,F,9606.0,,A549,,80682
6163,1,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,BAO_0000219,,Homo sapiens,,Intermediate,16825,,F,9606.0,,A549,,80682
6164,1,In vitro cytotoxicity against human tumor cell line A549,,BAO_0000219,,Homo sapiens,,Expert,3439,,F,9606.0,,A549,,80682
6165,1,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,BAO_0000219,,Homo sapiens,,Intermediate,10870,,F,9606.0,,A549,,80682
6166,1,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4845,,F,9606.0,,A549,,80682
6167,1,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,5822,,F,9606.0,,A549,,80682
6168,1,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,5822,,F,9606.0,,A549,,80682
6169,1,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,BAO_0000219,,Homo sapiens,,Intermediate,5822,,F,9606.0,,A549,,80682
6170,1,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,16381,,F,9606.0,,A549,,80682
6171,1,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,16381,,F,9606.0,,A549,,80682
6172,1,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,16381,,F,9606.0,,A549,,80682
6173,1,In vitro anticancer activity against human lung (A549) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,5609,,F,9606.0,,A549,,80682
6174,1,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,BAO_0000219,,Homo sapiens,,Intermediate,4644,,F,9606.0,,A549,,80682
6175,1,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,BAO_0000219,,Homo sapiens,,Intermediate,4644,,F,9606.0,,A549,,80682
6176,1,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,BAO_0000219,,Homo sapiens,,Intermediate,4644,,F,9606.0,,A549,,80682
6177,1,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,BAO_0000219,,Homo sapiens,,Intermediate,4644,,F,9606.0,,A549,,80682
6178,1,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,BAO_0000219,,Homo sapiens,,Intermediate,5822,,F,9606.0,,A549,,80682
6179,1,Percentage inhibition of human lung carcinoma (A549) cell lines,,BAO_0000219,,Homo sapiens,,Expert,3415,,F,9606.0,,A549,,80682
6180,1,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,BAO_0000219,,Homo sapiens,,Intermediate,16726,,F,9606.0,,A549,,80682
6181,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,BAO_0000219,,Homo sapiens,,Intermediate,17206,,F,9606.0,,A549,,80682
6182,1,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,F,9606.0,,A549,,80682
6183,1,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,F,9606.0,,A549,,80682
6184,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,BAO_0000219,,Homo sapiens,,Intermediate,17206,,F,9606.0,,A549,,80682
6185,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,BAO_0000219,,Homo sapiens,,Intermediate,17206,,F,9606.0,,A549,,80682
6186,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,BAO_0000219,,Homo sapiens,,Intermediate,17206,,F,9606.0,,A549,,80682
6187,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,BAO_0000219,,Homo sapiens,,Intermediate,17206,,F,9606.0,,A549,,80682
6188,1,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,BAO_0000219,,Homo sapiens,,Intermediate,17206,,F,9606.0,,A549,,80682
6189,1,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,F,9606.0,,A549,,80682
6190,1,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,F,9606.0,,A549,,80682
6191,1,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,BAO_0000219,,Homo sapiens,,Intermediate,16726,,F,9606.0,,A549,,80682
6192,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,F,9606.0,,A549,,80682
6193,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,F,9606.0,,A549,,80682
6194,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,F,9606.0,,A549,,80682
6195,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,F,9606.0,,A549,,80682
6196,1,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6084,In vivo,A,9615.0,,,,50588
6197,1,Pharmacokinetic activity (Cmax) in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6084,In vivo,A,9615.0,,,,50588
6198,1,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,4809,In vivo,A,9615.0,,,,50588
6199,1,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5983,In vivo,A,9615.0,,,,50588
6200,1,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6251,In vivo,A,9615.0,,,,50588
6201,1,Cmax in dog plasma after 30mg/kg oral dose,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5932,In vivo,A,9615.0,,,,50588
6202,1,Tested for the peak blood level in dog,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,4273,In vivo,A,9615.0,,,,50588
6203,1,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",,BAO_0000218,,Canis lupus familiaris,,Intermediate,5313,In vivo,A,9615.0,,,,50588
6204,1,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",,BAO_0000218,,Canis lupus familiaris,,Intermediate,5313,In vivo,A,9615.0,,,,50588
6205,1,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,6221,In vivo,A,9615.0,,,,50588
6206,1,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4709,,A,9615.0,,,,50588
6207,1,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,BAO_0000218,,Canis lupus familiaris,,Intermediate,167,,A,9615.0,,,,50588
6208,1,Final plasma concentration in dogs after oral administration at 1 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6241,,A,9615.0,,,,50588
6209,1,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,BAO_0000218,,Canis lupus familiaris,,Intermediate,344,,A,9615.0,,,,50588
6210,1,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,BAO_0000218,,Canis lupus familiaris,,Intermediate,344,,A,9615.0,,,,50588
6211,1,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,BAO_0000218,,Canis lupus familiaris,,Intermediate,344,,A,9615.0,,,,50588
6212,1,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2189,,A,9615.0,,,,50588
6213,1,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,2189,,A,9615.0,,,,50588
6214,1,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,2189,,A,9615.0,,,,50588
6215,1,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,2189,,A,9615.0,,,,50588
6216,1,Absolute bioavailability was evaluated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4257,In vivo,A,9615.0,,,,50588
6217,1,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6221,In vivo,A,9615.0,,,,50588
6218,1,Bioavailability after peroral administration (1 mg/kg) was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6215,In vivo,A,9615.0,,,,50588
6219,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17267,In vivo,A,9615.0,,,,50588
6220,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6621,In vivo,A,9615.0,,,,50588
6221,1,Bioavailability after intravenous administration in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3854,In vivo,A,9615.0,,,,50588
6222,1,Bioavailability after peroral administration in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3854,In vivo,A,9615.0,,,,50588
6223,1,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5007,In vivo,A,9615.0,,,,50588
6224,1,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4333,In vivo,A,9615.0,,,,50588
6225,1,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,4333,In vivo,A,9615.0,,,,50588
6226,1,Bioavailability,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5006,In vivo,A,9615.0,,,,50588
6227,1,Bioavailability,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5199,In vivo,A,9615.0,,,,50588
6228,1,Bioavailability by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4368,In vivo,A,9615.0,,,,50588
6229,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3771,In vivo,A,9615.0,,,,50588
6230,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4953,In vivo,A,9615.0,,,,50588
6231,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5064,In vivo,A,9615.0,,,,50588
6232,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17657,In vivo,A,9615.0,,,,50588
6233,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17796,In vivo,A,9615.0,,,,50588
6234,1,Bioavailability in dog (p.o.) at 2.0 mpk,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17853,In vivo,A,9615.0,,,,50588
6235,1,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,4521,In vivo,A,9615.0,,,,50588
6236,1,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4521,In vivo,A,9615.0,,,,50588
6237,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5006,In vivo,A,9615.0,,,,50588
6238,1,Bioavailability was evaluated after oral administration in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16365,In vivo,A,9615.0,,,,50588
6239,1,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1916,In vivo,A,9615.0,,,,50588
6240,1,Bioavailability was evaluated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1918,In vivo,A,9615.0,,,,50588
6241,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4239,In vivo,A,9615.0,,,,50588
6242,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6505,In vivo,A,9615.0,,,,50588
6243,1,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5334,In vivo,A,9615.0,,,,50588
6244,1,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5334,In vivo,A,9615.0,,,,50588
6245,1,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,4809,In vivo,A,9615.0,,,,50588
6246,1,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6348,In vivo,A,9615.0,,,,50588
6247,1,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6005,In vivo,A,9615.0,,,,50588
6248,1,Bioavailability of compound in dog was determined after peroral administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17804,In vivo,A,9615.0,,,,50588
6249,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3184,In vivo,A,9615.0,,,,50588
6250,1,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1806,In vivo,A,9615.0,,,,50588
6251,1,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1806,In vivo,A,9615.0,,,,50588
6252,1,Compound was evaluated for oral bioavailability in dogs; 37-38 %,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1806,In vivo,A,9615.0,,,,50588
6253,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4839,In vivo,A,9615.0,,,,50588
6254,1,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5017,In vivo,A,9615.0,,,,50588
6255,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Heart,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6256,1,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Heart,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6257,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Kidney,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6258,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Kidney,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6259,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Kidney,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6260,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Kidney,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6261,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Kidney,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6262,1,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Kidney,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6263,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Liver,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6264,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Liver,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6265,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Liver,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6266,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Liver,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6267,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Liver,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6268,1,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Liver,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6269,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Lung,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6270,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Lung,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6271,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Lung,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6272,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Lung,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6273,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Lung,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6274,1,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Lung,BAO_0000218,,Mus musculus,,Intermediate,846,In vivo,A,10090.0,,,,50594
6275,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6276,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6277,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6278,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6279,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6280,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,Brain,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6281,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,Brain,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6282,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,Brain,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6283,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,Brain,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6284,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,Brain,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6285,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,Heart,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6286,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6287,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,Heart,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6288,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6289,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6290,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,Kidney,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6291,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6292,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,Kidney,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6293,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,BAO_0000219,,Homo sapiens,,Intermediate,17130,,F,9606.0,,A549,,80682
6294,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,BAO_0000219,,Homo sapiens,,Intermediate,17130,,F,9606.0,,A549,,80682
6295,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,BAO_0000219,,Homo sapiens,,Intermediate,17130,,F,9606.0,,A549,,80682
6296,1,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,BAO_0000219,,Homo sapiens,,Intermediate,17130,,F,9606.0,,A549,,80682
6297,1,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,BAO_0000219,,Homo sapiens,,Expert,3263,,F,9606.0,,A549,,80682
6298,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,BAO_0000219,,Homo sapiens,,Expert,6663,,F,9606.0,,A549,,80682
6299,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,BAO_0000219,,Homo sapiens,,Expert,6663,,F,9606.0,,A549,,80682
6300,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,BAO_0000219,,Homo sapiens,,Expert,6663,,F,9606.0,,A549,,80682
6301,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,BAO_0000219,,Homo sapiens,,Expert,6663,,F,9606.0,,A549,,80682
6302,1,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,BAO_0000219,,Homo sapiens,,Expert,6663,,F,9606.0,,A549,,80682
6303,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,BAO_0000219,,Homo sapiens,,Intermediate,6663,,F,9606.0,,A549,,80682
6304,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,BAO_0000219,,Homo sapiens,,Intermediate,6663,,F,9606.0,,A549,,80682
6305,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,BAO_0000219,,Homo sapiens,,Intermediate,6663,,F,9606.0,,A549,,80682
6306,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,BAO_0000219,,Homo sapiens,,Intermediate,6663,,F,9606.0,,A549,,80682
6307,1,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,BAO_0000219,,Homo sapiens,,Intermediate,6663,,F,9606.0,,A549,,80682
6308,1,The compound was evaluated for its cytotoxic potency against A-549 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,3983,,F,9606.0,,A549,,80682
6309,1,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,BAO_0000219,,Homo sapiens,,Expert,11141,,F,9606.0,,A549,,80682
6310,1,Cytotoxic activity of compound against A-549 tumor cell line.,,BAO_0000219,,Homo sapiens,,Intermediate,5076,,F,9606.0,,A549,,80682
6311,1,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,BAO_0000219,,Homo sapiens,,Intermediate,3311,,F,9606.0,,A549,,80682
6312,1,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,BAO_0000219,,Homo sapiens,,Intermediate,3311,,F,9606.0,,A549,,80682
6313,1,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,BAO_0000219,,Homo sapiens,,Intermediate,3311,,F,9606.0,,A549,,80682
6314,1,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,5076,,F,9606.0,,A549,,80682
6315,1,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,BAO_0000219,,Homo sapiens,,Intermediate,4150,,F,9606.0,,A549,,80682
6316,1,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,BAO_0000219,,Homo sapiens,,Expert,2150,,F,9606.0,,A549,,80682
6317,1,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,BAO_0000219,,Homo sapiens,,Intermediate,4644,,F,9606.0,,A549,,80682
6318,1,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,BAO_0000219,,Homo sapiens,,Intermediate,263,,F,9606.0,,A549,,80682
6319,1,Cytotoxic concentration against A-549 tumor cells.,,BAO_0000219,,Homo sapiens,,Intermediate,11333,,F,9606.0,,A549,,80682
6320,1,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,BAO_0000219,,Homo sapiens,,Intermediate,11333,,F,9606.0,,A549,,80682
6321,1,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,BAO_0000219,,Homo sapiens,,Intermediate,15895,,F,9606.0,,A549,,80682
6322,1,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,BAO_0000218,,Acinetobacter baumannii,,Expert,16677,,F,470.0,,,,50191
6323,1,Activity against Acinetobacter calcoaceticus (AC54),,BAO_0000218,,Acinetobacter calcoaceticus,,Intermediate,10624,,F,471.0,,,,50192
6324,1,In vitro antifungal activity against Aspergillus flavus CM74,,BAO_0000218,,Aspergillus flavus,,Expert,16717,,F,5059.0,,,,50274
6325,1,In vitro antifungal activity against Aspergillus flavus CM74,,BAO_0000218,,Aspergillus flavus,,Expert,16717,,F,5059.0,,,,50274
6326,1,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,BAO_0000218,,Aspergillus fumigatus,,Intermediate,5513,,F,746128.0,,,,50416
6327,1,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,BAO_0000218,,Aspergillus fumigatus,,Intermediate,15962,,F,746128.0,,,,50416
6328,1,Antimicrobial activity against Aspergillus fumigatus (MIC),,BAO_0000218,,Aspergillus fumigatus,,Intermediate,15962,,F,746128.0,,,,50416
6329,1,Antimicrobial activity against Aspergillus fumigatus (MIC),,BAO_0000218,,Aspergillus fumigatus,,Intermediate,15962,,F,746128.0,,,,50416
6330,1,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,BAO_0000218,,Aspergillus fumigatus,,Intermediate,15962,,F,746128.0,,,,50416
6331,1,In vitro antifungal activity against Aspergillus fumigatus 48238E,,BAO_0000218,,Aspergillus fumigatus,,Expert,16717,,F,746128.0,,,,50416
6332,1,In vitro antifungal activity against Aspergillus fumigatus 48238E,,BAO_0000218,,Aspergillus fumigatus,,Expert,16717,,F,746128.0,,,,50416
6333,1,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,BAO_0000218,,Actinomyces naeslundii,,Intermediate,8117,,F,1655.0,,,,50296
6334,1,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,BAO_0000218,,Actinomyces viscosus,,Intermediate,8117,,F,1656.0,,,,50366
6335,1,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,BAO_0000218,,Acanthocheilonema viteae,,Intermediate,15472,,F,6277.0,,,,50535
6336,1,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,BAO_0000218,,Acanthocheilonema viteae,,Intermediate,15472,,F,6277.0,,,,50535
6337,1,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,BAO_0000218,,Aggregatibacter actinomycetemcomitans,,Intermediate,16443,,F,714.0,,,,50169
6338,1,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,BAO_0000218,,Aggregatibacter actinomycetemcomitans,,Intermediate,16443,,F,714.0,,,,50169
6339,1,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,BAO_0000218,,Aggregatibacter actinomycetemcomitans,,Intermediate,16443,,F,714.0,,,,50169
6340,1,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,F,9606.0,,A549,,80682
6341,1,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,F,9606.0,,A549,,80682
6342,1,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,16381,,F,9606.0,,A549,,80682
6343,1,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,16381,,F,9606.0,,A549,,80682
6344,1,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,BAO_0000219,,Homo sapiens,,Intermediate,16381,,F,9606.0,,A549,,80682
6345,1,GI values against A549 cells (lung cancer),,BAO_0000219,,Homo sapiens,,Intermediate,16381,,F,9606.0,,A549,,80682
6346,1,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,BAO_0000219,,Homo sapiens,,Intermediate,17206,,F,9606.0,,A549,,80682
6347,1,Inhibitory activity against A549 human adenocarcinoma,,BAO_0000219,,Homo sapiens,,Intermediate,16325,,F,9606.0,,A549,,80682
6348,1,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,BAO_0000218,,Homo sapiens,,Intermediate,10708,,F,9606.0,,A549,,80682
6349,1,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,BAO_0000218,,Homo sapiens,,Intermediate,10708,,F,9606.0,,A549,,80682
6350,1,Inhibitory activity against A549 lung adenocarcinoma cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17376,,F,9606.0,,A549,,80682
6351,1,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,BAO_0000219,,Homo sapiens,,Intermediate,17376,,F,9606.0,,A549,,80682
6352,1,Cytotoxicity against human A549 lung cells,,BAO_0000219,,Homo sapiens,,Intermediate,17488,,F,9606.0,,A549,,80682
6353,1,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,BAO_0000218,,Homo sapiens,,Intermediate,17404,,F,9606.0,,A549,,80682
6354,1,Growth inhibition of A549 (human lung carcinoma) cell line.,,BAO_0000219,,Homo sapiens,,Expert,10958,,F,9606.0,,A549,,80682
6355,1,Effective dose required for inhibitory activity against A549 human tumor cell line.,,BAO_0000219,,Homo sapiens,,Expert,17099,,F,9606.0,,A549,,80682
6356,1,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,BAO_0000219,,Homo sapiens,,Intermediate,17099,,F,9606.0,,A549,,80682
6357,1,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,BAO_0000219,,Homo sapiens,,Intermediate,4096,,F,9606.0,,A549,,80682
6358,1,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,BAO_0000219,,Homo sapiens,,Expert,4096,,F,9606.0,,A549,,80682
6359,1,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,BAO_0000219,,Homo sapiens,,Intermediate,4096,,F,9606.0,,A549,,80682
6360,1,In vitro inhibitory activity against A549 tumor cell culture,,BAO_0000219,,Homo sapiens,,Intermediate,2525,,F,9606.0,,A549,,80682
6361,1,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,BAO_0000219,,Homo sapiens,,Intermediate,2525,,F,9606.0,,A549,,80682
6362,1,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,BAO_0000219,,Homo sapiens,,Intermediate,5302,,F,9606.0,,A549,,80682
6363,1,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,BAO_0000219,,Homo sapiens,,Intermediate,16325,,F,9606.0,,A549,,80682
6364,1,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,16939,,F,9606.0,,A549,,80682
6365,1,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,17229,,F,9606.0,,A549,,80682
6366,1,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,BAO_0000219,,Homo sapiens,,Intermediate,17380,,F,9606.0,,A549,,80682
6367,1,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,BAO_0000219,,Homo sapiens,,Intermediate,17380,,F,9606.0,,A549,,80682
6368,1,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,BAO_0000219,,Homo sapiens,,Intermediate,1903,,F,9606.0,,A549,,80682
6369,1,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,BAO_0000219,,Homo sapiens,,Intermediate,3838,,F,9606.0,,A549,,80682
6370,1,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,14696,,F,9606.0,,A549,,80682
6371,1,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,BAO_0000219,,Homo sapiens,,Intermediate,3838,,F,9606.0,,A549,,80682
6372,1,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,BAO_0000219,,Homo sapiens,,Intermediate,1522,,F,9606.0,,A549,,80682
6373,1,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,12400,,F,9606.0,,A549,,80682
6374,1,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,14696,,F,9606.0,,A549,,80682
6375,1,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,BAO_0000219,,Homo sapiens,,Intermediate,14769,,F,9606.0,,A549,,80682
6376,1,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,BAO_0000219,,Homo sapiens,,Intermediate,14696,,F,9606.0,,A549,,80682
6377,1,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,1888,,F,9606.0,,A549,,80682
6378,1,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,BAO_0000219,,Homo sapiens,,Intermediate,12016,,F,9606.0,,A549,,80682
6379,1,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,BAO_0000219,,Homo sapiens,,Intermediate,6058,,F,9606.0,,A549,,80682
6380,1,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17708,,F,9606.0,,A549,,80682
6381,1,Antitumor activity against A549/ATCC cell line,,BAO_0000219,,Homo sapiens,,Intermediate,12301,,F,9606.0,,A549,,80682
6382,1,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,BAO_0000219,,Homo sapiens,,Intermediate,11970,,F,9606.0,,A549,,80682
6383,1,In vitro cytotoxicity against A549/ATCC cell line.,,BAO_0000219,,Homo sapiens,,Expert,11818,,F,9606.0,,A549,,80682
6384,1,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,BAO_0000219,,Homo sapiens,,Intermediate,12400,,F,9606.0,,A549,,80682
6385,1,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,3381,,F,9606.0,,A549,,80682
6386,1,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17376,,F,9606.0,,A549,,80682
6387,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,BAO_0000219,,Homo sapiens,,Intermediate,10708,,F,9606.0,,A549,,80682
6388,1,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,BAO_0000219,,Homo sapiens,,Autocuration,2964,,F,9606.0,,,,22226
6389,1,Compound was tested for oral bioavailability in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5005,In vivo,A,9615.0,,,,22224
6390,1,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6229,In vivo,A,9615.0,,,,50588
6391,1,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6229,In vivo,A,9615.0,,,,50588
6392,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5374,In vivo,A,9615.0,,,,50588
6393,1,Compound was tested for the oral bioavailability in dog; No availability,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5374,In vivo,A,9615.0,,,,50588
6394,1,Oral bioavailability in dog (dose 5 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6265,In vivo,A,9615.0,,,,50588
6395,1,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5654,In vivo,A,9615.0,,,,50588
6396,1,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5654,In vivo,A,9615.0,,,,50588
6397,1,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,16456,In vivo,A,9615.0,,,,50588
6398,1,Oral bioavailability in dog (dose 5 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5302,In vivo,A,9615.0,,,,50588
6399,1,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),,BAO_0000218,,Canis lupus familiaris,,Intermediate,3624,In vivo,A,9615.0,,,,50588
6400,1,Oral bioavailability of active FTIs in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,A,9615.0,,,,50588
6401,1,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5802,In vivo,A,9615.0,,,,50588
6402,1,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Expert,3598,In vivo,A,9615.0,,,,50588
6403,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17839,In vivo,A,9615.0,,,,50588
6404,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6762,In vivo,A,9615.0,,,,50588
6405,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6821,In vivo,A,9615.0,,,,50588
6406,1,Oral bioavailability of compound was determined in dog; Not tested,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6821,In vivo,A,9615.0,,,,50588
6407,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5210,In vivo,A,9615.0,,,,50588
6408,1,Oral bioavailability (10 mg/kg) was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,In vivo,A,9615.0,,,,50588
6409,1,Oral bioavailability,,BAO_0000218,,Canis lupus familiaris,,Intermediate,761,In vivo,A,9615.0,,,,50588
6410,1,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),,BAO_0000218,,Canis lupus familiaris,,Intermediate,761,In vivo,A,9615.0,,,,50588
6411,1,Oral bioavailability administered in solution in rats,,BAO_0000218,,Canis lupus familiaris,,Intermediate,761,In vivo,A,9615.0,,,,50588
6412,1,Oral bioavailability after 30 mg/kg po dose in Dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,In vivo,A,9615.0,,,,50588
6413,1,Oral bioavailability at a dose of 1 mg/kg in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5474,In vivo,A,9615.0,,,,50588
6414,1,Oral bioavailability in dog (dose 1 mg/kg p.o.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6535,In vivo,A,9615.0,,,,50588
6415,1,Oral bioavailability in Dog; ND = not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6535,In vivo,A,9615.0,,,,50588
6416,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3352,In vivo,A,9615.0,,,,50588
6417,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6168,In vivo,A,9615.0,,,,50588
6418,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5988,In vivo,A,9615.0,,,,50588
6419,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4942,In vivo,A,9615.0,,,,50588
6420,1,Oral bioavailability in dogs; No data,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4942,In vivo,A,9615.0,,,,50588
6421,1,Oral bioavailability measured in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14541,In vivo,A,9615.0,,,,50588
6422,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4449,In vivo,A,9615.0,,,,50588
6423,1,Oral bioavailability was calculated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6057,In vivo,A,9615.0,,,,50588
6424,1,Oral bioavailability after 0.3 mg/kg po administration in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5600,In vivo,A,9615.0,,,,50588
6425,1,Oral bioavailability in dog (i.v. dosing),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5542,In vivo,A,9615.0,,,,50588
6426,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5542,In vivo,A,9615.0,,,,50588
6427,1,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5546,In vivo,A,9615.0,,,,50588
6428,1,Oral bioavailability in Beagle dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4514,In vivo,A,9615.0,,,,50588
6429,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3624,In vivo,A,9615.0,,,,50588
6430,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3854,In vivo,A,9615.0,,,,50588
6431,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5836,In vivo,A,9615.0,,,,50588
6432,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5940,In vivo,A,9615.0,,,,50588
6433,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6168,In vivo,A,9615.0,,,,50588
6434,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,In vivo,A,9615.0,,,,50588
6435,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6251,In vivo,A,9615.0,,,,50588
6436,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6448,In vivo,A,9615.0,,,,50588
6437,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6647,In vivo,A,9615.0,,,,50588
6438,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5940,In vivo,A,9615.0,,,,50588
6439,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,933,In vivo,A,9615.0,,,,50588
6440,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5210,In vivo,A,9615.0,,,,50588
6441,1,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6642,In vivo,A,9615.0,,,,50588
6442,1,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6641,In vivo,A,9615.0,,,,50588
6443,1,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6642,In vivo,A,9615.0,,,,50588
6444,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5472,In vivo,A,9615.0,,,,50588
6445,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5985,In vivo,A,9615.0,,,,50588
6446,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15660,In vivo,A,9615.0,,,,50588
6447,1,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5530,In vivo,A,9615.0,,,,50588
6448,1,Oral bioavailability in dog (dose 1 mg/kg i.v.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5530,In vivo,A,9615.0,,,,50588
6449,1,Oral bioavailability (F) in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6305,In vivo,A,9615.0,,,,50588
6450,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5210,In vivo,A,9615.0,,,,50588
6451,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5238,In vivo,A,9615.0,,,,50588
6452,1,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,In vivo,A,9615.0,,,,50588
6453,1,Oral bioavailability after peroral administration at 5 mpk in Dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,In vivo,A,9615.0,,,,50588
6454,1,Oral bioavailability in dog (dose 5 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,In vivo,A,9615.0,,,,50588
6455,1,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6084,In vivo,A,9615.0,,,,50588
6456,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6457,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6458,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,Liver,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6459,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6460,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,Liver,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6461,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6462,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6463,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,Lung,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6464,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6465,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,Lung,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6466,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6467,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6468,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6469,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6470,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6471,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6472,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6473,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,Spleen,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6474,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6475,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,Spleen,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6476,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6477,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6478,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6479,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6480,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6481,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6482,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6483,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6484,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6485,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6486,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6487,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6488,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,Heart,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6489,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6490,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,Heart,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6491,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6492,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6493,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,Liver,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6494,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6495,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,Liver,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6496,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6497,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6498,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,Lung,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6499,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6500,1,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,BAO_0000218,,aeinetobacter anitrotap,,Intermediate,12269,,F,107673.0,,,,50067
6501,1,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,BAO_0000218,,Acinetobacter calcoaceticus subsp. anitratus,,Intermediate,12269,,F,107673.0,,,,50067
6502,1,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,BAO_0000218,,Acinetobacter calcoaceticus subsp. anitratus,,Intermediate,12269,,F,107673.0,,,,50067
6503,1,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,BAO_0000218,,aeinetobacter anitrotap,,Intermediate,12269,,F,107673.0,,,,50067
6504,1,Activity against Acinetobacter calcoaceticus (AC54),,BAO_0000218,,Acinetobacter calcoaceticus,,Intermediate,10624,,F,471.0,,,,50192
6505,1,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,BAO_0000218,,Anolis carolinensis,,Intermediate,17216,,F,28377.0,,,,50714
6506,1,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,BAO_0000218,,Anolis carolinensis,,Intermediate,17216,,F,28377.0,,,,50714
6507,1,Chlorohexidine coefficient for Actinomyces naeslundii 631,,BAO_0000218,,Actinomyces naeslundii,,Intermediate,9560,,F,1655.0,,,,50296
6508,1,Chlorohexidine coefficient for Actinomyces naeslundii B74,,BAO_0000218,,Actinomyces naeslundii,,Intermediate,9560,,F,1655.0,,,,50296
6509,1,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,BAO_0000218,,Actinomyces naeslundii,,Intermediate,9560,,F,1655.0,,,,50296
6510,1,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,BAO_0000218,,Actinomyces naeslundii,,Intermediate,9560,,F,1655.0,,,,50296
6511,1,Plaque bactericidal index against Actinomyces naeslundii 631,,BAO_0000218,,Actinomyces naeslundii,,Intermediate,9560,,F,1655.0,,,,50296
6512,1,Plaque bactericidal index against Actinomyces naeslundii N/9,,BAO_0000218,,Actinomyces naeslundii,,Intermediate,9560,,F,1655.0,,,,50296
6513,1,Plaque bactericidal index against Actinomyces naeslundii B74,,BAO_0000218,,Actinomyces naeslundii,,Intermediate,9560,,F,1655.0,,,,50296
6514,1,Plaque bactericidal index against Actinomyces naeslundii N/3,,BAO_0000218,,Actinomyces naeslundii,,Intermediate,9560,,F,1655.0,,,,50296
6515,1,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,BAO_0000218,,Artemia salina,,Intermediate,114,,F,85549.0,,,,50056
6516,1,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,BAO_0000218,,Artemia salina,,Intermediate,114,,F,85549.0,,,,50056
6517,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,BAO_0000218,,Ascaris suum,,Intermediate,10841,,F,6253.0,,,,50532
6518,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,BAO_0000218,,Ascaris suum,,Intermediate,10841,,F,6253.0,,,,50532
6519,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,BAO_0000218,,Ascaris suum,,Intermediate,10841,,F,6253.0,,,,50532
6520,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,BAO_0000218,,Ascaris suum,,Intermediate,10841,,F,6253.0,,,,50532
6521,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,BAO_0000218,,Ascaris suum,,Intermediate,10841,,F,6253.0,,,,50532
6522,1,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,BAO_0000218,,Ascaris suum,,Intermediate,10841,,F,6253.0,,,,50532
6523,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,BAO_0000218,,Ascaris suum,,Intermediate,10841,,F,6253.0,,,,50532
6524,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,BAO_0000218,,Ascaris suum,,Intermediate,10841,,F,6253.0,,,,50532
6525,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,BAO_0000218,,Ascaris suum,,Intermediate,10841,,F,6253.0,,,,50532
6526,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,BAO_0000218,,Ascaris suum,,Intermediate,10841,,F,6253.0,,,,50532
6527,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,BAO_0000218,,Ascaris suum,,Intermediate,10841,,F,6253.0,,,,50532
6528,1,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,BAO_0000218,,Ascaris suum,,Intermediate,10841,,F,6253.0,,,,50532
6529,1,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,BAO_0000218,,Actinomyces viscosus,,Intermediate,8117,,F,1656.0,,,,50366
6530,1,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,BAO_0000218,,Actinomyces viscosus,,Intermediate,8117,,F,1656.0,,,,50366
6531,1,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,BAO_0000218,,Actinomyces viscosus,,Intermediate,9560,,F,1656.0,,,,50366
6532,1,Chlorohexidine coefficient for Actinomyces viscosus M-100,,BAO_0000218,,Actinomyces viscosus,,Expert,9560,,F,1656.0,,,,50366
6533,1,Chlorohexidine coefficient for Actinomyces viscosus M-626,,BAO_0000218,,Actinomyces viscosus,,Intermediate,9560,,F,1656.0,,,,50366
6534,1,Chlorohexidine coefficient for Actinomyces viscosus T14V,,BAO_0000218,,Actinomyces viscosus,,Intermediate,9560,,F,1656.0,,,,50366
6535,1,Plaque bactericidal index against Actinomyces viscosus 8A06,,BAO_0000218,,Actinomyces viscosus,,Intermediate,9560,,F,1656.0,,,,50366
6536,1,Plaque bactericidal index against Actinomyces viscosus M-100,,BAO_0000218,,Actinomyces viscosus,,Intermediate,9560,,F,1656.0,,,,50366
6537,1,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,BAO_0000218,,Actinomyces viscosus,,Expert,9560,,F,1656.0,,,,50366
6538,1,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,BAO_0000218,,Actinomyces viscosus,,Intermediate,9560,,F,1656.0,,,,50366
6539,1,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,BAO_0000218,,Actinomyces viscosus,,Intermediate,9560,,F,1656.0,,,,50366
6540,1,Plaque bactericidal index against Actinomyces viscosus 626,,BAO_0000218,,Actinomyces viscosus,,Intermediate,9560,,F,1656.0,,,,50366
6541,1,Plaque bactericidal index against Actinomyces viscosus T14V,,BAO_0000218,,Actinomyces viscosus,,Intermediate,9560,,F,1656.0,,,,50366
6542,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,BAO_0000218,,Acanthocheilonema viteae,,Intermediate,10986,,F,6277.0,,,,50535
6543,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,BAO_0000218,,Acanthocheilonema viteae,,Intermediate,10986,,F,6277.0,,,,50535
6544,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,BAO_0000218,,Acanthocheilonema viteae,,Intermediate,10986,,F,6277.0,,,,50535
6545,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,BAO_0000218,,Acanthocheilonema viteae,,Intermediate,10986,,F,6277.0,,,,50535
6546,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,BAO_0000218,,Acanthocheilonema viteae,,Intermediate,10986,,F,6277.0,,,,50535
6547,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,BAO_0000219,,Homo sapiens,,Intermediate,10708,,F,9606.0,,A673,,80023
6548,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,BAO_0000219,,Homo sapiens,,Intermediate,10708,,F,9606.0,,A704,,80661
6549,1,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,BAO_0000219,,Rattus norvegicus,,Autocuration,416,,F,10116.0,,,,22226
6550,1,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,BAO_0000219,,Mus musculus,,Intermediate,14354,,F,10090.0,,A9,,80024
6551,1,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,BAO_0000219,,Mus musculus,,Intermediate,14354,,F,10090.0,,A9,,80024
6552,1,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,BAO_0000219,,Homo sapiens,,Intermediate,5116,,F,9606.0,,A9,,80024
6553,1,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,5116,,F,9606.0,,A9,,80024
6554,1,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,15694,,F,9606.0,,Human ovarian carcinoma cell line,,81037
6555,1,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,BAO_0000219,,Mus musculus,,Expert,13038,,F,10090.0,,A9,,80024
6556,1,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,BAO_0000219,,Mus musculus,,Expert,13038,,F,10090.0,,A9,,80024
6557,1,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,BAO_0000219,,Mus musculus,,Expert,10923,,F,10090.0,,A9,,80024
6558,1,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,BAO_0000219,,Mus musculus,,Intermediate,10923,,F,10090.0,,A9,,80024
6559,1,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,BAO_0000219,,Mus musculus,,Intermediate,10923,,F,10090.0,,A9,,80024
6560,1,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,BAO_0000019,,,,Expert,10923,,F,,,,,10649
6561,1,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,BAO_0000219,,Mus musculus,,Intermediate,10923,,F,10090.0,,A9,,80024
6562,1,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,BAO_0000219,,Mus musculus,,Intermediate,10923,,F,10090.0,,A9,,80024
6563,1,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,BAO_0000219,,Cricetulus griseus,,Intermediate,8158,,F,10029.0,,AA6,,80663
6564,1,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,BAO_0000219,,Homo sapiens,,Autocuration,15494,,F,9606.0,,,,22226
6565,1,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,BAO_0000219,,Homo sapiens,,Autocuration,15494,,F,9606.0,,,,22226
6566,1,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,BAO_0000219,,Homo sapiens,,Intermediate,12348,,F,9606.0,,AA5,,80662
6567,1,Cytotoxicity was measured against AA5/HIV-1(IIIB),,BAO_0000219,,Homo sapiens,,Intermediate,12348,,F,9606.0,,AA5,,80662
6568,1,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,BAO_0000219,,Homo sapiens,,Intermediate,2726,,F,9606.0,,AA5,,80662
6569,1,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,BAO_0000219,,Homo sapiens,,Intermediate,2726,,F,9606.0,,U-937,,80566
6570,1,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,BAO_0000219,,Cricetulus griseus,,Intermediate,10747,,F,10029.0,,UV4,,80578
6571,1,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,BAO_0000219,,Cricetulus griseus,,Expert,11005,,F,10029.0,,CHO-AA8,,80089
6572,1,Average intracellular compound concentration when the hypoxic SER=1.6,,BAO_0000219,,Cricetulus griseus,,Intermediate,12687,,F,10029.0,,CHO-AA8,,80089
6573,1,Average intracellular compound concentration when the hypoxic SER=1.6.,,BAO_0000219,,Cricetulus griseus,,Intermediate,12687,,F,10029.0,,CHO-AA8,,80089
6574,1,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,BAO_0000219,,Cricetulus griseus,,Intermediate,12687,,F,10029.0,,CHO-AA8,,80089
6575,1,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,BAO_0000219,,Cricetulus griseus,,Intermediate,12687,,F,10029.0,,CHO-AA8,,80089
6576,1,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,BAO_0000219,,Cricetulus griseus,,Intermediate,12687,,F,10029.0,,CHO-AA8,,80089
6577,1,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,BAO_0000219,,Cricetulus griseus,,Intermediate,13436,,F,10029.0,,CHO-AA8,,80089
6578,1,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,BAO_0000219,,Cricetulus griseus,,Intermediate,13435,,F,10029.0,,CHO-AA8,,80089
6579,1,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,BAO_0000219,,Cricetulus griseus,,Intermediate,13302,,F,10029.0,,CHO-AA8,,80089
6580,1,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,BAO_0000219,,Cricetulus griseus,,Intermediate,12687,,F,10029.0,,CHO-AA8,,80089
6581,1,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,BAO_0000219,,Cricetulus griseus,,Intermediate,12687,,A,10029.0,,CHO-AA8,,80089
6582,1,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,BAO_0000219,,Cricetulus griseus,,Intermediate,12687,,A,10029.0,,CHO-AA8,,80089
6583,1,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,BAO_0000219,,Cricetulus griseus,,Expert,12878,,A,10029.0,,CHO-AA8,,80089
6584,1,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,BAO_0000219,,Cricetulus griseus,,Intermediate,12878,,A,10029.0,,CHO-AA8,,80089
6585,1,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,BAO_0000219,,Cricetulus griseus,,Expert,14367,,F,10029.0,,CHO-AA8,,80089
6586,1,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,BAO_0000219,,Cricetulus griseus,,Intermediate,14367,,F,10029.0,,CHO-AA8,,80089
6587,1,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,BAO_0000219,,hampster,,Expert,12398,,F,36483.0,,CHO-AA8,,80089
6588,1,Aerobic growth inhibition in Chinese hamster cell line AA8,,BAO_0000219,,Cricetulus griseus,,Expert,12878,,F,10029.0,,CHO-AA8,,80089
6589,1,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,BAO_0000219,,Cricetulus griseus,,Expert,13820,,F,10029.0,,CHO-AA8,,80089
6590,1,Inhibition of growth under aerobic conditions in AA8 cells,,BAO_0000219,,Cricetulus griseus,,Expert,13436,,F,10029.0,,CHO-AA8,,80089
6591,1,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6084,In vivo,A,9615.0,,,,50588
6592,1,Oral bioavailability in dog at 10 mg/kg of the compound,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5711,In vivo,A,9615.0,,,,50588
6593,1,Oral bioavailability in dog (dose 5 uM/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,4353,In vivo,A,9615.0,,,,50588
6594,1,Oral bioavailability in dog (dose 5 uM/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,4353,In vivo,A,9615.0,,,,50588
6595,1,Oral bioavailability in dog (mongrel),,BAO_0000218,,Canis lupus familiaris,,Intermediate,17800,In vivo,A,9615.0,,,,50588
6596,1,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,3994,In vivo,A,9615.0,,,,50588
6597,1,Oral bioavailability in dog (dose 10 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,3994,In vivo,F,9615.0,,,,50588
6598,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5145,In vivo,A,9615.0,,,,50588
6599,1,Bioavailability in dog (dose 1 mg/kg i.v.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,A,9615.0,,,,50588
6600,1,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,A,9615.0,,,,50588
6601,1,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5983,In vivo,A,9615.0,,,,50588
6602,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4273,In vivo,A,9615.0,,,,50588
6603,1,Bioavailability in dog (dose 3-10 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,12500,In vivo,A,9615.0,,,,50588
6604,1,The compound was tested for bioavailability of compound in plasma of dog; Complete,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,12500,In vivo,A,9615.0,,,,50588
6605,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3639,In vivo,A,9615.0,,,,50588
6606,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3880,In vivo,A,9615.0,,,,50588
6607,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4838,In vivo,A,9615.0,,,,50588
6608,1,oral bioavailability was measured in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15600,In vivo,A,9615.0,,,,50588
6609,1,Compound was tested for plasma protein binding in dog; Not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17248,,A,9615.0,,,,50588
6610,1,Compound was tested for plasma protein binding of dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17248,,A,9615.0,,,,50588
6611,1,Compound was tested for plasma protein binding of dog; Not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17248,,A,9615.0,,,,50588
6612,1,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17443,,A,9615.0,,,,50588
6613,1,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4186,In vivo,A,9615.0,,,,50588
6614,1,Half life was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3749,,A,9615.0,,,,50588
6615,1,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3249,In vivo,A,9615.0,,,,50588
6616,1,Half life was evaluated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3022,,A,9615.0,,,,50588
6617,1,Half life was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3749,,A,9615.0,,,,50588
6618,1,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),,BAO_0000218,,Canis lupus familiaris,,Intermediate,2517,In vivo,A,9615.0,,,,50588
6619,1,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),Heart,BAO_0000218,,Canis lupus familiaris,,Intermediate,2517,In vivo,A,9615.0,,,,50588
6620,1,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),Kidney,BAO_0000218,,Canis lupus familiaris,,Intermediate,2517,In vivo,A,9615.0,,,,50588
6621,1,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),Liver,BAO_0000218,,Canis lupus familiaris,,Intermediate,2517,In vivo,A,9615.0,,,,50588
6622,1,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),Lung,BAO_0000218,,Canis lupus familiaris,,Intermediate,2517,In vivo,A,9615.0,,,,50588
6623,1,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),Spleen,BAO_0000218,,Canis lupus familiaris,,Intermediate,2517,In vivo,A,9615.0,,,,50588
6624,1,LogP in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3639,,A,9615.0,,,,50588
6625,1,Partition coefficient (logP),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,,A,9615.0,,,,50588
6626,1,Partition coefficient in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,,A,9615.0,,,,50588
6627,1,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17764,In vivo,A,9615.0,,,,50588
6628,1,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,4809,In vivo,A,9615.0,,,,50588
6629,1,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5600,,A,9615.0,,,,50588
6630,1,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,BAO_0000218,,Canis lupus familiaris,,Intermediate,14294,,A,9615.0,,,,50588
6631,1,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,BAO_0000218,,Canis lupus familiaris,,Intermediate,14294,,A,9615.0,,,,50588
6632,1,Metabolism of compound in dog S9 microsomes; Trace,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14294,,A,9615.0,,,,50588
6633,1,In vitro metabolic potential in dog liver microsomes,Liver,BAO_0000218,,Canis lupus familiaris,,Intermediate,6251,,A,9615.0,,,,50588
6634,1,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3748,In vivo,A,9615.0,,,,50588
6635,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2713,In vivo,A,9615.0,,,,50588
6636,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6512,In vivo,A,9615.0,,,,50588
6637,1,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6679,In vivo,A,9615.0,,,,50588
6638,1,The compound was tested for bioavailability in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3749,In vivo,A,9615.0,,,,50588
6639,1,The compound was tested for oral bioavailability in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3749,In vivo,A,9615.0,,,,50588
6640,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6742,In vivo,A,9615.0,,,,50588
6641,1,Compound was tested for percent protein binding (PB) in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,,A,9615.0,,,,50588
6642,1,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6874,,A,9615.0,,,,50588
6643,1,Compound was evaluated for plasma clearance.,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,2877,In vivo,A,9615.0,,,,50588
6644,1,The compound was tested for plasma clearance in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,12500,In vivo,A,9615.0,,,,50588
6645,1,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,12500,In vivo,A,9615.0,,,,50588
6646,1,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4709,,A,9615.0,,,,50588
6647,1,In vitro relative rate of metabolism was determined in dog liver microsomes,Liver,BAO_0000218,,Canis lupus familiaris,,Intermediate,5542,,A,9615.0,,,,50588
6648,1,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17594,In vivo,A,9615.0,,,,50588
6649,1,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2652,In vivo,A,9615.0,,,,50588
6650,1,Half life after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17764,In vivo,A,9615.0,,,,50588
6651,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,Lung,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6652,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6653,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6654,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6655,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6656,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6657,1,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6658,1,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,BAO_0000218,,Mus musculus,,Intermediate,6599,,A,10090.0,,CCRF S-180,,50594
6659,1,C2 in brain of mice at the oral dose of 50 mg/kg,Brain,BAO_0000218,,Mus musculus,,Intermediate,17641,,A,10090.0,,,,50594
6660,1,C2 in kidney of mice at the oral dose of 50 mg/kg,Kidney,BAO_0000218,,Mus musculus,,Intermediate,17641,,A,10090.0,,,,50594
6661,1,C2 in liver of mice at the oral dose of 50 mg/kg,Liver,BAO_0000218,,Mus musculus,,Intermediate,17641,,A,10090.0,,,,50594
6662,1,C2 in lungs of mice at the oral dose of 50 mg/kg,Lung,BAO_0000218,,Mus musculus,,Intermediate,17641,,A,10090.0,,,,50594
6663,1,C2 in spleen of mice at the oral dose of 50 mg/kg,Spleen,BAO_0000218,,Mus musculus,,Intermediate,17641,,A,10090.0,,,,50594
6664,1,Plasma clearance in mouse,,BAO_0000218,,Mus musculus,,Intermediate,17852,In vivo,A,10090.0,,,,50594
6665,1,Clearance of compound after intravenous administration in mice at 24 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,A,10090.0,,,,50594
6666,1,Clearance from mouse blood following i.v. administration of 10 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,17837,In vivo,A,10090.0,,,,50594
6667,1,Clearance was evaluated in mice after intravenous administration,,BAO_0000218,,Mus musculus,,Intermediate,2675,In vivo,A,10090.0,,,,50594
6668,1,Clearance was evaluated in mice after oral administration,,BAO_0000218,,Mus musculus,,Intermediate,2675,In vivo,A,10090.0,,,,50594
6669,1,Pharmacokinetic property (Plasma clearance) was measured in mouse,,BAO_0000218,,Mus musculus,,Intermediate,4239,In vivo,A,10090.0,,,,50594
6670,1,Plasma clearance of compound was determined at 40 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,In vivo,A,10090.0,,,,50594
6671,1,Plasma clearance of at 24 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,In vivo,A,10090.0,,,,50594
6672,1,Plasma clearance at 24 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,In vivo,A,10090.0,,,,50594
6673,1,Plasma clearance at 5 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,In vivo,A,10090.0,,,,50594
6674,1,Plasma clearance in mice,,BAO_0000218,,Mus musculus,,Intermediate,5727,In vivo,A,10090.0,,,,50594
6675,1,Plasma clearance value upon iv administration in mouse,,BAO_0000218,,Mus musculus,,Intermediate,2862,In vivo,A,10090.0,,,,50594
6676,1,Total plasma clearance in mice,Plasma,BAO_0000218,,Mus musculus,,Intermediate,5980,In vivo,A,10090.0,,,,50594
6677,1,Clearance in mouse,,BAO_0000218,,Mus musculus,,Intermediate,17592,In vivo,A,10090.0,,,,50594
6678,1,Clearance value was determined,,BAO_0000218,,Mus musculus,,Intermediate,17718,In vivo,A,10090.0,,,,50594
6679,1,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,A,10090.0,,,,50594
6680,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Intermediate,17384,,P,,,,,22229
6681,1,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,6062,In vivo,A,10090.0,,,,50594
6682,1,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,17734,In vivo,A,10090.0,,,,50594
6683,1,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,BAO_0000218,,Mus musculus,,Intermediate,6348,In vivo,A,10090.0,,,,50594
6684,1,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,5969,In vivo,A,10090.0,,,,50594
6685,1,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,5969,In vivo,A,10090.0,,,,50594
6686,1,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,BAO_0000218,,Mus musculus,,Intermediate,5969,In vivo,A,10090.0,,,,50594
6687,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,A,10090.0,,,,50594
6688,1,Cmax after oral administration at 30 mg/kg in ICR mouse,,BAO_0000218,,Mus musculus,,Intermediate,5781,In vivo,A,10090.0,,,,50594
6689,1,Cmax after peroral administration in mice at 2.4 uM/kg,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,A,10090.0,,,,50594
6690,1,Cmax in brain of mice at the oral dose of 50 mg/kg,Brain,BAO_0000218,,Mus musculus,,Intermediate,17641,In vivo,A,10090.0,,,,50594
6691,1,Cmax in kidney of mice at the oral dose of 50 mg/kg,Kidney,BAO_0000218,,Mus musculus,,Intermediate,17641,In vivo,A,10090.0,,,,50594
6692,1,Cmax in liver of mice at the oral dose of 50 mg/kg,Liver,BAO_0000218,,Mus musculus,,Intermediate,17641,In vivo,A,10090.0,,,,50594
6693,1,Cmax in lungs of mice at the oral dose of 50 mg/kg,Lung,BAO_0000218,,Mus musculus,,Intermediate,17641,In vivo,A,10090.0,,,,50594
6694,1,Cmax in mice at 18 uM/kg i.p. administration,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,F,10090.0,,,,50594
6695,1,Cmax in mice at 23 uM/kg i.v. administration,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,F,10090.0,,,,50594
6696,1,Cmax in mice at 24 uM/kg i.p. administration,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,F,10090.0,,,,50594
6697,1,Cmax in mice at 25 uM/kg i.p. administration,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,F,10090.0,,,,50594
6698,1,Cmax in mice at 26 uM/kg i.p. administration,,BAO_0000218,,Mus musculus,,Intermediate,17764,In vivo,F,10090.0,,,,50594
6699,1,Cmax in spleen of mice at the oral dose of 50 mg/kg,Spleen,BAO_0000218,,Mus musculus,,Intermediate,17641,In vivo,A,10090.0,,,,50594
6700,1,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,A,10090.0,,,,50594
6701,1,Cmax value at a dose of 10 mg/kg peroral administration in mice.,,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,A,10090.0,,,,50594
6702,1,Cmax value was determined,,BAO_0000218,,Mus musculus,,Intermediate,5727,In vivo,A,10090.0,,,,50594
6703,1,Cmax value in IRC mice,,BAO_0000218,,Mus musculus,,Intermediate,5951,In vivo,A,10090.0,,,,50594
6704,1,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,BAO_0000218,,Mus musculus,,Intermediate,5506,In vivo,A,10090.0,,,,50594
6705,1,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,BAO_0000218,,Mus musculus,,Intermediate,5506,In vivo,A,10090.0,,,,50594
6706,1,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14239,In vivo,A,10090.0,,,,50594
6707,1,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",Plasma,BAO_0000218,,Mus musculus,,Intermediate,4890,In vivo,A,10090.0,,,,50594
6708,1,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,429,In vivo,A,10090.0,,,,50594
6709,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,BAO_0000218,,Acanthocheilonema viteae,,Intermediate,10986,,F,6277.0,,,,50535
6710,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,BAO_0000218,,Acanthocheilonema viteae,,Intermediate,10986,,F,6277.0,,,,50535
6711,1,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,BAO_0000218,,Acanthocheilonema viteae,,Intermediate,10986,,F,6277.0,,,,50535
6712,1,Inhibitory activity against human tumor cell line A0375 melanoma.,,BAO_0000219,,Homo sapiens,,Intermediate,13227,,F,9606.0,,A-375,,80018
6713,1,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,BAO_0000249,,Rattus norvegicus,,Expert,4481,,B,10116.0,,,Brain membranes,12512
6714,1,Forskolin-induced cAMP production at human A1 adenosine receptor,,BAO_0000019,,Homo sapiens,,Expert,16931,,F,9606.0,,,,114
6715,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,BAO_0000219,,,,Autocuration,3850,,F,,,CHO,,114
6716,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,BAO_0000219,,,,Autocuration,3850,,F,,,CHO,,114
6717,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,BAO_0000219,,,,Expert,3850,,F,,,CHO,,114
6718,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,BAO_0000219,,,,Expert,3850,,F,,,CHO,,114
6719,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,BAO_0000219,,,,Autocuration,3850,,F,,,CHO,,114
6720,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,BAO_0000219,,,,Autocuration,3850,,F,,,CHO,,114
6721,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,BAO_0000219,,,,Autocuration,3850,,F,,,CHO,,114
6722,1,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,BAO_0000219,,Homo sapiens,,Expert,3850,,F,9606.0,,CHO,,114
6723,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,BAO_0000219,,,,Autocuration,3850,,F,,,CHO,,114
6724,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,BAO_0000219,,,,Autocuration,3850,,F,,,CHO,,114
6725,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,BAO_0000219,,,,Expert,3850,,F,,,CHO,,114
6726,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,BAO_0000219,,,,Autocuration,3850,,F,,,CHO,,114
6727,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,BAO_0000219,,,,Expert,3850,,F,,,CHO,,114
6728,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,BAO_0000219,,,,Autocuration,3850,,F,,,CHO,,114
6729,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,BAO_0000219,,,,Autocuration,3850,,F,,,CHO,,114
6730,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,BAO_0000219,,,,Autocuration,3850,,F,,,CHO,,114
6731,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,BAO_0000219,,,,Expert,3850,,F,,,CHO,,114
6732,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,BAO_0000219,,,,Autocuration,3850,,F,,,CHO,,114
6733,1,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,BAO_0000219,,,,Autocuration,3850,,F,,,CHO,,114
6734,1,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,BAO_0000219,,,,Expert,3850,,F,,,CHO,,114
6735,1,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,BAO_0000219,,Oryctolagus cuniculus,,Intermediate,12680,,F,9986.0,,A10,,80013
6736,1,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,BAO_0000219,,Rattus norvegicus,,Autocuration,1313,,F,10116.0,,A10,,22226
6737,1,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,BAO_0000219,,Rattus norvegicus,,Autocuration,1313,,F,10116.0,,A10,,22226
6738,1,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,BAO_0000219,,Rattus norvegicus,,Intermediate,17567,,F,10116.0,,A10,,80013
6739,1,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,BAO_0000219,,Rattus norvegicus,,Intermediate,17567,,F,10116.0,,A10,,80013
6740,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,BAO_0000219,,Rattus norvegicus,,Intermediate,11819,,F,10116.0,,A10,,80013
6741,1,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,BAO_0000219,,Cricetulus griseus,,Intermediate,13436,,F,10029.0,,CHO-AA8,,80089
6742,1,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,BAO_0000219,,Cricetulus griseus,,Intermediate,12687,,F,10029.0,,CHO-AA8,,80089
6743,1,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,BAO_0000219,,Cricetulus griseus,,Intermediate,12651,,F,10029.0,,CHO-AA8,,80089
6744,1,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,BAO_0000219,,Cricetulus griseus,,Intermediate,13300,,F,10029.0,,CHO-AA8,,80089
6745,1,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,BAO_0000219,,Cricetulus griseus,,Intermediate,15296,,F,10029.0,,CHO-AA8,,80089
6746,1,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,BAO_0000219,,Cricetulus griseus,,Intermediate,15328,,F,10029.0,,CHO-AA8,,80089
6747,1,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,BAO_0000219,,Cricetulus griseus,,Intermediate,13302,,F,10029.0,,CHO-AA8,,80089
6748,1,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,BAO_0000219,,Cricetulus griseus,,Expert,14367,,F,10029.0,,CHO-AA8,,80089
6749,1,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,BAO_0000219,,Cricetulus griseus,,Expert,17002,,F,10029.0,,CHO-AA8,,80089
6750,1,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,BAO_0000219,,Cricetulus griseus,,Intermediate,13436,,F,10029.0,,CHO-AA8,,80089
6751,1,Inhibitory activity against aerobic growth of AA8 cells.,,BAO_0000219,,Cricetulus griseus,,Intermediate,13435,,F,10029.0,,CHO-AA8,,80089
6752,1,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,BAO_0000219,,Cricetulus griseus,,Intermediate,10503,,A,10029.0,,CHO-AA8,,80089
6753,1,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,BAO_0000219,,Cricetulus griseus,,Expert,10503,,F,10029.0,,CHO-AA8,,80089
6754,1,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,BAO_0000219,,Cricetulus griseus,,Intermediate,10503,,F,10029.0,,CHO-AA8,,80089
6755,1,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,BAO_0000219,,Cricetulus griseus,,Expert,15090,,F,10029.0,,CHO-AA8,,80089
6756,1,Cytotoxicity against AA8 cell line,,BAO_0000219,,Cricetulus griseus,,Expert,10368,,F,10029.0,,CHO-AA8,,80089
6757,1,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,BAO_0000219,,Cricetulus griseus,,Intermediate,12651,,F,10029.0,,CHO-AA8,,80089
6758,1,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,BAO_0000219,,Cricetulus griseus,,Intermediate,12687,,A,10029.0,,CHO-AA8,,80089
6759,1,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,BAO_0000219,,Cricetulus griseus,,Intermediate,12687,,F,10029.0,,CHO-AA8,,80089
6760,1,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,BAO_0000219,,Cricetulus griseus,,Intermediate,12687,,A,10029.0,,CHO-AA8,,80089
6761,1,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,BAO_0000219,,Cricetulus griseus,,Intermediate,1890,,F,10029.0,,CHO-AA8,,80089
6762,1,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,BAO_0000219,,Cricetulus griseus,,Intermediate,10747,,F,10029.0,,CHO-AA8,,80089
6763,1,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,BAO_0000219,,Cricetulus griseus,,Intermediate,10747,,F,10029.0,,CHO-AA8,,80089
6764,1,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,BAO_0000218,,Cricetulus griseus,,Autocuration,11616,,F,10029.0,,,,22224
6765,1,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,BAO_0000219,,Cricetulus griseus,,Expert,11616,,F,10029.0,,CHO-AA8,,80089
6766,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,BAO_0000219,,Cricetulus griseus,,Autocuration,3471,,F,10029.0,,CHO-AA8,,22224
6767,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,BAO_0000219,,Cricetulus griseus,,Autocuration,3471,,F,10029.0,,CHO-AA8,,22224
6768,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,BAO_0000219,,Cricetulus griseus,,Autocuration,3471,,F,10029.0,,CHO-AA8,,22224
6769,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,BAO_0000219,,Cricetulus griseus,,Autocuration,3471,,F,10029.0,,CHO-AA8,,22224
6770,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,BAO_0000219,,Cricetulus griseus,,Autocuration,3471,,F,10029.0,,CHO-AA8,,22224
6771,1,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,BAO_0000219,,Cricetulus griseus,,Autocuration,3471,,F,10029.0,,CHO-AA8,,22224
6772,1,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,BAO_0000219,,Cricetulus griseus,,Autocuration,3471,,F,10029.0,,CHO-AA8,,22224
6773,1,Concentration required to reduce AA8 cell survival by 10%,,BAO_0000219,,Cricetulus griseus,,Expert,11616,,F,10029.0,,CHO-AA8,,80089
6774,1,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,BAO_0000219,,Cricetulus griseus,,Autocuration,2656,,F,10029.0,,CHO-AA8,,22224
6775,1,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,BAO_0000219,,Cricetulus griseus,,Autocuration,10518,,F,10029.0,,CHO-AA8,,22224
6776,1,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,BAO_0000219,,Cricetulus griseus,,Autocuration,10518,,F,10029.0,,CHO-AA8,,22224
6777,1,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,BAO_0000219,,Cricetulus griseus,,Autocuration,10518,,F,10029.0,,CHO-AA8,,22224
6778,1,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,BAO_0000219,,Cricetulus griseus,,Autocuration,10518,,F,10029.0,,CHO-AA8,,22224
6779,1,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,BAO_0000219,,Cricetulus griseus,,Autocuration,16156,,F,10029.0,,CHO-AA8,,22224
6780,1,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,BAO_0000219,,Cricetulus griseus,,Autocuration,2656,,F,10029.0,,CHO-AA8,,22224
6781,1,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,BAO_0000019,,Cricetulus griseus,,Autocuration,11005,,F,10029.0,,,,22224
6782,1,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,BAO_0000219,,Cricetulus griseus,,Autocuration,11942,,F,10029.0,,CHO-AA8,,22224
6783,1,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,BAO_0000219,,Cricetulus griseus,,Autocuration,2128,,F,10029.0,,CHO-AA8,,22224
6784,1,Half life period after 15 mg/kg iv dose in Dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,In vivo,A,9615.0,,,,50588
6785,1,Half life period after 30 mg/kg po dose in Dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,In vivo,A,9615.0,,,,50588
6786,1,Half life was measured after oral 2b administration (tested in 6 dogs),,BAO_0000218,,Canis lupus familiaris,,Intermediate,9579,In vivo,A,9615.0,,,,50588
6787,1,Half life was measured in dog after oral 17b administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9579,In vivo,A,9615.0,,,,50588
6788,1,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9579,In vivo,A,9615.0,,,,50588
6789,1,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9579,In vivo,A,9615.0,,,,50588
6790,1,Tmax value after 15 mg/kg iv dose in Dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,In vivo,A,9615.0,,,,50588
6791,1,Tmax value after 30 mg/kg po dose in Dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,In vivo,A,9615.0,,,,50588
6792,1,Compound was evaluated for its half life when administered intravenously in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3184,In vivo,A,9615.0,,,,50588
6793,1,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5017,In vivo,A,9615.0,,,,50588
6794,1,Elimination Half-life of compound was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6821,,A,9615.0,,,,50588
6795,1,Half life of compound in dog following oral administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17839,In vivo,A,9615.0,,,,50588
6796,1,Half life of compound was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17267,,A,9615.0,,,,50588
6797,1,Half life of compound was determined in dog blood,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,4727,,A,9615.0,,,,50588
6798,1,Half life after oral and iv dosing in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5238,In vivo,A,9615.0,,,,50588
6799,1,Half life in dogs in hours,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4942,,A,9615.0,,,,50588
6800,1,Half life on i.v. administration of 2 mg/kg was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6505,In vivo,A,9615.0,,,,50588
6801,1,t1/2 in dog after oral dose (1 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5130,In vivo,A,9615.0,,,,50588
6802,1,Half life was evaluated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1475,,A,9615.0,,,,50588
6803,1,Half life period of compound was determined after intravenous administration at 2 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17804,In vivo,A,9615.0,,,,50588
6804,1,Half life period of compound was determined after peroral administration at 2 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17804,In vivo,A,9615.0,,,,50588
6805,1,Half life period (10 mg/kg) was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6084,In vivo,A,9615.0,,,,50588
6806,1,Half life period (10 mg/kg) was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6084,In vivo,A,9615.0,,,,50588
6807,1,Half life period by iv administration in dog at a dose of 0.3 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5542,In vivo,A,9615.0,,,,50588
6808,1,Half life period by po administration in dog at a dose of 0.3 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5542,In vivo,A,9615.0,,,,50588
6809,1,Half life period in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6084,,A,9615.0,,,,50588
6810,1,Half life period in dogs after oral administration at 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6241,In vivo,A,9615.0,,,,50588
6811,1,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1916,In vivo,A,9615.0,,,,50588
6812,1,Half-life of compound was determined in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6621,,A,9615.0,,,,50588
6813,1,Half-life in dog plasma,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,1696,,A,9615.0,,,,50588
6814,1,Half-life in mongrel dogs was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17800,,A,9615.0,,,,50588
6815,1,Half-life in dog upon oral administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17657,In vivo,A,9615.0,,,,50588
6816,1,Half-life in dog upon oral administration; Unable to calculate,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17657,In vivo,A,9615.0,,,,50588
6817,1,Half-life was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4239,,A,9615.0,,,,50588
6818,1,Half-life was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5985,,A,9615.0,,,,50588
6819,1,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9932,,A,9615.0,,,,50588
6820,1,Oral half life was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5199,In vivo,A,9615.0,,,,50588
6821,1,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5199,In vivo,A,9615.0,,,,50588
6822,1,Plasma half life was evaluated,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,1475,,A,9615.0,,,,50588
6823,1,Plasma half life was evaluated in Dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,1475,,A,9615.0,,,,50588
6824,1,Plasma half life was evaluated in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,1475,,A,9615.0,,,,50588
6825,1,T1/2 (Half-life) was after oral administration at 5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6316,In vivo,A,9615.0,,,,50588
6826,1,Tested for the half life value in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4883,,A,9615.0,,,,50588
6827,1,Maximum time at the dose of 2 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4727,In vivo,A,9615.0,,,,50588
6828,1,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1916,In vivo,A,9615.0,,,,50588
6829,1,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,1337,In vivo,A,9615.0,,,,50588
6830,1,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,1337,In vivo,A,9615.0,,,,50588
6831,1,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6265,In vivo,A,9615.0,,,,50588
6832,1,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,4809,In vivo,A,9615.0,,,,50588
6833,1,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5983,In vivo,A,9615.0,,,,50588
6834,1,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,BAO_0000218,,Canis lupus familiaris,,Intermediate,5313,,A,9615.0,,,,50588
6835,1,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",,BAO_0000218,,Canis lupus familiaris,,Intermediate,5313,In vivo,A,9615.0,,,,50588
6836,1,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17650,In vivo,A,9615.0,,,,50588
6837,1,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5199,In vivo,A,9615.0,,,,50588
6838,1,Time taken for maximum plasma concentration in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,933,,A,9615.0,,,,50588
6839,1,Time to reach Cmax after oral administration to dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16367,In vivo,A,9615.0,,,,50588
6840,1,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6348,In vivo,A,9615.0,,,,50588
6841,1,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6316,In vivo,A,9615.0,,,,50588
6842,1,Tmax after peroral administration (1 mg/kg) was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6215,In vivo,A,9615.0,,,,50588
6843,1,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Expert,3598,In vivo,A,9615.0,,,,50588
6844,1,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4527,In vivo,A,9615.0,,,,50588
6845,1,Tmax after peroral administration in dogs at 2.4 uM/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17764,In vivo,A,9615.0,,,,50588
6846,1,In vivo Cmax in mice at dose of 100 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,5969,In vivo,A,10090.0,,,,50594
6847,1,In vivo Cmax in mice at dose of 50 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,5969,In vivo,A,10090.0,,,,50594
6848,1,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,,BAO_0000218,,Mus musculus,,Intermediate,4573,In vivo,A,10090.0,,,,50594
6849,1,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Plasma,BAO_0000218,,Mus musculus,,Intermediate,3277,In vivo,A,10090.0,,,,50594
6850,1,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17734,In vivo,A,10090.0,,,,50594
6851,1,Maximum concentration obtained in mouse plasma was determined,Plasma,BAO_0000218,,Mus musculus,,Intermediate,3132,In vivo,A,10090.0,,,,50594
6852,1,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,Plasma,BAO_0000218,,Mus musculus,,Intermediate,3132,In vivo,A,10090.0,,,,50594
6853,1,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Plasma,BAO_0000218,,Mus musculus,,Intermediate,6348,In vivo,A,10090.0,,,,50594
6854,1,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17729,In vivo,A,10090.0,,,,50594
6855,1,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17729,In vivo,A,10090.0,,,,50594
6856,1,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17729,In vivo,A,10090.0,,,,50594
6857,1,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17728,In vivo,A,10090.0,,,,50594
6858,1,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17728,In vivo,A,10090.0,,,,50594
6859,1,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17728,In vivo,A,10090.0,,,,50594
6860,1,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,4066,In vivo,A,10090.0,,,,50594
6861,1,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,6178,In vivo,A,10090.0,,,,50594
6862,1,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,6178,In vivo,A,10090.0,,,,50594
6863,1,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,,BAO_0000218,,Mus musculus,,Intermediate,3760,In vivo,A,10090.0,,,,50594
6864,1,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,,BAO_0000218,,Mus musculus,,Intermediate,3760,In vivo,A,10090.0,,,,50594
6865,1,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,,BAO_0000218,,Mus musculus,,Intermediate,3760,In vivo,A,10090.0,,,,50594
6866,1,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,,BAO_0000218,,Mus musculus,,Intermediate,3760,In vivo,A,10090.0,,,,50594
6868,1,Cmax in male mice after 2 mg/kg oral dose,,BAO_0000218,,Mus musculus,,Intermediate,5961,In vivo,A,10090.0,,,,50594
6869,1,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,,BAO_0000218,,Mus musculus,,Intermediate,6137,In vivo,A,10090.0,,,,50594
6870,1,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,,BAO_0000218,,Mus musculus,,Intermediate,3802,In vivo,A,10090.0,,,,50594
6871,1,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,BAO_0000218,,Mus musculus,,Intermediate,3535,,A,10090.0,,,,50594
6872,1,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,BAO_0000218,,Mus musculus,,Intermediate,3535,,A,10090.0,,,,50594
6873,1,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,BAO_0000218,,Mus musculus,,Intermediate,3535,,A,10090.0,,,,50594
6874,1,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,BAO_0000218,,Mus musculus,,Intermediate,3535,,A,10090.0,,,,50594
6875,1,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,BAO_0000218,,Mus musculus,,Intermediate,3535,,A,10090.0,,,,50594
6876,1,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,BAO_0000218,,Mus musculus,,Intermediate,3535,,A,10090.0,,,,50594
6877,1,Maximum concentration in plasma upon oral administration in mouse,Plasma,BAO_0000218,,Mus musculus,,Intermediate,2862,,A,10090.0,,,,50594
6878,1,Maximum plasma concentration was evaluated in mice after oral administration,Plasma,BAO_0000218,,Mus musculus,,Intermediate,2675,,A,10090.0,,,,50594
6879,1,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,Plasma,BAO_0000218,,Mus musculus,,Intermediate,2675,In vivo,A,10090.0,,,,50594
6880,1,Dose at which the compound induced fecal excretion in mice,,BAO_0000218,,Mus musculus,,Intermediate,5399,,A,10090.0,,,,50594
6893,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,BAO_0000219,,Rattus norvegicus,,Expert,11819,,F,10116.0,,A10,,80013
6894,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,BAO_0000219,,Rattus norvegicus,,Expert,11819,,F,10116.0,,A10,,80013
6895,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,BAO_0000219,,Rattus norvegicus,,Expert,11819,,F,10116.0,,A10,,80013
6896,1,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,BAO_0000219,,Rattus norvegicus,,Expert,11819,,F,10116.0,,A10,,80013
6897,1,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,BAO_0000219,,Rattus norvegicus,,Intermediate,16361,,F,10116.0,,A10,,80013
6898,1,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2288,,F,9606.0,,A121,,80655
6899,1,Anticancer activity against human ovarian carcinoma A121 cells,,BAO_0000219,,Homo sapiens,,Intermediate,10404,,F,9606.0,,A121,,80655
6900,1,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,BAO_0000219,,Homo sapiens,,Intermediate,14790,,F,9606.0,,A121,,80655
6901,1,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,BAO_0000219,,Homo sapiens,,Intermediate,14790,,F,9606.0,,A121,,80655
6902,1,Growth inhibition of human ovarian carcinoma (A121) cell line,,BAO_0000219,,Homo sapiens,,Expert,14253,,F,9606.0,,A121,,80655
6903,1,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,BAO_0000219,,Homo sapiens,,Expert,13617,,F,9606.0,,A121,,80655
6904,1,Cytotoxicity against human A121 ovarian cells,,BAO_0000219,,Homo sapiens,,Intermediate,1003,,F,9606.0,,A121,,80655
6905,1,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,830,,F,9606.0,,A121,,80655
6906,1,In vitro cytotoxicity against human ovarian carcinoma A21,,BAO_0000219,,Homo sapiens,,Intermediate,12307,,F,9606.0,,A121,,80655
6907,1,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,BAO_0000219,,Homo sapiens,,Intermediate,14254,,F,9606.0,,A121,,80655
6908,1,Inhibitory activity of compound against human A121 ovarian cell line.,,BAO_0000219,,Homo sapiens,,Intermediate,13370,,F,9606.0,,A121,,80655
6909,1,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,BAO_0000219,,Homo sapiens,,Intermediate,14790,,F,9606.0,,A121,,80655
6910,1,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,BAO_0000219,,Homo sapiens,,Intermediate,3614,,F,9606.0,,A121,,80655
6911,1,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2664,,F,9606.0,,A 172,,80012
6912,1,In vitro cytotoxicity against A172 human tumor cell lines.,,BAO_0000219,,Homo sapiens,,Expert,2037,,F,9606.0,,A 172,,80012
6913,1,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,BAO_0000219,,Homo sapiens,,Intermediate,14539,,F,9606.0,,A 172,,80012
6914,1,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2836,,F,9606.0,,A 172,,80012
6915,1,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,BAO_0000219,,Homo sapiens,,Intermediate,10708,,F,9606.0,,A 172,,80012
6916,1,Association constant against A2 adenosine receptor,,BAO_0000224,,Canis lupus familiaris,,Autocuration,8975,,B,9615.0,,,,104729
6917,1,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,BAO_0000219,,fish,,Intermediate,7645,,F,,,A2,,80656
6918,1,Ratio of Ki for adenosine A2 and A1 receptor binding,,BAO_0000224,,Rattus norvegicus,,Autocuration,11377,,B,10116.0,,,,104713
6919,1,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,BAO_0000219,,Homo sapiens,,Expert,13528,,F,9606.0,,A204,,80014
6920,1,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,BAO_0000219,,Homo sapiens,,Expert,10160,,F,9606.0,,A204,,80014
6921,1,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,15144,,F,9606.0,,A2058,,80015
6922,1,Growth inhibition against Human squamous cell line(A 253),,BAO_0000219,,Homo sapiens,,Intermediate,13160,,F,9606.0,,A253 cell line,,80657
6923,1,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,12898,,F,9606.0,,A253 cell line,,80657
6924,1,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,BAO_0000219,,Homo sapiens,,Intermediate,13069,,F,9606.0,,A253 cell line,,80657
6925,1,Growth inhibition of A253 cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,15984,,F,9606.0,,A253 cell line,,80657
6926,1,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,BAO_0000219,,Homo sapiens,,Intermediate,15564,,F,9606.0,,A253 cell line,,80657
6927,1,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,BAO_0000219,,Homo sapiens,,Intermediate,15564,,F,9606.0,,A253 cell line,,80657
6928,1,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,BAO_0000219,,Homo sapiens,,Intermediate,15564,,F,9606.0,,A253 cell line,,80657
6929,1,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4720,,F,9606.0,,A2780,,81034
6930,1,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,BAO_0000219,,Homo sapiens,,Intermediate,16112,,F,9606.0,,A2780,,81034
6931,1,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,BAO_0000219,,Homo sapiens,,Expert,16597,,F,9606.0,,A2780,,81034
6932,1,Cytotoxicity against human cancer cell lines A2780 (ovarian),,BAO_0000219,,Homo sapiens,,Intermediate,16378,,F,9606.0,,A2780,,81034
6933,1,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,BAO_0000219,,Homo sapiens,,Expert,16085,,F,9606.0,,A2780,,81034
6934,1,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,BAO_0000219,,Homo sapiens,,Intermediate,16317,,F,9606.0,,A2780,,81034
6935,1,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,BAO_0000219,,Homo sapiens,,Intermediate,15748,,F,9606.0,,A2780,,81034
6936,1,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,16597,,F,9606.0,,A2780,,81034
6937,1,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,16597,,F,9606.0,,A2780,,81034
6938,1,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,16597,,F,9606.0,,A2780,,81034
6939,1,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,BAO_0000219,,Homo sapiens,,Intermediate,15608,,F,9606.0,,A2780,,81034
6940,1,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,BAO_0000219,,Homo sapiens,,Intermediate,15608,,F,9606.0,,A2780,,81034
6941,1,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,BAO_0000219,,Homo sapiens,,Intermediate,15608,,F,9606.0,,A2780,,81034
6942,1,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,BAO_0000019,,Cricetulus griseus,,Autocuration,15296,,F,10029.0,,,,22224
6943,1,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,BAO_0000219,,Cricetulus griseus,,Autocuration,10251,,A,10029.0,,CHO-AA8,,22224
6944,1,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,BAO_0000219,,Cricetulus griseus,,Autocuration,10251,,F,10029.0,,CHO-AA8,,22224
6945,1,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,BAO_0000219,,Cricetulus griseus,,Autocuration,10251,,F,10029.0,,CHO-AA8,,22224
6946,1,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,BAO_0000219,,Cricetulus griseus,,Autocuration,10251,,F,10029.0,,CHO-AA8,,22224
6947,1,Growth inhibition against CHO-derived cell line AA8,,BAO_0000019,,Cricetulus griseus,,Autocuration,11858,,F,10029.0,,,,22224
6948,1,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,BAO_0000219,,Cricetulus griseus,,Autocuration,11858,,F,10029.0,,CHO-AA8,,22224
6949,1,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,BAO_0000219,,hampster,,Expert,11616,,F,36483.0,,CHO-AA8,,80089
6950,1,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,BAO_0000219,,Cricetulus griseus,,Expert,11616,,F,10029.0,,CHO-AA8,,80089
6951,1,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,BAO_0000219,,Cricetulus griseus,,Autocuration,10518,,F,10029.0,,CHO-AA8,,22224
6952,1,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,BAO_0000219,,Cricetulus griseus,,Autocuration,11396,,F,10029.0,,CHO-AA8,,22224
6953,1,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,BAO_0000219,,Cricetulus griseus,,Autocuration,10518,,F,10029.0,,CHO-AA8,,22224
6954,1,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,BAO_0000219,,Cricetulus griseus,,Expert,11616,,F,10029.0,,CHO-AA8,,80089
6955,1,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,BAO_0000019,,,,Autocuration,14837,,F,,,,,12675
6956,1,Number of binding sites (n) of isolated serum protein AAG,,BAO_0000019,,,,Autocuration,14837,,F,,,,,12675
6957,1,Association constant for binding to AATT duplex,,BAO_0000225,,,,Intermediate,16037,,B,,,,,22222
6958,1,Inhibition of ABAE human fibroblast cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,16597,,F,9606.0,,ABAE,,100090
6959,1,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,BAO_0000218,,Mus musculus,,Intermediate,8831,,F,10090.0,,AC755,,80668
6960,1,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,BAO_0000218,,Oryctolagus cuniculus,,Expert,13419,,F,9986.0,,,,102444
6961,1,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,,BAO_0000218,,Oryctolagus cuniculus,,Expert,13419,In vivo,F,9986.0,,,,102444
6962,1,Inhibitory activity against angiotensin-converting enzyme (ACE).,,BAO_0000357,,,,Autocuration,15778,,B,,,,,69
6963,1,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,BAO_0000357,,,,Autocuration,15778,,B,,,,,69
6964,1,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,BAO_0000219,,Homo sapiens,,Intermediate,12988,,F,9606.0,,ACH-2 cell line,,80669
6965,1,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,BAO_0000219,,Homo sapiens,,Intermediate,12988,,F,9606.0,,ACH-2 cell line,,80669
6966,1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,BAO_0000219,,Human immunodeficiency virus 1,,Autocuration,12988,,F,11676.0,,T cell line,,22224
6967,1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,BAO_0000219,,Human immunodeficiency virus 1,,Autocuration,12988,,F,11676.0,,T cell line,,22224
6968,1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,BAO_0000219,,Human immunodeficiency virus 1,,Autocuration,12988,,F,11676.0,,T cell line,,22224
6969,1,Inhibition of growth of renal cancer ACHN cell line,,BAO_0000219,,Homo sapiens,,Intermediate,11843,,F,9606.0,,ACHN,,80025
6970,1,Inhibition of growth of ACHN renal cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,16939,,F,9606.0,,ACHN,,80025
6971,1,Inhibitory concentration required against ACHN renal cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4782,,F,9606.0,,ACHN,,80025
6972,1,Concentration required to inhibit growth of human renal (ACHN) cell line,,BAO_0000219,,Homo sapiens,,Expert,6310,,F,9606.0,,ACHN,,80025
6973,1,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,BAO_0000219,,Homo sapiens,,Intermediate,6310,,F,9606.0,,ACHN,,80025
6974,1,Cytotoxic activity against ACHN Renal cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,12858,,F,9606.0,,ACHN,,80025
6975,1,Cytotoxicity evaluation against ACHN renal cancer cells,,BAO_0000219,,Homo sapiens,,Intermediate,17380,,F,9606.0,,ACHN,,80025
6976,1,In vitro antitumor activity against human renal ACHN cell line,,BAO_0000219,,Homo sapiens,,Intermediate,5858,,F,9606.0,,ACHN,,80025
6977,1,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,BAO_0000219,,Homo sapiens,,Intermediate,3838,,F,9606.0,,ACHN,,80025
6978,1,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,BAO_0000219,,Homo sapiens,,Intermediate,3838,,F,9606.0,,ACHN,,80025
6979,1,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,BAO_0000219,,Homo sapiens,,Intermediate,5406,,F,9606.0,,ACHN,,80025
6980,1,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,BAO_0000219,,Homo sapiens,,Intermediate,4071,,F,9606.0,,ACHN,,80025
6981,1,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,BAO_0000219,,Homo sapiens,,Expert,4071,,F,9606.0,,ACHN,,80025
6982,1,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,BAO_0000219,,Homo sapiens,,Intermediate,4071,,F,9606.0,,ACHN,,80025
6983,1,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,BAO_0000219,,Homo sapiens,,Intermediate,15002,,F,9606.0,,ACHN,,80025
6984,1,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,BAO_0000219,,Homo sapiens,,Intermediate,14769,,F,9606.0,,ACHN,,80025
6985,1,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,BAO_0000219,,Homo sapiens,,Intermediate,13958,,F,9606.0,,ACHN,,80025
6986,1,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,BAO_0000219,,Homo sapiens,,Intermediate,1665,,F,9606.0,,ACHN,,80025
6987,1,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,15354,,F,9606.0,,ACHN,,80025
6988,1,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,BAO_0000219,,Homo sapiens,,Intermediate,15354,,F,9606.0,,ACHN,,80025
6989,1,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,13978,,F,9606.0,,ACHN,,80025
6990,1,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,6798,,F,9606.0,,ACHN,,80025
6991,1,Tmax value after administration of 4 mg/Kg oral dose in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2959,In vivo,A,9615.0,,,,50588
6992,1,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,BAO_0000218,,Canis lupus familiaris,,Intermediate,9932,,A,9615.0,,,,50588
6993,1,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5546,,A,9615.0,,,,50588
6994,1,Volume distribution after 15 mg/kg iv dose in Dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,In vivo,A,9615.0,,,,50588
6995,1,Volume distribution after 30 mg/kg po dose in Dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,In vivo,A,9615.0,,,,50588
6996,1,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4257,In vivo,A,9615.0,,,,50588
6997,1,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4305,In vivo,A,9615.0,,,,50588
6998,1,Volume of distribution was evaluated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5472,In vivo,A,9615.0,,,,50588
6999,1,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6062,In vivo,A,9615.0,,,,50588
7000,1,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Expert,3598,,A,9615.0,,,,50588
7001,1,The compound was tested for volume of distribution in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12500,In vivo,A,9615.0,,,,50588
7002,1,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12500,In vivo,A,9615.0,,,,50588
7003,1,Vd (1 mg/kg) was determined in dog (in vivo),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,In vivo,A,9615.0,,,,50588
7004,1,Vd in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,In vivo,A,9615.0,,,,50588
7005,1,Volume distribution was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4219,In vivo,A,9615.0,,,,50588
7006,1,Volume of distribution in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1696,In vivo,A,9615.0,,,,50588
7007,1,Volume of distribution by as 4 fold increase by iv administration in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5542,In vivo,A,9615.0,,,,50588
7008,1,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5199,In vivo,A,9615.0,,,,50588
7009,1,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6348,In vivo,A,9615.0,,,,50588
7010,1,Volume distribution at the dose of 2 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4727,In vivo,A,9615.0,,,,50588
7011,1,Steady state volume of distribution was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16367,In vivo,A,9615.0,,,,50588
7012,1,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2652,In vivo,A,9615.0,,,,50588
7013,1,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,A,9615.0,,,,50588
7014,1,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,A,9615.0,,,,50588
7015,1,Bioavailability in dog (dose 1 mg/kg i.v.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,A,9615.0,,,,50588
7016,1,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5334,In vivo,A,9615.0,,,,50588
7017,1,Pharmacokinetic property (vdss) was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4239,In vivo,A,9615.0,,,,50588
7018,1,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4709,In vivo,A,9615.0,,,,50588
7019,1,Vdss was determined after iv 0.1 mg/kg administration in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5600,In vivo,A,9615.0,,,,50588
7020,1,Volume displacement was calculated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6057,In vivo,A,9615.0,,,,50588
7021,1,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5654,In vivo,A,9615.0,,,,50588
7022,1,Volume distribution constant was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5505,In vivo,A,9615.0,,,,50588
7023,1,Volume distribution at a dose of 1 uM/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4527,In vivo,A,9615.0,,,,50588
7024,1,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4521,In vivo,A,9615.0,,,,50588
7025,1,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4521,In vivo,A,9615.0,,,,50588
7026,1,Volume distribution (Vdss) was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15660,In vivo,A,9615.0,,,,50588
7027,1,Volume distribution (Vdss) was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15660,In vivo,A,9615.0,,,,50588
7028,1,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6679,In vivo,A,9615.0,,,,50588
7029,1,Volume of distribution in steady state was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5145,In vivo,A,9615.0,,,,50588
7030,1,Volume of distribution of compound was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6821,In vivo,A,9615.0,,,,50588
7031,1,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4137,In vivo,A,9615.0,,,,50588
7032,1,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5334,In vivo,A,9615.0,,,,50588
7033,1,Volume of distribution (Vdss) was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15660,In vivo,A,9615.0,,,,50588
7034,1,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6642,In vivo,A,9615.0,,,,50588
7035,1,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6641,In vivo,A,9615.0,,,,50588
7036,1,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6642,In vivo,A,9615.0,,,,50588
7037,1,Maximum rate of depolarization of the upstroke of the action potential,,BAO_0000218,,Canis lupus familiaris,,Intermediate,11659,,A,9615.0,,,,50588
7038,1,Steady state volume distribution in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6448,In vivo,A,9615.0,,,,50588
7039,1,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5474,In vivo,A,9615.0,,,,50588
7040,1,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1466,In vivo,A,9615.0,,,,50588
7041,1,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6535,In vivo,A,9615.0,,,,50588
7042,1,Volume distribution in dog after administration of 1 mg/kg iv,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6535,In vivo,A,9615.0,,,,50588
7043,1,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17764,In vivo,A,9615.0,,,,50588
7044,1,Vss after intravenous administration (0.5 mg/kg) was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6215,In vivo,A,9615.0,,,,50588
7045,1,Vss on i.v. administration of 2 mg/kg was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6505,In vivo,A,9615.0,,,,50588
7046,1,Vss was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3639,,A,9615.0,,,,50588
7047,1,Vss in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3639,,A,9615.0,,,,50588
7048,1,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6062,In vivo,A,9615.0,,,,50588
7049,1,Volume distribution in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4942,In vivo,A,9615.0,,,,50588
7050,1,Volume of distribution in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17796,In vivo,A,9615.0,,,,50588
7051,1,Tested for the oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4883,In vivo,A,9615.0,,,,50588
7060,1,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,17837,In vivo,A,10090.0,,,,50594
7061,1,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,,BAO_0000218,,Mus musculus,,Intermediate,17729,In vivo,A,10090.0,,,,50594
7062,1,Bioavailability after peroral administration of 50 mg/kg of dose in mice,,BAO_0000218,,Mus musculus,,Intermediate,17729,In vivo,A,10090.0,,,,50594
7063,1,Bioavailability was measured in mouse,,BAO_0000218,,Mus musculus,,Intermediate,4239,In vivo,A,10090.0,,,,50594
7064,1,Bioavailability in mouse,,BAO_0000218,,Mus musculus,,Intermediate,17592,In vivo,A,10090.0,,,,50594
7065,1,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,BAO_0000218,,Mus musculus,,Intermediate,6348,In vivo,A,10090.0,,,,50594
7066,1,Bioavailability in mouse,,BAO_0000218,,Mus musculus,,Intermediate,2801,In vivo,A,10090.0,,,,50594
7067,1,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,2801,In vivo,A,10090.0,,,,50594
7068,1,Oral bioavailability in mouse,,BAO_0000218,,Mus musculus,,Intermediate,17718,In vivo,A,10090.0,,,,50594
7069,1,Oral availability at 50 mg/kg po in male mice,,BAO_0000218,,Mus musculus,,Intermediate,5727,In vivo,A,10090.0,,,,50594
7070,1,Oral bioavailability in mouse (dose 10 mg/kg),,BAO_0000218,,Mus musculus,,Intermediate,5302,In vivo,A,10090.0,,,,50594
7071,1,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Mus musculus,,Expert,3598,In vivo,A,10090.0,,,,50594
7072,1,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",,BAO_0000218,,Mus musculus,,Intermediate,5961,In vivo,A,10090.0,,,,50594
7074,1,Oral bioavailability in mouse,,BAO_0000218,,Mus musculus,,Intermediate,6091,In vivo,A,10090.0,,,,50594
7075,1,Oral bioavailability in vivo in mice;ND=Not determined,,BAO_0000218,,Mus musculus,,Intermediate,6091,In vivo,A,10090.0,,,,50594
7076,1,Oral bioavailability in mouse at 10 mg/kg of the compound,,BAO_0000218,,Mus musculus,,Intermediate,5711,In vivo,A,10090.0,,,,50594
7077,1,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),,BAO_0000218,,Mus musculus,,Intermediate,17728,In vivo,A,10090.0,,,,50594
7078,1,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),,BAO_0000218,,Mus musculus,,Intermediate,17728,In vivo,A,10090.0,,,,50594
7079,1,Tested for bioavailability of the compound,,BAO_0000218,,Mus musculus,,Intermediate,3802,In vivo,A,10090.0,,,,50594
7080,1,Tested for half life at the dose of 10 mg/kg when administered intravenously,,BAO_0000218,,Mus musculus,,Intermediate,3802,In vivo,A,10090.0,,,,50594
7081,1,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14029,,A,10090.0,,,,50594
7082,1,The plasma half life of compound was determined on heparin prepared by human plasma. ,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14029,,A,10090.0,,,,50594
7083,1,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14029,,A,10090.0,,,,50594
7084,1,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14029,,A,10090.0,,,,50594
7085,1,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14029,,A,10090.0,,,,50594
7086,1,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,,F,10090.0,,,,50594
7087,1,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,,A,10090.0,,,,50594
7088,1,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,BAO_0000218,,Mus musculus,,Intermediate,17753,,A,10090.0,,,,50594
7089,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Blood,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7090,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Blood,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7091,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Blood,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7092,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Blood,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7093,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Blood,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7094,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Blood,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7095,1,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Blood,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7096,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Bone,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7097,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Bone,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7098,1,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,BAO_0000219,,Homo sapiens,,Intermediate,15608,,F,9606.0,,A2780,,81034
7099,1,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,BAO_0000219,,Homo sapiens,,Expert,3290,,F,9606.0,,A2780,,81034
7100,1,Compound was evaluated for cytotoxicity against A2780 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2859,,F,9606.0,,A2780,,81034
7101,1,Inhibition of A2780 cell clonogenic assay,,BAO_0000219,,Homo sapiens,,Expert,15688,,F,9606.0,,A2780,,81034
7102,1,Cytotoxic effect on ovarian cancer cell line (A2780),,BAO_0000219,,Homo sapiens,,Expert,5642,,F,9606.0,,A2780,,81034
7103,1,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,BAO_0000219,,Homo sapiens,,Intermediate,6633,,F,9606.0,,A2780,,81034
7104,1,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,BAO_0000219,,Homo sapiens,,Intermediate,3906,,F,9606.0,,A2780,,81034
7105,1,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,BAO_0000219,,Homo sapiens,,Expert,6788,,F,9606.0,,A2780,,81034
7106,1,Antiproliferative activity against human A2780 cells,,BAO_0000219,,Homo sapiens,,Expert,17582,,F,9606.0,,A2780,,81034
7107,1,Inhibition of human A2780 cell proliferation,,BAO_0000219,,Homo sapiens,,Expert,17764,,F,9606.0,,A2780,,81034
7108,1,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,BAO_0000219,,Homo sapiens,,Expert,17764,,F,9606.0,,A2780,,81034
7109,1,Inhibition of human A2780 cell proliferation (No data),,BAO_0000219,,Homo sapiens,,Expert,17764,,F,9606.0,,A2780,,81034
7110,1,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2815,,F,9606.0,,A2780,,81034
7111,1,Compound was evaluated against human Ovarian carcinoma cell line A2780,,BAO_0000219,,Homo sapiens,,Intermediate,16930,,F,9606.0,,A2780,,81034
7112,1,Growth inhibition against A2780 wild-type ovarian cell lines,,BAO_0000219,,Homo sapiens,,Expert,17777,,F,9606.0,,A2780,,81034
7113,1,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,BAO_0000219,,Homo sapiens,,Intermediate,17777,,F,9606.0,,A2780,,81034
7114,1,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,BAO_0000019,,Homo sapiens,,Autocuration,16936,,F,9606.0,,,,104766
7115,1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,BAO_0000219,,Homo sapiens,,Intermediate,13759,,F,9606.0,,A2780,,81034
7116,1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,BAO_0000219,,Homo sapiens,,Intermediate,13759,,F,9606.0,,A2780,,81034
7117,1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,BAO_0000219,,Homo sapiens,,Intermediate,13759,,F,9606.0,,A2780,,81034
7118,1,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,BAO_0000219,,Homo sapiens,,Intermediate,13759,,F,9606.0,,A2780,,81034
7119,1,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,BAO_0000219,,Homo sapiens,,Intermediate,15292,,F,9606.0,,A2780,,81034
7120,1,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,BAO_0000219,,Homo sapiens,,Intermediate,15292,,F,9606.0,,A2780,,81034
7121,1,In vitro inhibition of human ovarian cell line A2780,,BAO_0000219,,Homo sapiens,,Expert,15069,,F,9606.0,,A2780,,81034
7122,1,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,BAO_0000219,,Homo sapiens,,Expert,15069,,F,9606.0,,A2780,,81034
7123,1,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,BAO_0000219,,Homo sapiens,,Intermediate,14073,,F,9606.0,,A2780,,81034
7124,1,Concentration required to inhibit A2780-cell growth by 50%,,BAO_0000219,,Homo sapiens,,Expert,14553,,F,9606.0,,A2780,,81034
7125,1,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,BAO_0000219,,Homo sapiens,,Expert,13040,,F,9606.0,,A2780,,81034
7126,1,Cytotoxic effect on human ovarian (A2780) cancer cell line,,BAO_0000219,,Homo sapiens,,Expert,6891,,F,9606.0,,A2780,,81034
7127,1,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,BAO_0000219,,Homo sapiens,,Intermediate,15569,,F,9606.0,,A2780,,81034
7128,1,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,BAO_0000219,,Homo sapiens,,Expert,14190,,F,9606.0,,A2780,,81034
7129,1,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,BAO_0000219,,Homo sapiens,,Expert,15014,,F,9606.0,,A2780,,81034
7130,1,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,BAO_0000219,,Homo sapiens,,Intermediate,15014,,F,9606.0,,A2780,,81034
7131,1,Cytotoxicity against human ovarian carcinoma A2780 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17496,,F,9606.0,,A2780,,81034
7132,1,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,BAO_0000219,,Homo sapiens,,Intermediate,13617,,F,9606.0,,A2780,,81034
7133,1,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,BAO_0000219,,Homo sapiens,,Intermediate,13617,,F,9606.0,,A2780,,81034
7134,1,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,BAO_0000219,,Homo sapiens,,Intermediate,13617,,F,9606.0,,A2780,,81034
7135,1,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,BAO_0000219,,Homo sapiens,,Intermediate,13617,,F,9606.0,,A2780,,81034
7136,1,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,17672,,F,9606.0,,A2780,,81034
7137,1,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,BAO_0000219,,Homo sapiens,,Intermediate,4544,,F,9606.0,,A2780,,81034
7138,1,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,BAO_0000219,,Homo sapiens,,Intermediate,4544,,F,9606.0,,A2780,,81034
7139,1,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,BAO_0000219,,Homo sapiens,,Intermediate,16317,,F,9606.0,,A2780,,81034
7140,1,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,BAO_0000219,,Homo sapiens,,Intermediate,15099,,F,9606.0,,A2780,,81034
7141,1,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,13978,,F,9606.0,,A2780,,81034
7142,1,In vitro antitumor activity against A2780 cell line.,,BAO_0000219,,Homo sapiens,,Expert,12989,,F,9606.0,,A2780,,81034
7143,1,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,BAO_0000219,,Homo sapiens,,Intermediate,5574,,F,9606.0,,A2780,,81034
7144,1,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,BAO_0000219,,Homo sapiens,,Expert,13528,,F,9606.0,,A2780,,81034
7145,1,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,BAO_0000219,,Homo sapiens,,Intermediate,12782,,F,9606.0,,ACHN,,80025
7146,1,The IC50 value was measured on ACHN cell line in renal tumor type.,,BAO_0000219,,Homo sapiens,,Intermediate,14255,,F,9606.0,,ACHN,,80025
7147,1,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,BAO_0000219,,Homo sapiens,,Intermediate,16364,,F,9606.0,,ACHN,,80025
7148,1,In vitro lethal concentration against most sensitive ACHN cell line,,BAO_0000219,,Homo sapiens,,Expert,17376,,F,9606.0,,ACHN,,80025
7149,1,Tested for cytotoxic activity against renal cancer ACHN cell line,,BAO_0000219,,Homo sapiens,,Intermediate,12016,,F,9606.0,,ACHN,,80025
7150,1,Compound tested for growth inhibition of renal cancer cell line ACHN,,BAO_0000219,,Homo sapiens,,Intermediate,6058,,F,9606.0,,ACHN,,80025
7151,1,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17708,,F,9606.0,,ACHN,,80025
7152,1,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,BAO_0000219,,Homo sapiens,,Intermediate,15176,,F,9606.0,,ACHN,,80025
7153,1,In vitro anticancer activity against ACHN renal cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2806,,F,9606.0,,ACHN,,80025
7154,1,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,BAO_0000219,,Homo sapiens,,Intermediate,15300,,F,9606.0,,ACHN,,80025
7155,1,Percent selectivity was evaluated in renal ACHN cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,16364,,F,9606.0,,ACHN,,80025
7156,1,In vitro inhibitory activity against renal ACHN cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,13859,,F,9606.0,,ACHN,,80025
7157,1,Tested for cytotoxicity against ACHN cell lines in renal cancer,,BAO_0000219,,Homo sapiens,,Intermediate,11970,,F,9606.0,,ACHN,,80025
7158,1,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,2450,,F,9606.0,,ACHN,,80025
7159,1,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,BAO_0000219,,Homo sapiens,,Intermediate,12696,,F,9606.0,,ACHN,,80025
7160,1,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,BAO_0000219,,Homo sapiens,,Intermediate,12400,,F,9606.0,,ACHN,,80025
7161,1,Cytotoxic effect on renal cancer line ACHN,,BAO_0000219,,Homo sapiens,,Expert,12888,,F,9606.0,,ACHN,,80025
7162,1,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,BAO_0000219,,Homo sapiens,,Intermediate,3156,,F,9606.0,,ACHN,,80025
7163,1,In vitro inhibition of Renal Cancer ACHN cell lines,,BAO_0000219,,Homo sapiens,,Intermediate,3381,,F,9606.0,,ACHN,,80025
7164,1,Antitumor activity against human renal adenocarcinoma ACHN cells,,BAO_0000219,,Homo sapiens,,Intermediate,16747,,F,9606.0,,ACHN,,80025
7165,1,Antitumor activity against human renal adenocarcinoma ACHN cells.,,BAO_0000219,,Homo sapiens,,Expert,16748,,F,9606.0,,ACHN,,80025
7166,1,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,BAO_0000219,,Homo sapiens,,Intermediate,12062,,F,9606.0,,ACHN,,80025
7167,1,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,BAO_0000219,,Homo sapiens,,Intermediate,14769,,F,9606.0,,ACHN,,80025
7168,1,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,BAO_0000219,,Homo sapiens,,Intermediate,15895,,F,9606.0,,ACHN,,80025
7169,1,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17376,,F,9606.0,,ACHN,,80025
7170,1,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,BAO_0000219,,Homo sapiens,,Intermediate,14882,,F,9606.0,,ACHN,,80025
7171,1,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,BAO_0000219,,Homo sapiens,,Intermediate,14882,,F,9606.0,,ACHN,,80025
7172,1,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,15661,,F,9606.0,,ACHN,,80025
7173,1,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,BAO_0000019,,,,Autocuration,9680,,A,,,,,22224
7174,1,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,BAO_0000019,,,,Autocuration,14579,,F,,,,,10647
7175,1,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,BAO_0000218,,Cytomegalovirus,,Expert,17290,,F,10358.0,,HEL,,50529
7176,1,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,BAO_0000218,,Cytomegalovirus,,Intermediate,17290,,F,10358.0,,,,50529
7177,1,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,BAO_0000357,,,,Autocuration,15891,,B,,,,,12159
7178,1,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,BAO_0000357,,,,Autocuration,15890,,B,,,,,12159
7179,1,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,BAO_0000219,,Bos taurus,,Intermediate,3801,,F,9913.0,,ADDP cell line,,80670
7180,1,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,BAO_0000219,,Mus musculus,,Intermediate,9222,,F,10090.0,,ADJ/PC6,,80671
7181,1,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,BAO_0000219,,Mus musculus,,Intermediate,9222,,F,10090.0,,ADJ/PC6,,80671
7182,1,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,BAO_0000219,,Mus musculus,,Intermediate,7257,,F,10090.0,,ADJ/PC6,,80671
7183,1,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,BAO_0000219,,Mus musculus,,Intermediate,7257,,F,10090.0,,ADJ/PC6,,80671
7184,1,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,BAO_0000219,,Mus musculus,,Intermediate,7257,,A,10090.0,,ADJ/PC6,,80671
7185,1,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,BAO_0000219,,Mus musculus,,Intermediate,8084,,F,10090.0,,ADJ/PC6,,80671
7186,1,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,BAO_0000019,,Mus musculus,,Autocuration,14943,,F,10090.0,,,,22224
7187,1,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,BAO_0000019,,Mus musculus,,Autocuration,14943,,F,10090.0,,,,22224
7188,1,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,BAO_0000019,,Mus musculus,,Autocuration,14943,,F,10090.0,,,,22224
7189,1,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,BAO_0000218,,Bacillus subtilis,,Autocuration,10524,In vivo,A,1423.0,,,,22224
7190,1,AUC value in dog after IV administration at a dose of 5 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,3546,,A,9615.0,,,,50588
7191,1,AUC value in dog after oral administration at a dose of 5 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,3546,,A,9615.0,,,,50588
7192,1,Cmax value in dog after oral administration at a dose of 5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3546,In vivo,A,9615.0,,,,50588
7193,1,Bioavailability in dog after oral administration at a dose of 5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3546,In vivo,A,9615.0,,,,50588
7194,1,Tmax value in dog after oral administration at a dose of 5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3546,In vivo,A,9615.0,,,,50588
7195,1,Compound was evaluated for its clearance when administered intravenously in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3184,In vivo,A,9615.0,,,,50588
7196,1,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16456,In vivo,A,9615.0,,,,50588
7197,1,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,4809,In vivo,A,9615.0,,,,50588
7198,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Intermediate,4219,,P,,,,,22229
7199,1,Half life in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3748,,A,9615.0,,,,50588
7200,1,Time taken for EC90 was determined when tested in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3132,,A,9615.0,,,,50588
7201,1,Half life (iv) was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4219,,A,9615.0,,,,50588
7202,1,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Liver,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,,A,9615.0,,,,50588
7203,1,Area under the curve was calculated in dog after iv administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6057,,A,9615.0,,,,50588
7204,1,Area under the curve was calculated in dog after peroral administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6057,,A,9615.0,,,,50588
7205,1,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17853,,A,9615.0,,,,50588
7206,1,pKa was evaluated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3639,,A,9615.0,,,,50588
7207,1,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14541,,A,9615.0,,,,50588
7208,1,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16456,In vivo,A,9615.0,,,,50588
7209,1,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16456,In vivo,A,9615.0,,,,50588
7210,1,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2652,In vivo,A,9615.0,,,,50588
7211,1,Compound was evaluated for the half-life (t 1/2) in hours,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3624,,A,9615.0,,,,50588
7212,1,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,1337,In vivo,A,9615.0,,,,50588
7213,1,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,1337,In vivo,A,9615.0,,,,50588
7214,1,Half life after intravenous administration of 1 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4709,In vivo,A,9615.0,,,,50588
7215,1,Half life was measured in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15660,,A,9615.0,,,,50588
7216,1,Half life period in dog after 5 mg/kg dose,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5302,In vivo,A,9615.0,,,,50588
7217,1,Half life period was evaluated in dog; 4-4.8,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17791,,A,9615.0,,,,50588
7218,1,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6348,In vivo,A,9615.0,,,,50588
7219,1,Half-life was determined in dog after a3 mg/kg of iv dose,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4257,In vivo,A,9615.0,,,,50588
7220,1,Half-life was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3771,,A,9615.0,,,,50588
7221,1,Half life in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6305,,A,9615.0,,,,50588
7222,1,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,13501,In vivo,A,9615.0,,,,50588
7223,1,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17594,In vivo,A,9615.0,,,,50588
7224,1,Compound was evaluated for the half life period after iv administration in Beagle dog.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3045,In vivo,A,9615.0,,,,50588
7225,1,Compound was evaluated for the half life period after oral administration in conscious dog.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3043,In vivo,A,9615.0,,,,50588
7226,1,Compound was tested for half life in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4839,,A,9615.0,,,,50588
7227,1,Compound was tested for its half life in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4839,,A,9615.0,,,,50588
7228,1,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5802,In vivo,A,9615.0,,,,50588
7229,1,Half life of compound in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17839,,A,9615.0,,,,50588
7230,1,Half life (iv) was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4219,In vivo,A,9615.0,,,,50588
7231,1,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,13966,,A,9615.0,,,,50588
7232,1,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,3994,In vivo,A,9615.0,,,,50588
7233,1,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,3994,In vivo,F,9615.0,,,,50588
7234,1,Half life in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4453,,A,9615.0,,,,50588
7235,1,Half life in dog plasma,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6535,,A,9615.0,,,,50588
7236,1,Half life in dog plasma after administration of 0.25 mg/kg iv,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6535,In vivo,A,9615.0,,,,50588
7237,1,Half life in dog plasma after administration of 1 mg/kg iv,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,6535,In vivo,A,9615.0,,,,50588
7238,1,Half life in dog plasma was determined at dose 10 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,3132,In vivo,A,9615.0,,,,50588
7239,1,Half life in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5374,,A,9615.0,,,,50588
7240,1,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,5007,In vivo,A,9615.0,,,,50588
7241,1,Half life upon exposure to human plasma,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,16907,,A,9615.0,,,,50588
7242,1,Half life was calculated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6057,,A,9615.0,,,,50588
7243,1,Half life was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5006,,A,9615.0,,,,50588
7244,1,Half life was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5473,,A,9615.0,,,,50588
7245,1,Half life by intravenous administration of 1.2 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4368,In vivo,A,9615.0,,,,50588
7246,1,Half life in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6448,,A,9615.0,,,,50588
7247,1,Half life in dog after intra venous administration of the compound,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4353,,A,9615.0,,,,50588
7248,1,Half life in dog after intra venous administration of the compound; ND means Not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4353,,A,9615.0,,,,50588
7249,1,Half life in dog after po administration of the compound,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4353,In vivo,A,9615.0,,,,50588
7250,1,Half life in dog after po administration of the compound; ND means Not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4353,In vivo,A,9615.0,,,,50588
7251,1,Half life in dog at the single oral dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6265,In vivo,A,9615.0,,,,50588
7252,1,Half life in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5006,,A,9615.0,,,,50588
7253,1,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5356,In vivo,A,9615.0,,,,50588
7254,1,Half life in rat,,BAO_0000218,,Canis lupus familiaris,,Intermediate,405,,A,9615.0,,,,50588
7255,1,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6642,In vivo,A,9615.0,,,,50588
7256,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Bone,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7257,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Bone,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7258,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Bone,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7259,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Bone,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7260,1,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Bone,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7261,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Gut,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7262,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Gut,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7263,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Gut,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7264,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Gut,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7265,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Gut,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7266,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Gut,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7267,1,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Gut,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7268,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7269,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7270,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7271,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7272,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7273,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7274,1,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Heart,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7275,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7276,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7277,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7278,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7279,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7280,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7281,1,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Kidney,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7282,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7283,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7284,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7285,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7286,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7287,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7288,1,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Liver,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7289,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7290,1,In vitro cytotoxicity against A2780 (human ovarian cancer),,BAO_0000219,,Homo sapiens,,Intermediate,5895,,F,9606.0,,A2780,,81034
7291,1,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,BAO_0000219,,Homo sapiens,,Intermediate,6338,,F,9606.0,,A2780,,81034
7292,1,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,BAO_0000219,,Homo sapiens,,Intermediate,15163,,F,9606.0,,A2780,,81034
7293,1,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,BAO_0000219,,Homo sapiens,,Intermediate,15163,,F,9606.0,,A2780,,81034
7294,1,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,BAO_0000219,,Homo sapiens,,Expert,15000,,F,9606.0,,A2780,,81034
7295,1,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,BAO_0000219,,Homo sapiens,,Expert,15000,,F,9606.0,,A2780,,81034
7296,1,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,BAO_0000219,,Homo sapiens,,Expert,14729,,F,9606.0,,A2780,,81034
7297,1,In vitro cytotoxicity against A2780 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,17270,,F,9606.0,,A2780,,81034
7298,1,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,BAO_0000219,,Homo sapiens,,Intermediate,5685,,F,9606.0,,A2780,,81034
7299,1,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,BAO_0000219,,Homo sapiens,,Intermediate,3563,,F,9606.0,,A2780,,81034
7300,1,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,BAO_0000218,,Homo sapiens,,Intermediate,17753,,F,9606.0,,A2780,,81034
7301,1,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,BAO_0000219,,Homo sapiens,,Intermediate,16317,,F,9606.0,,A2780,,81034
7302,1,Inhibition of tubulin polymerization in analogy of ca.,,BAO_0000219,,Homo sapiens,,Intermediate,16936,,F,9606.0,,A2780,,81034
7303,1,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,BAO_0000219,,Homo sapiens,,Intermediate,3801,,F,9606.0,,A2780,,81034
7304,1,Cytotoxic effect in ovarian cancer cell line (A2780),,BAO_0000219,,Homo sapiens,,Expert,6181,,F,9606.0,,A2780,,81034
7305,1,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,BAO_0000219,,Homo sapiens,,Intermediate,5318,,F,9606.0,,A2780,,81034
7306,1,Tested for the cytotoxicity in A2780 ovarian cell line,,BAO_0000219,,Homo sapiens,,Intermediate,4840,,F,9606.0,,A2780,,81034
7307,1,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,BAO_0000219,,Homo sapiens,,Intermediate,15748,,F,9606.0,,A2780,,81034
7308,1,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,BAO_0000219,,Homo sapiens,,Intermediate,15748,,F,9606.0,,A2780,,81034
7309,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,BAO_0000219,,,,Intermediate,15748,,F,,,A2780cisR,,80017
7310,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,BAO_0000219,,,,Intermediate,15748,,F,,,A2780cisR,,80017
7311,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,BAO_0000219,,,,Intermediate,15748,,F,,,A2780cisR,,80017
7312,1,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,BAO_0000219,,,,Intermediate,15748,,F,,,A2780cisR,,80017
7313,1,In vivo log of cells killed after administration of compound in A2780 cell line,,BAO_0000218,,Homo sapiens,,Intermediate,17753,,F,9606.0,,A2780,,81034
7314,1,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,,BAO_0000218,,Homo sapiens,,Intermediate,17753,In vivo,F,9606.0,,A2780,,81034
7315,1,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,BAO_0000219,,Homo sapiens,,Intermediate,16936,,F,9606.0,,A2780,,81034
7316,1,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,BAO_0000219,,Homo sapiens,,Intermediate,16936,,F,9606.0,,A2780,,81034
7317,1,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,BAO_0000219,,Homo sapiens,,Intermediate,16936,,F,9606.0,,A2780,,81034
7318,1,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,BAO_0000219,,Homo sapiens,,Intermediate,16936,,F,9606.0,,A2780,,81034
7319,1,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,BAO_0000218,,Homo sapiens,,Intermediate,17528,,F,9606.0,,A2780,,81034
7320,1,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,BAO_0000219,,Homo sapiens,,Intermediate,6633,,F,9606.0,,A2780,,81034
7321,1,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,BAO_0000219,,Homo sapiens,,Expert,15000,,F,9606.0,,A2780,,81034
7322,1,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,BAO_0000219,,Homo sapiens,,Expert,17528,,F,9606.0,,A2780,,81034
7323,1,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,16936,,F,9606.0,,A2780,,81034
7324,1,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,BAO_0000219,,Homo sapiens,,Intermediate,16936,,F,9606.0,,A2780,,81034
7325,1,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,BAO_0000219,,Homo sapiens,,Intermediate,16936,,F,9606.0,,A2780,,81034
7326,1,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,BAO_0000219,,Homo sapiens,,Intermediate,16936,,F,9606.0,,A2780,,81034
7327,1,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,BAO_0000219,,Homo sapiens,,Intermediate,16936,,F,9606.0,,A2780,,81034
7328,1,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,BAO_0000219,,Homo sapiens,,Expert,16936,,F,9606.0,,A2780,,81034
7329,1,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,BAO_0000219,,Homo sapiens,,Intermediate,16936,,F,9606.0,,A2780,,81034
7330,1,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,BAO_0000219,,Homo sapiens,,Intermediate,16936,,F,9606.0,,A2780,,81034
7331,1,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,BAO_0000219,,Homo sapiens,,Intermediate,16936,,F,9606.0,,A2780,,81034
7332,1,In vitro antiproliferative activity against A2780 cell line,,BAO_0000219,,Mus musculus,,Intermediate,17737,,F,10090.0,,A2780,,81034
7333,1,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,BAO_0000219,,Mus musculus,,Expert,17764,,F,10090.0,,A2780,,81034
7334,1,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,BAO_0000219,,Homo sapiens,,Intermediate,3830,,F,9606.0,,A2780,,81034
7335,1,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,BAO_0000219,,Homo sapiens,,Intermediate,3829,,F,9606.0,,A2780,,81034
7336,1,Vc value in dog after IV administration at a dose of 5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3546,,A,9615.0,,,,50588
7337,1,Half life period in dog after IV administration at a dose of 5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3546,In vivo,A,9615.0,,,,50588
7338,1,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,BAO_0000019,,Cercopithecidae,,Autocuration,5668,,A,9527.0,,,,22224
7339,1,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,3443,,A,9527.0,,,,22224
7340,1,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Plasma,BAO_0000218,,Cercopithecidae,,Autocuration,3443,,A,9527.0,,,,22224
7341,1,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,BAO_0000218,,Macaca fascicularis,,Autocuration,4256,In vivo,A,9541.0,,,,22224
7342,1,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,,BAO_0000218,,Macaca fascicularis,,Autocuration,4256,In vivo,A,9541.0,,,,22224
7343,1,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,,BAO_0000218,,Macaca fascicularis,,Autocuration,4256,In vivo,A,9541.0,,,,22224
7344,1,Oral Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Autocuration,4256,In vivo,A,10116.0,,,,22224
7345,1,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,BAO_0000218,,Cercopithecidae,,Autocuration,1916,,A,9527.0,,,,22224
7346,1,Area under curve value in monkey at a dose of 5 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,5302,,A,9527.0,,,,22224
7347,1,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,BAO_0000218,,Cercopithecidae,,Autocuration,4257,,A,9527.0,,,,22224
7348,1,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,BAO_0000019,,Cercopithecidae,,Autocuration,5355,,A,9527.0,,,,22224
7349,1,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,BAO_0000019,,Cercopithecidae,,Autocuration,5355,,A,9527.0,,,,22224
7350,1,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,BAO_0000019,,Cercopithecidae,,Autocuration,5355,,A,9527.0,,,,22224
7351,1,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,6078,,A,9527.0,,,,22224
7352,1,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,6078,,A,9527.0,,,,22224
7353,1,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,6062,,A,9527.0,,,,22224
7354,1,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,2661,,A,9527.0,,,,22224
7355,1,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,BAO_0000019,,Cercopithecidae,,Autocuration,2661,,A,9527.0,,,,22224
7356,1,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,5394,,A,9527.0,,,,22224
7357,1,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,BAO_0000218,,Cercopithecidae,,Autocuration,4397,,A,9527.0,,,,22224
7358,1,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,BAO_0000218,,Cercopithecidae,,Autocuration,17509,,A,9527.0,,,,22224
7359,1,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,BAO_0000218,,Cercopithecidae,,Autocuration,17509,,A,9527.0,,,,22224
7360,1,Oral AUCN in monkey (dosed at 0.5 mpk iv ),,BAO_0000218,,Cercopithecidae,,Autocuration,6641,In vivo,A,9527.0,,,,22224
7361,1,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,BAO_0000218,,Cercopithecidae,,Autocuration,5355,,A,9527.0,,,,22224
7362,1,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,,Cercopithecidae,,Autocuration,3443,In vivo,A,9527.0,,,,22224
7363,1,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,BAO_0000218,,Cercopithecidae,,Autocuration,3443,In vivo,A,9527.0,,,,22224
7364,1,Binding towards monkey plasma protein at 10 uM,,BAO_0000019,,Cercopithecidae,,Autocuration,17409,,A,9527.0,,,,22224
7365,1,Binding towards monkey plasma protein at 100 uM,,BAO_0000019,,Cercopithecidae,,Autocuration,17409,,A,9527.0,,,,22224
7366,1,Apparent bioavailability in squirrel monkey was determined,,BAO_0000218,,Cercopithecidae,,Autocuration,1052,In vivo,A,9527.0,,,,22224
7367,1,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,13501,In vivo,A,9527.0,,,,22224
7368,1,Bioavailability in monkey (dose 2 mg/kg),,BAO_0000218,,monkey,,Autocuration,17509,In vivo,A,9443.0,,,,22224
7369,1,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,5394,In vivo,A,9527.0,,,,22224
7370,1,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,2661,In vivo,A,9527.0,,,,22224
7371,1,Bioavailability in monkey (i.d. dosing),,BAO_0000218,,monkey,,Autocuration,11219,In vivo,A,9443.0,,,,22224
7372,1,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,,BAO_0000218,,Cercopithecidae,,Autocuration,3045,In vivo,A,9527.0,,,,22224
7373,1,Clearance of the drug was measured in cynomolgus,,BAO_0000019,,Cercopithecidae,,Autocuration,17796,,A,9527.0,,,,22224
7374,1,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,,BAO_0000218,,Cercopithecidae,,Autocuration,1399,In vivo,A,9527.0,,,,22224
7375,1,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,2661,In vivo,A,9527.0,,,,22224
7376,1,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Plasma,BAO_0000218,,Macaca mulatta,,Autocuration,5005,In vivo,A,9544.0,,,,22224
7377,1,Plasma clearance in rhesus monkey was determined,,BAO_0000218,,Cercopithecidae,,Autocuration,17267,In vivo,A,9527.0,,,,22224
7378,1,Plasma clearance in monkey after administration of 1 mg/kg iv,,BAO_0000218,,Cercopithecidae,,Autocuration,6535,In vivo,A,9527.0,,,,22224
7379,1,Plasma clearance in cynomolgus monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,5922,In vivo,A,9527.0,,,,22224
7380,1,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,,BAO_0000218,,Cercopithecidae,,Autocuration,6221,In vivo,A,9527.0,,,,22224
7381,1,Plasma clearance after peroral administration at 10 mpk in Rhesus,,BAO_0000218,,Cercopithecidae,,Autocuration,5668,In vivo,A,9527.0,,,,22224
7382,1,The total clearance was determined after intravenous administration in cynomolgus monkeys,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,A,9527.0,,,,22224
7383,1,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,A,9527.0,,,,22224
7384,1,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,,BAO_0000218,,Cercopithecidae,,Autocuration,5355,In vivo,A,9527.0,,,,22224
7385,1,Tested for Clearance upon iv administration to african green monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,4578,In vivo,A,9527.0,,,,22224
7386,1,Clearance in monkey,,BAO_0000218,,Cercopithecidae,,Autocuration,17592,In vivo,A,9527.0,,,,22224
7387,1,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6641,In vivo,A,9615.0,,,,50588
7388,1,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6642,In vivo,A,9615.0,,,,50588
7389,1,Half life was evaluated after intravenous administration to dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16367,In vivo,A,9615.0,,,,50588
7390,1,Half life was evaluated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5472,,A,9615.0,,,,50588
7391,1,Half life was evaluated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5474,,A,9615.0,,,,50588
7392,1,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5654,In vivo,A,9615.0,,,,50588
7393,1,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,In vivo,A,9615.0,,,,50588
7394,1,Half life period after intravenous administration in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,In vivo,A,9615.0,,,,50588
7395,1,Half life period after oral administration (2.5 mg/kg) in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6221,In vivo,A,9615.0,,,,50588
7396,1,Half life period at a dose of 1 uM/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4527,,A,9615.0,,,,50588
7397,1,Half life period was determine after peroral administration at 10 mpk in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,In vivo,A,9615.0,,,,50588
7398,1,Half life period was determine after peroral administration at 5 mpk in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5668,In vivo,A,9615.0,,,,50588
7399,1,Half life period was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3854,,A,9615.0,,,,50588
7400,1,Half life period was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5505,,A,9615.0,,,,50588
7401,1,Half life period by iv administration in dog at a dose of 6 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6251,In vivo,A,9615.0,,,,50588
7402,1,Half life period was evaluated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,1918,,A,9615.0,,,,50588
7403,1,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5546,In vivo,A,9615.0,,,,50588
7404,1,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,4809,In vivo,A,9615.0,,,,50588
7405,1,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6215,In vivo,A,9615.0,,,,50588
7406,1,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4527,In vivo,A,9615.0,,,,50588
7407,1,Half-life after oral dose of compound at 3 mg/kg in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17594,In vivo,A,9615.0,,,,50588
7408,1,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17839,In vivo,A,9615.0,,,,50588
7409,1,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17839,In vivo,A,9615.0,,,,50588
7410,1,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17839,In vivo,A,9615.0,,,,50588
7411,1,Half-life of compound in dog following p.o. administration of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17839,In vivo,A,9615.0,,,,50588
7412,1,Half-life of compound in plasma of dog was determined,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5210,,A,9615.0,,,,50588
7413,1,Half-life of compound was determined in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5210,,A,9615.0,,,,50588
7414,1,Half-life after administration of 4 mg/Kg oral dose in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2959,In vivo,A,9615.0,,,,50588
7415,1,Half-life after intravenous administration of 1 mg/kg/h in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4137,In vivo,A,9615.0,,,,50588
7416,1,Half-life in Dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5064,,A,9615.0,,,,50588
7417,1,Half-life in Dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5147,,A,9615.0,,,,50588
7418,1,Half-life in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5145,,A,9615.0,,,,50588
7419,1,Half-life in dog after oral administration at 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6123,In vivo,A,9615.0,,,,50588
7420,1,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6123,In vivo,A,9615.0,,,,50588
7421,1,Half-life in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4333,,A,9615.0,,,,50588
7422,1,Half-life in dogs; ND indicates not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4333,,A,9615.0,,,,50588
7423,1,Half-life in plasma of dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,12500,,A,9615.0,,,,50588
7424,1,Half-life in plasma of dog at dose of 3-10 mgkg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,12500,,A,9615.0,,,,50588
7425,1,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6005,In vivo,A,9615.0,,,,50588
7426,1,Half-life was measured in dog after an iv dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6062,In vivo,A,9615.0,,,,50588
7427,1,Half-life was measured in dogs after an oral dose of 10 uM/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17650,In vivo,A,9615.0,,,,50588
7428,1,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5530,In vivo,A,9615.0,,,,50588
7429,1,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5530,In vivo,A,9615.0,,,,50588
7430,1,Half-life of the compound after 0.3 mg/kg po administration in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5600,In vivo,A,9615.0,,,,50588
7431,1,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6039,In vivo,A,9615.0,,,,50588
7432,1,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6039,In vivo,A,9615.0,,,,50588
7433,1,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6039,In vivo,A,9615.0,,,,50588
7434,1,t1/2 in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6227,,A,9615.0,,,,50588
7435,1,Half-life period measured in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14541,,A,9615.0,,,,50588
7436,1,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4521,In vivo,A,9615.0,,,,50588
7437,1,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4521,In vivo,A,9615.0,,,,50588
7438,1,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6679,In vivo,A,9615.0,,,,50588
7439,1,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,1116,In vitro,A,9615.0,,,,50588
7440,1,In vivo half life period was calculated at 1 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5444,In vivo,A,9615.0,,,,50588
7441,1,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5444,In vivo,A,9615.0,,,,50588
7442,1,Longer half-life in dog (i.v.) at 0.5 mpk,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17853,In vivo,A,9615.0,,,,50588
7443,1,Oral bioavailability in dog (dose 5 uM/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,4353,In vivo,A,9615.0,,,,50588
7444,1,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,A,9615.0,,,,50588
7445,1,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,A,9615.0,,,,50588
7446,1,Bioavailability in dog (dose 1 mg/kg i.v.),,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,A,9615.0,,,,50588
7447,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7448,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7449,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7450,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7451,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7452,1,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Lung,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7453,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7454,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7455,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7456,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7457,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7458,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7459,1,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7460,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7461,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7462,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7463,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7464,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7465,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7466,1,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7467,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7468,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7469,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7470,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7471,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7472,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7473,1,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Spleen,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7474,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Stomach,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7475,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Stomach,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7476,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Stomach,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7477,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Stomach,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7478,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Stomach,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7479,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Stomach,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7480,1,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Stomach,BAO_0000218,,Mus musculus,,Intermediate,10107,In vivo,A,10090.0,,,,50594
7481,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4689,In vivo,A,10116.0,,,,50597
7482,1,Tested for the bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4950,In vivo,A,10116.0,,,,50597
7483,1,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,5328,In vivo,A,10116.0,,,,50597
7484,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,406,In vivo,A,10116.0,,,,50597
7485,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12500,In vivo,A,10116.0,,,,50597
7486,1,Bioavailability in rat (dose 3-10 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,12500,In vivo,A,10116.0,,,,50597
7487,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5247,In vivo,A,10116.0,,,,50597
7488,1,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4186,In vivo,A,10116.0,,,,50597
7489,1,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4186,In vivo,A,10116.0,,,,50597
7490,1,Half life after oral administration was determined in rats at 6 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6647,In vivo,A,10116.0,,,,50597
7491,1,Half life was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6484,,A,10116.0,,,,50597
7492,1,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,3249,In vivo,A,10116.0,,,,50597
7493,1,Plasma half life in rat at oral dose 2.8 mg/mk body weight,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6281,In vivo,A,10116.0,,,,50597
7494,1,Half life in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3307,,A,10116.0,,,,50597
7495,1,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12058,In vivo,A,10116.0,,,,50597
7496,1,Hill coefficient of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8833,,A,10116.0,,,,50597
7497,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,3193,,A,10116.0,,,,50597
7498,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,3193,,A,10116.0,,,,50597
7499,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,3193,,A,10116.0,,,,50597
7500,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,3193,,A,10116.0,,,,50597
7501,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,3193,,A,10116.0,,,,50597
7502,1,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,3193,,A,10116.0,,,,50597
7503,1,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,3193,,A,10116.0,,,,50597
7504,1,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,BAO_0000218,,Rattus norvegicus,,Intermediate,5960,,A,10116.0,,,,50597
7505,1,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
7506,1,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
7507,1,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
7508,1,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
7509,1,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
7510,1,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
7511,1,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
7512,1,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
7513,1,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
7514,1,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
7515,1,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7516,1,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7517,1,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7518,1,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7519,1,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7520,1,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7521,1,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7522,1,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7523,1,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7524,1,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7525,1,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7526,1,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7527,1,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7528,1,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7529,1,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7530,1,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7531,1,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7532,1,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7533,1,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,6351,,A,10116.0,,,,50597
7534,1,Compound was tested for solubility in water,,BAO_0000218,,Rattus norvegicus,,Intermediate,1465,,A,10116.0,,,,50597
7535,1,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),,BAO_0000100,,,,Intermediate,5182,,P,,,,,22229
7536,1,Solubility was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,17847,,A,10116.0,,,,50597
7537,1,solubility in water (ug/mL) at 37 degree C.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15339,,A,10116.0,,,,50597
7538,1,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,,BAO_0000218,,Rattus norvegicus,,Intermediate,5202,,A,10116.0,,,,50597
7539,1,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,,BAO_0000218,,Rattus norvegicus,,Intermediate,1088,,A,10116.0,,,,50597
7540,1,Half life in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3169,,A,10116.0,,,,50597
7541,1,Half life in Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5353,,A,10116.0,,,,50597
7542,1,Half life period after 3 mg/kg iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,2864,In vivo,A,10116.0,,,,50597
7543,1,Half life period after 3 mg/kg iv administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2864,In vivo,A,10116.0,,,,50597
7544,1,Half life period after 3 mg/kg iv administration in the rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2864,In vivo,A,10116.0,,,,50597
7545,1,Half life period in female Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6362,,A,10116.0,,,,50597
7546,1,Half life period in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6249,,A,10116.0,,,,50597
7547,1,Half-life in rats was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,3169,,A,10116.0,,,,50597
7548,1,Half-life in rats with metabolic oxidation,,BAO_0000218,,Rattus norvegicus,,Intermediate,3169,,A,10116.0,,,,50597
7549,1,Half-life in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3169,,A,10116.0,,,,50597
7550,1,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17260,In vivo,A,10116.0,,,,50597
7551,1,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17260,In vivo,A,10116.0,,,,50597
7552,1,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17260,In vivo,A,10116.0,,,,50597
7553,1,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17260,In vivo,A,10116.0,,,,50597
7554,1,Biological half-life measured in plasma of rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2879,,A,10116.0,,,,50597
7555,1,Biological half-life measured in plasma of rat; 22-25,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2879,,A,10116.0,,,,50597
7556,1,Biological half-life measured in plasma of rat; 9-16,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2879,,A,10116.0,,,,50597
7557,1,Compound was evaluated for its half life when administered intravenously in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3184,In vivo,A,10116.0,,,,50597
7558,1,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,,BAO_0000218,,Rattus norvegicus,,Intermediate,4891,In vivo,A,10116.0,,,,50597
7559,1,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,429,In vivo,A,10116.0,,,,50597
7560,1,Half life (T1/2) after oral administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5656,In vivo,A,10116.0,,,,50597
7561,1,Half life of compound after iv administration of 20 mg/kg dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4413,In vivo,A,10116.0,,,,50597
7562,1,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Expert,3598,In vivo,A,10116.0,,,,50597
7563,1,Half life of compound was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17267,,A,10116.0,,,,50597
7564,1,Half life of compound was determined in rat blood,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,4727,,A,10116.0,,,,50597
7565,1,Half life at 1 mg/kg was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17651,In vivo,A,10116.0,,,,50597
7566,1,Half life at 10 mg/kg was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17651,In vivo,A,10116.0,,,,50597
7567,1,Half life in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,401,,A,10116.0,,,,50597
7568,1,Half life in rats in hours,,BAO_0000218,,Rattus norvegicus,,Intermediate,4942,,A,10116.0,,,,50597
7569,1,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,17735,In vivo,A,10116.0,,,,50597
7570,1,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6056,In vivo,A,10116.0,,,,50597
7571,1,Half life was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5213,,A,10116.0,,,,50597
7572,1,Half life after i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6616,In vivo,A,10116.0,,,,50597
7573,1,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5937,In vivo,A,10116.0,,,,50597
7574,1,Half life in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5819,,A,10116.0,,,,50597
7575,1,Half life in rat plasma; Not detected,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5819,,A,10116.0,,,,50597
7576,1,Half life in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6803,,A,10116.0,,,,50597
7577,1,Half life period of compound was determined after peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17804,In vivo,A,10116.0,,,,50597
7578,1,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17804,In vivo,A,10116.0,,,,50597
7579,1,Half life period in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5948,,A,10116.0,,,,50597
7580,1,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,1916,In vivo,A,10116.0,,,,50597
7581,1,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,1916,In vivo,A,10116.0,,,,50597
7582,1,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,,BAO_0000218,,Rattus norvegicus,,Intermediate,1916,In vivo,A,10116.0,,,,50597
7583,1,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4890,In vivo,A,10116.0,,,,50597
7584,1,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17764,In vivo,A,10116.0,,,,50597
7585,1,Half life time in rat the dose of 2 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4727,In vivo,A,10116.0,,,,50597
7586,1,Half-life 24 hr after 10 mg/kg iv administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17509,In vivo,A,10116.0,,,,50597
7587,1,Half-life 24 hr after 2 mg/kg iv administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17509,In vivo,A,10116.0,,,,50597
7588,1,Half-life consistent with the observed metabolic steady state in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6597,,A,10116.0,,,,50597
7589,1,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,17735,In vivo,A,10116.0,,,,50597
7590,1,Half-life for oxidative metabolic stability was determined using male human,,BAO_0000218,,Rattus norvegicus,,Intermediate,6597,,A,10116.0,,,,50597
7591,1,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",,BAO_0000218,,Rattus norvegicus,,Intermediate,17670,In vivo,A,10116.0,,,,50597
7592,1,Half-life in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1696,,A,10116.0,,,,50597
7593,1,Half-life in rat plasma was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1742,,A,10116.0,,,,50597
7594,1,Half-life in rats was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,17800,,A,10116.0,,,,50597
7595,1,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,,BAO_0000218,,,,Autocuration,12923,,A,,,,,22224
7596,1,Area under curve after oral dose of 0.1 mg//kg,,BAO_0000019,,,,Autocuration,11954,,A,,,,,22224
7597,1,Area under curve after oral dose of 0.3 mg/kg,,BAO_0000218,,,,Autocuration,11954,,A,,,,,22224
7598,1,Area under curve after oral dose of 1 mg/kg,,BAO_0000218,,,,Autocuration,11954,,A,,,,,22224
7599,1,Area under curve after oral dose of 10 mg/kg,,BAO_0000218,,,,Autocuration,11954,,A,,,,,22224
7600,1,Area under curve after oral dose of 23.4 mg/kg,,BAO_0000218,,,,Autocuration,11954,,A,,,,,22224
7601,1,Area under curve after oral dose of 3 mg/kg,,BAO_0000218,,,,Autocuration,11954,,A,,,,,22224
7602,1,Area under curve after oral dose of 3.87 mg/kg,,BAO_0000218,,,,Autocuration,11954,,A,,,,,22224
7603,1,Area under curve was determined,,BAO_0000019,,,,Autocuration,5237,,A,,,,,22224
7604,1,Area under curve at a dose of 10 mg/kg,,BAO_0000218,,,,Autocuration,4026,,A,,,,,22224
7605,1,Area under curve was determined; ND=No data,,BAO_0000218,,Rattus norvegicus,,Intermediate,5237,,A,10116.0,,,,50597
7606,1,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,A,10116.0,,,,50597
7607,1,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,A,10116.0,,,,50597
7608,1,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,A,10116.0,,,,50597
7609,1,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,A,10116.0,,,,50597
7610,1,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,A,10116.0,,,,50597
7611,1,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,A,10116.0,,,,50597
7612,1,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,A,10116.0,,,,50597
7613,1,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,A,10116.0,,,,50597
7614,1,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,A,10116.0,,,,50597
7615,1,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,A,10116.0,,,,50597
7616,1,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,A,10116.0,,,,50597
7617,1,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,A,10116.0,,,,50597
7618,1,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,A,10116.0,,,,50597
7619,1,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,A,10116.0,,,,50597
7620,1,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,A,10116.0,,,,50597
7621,1,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,,A,10116.0,,,,50597
7622,1,AUC in mice,Plasma,BAO_0000218,,Mus musculus,,Intermediate,11637,,A,10090.0,,,,50594
7623,1,Area under curve was measured from the graph obtained from concentration Vs time,,BAO_0000019,,,,Autocuration,11149,,A,,,,,22224
7624,1,Area under curve value of compound per hour after oral administration,,BAO_0000019,,,,Autocuration,10016,,A,,,,,22224
7625,1,Area under curve was determined after oral administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17796,,A,10116.0,,,,50597
7626,1,Area under curve was determined after oral administration in rats; No data,,BAO_0000218,,Rattus norvegicus,,Intermediate,17796,,A,10116.0,,,,50597
7627,1,Area under curve was determined after oral administration in rats;No data,,BAO_0000218,,Rattus norvegicus,,Intermediate,17796,,A,10116.0,,,,50597
7628,1,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12923,,A,9615.0,,,,50588
7629,1,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,,A,10116.0,,,,50597
7630,1,Area under curve was determined for the compound after iv dose of 5.06 in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,,A,10116.0,,,,50597
7631,1,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,,A,10116.0,,,,50597
7632,1,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,,A,10116.0,,,,50597
7633,1,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,,A,10116.0,,,,50597
7634,1,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,,A,10116.0,,,,50597
7635,1,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,,A,10116.0,,,,50597
7636,1,Area under curve was determined in Dogs after peroral administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14169,,A,9615.0,,,,50588
7637,1,Area under curve was determined in Rats after peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,14169,,A,10116.0,,,,50597
7638,1,Area under curve was determined in carotid blood of rat when administered intradermally,,BAO_0000218,,Rattus norvegicus,,Intermediate,14258,,A,10116.0,,,,50597
7639,1,Area under curve was determined in portal blood of rat when administered intradermally,,BAO_0000218,,Rattus norvegicus,,Intermediate,14258,,A,10116.0,,,,50597
7640,1,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,15011,,A,10090.0,,,,50594
7641,1,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,15011,,A,10090.0,,,,50594
7642,1,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,BAO_0000218,,Mus musculus,,Intermediate,15011,,A,10090.0,,,,50594
7643,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,15011,,A,10090.0,,,,50594
7644,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),,BAO_0000218,,Mus musculus,,Intermediate,15011,,A,10090.0,,,,50594
7645,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,15011,,A,10090.0,,,,50594
7646,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),,BAO_0000218,,Mus musculus,,Intermediate,15011,,A,10090.0,,,,50594
7647,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
7648,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7649,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7650,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7651,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7652,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7653,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7654,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7655,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7656,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7657,1,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7658,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7659,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7660,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7661,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7662,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7663,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7664,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7665,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7666,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7667,1,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7668,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7669,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7670,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7671,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7672,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7673,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7674,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7675,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7676,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7677,1,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
7678,1,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6295,,A,10116.0,,,,50597
7679,1,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6296,,A,10116.0,,,,50597
7680,1,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,,BAO_0000218,,Rattus norvegicus,,Intermediate,6296,,A,10116.0,,,,50597
7681,1,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6295,,A,10116.0,,,,50597
7682,1,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6296,,A,10116.0,,,,50597
7683,1,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17260,In vivo,A,10116.0,,,,50597
7684,1,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17260,In vivo,A,10116.0,,,,50597
7685,1,C24h in rat p.o. at 20 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17686,,A,10116.0,,,,50597
7686,1,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7687,1,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7688,1,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7689,1,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7690,1,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7691,1,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7692,1,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7693,1,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7694,1,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7695,1,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7696,1,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7697,1,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7698,1,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7699,1,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7700,1,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7701,1,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7702,1,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7703,1,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7704,1,Biodistribution in rat blood in the presence of GdDTPA at 15 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7705,1,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7706,1,Biodistribution in rat blood in the presence of GdDTPA at 30 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7707,1,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7708,1,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7709,1,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7710,1,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7711,1,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7712,1,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7713,1,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7714,1,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7715,1,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7716,1,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7717,1,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7718,1,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7719,1,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7720,1,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7721,1,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7722,1,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7723,1,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7724,1,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7725,1,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7726,1,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7727,1,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7728,1,Biodistribution in rat bone in the presence of GdDTPA at 15 min,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7729,1,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7730,1,Biodistribution in rat bone in the presence of GdDTPA at 30 min,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7731,1,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7732,1,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7733,1,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7734,1,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7735,1,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7736,1,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7737,1,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7738,1,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7739,1,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7740,1,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7741,1,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7742,1,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7743,1,Half-life from rat plasma at a single oral dose of 25 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17752,In vivo,A,10116.0,,,,50597
7744,1,Half-life in male rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5610,,A,10116.0,,,,50597
7745,1,Half-life in rat after peroral administration at 10 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5939,In vivo,A,10116.0,,,,50597
7746,1,Half-life in rat after peroral administration at 5 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5939,In vivo,A,10116.0,,,,50597
7747,1,Half-life in rat at a dose of 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17771,In vivo,A,10116.0,,,,50597
7748,1,Half-life was evaluated in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,1974,,A,10116.0,,,,50597
7749,1,Half-life was measured in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4239,,A,10116.0,,,,50597
7750,1,Half-life period for the compound was determined in rats at 50 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,6681,In vivo,A,10116.0,,,,50597
7751,1,Half-life period in rats after intravenous administration at 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17752,In vivo,A,10116.0,,,,50597
7752,1,Half-life period in rat at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6046,In vivo,A,10116.0,,,,50597
7753,1,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,A,10116.0,,,,50597
7754,1,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,A,10116.0,,,,50597
7755,1,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,A,10116.0,,,,50597
7756,1,Half-life time in rat the dose of 2 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4727,In vivo,A,10116.0,,,,50597
7757,1,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,1088,In vivo,A,10116.0,,,,50597
7758,1,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5610,In vivo,A,10116.0,,,,50597
7759,1,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3032,In vivo,A,10116.0,,,,50597
7760,1,Oral half life was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5199,In vivo,A,10116.0,,,,50597
7761,1,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",,BAO_0000218,,Rattus norvegicus,,Intermediate,14941,In vivo,A,10116.0,,,,50597
7762,1,Pharmacokinetic property (t1/2) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4408,In vivo,A,10116.0,,,,50597
7763,1,Plasma elimination half-life was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2552,,A,10116.0,,,,50597
7764,1,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5199,In vivo,A,10116.0,,,,50597
7765,1,Plasma half life was observed after intravenous administration in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,A,10116.0,,,,50597
7766,1,Plasma half-life was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1465,,A,10116.0,,,,50597
7767,1,Plasma half-life following oral administration in Fisher rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1446,In vivo,A,10116.0,,,,50597
7768,1,Plasma half-life in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6824,,A,10116.0,,,,50597
7769,1,Plasmatic Half-life after intravenous administration to rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17533,In vivo,A,10116.0,,,,50597
7770,1,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5979,In vivo,A,10116.0,,,,50597
7771,1,Terminal half life after intravenous administration (1 mg/kg) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4689,In vivo,A,10116.0,,,,50597
7772,1,Terminal half life in Rat at a oral dose of 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4689,In vivo,A,10116.0,,,,50597
7773,1,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,2463,In vivo,A,10116.0,,,,50597
7774,1,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4883,In vivo,A,10116.0,,,,50597
7775,1,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4883,In vivo,A,10116.0,,,,50597
7776,1,plasma half life was observed after intravenous administration in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,A,10116.0,,,,50597
7777,1,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Expert,3598,In vivo,A,10116.0,,,,50597
7778,1,Half life of compound determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4576,,A,10116.0,,,,50597
7779,1,Mean residence time determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4576,,A,10116.0,,,,50597
7780,1,Plasma half life determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4576,,A,10116.0,,,,50597
7781,1,Compound was evaluated for Tmax in brain after intravenous administration in male rats,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,In vivo,A,10116.0,,,,50597
7782,1,Compound was evaluated for pharmacokinetic parameter maximum time period,,BAO_0000218,,Rattus norvegicus,,Intermediate,4891,In vivo,A,10116.0,,,,50597
7783,1,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,429,In vivo,A,10116.0,,,,50597
7784,1,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,A,10116.0,,,,50597
7785,1,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,A,10116.0,,,,50597
7786,1,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,A,10116.0,,,,50597
7787,1,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,A,10116.0,,,,50597
7788,1,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17582,In vivo,A,10116.0,,,,50597
7789,1,Maximum time (Tmax) required to reach Cmax in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4026,,A,10116.0,,,,50597
7790,1,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4890,In vivo,A,10116.0,,,,50597
7791,1,Maximum time of clearance of compound in rats after peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6571,In vivo,A,10116.0,,,,50597
7792,1,Maximum time at the dose of 2 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4727,,A,10116.0,,,,50597
7793,1,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17651,In vivo,A,10116.0,,,,50597
7794,1,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17651,In vivo,A,10116.0,,,,50597
7795,1,Tmax in Guinea pig (PO dose),,BAO_0000218,,Rattus norvegicus,,Intermediate,14465,In vivo,A,10116.0,,,,50597
7796,1,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",,BAO_0000218,,Rattus norvegicus,,Intermediate,14941,In vivo,A,10116.0,,,,50597
7797,1,Pharmacokinetic parameter (Tmax) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5960,In vivo,A,10116.0,,,,50597
7798,1,Pharmacokinetic parameter (Tmax) was estimated,,BAO_0000218,,Rattus norvegicus,,Intermediate,5022,In vivo,A,10116.0,,,,50597
7799,1,Pharmacokinetic property (Tmax) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4408,In vivo,A,10116.0,,,,50597
7800,1,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5983,In vivo,A,10116.0,,,,50597
7801,1,T max in Rat at a oral dose of 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4689,In vivo,A,10116.0,,,,50597
7802,1,T max was determined at 10 mg/kg po dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,A,10116.0,,,,50597
7803,1,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),,BAO_0000218,,Mus musculus,,Intermediate,15011,,A,10090.0,,,,50594
7804,1,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14180,,A,9615.0,,,,50588
7805,1,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14180,,A,10116.0,,,,50597
7806,1,Area under curve was measured after i.v. administration into Beagle dog.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14599,,A,9615.0,,,,50588
7807,1,Area under curve was measured after iv administration into Beagle dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14599,,A,9615.0,,,,50588
7808,1,Area under curve was measured after po administration into Beagle dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14599,,A,9615.0,,,,50588
7809,1,Area under curve was measured after po administration into Beagle dog.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14599,,A,9615.0,,,,50588
7810,1,Area under curve was measured at peroral dose of 3 mg/kg,,BAO_0000218,,,,Autocuration,15675,,A,,,,,22224
7811,1,Area under curve was measured by using concentration Vs time,,BAO_0000019,,,,Autocuration,12706,,A,,,,,22224
7812,1,Area under curve was measured by using concentration Vs time; not tested,,BAO_0000019,,,,Autocuration,12706,,A,,,,,22224
7813,1,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),,BAO_0000218,,Mus musculus,,Intermediate,9750,,A,10090.0,,,,50594
7814,1,Area under curve(AUC) was measured in mice after oral administration.,,BAO_0000218,,Mus musculus,,Intermediate,9750,,A,10090.0,,,,50594
7815,1,Area under curve(AUC) value of the compound,,BAO_0000019,,,,Autocuration,14691,,A,,,,,22224
7816,1,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,,BAO_0000218,,,,Autocuration,14691,,A,,,,,22224
7817,1,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14691,,A,9615.0,,,,50588
7818,1,Area under curve(carotid artery) was determined by the availability in blood,Blood,BAO_0000019,,,,Autocuration,2939,,A,,,,,22224
7819,1,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,Blood,BAO_0000019,,,,Autocuration,2939,,A,,,,,22224
7820,1,Area under curve(carotid artery) was determined by the availability in blood; No data,Blood,BAO_0000019,,,,Autocuration,2939,,A,,,,,22224
7821,1,Area under curve(portal vein) was determined by the availability in blood,Blood,BAO_0000019,,,,Autocuration,2939,,A,,,,,22224
7822,1,Area under curve(portal vein) was determined by the availability in blood; ND means no data,Blood,BAO_0000019,,,,Autocuration,2939,,A,,,,,22224
7823,1,Area under curve(portal vein) was determined by the availability in blood; No data,Blood,BAO_0000019,,,,Autocuration,2939,,A,,,,,22224
7824,1,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",Plasma,BAO_0000218,,Macaca mulatta,,Intermediate,9552,,A,9544.0,,,,50797
7825,1,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",Plasma,BAO_0000218,,Macaca mulatta,,Intermediate,9552,,A,9544.0,,,,50797
7826,1,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,Plasma,BAO_0000218,,Macaca mulatta,,Intermediate,9552,,A,9544.0,,,,50797
7827,1,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,9552,,A,9615.0,,,,50588
7828,1,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,9552,,A,9615.0,,,,50588
7829,1,Area under plasma concentration vs time curve observed in rats for 0-3 h,Plasma,BAO_0000019,,,,Autocuration,9552,,A,,,,,22224
7830,1,Area under plasma time curve determined in male rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,11911,,A,10116.0,,,,50597
7831,1,Area under the MAP curve measured over 5 min.,,BAO_0000019,,,,Autocuration,16618,,A,,,,,22224
7832,1,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,,BAO_0000218,,Mus musculus,,Intermediate,14387,,A,10090.0,,,,50594
7833,1,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,,BAO_0000218,,Mus musculus,,Intermediate,14387,,A,10090.0,,,,50594
7834,1,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12836,,A,9615.0,,,,50588
7835,1,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,,BAO_0000218,,Cricetinae,,Intermediate,12836,,A,10026.0,,,,100712
7836,1,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,12836,,A,10116.0,,,,50597
7837,1,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14339,,A,9615.0,,,,50588
7838,1,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14339,,A,9615.0,,,,50588
7839,1,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14339,,A,9615.0,,,,50588
7840,1,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,10524,,A,9615.0,,,,50588
7841,1,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,9994,,A,9615.0,,,,50588
7842,1,Serum AUC in marmosets (IV dose),,BAO_0000218,,Canis lupus familiaris,,Intermediate,11325,,A,9615.0,,,,50588
7843,1,Area under the curve after intravenous administration at a dose of 10 umol/kg,,BAO_0000019,,,,Autocuration,12536,,A,,,,,22224
7844,1,Area under the curve after intravenous administration at a dose of 2 umol/kg,,BAO_0000019,,,,Autocuration,12536,,A,,,,,22224
7845,1,Area under the curve after intravenous administration at a dose of 4 umol/kg,,BAO_0000019,,,,Autocuration,12536,,A,,,,,22224
7846,1,Area under the curve after intravenous administration at a dose of 40 umol/kg,,BAO_0000019,,,,Autocuration,12536,,A,,,,,22224
7847,1,Area under the curve after intravenous administration at a dose of 5 umol/kg,,BAO_0000019,,,,Autocuration,12536,,A,,,,,22224
7848,1,Area under the curve for fumarate salt was evaluated in F344 Rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15556,,A,10116.0,,,,50597
7849,1,Area under the curve for the compound was calculated.,,BAO_0000019,,,,Autocuration,2809,,A,,,,,22224
7850,1,Area under the curve in concentration/ time,,BAO_0000019,,,,Autocuration,9511,,A,,,,,22224
7851,1,Area under the curve administered intraintestinal in rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,12818,,A,10116.0,,,,50597
7852,1,Area under the curve administered intravenously in rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,12818,,A,10116.0,,,,50597
7853,1,Area under the curve during intravenous administration,,BAO_0000019,,,,Autocuration,15118,,A,,,,,22224
7854,1,Area under the curve during intravenous administration; Not determined,,BAO_0000019,,,,Autocuration,15118,,A,,,,,22224
7855,1,Area under the curve during systemic administration,,BAO_0000019,,,,Autocuration,15118,,A,,,,,22224
7856,1,Area under the curve during systemic administration; Not determined,,BAO_0000019,,,,Autocuration,15118,,A,,,,,22224
7857,1,Area under the curve was calculated for the compound.,,BAO_0000019,,,,Autocuration,2632,,A,,,,,22224
7858,1,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14346,,A,9615.0,,,,50588
7859,1,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14346,,A,9615.0,,,,50588
7860,1,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,,A,10116.0,,,,50597
7861,1,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,,A,10116.0,,,,50597
7862,1,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11149,,A,10116.0,,,,50597
7863,1,Clearance of the drug was measured in the plasma of rat; No data,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17796,,A,10116.0,,,,50597
7864,1,The pharmacokinetic parameter plasma clearance in vivo in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5247,,A,10116.0,,,,50597
7865,1,Plasma clearance at the dose of 2 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4727,,A,10116.0,,,,50597
7866,1,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5654,In vivo,A,10116.0,,,,50597
7867,1,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5654,In vivo,A,10116.0,,,,50597
7868,1,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17260,In vivo,A,10116.0,,,,50597
7869,1,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17065,In vivo,A,10116.0,,,,50597
7870,1,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17671,In vivo,A,10116.0,,,,50597
7871,1,Clearance rate in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6672,In vivo,A,10116.0,,,,50597
7872,1,Clearance rate in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6673,In vivo,A,10116.0,,,,50597
7873,1,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
7874,1,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
7875,1,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
7876,1,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
7877,1,Clearance of compound after iv administration of 20 mg/kg dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4413,In vivo,A,10116.0,,,,50597
7878,1,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,In vivo,A,10116.0,,,,50597
7879,1,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,In vivo,A,10116.0,,,,50597
7880,1,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Plasma,BAO_0000218,,Macaca mulatta,,Intermediate,5005,In vivo,A,9544.0,,,,22224
7881,1,Compound was tested for its plasma clearance rate in Sprague Dawley rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5005,In vivo,A,10116.0,,,,22224
7882,1,Mean (%CV) PK parameters for CL(mL/min/kg).,,BAO_0000218,,Rattus norvegicus,,Intermediate,15765,In vivo,A,10116.0,,,,50597
7883,1,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3747,In vivo,A,10116.0,,,,50597
7884,1,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,16366,In vivo,A,10116.0,,,,50597
7885,1,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4199,In vivo,A,10116.0,,,,50597
7886,1,Plasma clearance in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,17267,In vivo,A,10116.0,,,,50597
7887,1,Plasma clearance in rat after administration of 2 mg/kg iv,,BAO_0000218,,Rattus norvegicus,,Intermediate,6535,In vivo,A,10116.0,,,,50597
7888,1,Plasma clearance in rat after administration of 2 mg/kg iv,,BAO_0000218,,Rattus norvegicus,,Intermediate,6535,In vivo,A,10116.0,,,,50597
7889,1,Plasma clearance was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,In vivo,A,10116.0,,,,50597
7890,1,Plasma clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5960,In vivo,A,10116.0,,,,50597
7891,1,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5937,In vivo,A,10116.0,,,,50597
7892,1,Plasma clearance in rat by iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5871,In vivo,A,10116.0,,,,50597
7893,1,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5874,In vivo,A,10116.0,,,,50597
7894,1,Plasma clearance in rat p.o.,,BAO_0000218,,Rattus norvegicus,,Intermediate,6504,In vivo,A,10116.0,,,,50597
7895,1,Plasma clearance in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6803,In vivo,A,10116.0,,,,50597
7896,1,Plasma clearance was determined; ND denotes no data,,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,In vivo,A,10116.0,,,,50597
7897,1,Plasma clearance was determined; ND denotes not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,In vivo,A,10116.0,,,,50597
7898,1,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,1916,In vivo,A,10116.0,,,,50597
7899,1,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,BAO_0000218,,Rattus norvegicus,,Intermediate,5199,In vivo,A,10116.0,,,,50597
7900,1,Plasma administration to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,16367,In vivo,A,10116.0,,,,50597
7901,1,Plasma clearance of the compound in female Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6362,In vivo,A,10116.0,,,,50597
7902,1,Plasma clearance was observed after intravenous administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,A,10116.0,,,,50597
7903,1,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6215,In vivo,A,10116.0,,,,50597
7904,1,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1466,In vivo,A,10116.0,,,,50597
7905,1,plasma clearance was observed after intravenous administration in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,A,10116.0,,,,50597
7906,1,In vivo CL/F determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,In vivo,A,10116.0,,,,50597
7907,1,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,A,10116.0,,,,50597
7908,1,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,A,10116.0,,,,50597
7909,1,Compound was tested for the lower blood clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5213,In vivo,A,10116.0,,,,50597
7910,1,Evaluated for the low clearance in rat (in vivo),,BAO_0000218,,Rattus norvegicus,,Intermediate,4687,In vivo,A,10116.0,,,,50597
7911,1,Pharmacokinetic property (CLb)of the compound was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3371,In vivo,A,10116.0,,,,50597
7912,1,Rapid clearance after intravenous administration in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4690,In vivo,A,10116.0,,,,50597
7913,1,Clearance measured in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5702,In vivo,A,10116.0,,,,50597
7914,1,Compound was evaluated for plasma clearance in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,740,In vivo,A,10116.0,,,,50597
7915,1,Low plasma clearance was calculated in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4853,In vivo,A,10116.0,,,,50597
7916,1,Pharmacokinetic property (Clp) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5789,In vivo,A,10116.0,,,,50597
7917,1,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4527,In vivo,A,10116.0,,,,50597
7918,1,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4527,In vivo,A,10116.0,,,,50597
7919,1,Plasma clearance after IV dosing at 0.5 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,A,10116.0,,,,50597
7920,1,Plasma clearance after IV dosing at 1 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,A,10116.0,,,,50597
7921,1,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7922,1,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7923,1,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7924,1,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7925,1,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7926,1,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7927,1,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7928,1,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7929,1,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7930,1,Biodistribution in rat heart in the presence of GdDTPA at 15 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7931,1,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7932,1,Biodistribution in rat heart in the presence of GdDTPA at 30 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7933,1,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7934,1,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7935,1,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7936,1,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7937,1,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7938,1,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7939,1,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7940,1,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7941,1,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7942,1,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7943,1,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7944,1,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7945,1,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7946,1,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7947,1,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7948,1,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7949,1,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7950,1,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7951,1,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7952,1,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7953,1,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7954,1,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7955,1,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7956,1,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7957,1,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7958,1,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7959,1,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7960,1,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7961,1,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7962,1,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7963,1,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7964,1,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7965,1,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7966,1,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7967,1,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7968,1,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7969,1,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7970,1,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7971,1,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7972,1,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7973,1,Biodistribution in rat liver in the presence of GdDTPA at 15 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7974,1,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7975,1,Biodistribution in rat liver in the presence of GdDTPA at 30 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7976,1,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7977,1,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
7978,1,T max was determined at 3 mg/kg po dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,A,10116.0,,,,50597
7979,1,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,In vivo,A,10116.0,,,,50597
7980,1,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,In vivo,A,10116.0,,,,50597
7981,1,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,15022,,A,10116.0,,,,50597
7982,1,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,15022,,A,10116.0,,,,50597
7983,1,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,15022,,A,10116.0,,,,50597
7984,1,Time for maximum plasma concentration determined in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4576,,A,10116.0,,,,50597
7985,1,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6681,In vivo,A,10116.0,,,,50597
7986,1,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,A,10116.0,,,,50597
7987,1,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,A,10116.0,,,,50597
7988,1,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,A,10116.0,,,,50597
7989,1,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,A,10116.0,,,,50597
7990,1,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,A,10116.0,,,,50597
7991,1,Time of maximum plasma concentration in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6824,,A,10116.0,,,,50597
7992,1,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,,A,10116.0,,,,50597
7993,1,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,,A,10116.0,,,,50597
7994,1,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,,A,10116.0,,,,50597
7995,1,Time required to reach maximum concentration (Cmax) after oral administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,A,10116.0,,,,50597
7996,1,Time required to reach maximum concentration in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1742,,A,10116.0,,,,50597
7997,1,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2774,In vivo,A,10116.0,,,,50597
7998,1,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5199,In vivo,A,10116.0,,,,50597
7999,1,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12873,In vivo,A,10116.0,,,,50597
8000,1,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12873,In vivo,A,10116.0,,,,50597
8001,1,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1916,In vivo,A,10116.0,,,,50597
8002,1,Time to reach Cmax after oral administration to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,16367,In vivo,A,10116.0,,,,50597
8003,1,Time to reach Cmax when a dose of 1 mg/kg is administered orally,,BAO_0000218,,Rattus norvegicus,,Intermediate,16366,In vivo,A,10116.0,,,,50597
8004,1,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,,BAO_0000218,,Rattus norvegicus,,Intermediate,216,,A,10116.0,,,,50597
8005,1,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,In vivo,A,10116.0,,,,50597
8006,1,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,In vivo,A,10116.0,,,,50597
8007,1,Tmax after peroral administration (10 mg/kg) was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6215,In vivo,A,10116.0,,,,50597
8008,1,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Expert,3598,In vivo,A,10116.0,,,,50597
8009,1,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4527,In vivo,A,10116.0,,,,50597
8010,1,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",,BAO_0000218,,Rattus norvegicus,,Intermediate,17670,In vivo,A,10116.0,,,,50597
8011,1,Tmax was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,1465,,A,10116.0,,,,50597
8012,1,Tmax was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,2552,,A,10116.0,,,,50597
8013,1,Tmax after oral administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5656,In vivo,A,10116.0,,,,50597
8014,1,Tmax after peroral administration in rats at 2.4 uM/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17764,In vivo,A,10116.0,,,,50597
8015,1,Tmax in male rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5610,,A,10116.0,,,,50597
8016,1,Tmax in rat at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6046,In vivo,A,10116.0,,,,50597
8017,1,Tmax in rat by po administration at a dose of 40 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5874,In vivo,A,10116.0,,,,50597
8018,1,Tmax in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17596,,A,10116.0,,,,50597
8019,1,Tmax was measured in rats after peroral administration at 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17804,In vivo,A,10116.0,,,,50597
8020,1,Tmax value after oral dose at a dose of 10 mg/kg in rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,1908,In vivo,A,10116.0,,,,50597
8021,1,Tmax value after administration of 20 mg/Kg oral dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2959,In vivo,A,10116.0,,,,50597
8022,1,Tmax value at a dose of 10 mg/kg in male SD rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6757,In vivo,A,10116.0,,,,50597
8023,1,Tmax value at a dose of 100 mg/kg in male SD rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6757,In vivo,A,10116.0,,,,50597
8024,1,Tmax value at a dose of 50 mg/kg in male SD rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6757,In vivo,A,10116.0,,,,50597
8025,1,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4186,In vivo,A,10116.0,,,,50597
8026,1,time required to reach maximum concentration (Cmax) after oral administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,A,10116.0,,,,50597
8027,1,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,429,,A,10116.0,,,,50597
8028,1,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,429,,A,10116.0,,,,50597
8029,1,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5546,,A,10116.0,,,,50597
8030,1,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,3173,,A,10116.0,,,,50597
8031,1,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,3173,,A,10116.0,,,,50597
8032,1,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,3173,,A,10116.0,,,,50597
8033,1,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,4257,In vivo,A,10116.0,,,,50597
8034,1,Compound distribution in rat tissues was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6011,In vivo,A,10116.0,,,,50597
8035,1,Volume of distribution was evaluated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5472,In vivo,A,10116.0,,,,50597
8036,1,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,,A,10116.0,,,,50597
8037,1,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,,A,10116.0,,,,50597
8038,1,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14346,,A,9615.0,,,,50588
8039,1,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,,A,10116.0,,,,50597
8040,1,Area under the curve was determined after oral administration (300 uM/Kg),,BAO_0000019,,,,Autocuration,15469,,A,,,,,22224
8041,1,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,,A,10116.0,,,,50597
8042,1,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,,A,10116.0,,,,50597
8043,1,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,,A,10116.0,,,,50597
8044,1,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,,A,10116.0,,,,50597
8045,1,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,,A,10116.0,,,,50597
8046,1,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,,A,10116.0,,,,50597
8047,1,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,12935,,A,9615.0,,,,50588
8048,1,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,12935,,A,9615.0,,,,50588
8049,1,Plasma drug AUC in rat (PO dose),,BAO_0000218,,,,Autocuration,14813,,A,,,,,22224
8050,1,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,,BAO_0000218,,Mus musculus,,Intermediate,15792,,A,10090.0,,,,50594
8051,1,Area under was determined at a dose of 30 mg/kg,,BAO_0000218,,,,Autocuration,3579,,A,,,,,22224
8052,1,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,,BAO_0000218,,Mustela putorius furo,,Intermediate,12487,,A,9669.0,,,,50506
8053,1,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12487,,A,10116.0,,,,50597
8054,1,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12487,,A,10116.0,,,,50597
8055,1,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,,BAO_0000218,,Mustela putorius furo,,Intermediate,12487,,A,9669.0,,,,50506
8056,1,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12487,,A,9615.0,,,,50588
8057,1,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12487,,A,9615.0,,,,50588
8058,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",,BAO_0000218,,Rattus norvegicus,,Intermediate,12902,,A,10116.0,,,,50597
8059,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",,BAO_0000218,,Rattus norvegicus,,Intermediate,12902,,A,10116.0,,,,50597
8060,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",,BAO_0000218,,Rattus norvegicus,,Intermediate,12902,,A,10116.0,,,,50597
8061,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",,BAO_0000218,,Rattus norvegicus,,Intermediate,12902,,A,10116.0,,,,50597
8062,1,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",,BAO_0000218,,Rattus norvegicus,,Intermediate,12902,,A,10116.0,,,,50597
8063,1,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",,BAO_0000218,,Rattus norvegicus,,Intermediate,12902,,A,10116.0,,,,50597
8064,1,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",,BAO_0000218,,Rattus norvegicus,,Intermediate,12902,,A,10116.0,,,,50597
8065,1,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",,BAO_0000218,,Rattus norvegicus,,Intermediate,12902,,A,10116.0,,,,50597
8066,1,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,,BAO_0000218,,Mus musculus,,Intermediate,12745,,A,10090.0,,,,50594
8067,1,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,BAO_0000218,,Mus musculus,,Intermediate,12745,,A,10090.0,,,,50594
8068,1,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,,BAO_0000218,,Mus musculus,,Intermediate,12745,,A,10090.0,,,,50594
8069,1,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,BAO_0000218,,Mus musculus,,Intermediate,12745,,A,10090.0,,,,50594
8070,1,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,,BAO_0000218,,Mus musculus,,Intermediate,12745,,A,10090.0,,,,50594
8071,1,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,BAO_0000218,,Mus musculus,,Intermediate,12745,,A,10090.0,,,,50594
8072,1,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,,BAO_0000218,,Mus musculus,,Intermediate,12745,,A,10090.0,,,,50594
8073,1,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),,BAO_0000218,,Mus musculus,,Intermediate,12745,,A,10090.0,,,,50594
8074,1,AUC in mice after oral dose (50 mg/kg),Plasma,BAO_0000218,,,,Autocuration,13298,,A,,,,,22224
8075,1,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,Serum,BAO_0000218,,Mus musculus,,Intermediate,12226,,A,10090.0,,,,50594
8076,1,AUC (0-4 hr) ug/ml/h,Plasma,BAO_0000019,,,,Autocuration,12634,,A,,,,,22224
8077,1,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,,BAO_0000218,,Rattus norvegicus,,Intermediate,14810,,A,10116.0,,,,50597
8078,1,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,,BAO_0000218,,,,Autocuration,13889,,A,,,,,22224
8079,1,Compound was evaluated for Area under curve in mice,,BAO_0000218,,Mus musculus,,Intermediate,10018,,A,10090.0,,,,50594
8080,1,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,BAO_0000218,,Rattus norvegicus,,Intermediate,8758,,A,10116.0,,,,50597
8081,1,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,BAO_0000218,,,,Autocuration,8758,,F,,,,,22224
8082,1,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,BAO_0000218,,Rattus norvegicus,,Intermediate,8758,,A,10116.0,,,,50597
8083,1,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,,BAO_0000019,,,,Autocuration,2249,,A,,,,,22224
8084,1,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,,BAO_0000019,,,,Autocuration,2249,,A,,,,,22224
8085,1,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,,BAO_0000019,,,,Autocuration,2249,,A,,,,,22224
8086,1,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,,BAO_0000019,,,,Autocuration,2249,,A,,,,,22224
8087,1,Compound was evaluated for area under curve when administered through oral route in mouse,,BAO_0000218,,Mus musculus,,Intermediate,15115,,A,10090.0,,,,50594
8088,1,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,A,10116.0,,,,50597
8089,1,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,A,10116.0,,,,50597
8090,1,Plasma clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6249,In vivo,A,10116.0,,,,50597
8091,1,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,2463,In vivo,A,10116.0,,,,50597
8092,1,Plasma clearance rate in Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4969,In vivo,A,10116.0,,,,50597
8093,1,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17720,In vivo,F,10116.0,,,,50597
8094,1,Pharmacokinetic property (total body clearance) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3457,In vivo,A,10116.0,,,,50597
8095,1,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5983,In vivo,A,10116.0,,,,50597
8096,1,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6295,,A,10116.0,,,,50597
8097,1,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6296,,A,10116.0,,,,50597
8098,1,Cl in rat i.v. at 2 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17686,In vivo,A,10116.0,,,,50597
8099,1,Clearance of compound after intravenous administration in rats at 24 uM/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17764,In vivo,A,10116.0,,,,50597
8100,1,Clearance was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5503,In vivo,A,10116.0,,,,50597
8101,1,Clearance by intravenous administration of 3.4 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4368,In vivo,A,10116.0,,,,50597
8102,1,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6005,In vivo,A,10116.0,,,,50597
8103,1,Clearance rate after i.v. administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5031,In vivo,A,10116.0,,,,50597
8104,1,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4890,In vivo,A,10116.0,,,,50597
8105,1,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5182,In vivo,A,10116.0,,,,50597
8106,1,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5979,In vivo,A,10116.0,,,,50597
8107,1,Clearance (Cl) after oral administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5656,In vivo,A,10116.0,,,,50597
8108,1,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17804,In vivo,A,10116.0,,,,50597
8109,1,Compound was tested for plasma clearance in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4839,In vivo,A,10116.0,,,,50597
8110,1,In vitro microsome metabolism clearance in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,In vitro,A,10116.0,,,Microsomes,50597
8111,1,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,In vitro,A,10116.0,,,Microsomes,50597
8112,1,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,A,10116.0,,,,50597
8113,1,In vivo plasma clearance was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5496,In vivo,A,10116.0,,,,50597
8114,1,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5739,In vivo,A,10116.0,,,,50597
8115,1,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,5676,In vivo,A,10116.0,,Hepatocyte,,50597
8116,1,Pharmacokinetic property (Plasma clearance) was measured in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4239,In vivo,A,10116.0,,,,50597
8117,1,Pharmacokinetic property (clearance) in rat i.v.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5676,In vivo,A,10116.0,,,,50597
8118,1,"Plasma Clearance was evaluated in rats, iv",,BAO_0000218,,Rattus norvegicus,,Intermediate,1918,In vivo,A,10116.0,,,,50597
8119,1,Plasma clearance (in vivo) in rats was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,17800,In vivo,A,10116.0,,,,50597
8120,1,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6056,In vivo,A,10116.0,,,,50597
8121,1,Plasma clearance was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5496,In vivo,A,10116.0,,,,50597
8122,1,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5939,In vivo,A,10116.0,,,,50597
8123,1,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5939,In vivo,A,10116.0,,,,50597
8124,1,Plasma clearance in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17752,In vivo,A,10116.0,,,,50597
8125,1,Plasma clearance rate determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4576,In vivo,A,10116.0,,,,50597
8126,1,Plasma clearance was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6011,In vivo,A,10116.0,,,,50597
8127,1,Plasma clearance was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5510,In vivo,A,10116.0,,,,50597
8128,1,Plasma clearance value in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5948,In vivo,A,10116.0,,,,50597
8129,1,Clearance rate constant using isolated perfused rat liver (IPRL) assay,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,6125,Ex vivo,A,10116.0,,,,50597
8130,1,Clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4839,In vivo,A,10116.0,,,,50597
8131,1,Total body clearance in rat i.v. at 2 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17686,In vivo,A,10116.0,,,,50597
8132,1,Clearance of compound in rats after intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6571,In vivo,A,10116.0,,,,50597
8133,1,Clearance after iv administration to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3364,In vivo,A,10116.0,,,,50597
8134,1,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,A,10116.0,,,,50597
8135,1,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,A,10116.0,,,,50597
8136,1,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,A,10116.0,,,,50597
8137,1,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,A,10116.0,,,,50597
8138,1,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,A,10116.0,,,,50597
8139,1,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,A,10116.0,,,,50597
8140,1,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,A,10116.0,,,,50597
8141,1,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",,BAO_0000218,,Rattus norvegicus,,Intermediate,17670,In vivo,A,10116.0,,,,50597
8142,1,Clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5970,In vivo,A,10116.0,,,,50597
8143,1,Clearance in rat after oral administration at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6495,In vivo,A,10116.0,,,,50597
8144,1,Clearance in rat.,,BAO_0000218,,Rattus norvegicus,,Intermediate,4590,In vivo,A,10116.0,,,,50597
8145,1,Clearance rate following an oral dose of 20 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6193,In vivo,A,10116.0,,,,50597
8146,1,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,2832,In vivo,A,10116.0,,,,50597
8147,1,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1052,In vivo,A,10116.0,,,,50597
8148,1,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8149,1,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8150,1,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8151,1,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8152,1,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8153,1,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8154,1,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8155,1,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8156,1,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8157,1,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8158,1,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8159,1,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8160,1,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8161,1,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8162,1,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8163,1,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8164,1,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8165,1,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8166,1,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8167,1,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8168,1,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8169,1,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8170,1,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8171,1,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8172,1,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8173,1,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8174,1,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8175,1,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8176,1,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8177,1,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8178,1,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8179,1,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8180,1,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8181,1,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8182,1,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8183,1,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8184,1,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8185,1,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,9866,In vivo,A,10116.0,,,,50597
8186,1,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8187,1,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8188,1,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8189,1,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8190,1,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8191,1,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8192,1,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8193,1,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8194,1,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8195,1,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8196,1,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8197,1,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8198,1,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8199,1,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6062,In vivo,A,10116.0,,,,50597
8200,1,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Expert,3598,,A,10116.0,,,,50597
8201,1,Vc value after IV dose at a dose of 5 mg/kg in rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,1908,In vivo,A,10116.0,,,,50597
8202,1,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17596,In vivo,A,10116.0,,,,50597
8203,1,Compound was evaluated for pharmacokinetic parameter volume of distribution,,BAO_0000218,,Rattus norvegicus,,Intermediate,4891,In vivo,A,10116.0,,,,50597
8204,1,Compound was evaluated for volume of distribution in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,740,In vivo,A,10116.0,,,,50597
8205,1,Steady state volume distribution was determined; steady state(ss),,BAO_0000218,,Rattus norvegicus,,Intermediate,16366,In vivo,A,10116.0,,,,50597
8206,1,Steady state volume of distribution after iv administration to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3364,In vivo,A,10116.0,,,,50597
8207,1,Steady state volume of distribution dosing at 3 mg/kg iv,,BAO_0000218,,Rattus norvegicus,,Intermediate,2552,In vivo,A,10116.0,,,,50597
8208,1,The compound was evaluated for volume of distribution in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,406,In vivo,A,10116.0,,,,50597
8209,1,The compound was tested for volume of distribution in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12500,In vivo,A,10116.0,,,,50597
8210,1,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,,BAO_0000218,,Rattus norvegicus,,Intermediate,12500,In vivo,A,10116.0,,,,50597
8211,1,Volume distribution (VD) after oral administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5656,In vivo,A,10116.0,,,,50597
8212,1,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17671,In vivo,A,10116.0,,,,50597
8213,1,Volume distribution in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1094,In vivo,A,10116.0,,,,50597
8214,1,Volume distribution in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5833,In vivo,A,10116.0,,,,50597
8215,1,Volume distribution in rat after peroral administration at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5939,In vivo,A,10116.0,,,,50597
8216,1,Volume distribution in rat after peroral administration at 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5939,In vivo,A,10116.0,,,,50597
8217,1,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6005,In vivo,A,10116.0,,,,50597
8218,1,Volume of distribution in rat.,,BAO_0000218,,Rattus norvegicus,,Intermediate,1696,In vivo,A,10116.0,,,,50597
8219,1,Volume of distribution in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6672,In vivo,A,10116.0,,,,50597
8220,1,Volume of distribution in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6673,In vivo,A,10116.0,,,,50597
8221,1,Volume of distribution in rat by iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5871,In vivo,A,10116.0,,,,50597
8222,1,Volume of distribution in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6803,In vivo,A,10116.0,,,,50597
8223,1,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,,BAO_0000218,,Rattus norvegicus,,Intermediate,5199,In vivo,A,10116.0,,,,50597
8224,1,Volume distribution at the dose of 2 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4727,,A,10116.0,,,,50597
8225,1,Steady state volume of distribution was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,16367,In vivo,A,10116.0,,,,50597
8226,1,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,BAO_0000218,,Macaca mulatta,,Intermediate,5005,In vivo,A,9544.0,,,,22224
8227,1,Compound was tested for its plasma volume distribution in Sprague Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5005,In vivo,A,10116.0,,,,22224
8228,1,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5005,In vivo,A,10116.0,,,,22224
8229,1,Mean (%CV) PK parameters for Vdss(mL/kg).,,BAO_0000218,,Rattus norvegicus,,Intermediate,15765,In vivo,A,10116.0,,,,50597
8230,1,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,A,10116.0,,,,50597
8231,1,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,A,10116.0,,,,50597
8232,1,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,In vivo,A,10116.0,,,,50597
8233,1,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,In vivo,A,10116.0,,,,50597
8234,1,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5739,In vivo,A,10116.0,,,,50597
8235,1,Pharmacokinetic property (Vdss) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5789,In vivo,A,10116.0,,,,50597
8236,1,Pharmacokinetic property (vdss) was measured in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4239,In vivo,A,10116.0,,,,50597
8237,1,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4709,In vivo,A,10116.0,,,,50597
8238,1,Volume of distribution in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6642,In vivo,A,10116.0,,,,50597
8239,1,The pharmacokinetic parameter volume of distribution in vivo in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5247,In vivo,A,10116.0,,,,50597
8240,1,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17720,In vivo,F,10116.0,,,,50597
8241,1,Vdss in rat i.v. at 2 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17686,In vivo,A,10116.0,,,,50597
8242,1,Volume distribution after intravenous administration (1 mg/kg) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4689,In vivo,A,10116.0,,,,50597
8243,1,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5654,In vivo,A,10116.0,,,,50597
8244,1,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5654,In vivo,A,10116.0,,,,50597
8245,1,Volume distribution at a dose of 10 uM/kg in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4527,In vivo,A,10116.0,,,,50597
8246,1,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,4521,In vivo,A,10116.0,,,,50597
8247,1,Volume distribution was calculated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6057,In vivo,A,10116.0,,,,50597
8248,1,Volume distribution was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5510,In vivo,A,10116.0,,,,50597
8249,1,Volume of distribution after intravenous administration was evaluated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2938,In vivo,A,10116.0,,,,50597
8250,1,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6679,In vivo,A,10116.0,,,,50597
8251,1,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,A,10116.0,,,,50597
8252,1,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,A,10116.0,,,,50597
8253,1,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,A,10116.0,,,,50597
8254,1,Volume of distribution in steady state was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5145,In vivo,A,10116.0,,,,50597
8255,1,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6467,In vivo,A,10116.0,,,,50597
8256,1,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6467,In vivo,A,10116.0,,,,50597
8257,1,Compound was evaluated for area under curve when administered through oral route to mouse,,BAO_0000218,,Mus musculus,,Intermediate,15115,,A,10090.0,,,,50594
8258,1,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,,BAO_0000218,,Rattus norvegicus,,Intermediate,8758,,A,10116.0,,,,50597
8259,1,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,,BAO_0000218,,Rattus norvegicus,,Intermediate,8758,,A,10116.0,,,,50597
8260,1,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,,BAO_0000218,,,,Autocuration,8267,In vivo,F,,,,,22224
8261,1,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8267,,A,9615.0,,,,50588
8262,1,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,14239,,A,10090.0,,,,50594
8263,1,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,14239,,A,10090.0,,,,50594
8264,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,Blood,BAO_0000218,,Mus musculus,,Intermediate,10754,,A,10090.0,,,,50594
8265,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,Blood,BAO_0000218,,Mus musculus,,Intermediate,10754,,A,10090.0,,,,50594
8266,1,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,10754,,A,9615.0,,,,50588
8267,1,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,14681,,A,10116.0,,,,50597
8268,1,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,,BAO_0000218,,Rattus norvegicus,,Intermediate,14681,,A,10116.0,,,,50597
8269,1,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,14681,,A,10116.0,,,,50597
8270,1,Concentration of compound in Central nervous system,,BAO_0000019,,,,Autocuration,13118,,A,,,,,22224
8271,1,Concentration of compound in Central nervous system; Not detectable,,BAO_0000019,,,,Autocuration,13118,,A,,,,,22224
8272,1,"Concentration of diester in the blood, following oral administration in mice",,BAO_0000218,,Mus musculus,,Intermediate,13318,,A,10090.0,,,,50594
8273,1,"Concentration of monoester in the blood, following oral administration in mice",,BAO_0000218,,Mus musculus,,Intermediate,13318,,A,10090.0,,,,50594
8274,1,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,,BAO_0000218,,Mus musculus,,Intermediate,13318,,A,10090.0,,,,50594
8275,1,Evaluated for Pharmacokinetic property: Area under the curve,,BAO_0000019,,,,Autocuration,15692,,A,,,,,22224
8276,1,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,,BAO_0000218,,Mus musculus,,Intermediate,14839,,A,10090.0,,,,50594
8277,1,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,,A,9541.0,,,,100710
8278,1,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,,A,9541.0,,,,100710
8279,1,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,,A,9541.0,,,,100710
8280,1,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,,A,9541.0,,,,100710
8281,1,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,,A,9541.0,,,,100710
8282,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,,A,9541.0,,,,100710
8283,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,,A,9541.0,,,,100710
8284,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,,A,9541.0,,,,100710
8285,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,,A,9541.0,,,,100710
8286,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,,A,9541.0,,,,100710
8287,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,,A,9541.0,,,,100710
8288,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,,A,9541.0,,,,100710
8289,1,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,,BAO_0000218,,Mus musculus,,Intermediate,14839,,A,10090.0,,,,50594
8290,1,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,,BAO_0000218,,Mus musculus,,Intermediate,14839,,A,10090.0,,,,50594
8291,1,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,,BAO_0000218,,Mus musculus,,Intermediate,14839,,A,10090.0,,,,50594
8292,1,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,,BAO_0000218,,Mus musculus,,Intermediate,14839,,A,10090.0,,,,50594
8293,1,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,,BAO_0000218,,Mus musculus,,Intermediate,14839,,A,10090.0,,,,50594
8294,1,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,,BAO_0000218,,Mus musculus,,Intermediate,14839,,A,10090.0,,,,50594
8295,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",,BAO_0000218,,Mus musculus,,Intermediate,14839,,A,10090.0,,,,50594
8296,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",,BAO_0000218,,Mus musculus,,Intermediate,14839,,A,10090.0,,,,50594
8297,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",,BAO_0000218,,Mus musculus,,Intermediate,14839,,A,10090.0,,,,50594
8298,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",,BAO_0000218,,Mus musculus,,Intermediate,14839,,A,10090.0,,,,50594
8299,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",,BAO_0000218,,Mus musculus,,Intermediate,14839,,A,10090.0,,,,50594
8300,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",,BAO_0000218,,Mus musculus,,Intermediate,14839,,A,10090.0,,,,50594
8301,1,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5408,In vivo,A,10116.0,,,,50597
8302,1,High i.v. clearance in Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6827,In vivo,A,10116.0,,,,50597
8303,1,In vitro clearance in rat liver microsomes,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,17538,In vitro,A,10116.0,,,Microsomes,50597
8304,1,Intrinsic clearance in rat liver microsomes was determined,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,6331,In vitro,A,10116.0,,,Microsomes,50597
8305,1,Intrinsic clearance in rat hepatocytes was determined,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,5948,In vitro,A,10116.0,,Hepatocyte,,50597
8306,1,Plasma Clearance was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4026,In vivo,A,10116.0,,,,50597
8307,1,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6647,In vivo,A,10116.0,,,,50597
8308,1,Plasma clearance in rat.,,BAO_0000218,,Rattus norvegicus,,Intermediate,1696,In vivo,A,10116.0,,,,50597
8309,1,Plasma clearance in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6597,In vivo,A,10116.0,,,,50597
8310,1,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,347,In vivo,A,10116.0,,,,50597
8311,1,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,16423,In vivo,A,10116.0,,,,50597
8312,1,Plasma clearance was measured in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2879,In vivo,A,10116.0,,,,50597
8313,1,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4883,In vivo,A,10116.0,,,,50597
8314,1,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5328,In vivo,A,10116.0,,,,50597
8315,1,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5160,In vivo,A,10116.0,,,,50597
8316,1,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17582,In vivo,A,10116.0,,,,50597
8317,1,Total clearance at 1 mg/kg was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17651,In vivo,A,10116.0,,,,50597
8318,1,Total clearance at 10 mg/kg was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17651,In vivo,A,10116.0,,,,50597
8319,1,Clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6596,In vivo,A,10116.0,,,,50597
8320,1,Plasma clearance rate determined in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4796,In vivo,A,10116.0,,,,50597
8321,1,Clearance of compound in rat was evaluated,,BAO_0000218,,Rattus norvegicus,,Intermediate,6850,In vivo,A,10116.0,,,,50597
8322,1,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5932,In vivo,A,10116.0,,,,50597
8323,1,Pharmacokinetic property (blood clearance) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3371,In vivo,A,10116.0,,,,50597
8324,1,Plasma clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2083,In vivo,A,10116.0,,,,50597
8325,1,Plasma clearance in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4942,In vivo,A,10116.0,,,,50597
8326,1,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,6838,In vitro,A,10116.0,,,Microsomes,50597
8327,1,Clearance in Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5353,In vivo,A,10116.0,,,,50597
8328,1,Clearance rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,In vivo,A,10116.0,,,,50597
8329,1,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,In vivo,A,10116.0,,,,50597
8330,1,Clearance rat; Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,In vivo,A,10116.0,,,,50597
8331,1,Clearance rate was determined in rat at a dose of 1 mpk i.v.,,BAO_0000218,,Rattus norvegicus,,Intermediate,6444,In vivo,A,10116.0,,,,50597
8332,1,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6444,In vivo,A,10116.0,,,,50597
8333,1,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6444,In vivo,A,10116.0,,,,50597
8334,1,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6211,In vivo,A,10116.0,,,,50597
8335,1,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12873,In vivo,A,10116.0,,,,50597
8336,1,Clearance of compound in rat after 1 mg/kg i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6570,In vivo,A,10116.0,,,,50597
8337,1,Compound was evaluated for Hepatic clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3341,In vivo,A,10116.0,,,,50597
8338,1,In vivo clearance after 5 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,4891,In vivo,A,10116.0,,,,50597
8339,1,Compound was tested for plasma clearance in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1094,In vivo,A,10116.0,,,,50597
8340,1,Hepatic clearance after intravenous administration was evaluated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2938,In vivo,A,10116.0,,,,50597
8341,1,Lower clearance in rat (i.v.) at 0.5 mpk,,BAO_0000218,,Rattus norvegicus,,Intermediate,17853,In vivo,A,10116.0,,,,50597
8342,1,Pharmacokinetic parameter expressed as plasma clearance in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6049,In vivo,A,10116.0,,,,50597
8343,1,Pharmacokinetic property (Clp) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5789,In vivo,A,10116.0,,,,50597
8344,1,Plasma clearance in Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4514,In vivo,A,10116.0,,,,50597
8345,1,Plasma clearance (Clp) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6448,In vivo,A,10116.0,,,,50597
8346,1,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6062,In vivo,A,10116.0,,,,50597
8347,1,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,5710,In vivo,A,10116.0,,,,50597
8348,1,Plasma clearance after intravenous administration of 1 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4709,In vivo,A,10116.0,,,,50597
8349,1,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,4521,In vivo,A,10116.0,,,,50597
8350,1,Plasma clearance in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,1742,In vivo,A,10116.0,,,,50597
8351,1,Plasma clearance measured in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6057,In vivo,A,10116.0,,,,50597
8352,1,Plasma clearance was calculated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6057,In vivo,A,10116.0,,,,50597
8353,1,Plasma clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5145,In vivo,A,10116.0,,,,50597
8354,1,Plasma clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5833,In vivo,A,10116.0,,,,50597
8355,1,Plasma clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6453,In vivo,A,10116.0,,,,50597
8356,1,Plasma clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6640,In vivo,A,10116.0,,,,50597
8357,1,Plasma clearance in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6305,In vivo,A,10116.0,,,,50597
8358,1,Plasma clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6642,In vivo,A,10116.0,,,,50597
8359,1,Plasma clearance was evaluated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5472,In vivo,A,10116.0,,,,50597
8360,1,Plasma clearance was evaluated in rat; Not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,5472,In vivo,A,10116.0,,,,50597
8361,1,Plasma clearance rate was determined for the compound in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5144,In vivo,A,10116.0,,,,50597
8362,1,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,A,10116.0,,,,50597
8363,1,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,A,10116.0,,,,50597
8364,1,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,A,10116.0,,,,50597
8365,1,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8366,1,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8367,1,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8368,1,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8369,1,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8370,1,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8371,1,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8372,1,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8373,1,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8374,1,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8375,1,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8376,1,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8377,1,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8378,1,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8379,1,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8380,1,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8381,1,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8382,1,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8383,1,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8384,1,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8385,1,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8386,1,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8387,1,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8388,1,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8389,1,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8390,1,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8391,1,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8392,1,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8393,1,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8394,1,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8395,1,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8396,1,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8397,1,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8398,1,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8399,1,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8400,1,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8401,1,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,In vivo,A,10116.0,,,,50597
8402,1,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,A,10116.0,,,,50597
8403,1,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,A,10116.0,,,,50597
8404,1,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,A,10116.0,,,,50597
8405,1,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6570,In vivo,A,10116.0,,,,50597
8406,1,Volume of distribution of compound in rats after intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6571,In vivo,A,10116.0,,,,50597
8407,1,Volume of distribution in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6453,In vivo,A,10116.0,,,,50597
8408,1,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,,BAO_0000218,,Rattus norvegicus,,Intermediate,6444,In vivo,A,10116.0,,,,50597
8409,1,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6444,In vivo,A,10116.0,,,,50597
8410,1,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6444,In vivo,A,10116.0,,,,50597
8411,1,Volume of distribution was determined in Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5353,In vivo,A,10116.0,,,,50597
8412,1,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,In vivo,A,10116.0,,,,50597
8413,1,Volume of distribution was reported in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,In vivo,A,10116.0,,,,50597
8414,1,Volumes of distribution in rat after peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,In vivo,A,10116.0,,,,50597
8415,1,Volumes of distribution in rat after po administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,In vivo,A,10116.0,,,,50597
8416,1,Volumes of distribution in rat after po administration; Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,In vivo,A,10116.0,,,,50597
8417,1,Pharmacokinetic property (Volume) in rat i.v.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5676,In vivo,A,10116.0,,,,50597
8418,1,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,In vivo,A,10116.0,,,,50597
8419,1,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",,BAO_0000218,,Rattus norvegicus,,Intermediate,17670,In vivo,A,10116.0,,,,50597
8420,1,Volume distribution in rat after oral administration at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6495,In vivo,A,10116.0,,,,50597
8421,1,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5408,In vivo,A,10116.0,,,,50597
8422,1,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4883,In vivo,A,10116.0,,,,50597
8423,1,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6647,In vivo,A,10116.0,,,,50597
8424,1,Volume of distribution in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6495,In vivo,A,10116.0,,,,50597
8425,1,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,In vivo,A,10116.0,,,,50597
8426,1,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,In vivo,A,10116.0,,,,50597
8427,1,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,A,10116.0,,,,50597
8428,1,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,A,10116.0,,,,50597
8429,1,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,A,10116.0,,,,50597
8430,1,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,A,10116.0,,,,50597
8431,1,Pharmacokinetic parameter (Vss) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5960,In vivo,A,10116.0,,,,50597
8432,1,Pharmacokinetic property (Volume) in rat i.v.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5676,In vivo,A,10116.0,,,,50597
8433,1,Pharmacokinetic property (Vss) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5948,,A,10116.0,,,,50597
8434,1,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5979,In vivo,A,10116.0,,,,50597
8435,1,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
8436,1,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
8437,1,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
8438,1,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
8439,1,Steady state volume distribution in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6448,In vivo,A,10116.0,,,,50597
8440,1,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12873,In vivo,A,10116.0,,,,50597
8441,1,Steady state volume of distribution determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4576,In vivo,A,10116.0,,,,50597
8442,1,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17582,In vivo,A,10116.0,,,,50597
8443,1,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1466,In vivo,A,10116.0,,,,50597
8444,1,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5182,,A,10116.0,,,,50597
8445,1,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,,BAO_0000218,,Rattus norvegicus,,Intermediate,5182,,A,10116.0,,,,50597
8446,1,Volume distribution in rat after administration of 2 mg/kg iv,,BAO_0000218,,Rattus norvegicus,,Intermediate,6535,In vivo,A,10116.0,,,,50597
8447,1,Volume distribution in rat after administration of 2 mg/kg iv,,BAO_0000218,,Rattus norvegicus,,Intermediate,6535,In vivo,A,10116.0,,,,50597
8448,1,Volume in steady state distribution value was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,In vivo,A,10116.0,,,,50597
8449,1,Volume in steady state distribution value was determined; ND denotes no data,,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,In vivo,A,10116.0,,,,50597
8450,1,Volume in steady state distribution value was determined; ND denotes not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,In vivo,A,10116.0,,,,50597
8451,1,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17065,In vivo,A,10116.0,,,,50597
8452,1,Volume of distribution at steady state was evaluated in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6597,In vivo,A,10116.0,,,,50597
8453,1,Volume of distribution at steady state was observed after intravenous administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,A,10116.0,,,,50597
8454,1,Volume of distribution in steady state was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6485,In vivo,A,10116.0,,,,50597
8455,1,Volume of distribution in steady state was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17655,In vivo,A,10116.0,,,,50597
8456,1,Volume of distribution after i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6616,In vivo,A,10116.0,,,,50597
8457,1,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,1916,In vivo,A,10116.0,,,,50597
8458,1,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Liver,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
8459,1,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Liver,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
8460,1,Biodistribution of compound (oxidized form) in spleen tissue,Spleen,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
8461,1,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Spleen,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
8462,1,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Spleen,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
8463,1,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Spleen,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
8464,1,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Spleen,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
8465,1,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Spleen,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
8466,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,Blood,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
8467,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Blood,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
8468,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,Brain,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
8469,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",Brain,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
8470,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Brain,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
8471,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,Heart,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
8472,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",Heart,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
8473,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Heart,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
8474,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,Kidney,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
8475,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",Kidney,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
8476,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Kidney,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
8477,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,Liver,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
8478,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Liver,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
8479,1,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,Spleen,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
8480,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",Spleen,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
8481,1,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Spleen,BAO_0000218,,Mus musculus,,Intermediate,16438,In vivo,A,10090.0,,,,50594
8482,1,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,,BAO_0000218,,Mus musculus,,Intermediate,12467,,A,10090.0,,,,50594
8483,1,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),Brain,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8484,1,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),Brain,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8485,1,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),Brain,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8486,1,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),Brain,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8487,1,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),Brain,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8488,1,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),Brain,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8489,1,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),Heart,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8490,1,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),Heart,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8491,1,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),Heart,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8492,1,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),Heart,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8493,1,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),Heart,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8494,1,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),Heart,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8495,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),Kidney,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8496,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),Kidney,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8497,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),Kidney,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8498,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),Kidney,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8499,1,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5089,In vivo,A,10116.0,,,,50597
8500,1,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5089,In vivo,A,10116.0,,,,50597
8501,1,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,4257,In vivo,A,10116.0,,,,50597
8502,1,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6679,In vivo,A,10116.0,,,,50597
8503,1,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5546,In vivo,A,10116.0,,,,50597
8504,1,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6141,In vivo,A,10116.0,,,,50597
8505,1,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,In vivo,A,10116.0,,,,50597
8506,1,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,In vivo,A,10116.0,,,,50597
8507,1,Plasma clearance was reported in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,In vivo,A,10116.0,,,,50597
8508,1,Plasma clearance after intravenous administration (1 mg/kg) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4689,In vivo,A,10116.0,,,,50597
8509,1,Plasma clearance of compound in rats was evaluated,,BAO_0000218,,Rattus norvegicus,,Intermediate,6848,In vivo,A,10116.0,,,,50597
8510,1,Plasma clearance of compound in rats was evaluated; ND indicates not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6848,In vivo,A,10116.0,,,,50597
8511,1,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6467,In vivo,A,10116.0,,,,50597
8512,1,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6467,In vivo,A,10116.0,,,,50597
8513,1,Plasma clearance rate in Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4956,In vivo,A,10116.0,,,,50597
8514,1,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,5529,In vivo,A,10116.0,,,,50597
8515,1,The compound was evaluated for plasma clearance in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,406,In vivo,A,10116.0,,,,50597
8516,1,Total plasma clearance in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17655,In vivo,A,10116.0,,,,50597
8517,1,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,3293,In vivo,A,10116.0,,,,50597
8518,1,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,4075,In vivo,A,10116.0,,,,50597
8519,1,C max was determined at 10 mg/kg po dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,A,10116.0,,,,50597
8520,1,C max was determined at 3 mg/kg po dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,A,10116.0,,,,50597
8521,1,Cmax after repeated oral dose of compound at 1 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17594,In vivo,A,10116.0,,,,50597
8522,1,Cmax after single intravenous bolus of 1 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17594,In vivo,A,10116.0,,,,50597
8523,1,Cmax of compound at 5 mg/kg after po administration was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4762,In vivo,A,10116.0,,,,50597
8524,1,Cmax 24 hr after 10 mg/kg oral administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17509,In vivo,A,10116.0,,,,50597
8525,1,Cmax 24 hr after 2 mg/kg oral administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17509,In vivo,A,10116.0,,,,50597
8526,1,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1466,In vivo,A,10116.0,,,,50597
8527,1,Cmax in rat after administration of 2 mg/kg iv,,BAO_0000218,,Rattus norvegicus,,Intermediate,6535,In vivo,A,10116.0,,,,50597
8528,1,Cmax in rat after administration of 2 mg/kg iv,,BAO_0000218,,Rattus norvegicus,,Intermediate,6535,In vivo,A,10116.0,,,,50597
8529,1,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,3169,In vivo,A,10116.0,,,,50597
8530,1,Cmax wa determined in rat plasma at 30 mg/kg after po administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6515,In vivo,A,10116.0,,,,50597
8531,1,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11149,In vivo,A,10116.0,,,,50597
8532,1,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11149,In vivo,A,10116.0,,,,50597
8533,1,Cmax after 10 mg/kg oral administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17858,In vivo,A,10116.0,,,,50597
8534,1,Cmax after IV dosing at 0.5 mg/kg in rat; no data,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,A,10116.0,,,,50597
8535,1,Cmax after IV dosing at 1 mg/kg in rat; no data,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,A,10116.0,,,,50597
8536,1,Cmax after oral administration at 20 mpk in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4426,In vivo,A,10116.0,,,,50597
8537,1,Cmax after oral administration at 20 mpk in rats; Not performed.,,BAO_0000218,,Rattus norvegicus,,Intermediate,4426,In vivo,A,10116.0,,,,50597
8538,1,Cmax after oral administration at 20 mpk in rats d; Not performed.,,BAO_0000218,,Rattus norvegicus,,Intermediate,4426,In vivo,A,10116.0,,,,50597
8539,1,Cmax after oral administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5656,In vivo,A,10116.0,,,,50597
8540,1,Cmax after oral administration at a dose of 2 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,A,10116.0,,,,50597
8541,1,Cmax after oral administration at a dose of 4 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,A,10116.0,,,,50597
8542,1,Cmax in rats after 20 mg/kg oral dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,6113,In vivo,A,10116.0,,,,50597
8543,1,Cmax after peroral administration in rats at 2.4 uM/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17764,In vivo,A,10116.0,,,,50597
8544,1,Cmax at the dose of 2 mg/Kg administered perorally in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4756,In vivo,A,10116.0,,,,50597
8545,1,Cmax at the dose of 5 mg/Kg administered perorally in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4756,In vivo,A,10116.0,,,,50597
8546,1,Cmax by administering at 20 mg/kg p.o. in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6402,In vivo,A,10116.0,,,,50597
8547,1,Cmax in male rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5610,In vivo,A,10116.0,,,,50597
8548,1,Cmax in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5207,In vivo,A,10116.0,,,,50597
8549,1,Cmax in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6011,In vivo,A,10116.0,,,,50597
8550,1,Cmax in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6504,In vivo,A,10116.0,,,,50597
8551,1,Cmax in rat at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6046,In vivo,A,10116.0,,,,50597
8552,1,Cmax in rat at the dose of 1 mg/kg i.v.,,BAO_0000218,,Rattus norvegicus,,Intermediate,6504,In vivo,A,10116.0,,,,50597
8553,1,Cmax in rat by po administration at a dose of 40 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5874,In vivo,A,10116.0,,,,50597
8554,1,Cmax in rat p.o. at 20 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17686,In vivo,A,10116.0,,,,50597
8555,1,Cmax in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5836,In vivo,A,10116.0,,,,50597
8556,1,Cmax in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17596,In vivo,A,10116.0,,,,50597
8557,1,Cmax was evaluated after 20 uM/kg of peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,16423,In vivo,A,10116.0,,,,50597
8558,1,Cmax was measured in rats after peroral administration at 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17804,In vivo,A,10116.0,,,,50597
8559,1,Cmax value after oral dose at a dose of 10 mg/kg in rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,1908,In vivo,A,10116.0,,,,50597
8560,1,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,A,10116.0,,,,50597
8561,1,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,Frontal cortex,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,A,10116.0,,,,50597
8562,1,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,Frontal cortex,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,A,10116.0,,,,50597
8563,1,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,A,10116.0,,,,50597
8564,1,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,A,10116.0,,,,50597
8565,1,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,A,10116.0,,,,50597
8566,1,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,A,10116.0,,,,50597
8567,1,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,Midbrain,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,A,10116.0,,,,50597
8568,1,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,Midbrain,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,A,10116.0,,,,50597
8569,1,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,A,10116.0,,,,50597
8570,1,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,A,10116.0,,,,50597
8571,1,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,A,10116.0,,,,50597
8572,1,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,13950,,A,10116.0,,,,50597
8573,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8574,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8575,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8576,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8577,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8578,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8579,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8580,1,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8581,1,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8582,1,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8583,1,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8584,1,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8585,1,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8586,1,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8587,1,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8588,1,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8589,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8590,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8591,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8592,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8593,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8594,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8595,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8596,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8597,1,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8598,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8599,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8600,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8601,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8602,1,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17764,In vivo,A,10116.0,,,,50597
8603,1,Volume of steady state distribution after i.v. administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5031,In vivo,A,10116.0,,,,50597
8604,1,Vss after intravenous administration (5.0 mg/kg) was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6215,In vivo,A,10116.0,,,,50597
8605,1,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17671,In vivo,A,10116.0,,,,50597
8606,1,Vss was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,17752,In vivo,A,10116.0,,,,50597
8607,1,Vss in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6596,In vivo,A,10116.0,,,,50597
8608,1,Vss was evaluated after 10 uM/kg of intra arterial administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,16423,In vivo,A,10116.0,,,,50597
8609,1,volume of distribution at steady state was observed after intravenous administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,A,10116.0,,,,50597
8610,1,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6062,In vivo,A,10116.0,,,,50597
8611,1,Pharmacokinetic (PK) parameter Vz in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5874,In vivo,A,10116.0,,,,50597
8612,1,Volume distribution in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4942,In vivo,A,10116.0,,,,50597
8613,1,Volume of distribution in rat; No data,,BAO_0000218,,Rattus norvegicus,,Intermediate,17796,In vivo,A,10116.0,,,,50597
8614,1,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4890,In vivo,A,10116.0,,,,50597
8615,1,% absorption predicted from in vitro rat ileum transport studies,Ileum,BAO_0000218,,Rattus norvegicus,,Intermediate,15765,,A,10116.0,,,,50597
8616,1,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,A,10116.0,,,,50597
8617,1,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,A,10116.0,,,,50597
8618,1,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,A,10116.0,,,,50597
8619,1,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,A,10116.0,,,,50597
8620,1,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,A,10116.0,,,,50597
8621,1,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,A,10116.0,,,,50597
8622,1,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,A,10116.0,,,,50597
8623,1,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,13569,In vivo,A,10116.0,,,,50597
8624,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4576,In vivo,A,10116.0,,,,50597
8625,1,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,750,In vivo,A,10116.0,,,,50597
8626,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,750,In vivo,A,10116.0,,,,50597
8627,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4590,In vivo,A,10116.0,,,,50597
8628,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1716,In vivo,A,10116.0,,,,50597
8629,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1974,In vivo,A,10116.0,,,,50597
8630,1,Oral bioavailability in rat (dose 30 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,4502,In vivo,A,10116.0,,,,50597
8631,1,Pharmacokinetic property (cLogP) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3371,,A,10116.0,,,,50597
8632,1,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9099,,F,10116.0,,,,50597
8633,1,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9099,,F,10116.0,,,,50597
8634,1,Clearance in rat.,,BAO_0000218,,Rattus norvegicus,,Intermediate,4590,In vivo,A,10116.0,,,,50597
8635,1,Compound was evaluated for its clearance when administered intravenously in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3184,In vivo,A,10116.0,,,,50597
8636,1,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,16456,In vivo,A,10116.0,,,,50597
8637,1,Blood: Brain distribution ratio is determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4199,,A,10116.0,,,,50597
8638,1,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,,BAO_0000218,,Rattus norvegicus,,Intermediate,4199,,A,10116.0,,,,50597
8639,1,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,,BAO_0000218,,Rattus norvegicus,,Intermediate,4199,,A,10116.0,,,,50597
8640,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
8641,1,Percent dose excreted in 0-48 hours administered ip to male rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,7449,,F,10116.0,,,,50597
8642,1,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,A,10116.0,,,,50597
8643,1,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,A,10116.0,,,,50597
8644,1,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,A,10116.0,,,,50597
8645,1,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,A,10116.0,,,,50597
8646,1,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,A,10116.0,,,,50597
8647,1,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,A,10116.0,,,,50597
8648,1,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,A,10116.0,,,,50597
8649,1,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,A,10116.0,,,,50597
8650,1,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,A,10116.0,,,,50597
8651,1,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,A,10116.0,,,,50597
8652,1,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,A,10116.0,,,,50597
8653,1,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,A,10116.0,,,,50597
8654,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),Kidney,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8655,1,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),Kidney,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8656,1,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),Liver,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8657,1,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),Liver,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8658,1,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),Liver,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8659,1,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),Liver,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8660,1,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),Liver,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8661,1,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),Liver,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8662,1,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),Lung,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8663,1,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),Lung,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8664,1,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),Lung,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8665,1,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),Lung,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8666,1,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),Lung,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8667,1,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),Lung,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8668,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8669,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8670,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8671,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8672,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8673,1,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8674,1,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8675,1,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8676,1,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8677,1,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8678,1,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8679,1,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8680,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),Spleen,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8681,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),Spleen,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8682,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),Spleen,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8683,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),Spleen,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8684,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),Spleen,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8685,1,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),Spleen,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8686,1,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),Blood,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8687,1,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),Blood,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8688,1,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),Blood,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8689,1,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),Blood,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8690,1,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),Blood,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8691,1,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),Blood,BAO_0000218,,Mus musculus,,Intermediate,17208,In vivo,A,10090.0,,,,50594
8692,1,Time taken for EC90 was determined when tested in mouse,,BAO_0000218,,Mus musculus,,Intermediate,3132,,A,10090.0,,,,50594
8693,1,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,3132,,A,10090.0,,,,50594
8694,1,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,BAO_0000218,,Mus musculus,,Intermediate,16597,In vivo,A,10090.0,,,,50594
8695,1,Half life in mice,,BAO_0000218,,Mus musculus,,Intermediate,5727,,A,10090.0,,,,50594
8696,1,Half life period in mouse after 10 mg/Kg dose,,BAO_0000218,,Mus musculus,,Intermediate,5302,In vivo,A,10090.0,,,,50594
8697,1,Half life period in mouse after 10 mg/kg dose,,BAO_0000218,,Mus musculus,,Intermediate,5302,In vivo,A,10090.0,,,,50594
8698,1,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,BAO_0000218,,Mus musculus,,Intermediate,6348,In vivo,A,10090.0,,,,50594
8699,1,Cmax value at 5 mg/kg po was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5964,In vivo,A,10116.0,,,,50597
8700,1,Cmax value evaluated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6078,In vivo,A,10116.0,,,,50597
8701,1,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,5206,In vivo,A,10116.0,,,,50597
8702,1,Cmax value after administration of 20 mg/Kg oral dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2959,In vivo,A,10116.0,,,,50597
8703,1,Cmax value at 1 mg/kg po in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5964,In vivo,A,10116.0,,,,50597
8704,1,Cmax value at 5 mg/kg po in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5964,In vivo,A,10116.0,,,,50597
8705,1,Cmax value at a dose of 10 mg/kg in male SD rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6757,In vivo,A,10116.0,,,,50597
8706,1,Cmax value at a dose of 100 mg/kg in male SD rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6757,In vivo,A,10116.0,,,,50597
8707,1,Cmax value at a dose of 50 mg/kg in male SD rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6757,In vivo,A,10116.0,,,,50597
8708,1,Cmax value in rats at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17617,In vivo,A,10116.0,,,,50597
8709,1,Cmax value was evaluated in rats at a dose of 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,1445,In vivo,A,10116.0,,,,50597
8710,1,Cmax value was determined after peroral administration of 20 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6082,In vivo,A,10116.0,,,,50597
8711,1,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,BAO_0000218,,Rattus norvegicus,,Intermediate,1446,In vivo,A,10116.0,,,,50597
8712,1,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5407,In vivo,A,10116.0,,,,50597
8713,1,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2690,In vivo,A,10116.0,,,,50597
8714,1,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,In vivo,A,10116.0,,,,50597
8715,1,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,In vivo,A,10116.0,,,,50597
8716,1,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4891,In vivo,A,10116.0,,,,50597
8717,1,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2807,In vivo,A,10116.0,,,,50597
8718,1,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2807,In vivo,A,10116.0,,,,50597
8719,1,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2807,In vivo,A,10116.0,,,,50597
8720,1,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,3634,In vivo,A,10116.0,,,,50597
8721,1,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1881,In vivo,A,10116.0,,,,50597
8722,1,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1881,In vivo,A,10116.0,,,,50597
8723,1,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,429,In vivo,A,10116.0,,,,50597
8724,1,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,A,10116.0,,,,50597
8725,1,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,A,10116.0,,,,50597
8726,1,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,A,10116.0,,,,50597
8727,1,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,A,10116.0,,,,50597
8728,1,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,17582,In vivo,A,10116.0,,,,50597
8729,1,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,17582,In vivo,A,10116.0,,,,50597
8730,1,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3032,In vivo,A,10116.0,,,,50597
8731,1,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6295,In vivo,A,10116.0,,,,50597
8732,1,Maximal concentration in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6619,In vivo,A,10116.0,,,,50597
8733,1,Maximal concentration after i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6616,In vivo,A,10116.0,,,,50597
8734,1,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3249,In vivo,A,10116.0,,,,50597
8735,1,Maximal plasma concentration in rat after oral administration at 50 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,In vivo,A,10116.0,,,,50597
8736,1,Cmax in rat plasma after oral dose (50 mg/Kg),Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,In vivo,A,10116.0,,,,50597
8737,1,Maximal plasma concentration was determined.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1360,In vivo,A,10116.0,,,,50597
8738,1,Maximal plasma drug concentration was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2552,In vivo,A,10116.0,,,,50597
8739,1,Maximal concentration in rats after peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6571,In vivo,A,10116.0,,,,50597
8740,1,Maximum concentration in rat after 2 mg/kg peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6570,In vivo,A,10116.0,,,,50597
8741,1,Maximum concentration in rat plasma after 5 mg/kg oral gavage,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6567,In vivo,A,10116.0,,,,50597
8742,1,Maximum concentration of compound in rat was evaluated.,,BAO_0000218,,Rattus norvegicus,,Intermediate,3031,In vivo,A,10116.0,,,,50597
8743,1,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3436,In vivo,A,10116.0,,,,50597
8744,1,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3436,In vivo,A,10116.0,,,,50597
8745,1,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2083,In vivo,A,10116.0,,,,50597
8746,1,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3436,In vivo,A,10116.0,,,,50597
8747,1,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4527,In vivo,A,10116.0,,,,50597
8748,1,Maximum concentration was evaluated in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,1974,In vivo,A,10116.0,,,,50597
8749,1,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,Cerebrospinal fluid,BAO_0000218,,Rattus norvegicus,,Intermediate,3307,In vivo,A,10116.0,,,,50597
8750,1,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3307,In vivo,A,10116.0,,,,50597
8751,1,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1916,In vivo,A,10116.0,,,,50597
8752,1,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,1500,In vivo,A,10116.0,,,,50597
8753,1,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,1500,In vivo,A,10116.0,,,,50597
8754,1,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4186,In vivo,A,10116.0,,,,50597
8755,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8756,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8757,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8758,1,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8759,1,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8760,1,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8761,1,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8762,1,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8763,1,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8764,1,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8765,1,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8766,1,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8767,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8768,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8769,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8770,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8771,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8772,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8773,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8774,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8775,1,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8776,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8777,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8778,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8779,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8780,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8781,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8782,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8783,1,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8784,1,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8785,1,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8786,1,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8787,1,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8788,1,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8789,1,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8790,1,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8791,1,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8792,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8793,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8794,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8795,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8796,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8797,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8798,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8799,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8800,1,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8801,1,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,A,10116.0,,,,50597
8802,1,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,A,10116.0,,,,50597
8803,1,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,A,10116.0,,,,50597
8804,1,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,A,10116.0,,,,50597
8805,1,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,A,10116.0,,,,50597
8806,1,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,A,10116.0,,,,50597
8807,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,A,10116.0,,,,50597
8808,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,A,10116.0,,,,50597
8809,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,A,10116.0,,,,50597
8810,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,A,10116.0,,,,50597
8811,1,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,A,10116.0,,,,50597
8812,1,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8813,1,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8814,1,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8815,1,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8816,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8817,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8818,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8819,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8820,1,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8821,1,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8822,1,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8823,1,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8824,1,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8825,1,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8826,1,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8827,1,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8828,1,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8829,1,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8830,1,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8831,1,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8832,1,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8833,1,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8834,1,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8835,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8836,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8837,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8838,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8839,1,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8840,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8841,1,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,,BAO_0000218,,Mus musculus,,Intermediate,4573,In vivo,A,10090.0,,,,50594
8842,1,Half life in mouse plasma was determined at dose 25 mg/kg,Plasma,BAO_0000218,,Mus musculus,,Intermediate,3132,In vivo,A,10090.0,,,,50594
8843,1,Half life was determined,,BAO_0000218,,Mus musculus,,Intermediate,17718,,A,10090.0,,,,50594
8844,1,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,BAO_0000218,,Mus musculus,,Intermediate,17728,In vivo,A,10090.0,,,,50594
8845,1,Half-life in male mice after 1 mg/kg intravenous dose,,BAO_0000218,,Mus musculus,,Intermediate,5961,In vivo,A,10090.0,,,,50594
8847,1,Half life in mice plasma,Plasma,BAO_0000218,,Mus musculus,,Intermediate,17731,,A,10090.0,,,,50594
8848,1,Half life in mouse,,BAO_0000218,,Mus musculus,,Intermediate,17592,,A,10090.0,,,,50594
8849,1,Half life in mouse plasma at dose 25 mg/kg,Plasma,BAO_0000218,,Mus musculus,,Intermediate,3132,In vivo,A,10090.0,,,,50594
8850,1,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,,BAO_0000218,,Mus musculus,,Intermediate,17729,In vivo,A,10090.0,,,,50594
8851,1,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,,BAO_0000218,,Mus musculus,,Intermediate,17729,In vivo,A,10090.0,,,,50594
8852,1,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,,BAO_0000218,,Mus musculus,,Intermediate,17729,In vivo,A,10090.0,,,,50594
8853,1,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,BAO_0000218,,Mus musculus,,Intermediate,3277,In vivo,A,10090.0,,,,50594
8854,1,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",,BAO_0000218,,Mus musculus,,Intermediate,3760,In vivo,A,10090.0,,,,50594
8855,1,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",,BAO_0000218,,Mus musculus,,Intermediate,3760,In vivo,A,10090.0,,,,50594
8856,1,Half-life by iv administration in mouse,,BAO_0000218,,Mus musculus,,Intermediate,2862,In vivo,A,10090.0,,,,50594
8857,1,Half-life by oral administration in mouse,,BAO_0000218,,Mus musculus,,Intermediate,2862,In vivo,A,10090.0,,,,50594
8858,1,Half-life in mice,,BAO_0000218,,Mus musculus,,Intermediate,5980,,A,10090.0,,,,50594
8859,1,Half-life using mouse brain homogenate,Brain,BAO_0000218,,Mus musculus,,Intermediate,6159,,A,10090.0,,,,50594
8860,1,Half-life was measured in mice,,BAO_0000218,,Mus musculus,,Intermediate,6254,,A,10090.0,,,,50594
8861,1,Half-life was measured in mouse after an iv dose of 1 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,6062,In vivo,A,10090.0,,,,50594
8862,1,Half-life period was determined in mouse blood,Blood,BAO_0000218,,Mus musculus,,Intermediate,1574,,A,10090.0,,,,50594
8863,1,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",Brain,BAO_0000218,,Mus musculus,,Intermediate,56,,A,10090.0,,,,50594
8864,1,Plasma half life in mouse,Plasma,BAO_0000218,,Mus musculus,,Intermediate,993,,A,10090.0,,,,50594
8865,1,Stability of the peptide in the presence of mouse serum,,BAO_0000218,,Mus musculus,,Intermediate,6652,,A,10090.0,,,,50594
8866,1,Terminal half life of compound was determined in mouse,,BAO_0000218,,Mus musculus,,Intermediate,17852,,A,10090.0,,,,50594
8867,1,Terminal half life was evaluated in mice after intravenous administration,,BAO_0000218,,Mus musculus,,Intermediate,2675,In vivo,A,10090.0,,,,50594
8868,1,Terminal half life was evaluated in mice after oral administration,,BAO_0000218,,Mus musculus,,Intermediate,2675,In vivo,A,10090.0,,,,50594
8869,1,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,,BAO_0000218,,Mus musculus,,Intermediate,499,,A,10090.0,,,,50594
8870,1,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,,BAO_0000218,,Mus musculus,,Intermediate,499,,A,10090.0,,,,50594
8871,1,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,,BAO_0000218,,Mus musculus,,Intermediate,499,,A,10090.0,,,,50594
8872,1,half life period is evaluated by administering intravenously at 25 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,14239,In vivo,A,10090.0,,,,50594
8873,1,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",,BAO_0000218,,Mus musculus,,Intermediate,5506,In vivo,A,10090.0,,,,50594
8874,1,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",,BAO_0000218,,Mus musculus,,Intermediate,5506,In vivo,A,10090.0,,,,50594
8875,1,Half life after intraperitoneal administration of 100 mg/kg in mice,,BAO_0000218,,Mus musculus,,Intermediate,17734,,A,10090.0,,,,50594
8876,1,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,,BAO_0000218,,Mus musculus,,Intermediate,17728,In vivo,A,10090.0,,,,50594
8877,1,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,,BAO_0000218,,Mus musculus,,Intermediate,17728,In vivo,A,10090.0,,,,50594
8878,1,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,,BAO_0000218,,Mus musculus,,Intermediate,17728,In vivo,A,10090.0,,,,50594
8879,1,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,,BAO_0000218,,Mus musculus,,Intermediate,17728,In vivo,A,10090.0,,,,50594
8880,1,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,,BAO_0000218,,Mus musculus,,Intermediate,17728,In vivo,A,10090.0,,,,50594
8881,1,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),,BAO_0000251,,Sus scrofa,,Autocuration,14294,,A,9823.0,,,Microsomes,22224
8882,1,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),,BAO_0000251,,Sus scrofa,,Autocuration,14294,,A,9823.0,,,Microsomes,22224
8883,1,Stability to porcine renal DHP-I,,BAO_0000019,,Sus scrofa,,Autocuration,6056,,A,9823.0,,,,22224
8884,1,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,,BAO_0000218,,Sus scrofa,,Autocuration,1317,In vivo,A,9823.0,,,,22224
8885,1,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,,BAO_0000218,,Sus scrofa,,Autocuration,1317,In vivo,A,9823.0,,,,22224
8886,1,Half-life of the parent prodrug in porcine esterase solution,,BAO_0000019,,Sus scrofa,,Autocuration,5229,,A,9823.0,,,,22224
8887,1,"First order rate constant, k was determined in in pig liver Esterase",,BAO_0000019,,Sus scrofa,,Autocuration,4231,,A,9823.0,,,,22224
8888,1,Half life of the in pig liver Esterase,Liver,BAO_0000221,,Sus scrofa,,Autocuration,4231,,A,9823.0,,,,22224
8889,1,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,Liver,BAO_0000221,,Sus scrofa,,Autocuration,5318,,A,9823.0,,,,22224
8890,1,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,Liver,BAO_0000221,,Sus scrofa,,Autocuration,5318,,A,9823.0,,,,22224
8891,1,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,Liver,BAO_0000221,,Sus scrofa,,Autocuration,5318,,A,9823.0,,,,22224
8892,1,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,Liver,BAO_0000221,,Sus scrofa,,Autocuration,3305,,A,9823.0,,,,22224
8893,1,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,Liver,BAO_0000221,,Sus scrofa,,Autocuration,3305,,A,9823.0,,,,22224
8894,1,Half-life in the presence of pig liver esterase(PLE) was evaluated.,Liver,BAO_0000221,,Sus scrofa,,Autocuration,2842,,A,9823.0,,,,22224
8895,1,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,Liver,BAO_0000221,,Sus scrofa,,Autocuration,2842,,A,9823.0,,,,22224
8896,1,Half-life in vitro in pig liver,Liver,BAO_0000221,,Sus scrofa,,Autocuration,889,In vitro,A,9823.0,,,,22224
8897,1,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,Liver,BAO_0000221,,Sus scrofa,,Autocuration,1904,,A,9823.0,,,,22224
8898,1,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4186,In vivo,A,10116.0,,,,50597
8899,1,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2774,In vivo,A,10116.0,,,,50597
8900,1,Maximum concentration in rat plasma was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1742,In vivo,A,10116.0,,,,50597
8901,1,Maximum concentration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3169,In vivo,A,10116.0,,,,50597
8902,1,Maximum concentration in rats at 1-2 hours,,BAO_0000218,,Rattus norvegicus,,Intermediate,3169,In vivo,A,10116.0,,,,50597
8903,1,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,,BAO_0000218,,Rattus norvegicus,,Intermediate,2081,In vivo,A,10116.0,,,,50597
8904,1,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,3307,In vivo,A,10116.0,,,,50597
8905,1,Maximum concentration at the dose of 2 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4727,In vivo,A,10116.0,,,,50597
8906,1,Maximum concentration was evaluated in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6597,In vivo,A,10116.0,,,,50597
8907,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,A,10116.0,,,,50597
8908,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,A,10116.0,,,,50597
8909,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,A,10116.0,,,,50597
8910,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,A,10116.0,,,,50597
8911,1,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,A,10116.0,,,,50597
8912,1,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,2591,In vivo,A,10116.0,,,,50597
8913,1,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,2591,In vivo,A,10116.0,,,,50597
8914,1,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,2591,In vivo,A,10116.0,,,,50597
8915,1,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
8916,1,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
8917,1,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
8918,1,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
8919,1,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
8920,1,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
8921,1,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
8922,1,Cmax in rat (PO dose),,BAO_0000218,,Rattus norvegicus,,Intermediate,14465,In vivo,A,10116.0,,,,50597
8923,1,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,In vivo,A,10116.0,,,,50597
8924,1,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,In vivo,A,10116.0,,,,50597
8925,1,Maximum plasma concentration determined in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4576,In vivo,A,10116.0,,,,50597
8926,1,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12873,In vivo,A,10116.0,,,,50597
8927,1,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12873,In vivo,A,10116.0,,,,50597
8928,1,Maximum plasma concentration in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6824,In vivo,A,10116.0,,,,50597
8929,1,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17065,In vivo,A,10116.0,,,,50597
8930,1,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2932,In vivo,A,10116.0,,,,50597
8931,1,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2932,In vivo,A,10116.0,,,,50597
8932,1,Maximum plasma concentration of compound was measured in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2879,In vivo,A,10116.0,,,,50597
8933,1,Maximum plasma concentration after 20 mg/kg oral administration in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2864,In vivo,A,10116.0,,,,50597
8934,1,Maximum plasma concentration after oral administration to rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,16367,In vivo,A,10116.0,,,,50597
8935,1,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,A,10116.0,,,,50597
8936,1,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,A,10116.0,,,,50597
8937,1,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,A,10116.0,,,,50597
8938,1,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,A,10116.0,,,,50597
8939,1,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17720,In vivo,F,10116.0,,,,50597
8940,1,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17720,In vivo,F,10116.0,,,,50597
8941,1,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17720,In vivo,F,10116.0,,,,50597
8942,1,Maximum plasma concentration dosed orally in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4516,In vivo,A,10116.0,,,,50597
8943,1,Maximum plasma concentration dosed orally in rats after 6 hours,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4516,In vivo,A,10116.0,,,,50597
8944,1,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4516,In vivo,A,10116.0,,,,50597
8945,1,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5199,In vivo,A,10116.0,,,,50597
8946,1,Maximum plasma concentration in rat after po administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17538,In vivo,A,10116.0,,,,50597
8947,1,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,A,10116.0,,,,50597
8948,1,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,A,10116.0,,,,50597
8949,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8950,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8951,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8952,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8953,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8954,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8955,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8956,1,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8957,1,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8958,1,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8959,1,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8960,1,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8961,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8962,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8963,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8964,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8965,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8966,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8967,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8968,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8969,1,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8970,1,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8971,1,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8972,1,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8973,1,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8974,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8975,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8976,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8977,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8978,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8979,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8980,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8981,1,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8982,1,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8983,1,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8984,1,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8985,1,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8986,1,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8987,1,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8988,1,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8989,1,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8990,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8991,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8992,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
8993,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
8994,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8995,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8996,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8997,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8998,1,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
8999,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
9000,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
9001,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
9002,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
9003,1,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
9004,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
9005,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
9006,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
9007,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
9008,1,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
9009,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
9010,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
9011,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
9012,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
9013,1,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
9014,1,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,In vivo,A,10116.0,,,,50597
9015,1,Half life in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3748,,A,10116.0,,,,50597
9016,1,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,,BAO_0000218,,Rattus norvegicus,,Intermediate,15765,,A,10116.0,,,,50597
9017,1,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),,BAO_0000218,,Rattus norvegicus,,Intermediate,4871,,A,10116.0,,,,50597
9018,1,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4871,,A,10116.0,,,,50597
9019,1,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),,BAO_0000218,,Rattus norvegicus,,Intermediate,4872,,A,10116.0,,,,50597
9020,1,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4872,,A,10116.0,,,,50597
9021,1,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),,BAO_0000218,,Rattus norvegicus,,Intermediate,5413,,A,10116.0,,,,50597
9022,1,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5413,,A,10116.0,,,,50597
9023,1,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,15272,In vivo,A,10116.0,,,,50597
9024,1,Stability (%) in rat liver microsomes,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,4689,,A,10116.0,,,,50597
9025,1,Area under curve was calculated after intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6057,,A,10116.0,,,,50597
9026,1,Area under the curve was calculated after iv administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6057,,A,10116.0,,,,50597
9027,1,Area under the curve was calculated in rat after peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6057,,A,10116.0,,,,50597
9028,1,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6211,,A,10116.0,,,,50597
9029,1,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5710,,A,10116.0,,,,50597
9030,1,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5710,,A,10116.0,,,,50597
9031,1,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,,BAO_0000218,,Rattus norvegicus,,Intermediate,17853,,A,10116.0,,,,50597
9032,1,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,,BAO_0000218,,Rattus norvegicus,,Intermediate,17853,,A,10116.0,,,,50597
9033,1,p value of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,15765,,A,10116.0,,,,50597
9034,1,p value of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,15765,,F,10116.0,,,,50597
9035,1,p value of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,15765,,A,10116.0,,,,50597
9036,1,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,6175,,A,10116.0,,,,50597
9037,1,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,6175,,A,10116.0,,,,50597
9038,1,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,6175,,A,10116.0,,,,50597
9039,1,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,7991,,F,9986.0,,,,22224
9040,1,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,429,,A,9986.0,,,,22224
9041,1,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,429,,A,9986.0,,,,22224
9042,1,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,6253,In vivo,A,9986.0,,,,22224
9043,1,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,6253,In vivo,A,9986.0,,,,22224
9044,1,Clearance rate in rabbits,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,3615,In vivo,A,9986.0,,,,22224
9045,1,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,4059,In vivo,A,9986.0,,,,22224
9046,1,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,5124,In vivo,A,9986.0,,,,22224
9047,1,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,5124,In vivo,A,9986.0,,,,22224
9048,1,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,5124,In vivo,A,9986.0,,,,22224
9049,1,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,429,In vivo,A,9986.0,,,,22224
9050,1,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,Plasma,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,4059,In vivo,A,9986.0,,,,22224
9051,1,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,Liver,BAO_0000251,,Oryctolagus cuniculus,,Autocuration,9659,,A,9986.0,,,Microsomes,22224
9052,1,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,Liver,BAO_0000251,,Oryctolagus cuniculus,,Autocuration,9659,,A,9986.0,,,Microsomes,22224
9053,1,Dose at which bioavailability of intravenously administered compound was tested in rabbit,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,3639,,A,9986.0,,,,22224
9054,1,Dose at which bioavailability of perorally administered compound was tested in rabbit,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,3639,,A,9986.0,,,,22224
9055,1,The compound was tested for its bioavailability in rabbit (by oral dosage).,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,3639,In vivo,A,9986.0,,,,22224
9056,1,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,5124,In vivo,A,9986.0,,,,22224
9057,1,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,5124,In vivo,A,9986.0,,,,22224
9058,1,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,5124,In vivo,A,9986.0,,,,22224
9059,1,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),,BAO_0000251,,Oryctolagus cuniculus,,Autocuration,14294,,A,9986.0,,,Microsomes,22224
9060,1,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),,BAO_0000251,,Oryctolagus cuniculus,,Autocuration,14294,,A,9986.0,,,Microsomes,22224
9061,1,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,429,In vivo,A,9986.0,,,,22224
9062,1,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,Plasma,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,5124,In vivo,A,9986.0,,,,22224
9063,1,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,Plasma,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,5124,In vivo,A,9986.0,,,,22224
9064,1,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,Plasma,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,5124,In vivo,A,9986.0,,,,22224
9065,1,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,429,In vivo,A,9986.0,,,,22224
9066,1,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),Urine,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,429,,A,9986.0,,,,22224
9067,1,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),Urine,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,429,,A,9986.0,,,,22224
9068,1,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,4059,In vivo,A,9986.0,,,,22224
9069,1,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,4137,In vivo,A,9986.0,,,,22224
9070,1,In vitro Biological half-life in crude homogenate of rabbit renal cortex,,BAO_0000221,,Oryctolagus cuniculus,,Autocuration,11672,In vitro,A,9986.0,,,,22224
9071,1,Time within which only 10% of the drug was degraded,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,12886,,A,9986.0,,,,22224
9072,1,Half life period in rabbit liver homogenate,Liver,BAO_0000221,,Oryctolagus cuniculus,,Autocuration,3853,,A,9986.0,,,,22224
9073,1,Half life value in rabbits,,BAO_0000019,,Oryctolagus cuniculus,,Autocuration,3615,,A,9986.0,,,,22224
9074,1,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,Blood,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,6253,In vivo,A,9986.0,,,,22224
9075,1,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,Blood,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,6253,In vivo,A,9986.0,,,,22224
9076,1,Half-life period in rabbits following intravenous administration at 2 mg/kg,,BAO_0000218,,Oryctolagus cuniculus,,Autocuration,6077,In vivo,A,9986.0,,,,22224
9077,1,AUC 0-8 hr value in rats at 10 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17617,,A,10116.0,,,,50597
9078,1,AUC after administration at 2000 mg/kg/day in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17594,,A,10116.0,,,,50597
9079,1,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6149,,A,10116.0,,,,50597
9080,1,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17260,,A,10116.0,,,,50597
9081,1,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17260,,A,10116.0,,,,50597
9082,1,AUC in rat after oral administration at 10.5 mg/kg dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6644,,A,10116.0,,,,50597
9083,1,AUC in rat after oral administration at 11.2 mg/kg dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6644,,A,10116.0,,,,50597
9084,1,AUC in rat after oral administration at 9.7 mg/kg dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6644,,A,10116.0,,,,50597
9085,1,AUC in rat brain after oral administration at 10 mg/kg,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,6495,,A,10116.0,,,,50597
9086,1,AUC in rat p.o.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6504,,A,10116.0,,,,50597
9087,1,AUC in rat p.o. at 20 mg/kg concentration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17686,,A,10116.0,,,,50597
9088,1,AUC in rat plasma after oral administration at 10 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6495,,A,10116.0,,,,50597
9089,1,AUC in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,216,,A,10116.0,,,,50597
9090,1,AUC value after IV dose at a dose of 5 mg/kg in rats.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1908,,A,10116.0,,,,50597
9091,1,AUC value after oral dose at a dose of 10 mg/kg in rats.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1908,,A,10116.0,,,,50597
9092,1,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,A,10116.0,,,,50597
9093,1,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,216,In vivo,A,10116.0,,,,50597
9094,1,Maximum plasma concentration was evaluated in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6049,In vivo,A,10116.0,,,,50597
9095,1,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2463,In vivo,A,10116.0,,,,50597
9096,1,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6679,In vivo,A,10116.0,,,,50597
9097,1,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6681,In vivo,A,10116.0,,,,50597
9098,1,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4890,In vivo,A,10116.0,,,,50597
9099,1,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,In vivo,A,10116.0,,,,50597
9100,1,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,In vivo,A,10116.0,,,,50597
9101,1,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,16366,In vivo,A,10116.0,,,,50597
9102,1,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6227,In vivo,A,10116.0,,,,50597
9103,1,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Expert,3598,In vivo,A,10116.0,,,,50597
9104,1,Maximum plasma drug concentration was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1465,In vivo,A,10116.0,,,,50597
9105,1,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4368,In vivo,A,10116.0,,,,50597
9106,1,Mean peak plasma concentration was observed after intravenous administration in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,A,10116.0,,,,50597
9107,1,Mean peak plasma concentration was observed after oral administration in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,A,10116.0,,,,50597
9108,1,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5355,In vivo,A,10116.0,,,,50597
9109,1,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5355,In vivo,A,10116.0,,,,50597
9110,1,Peak oral plasma concentration was determined in rats by oral administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1567,In vivo,A,10116.0,,,,50597
9111,1,Peak plasma concentration (Cmax) was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4026,In vivo,A,10116.0,,,,50597
9112,1,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6193,In vivo,A,10116.0,,,,50597
9113,1,Peak plasma concentration (Cmax) in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4026,In vivo,A,10116.0,,,,50597
9114,1,Peak plasma concentration at 1 mg/kg peroral administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6485,In vivo,A,10116.0,,,,50597
9115,1,Peak plasma concentration in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17655,In vivo,A,10116.0,,,,50597
9116,1,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14941,In vivo,A,10116.0,,,,50597
9117,1,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5394,In vivo,A,10116.0,,,,50597
9118,1,Pharmacokinetic property (Cmax) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4408,In vivo,A,10116.0,,,,50597
9119,1,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5983,In vivo,A,10116.0,,,,50597
9120,1,Cmax in rat after 3mg/kg oral dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,4878,In vivo,A,10116.0,,,,50597
9121,1,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,5862,In vivo,A,10116.0,Sprague-Dawley,,,50597
9122,1,Cmax in rats after 20 mg/kg oral dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,4517,In vivo,A,10116.0,,,,50597
9123,1,Cmax in rat plasma after 30mg/kg oral dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5932,In vivo,A,10116.0,,,,50597
9124,1,Plasma concentration after oral administration of 100 mg/kg to rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5436,In vivo,A,10116.0,,,,50597
9125,1,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,In vivo,A,10116.0,,,,50597
9126,1,Tested for the Cmax in rat at 10 mg/kg per orally,,BAO_0000218,,Rattus norvegicus,,Intermediate,4950,In vivo,A,10116.0,,,,50597
9127,1,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,In vivo,A,10116.0,,,,50597
9128,1,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,In vivo,A,10116.0,,,,50597
9129,1,Bioavailability as oral Cmax in rats at 30 mins,,BAO_0000218,,Rattus norvegicus,,Intermediate,3360,In vivo,A,10116.0,,,,50597
9130,1,Bioavailability as oral Cmax in rats at 6hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,3360,In vivo,A,10116.0,,,,50597
9131,1,The maximum concentration of compound was measured at the dose of 100 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,15022,In vivo,A,10116.0,,,,50597
9132,1,The maximum concentration of compound was measured at the dose of 300 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,15022,In vivo,A,10116.0,,,,50597
9133,1,The maximum concentration of compound was measured at the dose of 30 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,15022,In vivo,A,10116.0,,,,50597
9134,1,The maximum plasma levels for the compounds were determined by LC-MS.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5160,In vivo,A,10116.0,,,,50597
9135,1,mean peak plasma concentration was observed after intravenous administration in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,A,10116.0,,,,50597
9136,1,mean peak plasma concentration was observed after oral administration in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,A,10116.0,,,,50597
9137,1,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4709,,A,10116.0,,,,50597
9138,1,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,3535,,A,10116.0,,,,50597
9139,1,Concentration in plasma (portal) following oral dose in rats at 1 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,3535,,A,10116.0,,,,50597
9140,1,Concentration in plasma (portal) following oral dose in rats at 2 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,3535,,A,10116.0,,,,50597
9141,1,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,3535,,A,10116.0,,,,50597
9142,1,Concentration in plasma (systemic) following oral dose in rats at 1 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,3535,,A,10116.0,,,,50597
9143,1,Concentration in plasma (systemic) following oral dose in rats at 2 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,3535,,A,10116.0,,,,50597
9144,1,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5005,In vivo,A,10116.0,,,,22224
9145,1,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",Hypothalamus,BAO_0000218,,Rattus norvegicus,,Intermediate,6326,,A,10116.0,,,,50597
9146,1,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",Hypothalamus,BAO_0000218,,Rattus norvegicus,,Intermediate,6326,,A,10116.0,,,,50597
9147,1,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",,BAO_0000218,,Rattus norvegicus,,Intermediate,6326,,A,10116.0,,,,50597
9148,1,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",,BAO_0000218,,Rattus norvegicus,,Intermediate,6326,,A,10116.0,,,,50597
9149,1,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17411,,A,10116.0,,,,50597
9150,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9151,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9152,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9153,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9154,1,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9155,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9156,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9157,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9158,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9159,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9160,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9161,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9162,1,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9163,1,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9164,1,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9165,1,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9166,1,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9167,1,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9168,1,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9169,1,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9170,1,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9171,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9172,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9173,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9174,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9175,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9176,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9177,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9178,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9179,1,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9180,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9181,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9182,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9183,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9184,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9185,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9186,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9187,1,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9188,1,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9189,1,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9190,1,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9191,1,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9192,1,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9193,1,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9194,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9195,1,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,6175,,A,10116.0,,,,50597
9196,1,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,6175,,A,10116.0,,,,50597
9197,1,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,6175,,A,10116.0,,,,50597
9198,1,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,6175,,A,10116.0,,,,50597
9199,1,The compound was tested for the plasma binding in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,,A,10116.0,,,,50597
9200,1,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",,BAO_0000218,,Rattus norvegicus,,Intermediate,16459,,A,10116.0,,,,50597
9201,1,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",,BAO_0000218,,Rattus norvegicus,,Intermediate,16459,,A,10116.0,,,,50597
9202,1,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",,BAO_0000218,,Rattus norvegicus,,Intermediate,16459,,A,10116.0,,,,50597
9203,1,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,16459,,A,10116.0,,,,50597
9204,1,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,16459,,A,10116.0,,,,50597
9205,1,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,16459,,A,10116.0,,,,50597
9206,1,Plasma level at 2 hr after administration of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,3278,,A,10116.0,,,,50597
9207,1,plasma level at 2 hr after administration of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,3278,,A,10116.0,,,,50597
9208,1,Stability in rat serum measured as % recovery at 1 min,Serum,BAO_0000218,,Rattus norvegicus,,Intermediate,4684,,A,10116.0,,,,50597
9209,1,Stability in rat serum measured as % recovery at 10 min,Serum,BAO_0000218,,Rattus norvegicus,,Intermediate,4684,,A,10116.0,,,,50597
9210,1,Stability in rat serum measured as % recovery at 10 mins,Serum,BAO_0000218,,Rattus norvegicus,,Intermediate,4684,,A,10116.0,,,,50597
9211,1,Stability in rat serum measured as % recovery at 2 hr,Serum,BAO_0000218,,Rattus norvegicus,,Intermediate,4684,,A,10116.0,,,,50597
9212,1,Stability in rat serum measured as % recovery at 3 min,Serum,BAO_0000218,,Rattus norvegicus,,Intermediate,4684,,A,10116.0,,,,50597
9213,1,Stability in rat serum measured as % recovery at 3 mins,Serum,BAO_0000218,,Rattus norvegicus,,Intermediate,4684,,A,10116.0,,,,50597
9214,1,Stability in rat serum measured as % recovery at 5 min,Serum,BAO_0000218,,Rattus norvegicus,,Intermediate,4684,,A,10116.0,,,,50597
9215,1,Stability in rat serum measured as % recovery at 5 mins,Serum,BAO_0000218,,Rattus norvegicus,,Intermediate,4684,,A,10116.0,,,,50597
9216,1,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,16456,In vivo,A,10116.0,,,,50597
9217,1,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,16456,In vivo,A,10116.0,,,,50597
9218,1,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,723,,A,10116.0,,,,50597
9219,1,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,723,,A,10116.0,,,,50597
9220,1,Half life tested in mature male rat at a dose of 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5160,In vivo,A,10116.0,,,,50597
9221,1,Half life after intravenous administration of 1 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4709,In vivo,A,10116.0,,,,50597
9222,1,Half life period after administration (30 mg/kg) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5633,In vivo,A,10116.0,,,,50597
9223,1,Half life period in rat after 5 mg/Kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,5302,In vivo,A,10116.0,,,,50597
9224,1,Half life period in rat after 5 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,5302,In vivo,A,10116.0,,,,50597
9225,1,Half life period was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,,A,10116.0,,,,50597
9226,1,Half life period was evaluated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,,A,10116.0,,,,50597
9227,1,Half life period was evaluated in rat; 0.5-1.0,,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,,A,10116.0,,,,50597
9228,1,Half life period was evaluated in rat; 5.9-7.5,,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,,A,10116.0,,,,50597
9229,1,Half-life in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14512,,A,10116.0,,,,50597
9230,1,Half-life time in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6230,,A,10116.0,,,,50597
9231,1,Terminal half-life after iv administration to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3364,In vivo,A,10116.0,,,,50597
9232,1,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6874,In vivo,A,10116.0,,,,50597
9233,1,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,857,,A,10116.0,,,,50597
9234,1,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),,BAO_0000218,,Rattus norvegicus,,Intermediate,858,In vivo,A,10116.0,,,,50597
9235,1,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),,BAO_0000218,,Rattus norvegicus,,Intermediate,858,In vivo,A,10116.0,,,,50597
9236,1,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5355,In vivo,A,10116.0,,,,50597
9237,1,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5355,In vivo,A,10116.0,,,,50597
9238,1,Half life in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6305,,A,10116.0,,,,50597
9239,1,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13501,In vivo,A,10116.0,,,,50597
9240,1,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17594,In vivo,A,10116.0,,,,50597
9241,1,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4186,In vivo,A,10116.0,,,,50597
9242,1,Biological half-life was measured in plasma of rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2932,,A,10116.0,,,,50597
9243,1,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17065,In vivo,A,10116.0,,,,50597
9244,1,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15765,In vivo,A,10116.0,,,,50597
9245,1,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2713,In vivo,A,10116.0,,,,50597
9246,1,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,In vivo,A,10116.0,,,,50597
9247,1,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,In vivo,A,10116.0,,,,50597
9248,1,Compound was evaluated for plasma half life in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,740,,A,10116.0,,,,50597
9249,1,AUC value at a dose of 5 mg/kg (p.o.) in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6597,,A,10116.0,,,,50597
9250,1,AUC value after administration of 20 mg/Kg oral dose in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2959,,A,10116.0,,,,50597
9251,1,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17594,,A,10116.0,,,,50597
9252,1,AUC0-96 after administration at 50 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17596,,A,10116.0,,,,50597
9253,1,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17594,,A,10116.0,,,,50597
9254,1,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",,BAO_0000218,,Rattus norvegicus,,Intermediate,3293,,A,10116.0,,,,50597
9255,1,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6757,,A,10116.0,,,,50597
9256,1,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6757,,A,10116.0,,,,50597
9257,1,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6757,,A,10116.0,,,,50597
9258,1,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,5979,,A,10116.0,,,,50597
9259,1,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,,BAO_0000218,,Rattus norvegicus,,Intermediate,5979,,A,10116.0,,,,50597
9260,1,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,,BAO_0000218,,Rattus norvegicus,,Intermediate,5979,,A,10116.0,,,,50597
9261,1,Area under curve (AUC) at a dose of 30 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4026,,A,10116.0,,,,50597
9262,1,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5355,,A,10116.0,,,,50597
9263,1,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5355,,A,10116.0,,,,50597
9264,1,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5355,,A,10116.0,,,,50597
9265,1,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5633,,A,10116.0,,,,50597
9266,1,Area under curve (Pharmacokinetic property) was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,1716,,A,10116.0,,,,50597
9267,1,Area under curve (Pharmacokinetic property) of the compound; Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,1716,,A,10116.0,,,,50597
9268,1,Area under curve after intravenous administration (1 mg/kg) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4689,,A,10116.0,,,,50597
9269,1,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4527,,A,10116.0,,,,50597
9270,1,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4527,,A,10116.0,,,,50597
9271,1,Area under curve in male SD rats was observed after oral administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,,A,10116.0,,,,50597
9272,1,Area under curve of compound after iv administration of 20 mg/kg dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4413,,A,10116.0,,,,50597
9273,1,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Expert,3598,,A,10116.0,,,,50597
9274,1,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Expert,3598,,A,10116.0,,,,50597
9275,1,Area under curve at 5 mg/kg po was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5964,,A,10116.0,,,,50597
9276,1,Area under curve in Rat at a oral dose of 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4689,,A,10116.0,,,,50597
9277,1,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,,BAO_0000218,,Rattus norvegicus,,Intermediate,4186,,A,10116.0,,,,50597
9278,1,Area under curve was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5510,,A,10116.0,,,,50597
9279,1,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,17858,,A,10116.0,,,,50597
9280,1,Area under curve after intravenous administration at 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17804,,A,10116.0,,,,50597
9281,1,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,,BAO_0000218,,Rattus norvegicus,,Intermediate,6106,,A,10116.0,,,,50597
9282,1,Area under curve at 4 hr in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5964,,A,10116.0,,,,50597
9283,1,Area under curve at a dose of 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4026,,A,10116.0,,,,50597
9284,1,Area under curve at the dose of 2 mg/Kg administered perorally in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4756,,A,10116.0,,,,50597
9285,1,Area under curve at the dose of 5 mg/Kg administered perorally in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4756,,A,10116.0,,,,50597
9286,1,Area under curve for a 2-mpk po dose in SD rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5862,,A,10116.0,,,,50597
9287,1,Area under curve in SD rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5862,,A,10116.0,,,,50597
9288,1,Area under curve in rat after oral administration at 13 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,6644,,A,10116.0,,,,50597
9289,1,Area under curve in rat by po administration at 0-24 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,5871,,A,10116.0,,,,50597
9290,1,Area under curve in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5919,,A,10116.0,,,,50597
9291,1,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5939,,A,10116.0,,,,50597
9292,1,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5939,,A,10116.0,,,,50597
9293,1,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,,BAO_0000218,,Rattus norvegicus,,Intermediate,10,,A,10116.0,,,,50597
9294,1,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11149,,A,10116.0,,,,50597
9295,1,Area under curve value in rat at a dose of 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5302,,A,10116.0,,,,50597
9296,1,Area under curve was determined after oral administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17796,,A,10116.0,,,,50597
9297,1,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4890,,A,10116.0,,,,50597
9298,1,Area under curve was determined after peroral administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6011,,A,10116.0,,,,50597
9299,1,Area under curve was determined at a dose 30 mpk administered orally.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5375,,A,10116.0,,,,50597
9300,1,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17764,,A,10116.0,,,,50597
9301,1,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4368,,A,10116.0,,,,50597
9302,1,Area under curve was determined in male rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5610,,A,10116.0,,,,50597
9303,1,Area under curve was determined in rat after PO administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5833,,A,10116.0,,,,50597
9304,1,Area under curve was determined in rat after a 3 mg/kg of oral dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,4257,,A,10116.0,,,,50597
9305,1,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5937,,A,10116.0,,,,50597
9306,1,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5932,,A,10116.0,,,,50597
9307,1,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,,BAO_0000218,,Rattus norvegicus,,Intermediate,5932,,A,10116.0,,,,50597
9308,1,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17411,,A,10116.0,,,,50597
9309,1,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17411,,A,10116.0,,,,50597
9310,1,Peak plasma concentration in rat at a dose of 3 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17771,,A,10116.0,,,,50597
9311,1,Plasma concentration at 2 hr in rats was evaluated.,,BAO_0000218,,Rattus norvegicus,,Intermediate,1628,,A,10116.0,,,,50597
9312,1,Plasma concentration at 2 hr in rats was evaluated; Not available,,BAO_0000218,,Rattus norvegicus,,Intermediate,1628,,A,10116.0,,,,50597
9313,1,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17411,,A,10116.0,,,,50597
9314,1,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,A,10116.0,,,,50597
9315,1,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,A,10116.0,,,,50597
9316,1,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,A,10116.0,,,,50597
9317,1,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,A,10116.0,,,,50597
9318,1,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,A,10116.0,,,,50597
9319,1,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,A,10116.0,,,,50597
9320,1,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,,BAO_0000218,,Rattus norvegicus,,Intermediate,5510,,A,10116.0,,,,50597
9321,1,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,5510,,A,10116.0,,,,50597
9322,1,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5510,,A,10116.0,,,,50597
9323,1,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,5510,,A,10116.0,,,,50597
9324,1,PK study was carried to determine the relative absorption ranking in rat.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16427,,A,10116.0,,,,50597
9325,1,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4689,In vivo,A,10116.0,,,,50597
9326,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9327,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9328,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9329,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9330,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9331,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9332,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9333,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9334,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9335,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9336,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9337,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9338,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9339,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9340,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9341,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9342,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9343,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9344,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9345,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9346,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9347,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9348,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9349,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9350,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9351,1,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9352,1,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9353,1,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9354,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9355,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9356,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9357,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9358,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9359,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9360,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9361,1,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9362,1,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9363,1,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9364,1,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9365,1,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9366,1,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9367,1,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9368,1,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9369,1,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9370,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9371,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9372,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9373,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9374,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9375,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9376,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9377,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9378,1,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9379,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9380,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9381,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9382,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9383,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9384,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9385,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9386,1,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9387,1,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9388,1,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9389,1,Compound was evaluated for terminal half life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3341,,A,10116.0,,,,50597
9390,1,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3634,In vivo,A,10116.0,,,,50597
9391,1,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3634,In vivo,A,10116.0,,,,50597
9392,1,Compound was tested for its half life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4839,,A,10116.0,,,,50597
9393,1,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,Plasma,BAO_0000218,,Macaca mulatta,,Intermediate,5005,In vivo,A,9544.0,,,,22224
9394,1,Compound was tested for its plasma half life in Sprague Dawley rats,Plasma,BAO_0000366,,Rattus norvegicus,,Intermediate,5005,,A,10116.0,,,,22224
9395,1,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,Plasma,BAO_0000366,,Rattus norvegicus,,Intermediate,5005,,A,10116.0,,,,22224
9396,1,Compound was tested for plasma half-life period in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1094,,A,10116.0,,,,50597
9397,1,Elimination half life after i.v. administration of compound in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5031,In vivo,A,10116.0,,,,50597
9398,1,Elimination half-life after IV dosing at 0.5 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,A,10116.0,,,,50597
9399,1,Elimination half-life after IV dosing at 1 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,A,10116.0,,,,50597
9400,1,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,A,10116.0,,,,50597
9401,1,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,A,10116.0,,,,50597
9402,1,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,5408,In vivo,A,10116.0,,,,50597
9403,1,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5408,In vivo,A,10116.0,,,,50597
9404,1,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,5408,In vivo,A,10116.0,,,,50597
9405,1,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5408,In vivo,A,10116.0,,,,50597
9406,1,Evaluated for the half life in rat (in vivo),,BAO_0000218,,Rattus norvegicus,,Intermediate,4687,In vivo,A,10116.0,,,,50597
9407,1,Hafl life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6640,,A,10116.0,,,,50597
9408,1,Hafl life rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6640,,A,10116.0,,,,50597
9409,1,Hafl life rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,,A,10116.0,,,,50597
9410,1,Hafl life rat; Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6640,,A,10116.0,,,,50597
9411,1,Hafl life rat; Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,,A,10116.0,,,,50597
9412,1,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,17411,In vivo,A,10116.0,,,,50597
9413,1,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,17411,In vivo,A,10116.0,,,,50597
9414,1,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,17411,In vivo,A,10116.0,,,,50597
9415,1,Half life in rat after 1 mg/kg i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6570,In vivo,A,10116.0,,,,50597
9416,1,Half life in rat after 2 mg/kg peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6570,In vivo,A,10116.0,,,,50597
9417,1,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17411,In vivo,A,10116.0,,,,50597
9418,1,Half life of 10 mg/kg oral dose determined in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4722,In vivo,A,10116.0,,,,50597
9419,1,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
9420,1,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
9421,1,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
9422,1,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
9423,1,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
9424,1,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
9425,1,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
9426,1,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
9427,1,Half life of compound at 5 mg/kg after po administration was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4762,In vivo,A,10116.0,,,,50597
9428,1,Half life of compound determined after intravenous administration to rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5327,In vivo,A,10116.0,,,,50597
9429,1,Half life of compound was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4847,,A,10116.0,,,,50597
9430,1,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17720,In vivo,A,10116.0,,,,50597
9431,1,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,In vivo,A,10116.0,,,,50597
9432,1,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,In vivo,A,10116.0,,,,50597
9433,1,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,BAO_0000218,,Macaca fascicularis,,Intermediate,4256,In vivo,A,9541.0,,,,22224
9434,1,Half life determined in rat by intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,4256,In vivo,A,10116.0,,,,22224
9435,1,Half life determined in rats after iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,4722,In vivo,A,10116.0,,,,50597
9436,1,Half life in rat plasma after administration of 2 mg/kg iv,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6535,In vivo,A,10116.0,,,,50597
9437,1,Half life in rat plasma after administration of 2 mg/kg iv,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6535,In vivo,A,10116.0,,,,50597
9438,1,Half life in rat plasma was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1435,,A,10116.0,,,,50597
9439,1,Half life in rat plasma was determined; NA means not applicable,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1435,,A,10116.0,,,,50597
9440,1,Half life in rat was tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,5206,,A,10116.0,,,,50597
9441,1,Half life measured in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6080,,A,10116.0,,,,50597
9442,1,Half life recorded in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4449,,A,10116.0,,,,50597
9443,1,Half life was calculated,,BAO_0000218,,Rattus norvegicus,,Intermediate,6057,,A,10116.0,,,,50597
9444,1,Half life was calculated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6057,,A,10116.0,,,,50597
9445,1,Half life was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,3747,,A,10116.0,,,,50597
9446,1,Half life after 10 mg/kg oral administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17858,In vivo,A,10116.0,,,,50597
9447,1,Half life after administering orally a dose of 10 mg/kg to a fasting rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,A,10116.0,,,,50597
9448,1,Half life after administering orally a dose of 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,A,10116.0,,,,50597
9449,1,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5031,,A,10116.0,,,,50597
9450,1,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,,BAO_0000218,,Rattus norvegicus,,Intermediate,4722,,A,10116.0,,,,50597
9451,1,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6078,,A,10116.0,,,,50597
9452,1,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6078,,A,10116.0,,,,50597
9453,1,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6078,,A,10116.0,,,,50597
9454,1,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6078,,A,10116.0,,,,50597
9455,1,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17065,,A,10116.0,,,,50597
9456,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,1353,,A,10116.0,,,,50597
9457,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),,BAO_0000218,,Rattus norvegicus,,Intermediate,1353,,A,10116.0,,,,50597
9458,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),,BAO_0000218,,Rattus norvegicus,,Intermediate,1353,,A,10116.0,,,,50597
9459,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),,BAO_0000218,,Rattus norvegicus,,Intermediate,1353,,A,10116.0,,,,50597
9460,1,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),,BAO_0000218,,Rattus norvegicus,,Intermediate,1353,,A,10116.0,,,,50597
9461,1,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,16423,,A,10116.0,,,,50597
9462,1,Area under the curve was evaluated after 20 uM/kg of peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,16423,,A,10116.0,,,,50597
9463,1,Area under the curve was measured in rat after an iv dose of 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6062,,A,10116.0,,,,50597
9464,1,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6056,,A,10116.0,,,,50597
9465,1,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5182,,A,10116.0,,,,50597
9466,1,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,,A,10116.0,,,,50597
9467,1,Area under the curve was evaluated at an oral dose of 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,,A,10116.0,,,,50597
9468,1,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,,A,10116.0,,,,50597
9469,1,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,,A,10116.0,,,,50597
9470,1,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,,A,10116.0,,,,50597
9471,1,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,,A,10116.0,,,,50597
9472,1,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,,A,10116.0,,,,50597
9473,1,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,,A,10116.0,,,,50597
9474,1,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2463,,A,10116.0,,,,50597
9475,1,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4709,,A,10116.0,,,,50597
9476,1,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4075,,A,10116.0,,,,50597
9477,1,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,,BAO_0000218,,Rattus norvegicus,,Intermediate,5394,,A,10116.0,,,,50597
9478,1,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,,A,10116.0,,,,50597
9479,1,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,,A,10116.0,,,,50597
9480,1,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,,A,10116.0,,,,50597
9481,1,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,,A,10116.0,,,,50597
9482,1,Compound was evaluated for area under the curve expressed as (h*ug/ml),,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,,A,10116.0,,,,50597
9483,1,Compound was tested for area under curve in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2591,,A,10116.0,,,,50597
9484,1,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,,BAO_0000218,,Rattus norvegicus,,Intermediate,6567,,A,10116.0,,,,50597
9485,1,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6211,,A,10116.0,,,,50597
9486,1,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,5529,,A,10116.0,,,,50597
9487,1,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5408,,A,10116.0,,,,50597
9488,1,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,,BAO_0000218,,Rattus norvegicus,,Intermediate,5408,,A,10116.0,,,,50597
9489,1,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,,BAO_0000218,,Rattus norvegicus,,Intermediate,5408,,A,10116.0,,,,50597
9490,1,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,,BAO_0000218,,Rattus norvegicus,,Intermediate,5408,,A,10116.0,,,,50597
9491,1,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,429,,A,10116.0,,,,50597
9492,1,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,429,,A,10116.0,,,,50597
9493,1,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,429,,A,10116.0,,,,50597
9494,1,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4796,,A,10116.0,,,,50597
9495,1,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,,A,10116.0,,,,50597
9496,1,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,,A,10116.0,,,,50597
9497,1,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,,A,10116.0,,,,50597
9498,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9499,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9500,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9501,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9502,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9503,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9504,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9505,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9506,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9507,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9508,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9509,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9510,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9511,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9512,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9513,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9514,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9515,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9516,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9517,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9518,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9519,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9520,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9521,1,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9522,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9523,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9524,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9525,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9526,1,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9527,1,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9528,1,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9529,1,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9530,1,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9531,1,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9532,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9533,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9534,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9535,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9536,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9537,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9538,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9539,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9540,1,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9541,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9542,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9543,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9544,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9545,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9546,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9547,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9548,1,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9549,1,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9550,1,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9551,1,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9552,1,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9553,1,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9554,1,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9555,1,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9556,1,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9557,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9558,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9559,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9560,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9561,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9562,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9563,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9564,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9565,1,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9566,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9567,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9568,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9569,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9570,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9571,1,Half life after administering orally a dose of 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,A,10116.0,,,,50597
9572,1,Half life after administering orally a dose of 3 mg/kg to a fasting rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,A,10116.0,,,,50597
9573,1,Half life after administering intravenously a dose of 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,A,10116.0,,,,50597
9574,1,Half life after oral dosing in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,526,In vivo,A,10116.0,,,,50597
9575,1,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,A,10116.0,,,,50597
9576,1,Half life by intravenous administration of 3.4 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4368,In vivo,A,10116.0,,,,50597
9577,1,Half life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3371,,A,10116.0,,,,50597
9578,1,Half life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6448,,A,10116.0,,,,50597
9579,1,Half life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6453,,A,10116.0,,,,50597
9580,1,Half life in rat after intravenous administration of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,4353,In vivo,A,10116.0,,,,50597
9581,1,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4353,In vivo,A,10116.0,,,,50597
9582,1,Half life in rat after po administration of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,4353,In vivo,A,10116.0,,,,50597
9583,1,Half life in rat after po administration of the compound; ND means Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4353,In vivo,A,10116.0,,,,50597
9584,1,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4353,In vivo,A,10116.0,,,,50597
9585,1,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4353,In vivo,A,10116.0,,,,50597
9586,1,Half life in rat i.v.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5789,In vivo,A,10116.0,,,,50597
9587,1,Half life in rat i.v. at 2 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17686,In vivo,A,10116.0,,,,50597
9588,1,Half life in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6495,,A,10116.0,,,,50597
9589,1,Half life in rats after intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,484,In vivo,A,10116.0,,,,50597
9590,1,Half life in rats at the dose of 1.0 mpk by i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6467,In vivo,A,10116.0,,,,50597
9591,1,Half life in rat,,BAO_0000218,,Rattus norvegicus,,Expert,6642,,A,10116.0,,,,50597
9592,1,Half life was evaluated after intravenous administration to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,16367,In vivo,A,10116.0,,,,50597
9593,1,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),,BAO_0000218,,Rattus norvegicus,,Intermediate,1369,,A,10116.0,,,,50597
9594,1,Half life was evaluated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5472,,A,10116.0,,,,50597
9595,1,Half life was evaluated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6049,,A,10116.0,,,,50597
9596,1,Half life was evaluated in rat; Not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,5472,,A,10116.0,,,,50597
9597,1,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,16366,In vivo,A,10116.0,,,,50597
9598,1,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11149,In vivo,A,10116.0,,,,50597
9599,1,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11149,In vivo,A,10116.0,,,,50597
9600,1,Half life was measured in monkey at dose of 10 mg/kg by po administration,,BAO_0000218,,Primates,,Intermediate,2891,In vivo,A,9443.0,,,,22224
9601,1,Half life was measured in monkey at dose of 10 mg/kg by po administration,,BAO_0000218,,Primates,,Intermediate,2891,In vivo,A,9443.0,,,,22224
9602,1,Half life was measured in rat at dose of 30 mg/kg by iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,2891,In vivo,A,10116.0,,,,22224
9603,1,Half life was measured in rat at dose of 30 mg/kg by po administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,2891,In vivo,A,10116.0,,,,22224
9604,1,Half life (t1/2) was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4026,,A,10116.0,,,,50597
9605,1,Half life period at a dose of 10 uM/kg in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4527,,A,10116.0,,,,50597
9606,1,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4527,In vivo,A,10116.0,,,,50597
9607,1,Half life period was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5503,,A,10116.0,,,,50597
9608,1,Half life period after intravenous administration at 20 mpk in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4426,In vivo,A,10116.0,,,,50597
9609,1,Half life period after intravenous administration at 20 mpk in rats; Not performed.,,BAO_0000218,,Rattus norvegicus,,Intermediate,4426,In vivo,A,10116.0,,,,50597
9610,1,Half life period after intravenous administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6109,In vivo,A,10116.0,,,,50597
9611,1,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5654,In vivo,A,10116.0,,,,50597
9612,1,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5654,In vivo,A,10116.0,,,,50597
9613,1,Half life period in 80% rat plasma at 37 degree Centigrade,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4755,,A,10116.0,,,,50597
9614,1,Half life period in SD rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5862,,A,10116.0,,,,50597
9615,1,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1515,,A,10116.0,,,,50597
9616,1,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1515,,A,10116.0,,,,50597
9617,1,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1515,,A,10116.0,,,,50597
9618,1,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1515,,A,10116.0,,,,50597
9619,1,Half life period in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5960,,A,10116.0,,,,50597
9620,1,Half life period in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6103,,A,10116.0,,,,50597
9621,1,Half life period in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6317,,A,10116.0,,,,50597
9622,1,Half life period in rat after oral administration at 10.5 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,6644,In vivo,A,10116.0,,,,50597
9623,1,Half life period in rat after oral administration at 11.2 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,6644,In vivo,A,10116.0,,,,50597
9624,1,Half life period in rat after oral administration at 13 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,6644,In vivo,A,10116.0,,,,50597
9625,1,Half life period in rat after oral administration at 9.7 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,6644,In vivo,A,10116.0,,,,50597
9626,1,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,,A,10116.0,,,,50597
9627,1,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6295,,A,10116.0,,,,50597
9628,1,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6296,,A,10116.0,,,,50597
9629,1,PK study was carried to determine AUC (area under curve) value in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,16427,,A,10116.0,,,,50597
9630,1,Pharmacokinetic parameter AUC after intravenous administration to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,16367,,A,10116.0,,,,50597
9631,1,Pharmacokinetic parameter AUC after oral administration to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,16367,,A,10116.0,,,,50597
9632,1,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,,A,10116.0,,,,50597
9633,1,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,,A,10116.0,,,,50597
9634,1,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,,A,10116.0,,,,50597
9635,1,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,,A,10116.0,,,,50597
9636,1,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,,A,10116.0,,,,50597
9637,1,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,,A,10116.0,,,,50597
9638,1,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5394,,A,10116.0,,,,50597
9639,1,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5394,,A,10116.0,,,,50597
9640,1,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,,A,10116.0,,,,50597
9641,1,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,,A,10116.0,,,,50597
9642,1,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,,A,10116.0,,,,50597
9643,1,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,,A,10116.0,,,,50597
9644,1,Pharmacokinetic parameter area under curve was reported,,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,,A,10116.0,,,,50597
9645,1,Pharmacokinetic property (AUC) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4408,,A,10116.0,,,,50597
9646,1,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5983,,A,10116.0,,,,50597
9647,1,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,,BAO_0000218,,Rattus norvegicus,,Intermediate,4397,,A,10116.0,,,,50597
9648,1,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,4397,,A,10116.0,,,,50597
9649,1,Pharmacokinetic property was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5491,,A,10116.0,,,,50597
9650,1,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5491,,A,10116.0,,,,50597
9651,1,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,5491,,A,10116.0,,,,50597
9652,1,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4199,,A,10116.0,,,,50597
9653,1,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4199,,A,10116.0,,,,50597
9654,1,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4199,,A,10116.0,,,,50597
9655,1,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",,BAO_0000218,,Rattus norvegicus,,Intermediate,5173,,A,10116.0,,,,50597
9656,1,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",,BAO_0000218,,Rattus norvegicus,,Intermediate,5173,,A,10116.0,,,,50597
9657,1,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",,BAO_0000218,,Rattus norvegicus,,Intermediate,5173,,A,10116.0,,,,50597
9658,1,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",,BAO_0000218,,Rattus norvegicus,,Intermediate,5173,,A,10116.0,,,,50597
9659,1,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,,BAO_0000218,,Rattus norvegicus,,Intermediate,16366,,A,10116.0,,,,50597
9660,1,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,,BAO_0000218,,Rattus norvegicus,,Intermediate,16366,,A,10116.0,,,,50597
9661,1,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5327,,A,10116.0,,,,50597
9662,1,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,6681,,A,10116.0,,,,50597
9663,1,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),,BAO_0000218,,Rattus norvegicus,,Intermediate,12873,,A,10116.0,,,,50597
9664,1,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),,BAO_0000218,,Rattus norvegicus,,Intermediate,12873,,A,10116.0,,,,50597
9665,1,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,,A,10116.0,,,,50597
9666,1,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,,A,10116.0,,,,50597
9667,1,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,,A,10116.0,,,,50597
9668,1,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",,BAO_0000218,,Rattus norvegicus,,Intermediate,6619,,A,10116.0,,,,50597
9669,1,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",,BAO_0000218,,Rattus norvegicus,,Intermediate,6619,,A,10116.0,,,,50597
9670,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,BAO_0000218,,Rattus norvegicus,,Intermediate,10363,,A,10116.0,,,,50597
9671,1,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4796,,A,10116.0,,,,50597
9672,1,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,A,10116.0,,,,50597
9673,1,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,A,10116.0,,,,50597
9674,1,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,,BAO_0000218,,Rattus norvegicus,,Intermediate,4839,,A,10116.0,,,,50597
9675,1,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,,A,10116.0,,,,50597
9676,1,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,,A,10116.0,,,,50597
9677,1,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,,A,10116.0,,,,50597
9678,1,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,,A,10116.0,,,,50597
9679,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9680,1,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,11450,,A,10116.0,,,,50597
9681,1,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,BAO_0000218,,Rattus norvegicus,,Intermediate,8151,,A,10116.0,,,,50597
9682,1,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,8151,,A,10116.0,,,,50597
9683,1,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8151,,A,10116.0,,,,50597
9684,1,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9685,1,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9686,1,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9687,1,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9688,1,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9689,1,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9690,1,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9691,1,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9692,1,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9693,1,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9694,1,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9695,1,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9696,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9697,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9698,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9699,1,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9700,1,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9701,1,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9702,1,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9703,1,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9704,1,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9705,1,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9706,1,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9707,1,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9708,1,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9709,1,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9710,1,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9711,1,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9712,1,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9713,1,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9714,1,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9715,1,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9716,1,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9717,1,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9718,1,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9719,1,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9720,1,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9721,1,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9722,1,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9723,1,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9724,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9725,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9726,1,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9727,1,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9728,1,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9729,1,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9730,1,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9731,1,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9732,1,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9733,1,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9734,1,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9735,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9736,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9737,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9738,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9739,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9740,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9741,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9742,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9743,1,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9744,1,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9745,1,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9746,1,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9747,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9748,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9749,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16434,,A,10116.0,,,,50597
9750,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,F,10116.0,,,,50597
9751,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9752,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9753,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,F,10116.0,,,,50597
9754,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9755,1,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,16435,,A,10116.0,,,,50597
9756,1,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9757,1,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9758,1,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9759,1,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9760,1,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9761,1,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9762,1,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9763,1,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9764,1,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9765,1,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9766,1,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9767,1,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9768,1,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9769,1,Half life period in rat by iv administration at a dose of 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5874,In vivo,A,10116.0,,,,50597
9770,1,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1515,,A,10116.0,,,,50597
9771,1,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1515,,A,10116.0,,,,50597
9772,1,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1515,,A,10116.0,,,,50597
9773,1,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1515,,A,10116.0,,,,50597
9774,1,Half life period was evaluated in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5491,,A,10116.0,,,,50597
9775,1,Half life period was evaluated in rat plasma; Not tested,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5491,,A,10116.0,,,,50597
9776,1,Half life period was evaluated in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,1918,,A,10116.0,,,,50597
9777,1,"Half life period was evaluated in rats, iv",,BAO_0000218,,Rattus norvegicus,,Intermediate,1918,In vivo,A,10116.0,,,,50597
9778,1,Half life period after intravenous administration at 5 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6113,In vivo,A,10116.0,,,,50597
9779,1,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5546,In vivo,A,10116.0,,,,50597
9780,1,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5553,In vivo,A,10116.0,,,,50597
9781,1,Half life stability of compound was evaluated in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4188,,A,10116.0,,,,50597
9782,1,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6215,In vivo,A,10116.0,,,,50597
9783,1,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6141,In vivo,A,10116.0,,,,50597
9784,1,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5182,In vivo,A,10116.0,,,,50597
9785,1,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,,BAO_0000218,,Rattus norvegicus,,Intermediate,5182,In vivo,A,10116.0,,,,50597
9786,1,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5710,In vivo,A,10116.0,,,,50597
9787,1,Half in rat i.v.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5789,In vivo,A,10116.0,,,,50597
9788,1,Half period in rat after intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6011,In vivo,A,10116.0,,,,50597
9789,1,Half-life after repeated oral dose of compound at 1 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17594,In vivo,A,10116.0,,,,50597
9790,1,Half-life measured in in vitro Cathepsin B assay in rat liver,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12357,In vitro,A,10116.0,,,,50597
9791,1,Half-life of compound was determined in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5210,,A,10116.0,,,,50597
9792,1,Half-life at 10 mg/kg in rat upon intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17596,In vivo,A,10116.0,,,,50597
9793,1,Half-life determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6672,,A,10116.0,,,,50597
9794,1,Half-life determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6673,,A,10116.0,,,,50597
9795,1,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,In vivo,A,10116.0,,,,50597
9796,1,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3741,,A,10116.0,,,,50597
9797,1,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17671,In vivo,A,10116.0,,,,50597
9798,1,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,In vivo,A,10116.0,,,,50597
9799,1,Half-life in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17537,,A,10116.0,,,,50597
9800,1,Half-life in rat plasma was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4965,,A,10116.0,,,,50597
9801,1,Half-life in rat plasma; Not tested,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17537,,A,10116.0,,,,50597
9802,1,Half-life in rat serum,Serum,BAO_0000218,,Rattus norvegicus,,Intermediate,6124,,A,10116.0,,,,50597
9803,1,Half-life in rat serum; na is not available,Serum,BAO_0000218,,Rattus norvegicus,,Intermediate,6124,,A,10116.0,,,,50597
9804,1,Half-life was calculated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6078,,A,10116.0,,,,50597
9805,1,Half-life was calculated in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17668,,A,10116.0,,,,50597
9806,1,Half-life was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,3185,,A,10116.0,,,,50597
9807,1,Half-life was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4883,,A,10116.0,,,,50597
9808,1,Half-life after administration of 20 mg/Kg oral dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2959,In vivo,A,10116.0,,,,50597
9809,1,Half-life after administration of 3.2 mg/kg intravenously in male rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4029,In vivo,A,10116.0,,,,50597
9810,1,Half-life after intravenous administration in female rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4029,In vivo,A,10116.0,,,,50597
9811,1,Half-life after intravenous administration in male rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4029,In vivo,A,10116.0,,,,50597
9812,1,Half-life after intravenous dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6180,In vivo,A,10116.0,,,,50597
9813,1,Half-life in a rat liver homogenate preparation,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,1557,,A,10116.0,,,,50597
9814,1,Half-life in plasma of rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12500,,A,10116.0,,,,50597
9815,1,Half-life in plasma of rat at dose of 3-10 mgkg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12500,,A,10116.0,,,,50597
9816,1,Half-life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5064,,A,10116.0,,,,50597
9817,1,Half-life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5145,,A,10116.0,,,,50597
9818,1,Half-life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5147,,A,10116.0,,,,50597
9819,1,Half-life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5833,,A,10116.0,,,,50597
9820,1,Half-life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6596,,A,10116.0,,,,50597
9821,1,Half-life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17655,,A,10116.0,,,,50597
9822,1,Half-life in rat after oral administration at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6495,In vivo,A,10116.0,,,,50597
9823,1,Half-life in rat after po administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17538,In vivo,A,10116.0,,,,50597
9824,1,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,17538,In vivo,A,10116.0,,,,50597
9825,1,Half-life in rat at 3 mg/kg dose administered intravenously,,BAO_0000218,,Rattus norvegicus,,Intermediate,10,In vivo,A,10116.0,,,,50597
9826,1,Half-life in rat brain homogenate,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,17669,,A,10116.0,,,,50597
9827,1,Half-life in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17065,,A,10116.0,,,,50597
9828,1,Half-life in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4333,,A,10116.0,,,,50597
9829,1,Half-life in Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6827,,A,10116.0,,,,50597
9830,1,Half-life in vitro in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,889,In vitro,A,10116.0,,,,50597
9831,1,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,889,In vitro,A,10116.0,,,,50597
9832,1,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",,BAO_0000218,,Rattus norvegicus,,Intermediate,3747,,A,10116.0,,,,50597
9833,1,The area under the curve of compound was measured at the dose of 100 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,15022,,A,10116.0,,,,50597
9834,1,The area under the curve of compound was measured at the dose of 300 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,15022,,A,10116.0,,,,50597
9835,1,The area under the curve of compound was measured at the dose of 30 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,15022,,A,10116.0,,,,50597
9836,1,Bioavailability as oral AUC in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3360,In vivo,A,10116.0,,,,50597
9837,1,The plasma concentration versus time curve (AUC) was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,,A,10116.0,,,,50597
9838,1,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17411,,A,10116.0,,,,50597
9839,1,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17411,,A,10116.0,,,,50597
9840,1,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17411,,A,10116.0,,,,50597
9841,1,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,,BAO_0000218,,Rattus norvegicus,,Intermediate,6570,,A,10116.0,,,,50597
9842,1,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,,BAO_0000218,,Rattus norvegicus,,Intermediate,6570,,A,10116.0,,,,50597
9843,1,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17411,,A,10116.0,,,,50597
9844,1,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14941,,A,10116.0,,,,50597
9845,1,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14941,,A,10116.0,,,,50597
9846,1,AUC in rat after po administration at a dose of 10 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17538,,A,10116.0,,,,50597
9847,1,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17752,,A,10116.0,,,,50597
9848,1,Area under curve value 24 hr after 10 mg/kg iv administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17509,,A,10116.0,,,,50597
9849,1,Area under curve value 24 hr after 10 mg/kg oral administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17509,,A,10116.0,,,,50597
9850,1,Area under curve value 24 hr after 2 mg/kg iv administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17509,,A,10116.0,,,,50597
9851,1,Area under curve value 24 hr after 2 mg/kg oral administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17509,,A,10116.0,,,,50597
9852,1,Area under curve value 6 hr after po administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17509,,A,10116.0,,,,50597
9853,1,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,,A,10116.0,,,,50597
9854,1,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,,A,10116.0,,,,50597
9855,1,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,,A,10116.0,,,,50597
9856,1,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,,A,10116.0,,,,50597
9857,1,AUC normalized for dose (AUCN) in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6642,,A,10116.0,,,,50597
9858,1,Area under curve in rat after p.o. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6640,,A,10116.0,,,,50597
9859,1,Area under curve in rat after p.o. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,,A,10116.0,,,,50597
9860,1,Area under curve in rat after p.o. administration; Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,,A,10116.0,,,,50597
9861,1,Area under curve in rat after peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,,A,10116.0,,,,50597
9862,1,Area under curve (carotid artery) value of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,3603,,A,10116.0,,,,50597
9863,1,Bioavailability expressed as the area under curve of rat carotid artery,,BAO_0000218,,Rattus norvegicus,,Intermediate,3550,,A,10116.0,,,,50597
9864,1,Area under curve in male SD rats was observed after intravenous administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,,A,10116.0,,,,50597
9865,1,Area under curve of the compound was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,17720,,A,10116.0,,,,50597
9866,1,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,,BAO_0000218,,Rattus norvegicus,,Intermediate,5407,,A,10116.0,,,,50597
9867,1,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17752,,A,10116.0,,,,50597
9868,1,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17752,,A,10116.0,,,,50597
9869,1,Area under curve (portal vein) value of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,3603,,A,10116.0,,,,50597
9870,1,Bioavailability expressed as the area under curve of rat portal vein,,BAO_0000218,,Rattus norvegicus,,Intermediate,3550,,A,10116.0,,,,50597
9871,1,Area Under plasma concentration time curve in rat upon peroral administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17655,,A,10116.0,,,,50597
9872,1,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17582,,A,10116.0,,,,50597
9873,1,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17582,,A,10116.0,,,,50597
9874,1,Compound was evaluated for oral bioavailability in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,,A,10116.0,,,,50597
9875,1,Compound was evaluated for oral bioavailability in rats after iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,,A,10116.0,,,,50597
9876,1,Compound was evaluated for oral bioavailability in rats; 30-80,,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,,A,10116.0,,,,50597
9877,1,Compound was evaluated for oral bioavailability in rats; 50-60,,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,,A,10116.0,,,,50597
9878,1,Compound was evaluated for oral bioavailability in rats; no data,,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,,A,10116.0,,,,50597
9879,1,Compound was evaluated for oral bioavailability in rats; peptide,,BAO_0000218,,Rattus norvegicus,,Intermediate,17791,,A,10116.0,,,,50597
9880,1,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
9881,1,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
9882,1,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
9883,1,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
9884,1,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9885,1,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9886,1,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9887,1,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Stomach,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9888,1,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9889,1,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9890,1,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9891,1,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9892,1,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,In vivo,A,10116.0,,,,50597
9893,1,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,6899,,A,10116.0,,,,50597
9894,1,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,6899,,A,10116.0,,,,50597
9895,1,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,6899,,A,10116.0,,,,50597
9896,1,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,6899,,A,10116.0,,,,50597
9897,1,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,6899,,A,10116.0,,,,50597
9898,1,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8677,,A,10116.0,,,,50597
9899,1,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,,BAO_0000218,,Rattus norvegicus,,Intermediate,6899,,A,10116.0,,,,50597
9900,1,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,6899,,A,10116.0,,,,50597
9901,1,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2189,,A,10116.0,,,,50597
9902,1,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,2189,,A,10116.0,,,,50597
9903,1,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,2189,,A,10116.0,,,,50597
9904,1,Biodistribution of compound in rat blood after 5 min of administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,A,10116.0,,,,50597
9905,1,Biodistribution of compound in rat blood after 5 min of administration.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,A,10116.0,,,,50597
9906,1,Biodistribution of compound in rat brain after 5 min of administration,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,A,10116.0,,,,50597
9907,1,Biodistribution of compound in rat heart after 5 min of administration,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,A,10116.0,,,,50597
9908,1,Biodistribution of compound in rat heart after 5 min of administration.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,A,10116.0,,,,50597
9909,1,Biodistribution of compound in rat kidney after 5 min of administration,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,A,10116.0,,,,50597
9910,1,Biodistribution of compound in rat kidney after 5 min of administration.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,A,10116.0,,,,50597
9911,1,Biodistribution of compound in rat liver after 5 min of administration,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,A,10116.0,,,,50597
9912,1,Biodistribution of compound in rat liver after 5 min of administration.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,A,10116.0,,,,50597
9913,1,Biodistribution of compound in rat lung after 5 min of administration,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,A,10116.0,,,,50597
9914,1,Biodistribution of compound in rat lung after 5 min of administration.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,A,10116.0,,,,50597
9915,1,Biodistribution of compound in rat muscle after 5 min of administration,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,A,10116.0,,,,50597
9916,1,Biodistribution of compound in rat muscle after 5 min of administration.,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,10839,In vivo,A,10116.0,,,,50597
9917,1,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,4043,,A,10116.0,,,,50597
9918,1,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,4043,,A,10116.0,,,,50597
9919,1,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,4043,,A,10116.0,,,,50597
9920,1,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,4043,,A,10116.0,,,,50597
9921,1,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,BAO_0000218,,Rattus norvegicus,,Intermediate,4043,,A,10116.0,,,,50597
9922,1,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,BAO_0000218,,Rattus norvegicus,,Intermediate,4043,,A,10116.0,,,,50597
9923,1,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,4043,,A,10116.0,,,,50597
9924,1,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,4043,,A,10116.0,,,,50597
9925,1,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,BAO_0000218,,Rattus norvegicus,,Intermediate,4043,,A,10116.0,,,,50597
9926,1,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,,BAO_0000218,,Rattus norvegicus,,Intermediate,4043,,A,10116.0,,,,50597
9927,1,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,,BAO_0000218,,Rattus norvegicus,,Intermediate,1446,,A,10116.0,,,,50597
9928,1,Dose required to lower urine osmolality to 300 mOsm/kg in rat,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,9971,,A,10116.0,,,,50597
9929,1,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,9971,,A,10116.0,,,,50597
9930,1,% Bioavailability after 1 day of the drug administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5765,In vivo,A,10116.0,,,,50597
9931,1,% Bioavailability after 4 day of the drug administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5765,In vivo,A,10116.0,,,,50597
9932,1,Absolute bioavailability was evaluated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4257,In vivo,A,10116.0,,,,50597
9933,1,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9934,1,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9935,1,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9936,1,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9937,1,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9938,1,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9939,1,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9940,1,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9941,1,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9942,1,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9943,1,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9944,1,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9945,1,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9946,1,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9947,1,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9948,1,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9949,1,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9950,1,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9951,1,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9952,1,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9953,1,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,Female gonad,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9954,1,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,Female gonad,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9955,1,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,Female gonad,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9956,1,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9957,1,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9958,1,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9959,1,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9960,1,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9961,1,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9962,1,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9963,1,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9964,1,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9965,1,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9966,1,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9967,1,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13091,,A,10116.0,,,,50597
9968,1,Dissociation constant was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,11977,,A,10116.0,,,,50597
9969,1,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",,BAO_0000218,,Rattus norvegicus,,Intermediate,14941,,A,10116.0,,,,50597
9970,1,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,,A,10116.0,,,,50597
9971,1,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,,A,10116.0,,,,50597
9972,1,Observed rate constant in 80% rat plasma at 37 degree Centigrade,,BAO_0000218,,Rattus norvegicus,,Intermediate,4755,,A,10116.0,,,,50597
9973,1,LogP value was evaluated in the in situ rat gut perfusion assay,,BAO_0000218,,Rattus norvegicus,,Intermediate,589,,A,10116.0,,,,50597
9974,1,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17582,In vivo,A,10116.0,,,,50597
9975,1,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5031,In vivo,A,10116.0,,,,50597
9976,1,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17764,In vivo,A,10116.0,,,,50597
9977,1,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17720,,A,10116.0,,,,50597
9978,1,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,,BAO_0000218,,Rattus norvegicus,,Expert,2862,,F,10116.0,,,,50597
9979,1,Half-life was evaluated after 10 uM/kg of intra arterial administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,16423,,A,10116.0,,,,50597
9980,1,Half-life was evaluated after 20 uM/kg of peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,16423,In vivo,A,10116.0,,,,50597
9981,1,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6005,In vivo,A,10116.0,,,,50597
9982,1,Half-life was evaluated in plasma of rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2938,,A,10116.0,,,,50597
9983,1,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,In vivo,A,10116.0,,,,50597
9984,1,Half-life was evaluated in rats at an oral dose of 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,In vivo,A,10116.0,,,,50597
9985,1,Half-life was measured in rat after an iv dose of 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6062,In vivo,A,10116.0,,,,50597
9986,1,Half-life period of compound in rats after peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6571,In vivo,A,10116.0,,,,50597
9987,1,Half-life period of compound was measured in rat plasma.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3136,,A,10116.0,,,,50597
9988,1,Half-life period of compound was measured in rat plasma; ND is not determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3136,,A,10116.0,,,,50597
9989,1,Half-life period of compound was measured in rat plasma; not determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3136,,A,10116.0,,,,50597
9990,1,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,4521,In vivo,A,10116.0,,,,50597
9991,1,Half-life period in rat by iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5871,In vivo,A,10116.0,,,,50597
9992,1,Half-life period in rats following intravenous administration at 2 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6077,In vivo,A,10116.0,,,,50597
9993,1,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6679,In vivo,A,10116.0,,,,50597
9994,1,Half-life period was determined for the compound in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5144,,A,10116.0,,,,50597
9995,1,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",,BAO_0000218,,Rattus norvegicus,,Intermediate,4498,In vivo,A,10116.0,,,,50597
9996,1,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",,BAO_0000218,,Rattus norvegicus,,Intermediate,4498,In vivo,A,10116.0,,,,50597
9997,1,Half-life value after IV dose at a dose of 5 mg/kg in rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,1908,In vivo,A,10116.0,,,,50597
9998,1,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6211,In vivo,A,10116.0,,,,50597
9999,1,Half-life was determined in rat after intravenous administration (0.5 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,5529,In vivo,A,10116.0,,,,50597
10000,1,Half-life was determined in rat at a dose of 1 mpk i.v.,,BAO_0000218,,Rattus norvegicus,,Intermediate,6444,In vivo,A,10116.0,,,,50597
10001,1,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6444,In vivo,A,10116.0,,,,50597
10002,1,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6444,In vivo,A,10116.0,,,,50597
10003,1,Half-life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5207,,A,10116.0,,,,50597
10004,1,In vitro half life in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,530,In vitro,A,10116.0,,,,50597
10005,1,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1116,In vitro,A,10116.0,,,,50597
10006,1,In vitro half life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3219,In vitro,A,10116.0,,,,50597
10007,1,In vivo half life period after intravenous administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6109,In vivo,A,10116.0,,,,50597
10008,1,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17582,In vivo,A,10116.0,,,,50597
10009,1,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17582,In vivo,A,10116.0,,,,50597
10010,1,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,A,10116.0,,,,50597
10011,1,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,A,10116.0,,,,50597
10012,1,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,A,10116.0,,,,50597
10013,1,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,A,10116.0,,,,50597
10014,1,Longer half-life in rat (i.v.) at 0.5 mpk,,BAO_0000218,,Rattus norvegicus,,Intermediate,17853,In vivo,A,10116.0,,,,50597
10015,1,Longer half-life in rat (p.o.) at 2.0 mpk,,BAO_0000218,,Rattus norvegicus,,Intermediate,17853,In vivo,A,10116.0,,,,50597
10016,1,Pharmacokinetic property (half life) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3457,,A,10116.0,,,,50597
10017,1,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,A,10116.0,,,,50597
10018,1,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,A,10116.0,,,,50597
10019,1,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,A,10116.0,,,,50597
10020,1,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,A,10116.0,,,,50597
10021,1,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5739,In vivo,A,10116.0,,,,50597
10022,1,Pharmacokinetic half time was determined intravenously in rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15765,In vivo,A,10116.0,,,,50597
10023,1,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6567,In vivo,A,10116.0,,,,50597
10024,1,Plasma half life of hydrolysis of the compound,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2448,,A,10116.0,,,,50597
10025,1,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5423,In vivo,A,10116.0,,,,50597
10026,1,Plasma half life period was calculated in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4853,,A,10116.0,,,,50597
10027,1,Plasma half-life in Sprague-Dawley rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4514,,A,10116.0,,,,50597
10028,1,Plasma half-life in Sprague-Dawley rats; Not determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4514,,A,10116.0,,,,50597
10029,1,Plasma half-life in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1500,,A,10116.0,,,,50597
10030,1,Plasma half-life in rats; <MQL,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,1500,,A,10116.0,,,,50597
10031,1,Plasma half-life period (0-8 h) was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,,A,10116.0,,,,50597
10032,1,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,,A,10116.0,,,,50597
10033,1,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,In vivo,A,10116.0,,,,50597
10034,1,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,In vivo,A,10116.0,,,,50597
10035,1,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4956,,A,10116.0,,,,50597
10036,1,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4956,,A,10116.0,,,,50597
10037,1,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10038,1,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10039,1,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10040,1,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10041,1,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10042,1,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10043,1,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10044,1,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10045,1,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10046,1,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10047,1,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10048,1,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10049,1,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10050,1,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10051,1,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10052,1,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10053,1,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10054,1,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10055,1,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10056,1,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10057,1,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10058,1,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10059,1,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10060,1,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10061,1,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10062,1,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10063,1,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10064,1,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10065,1,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10066,1,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10067,1,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10068,1,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10069,1,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10070,1,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10071,1,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10072,1,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10073,1,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10074,1,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",,BAO_0000218,,Rattus norvegicus,,Intermediate,4498,In vivo,A,10116.0,,,,50597
10075,1,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",,BAO_0000218,,Rattus norvegicus,,Intermediate,4498,In vivo,A,10116.0,,,,50597
10076,1,Bioavailability after a dose of 10 mg/kg p.o.,,BAO_0000218,,Rattus norvegicus,,Intermediate,3603,In vivo,A,10116.0,,,,50597
10077,1,Bioavailability after peroral administration (10 mg/kg) was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6215,In vivo,A,10116.0,,,,50597
10078,1,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5710,In vivo,A,10116.0,,,,50597
10079,1,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,5710,In vivo,A,10116.0,,,,50597
10080,1,Bioavailability in rat po was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5676,In vivo,A,10116.0,,,,50597
10081,1,Bioavailability of compound at 10 mg/kg in rat after oral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17667,In vivo,A,10116.0,,,,50597
10082,1,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17667,In vivo,A,10116.0,,,,50597
10083,1,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,6848,In vivo,A,10116.0,,,,50597
10084,1,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,6848,In vivo,A,10116.0,,,,50597
10085,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17267,In vivo,A,10116.0,,,,50597
10086,1,Bioavailability in rat (Sprague-Dawley) (female),,BAO_0000218,,Rattus norvegicus,,Intermediate,6362,In vivo,A,10116.0,,,,50597
10087,1,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17671,In vivo,A,10116.0,,,,50597
10088,1,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,17671,In vivo,A,10116.0,,,,50597
10089,1,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,4333,In vivo,A,10116.0,,,,50597
10090,1,Bioavailability in rat at an oral dose of 2 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6077,In vivo,A,10116.0,,,,50597
10091,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3278,In vivo,A,10116.0,,,,50597
10092,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5964,In vivo,A,10116.0,,,,50597
10093,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4884,In vivo,A,10116.0,,,,50597
10094,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4905,In vivo,A,10116.0,,,,50597
10095,1,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,,BAO_0000218,,Rattus norvegicus,,Intermediate,4884,In vivo,A,10116.0,,,,50597
10096,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6850,In vivo,A,10116.0,,,,50597
10097,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2864,In vivo,A,10116.0,,,,50597
10098,1,Bioavailability was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5780,In vivo,A,10116.0,,,,50597
10099,1,Bioavailability,,BAO_0000218,,Rattus norvegicus,,Intermediate,1465,In vivo,A,10116.0,,,,50597
10100,1,Bioavailability,,BAO_0000218,,Rattus norvegicus,,Intermediate,5199,In vivo,A,10116.0,,,,50597
10101,1,Bioavailability in rat after 1 day dosing,,BAO_0000218,,Rattus norvegicus,,Intermediate,5765,In vivo,A,10116.0,,,,50597
10102,1,Bioavailability in rat after 4 day dosing,,BAO_0000218,,Rattus norvegicus,,Intermediate,5765,In vivo,A,10116.0,,,,50597
10103,1,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,A,10116.0,,,,50597
10104,1,Bioavailability after IV dosing at 1 mg/kg in rat; no data,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,A,10116.0,,,,50597
10105,1,Bioavailability after oral administration at a dose of 2 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,A,10116.0,,,,50597
10106,1,Bioavailability after oral administration at a dose of 4 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6518,In vivo,A,10116.0,,,,50597
10107,1,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2083,In vivo,A,10116.0,,,,50597
10108,1,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17260,In vivo,A,10116.0,,,,50597
10109,1,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,4956,In vivo,A,10116.0,,,,50597
10110,1,Bioavailability by intravenous administration of 3.4 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4368,In vivo,A,10116.0,,,,50597
10111,1,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17752,In vivo,A,10116.0,,,,50597
10112,1,Bioavailability in rat (Fisher) (fasted),,BAO_0000218,,Rattus norvegicus,,Intermediate,1446,In vivo,A,10116.0,,,,50597
10113,1,Bioavailability in monkey after po administration of 10 mg/kg dose,,BAO_0000218,,Primates,,Intermediate,2891,In vivo,A,9443.0,,,,22224
10114,1,Oral bioavailability in monkey (dose 10 mg/kg),,BAO_0000218,,Primates,,Intermediate,2891,In vivo,A,9443.0,,,,22224
10115,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6672,In vivo,A,10116.0,,,,50597
10116,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6673,In vivo,A,10116.0,,,,50597
10117,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17655,In vivo,A,10116.0,,,,50597
10118,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17796,In vivo,A,10116.0,,,,50597
10119,1,Bioavailability in rat (dose 2.0 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,17853,In vivo,A,10116.0,,,,50597
10120,1,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),,BAO_0000218,,Rattus norvegicus,,Intermediate,4521,In vivo,A,10116.0,,,,50597
10121,1,Oral bioavailability in rat (dose 5 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,4940,In vivo,A,10116.0,,,,50597
10122,1,Bioavailability in rat after po administration of 30 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,2891,In vivo,A,10116.0,,,,22224
10123,1,Bioavailability in rat after po administration of 30 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,2891,In vivo,A,10116.0,,,,22224
10124,1,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,4521,In vivo,A,10116.0,,,,50597
10125,1,Bioavailability in rat (dose 2 mg/kg i.v.),,BAO_0000218,,Rattus norvegicus,,Intermediate,17686,In vivo,A,10116.0,,,,50597
10126,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17796,In vivo,A,10116.0,,,,50597
10127,1,Bioavailability in rat; Only traces detected in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17796,In vivo,A,10116.0,,,,50597
10128,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5064,In vivo,A,10116.0,,,,50597
10129,1,Bioavailability upon oral administration of compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,5147,In vivo,A,10116.0,,,,50597
10130,1,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,1916,In vivo,A,10116.0,,,,50597
10131,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6049,In vivo,A,10116.0,,,,50597
10132,1,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",,BAO_0000218,,Rattus norvegicus,,Intermediate,1445,In vivo,A,10116.0,,,,50597
10133,1,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",,BAO_0000218,,Rattus norvegicus,,Intermediate,1445,In vivo,A,10116.0,,,,50597
10134,1,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,,BAO_0000218,,Rattus norvegicus,,Expert,2862,,F,10116.0,,,,50597
10135,1,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,,BAO_0000218,,Rattus norvegicus,,Expert,2862,,F,10116.0,,,,50597
10136,1,In vitro and metabolic stability was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4194,,A,10116.0,,,,50597
10137,1,In vitro metabolic stability in rat hepatocytes,,BAO_0000218,,Rattus norvegicus,,Intermediate,4194,,A,10116.0,,,,50597
10138,1,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,,BAO_0000218,,Rattus norvegicus,,Intermediate,5486,,A,10116.0,,,,50597
10139,1,Metabolic rate for compound was observed in rat hepatocytes,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,17582,In vitro,A,10116.0,,Hepatocyte,,50597
10140,1,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,,BAO_0000218,,Rattus norvegicus,,Intermediate,5600,,A,10116.0,,,,50597
10141,1,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),,BAO_0000218,,Rattus norvegicus,,Intermediate,14294,,A,10116.0,,,,50597
10142,1,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),,BAO_0000218,,Rattus norvegicus,,Intermediate,14294,,A,10116.0,,,,50597
10143,1,Metabolism of compound in rat S9 microsomes; Trace,,BAO_0000218,,Rattus norvegicus,,Intermediate,14294,,A,10116.0,,,,50597
10144,1,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,,BAO_0000218,,Rattus norvegicus,,Intermediate,17847,,A,10116.0,,,,50597
10145,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10146,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10147,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10148,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10149,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10150,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10151,1,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10152,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10153,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10154,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10155,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10156,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10157,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10158,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10159,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10160,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10161,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10162,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10163,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10164,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10165,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10166,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10167,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10168,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10169,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10170,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10171,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10172,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10173,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10174,1,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4969,,A,10116.0,,,,50597
10175,1,Stability in rat plasma was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6737,,A,10116.0,,,,50597
10176,1,Stability in rat plasma was determined; ND= no data,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,6737,,A,10116.0,,,,50597
10177,1,Tested for plasma half life period in rat (0-8 hr),Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5089,,A,10116.0,,,,50597
10178,1,Tested for plasma half life period in rat (0-8 hr); Not determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5089,,A,10116.0,,,,50597
10179,1,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1466,In vivo,A,10116.0,,,,50597
10180,1,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1466,In vivo,A,10116.0,,,,50597
10181,1,Tested for the half life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4950,,A,10116.0,,,,50597
10182,1,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,,BAO_0000218,,Rattus norvegicus,,Intermediate,2412,In vitro,A,10116.0,,,,50597
10183,1,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,2412,In vitro,A,10116.0,,,,50597
10184,1,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,,BAO_0000218,,Rattus norvegicus,,Intermediate,2412,In vitro,A,10116.0,,,,50597
10185,1,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,2412,In vitro,A,10116.0,,,,50597
10186,1,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,,BAO_0000218,,Rattus norvegicus,,Intermediate,2412,In vitro,A,10116.0,,,,50597
10187,1,The biological half life the compound was measured at the dose of 100 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,15022,,A,10116.0,,,,50597
10188,1,The biological half life the compound was measured at the dose of 30 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,15022,,A,10116.0,,,,50597
10189,1,The compound was evaluated for plasma half life period in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,406,,A,10116.0,,,,50597
10190,1,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,In vivo,A,10116.0,,,,50597
10191,1,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,In vivo,A,10116.0,,,,50597
10192,1,The pharmacokinetic parameter half-life period in vivo in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5247,In vivo,A,10116.0,,,,50597
10193,1,"The pharmacokinetic property, Half-life was determined",,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,In vivo,A,10116.0,,,,50597
10194,1,"The pharmacokinetic property, Half-life in rat in vivo",,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,In vivo,A,10116.0,,,,50597
10195,1,"The pharmacokinetic property, Half-life was determined; ND denotes no data",,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,In vivo,A,10116.0,,,,50597
10196,1,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,In vivo,A,10116.0,,,,50597
10197,1,The plasma half life period in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,3918,,A,10116.0,,,,50597
10198,1,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,2906,,A,10116.0,,,,50597
10199,1,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,6467,In vivo,A,10116.0,,,,50597
10200,1,t1/2 (apparent elimination)of the compound was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5510,,A,10116.0,,,,50597
10201,1,t1/2 value in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3788,,A,10116.0,,,,50597
10202,1,Half life in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17796,,A,10116.0,,,,50597
10203,1,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12873,In vivo,A,10116.0,,,,50597
10204,1,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,,BAO_0000218,,Rattus norvegicus,,Intermediate,5983,In vivo,A,10116.0,,,,50597
10205,1,Half-life period in fasted rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15765,,A,10116.0,,,,50597
10206,1,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,In vivo,A,10116.0,,,,50597
10207,1,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,In vivo,A,10116.0,,,,50597
10208,1,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,429,In vivo,A,10116.0,,,,50597
10209,1,Maximum time required to achieve Cmax was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17655,,A,10116.0,,,,50597
10210,1,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,A,10116.0,,,,50597
10211,1,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,A,10116.0,,,,50597
10212,1,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,A,10116.0,,,,50597
10213,1,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6570,In vivo,A,10116.0,,,,50597
10214,1,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,,BAO_0000218,,Rattus norvegicus,,Intermediate,6570,In vivo,A,10116.0,,,,50597
10215,1,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
10216,1,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
10217,1,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
10218,1,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
10219,1,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17720,In vivo,A,10116.0,,,,50597
10220,1,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,In vivo,A,10116.0,,,,50597
10221,1,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4723,In vivo,A,10116.0,,,,50597
10222,1,Tmax at the dose of 2 mg/Kg administered perorally in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4756,In vivo,A,10116.0,,,,50597
10223,1,Tmax at the dose of 5 mg/Kg administered perorally in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4756,In vivo,A,10116.0,,,,50597
10224,1,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17720,In vivo,A,10116.0,,,,50597
10225,1,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17720,In vivo,A,10116.0,,,,50597
10226,1,tmax upon peroral administration of 10.0 mg/Kg dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1466,In vivo,A,10116.0,,,,50597
10227,1,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,,BAO_0000218,,Rattus norvegicus,,Intermediate,7449,,F,10116.0,,,,50597
10228,1,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,,BAO_0000218,,Rattus norvegicus,,Intermediate,7449,,F,10116.0,,,,50597
10229,1,Percent total excretion of 3-methoxyacetaminophen glucuronide,,BAO_0000218,,Rattus norvegicus,,Intermediate,7449,,F,10116.0,,,,50597
10230,1,Percent total excretion of N-methoxyacetaminophen glucuronide,,BAO_0000218,,Rattus norvegicus,,Intermediate,7449,,F,10116.0,,,,50597
10231,1,Percent total excretion of N-methoxyacetaminophen sulfate,,BAO_0000218,,Rattus norvegicus,,Intermediate,7449,,F,10116.0,,,,50597
10232,1,Percent total excretion of acetaminophen,,BAO_0000218,,Rattus norvegicus,,Intermediate,7449,,F,10116.0,,,,50597
10233,1,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,7768,,A,10116.0,,,,50597
10234,1,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",,BAO_0000218,,Rattus norvegicus,,Intermediate,17655,,A,10116.0,,,,50597
10235,1,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17735,,A,10116.0,,,,50597
10236,1,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,BAO_0000218,,Rattus norvegicus,,Intermediate,5960,,A,10116.0,,,,50597
10237,1,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,17735,,A,10116.0,,,,50597
10238,1,Compound was tested for antidiuretic activity in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,7116,,A,10116.0,,,,50597
10239,1,AUC in rat after 3mg/kg oral dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,4878,In vivo,A,10116.0,,,,50597
10240,1,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5939,,A,10116.0,,,,50597
10241,1,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5939,,A,10116.0,,,,50597
10242,1,Bioavailability administered orally at a dose of 10 mg/kg to rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,16367,,A,10116.0,,,,50597
10243,1,Oral Bioavailability was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,16366,,A,10116.0,,,,50597
10244,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4426,,A,10116.0,,,,50597
10245,1,Oral bioavailability in rat; Not performed.,,BAO_0000218,,Rattus norvegicus,,Intermediate,4426,,A,10116.0,,,,50597
10246,1,Bioavailability,,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,,A,10116.0,,,,50597
10247,1,Bioavailability was determined; ND denotes no data,,BAO_0000218,,Rattus norvegicus,,Intermediate,5041,,A,10116.0,,,,50597
10248,1,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,1500,,A,10116.0,,,,50597
10249,1,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,1500,,A,10116.0,,,,50597
10250,1,Binding towards rat plasma protein at 10 uM,,BAO_0000218,,Rattus norvegicus,,Intermediate,17409,,A,10116.0,,,,50597
10251,1,Binding towards rat plasma protein at 100 uM,,BAO_0000218,,Rattus norvegicus,,Intermediate,17409,,A,10116.0,,,,50597
10252,1,Bioavailability in rat (dose 20 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,2959,In vivo,A,10116.0,,,,50597
10253,1,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13501,In vivo,A,10116.0,,,,50597
10254,1,Bioavailability in rat after 5 mg/kg oral gavage,,BAO_0000218,,Rattus norvegicus,,Intermediate,6567,In vivo,A,10116.0,,,,50597
10255,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6571,In vivo,A,10116.0,,,,50597
10256,1,Bioavailability in rat (dose 1 mg/kg i.v.),,BAO_0000218,,Rattus norvegicus,,Intermediate,6715,In vivo,A,10116.0,,,,50597
10257,1,Bioavailability in rat (dose 3 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,6715,In vivo,A,10116.0,,,,50597
10258,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2932,In vivo,A,10116.0,,,,50597
10259,1,Bioavailability of the compound in rats after administration of 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4171,In vivo,A,10116.0,,,,50597
10260,1,Bioavailability after administration of 10 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17509,In vivo,A,10116.0,,,,50597
10261,1,Bioavailability after administration of 2 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17509,In vivo,A,10116.0,,,,50597
10262,1,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4527,In vivo,A,10116.0,,,,50597
10263,1,Bioavailability in dogs was determined; high,,BAO_0000218,,Rattus norvegicus,,Intermediate,4026,In vivo,A,10116.0,,,,50597
10264,1,Bioavailability in monkey after intravenous administration at 1 mpk,,BAO_0000218,,Rattus norvegicus,,Intermediate,6659,In vivo,A,10116.0,,,,50597
10265,1,Bioavailability in monkey after peroral administration at 10 mpk,,BAO_0000218,,Rattus norvegicus,,Intermediate,6659,In vivo,A,10116.0,,,,50597
10266,1,Bioavailability in rat after intravenous administration at 1 mpk,,BAO_0000218,,Rattus norvegicus,,Intermediate,6659,In vivo,A,10116.0,,,,50597
10267,1,Bioavailability in rat after intravenous administration at 2 mpk,,BAO_0000218,,Rattus norvegicus,,Intermediate,6659,In vivo,F,10116.0,,,,50597
10268,1,Bioavailability in rat after peroral administration at 30 mpk,,BAO_0000218,,Rattus norvegicus,,Intermediate,6659,In vivo,A,10116.0,,,,50597
10269,1,Bioavailability in rat after peroral administration at at 100 mpk,,BAO_0000218,,Rattus norvegicus,,Intermediate,6659,In vivo,F,10116.0,,,,50597
10270,1,Bioavailability in rats was evaluated,,BAO_0000218,,Rattus norvegicus,,Intermediate,6597,In vivo,A,10116.0,,,,50597
10271,1,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,1202,In vivo,A,10116.0,,,,50597
10272,1,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,1202,In vivo,A,10116.0,,,,50597
10273,1,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,1202,In vivo,A,10116.0,,,,50597
10274,1,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,1202,In vivo,A,10116.0,,,,50597
10275,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5207,In vivo,A,10116.0,,,,50597
10276,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5970,In vivo,A,10116.0,,,,50597
10277,1,Oral bioavailability in rat (dose 10 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,17538,In vivo,A,10116.0,,,,50597
10278,1,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,17538,In vivo,A,10116.0,,,,50597
10279,1,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1466,In vivo,A,10116.0,,,,50597
10280,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,2879,In vivo,A,10116.0,,,,50597
10281,1,Bioavailability was measured in rat after oral administration; 2-4,,BAO_0000218,,Rattus norvegicus,,Intermediate,2879,In vivo,A,10116.0,,,,50597
10282,1,Bioavailability was measured in rat after oral administration; 3-7,,BAO_0000218,,Rattus norvegicus,,Intermediate,2879,In vivo,A,10116.0,,,,50597
10283,1,Bioavailability in rat (intraduodenal administration),,BAO_0000218,,Rattus norvegicus,,Intermediate,3777,In vivo,A,10116.0,,,,50597
10284,1,Bioavailability in rat (intraduodenal administration),,BAO_0000218,,Rattus norvegicus,,Intermediate,3777,In vivo,A,10116.0,,,,50597
10285,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3777,In vivo,A,10116.0,,,,50597
10286,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3777,In vivo,A,10116.0,,,,50597
10287,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,5423,In vivo,A,10116.0,,,,50597
10288,1,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,A,10116.0,,,,50597
10289,1,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,16365,In vivo,A,10116.0,,,,50597
10290,1,Bioavailability was measured in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4239,In vivo,A,10116.0,,,,50597
10291,1,Bioavailability was reported,,BAO_0000218,,Rattus norvegicus,,Intermediate,5438,In vivo,A,10116.0,,,,50597
10292,1,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,In vivo,A,10116.0,,,,50597
10293,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,In vivo,A,10116.0,,,,50597
10294,1,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4199,In vivo,A,10116.0,,,,50597
10295,1,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,4199,In vivo,A,10116.0,,,,50597
10296,1,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),,BAO_0000218,,Rattus norvegicus,,Intermediate,4199,In vivo,A,10116.0,,,,50597
10297,1,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4890,In vivo,A,10116.0,,,,50597
10298,1,Bioavailability was determined at 3 mg/kg po dose in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2792,In vivo,A,10116.0,,,,50597
10299,1,Oral bioavailability in rat (dose 2 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,5529,In vivo,A,10116.0,,,,50597
10300,1,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,A,10116.0,,,,50597
10301,1,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,A,10116.0,,,,50597
10302,1,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",,BAO_0000218,,Rattus norvegicus,,Intermediate,6685,In vivo,A,10116.0,,,,50597
10303,1,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6005,In vivo,A,10116.0,,,,50597
10304,1,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,In vivo,A,10116.0,,,,50597
10305,1,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,In vivo,A,10116.0,,,,50597
10306,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6103,In vivo,A,10116.0,,,,50597
10307,1,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,In vivo,A,10116.0,,,,50597
10308,1,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6410,In vivo,A,10116.0,,,,50597
10309,1,Bioavailability in rat (Sprague-Dawley),,BAO_0000218,,Rattus norvegicus,,Intermediate,5353,In vivo,A,10116.0,,,,50597
10310,1,Bioavailability in rat at the dose of 2 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4727,In vivo,A,10116.0,,,,50597
10311,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17804,In vivo,A,10116.0,,,,50597
10312,1,Bioavailability in rat (cannulated) (dose 2 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,5809,In vivo,A,10116.0,,,,50597
10313,1,Bioavailability value of compound in rats was determined after peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17804,In vivo,A,10116.0,,,,50597
10314,1,Oral bioavailability in rat (dose 20 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,3634,In vivo,A,10116.0,,,,50597
10315,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3341,In vivo,A,10116.0,,,,50597
10316,1,Oral bioavailability in rat (dose 5 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,2690,In vivo,A,10116.0,,,,50597
10317,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3184,In vivo,A,10116.0,,,,50597
10318,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,740,In vivo,A,10116.0,,,,50597
10319,1,Compound was evaluated for oral bioavailability in rats; 15-27 %,,BAO_0000218,,Rattus norvegicus,,Intermediate,1806,In vivo,A,10116.0,,,,50597
10320,1,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,,BAO_0000218,,Rattus norvegicus,,Intermediate,4891,In vivo,A,10116.0,,,,50597
10321,1,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),,BAO_0000218,,Rattus norvegicus,,Intermediate,3634,In vivo,A,10116.0,,,,50597
10322,1,Compound was tested for bioavailability in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,64,In vivo,A,10116.0,,,,50597
10323,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4839,In vivo,A,10116.0,,,,50597
10324,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1094,In vivo,A,10116.0,,,,50597
10325,1,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,,BAO_0000218,,Macaca mulatta,,Intermediate,5005,In vivo,A,9544.0,,,,22224
10326,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,5005,In vivo,A,10116.0,,,,22224
10327,1,Evaluated for the bioavailability in rat (in vivo),,BAO_0000218,,Rattus norvegicus,,Intermediate,4687,In vivo,A,10116.0,,,,50597
10328,1,F value of compound in rats was determined after peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17804,In vivo,A,10116.0,,,,50597
10329,1,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,A,10116.0,,,,50597
10330,1,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,A,10116.0,,,,50597
10331,1,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,A,10116.0,,,,50597
10332,1,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5974,In vivo,A,10116.0,,,,50597
10333,1,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",,BAO_0000218,,Rattus norvegicus,,Intermediate,1088,In vivo,A,10116.0,,,,50597
10334,1,Maximum fall in carotid flow in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1742,In vivo,A,10116.0,,,,50597
10335,1,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4689,In vivo,A,10116.0,,,,50597
10336,1,Oral bioavailability in rat (dose 5 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,2463,In vivo,A,10116.0,,,,50597
10337,1,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5654,In vivo,A,10116.0,,,,50597
10338,1,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5654,In vivo,A,10116.0,,,,50597
10339,1,Oral bioavailability in rat (male Wistar),,BAO_0000218,,Rattus norvegicus,,Intermediate,6874,In vivo,A,10116.0,,,,50597
10340,1,Oral bioavailability after administration (30 mg/kg) in rat; good,,BAO_0000218,,Rattus norvegicus,,Intermediate,5633,In vivo,A,10116.0,,,,50597
10341,1,Oral bioavailability at the dose of 2 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5496,In vivo,A,10116.0,,,,50597
10342,1,Oral bioavailability determined in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2358,In vivo,A,10116.0,,,,50597
10343,1,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,16456,In vivo,A,10116.0,,,,50597
10344,1,Oral bioavailability in rat (dose single 10 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,5302,In vivo,A,10116.0,,,,50597
10345,1,Oral bioavailability in rat (dose single 10 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,5302,In vivo,A,10116.0,,,,50597
10346,1,Oral bioavailability in rat (dose 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5302,In vivo,A,10116.0,,,,50597
10347,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10348,1,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10349,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10350,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10351,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10352,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10353,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10354,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10355,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10356,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10357,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10358,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10359,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10360,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10361,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10362,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10363,1,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10364,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10365,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10366,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10367,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10368,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10369,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10370,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10371,1,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10372,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10373,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10374,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10375,1,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10376,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10377,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10378,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10379,1,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10380,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10381,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10382,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10383,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10384,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10385,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10386,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10387,1,Percent total excretion of acetaminophen cysteine conjugate,,BAO_0000218,,Rattus norvegicus,,Intermediate,7449,,F,10116.0,,,,50597
10388,1,Percent total excretion of acetaminophen glucuronide,,BAO_0000218,,Rattus norvegicus,,Intermediate,7449,,F,10116.0,,,,50597
10389,1,Percent total excretion of acetaminophen sulfate,,BAO_0000218,,Rattus norvegicus,,Intermediate,7449,,F,10116.0,,,,50597
10390,1,Percent total excretion of acetaminophen-mercapturic acid,,BAO_0000218,,Rattus norvegicus,,Intermediate,7449,,F,10116.0,,,,50597
10391,1,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,3172,,A,10116.0,,,,50597
10392,1,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,16456,In vivo,A,10116.0,,,,50597
10393,1,Biodistribution of compound in rat muscle after 5 min of administration,Muscle tissue,BAO_0000218,,ratrat,,Autocuration,10839,In vivo,A,8656.0,,,,22224
10394,1,Biodistribution of compound in rat muscle after 5 min of administration.,Muscle tissue,BAO_0000218,,ratrat,,Autocuration,10839,In vivo,A,8656.0,,,,22224
10395,1,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,BAO_0000218,,Ovis aries,,Autocuration,5334,In vivo,A,9940.0,,,,22224
10396,1,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,BAO_0000218,,Ovis aries,,Autocuration,5334,In vivo,A,9940.0,,,,22224
10397,1,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,BAO_0000218,,Ovis aries,,Autocuration,5334,In vivo,A,9940.0,,,,22224
10398,1,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,BAO_0000218,,Ovis aries,,Autocuration,5334,In vivo,A,9940.0,,,,22224
10399,1,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),,BAO_0000218,,Ovis aries,,Autocuration,5334,In vivo,A,9940.0,,,,22224
10400,1,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),,BAO_0000218,,Ovis aries,,Autocuration,5334,In vivo,A,9940.0,,,,22224
10401,1,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),Plasma,BAO_0000218,,Ovis aries,,Autocuration,5334,In vivo,A,9940.0,,,,22224
10402,1,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),Plasma,BAO_0000218,,Ovis aries,,Autocuration,5334,In vivo,A,9940.0,,,,22224
10403,1,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),,BAO_0000218,,Serpentes,,Intermediate,1735,,A,8570.0,,,,50497
10404,1,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,,BAO_0000218,,Serpentes,,Intermediate,1469,,A,8570.0,,,,50497
10405,1,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,,BAO_0000218,,Serpentes,,Intermediate,1336,,A,8570.0,,,,50497
10406,1,The human biological plasma half life of the compound,Plasma,BAO_0000366,,Homo sapiens,,Autocuration,12403,,A,9606.0,,,,22224
10407,1,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8151,,A,10116.0,,,,50597
10408,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,A,10116.0,,,,50597
10409,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,A,10116.0,,,,50597
10410,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,A,10116.0,,,,50597
10411,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,A,10116.0,,,,50597
10412,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,A,10116.0,,,,50597
10413,1,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,A,10116.0,,,,50597
10414,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,A,10116.0,,,,50597
10415,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,A,10116.0,,,,50597
10416,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,A,10116.0,,,,50597
10417,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,A,10116.0,,,,50597
10418,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,A,10116.0,,,,50597
10419,1,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,A,10116.0,,,,50597
10420,1,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,A,10116.0,,,,50597
10421,1,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,A,10116.0,,,,50597
10422,1,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8004,,A,10116.0,,,,50597
10423,1,Dissociation constant against binding to human cyclophilin A,,BAO_0000357,,Homo sapiens,,Expert,15917,,B,9606.0,,,,180
10424,1,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,,BAO_0000019,,Bos taurus,,Expert,12396,,B,9913.0,,,,11591
10425,1,-Log C was determined by performing the electroshock minimum test,,BAO_0000019,,,,Autocuration,7065,,A,,,,,22224
10426,1,-Log C was determined by performing the foot shock test,,BAO_0000019,,,,Autocuration,7065,,A,,,,,22224
10427,1,-Log C was determined by performing the incl screen test,,BAO_0000019,,,,Autocuration,7065,,A,,,,,22224
10428,1,-Log C was determined by performing the maximum electroshock test,,BAO_0000019,,,,Autocuration,7065,,A,,,,,22224
10429,1,-Log C was determined by performing the pentylenetetrazole test,,BAO_0000019,,,,Autocuration,7065,,A,,,,,22224
10430,1,Tested for experimental arotinoid inhibitory dose,,BAO_0000019,,,,Autocuration,12415,,A,,,,,22224
10431,1,Negative log transformed activity,,BAO_0000019,,,,Autocuration,10256,,A,,,,,22224
10432,1,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",,BAO_0000019,,,,Autocuration,7991,,A,,,,,22224
10433,1,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,,BAO_0000218,,Cavia porcellus,,Intermediate,14342,,A,10141.0,,,,50512
10434,1,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,,BAO_0000218,,Cavia porcellus,,Intermediate,14342,,A,10141.0,,,,50512
10435,1,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,,BAO_0000218,,Cavia porcellus,,Intermediate,14342,,A,10141.0,,,,50512
10436,1,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,Ileum,BAO_0000218,,Cavia porcellus,,Intermediate,14342,,A,10141.0,,,,50512
10437,1,Solubility in water was determined; values expressed as -log,,BAO_0000100,,,,Autocuration,6047,,P,,,,,22229
10438,1,Ratio of Kcat to that of Km was determined,,BAO_0000019,,,,Autocuration,17269,,A,,,,,22224
10439,1,Observed first order rate constant,,BAO_0000019,,,,Autocuration,10026,,A,,,,,22224
10440,1,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,,BAO_0000019,,,,Autocuration,14583,,A,,,,,22224
10441,1,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,In vivo,A,10116.0,,,,50597
10442,1,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2661,In vivo,A,10116.0,,,,50597
10443,1,Oral Bioavailability after administration of 10 mg/kg in male rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4029,In vivo,A,10116.0,,,,50597
10444,1,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,17735,In vivo,A,10116.0,,,,50597
10445,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4576,In vivo,A,10116.0,,,,50597
10446,1,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17582,In vivo,A,10116.0,,,,50597
10447,1,Oral bioavailability at 1 mg/kg was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17651,In vivo,A,10116.0,,,,50597
10448,1,Oral bioavailability at 10 mg/kg was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17651,In vivo,A,10116.0,,,,50597
10449,1,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",,BAO_0000218,,Rattus norvegicus,,Intermediate,17670,In vivo,A,10116.0,,,,50597
10450,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5045,In vivo,A,10116.0,,,,50597
10451,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1696,In vivo,A,10116.0,,,,50597
10452,1,Oral bioavailability after intravenous administration in rats at 24 uM/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17764,In vivo,A,10116.0,,,,50597
10453,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6448,In vivo,A,10116.0,,,,50597
10454,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6596,In vivo,A,10116.0,,,,50597
10455,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17547,In vivo,A,10116.0,,,,50597
10456,1,Oral bioavailability in rat at a dose of 3 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17771,In vivo,A,10116.0,,,,50597
10457,1,Oral bioavailability in rat after oral administration at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6495,In vivo,A,10116.0,,,,50597
10458,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4558,In vivo,A,10116.0,,,,50597
10459,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17596,In vivo,A,10116.0,,,,50597
10460,1,Oral bioavailability in Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6827,In vivo,A,10116.0,,,,50597
10461,1,Oral bioavailability,,BAO_0000218,,Rattus norvegicus,,Intermediate,4026,In vivo,A,10116.0,,,,50597
10462,1,Oral bioavailability in rat (dose 30 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,10,In vivo,A,10116.0,,,,50597
10463,1,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,A,10116.0,,,,50597
10464,1,Bioavailability in rat (dose 3 mg/kg i.v.),,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,A,10116.0,,,,50597
10465,1,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,A,10116.0,,,,50597
10466,1,Oral bioavailability in rat (dose 60 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,A,10116.0,,,,50597
10467,1,Percent oral bioavailability determined in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4796,In vivo,A,10116.0,,,,50597
10468,1,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4883,In vivo,A,10116.0,,,,50597
10469,1,The compound was evaluated for bioavailability in rats; 32-51,,BAO_0000218,,Rattus norvegicus,,Intermediate,2137,In vivo,A,10116.0,,,,50597
10470,1,Bioavailability in rat (dose 20 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,2959,In vivo,A,10116.0,,,,50597
10471,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,1361,In vivo,A,10116.0,,,,50597
10472,1,Bioavailability percent in rat at the dose of 2 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4727,In vivo,A,10116.0,,,,50597
10473,1,Bioavailability was evaluated after 20 uM/kg of peroral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,16423,In vivo,A,10116.0,,,,50597
10474,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5206,In vivo,A,10116.0,,,,50597
10475,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6448,In vivo,A,10116.0,,,,50597
10476,1,Bioavailability in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,17723,In vivo,A,10116.0,,,,50597
10477,1,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10478,1,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10479,1,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10480,1,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10481,1,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10482,1,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10483,1,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10484,1,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10485,1,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10486,1,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10487,1,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10488,1,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10489,1,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10490,1,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10491,1,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10492,1,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10493,1,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10494,1,Oral bioavailability in rats was determined; High,,BAO_0000218,,Rattus norvegicus,,Intermediate,5237,In vivo,A,10116.0,,,,50597
10495,1,Oral bioavailability in the rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5503,In vivo,A,10116.0,,,,50597
10496,1,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15765,In vivo,A,10116.0,,,,50597
10497,1,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),,BAO_0000218,,Rattus norvegicus,,Intermediate,15660,In vivo,A,10116.0,,,,50597
10498,1,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
10499,1,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
10500,1,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
10501,1,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5978,In vivo,A,10116.0,,,,50597
10502,1,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5656,In vivo,A,10116.0,,,,50597
10503,1,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Expert,3598,In vivo,A,10116.0,,,,50597
10504,1,Oral bioavailability of compound in Sprague Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4216,In vivo,A,10116.0,,,,50597
10505,1,Oral bioavailability of compound in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17839,In vivo,A,10116.0,,,,50597
10506,1,Oral bioavailability in rat (dose 2 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,6570,In vivo,A,10116.0,,,,50597
10507,1,Oral bioavailability of compound in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5334,In vivo,A,10116.0,,,,50597
10508,1,Oral bioavailability of compound in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6886,In vivo,A,10116.0,,,,50597
10509,1,Oral bioavailability of compound was determined in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,5210,In vivo,A,10116.0,,,,50597
10510,1,Oral bioavailability at a dose of 30 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4170,In vivo,A,10116.0,,,,50597
10511,1,Oral bioavailability in rat (dose 10 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,6028,In vivo,A,10116.0,,,,50597
10512,1,Oral bioavailability in rat (dose 10 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,6028,In vivo,A,10116.0,,,,50597
10513,1,Oral bioavailability evaluated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6078,In vivo,A,10116.0,,,,50597
10514,1,Oral bioavailability in fasted rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6168,In vivo,A,10116.0,,,,50597
10515,1,Oral bioavailability in fed rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6168,In vivo,A,10116.0,,,,50597
10516,1,Oral bioavailability in rat (mature male) (dose 30 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,5160,In vivo,A,10116.0,,,,50597
10517,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6057,In vivo,A,10116.0,,,,50597
10518,1,Oral bioavailability in rat (dose 10 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,6535,In vivo,A,10116.0,,,,50597
10519,1,Oral bioavailability in rat after administration of 10 mg/kg po,,BAO_0000218,,Rattus norvegicus,,Intermediate,6535,In vivo,A,10116.0,,,,50597
10520,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4194,In vivo,A,10116.0,,,,50597
10521,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6230,In vivo,A,10116.0,,,,50597
10522,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6619,In vivo,A,10116.0,,,,50597
10523,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17607,In vivo,A,10116.0,,,,50597
10524,1,Oral bioavailability in ratrs,,BAO_0000218,,Rattus norvegicus,,Intermediate,4942,In vivo,A,10116.0,,,,50597
10525,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4942,In vivo,A,10116.0,,,,50597
10526,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6646,In vivo,A,10116.0,,,,50597
10527,1,Oral bioavailability in rats was determined; High,,BAO_0000218,,Rattus norvegicus,,Intermediate,5237,In vivo,A,10116.0,,,,50597
10528,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6646,In vivo,A,10116.0,,,,50597
10529,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4449,In vivo,A,10116.0,,,,50597
10530,1,Oral bioavailability was calculated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6057,In vivo,A,10116.0,,,,50597
10531,1,Oral bioavailability,,BAO_0000218,,Rattus norvegicus,,Intermediate,2552,In vivo,A,10116.0,,,,50597
10532,1,Oral bioavailability,,BAO_0000218,,Rattus norvegicus,,Intermediate,5496,In vivo,A,10116.0,,,,50597
10533,1,Oral bioavailability,,BAO_0000218,,Rattus norvegicus,,Intermediate,6484,In vivo,A,10116.0,,,,50597
10534,1,Oral bioavailability,,BAO_0000218,,Rattus norvegicus,,Intermediate,6485,In vivo,A,10116.0,,,,50597
10535,1,Oral bioavailability after i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6616,In vivo,A,10116.0,,,,50597
10536,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,BAO_0000218,,Rattus norvegicus,,Intermediate,4969,In vivo,A,10116.0,,,,50597
10537,1,Oral bioavailability in rat (Sprague-Dawley),,BAO_0000218,,Rattus norvegicus,,Intermediate,5862,In vivo,A,10116.0,,,,50597
10538,1,Oral bioavailability in Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4514,In vivo,A,10116.0,,,,50597
10539,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,BAO_0000218,,Rattus norvegicus,,Intermediate,4514,In vivo,A,10116.0,,,,50597
10540,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,4514,In vivo,A,10116.0,,,,50597
10541,1,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,5546,In vivo,A,10116.0,,,,50597
10542,1,Oral bioavailability in fasted rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6168,In vivo,A,10116.0,,,,50597
10543,1,Oral bioavailability in fed rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6168,In vivo,A,10116.0,,,,50597
10544,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3624,In vivo,A,10116.0,,,,50597
10545,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5213,In vivo,A,10116.0,,,,50597
10546,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5496,In vivo,A,10116.0,,,,50597
10547,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5553,In vivo,A,10116.0,,,,50597
10548,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5833,In vivo,A,10116.0,,,,50597
10549,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5836,In vivo,A,10116.0,,,,50597
10550,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5865,In vivo,A,10116.0,,,,50597
10551,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5960,In vivo,A,10116.0,,,,50597
10552,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6249,In vivo,A,10116.0,,,,50597
10553,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6448,In vivo,A,10116.0,,,,50597
10554,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6453,In vivo,A,10116.0,,,,50597
10555,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6640,In vivo,A,10116.0,,,,50597
10556,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17607,In vivo,A,10116.0,,,,50597
10557,1,Oral bioavailability in rat after peroral administration at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5939,In vivo,A,10116.0,,,,50597
10558,1,Oral bioavailability in rat after peroral administration at 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5939,In vivo,A,10116.0,,,,50597
10559,1,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,6281,In vivo,A,10116.0,,,,50597
10560,1,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5874,In vivo,A,10116.0,,,,50597
10561,1,Oral bioavailability in rat; Not measured,,BAO_0000218,,Rattus norvegicus,,Intermediate,5213,In vivo,A,10116.0,,,,50597
10562,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4964,In vivo,A,10116.0,,,,50597
10563,1,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,,BAO_0000218,,Rattus norvegicus,,Intermediate,11020,,A,10116.0,,,,50597
10564,1,In vitro metabolic potential in rat liver microsomes,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,6251,,A,10116.0,,,,50597
10565,1,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",,BAO_0000218,,Rattus norvegicus,,Intermediate,1568,In vivo,A,10116.0,,,,50597
10566,1,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",,BAO_0000218,,Rattus norvegicus,,Intermediate,3032,In vivo,A,10116.0,,,,50597
10567,1,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,3748,In vivo,A,10116.0,,,,50597
10568,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,401,In vivo,A,10116.0,,,,50597
10569,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6512,In vivo,A,10116.0,,,,50597
10570,1,Oral bioavailability in rats at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17617,In vivo,A,10116.0,,,,50597
10571,1,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6679,In vivo,A,10116.0,,,,50597
10572,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6742,In vivo,A,10116.0,,,,50597
10573,1,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,,BAO_0000218,,Rattus norvegicus,,Intermediate,589,,A,10116.0,,,,50597
10574,1,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,589,,A,10116.0,,,,50597
10575,1,Plasma clearance of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,3185,In vivo,A,10116.0,,,,50597
10576,1,Plasma clearance at 10 mg/kg in rat upon intravenous administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,17596,In vivo,A,10116.0,,,,50597
10577,1,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2713,In vivo,A,10116.0,,,,50597
10578,1,The compound was tested for plasma clearance in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12500,In vivo,A,10116.0,,,,50597
10579,1,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12500,In vivo,A,10116.0,,,,50597
10580,1,Plasma concentration upon oral administration of 1 mg/Kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2713,,A,10116.0,,,,50597
10581,1,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,,BAO_0000218,,Rattus norvegicus,,Intermediate,1446,,A,10116.0,,,,50597
10582,1,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,,BAO_0000218,,Rattus norvegicus,,Intermediate,6227,,A,10116.0,,,,50597
10583,1,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4709,,A,10116.0,,,,50597
10584,1,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",,BAO_0000218,,Rattus norvegicus,,Intermediate,5510,,A,10116.0,,,,50597
10585,1,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,BAO_0000218,,Rattus norvegicus,,Intermediate,5510,,A,10116.0,,,,50597
10586,1,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",,BAO_0000218,,Rattus norvegicus,,Intermediate,5510,,A,10116.0,,,,50597
10587,1,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",,BAO_0000218,,Rattus norvegicus,,Intermediate,5510,,A,10116.0,,,,50597
10588,1,Compound was tested for protein binding in rat plasma,,BAO_0000218,,Rattus norvegicus,,Intermediate,4514,,A,10116.0,,,,50597
10589,1,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,,BAO_0000218,,Rattus norvegicus,,Intermediate,2713,,A,10116.0,,,,50597
10590,1,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2713,,A,10116.0,,,,50597
10591,1,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,5340,,A,10116.0,,,,50597
10592,1,Area under curve ratio was determined (po/iv) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12058,,A,10116.0,,,,50597
10593,1,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,,A,10116.0,,,,50597
10594,1,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,,A,10116.0,,,,50597
10595,1,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,,A,10116.0,,,,50597
10596,1,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6495,,A,10116.0,,,,50597
10597,1,Ratio of AUCbrain to AUCplasma,,BAO_0000218,,Rattus norvegicus,,Intermediate,6078,,A,10116.0,,,,50597
10598,1,Ratio of brain to plasma,,BAO_0000218,,Rattus norvegicus,,Intermediate,5656,,A,10116.0,,,,50597
10599,1,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,A,10116.0,,,,50597
10600,1,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,A,10116.0,,,,50597
10601,1,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,A,10116.0,,,,50597
10602,1,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
10603,1,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
10604,1,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,,BAO_0000218,,Rattus norvegicus,,Intermediate,10130,,A,10116.0,,,,50597
10605,1,Steady state brain :blood ratio was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5213,,A,10116.0,,,,50597
10606,1,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,A,10116.0,,,,50597
10607,1,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,A,10116.0,,,,50597
10608,1,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,A,10116.0,,,,50597
10609,1,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,4910,,A,10116.0,,,,50597
10610,1,Percentage recovery after 3h incubation with rat hapatocytes was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,2083,,A,10116.0,,,,50597
10611,1,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,,BAO_0000218,,Rattus norvegicus,,Intermediate,2082,,A,10116.0,,,,50597
10612,1,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,,BAO_0000218,,Rattus norvegicus,,Intermediate,2082,,A,10116.0,,,,50597
10613,1,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,6351,,A,10116.0,,,,50597
10614,1,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",,BAO_0000019,,,,Autocuration,14583,,A,,,,,22224
10615,1,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,,BAO_0000019,,,,Autocuration,14583,,A,,,,,22224
10616,1,In vivo absorption in Caco-2 cell line monolayers was determined,,BAO_0000218,,Homo sapiens,,Intermediate,4608,,A,9606.0,,Caco-2,,50587
10617,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,13668,,P,,,,,22229
10618,1,Area under curve was determine after peroral administration at 10 mpk in Rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5669,,A,10116.0,,,,50597
10619,1,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,BAO_0000218,,Macaca mulatta,,Intermediate,5669,,A,9544.0,,,,50797
10620,1,Area under curve was determine after peroral administration at 160 mpk in Rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5669,,A,10116.0,,,,50597
10621,1,Area under curve was determine after peroral administration at 20 mpk in Rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5669,,A,10116.0,,,,50597
10622,1,Area under curve was determine after peroral administration at 50 mpk in Rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5669,,A,10116.0,,,,50597
10623,1,Calculated partition coefficient (clogP) (AlogP),,BAO_0000100,,,,Autocuration,6472,,P,,,,,22229
10624,1,Activated partial thromboplastin time measured,,BAO_0000019,,,,Autocuration,15106,,A,,,,,22224
10625,1,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),,BAO_0000100,,,,Autocuration,15207,,P,,,,,22224
10626,1,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),,BAO_0000100,,,,Autocuration,15207,,P,,,,,22224
10627,1,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,13941,,A,9615.0,,,,50588
10628,1,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13941,,A,10116.0,,,,50597
10629,1,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13941,,A,10116.0,,,,50597
10630,1,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,13941,,A,9615.0,,,,50588
10631,1,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,Plasma,BAO_0000218,,Cavia porcellus,,Intermediate,15240,,A,10141.0,,,,50512
10632,1,AUC in brain,Brain,BAO_0000019,,,,Autocuration,10655,,A,,,,,22224
10633,1,AUC in serum,Serum,BAO_0000019,,,,Autocuration,10655,,A,,,,,22224
10634,1,AUC was determined,Plasma,BAO_0000019,,,,Autocuration,6504,,A,,,,,22224
10635,1,AUC of the compound.,Plasma,BAO_0000019,,,,Autocuration,10615,,A,,,,,22224
10636,1,AUC value (0-4 hr),Plasma,BAO_0000019,,,,Autocuration,10353,,A,,,,,22224
10637,1,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",Plasma,BAO_0000019,,,,Autocuration,14907,,A,,,,,22224
10638,1,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,Plasma,BAO_0000019,,,,Autocuration,14907,,A,,,,,22224
10639,1,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",Plasma,BAO_0000019,,,,Autocuration,14907,,A,,,,,22224
10640,1,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",Plasma,BAO_0000019,,,,Autocuration,14907,,A,,,,,22224
10641,1,AUC(area under curve) was determined after intravenous administration in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,16359,,A,10116.0,,,,50597
10642,1,AUC(area under curve) was determined after oral administration in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,16359,,A,10116.0,,,,50597
10643,1,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,Plasma,BAO_0000218,,Cavia porcellus,,Intermediate,15240,,A,10141.0,,,,50512
10644,1,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15240,,A,10116.0,,,,50597
10645,1,Area Under Curve after oral dosing of 100 uM/Kg,,BAO_0000019,,,,Autocuration,15469,,A,,,,,22224
10646,1,Area Under Curve after oral dosing of 30 uM/Kg,,BAO_0000019,,,,Autocuration,15469,,A,,,,,22224
10647,1,Area Under Curve was measured by ploting the graph between concentration verses time,,BAO_0000019,,,,Autocuration,13520,,A,,,,,22224
10648,1,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17025,,A,9615.0,,,,50588
10649,1,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,,BAO_0000218,,Simiiformes,,Autocuration,17025,,A,314293.0,,,,22224
10650,1,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,17025,,A,9986.0,,,,50592
10651,1,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,,BAO_0000218,,Rattus norvegicus,,Intermediate,17025,,A,10116.0,,,,50597
10652,1,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12032,,A,10116.0,,,,50597
10653,1,Area under curve (AUC) was determined,,BAO_0000019,,,,Autocuration,10291,,A,,,,,22224
10654,1,Area under curve (AUC) following ip administration at 1 mg/kg,,BAO_0000218,,,,Autocuration,5767,,A,,,,,22224
10655,1,Area under curve (AUC) was determined; ND is Not determined,,BAO_0000019,,,,Autocuration,1434,,A,,,,,22224
10656,1,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14925,,A,9615.0,,,,50588
10657,1,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14925,,A,9615.0,,,,50588
10658,1,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14925,,A,9615.0,,,,50588
10659,1,Area under curve (AUR) was determined,,BAO_0000019,,,,Autocuration,1434,,A,,,,,22224
10660,1,Area under curve at 1 uM/dg administered intravenously,,BAO_0000019,,,,Autocuration,11883,,A,,,,,22224
10661,1,Area under curve at 10 uM/dg administered perorally,,BAO_0000019,,,,Autocuration,11883,,A,,,,,22224
10662,1,Area under curve at 2 uM/dg administered intravenously,,BAO_0000019,,,,Autocuration,11883,,A,,,,,22224
10663,1,Area under curve at 20 uM/dg administered perorally,,BAO_0000019,,,,Autocuration,11883,,A,,,,,22224
10664,1,Area under curve at a peroral dose of 3 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15233,,A,9615.0,,,,50588
10665,1,Area under curve at a peroral dose of 3 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15233,,A,10116.0,,,,50597
10666,1,Area under curve at an iv dose of 1 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15233,,A,9615.0,,,,50588
10667,1,Area under curve at an iv dose of 1 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15233,,A,10116.0,,,,50597
10668,1,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,,BAO_0000019,,,,Autocuration,12978,,A,,,,,22224
10669,1,Area under curve gives the effective duration for the angiotensin II antagonist effect.,,BAO_0000019,,,,Autocuration,12978,,A,,,,,22224
10670,1,Area under curve measured as conc vs time after intravenous administration to mice.,,BAO_0000218,,Mus musculus,,Intermediate,11355,,A,10090.0,,,,50594
10671,1,Area under curve measured as conc vs time after peroral administration to mice.,,BAO_0000218,,Mus musculus,,Intermediate,11355,,A,10090.0,,,,50594
10672,1,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12923,,A,9615.0,,,,50588
10673,1,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12923,,A,9615.0,,,,50588
10674,1,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12923,,A,9615.0,,,,50588
10675,1,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12923,,A,9615.0,,,,50588
10676,1,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10677,1,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10678,1,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10679,1,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10680,1,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10681,1,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10682,1,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10683,1,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10684,1,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10685,1,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10686,1,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10687,1,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10688,1,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10689,1,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10690,1,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10691,1,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10692,1,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10693,1,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10694,1,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10695,1,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10696,1,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10697,1,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,17738,In vivo,A,10116.0,,,,50597
10698,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10699,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10700,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10701,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10702,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10703,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10704,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10705,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10706,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10707,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10708,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10709,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10710,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10711,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10712,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10713,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10714,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10715,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10716,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10717,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10718,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10719,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10720,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10721,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10722,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10723,1,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,11195,In vivo,A,10116.0,,,,50597
10724,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6193,In vivo,A,10116.0,,,,50597
10725,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6803,In vivo,A,10116.0,,,,50597
10726,1,Oral bioavailability in rats at 6 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6647,In vivo,A,10116.0,,,,50597
10727,1,Oral bioavailability in rat (dose 6 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,6647,In vivo,A,10116.0,,,,50597
10728,1,Oral bioavailability in rats at 6 mg/kg dose; Not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,6647,In vivo,A,10116.0,,,,50597
10729,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6640,In vivo,A,10116.0,,,,50597
10730,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,In vivo,A,10116.0,,,,50597
10731,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6641,In vivo,A,10116.0,,,,50597
10732,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6642,In vivo,A,10116.0,,,,50597
10733,1,Oral bioavailability,,BAO_0000218,,Rattus norvegicus,,Intermediate,5472,In vivo,A,10116.0,,,,50597
10734,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,6141,In vivo,A,10116.0,,,,50597
10735,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4390,In vivo,A,10116.0,,,,50597
10736,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5472,In vivo,A,10116.0,,,,50597
10737,1,Oral bioavailability was evaluated; Not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,5472,In vivo,A,10116.0,,,,50597
10738,1,Oral bioavailability,,BAO_0000218,,Rattus norvegicus,,Intermediate,5438,In vivo,A,10116.0,,,,50597
10739,1,Oral bioavailability in rat by oral dosing,,BAO_0000218,,Rattus norvegicus,,Intermediate,4883,In vivo,A,10116.0,,,,50597
10740,1,Oral bioavailability in rat (dose 10 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,1908,In vivo,A,10116.0,,,,50597
10741,1,Oral bioavailability in rat (Sprague-Dawley),,BAO_0000218,,Rattus norvegicus,,Intermediate,4853,In vivo,A,10116.0,,,,50597
10742,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,BAO_0000218,,Rattus norvegicus,,Intermediate,4853,In vivo,A,10116.0,,,,50597
10743,1,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),,BAO_0000218,,Rattus norvegicus,,Intermediate,4853,In vivo,A,10116.0,,,,50597
10744,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,4853,In vivo,A,10116.0,,,,50597
10745,1,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,4853,In vivo,A,10116.0,,,,50597
10746,1,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4853,In vivo,A,10116.0,,,,50597
10747,1,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4853,In vivo,A,10116.0,,,,50597
10748,1,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,,BAO_0000218,,Rattus norvegicus,,Intermediate,12873,In vivo,A,10116.0,,,,50597
10749,1,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,,BAO_0000218,,Rattus norvegicus,,Intermediate,12873,In vivo,A,10116.0,,,,50597
10750,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3169,In vivo,A,10116.0,,,,50597
10751,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6305,In vivo,A,10116.0,,,,50597
10752,1,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,4762,In vivo,A,10116.0,,,,50597
10753,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17847,In vivo,A,10116.0,,,,50597
10754,1,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,6211,In vivo,A,10116.0,,,,50597
10755,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6011,In vivo,A,10116.0,,,,50597
10756,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6317,In vivo,A,10116.0,,,,50597
10757,1,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,6644,In vivo,A,10116.0,,,,50597
10758,1,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,6644,In vivo,A,10116.0,,,,50597
10759,1,Oral bioavailability in rat after oral administration at 13 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,6644,In vivo,A,10116.0,,,,50597
10760,1,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,6644,In vivo,A,10116.0,,,,50597
10761,1,Oral bioavailability (dose 20 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,6113,In vivo,A,10116.0,,,,50597
10762,1,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5937,In vivo,A,10116.0,,,,50597
10763,1,Oral bioavailability in rat at 10 mg/kg of the compound,,BAO_0000218,,Rattus norvegicus,,Intermediate,5711,In vivo,A,10116.0,,,,50597
10764,1,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,A,10116.0,,,,50597
10765,1,Bioavailability in rat (dose 3 mg/kg i.v.),,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,A,10116.0,,,,50597
10766,1,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,A,10116.0,,,,50597
10767,1,Oral bioavailability in rat (dose 60 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,17717,In vivo,A,10116.0,,,,50597
10768,1,Percent bioavailability (F) in rats after iv administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,4722,In vivo,A,10116.0,,,,50597
10769,1,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,4722,In vivo,A,10116.0,,,,50597
10770,1,Bioavailability in rat (dose 5 uM/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,4353,In vivo,A,10116.0,,,,50597
10771,1,Oral bioavailability,,BAO_0000218,,Rattus norvegicus,,Intermediate,15662,In vivo,A,10116.0,,,,50597
10772,1,Bioavailability in rat (dose 2 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,4756,In vivo,A,10116.0,,,,50597
10773,1,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,4756,In vivo,A,10116.0,,,,50597
10774,1,Oral bioavailability in rat (dose 20 mg/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,3436,In vivo,A,10116.0,,,,50597
10775,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,17800,In vivo,A,10116.0,,,,50597
10776,1,Percent oral bioavailability evaluated in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15762,In vivo,A,10116.0,,,,50597
10777,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5089,In vivo,A,10116.0,,,,50597
10778,1,Percent oral bioavailability in rat; Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,5089,In vivo,A,10116.0,,,,50597
10779,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3185,In vivo,A,10116.0,,,,50597
10780,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5145,In vivo,A,10116.0,,,,50597
10781,1,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),,BAO_0000218,,Rattus norvegicus,,Intermediate,3457,In vivo,A,10116.0,,,,50597
10782,1,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),,BAO_0000218,,Rattus norvegicus,,Intermediate,3457,In vivo,A,10116.0,,,,50597
10783,1,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,5983,In vivo,A,10116.0,,,,50597
10784,1,Oral bioavailability in rat (dose 20 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Intermediate,5739,In vivo,A,10116.0,,,,50597
10785,1,Cmax at a dose of 30 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,3579,In vivo,A,10116.0,,,,50597
10786,1,Cmax in monkeys at a dose of 1 mg/kg,,BAO_0000218,,Simiiformes,,Autocuration,17788,In vivo,A,314293.0,,,,22224
10787,1,Cmax in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14956,In vivo,A,10116.0,,,,50597
10788,1,Cmax in rats at a dose of 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,17788,In vivo,A,10116.0,,,,50597
10789,1,Cmax was measured in mice after an oral dose of 50 mg/kg.,,BAO_0000218,,Mus musculus,,Intermediate,9750,In vivo,A,10090.0,,,,50594
10790,1,"Cmax value at a dose of 12.7 uM/kg, po",,BAO_0000218,,,,Autocuration,12767,In vivo,A,,,,,22224
10791,1,"Cmax value at a dose of 6.3 uM/kg, iv",,BAO_0000218,,,,Autocuration,12767,In vivo,A,,,,,22224
10792,1,"Cmax value at a dose of 7.1 uM/kg, iv",,BAO_0000218,,,,Autocuration,12767,In vivo,A,,,,,22224
10793,1,Cmax value of compound was determined after 1 hr,,BAO_0000218,,,,Autocuration,12703,In vivo,A,,,,,22224
10794,1,Cmax value of the compound,,BAO_0000218,,,,Autocuration,15778,In vivo,A,,,,,22224
10795,1,Cmax value administered intraintestinal in rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,12818,In vivo,A,10116.0,,,,50597
10796,1,Cmax value administered perorally was determined in rat; Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,14964,In vivo,A,10116.0,,,,50597
10797,1,Cmax value at the dose of 2.3 mg/kg,,BAO_0000218,,,,Autocuration,15808,In vivo,A,,,,,22224
10798,1,Cmax value at the dose of 5 mg/kg,,BAO_0000218,,,,Autocuration,15808,In vivo,A,,,,,22224
10799,1,Cmax value in the period of 8 hr after dosing. ,,BAO_0000218,,,,Autocuration,15778,In vivo,A,,,,,22224
10800,1,Cmax value at a oral dose of 20 mg/kg; Not tested,,BAO_0000218,,,,Autocuration,3715,In vivo,A,,,,,22224
10801,1,Cmax value at a oral dose of 20 mg/kg,,BAO_0000218,,,,Autocuration,3715,In vivo,A,,,,,22224
10802,1,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,,BAO_0000218,,Rattus norvegicus,,Intermediate,1446,In vivo,A,10116.0,,,,50597
10803,1,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,,BAO_0000218,,Cavia porcellus,,Intermediate,15240,In vivo,A,10141.0,,,,50512
10804,1,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15240,In vivo,A,10116.0,,,,50597
10805,1,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14810,In vivo,A,10116.0,,,,50597
10806,1,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14239,In vivo,A,10090.0,,,,50594
10807,1,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,Liver,BAO_0000218,,Canis lupus familiaris,,Intermediate,12555,In vivo,A,9615.0,,,,50588
10808,1,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,10754,In vivo,A,9615.0,,,,50588
10809,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,Blood,BAO_0000218,,Mus musculus,,Intermediate,10754,In vivo,A,10090.0,,,,50594
10810,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,Blood,BAO_0000218,,Mus musculus,,Intermediate,10754,In vivo,A,10090.0,,,,50594
10811,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,Blood,BAO_0000218,,Mus musculus,,Intermediate,10754,In vivo,A,10090.0,,,,50594
10812,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,Blood,BAO_0000218,,Mus musculus,,Intermediate,10754,In vivo,A,10090.0,,,,50594
10813,1,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,Blood,BAO_0000218,,Mus musculus,,Intermediate,10754,In vivo,A,10090.0,,,,50594
10814,1,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14600,In vivo,F,9615.0,,,,50588
10815,1,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14600,In vivo,F,9615.0,,,,50588
10816,1,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14600,In vivo,F,9615.0,,,,50588
10817,1,Bioavailability as maximal plasma concentration in dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,13543,In vivo,A,9615.0,,,,50588
10818,1,Bioavailability as maximal plasma concentration in dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,13543,In vivo,A,9615.0,,,,50588
10819,1,Bioavailability as maximal plasma concentration in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13543,In vivo,A,10116.0,,,,50597
10820,1,Bioavailability as maximal plasma concentration in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Autocuration,13543,In vivo,A,10116.0,,,,22224
10821,1,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,14600,In vivo,A,9615.0,,,,50588
10822,1,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,14600,In vivo,A,9615.0,,,,50588
10823,1,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,14600,In vivo,A,9615.0,,,,50588
10824,1,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,14600,In vivo,A,9615.0,,,,50588
10825,1,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,14600,In vivo,A,9615.0,,,,50588
10826,1,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,14600,In vivo,A,9615.0,,,,50588
10827,1,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,14681,In vivo,A,10116.0,,,,50597
10828,1,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,,BAO_0000218,,,,Autocuration,15905,In vivo,A,,,,,22224
10829,1,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,Plasma,BAO_0000218,,,,Autocuration,15905,In vivo,A,,,,,22224
10830,1,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13304,In vivo,A,10116.0,,,,50597
10831,1,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15137,In vivo,A,10116.0,,,,50597
10832,1,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15137,In vivo,A,10116.0,,,,50597
10833,1,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15137,In vivo,A,10116.0,,,,50597
10834,1,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15137,In vivo,A,10116.0,,,,50597
10835,1,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15137,In vivo,A,10116.0,,,,50597
10836,1,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,Plasma,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,In vivo,A,9541.0,,,,100710
10837,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14839,In vivo,A,10090.0,,,,50594
10838,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14839,In vivo,A,10090.0,,,,50594
10839,1,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,Plasma,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,In vivo,A,9541.0,,,,100710
10840,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10841,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10842,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10843,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10844,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10845,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10846,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10847,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10848,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10849,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10850,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10851,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10852,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10853,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10854,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10855,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10856,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10857,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10858,1,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10859,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10860,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10861,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10862,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10863,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10864,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10865,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10866,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10867,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10868,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10869,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10870,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10871,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10872,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10873,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10874,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10875,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10876,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10877,1,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10878,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10879,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10880,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10881,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10882,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
10883,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
10884,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
10885,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
10886,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
10887,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
10888,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
10889,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
10890,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
10891,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
10892,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
10893,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
10894,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
10895,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
10896,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
10897,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
10898,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
10899,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
10900,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
10901,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
10902,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
10903,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
10904,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
10905,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
10906,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
10907,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
10908,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
10909,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
10910,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
10911,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
10912,1,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
10913,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
10914,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
10915,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
10916,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
10917,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
10918,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
10919,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
10920,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
10921,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
10922,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
10923,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
10924,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
10925,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
10926,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
10927,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
10928,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
10929,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
10930,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
10931,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
10932,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
10933,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
10934,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
10935,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
10936,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
10937,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
10938,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
10939,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
10940,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
10941,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
10942,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
10943,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
10944,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
10945,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
10946,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
10947,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
10948,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
10949,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
10950,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
10951,1,Compound was evaluated for its bioavailability in the dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,2249,In vivo,A,9615.0,,,,50588
10952,1,Compound was evaluated for its bioavailability in the rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2249,In vivo,A,10116.0,,,,50597
10953,1,Compound was evaluated for oral bioavailability,,BAO_0000218,,,,Autocuration,17515,In vivo,A,,,,,22224
10954,1,Compound was evaluated for percentage of Oral bioavailability in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14541,In vivo,A,10116.0,,,,50597
10955,1,Bioavailability in guinea pig,,BAO_0000218,,Cavia porcellus,,Autocuration,12797,In vivo,A,10141.0,,,,22224
10956,1,Compound was evaluated for the oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12797,In vivo,A,10116.0,,,,50597
10957,1,Compound was evaluated for the oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12797,In vivo,A,9615.0,,,,50588
10958,1,Compound was evaluated for the oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12797,In vivo,A,10116.0,,,,50597
10959,1,Bioavailability in dog (dosed i.v.),,BAO_0000218,,Canis lupus familiaris,,Autocuration,11727,In vivo,F,9615.0,,,,22224
10960,1,Compound was tested for in vivo bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13249,In vivo,A,9615.0,,,,50588
10961,1,Compound was tested for in vivo bioavailability in hamsters,,BAO_0000218,,Cricetinae,,Intermediate,13249,In vivo,A,10026.0,,,,100712
10962,1,Compound was tested for in vivo bioavailability in monkey,,BAO_0000218,,Simiiformes,,Autocuration,13249,In vivo,A,314293.0,,,,22224
10963,1,Compound was tested for in vivo bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13249,In vivo,A,10116.0,,,,50597
10964,1,Oral bioavailability in mouse,,BAO_0000218,,Mus musculus,,Autocuration,9552,In vivo,A,10090.0,,,,22224
10965,1,Compound was tested for percent of oral bioavailability in mice; 56-74,,BAO_0000218,,Mus musculus,,Intermediate,9552,In vivo,A,10090.0,,,,50594
10966,1,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),,BAO_0000218,,Mus musculus,,Autocuration,14839,In vivo,A,10090.0,,,,22224
10967,1,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),,BAO_0000218,,Macaca fascicularis,,Autocuration,14839,In vivo,A,9541.0,,,,22224
10968,1,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),,BAO_0000218,,Macaca fascicularis,,Autocuration,14839,In vivo,A,9541.0,,,,22224
10969,1,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),,BAO_0000218,,Mus musculus,,Intermediate,14839,In vivo,A,10090.0,,,,50594
10970,1,Oral bioavailability in nude mice,,BAO_0000218,,Mus musculus,,Intermediate,14839,In vivo,A,10090.0,,,,50594
10971,1,Bioavailability in monkey (i.d. dosing),,BAO_0000218,,Primates,,Autocuration,11219,In vivo,A,9443.0,,,,22224
10972,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Autocuration,9552,In vivo,A,10116.0,,,,22224
10973,1,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,,BAO_0000218,,,,Autocuration,11732,In vivo,A,,,,,22224
10974,1,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,,BAO_0000218,,,,Autocuration,11732,In vivo,A,,,,,22224
10975,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,In vivo,A,9541.0,,,,100710
10976,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,In vivo,A,9541.0,,,,100710
10977,1,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,In vivo,A,9541.0,,,,100710
10978,1,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,Plasma,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,In vivo,A,9541.0,,,,100710
10979,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14839,In vivo,A,10090.0,,,,50594
10980,1,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,Plasma,BAO_0000218,,Macaca fascicularis,,Intermediate,14839,In vivo,A,9541.0,,,,100710
10981,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14839,In vivo,A,10090.0,,,,50594
10982,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14839,In vivo,A,10090.0,,,,50594
10983,1,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14839,In vivo,A,10090.0,,,,50594
10984,1,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,Plasma,BAO_0000218,,,,Autocuration,13932,In vivo,A,,,,,22224
10985,1,Cmax in mouse plasma,Plasma,BAO_0000218,,Mus musculus,,Intermediate,11637,In vivo,A,10090.0,,,,50594
10986,1,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,Plasma,BAO_0000218,,,,Autocuration,11637,In vivo,A,,,,,22224
10987,1,Maximal plasma concentration in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13960,In vivo,A,10116.0,,,,50597
10988,1,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15905,In vivo,A,10116.0,,,,50597
10989,1,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14062,In vivo,A,10116.0,,,,50597
10990,1,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14062,In vivo,A,10116.0,,,,50597
10991,1,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14062,In vivo,A,10116.0,,,,50597
10992,1,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14062,In vivo,A,10116.0,,,,50597
10993,1,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14062,In vivo,A,10116.0,,,,50597
10994,1,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14062,In vivo,A,10116.0,,,,50597
10995,1,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,15011,In vivo,A,10090.0,,,,50594
10996,1,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,15011,In vivo,A,10090.0,,,,50594
10997,1,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),,BAO_0000218,,Mus musculus,,Intermediate,15011,In vivo,A,10090.0,,,,50594
10998,1,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,15011,In vivo,A,10090.0,,,,50594
10999,1,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,15011,In vivo,A,10090.0,,,,50594
11000,1,Maximum Concentration of the compound.,,BAO_0000218,,,,Autocuration,10291,In vivo,A,,,,,22224
11001,1,Maximum Concentration was measured after iv administration into Beagle dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14599,In vivo,A,9615.0,,,,50588
11002,1,Maximum Concentration was measured after iv administration into Beagle dog.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14599,In vivo,A,9615.0,,,,50588
11003,1,Maximum Concentration was measured after po administration into Beagle dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14599,In vivo,A,9615.0,,,,50588
11004,1,Maximum Concentration was measured after po administration into Beagle dog.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14599,In vivo,A,9615.0,,,,50588
11005,1,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,Blood,BAO_0000218,,,,Autocuration,12767,In vivo,A,,,,,22224
11006,1,Maximum blood level reached after an iv dose of 12.2 uM/kg,Blood,BAO_0000218,,,,Autocuration,12767,In vivo,A,,,,,22224
11007,1,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,Blood,BAO_0000218,,,,Autocuration,12767,In vivo,A,,,,,22224
11008,1,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,Blood,BAO_0000218,,,,Autocuration,12767,In vivo,A,,,,,22224
11009,1,Maximum blood level reached after an oral dose of 5.0 mg/kg,Blood,BAO_0000218,,,,Autocuration,12767,In vivo,A,,,,,22224
11010,1,Maximum blood level reached at dose of 10.6 uM/kg orally,Blood,BAO_0000218,,,,Autocuration,12767,In vivo,A,,,,,22224
11011,1,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,,BAO_0000218,,Cavia porcellus,,Intermediate,14706,In vivo,A,10141.0,,,,50512
11012,1,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,,BAO_0000218,,Cavia porcellus,,Intermediate,14706,In vivo,A,10141.0,,,,50512
11013,1,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,In vivo,A,10116.0,,,,50597
11014,1,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,In vivo,A,10116.0,,,,50597
11015,1,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,In vivo,A,10116.0,,,,50597
11016,1,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,In vivo,A,10116.0,,,,50597
11017,1,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,In vivo,A,10116.0,,,,50597
11018,1,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,In vivo,A,10116.0,,,,50597
11019,1,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,In vivo,A,10116.0,,,,50597
11020,1,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,In vivo,A,10116.0,,,,50597
11021,1,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,BAO_0000218,,Bacillus subtilis,,Intermediate,10524,In vivo,A,1423.0,,,,50278
11022,1,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,,BAO_0000218,,Simiiformes,,Autocuration,11871,In vivo,A,314293.0,,,,22224
11023,1,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11871,In vivo,A,10116.0,,,,50597
11024,1,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,,BAO_0000218,,,,Autocuration,3437,In vivo,A,,,,,22224
11025,1,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,,BAO_0000218,,Mus musculus,,Intermediate,12038,In vivo,A,10090.0,,,,50594
11026,1,Maximum concentration in male rats after iv administration of 20 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,12038,In vivo,A,10116.0,,,,50597
11027,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11028,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11029,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11030,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11031,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11032,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11033,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11034,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11035,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11036,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11037,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11038,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11039,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11040,1,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11041,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11042,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11043,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11044,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11045,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11046,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11047,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11048,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11049,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11050,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11051,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11052,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11053,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11054,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11055,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11056,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11057,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11058,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11059,1,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
11060,1,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,A,10116.0,,,,50597
11061,1,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,A,10116.0,,,,50597
11062,1,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,A,10116.0,,,,50597
11063,1,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,A,10116.0,,,,50597
11064,1,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,A,10116.0,,,,50597
11065,1,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,A,10116.0,,,,50597
11066,1,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,A,10116.0,,,,50597
11067,1,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,A,10116.0,,,,50597
11068,1,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,A,10116.0,,,,50597
11069,1,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,A,10116.0,,,,50597
11070,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11071,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11072,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11073,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11074,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11075,1,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11076,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
11077,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
11078,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
11079,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
11080,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
11081,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
11082,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
11083,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
11084,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
11085,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
11086,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
11087,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
11088,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
11089,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
11090,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
11091,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
11092,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
11093,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
11094,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
11095,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
11096,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
11097,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
11098,1,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
11099,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11100,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11101,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11102,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11103,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11104,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11105,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11106,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11107,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11108,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11109,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11110,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11111,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11112,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11113,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11114,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11115,1,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,,BAO_0000218,,,,Autocuration,11732,In vivo,A,,,,,22224
11116,1,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,,BAO_0000218,,,,Autocuration,11732,In vivo,A,,,,,22224
11117,1,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,,BAO_0000218,,,,Autocuration,11732,In vivo,A,,,,,22224
11118,1,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,,BAO_0000218,,,,Autocuration,11732,In vivo,A,,,,,22224
11119,1,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,,BAO_0000218,,,,Autocuration,11732,In vivo,A,,,,,22224
11120,1,Oral bioavailability in rat (dose 10 mg/kg),,BAO_0000218,,Rattus norvegicus,,Autocuration,13359,In vivo,A,10116.0,,,,22224
11121,1,Oral bioavailability in rat (Sprague-Dawley),,BAO_0000218,,Rattus norvegicus,,Autocuration,16618,In vivo,A,10116.0,,,,22224
11122,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Autocuration,13960,In vivo,A,10116.0,,,,22224
11123,1,Oral bioavailability in rats was determined in vivo,,BAO_0000218,,Rattus norvegicus,,Autocuration,13917,In vivo,A,10116.0,,,,22224
11124,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Autocuration,14266,In vivo,A,9615.0,,,,22224
11125,1,Oral bioavailability of compound in monkey,,BAO_0000218,,Simiiformes,,Autocuration,12359,In vivo,A,314293.0,,,,22224
11126,1,Oral bioavailability of compound in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12359,In vivo,A,10116.0,,,,50597
11127,1,Bioavailability in rat of PMEA prodrug,,BAO_0000218,,Rattus norvegicus,,Autocuration,12359,In vivo,A,10116.0,,,,22224
11128,1,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,,BAO_0000218,,Rattus norvegicus,,Intermediate,12359,In vivo,A,10116.0,,,,50597
11129,1,Serum conc at 3 hours following 25 mg/kg dose,,BAO_0000218,,Macaca mulatta,,Autocuration,10791,In vivo,A,9544.0,,,,22224
11130,1,Urine conc 0-5 hours following 25 mg/kg dose,Urine,BAO_0000218,,Macaca mulatta,,Autocuration,10791,In vivo,A,9544.0,,,,22224
11131,1,Urine conc 0-24 hours following 25 mg/kg dose,Urine,BAO_0000218,,Macaca mulatta,,Autocuration,10791,In vivo,A,9544.0,,,,22224
11132,1,Oral bioavailability in African green monkeys; 20-25,,BAO_0000218,,Chlorocebus aethiops,,Autocuration,138,In vivo,A,9534.0,,,,22224
11133,1,Oral bioavailability in cynomolgus monkey.,,BAO_0000218,,Macaca fascicularis,,Intermediate,14521,In vivo,A,9541.0,,,,100710
11134,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Autocuration,13953,In vivo,A,9615.0,,,,22224
11135,1,Oral bioavailability in dog at 10 mg/kg oral dose,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12836,In vivo,A,9615.0,,,,50588
11136,1,Oral bioavailability in hamster at 10 mg/kg oral dose,,BAO_0000218,,Cricetinae,,Intermediate,12836,In vivo,A,10026.0,,,,100712
11137,1,Oral bioavailability in rat at 10 mg/kg oral dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,12836,In vivo,A,10116.0,,,,50597
11138,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Autocuration,14521,In vivo,A,10116.0,,,,22224
11139,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Autocuration,13953,In vivo,A,10116.0,,,,22224
11140,1,Oral bioavailability,,BAO_0000218,,Eutheria,,Autocuration,6799,In vivo,A,9347.0,,,,22224
11141,1,Oral bioavailability was determined; range 49-102%,,BAO_0000218,,,,Autocuration,11311,In vivo,A,,,,,22224
11142,1,Oral bioavailability was determined in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,4013,In vivo,A,9615.0,,,,50588
11143,1,Oral bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Autocuration,4013,In vivo,A,10116.0,,,,22224
11144,1,Oral bioavailability,,BAO_0000218,,Eutheria,,Autocuration,17591,In vivo,A,9347.0,,,,22224
11145,1,Oral bioavailability was determined; Not orally available,,BAO_0000218,,,,Autocuration,17591,In vivo,A,,,,,22224
11146,1,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),,BAO_0000218,,Mus musculus,,Intermediate,15011,In vivo,A,10090.0,,,,50594
11147,1,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),,BAO_0000218,,Mus musculus,,Autocuration,15011,In vivo,A,10090.0,,,,22224
11148,1,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,,BAO_0000218,,Mus musculus,,Autocuration,15011,In vivo,A,10090.0,,,,22224
11149,1,Oral bioavailability in Rhesus monkey,,BAO_0000218,,Macaca mulatta,,Autocuration,9552,In vivo,A,9544.0,,,,22224
11150,1,Oral bioavailability in dog (female mongrel),,BAO_0000218,,Canis lupus familiaris,,Autocuration,9552,In vivo,A,9615.0,,,,22224
11151,1,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,,BAO_0000218,,,,Autocuration,3639,In vivo,A,,,,,22224
11152,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Autocuration,13397,In vivo,A,9615.0,,,,22224
11153,1,Percentage Bioavailability was evaluated.,,BAO_0000218,,,,Autocuration,3031,In vivo,A,,,,,22224
11154,1,Bioavailability in rat administered i.d.,,BAO_0000218,,Rattus norvegicus,,Autocuration,12818,In vivo,A,10116.0,,,,22224
11155,1,Bioavailability,,BAO_0000218,,Eutheria,,Autocuration,4847,In vivo,A,9347.0,,,,22224
11156,1,Bioavailability in dog (male Beagle) i.v. administration,,BAO_0000218,,Canis lupus familiaris,,Autocuration,12421,In vivo,A,9615.0,,,,22224
11157,1,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",,BAO_0000218,,Rattus norvegicus,,Autocuration,11966,In vivo,A,10116.0,,,,22224
11158,1,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),,BAO_0000218,,Primates,,Autocuration,11218,In vivo,A,9443.0,,,,22224
11159,1,Oral bioavailability in rat (Sprague-Dawley) (male),,BAO_0000218,,Rattus norvegicus,,Autocuration,13129,In vivo,A,10116.0,,,,22224
11160,1,The oral bioavailability was measured on rats after oral administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,12350,In vivo,A,10116.0,,,,50597
11161,1,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,2231,In vivo,A,10116.0,,,,50597
11162,1,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,,BAO_0000218,,Macaca mulatta,,Intermediate,2231,In vivo,A,9544.0,,,,50797
11163,1,Bioavailability in rat (dose 10 mg/kg i.d.),,BAO_0000218,,Rattus norvegicus,,Autocuration,12187,In vivo,A,10116.0,,,,22224
11164,1,Bioavailability in dog (male Beagle) i.v. administration,,BAO_0000218,,Canis lupus familiaris,,Autocuration,12421,In vivo,A,9615.0,,,,22224
11165,1,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11166,1,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),Blood,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11167,1,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),Cerebellum,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11168,1,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11169,1,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2231,In vivo,A,10116.0,,,,50597
11170,1,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,Plasma,BAO_0000218,,Macaca mulatta,,Intermediate,2231,In vivo,A,9544.0,,,,50797
11171,1,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12178,In vivo,A,10116.0,,,,50597
11172,1,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),Blood,BAO_0000218,,,,Autocuration,12178,In vivo,A,,,,,22224
11173,1,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),Blood,BAO_0000218,,,,Autocuration,12178,In vivo,A,,,,,22224
11174,1,Maximum concentration observed in rats at an oral dose of 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Expert,15633,In vivo,A,10116.0,,,,50597
11175,1,Maximum concentration of compound in plasma administered orally to rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14258,In vivo,A,10116.0,,,,50597
11176,1,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14224,In vivo,A,9615.0,,,,50588
11177,1,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14224,In vivo,A,9615.0,,,,50588
11178,1,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14224,In vivo,A,9615.0,,,,50588
11179,1,Maximum concentration after 10 mg/kg by oral administration,,BAO_0000218,,,,Autocuration,5566,In vivo,A,,,,,22224
11180,1,Maximum concentration at a dose of 1.5 mg/kg,,BAO_0000218,,,,Autocuration,16935,In vivo,A,,,,,22224
11181,1,Maximum concentration at a dose of 2.0 mg/kg,,BAO_0000218,,,,Autocuration,16935,In vivo,A,,,,,22224
11182,1,Maximum concentration in dog plasma,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14224,In vivo,A,9615.0,,,,50588
11183,1,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,Plasma,BAO_0000218,,,,Autocuration,12536,In vivo,A,,,,,22224
11184,1,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,Plasma,BAO_0000218,,,,Autocuration,12536,In vivo,A,,,,,22224
11185,1,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,Plasma,BAO_0000218,,,,Autocuration,12536,In vivo,A,,,,,22224
11186,1,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,Plasma,BAO_0000218,,,,Autocuration,12536,In vivo,A,,,,,22224
11187,1,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,Plasma,BAO_0000218,,,,Autocuration,12536,In vivo,A,,,,,22224
11188,1,Maximum concentration in plasma after oral administration in dog (25 mg/kg),Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,9994,In vivo,A,9615.0,,,,50588
11189,1,Maximum concentration in plasma at Tmax,Plasma,BAO_0000218,,,,Autocuration,1434,In vivo,A,,,,,22224
11190,1,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,Plasma,BAO_0000218,,Canis lupus familiaris,,Expert,12836,In vivo,A,9615.0,,,,50588
11191,1,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,Plasma,BAO_0000218,,Cricetinae,,Intermediate,12836,In vivo,A,10026.0,,,,100712
11192,1,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12836,In vivo,A,10116.0,,,,50597
11193,1,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12545,In vivo,A,10116.0,,,,50597
11194,1,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,Plasma,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,13856,In vivo,A,9986.0,,,,50592
11195,1,Maximum concentration was calculated,,BAO_0000218,,,,Autocuration,3550,In vivo,A,,,,,22224
11196,1,Maximum concentration was calculated.,,BAO_0000218,,,,Autocuration,2632,In vivo,A,,,,,22224
11197,1,Maximum concentration at a peroral dose of 10 mg/kg,,BAO_0000218,,,,Autocuration,5566,In vivo,A,,,,,22224
11198,1,Maximum concentration of the drug at 10 uM/dg administered perorally,,BAO_0000218,,,,Autocuration,11883,In vivo,A,,,,,22224
11199,1,Maximum concentration of the drug at 2 uM/dg administered intravenously,,BAO_0000218,,,,Autocuration,11883,In vivo,A,,,,,22224
11200,1,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14122,In vivo,A,9615.0,,,,50588
11201,1,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",Plasma,BAO_0000218,,Cricetinae,,Intermediate,14122,In vivo,A,10026.0,,,,100712
11202,1,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14122,In vivo,A,10116.0,,,,50597
11203,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12542,In vivo,A,10116.0,,,,50597
11204,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,12542,In vivo,A,9615.0,,,,50588
11205,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,Plasma,BAO_0000218,,Cricetinae,,Intermediate,12542,In vivo,A,10026.0,,,,100712
11206,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,Plasma,BAO_0000218,,Cricetinae,,Intermediate,12542,In vivo,A,10026.0,,,,100712
11207,1,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12542,In vivo,A,10116.0,,,,50597
11208,1,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14080,In vivo,A,10116.0,,,,50597
11209,1,Maximum concentration reached following intravenous administration in male rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,11911,In vivo,A,10116.0,,,,50597
11210,1,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13204,In vivo,A,9615.0,,,,50588
11211,1,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13204,In vivo,A,10116.0,,,,50597
11212,1,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14346,In vivo,A,9615.0,,,,50588
11213,1,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,In vivo,A,10116.0,,,,50597
11214,1,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,In vivo,A,10116.0,,,,50597
11215,1,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,In vivo,A,10116.0,,,,50597
11216,1,Maximum drug concentration is determined after oral dosing in rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,14127,In vivo,A,10116.0,,,,50597
11217,1,Maximum observed concentration in oral (5 mg/kg) fasted dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14339,In vivo,A,9615.0,,,,50588
11218,1,Maximum observed concentration in oral (5 mg/kg) fed dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14339,In vivo,A,9615.0,,,,50588
11219,1,Maximum plasma concentration,Plasma,BAO_0000218,,,,Autocuration,13494,In vivo,A,,,,,22224
11220,1,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14925,In vivo,A,10116.0,,,,50597
11221,1,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14474,In vivo,A,10116.0,,,,50597
11222,1,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14474,In vivo,A,9615.0,,,,50588
11223,1,Maximum plasma concentration following oral administration of 30 umol/kg,Plasma,BAO_0000218,,,,Autocuration,13917,In vivo,A,,,,,22224
11224,1,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,A,10116.0,,,,50597
11225,1,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,A,10116.0,,,,50597
11226,1,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,A,10116.0,,,,50597
11227,1,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,A,10116.0,,,,50597
11228,1,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,A,10116.0,,,,50597
11229,1,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,A,10116.0,,,,50597
11230,1,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,A,10116.0,,,,50597
11231,1,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,A,10116.0,,,,50597
11232,1,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,A,10116.0,,,,50597
11233,1,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,9796,,A,10116.0,,,,50597
11234,1,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),,BAO_0000218,,Rattus norvegicus,,Intermediate,8363,,A,10116.0,,,,50597
11235,1,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),,BAO_0000218,,Rattus norvegicus,,Intermediate,8363,,A,10116.0,,,,50597
11236,1,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),,BAO_0000218,,Rattus norvegicus,,Intermediate,8363,,A,10116.0,,,,50597
11237,1,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),,BAO_0000218,,Rattus norvegicus,,Intermediate,8363,,A,10116.0,,,,50597
11238,1,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),,BAO_0000218,,Rattus norvegicus,,Intermediate,8363,,A,10116.0,,,,50597
11239,1,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),,BAO_0000218,,Rattus norvegicus,,Intermediate,8363,,A,10116.0,,,,50597
11240,1,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),,BAO_0000218,,Rattus norvegicus,,Intermediate,8363,,A,10116.0,,,,50597
11241,1,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),,BAO_0000218,,Rattus norvegicus,,Intermediate,8363,,A,10116.0,,,,50597
11242,1,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),,BAO_0000218,,Rattus norvegicus,,Intermediate,8363,,A,10116.0,,,,50597
11243,1,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),,BAO_0000218,,Rattus norvegicus,,Intermediate,8363,,A,10116.0,,,,50597
11244,1,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),,BAO_0000218,,Rattus norvegicus,,Intermediate,8363,,A,10116.0,,,,50597
11245,1,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),,BAO_0000218,,Rattus norvegicus,,Intermediate,8363,,A,10116.0,,,,50597
11246,1,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11247,1,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11248,1,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11249,1,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11250,1,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11251,1,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11252,1,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11253,1,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11254,1,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11255,1,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11256,1,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11257,1,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11258,1,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11259,1,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11260,1,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11261,1,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11262,1,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11263,1,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11264,1,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11265,1,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11266,1,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11267,1,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11268,1,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11269,1,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11270,1,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11271,1,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11272,1,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11273,1,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11274,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11275,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11276,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11277,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11278,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11279,1,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
11280,1,Observed diffusion coefficient in organic solvent for Escherichia coli,,BAO_0000218,,Escherichia coli,,Intermediate,15599,,A,562.0,,,,50212
11281,1,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,A,10116.0,,,,50597
11282,1,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,A,10116.0,,,,50597
11283,1,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Cardiac atrium,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,A,10116.0,,,,50597
11284,1,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Cardiac atrium,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,A,10116.0,,,,50597
11285,1,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,A,10116.0,,,,50597
11286,1,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,A,10116.0,,,,50597
11287,1,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,A,10116.0,,,,50597
11288,1,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,A,10116.0,,,,50597
11289,1,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Cardiac atrium,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,A,10116.0,,,,50597
11290,1,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Cardiac atrium,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,A,10116.0,,,,50597
11291,1,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,A,10116.0,,,,50597
11292,1,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,A,10116.0,,,,50597
11293,1,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,A,10116.0,,,,50597
11294,1,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,9614,,A,10116.0,,,,50597
11295,1,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,A,10116.0,,,,50597
11296,1,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,A,10116.0,,,,50597
11297,1,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,A,10116.0,,,,50597
11298,1,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,A,10116.0,,,,50597
11299,1,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,A,10116.0,,,,50597
11300,1,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,A,10116.0,,,,50597
11301,1,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,A,10116.0,,,,50597
11302,1,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,A,10116.0,,,,50597
11303,1,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,A,10116.0,,,,50597
11304,1,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,A,10116.0,,,,50597
11305,1,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,A,10116.0,,,,50597
11306,1,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,A,10116.0,,,,50597
11307,1,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,A,10116.0,,,,50597
11308,1,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,A,10116.0,,,,50597
11309,1,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,9071,,A,10116.0,,,,50597
11310,1,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",,BAO_0000218,,,,Autocuration,10677,,A,,,,,22224
11311,1,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,Urine,BAO_0000218,,Mus musculus,,Intermediate,9750,,A,10090.0,,,,50594
11312,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11313,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11314,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11315,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11316,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11317,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11318,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11319,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11320,1,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11321,1,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),Liver,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11322,1,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11323,1,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11324,1,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),Blood,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11325,1,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),Cerebellum,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11326,1,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11327,1,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11328,1,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),Liver,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11329,1,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11330,1,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11331,1,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),Blood,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11332,1,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),Cerebellum,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11333,1,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11334,1,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11335,1,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),Liver,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11336,1,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11337,1,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11338,1,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),Blood,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11339,1,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),Cerebellum,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11340,1,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11341,1,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11342,1,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),Liver,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11343,1,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),,BAO_0000218,,Mus musculus,,Intermediate,13256,In vivo,A,10090.0,,,,50594
11344,1,Biodistribution in Rat blood after 24 hours of iv administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11345,1,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11346,1,Biodistribution in Rat blood after 30 minutes of iv administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11347,1,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11348,1,Biodistribution in Rat blood after 5 minutes of iv administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11349,1,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11350,1,Biodistribution in Rat heart after 24 hours of iv administration,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11351,1,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11352,1,Biodistribution in Rat heart after 30 minutes of iv administration,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11353,1,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11354,1,Biodistribution in Rat heart after 5 minutes of iv administration,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11355,1,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11356,1,Biodistribution in Rat liver after 24 hours of iv administration,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11357,1,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11358,1,Biodistribution in Rat liver after 30 minutes of iv administration,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11359,1,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11360,1,Biodistribution in Rat liver after 30 minutes of iv administration,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11361,1,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,13249,In vivo,A,9615.0,,,,50588
11362,1,Cmax in cynomolgus monkey (PO dose),,BAO_0000218,,Macaca fascicularis,,Intermediate,13622,In vivo,A,9541.0,,,,100710
11363,1,Cmax in rat (PO dose),,BAO_0000218,,Rattus norvegicus,,Intermediate,13622,In vivo,A,10116.0,,,,50597
11364,1,Cmax in rat (PO dose),,BAO_0000218,,Rattus norvegicus,,Intermediate,13622,In vivo,A,10116.0,,,,50597
11365,1,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13494,In vivo,A,10116.0,,,,50597
11366,1,Cmax in rat plasma after oral dose (10 mg/kg),Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12170,In vivo,A,10116.0,,,,50597
11367,1,Cmax in plasma after oral dose (10 mg/kg),Plasma,BAO_0000218,,,,Autocuration,12170,In vivo,A,,,,,22224
11368,1,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17025,In vivo,A,9615.0,,,,50588
11369,1,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,Plasma,BAO_0000218,,Simiiformes,,Autocuration,17025,In vivo,A,314293.0,,,,22224
11370,1,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,Plasma,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,17025,In vivo,A,9986.0,,,,50592
11371,1,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17025,In vivo,A,10116.0,,,,50597
11372,1,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14187,In vivo,A,10116.0,,,,50597
11373,1,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14816,In vivo,A,10090.0,,,,50594
11374,1,Maximum plasma concentration after oral dosing in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17820,In vivo,A,10116.0,,,,50597
11375,1,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,Plasma,BAO_0000218,,,,Autocuration,14380,In vivo,A,,,,,22224
11376,1,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,Plasma,BAO_0000218,,,,Autocuration,14380,In vivo,A,,,,,22224
11377,1,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14691,In vivo,A,9615.0,,,,50588
11378,1,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14691,In vivo,A,9615.0,,,,50588
11379,1,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13375,In vivo,A,10116.0,,,,50597
11380,1,Maximum plasma concentration was determined,Plasma,BAO_0000218,,,,Autocuration,6236,In vivo,A,,,,,22224
11381,1,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,Plasma,BAO_0000218,,,,Autocuration,14380,In vivo,A,,,,,22224
11382,1,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,Plasma,BAO_0000218,,,,Autocuration,14380,In vivo,A,,,,,22224
11383,1,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,Plasma,BAO_0000218,,,,Autocuration,14380,In vivo,A,,,,,22224
11384,1,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,Plasma,BAO_0000218,,,,Autocuration,14380,In vivo,A,,,,,22224
11385,1,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,Plasma,BAO_0000218,,,,Autocuration,14380,In vivo,A,,,,,22224
11386,1,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,Plasma,BAO_0000218,,,,Autocuration,14380,In vivo,A,,,,,22224
11387,1,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,Plasma,BAO_0000218,,,,Autocuration,14380,In vivo,A,,,,,22224
11388,1,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,Plasma,BAO_0000218,,,,Autocuration,14380,In vivo,A,,,,,22224
11389,1,Plasma Cmax in rat (PO dose),Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13622,In vivo,A,10116.0,,,,50597
11390,1,Maximum serum concentration after po dose of 5.22 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,In vivo,A,10116.0,,,,50597
11391,1,Maximum serum concentration after po dose of 5.46 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,In vivo,A,10116.0,,,,50597
11392,1,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,In vivo,A,10116.0,,,,50597
11393,1,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,In vivo,A,10116.0,,,,50597
11394,1,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14925,In vivo,A,9615.0,,,,50588
11395,1,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14925,In vivo,A,9615.0,,,,50588
11396,1,Maximum concentration of the drug at 1 uM/dg administered intravenously,,BAO_0000218,,,,Autocuration,11883,In vivo,A,,,,,22224
11397,1,Maximum concentration of the drug at 20 uM/dg administered perorally,,BAO_0000218,,,,Autocuration,11883,In vivo,A,,,,,22224
11398,1,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,,BAO_0000218,,,,Autocuration,13391,In vivo,A,,,,,22224
11399,1,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,Blood,BAO_0000218,,,,Autocuration,13391,In vivo,A,,,,,22224
11400,1,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,Blood,BAO_0000218,,,,Autocuration,13391,In vivo,A,,,,,22224
11401,1,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,Blood,BAO_0000218,,,,Autocuration,13391,In vivo,A,,,,,22224
11402,1,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,16360,In vivo,A,10116.0,,,,50597
11403,1,Cmax in dog plasma after 1mg/kg oral dose,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,3673,In vivo,A,9615.0,,,,50588
11404,1,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14431,In vivo,A,9615.0,,,,50588
11405,1,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14431,In vivo,A,10116.0,,,,50597
11406,1,Oral maximum concentration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14964,In vivo,A,10116.0,,,,50597
11407,1,Oral maximum concentration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14964,In vivo,A,10116.0,,,,50597
11408,1,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,Plasma,BAO_0000218,,Mus musculus,,Intermediate,14209,In vivo,A,10090.0,,,,50594
11409,1,Peak concentration in blood after intravenous administration to mice,Blood,BAO_0000218,,Mus musculus,,Intermediate,11355,In vivo,A,10090.0,,,,50594
11410,1,Peak concentration in blood after peroral administration to mice,Blood,BAO_0000218,,Mus musculus,,Intermediate,11355,In vivo,A,10090.0,,,,50594
11411,1,Peak concentration in rat plasma was determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,11966,In vivo,A,10116.0,,,,50597
11412,1,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,Plasma,BAO_0000218,,Simiiformes,,Autocuration,8918,In vivo,A,314293.0,,,,22224
11413,1,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,Plasma,BAO_0000218,,Mus musculus,,Intermediate,8918,In vivo,A,10090.0,,,,50594
11414,1,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,8918,In vivo,A,10116.0,,,,50597
11415,1,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11416,1,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11417,1,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11418,1,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11419,1,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11420,1,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11421,1,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11422,1,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11423,1,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11424,1,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11425,1,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11426,1,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11427,1,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11428,1,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11429,1,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11430,1,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11431,1,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11432,1,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11433,1,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11434,1,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11435,1,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11436,1,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11437,1,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11438,1,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11439,1,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11440,1,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11441,1,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11442,1,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11443,1,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11444,1,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11445,1,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11446,1,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11447,1,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11448,1,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11449,1,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11450,1,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11451,1,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11452,1,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11453,1,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11454,1,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11455,1,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11456,1,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11457,1,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11458,1,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11459,1,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11460,1,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11461,1,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11462,1,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11463,1,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11464,1,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11465,1,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11466,1,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11467,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11468,1,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11469,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11470,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11471,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11472,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11473,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11474,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11475,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11476,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11477,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11478,1,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11479,1,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,Urine,BAO_0000218,,Mus musculus,,Intermediate,14571,,A,10090.0,,,,50594
11480,1,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,14571,,A,10116.0,,,,50597
11481,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11482,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11483,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11484,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11485,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11486,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11487,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11488,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11489,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11490,1,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11491,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11492,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11493,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11494,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11495,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11496,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11497,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11498,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11499,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11500,1,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,,BAO_0000218,,Rattus norvegicus,,Intermediate,8319,,A,10116.0,,,,50597
11501,1,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12064,,A,10116.0,,,,50597
11502,1,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12064,,A,10116.0,,,,50597
11503,1,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12064,,A,10116.0,,,,50597
11504,1,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12038,,A,10116.0,,,,50597
11505,1,% dose converted to 2-amino-5-chlorophenyl sulfate,,BAO_0000019,,,,Autocuration,14314,,A,,,,,22224
11506,1,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),,BAO_0000019,,,,Autocuration,14314,,A,,,,,22224
11507,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",Feces,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
11508,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",Feces,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
11509,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",Feces,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
11510,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",Feces,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
11511,1,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11512,1,Biodistribution in Rat liver after 5 minutes of iv administration,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11513,1,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11514,1,Biodistribution in Rat lung after 24 hours of iv administration,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11515,1,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11516,1,Biodistribution in Rat lung after 30 minutes of iv administration,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11517,1,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11518,1,Biodistribution in Rat lung after 5 minutes of iv administration,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11519,1,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8829,In vivo,A,10116.0,,,,50597
11520,1,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,14972,In vivo,A,10116.0,,,,50597
11521,1,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",,BAO_0000218,,Rattus norvegicus,,Intermediate,14972,In vivo,A,10116.0,,,,50597
11522,1,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",Thalamus,BAO_0000218,,Rattus norvegicus,,Intermediate,14972,In vivo,A,10116.0,,,,50597
11523,1,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11524,1,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11525,1,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11526,1,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,Hippocampus,BAO_0000218,,,,Autocuration,14608,In vivo,A,,,,,22224
11527,1,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,Hippocampus,BAO_0000218,,,,Autocuration,14608,In vivo,A,,,,,22224
11528,1,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,Hippocampus,BAO_0000218,,,,Autocuration,14608,In vivo,A,,,,,22224
11529,1,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11530,1,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11531,1,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11532,1,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11533,1,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11534,1,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11535,1,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11536,1,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11537,1,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11538,1,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11539,1,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11540,1,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11541,1,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11542,1,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11543,1,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11544,1,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11545,1,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11546,1,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11547,1,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11548,1,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11549,1,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11550,1,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11551,1,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11552,1,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11553,1,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11554,1,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,Plasma,BAO_0000218,,Simiiformes,,Autocuration,8918,In vivo,A,314293.0,,,,22224
11555,1,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,Plasma,BAO_0000218,,Mus musculus,,Intermediate,8918,In vivo,A,10090.0,,,,50594
11556,1,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,8918,In vivo,A,10116.0,,,,50597
11557,1,Peak plasma concentration was measured in dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14470,In vivo,A,9615.0,,,,50588
11558,1,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,In vivo,A,10116.0,,,,50597
11559,1,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,14886,In vivo,A,10116.0,,,,50597
11560,1,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,14886,In vivo,A,10116.0,,,,50597
11561,1,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,14886,In vivo,A,10116.0,,,,50597
11562,1,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,In vivo,A,10116.0,,,,50597
11563,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13465,In vivo,A,9615.0,,,,50588
11564,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,,BAO_0000218,,Simiiformes,,Autocuration,13465,In vivo,A,314293.0,,,,22224
11565,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13465,In vivo,A,9615.0,,,,50588
11566,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13465,In vivo,A,9615.0,,,,50588
11567,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13465,In vivo,A,10116.0,,,,50597
11568,1,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13465,In vivo,A,10116.0,,,,50597
11569,1,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13465,In vivo,A,9615.0,,,,50588
11570,1,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13465,In vivo,A,10116.0,,,,50597
11571,1,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,,BAO_0000218,,Rattus norvegicus,,Intermediate,13465,In vivo,A,10116.0,,,,50597
11572,1,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13465,In vivo,A,9615.0,,,,50588
11573,1,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13465,In vivo,A,9615.0,,,,50588
11574,1,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,,BAO_0000218,,Simiiformes,,Autocuration,13465,In vivo,A,314293.0,,,,22224
11575,1,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,,BAO_0000218,,Simiiformes,,Autocuration,13465,In vivo,A,314293.0,,,,22224
11576,1,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13465,In vivo,A,10116.0,,,,50597
11577,1,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,BAO_0000218,,Macaca fascicularis,,Intermediate,14731,In vivo,A,9541.0,,,,100710
11578,1,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,,BAO_0000218,,Mus musculus,,Intermediate,14731,In vivo,A,10090.0,,,,50594
11579,1,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13376,In vivo,A,9615.0,,,,50588
11580,1,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13376,In vivo,A,9615.0,,,,50588
11581,1,Maximum concentration (Cmax) in rat when administered orally,,BAO_0000218,,Rattus norvegicus,,Intermediate,14443,In vivo,A,10116.0,,,,50597
11582,1,Maximal concentration in monkey plasma after 25 mg/kg oral dose,Plasma,BAO_0000218,,Simiiformes,,Autocuration,13465,In vivo,A,314293.0,,,,22224
11583,1,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",,BAO_0000218,,Rattus norvegicus,,Autocuration,16359,In vivo,A,10116.0,,,,22224
11584,1,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",,BAO_0000218,,Rattus norvegicus,,Autocuration,16359,In vivo,A,10116.0,,,,22224
11585,1,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,Plasma,BAO_0000218,,,,Autocuration,15618,In vivo,A,,,,,22224
11586,1,Pharmacokinetic profile Cmax was evaluated in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14554,In vivo,A,10116.0,,,,50597
11587,1,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,11537,In vivo,A,9615.0,,,,50588
11588,1,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),,BAO_0000218,,Mus musculus,,Intermediate,11537,In vivo,A,10090.0,,,,50594
11589,1,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),,BAO_0000218,,Canis lupus familiaris,,Intermediate,11537,In vivo,A,9615.0,,,,50588
11590,1,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),,BAO_0000218,,Mus musculus,,Intermediate,11537,In vivo,A,10090.0,,,,50594
11591,1,Cmax in rat plasma,Plasma,BAO_0000218,,Rattus norvegicus,,Autocuration,2021,In vivo,A,10116.0,,,,22224
11592,1,Cmax in dog plasma after 30mg/kg oral dose,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5932,In vivo,A,9615.0,,,,50588
11593,1,Cmax in rat plasma after 30mg/kg oral dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5932,In vivo,A,10116.0,,,,50597
11594,1,Plasma level in rats at 30 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17320,In vivo,A,10116.0,,,,50597
11595,1,Tested for maximum plasma concentration in mice,Plasma,BAO_0000218,,Mus musculus,,Intermediate,15831,In vivo,A,10090.0,,,,50594
11596,1,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,In vivo,A,10116.0,,,,50597
11597,1,The Cmax values in female wistar rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,14941,In vivo,A,10116.0,,,,50597
11598,1,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,15343,In vivo,A,9615.0,,,,50588
11599,1,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15343,In vivo,A,10116.0,,,,50597
11600,1,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14856,In vivo,A,10116.0,,,,50597
11601,1,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13129,In vivo,A,10116.0,,,,50597
11602,1,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13098,In vivo,A,10116.0,,,,50597
11603,1,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13098,In vivo,A,10116.0,,,,50597
11604,1,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13098,In vivo,A,10116.0,,,,50597
11605,1,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,Blood,BAO_0000218,,Mus musculus,,Autocuration,15478,In vivo,A,10090.0,,,,22224
11606,1,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15341,In vivo,A,9615.0,,,,50588
11607,1,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15341,In vivo,A,10116.0,,,,50597
11608,1,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11609,1,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11610,1,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11611,1,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11612,1,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11613,1,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11614,1,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11615,1,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11616,1,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11617,1,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11618,1,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11619,1,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11620,1,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11621,1,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11622,1,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11623,1,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11624,1,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11625,1,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11626,1,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11627,1,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11628,1,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11629,1,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11630,1,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11631,1,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8684,,A,10116.0,,,,50597
11632,1,Distribution in the blood after 120 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11633,1,Distribution in the blood after 15 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11634,1,Distribution in the blood after 30 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11635,1,Distribution in the blood after 5 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11636,1,Distribution in the blood after 60 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11637,1,Distribution in the blood after 90 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11638,1,Distribution in the bone after 120 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11639,1,Distribution in the bone after 15 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11640,1,Distribution in the bone after 30 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11641,1,Distribution in the bone after 5 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11642,1,Distribution in the bone after 60 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11643,1,Distribution in the bone after 90 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11644,1,Distribution in the heart after 120 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11645,1,Distribution in the heart after 15 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11646,1,Distribution in the heart after 30 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11647,1,Distribution in the heart after 5 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11648,1,Distribution in the heart after 60 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11649,1,Distribution in the heart after 90 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11650,1,Distribution in the kidneys after 120 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11651,1,Distribution in the kidneys after 15 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11652,1,Distribution in the kidneys after 30 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11653,1,Distribution in the kidneys after 5 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11654,1,Distribution in the kidneys after 60 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11655,1,Distribution in the kidneys after 90 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11656,1,Distribution in the liver after 120 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11657,1,Distribution in the liver after 15 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11658,1,Distribution in the liver after 30 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11659,1,Distribution in the liver after 5 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11660,1,Distribution in the liver after 60 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11661,1,Distribution in the liver after 90 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11662,1,Distribution in the lung after 120 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11663,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",,BAO_0000218,,Mus musculus,,Intermediate,14839,,A,10090.0,,,,50594
11664,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",,BAO_0000218,,Mus musculus,,Intermediate,14839,,A,10090.0,,,,50594
11665,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",,BAO_0000218,,Mus musculus,,Intermediate,14839,,A,10090.0,,,,50594
11666,1,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",,BAO_0000218,,Mus musculus,,Intermediate,14839,,A,10090.0,,,,50594
11667,1,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12178,,A,10116.0,,,,50597
11668,1,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12178,,A,10116.0,,,,50597
11669,1,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,,BAO_0000218,,,,Autocuration,12178,,A,,,,,22224
11670,1,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,BAO_0000218,,Macaca fascicularis,,Intermediate,12186,,A,9541.0,,,,100710
11671,1,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,BAO_0000218,,Macaca fascicularis,,Intermediate,12186,,A,9541.0,,,,100710
11672,1,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,BAO_0000218,,Macaca fascicularis,,Intermediate,12186,,A,9541.0,,,,100710
11673,1,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,BAO_0000218,,Macaca fascicularis,,Intermediate,12186,,A,9541.0,,,,100710
11674,1,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,BAO_0000218,,Simiiformes,,Autocuration,12187,,A,314293.0,,,,22224
11675,1,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,BAO_0000218,,Mustela putorius furo,,Intermediate,12187,,A,9669.0,,,,50506
11676,1,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,BAO_0000218,,Mustela putorius furo,,Intermediate,12187,,A,9669.0,,,,50506
11677,1,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,BAO_0000218,,Simiiformes,,Autocuration,12187,,A,314293.0,,,,22224
11678,1,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,,BAO_0000218,,Simiiformes,,Autocuration,12187,,A,314293.0,,,,22224
11679,1,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12187,,A,10116.0,,,,50597
11680,1,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,BAO_0000218,,Rattus norvegicus,,Intermediate,12187,,A,10116.0,,,,50597
11681,1,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",,BAO_0000218,,Canis lupus familiaris,,Intermediate,14122,,A,9615.0,,,,50588
11682,1,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",,BAO_0000218,,Cricetinae,,Intermediate,14122,,A,10026.0,,,,100712
11683,1,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",,BAO_0000218,,Rattus norvegicus,,Intermediate,14122,,A,10116.0,,,,50597
11684,1,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,,BAO_0000218,,,,Autocuration,13391,,A,,,,,22224
11685,1,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,Blood,BAO_0000218,,,,Autocuration,13391,,A,,,,,22224
11686,1,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,Blood,BAO_0000218,,,,Autocuration,13391,,A,,,,,22224
11687,1,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,Blood,BAO_0000218,,,,Autocuration,13391,,A,,,,,22224
11688,1,Oral absorption expressed as Area under curve was determined,,BAO_0000019,,,,Autocuration,16360,,A,,,,,22224
11689,1,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,3673,,A,9615.0,,,,50588
11690,1,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",,BAO_0000218,,Canis lupus familiaris,,Intermediate,14122,,A,9615.0,,,,50588
11691,1,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,BAO_0000218,,Cricetinae,,Intermediate,14122,,A,10026.0,,,,100712
11692,1,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",,BAO_0000218,,Cricetinae,,Intermediate,14122,,A,10026.0,,,,100712
11693,1,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",,BAO_0000218,,Rattus norvegicus,,Intermediate,14122,,A,10116.0,,,,50597
11694,1,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,,BAO_0000019,,,,Autocuration,13889,,A,,,,,22224
11695,1,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,,A,10116.0,,,,50597
11696,1,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),,BAO_0000218,,Rattus norvegicus,,Intermediate,17279,,A,10116.0,,,,50597
11697,1,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,BAO_0000218,,Macaca fascicularis,,Intermediate,14548,,A,9541.0,,,,100710
11698,1,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,BAO_0000218,,Macaca fascicularis,,Intermediate,14548,,A,9541.0,,,,100710
11699,1,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,,BAO_0000218,,Macaca fascicularis,,Intermediate,14548,,A,9541.0,,,,100710
11700,1,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14548,,A,9615.0,,,,50588
11701,1,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14548,,A,9615.0,,,,50588
11702,1,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,14548,,A,10116.0,,,,50597
11703,1,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,14548,,A,10116.0,,,,50597
11704,1,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,14548,,A,10116.0,,,,50597
11705,1,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11706,1,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11707,1,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,14608,In vivo,A,10090.0,,,,50594
11708,1,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11709,1,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11710,1,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11711,1,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11712,1,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11713,1,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11714,1,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11715,1,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11716,1,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11717,1,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11718,1,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,14608,In vivo,A,10116.0,,,,50597
11719,1,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11720,1,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11721,1,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11722,1,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11723,1,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11724,1,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Brain,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11725,1,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Brain,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11726,1,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Brain,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11727,1,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11728,1,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11729,1,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,Kidney,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11730,1,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Kidney,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11731,1,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Kidney,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11732,1,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Kidney,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11733,1,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Kidney,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11734,1,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Kidney,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11735,1,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,Liver,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11736,1,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Liver,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11737,1,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Liver,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11738,1,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Liver,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11739,1,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Liver,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11740,1,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Liver,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11741,1,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11742,1,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11743,1,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11744,1,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11745,1,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11746,1,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11747,1,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11748,1,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11749,1,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11750,1,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11751,1,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15341,In vivo,A,10116.0,,,,50597
11752,1,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15341,In vivo,A,10116.0,,,,50597
11753,1,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15341,In vivo,A,10116.0,,,,50597
11754,1,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14906,In vivo,A,9615.0,,,,50588
11755,1,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14906,In vivo,A,10116.0,,,,50597
11756,1,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14906,In vivo,A,10116.0,,,,50597
11757,1,The maximum plasma concentration (100 mg/kg) administered orally in human,Plasma,BAO_0000218,,Homo sapiens,,Intermediate,14215,In vivo,A,9606.0,,,,50587
11758,1,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,Plasma,BAO_0000218,,Callithrix,,Autocuration,14215,In vivo,A,9481.0,,,,22224
11759,1,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,Plasma,BAO_0000218,,Simiiformes,,Autocuration,14215,In vivo,A,314293.0,,,,22224
11760,1,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14215,In vivo,A,9615.0,,,,50588
11761,1,The maximum plasma concentration (200 mg/kg) administered orally in human,Plasma,BAO_0000218,,Homo sapiens,,Intermediate,14215,In vivo,A,9606.0,,,,50587
11762,1,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14215,In vivo,A,10116.0,,,,50597
11763,1,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,Plasma,BAO_0000218,,Callithrix,,Autocuration,14215,In vivo,A,9481.0,,,,22224
11764,1,The maximum plasma concentration (25 mg/kg) administered orally in monkey,Plasma,BAO_0000218,,Simiiformes,,Autocuration,14215,In vivo,A,314293.0,,,,22224
11765,1,The maximum plasma concentration (30 mg/kg) administered orally in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Autocuration,14215,In vivo,A,9615.0,,,,22224
11766,1,The maximum plasma concentration (400 mg/kg) administered orally in human,Plasma,BAO_0000218,,Homo sapiens,,Intermediate,14215,In vivo,A,9606.0,,,,50587
11767,1,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14215,In vivo,A,10116.0,,,,50597
11768,1,The maximum plasma concentration (50 mg/kg) administered orally in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14215,In vivo,A,10116.0,,,,50597
11769,1,The maximum plasma concentration (800 mg/kg) administered orally in human,Plasma,BAO_0000218,,Homo sapiens,,Intermediate,14215,In vivo,A,9606.0,,,,50587
11770,1,The maximum plasma concentration was measured on rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14067,In vivo,A,10116.0,,,,50597
11771,1,The maximum plasma concentration was measured on rats after oral administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12350,In vivo,A,10116.0,,,,50597
11772,1,Plasma drug Cmax in rat (PO dose),Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14813,In vivo,A,10116.0,,,,50597
11773,1,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,,BAO_0000218,,,,Autocuration,12536,In vivo,A,,,,,22224
11774,1,maximum Plasma concentration in Dog was determined after Peroral administration,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14169,In vivo,A,9615.0,,,,50588
11775,1,maximum Plasma concentration in Rats was determined after Peroral administration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14169,In vivo,A,10116.0,,,,50597
11776,1,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,15604,In vivo,A,9615.0,,,,50588
11777,1,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,Plasma,BAO_0000218,,Simiiformes,,Autocuration,15604,In vivo,A,314293.0,,,,22224
11778,1,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15604,In vivo,A,10116.0,,,,50597
11779,1,maximum concentration was measured when administered through oral route in mice,,BAO_0000218,,Mus musculus,,Intermediate,14387,In vivo,A,10090.0,,,,50594
11780,1,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,,BAO_0000218,,Mus musculus,,Intermediate,15115,,A,10090.0,,,,50594
11781,1,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,,BAO_0000019,,Simiiformes,,Autocuration,15115,,A,314293.0,,,,22224
11782,1,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,,BAO_0000019,,Simiiformes,,Autocuration,15115,,A,314293.0,,,,22224
11783,1,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,,BAO_0000019,,Simiiformes,,Autocuration,15115,,A,314293.0,,,,22224
11784,1,Pharmacokinetic parameter was evaluated in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,16359,,A,10116.0,,,,50597
11785,1,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,BAO_0000218,,Mus musculus,,Intermediate,12829,,A,10090.0,,,,50594
11786,1,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,,BAO_0000218,,Mus musculus,,Intermediate,12829,,A,10090.0,,,,50594
11787,1,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,,BAO_0000218,,Mus musculus,,Intermediate,12829,,A,10090.0,,,,50594
11788,1,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,,BAO_0000218,,Mus musculus,,Intermediate,12829,,A,10090.0,,,,50594
11789,1,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,,BAO_0000218,,Mus musculus,,Intermediate,12829,,A,10090.0,,,,50594
11790,1,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15137,,A,10116.0,,,,50597
11791,1,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15137,,A,10116.0,,,,50597
11792,1,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15137,,A,10116.0,,,,50597
11793,1,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,Plasma,BAO_0000218,,Mus musculus,,Intermediate,15137,,A,10090.0,,,,50594
11794,1,Plasma Concentration after 120 min of oral administration to mice,,BAO_0000218,,Mus musculus,,Intermediate,13509,,A,10090.0,,,,50594
11795,1,Plasma Concentration after 30 min of oral administration to mice,,BAO_0000218,,Mus musculus,,Intermediate,13509,,A,10090.0,,,,50594
11796,1,Plasma Concentration after 60 min of oral administration to mice,,BAO_0000218,,Macaca fascicularis,,Intermediate,13509,,A,9541.0,,,,100710
11797,1,Plasma Concentration after 60 min of oral administration to mice; Not determined,,BAO_0000218,,Mus musculus,,Intermediate,13509,,A,10090.0,,,,50594
11798,1,Plasma Concentration after 90 min of oral administration to mice,,BAO_0000218,,Mus musculus,,Intermediate,13509,,A,10090.0,,,,50594
11799,1,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,12064,,A,10116.0,,,,50597
11800,1,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,12064,,A,10116.0,,,,50597
11801,1,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,12064,,A,10116.0,,,,50597
11802,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,,BAO_0000218,,Rattus norvegicus,,Intermediate,10677,,A,10116.0,,,,50597
11803,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,,BAO_0000218,,Rattus norvegicus,,Intermediate,10677,,A,10116.0,,,,50597
11804,1,Distribution in the lung after 15 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11805,1,Distribution in the lung after 30 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11806,1,Distribution in the lung after 5 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11807,1,Distribution in the lung after 60 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11808,1,Distribution in the lung after 90 min of intravenous administration,,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11809,1,Distribution in the muscle after 120 min of intravenous administration,Muscle tissue,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11810,1,Distribution in the muscle after 15 min of intravenous administration,Muscle tissue,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11811,1,Distribution in the muscle after 30 min of intravenous administration,Muscle tissue,BAO_0000218,,Mus musculus,,Intermediate,8926,,A,10090.0,,,,50594
11812,1,Distribution in the muscle after 5 min of intravenous administration,Muscle tissue,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11813,1,Distribution in the muscle after 60 min of intravenous administration,Muscle tissue,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11814,1,Distribution in the muscle after 90 min of intravenous administration,Muscle tissue,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11815,1,Distribution in the spleen after 120 min of intravenous administration,Spleen,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11816,1,Distribution in the spleen after 15 min of intravenous administration,Spleen,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11817,1,Distribution in the spleen after 30 min of intravenous administration,Spleen,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11818,1,Distribution in the spleen after 5 min of intravenous administration,Spleen,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11819,1,Distribution in the spleen after 60 min of intravenous administration,Spleen,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11820,1,Distribution in the spleen after 90 min of intravenous administration,Spleen,BAO_0000019,,,,Autocuration,8926,,A,,,,,22224
11821,1,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,Adrenal cortex,BAO_0000218,,Rattus norvegicus,,Intermediate,7570,,A,10116.0,,,,50597
11822,1,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,7570,,A,10116.0,,,,50597
11823,1,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,7570,,A,10116.0,,,,50597
11824,1,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,Female gonad,BAO_0000218,,Rattus norvegicus,,Intermediate,7570,,A,10116.0,,,,50597
11825,1,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,7570,,A,10116.0,,,,50597
11826,1,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,Adrenal cortex,BAO_0000218,,Rattus norvegicus,,Intermediate,7570,,A,10116.0,,,,50597
11827,1,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,7570,,A,10116.0,,,,50597
11828,1,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,7570,,A,10116.0,,,,50597
11829,1,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,Female gonad,BAO_0000218,,Rattus norvegicus,,Intermediate,7570,,A,10116.0,,,,50597
11830,1,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,7570,,A,10116.0,,,,50597
11831,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11832,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11833,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11834,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11835,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11836,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11837,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11838,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11839,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11840,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11841,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11842,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11843,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11844,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11845,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11846,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11847,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11848,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11849,1,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,,BAO_0000218,,Mus musculus,,Intermediate,13792,,A,10090.0,,,,50594
11850,1,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13376,,A,9615.0,,,,50588
11851,1,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13376,,A,9615.0,,,,50588
11852,1,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,BAO_0000218,,,,Autocuration,14380,,A,,,,,22224
11853,1,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,,BAO_0000218,,,,Autocuration,14380,,A,,,,,22224
11854,1,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,,BAO_0000218,,,,Autocuration,14380,,A,,,,,22224
11855,1,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,,BAO_0000218,,,,Autocuration,14380,,A,,,,,22224
11856,1,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,,BAO_0000218,,,,Autocuration,14380,,A,,,,,22224
11857,1,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,,BAO_0000218,,,,Autocuration,14380,,A,,,,,22224
11858,1,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,,BAO_0000019,,,,Autocuration,14380,,A,,,,,22224
11859,1,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,,BAO_0000218,,,,Autocuration,14380,,A,,,,,22224
11860,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
11861,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
11862,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
11863,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
11864,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
11865,1,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
11866,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
11867,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
11868,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
11869,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
11870,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
11871,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
11872,1,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
11873,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
11874,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
11875,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
11876,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
11877,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
11878,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
11879,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
11880,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
11881,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
11882,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
11883,1,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
11884,1,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,,A,10116.0,,,,50597
11885,1,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,,BAO_0000218,,Mus musculus,,Intermediate,14731,,A,10090.0,,,,50594
11886,1,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,,BAO_0000218,,Macaca fascicularis,,Intermediate,14731,,A,9541.0,,,,100710
11887,1,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,,BAO_0000218,,Macaca fascicularis,,Intermediate,14731,,A,9541.0,,,,100710
11888,1,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,Brain,BAO_0000218,,,,Autocuration,13758,,A,,,,,22224
11889,1,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,Serum,BAO_0000218,,,,Autocuration,13758,,A,,,,,22224
11890,1,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,Brain,BAO_0000218,,,,Autocuration,13758,,A,,,,,22224
11891,1,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,Serum,BAO_0000218,,,,Autocuration,13758,,A,,,,,22224
11892,1,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),,BAO_0000019,,,,Autocuration,16359,,A,,,,,22224
11893,1,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),,BAO_0000218,,,,Autocuration,16359,,A,,,,,22224
11894,1,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,Spleen,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11895,1,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,Spleen,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11896,1,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,Spleen,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11897,1,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11898,1,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11899,1,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11900,1,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,,BAO_0000218,,Mus musculus,,Intermediate,15383,,A,10090.0,,,,50594
11901,1,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),,BAO_0000218,,Mus musculus,,Intermediate,14439,,A,10090.0,,,,50594
11902,1,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),,BAO_0000218,,Mus musculus,,Intermediate,14439,,A,10090.0,,,,50594
11903,1,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),,BAO_0000218,,Mus musculus,,Intermediate,14439,,A,10090.0,,,,50594
11904,1,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),,BAO_0000218,,Mus musculus,,Intermediate,14439,,A,10090.0,,,,50594
11905,1,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),,BAO_0000218,,Mus musculus,,Intermediate,14439,,A,10090.0,,,,50594
11906,1,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),,BAO_0000218,,Mus musculus,,Intermediate,14439,,A,10090.0,,,,50594
11907,1,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),,BAO_0000218,,Mus musculus,,Intermediate,14439,,A,10090.0,,,,50594
11908,1,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),,BAO_0000218,,Mus musculus,,Intermediate,14439,,A,10090.0,,,,50594
11909,1,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),,BAO_0000218,,Mus musculus,,Intermediate,14439,,A,10090.0,,,,50594
11910,1,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),,BAO_0000218,,Mus musculus,,Intermediate,14439,,A,10090.0,,,,50594
11911,1,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),,BAO_0000218,,Mus musculus,,Intermediate,14439,,A,10090.0,,,,50594
11912,1,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),,BAO_0000218,,Mus musculus,,Intermediate,14439,,A,10090.0,,,,50594
11913,1,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11914,1,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11915,1,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11916,1,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11917,1,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11918,1,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11919,1,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11920,1,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11921,1,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11922,1,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11923,1,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11924,1,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11925,1,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11926,1,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11927,1,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11928,1,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11929,1,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11930,1,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11931,1,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11932,1,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11933,1,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11934,1,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11935,1,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11936,1,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11937,1,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
11938,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,,BAO_0000218,,Rattus norvegicus,,Intermediate,10677,,A,10116.0,,,,50597
11939,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,,BAO_0000218,,Rattus norvegicus,,Intermediate,10677,,A,10116.0,,,,50597
11940,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,,BAO_0000218,,Rattus norvegicus,,Intermediate,10677,,A,10116.0,,,,50597
11941,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,,BAO_0000218,,Rattus norvegicus,,Intermediate,10677,,A,10116.0,,,,50597
11942,1,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,,BAO_0000218,,Rattus norvegicus,,Intermediate,10677,,A,10116.0,,,,50597
11943,1,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Adrenal gland,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11944,1,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Adrenal gland,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11945,1,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Adrenal gland,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11946,1,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,Adrenal gland,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11947,1,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Adrenal gland,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11948,1,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11949,1,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11950,1,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11951,1,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11952,1,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11953,1,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11954,1,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11955,1,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11956,1,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11957,1,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11958,1,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11959,1,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11960,1,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11961,1,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11962,1,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11963,1,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11964,1,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11965,1,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11966,1,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11967,1,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11968,1,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11969,1,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11970,1,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11971,1,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11972,1,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11973,1,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11974,1,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11975,1,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11976,1,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
11977,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11978,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11979,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11980,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11981,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11982,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11983,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11984,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11985,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11986,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11987,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11988,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11989,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11990,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11991,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11992,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11993,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11994,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11995,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11996,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11997,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11998,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
11999,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12000,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12001,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12002,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12003,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12004,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12005,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12006,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12007,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12008,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12009,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12010,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12011,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12012,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12013,1,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),,BAO_0000218,,,,Autocuration,16359,,A,,,,,22224
12014,1,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),,BAO_0000218,,Mus musculus,,Intermediate,13701,,A,10090.0,,,,50594
12015,1,Pharmacokinetic profile AUC was evaluated in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14554,,A,10116.0,,,,50597
12016,1,Pharmacokinetic property (Area under curve),,BAO_0000019,,,,Autocuration,6241,,A,,,,,22224
12017,1,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",,BAO_0000218,,Canis lupus familiaris,,Intermediate,11537,,A,9615.0,,,,50588
12018,1,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",,BAO_0000218,,Mus musculus,,Intermediate,11537,,A,10090.0,,,,50594
12019,1,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",,BAO_0000218,,Canis lupus familiaris,,Intermediate,11537,,A,9615.0,,,,50588
12020,1,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",,BAO_0000218,,Mus musculus,,Intermediate,11537,,A,10090.0,,,,50594
12021,1,Plasma concentration (AUC) was determined,,BAO_0000019,,,,Autocuration,13118,,A,,,,,22224
12022,1,Plasma concentration (AUC) was determined; Not detectable,,BAO_0000019,,,,Autocuration,13118,,A,,,,,22224
12023,1,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),,BAO_0000218,,Cavia porcellus,,Intermediate,9562,,A,10141.0,,,,50512
12024,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,10363,,A,10116.0,,,,50597
12025,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,,BAO_0000218,,Rattus norvegicus,,Intermediate,10363,,A,10116.0,,,,50597
12026,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,10363,,A,10116.0,,,,50597
12027,1,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,10363,,A,10116.0,,,,50597
12028,1,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,,BAO_0000218,,Rattus norvegicus,,Intermediate,12504,,A,10116.0,,,,50597
12029,1,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,,BAO_0000218,,Rattus norvegicus,,Intermediate,12504,,A,10116.0,,,,50597
12030,1,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,,BAO_0000218,,Rattus norvegicus,,Intermediate,12504,,A,10116.0,,,,50597
12031,1,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,,BAO_0000218,,Rattus norvegicus,,Intermediate,12504,,A,10116.0,,,,50597
12032,1,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13317,,A,9615.0,,,,50588
12033,1,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,,A,10116.0,,,,50597
12034,1,The AUC(0-infinity) values in female wistar rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,14941,,A,10116.0,,,,50597
12035,1,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,,A,10116.0,,,,50597
12036,1,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,,A,10116.0,,,,50597
12037,1,The AUC(0-t)values in female wistar rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,14941,,A,10116.0,,,,50597
12038,1,The Area under the concentration time curve of compound was measured on rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14067,,A,10116.0,,,,50597
12039,1,The area under curve (100 mg/kg) administered orally in humans,,BAO_0000218,,Homo sapiens,,Intermediate,14215,,A,9606.0,,,,50587
12040,1,The area under curve (12.5 mg/kg) administered intravenously in marmoset,,BAO_0000218,,Callithrix,,Autocuration,14215,,A,9481.0,,,,22224
12041,1,The area under curve (12.5 mg/kg) administered intravenously in monkey,,BAO_0000218,,Simiiformes,,Autocuration,14215,,A,314293.0,,,,22224
12042,1,The area under curve (15 mg/kg) administered intravenously in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14215,,A,9615.0,,,,50588
12043,1,The area under curve (200 mg/kg) administered orally in humans,,BAO_0000218,,Homo sapiens,,Intermediate,14215,,A,9606.0,,,,50587
12044,1,The area under curve (25 mg/kg) administered intravenously in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14215,,A,10116.0,,,,50597
12045,1,The area under curve (25 mg/kg) administered orally in marmoset,,BAO_0000218,,Callithrix,,Autocuration,14215,,A,9481.0,,,,22224
12046,1,The area under curve (25 mg/kg) administered orally in monkey,,BAO_0000218,,Simiiformes,,Autocuration,14215,,A,314293.0,,,,22224
12047,1,The area under curve (30 mg/kg) administered orally in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14215,,A,9615.0,,,,50588
12048,1,The area under curve (400 mg/kg) administered orally in humans,,BAO_0000218,,Homo sapiens,,Intermediate,14215,,A,9606.0,,,,50587
12049,1,The area under curve (50 mg/kg) administered orally in fasted rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14215,,A,10116.0,,,,50597
12050,1,The area under curve (50 mg/kg) administered orally in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14215,,A,10116.0,,,,50597
12051,1,The area under curve (800 mg/kg) administered orally in humans,,BAO_0000218,,Homo sapiens,,Intermediate,14215,,A,9606.0,,,,50587
12052,1,The compound was evaluated for area under the curve,,BAO_0000019,,,,Autocuration,11324,,A,,,,,22224
12053,1,The compound was evaluated for area under the curve in marmosets,,BAO_0000019,,Callithrix,,Autocuration,11324,,A,9481.0,,,,22224
12054,1,The compound was evaluated for area under the curve in marmosets,,BAO_0000019,,Callithrix,,Autocuration,11324,,A,9481.0,,,,22224
12055,1,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13875,,A,10116.0,,,,50597
12056,1,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13875,,A,10116.0,,,,50597
12057,1,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),,BAO_0000218,,,,Autocuration,13875,,A,,,,,22224
12058,1,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13875,,A,10116.0,,,,50597
12059,1,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13875,,A,10116.0,,,,50597
12060,1,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13875,,A,10116.0,,,,50597
12061,1,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13807,,A,10116.0,,,,50597
12062,1,Total drug exposure is determined after oral dosing in rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,14127,,A,10116.0,,,,50597
12063,1,Total drug exposure (5 mg/kg) when administered intravenously,,BAO_0000218,,,,Autocuration,15116,,A,,,,,22224
12064,1,Total drug exposure (5 mg/kg) when administered orally,,BAO_0000218,,,,Autocuration,15116,,A,,,,,22224
12065,1,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,,BAO_0000218,,Simiiformes,,Autocuration,15604,,A,314293.0,,,,22224
12066,1,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15604,,A,10116.0,,,,50597
12067,1,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15604,,A,9615.0,,,,50588
12068,1,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15604,,A,9615.0,,,,50588
12069,1,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12070,1,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12071,1,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12072,1,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12073,1,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12074,1,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12075,1,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12076,1,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12077,1,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12078,1,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12079,1,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12080,1,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12081,1,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12082,1,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12083,1,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12084,1,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12085,1,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12086,1,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12087,1,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12088,1,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12089,1,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12090,1,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12091,1,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12092,1,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12093,1,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12094,1,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12095,1,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12096,1,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12097,1,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12098,1,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12099,1,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12100,1,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12101,1,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12102,1,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12103,1,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12104,1,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12105,1,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12106,1,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12107,1,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12108,1,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12109,1,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12110,1,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12111,1,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
12112,1,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
12113,1,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
12114,1,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Female gonad,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
12115,1,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Female gonad,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
12116,1,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Female gonad,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
12117,1,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,Female gonad,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
12118,1,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Female gonad,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
12119,1,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
12120,1,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
12121,1,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
12122,1,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
12123,1,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
12124,1,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
12125,1,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
12126,1,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
12127,1,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
12128,1,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
12129,1,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
12130,1,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
12131,1,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
12132,1,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
12133,1,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
12134,1,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,10911,In vivo,A,10116.0,,,,50597
12135,1,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,,BAO_0000019,,,,Autocuration,8081,,A,,,,,22224
12136,1,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),Plasma,BAO_0000218,,Macaca fascicularis,,Intermediate,17248,,A,9541.0,,,,100710
12137,1,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,Plasma,BAO_0000218,,Macaca fascicularis,,Intermediate,17248,,A,9541.0,,,,100710
12138,1,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,Plasma,BAO_0000218,,Macaca fascicularis,,Intermediate,17248,,A,9541.0,,,,100710
12139,1,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17248,,A,9615.0,,,,50588
12140,1,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17248,,A,9615.0,,,,50588
12141,1,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17248,,A,9615.0,,,,50588
12142,1,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17248,,A,9615.0,,,,50588
12143,1,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,BAO_0000218,,Canis lupus familiaris,,Intermediate,15592,,A,9615.0,,,,50588
12144,1,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,,BAO_0000019,,,,Autocuration,7040,,A,,,,,22224
12145,1,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,,BAO_0000019,,,,Autocuration,7040,,A,,,,,22224
12146,1,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,,BAO_0000019,,,,Autocuration,7040,,A,,,,,22224
12147,1,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,,BAO_0000019,,,,Autocuration,7040,,A,,,,,22224
12148,1,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,,BAO_0000019,,,,Autocuration,7040,,A,,,,,22224
12149,1,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,,BAO_0000019,,,,Autocuration,7040,,A,,,,,22224
12150,1,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,,BAO_0000019,,,,Autocuration,7040,,A,,,,,22224
12151,1,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",Adrenal medulla,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,A,9615.0,,,,50588
12152,1,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",Adrenal medulla,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,A,9615.0,,,,50588
12153,1,"Concentration of compound in blood of dog 1, after administering intravenously",Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,A,9615.0,,,,50588
12154,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12155,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12156,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12157,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12158,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12159,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12160,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12161,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12162,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12163,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12164,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12165,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12166,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12167,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12168,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12169,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12170,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12171,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12172,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12173,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12174,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12175,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12176,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12177,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12178,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12179,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12180,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12181,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12182,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12183,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12184,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12185,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12186,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12187,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12188,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12189,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12190,1,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,,BAO_0000218,,Simiiformes,,Autocuration,15604,,A,314293.0,,,,22224
12191,1,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15604,,A,10116.0,,,,50597
12192,1,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,Plasma,BAO_0000218,,,,Autocuration,1806,,A,,,,,22224
12193,1,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,Plasma,BAO_0000218,,,,Autocuration,1806,,A,,,,,22224
12194,1,AUC 0-inf in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17237,,A,9615.0,,,,50588
12195,1,AUC 0-inf in guinea pig,Plasma,BAO_0000218,,Cavia porcellus,,Intermediate,17237,,A,10141.0,,,,50512
12196,1,AUC 0-t in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,17237,,A,9615.0,,,,50588
12197,1,AUC 0-t in guinea pig,Plasma,BAO_0000218,,Cavia porcellus,,Intermediate,17237,,A,10141.0,,,,50512
12198,1,The compound was tested for brain to plasma partition in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,15194,,A,10116.0,,,,50597
12199,1,The compound was tested for brain to plasma partition in rat.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15194,,A,10116.0,,,,50597
12200,1,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,Blood,BAO_0000019,,,,Autocuration,8787,,A,,,,,22224
12201,1,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17025,,A,9615.0,,,,50588
12202,1,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,,BAO_0000218,,Simiiformes,,Autocuration,17025,,A,314293.0,,,,22224
12203,1,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,17025,,A,9986.0,,,,50592
12204,1,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,,BAO_0000218,,Rattus norvegicus,,Intermediate,17025,,A,10116.0,,,,50597
12205,1,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,,BAO_0000218,,Macaca mulatta,,Intermediate,4236,,A,9544.0,,,,50797
12206,1,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15343,,A,9615.0,,,,50588
12207,1,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,15343,,A,10116.0,,,,50597
12208,1,Area under curve of the compound was determined,,BAO_0000019,,,,Autocuration,17720,,A,,,,,22224
12209,1,AUC in monkeys at a dose of 1 mg/kg,Plasma,BAO_0000218,,Simiiformes,,Autocuration,17788,,A,314293.0,,,,22224
12210,1,AUC in rats at a dose of 1 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,17788,,A,10116.0,,,,50597
12211,1,Compound was evaluated for the overall absorbance loss at pH of 2,,BAO_0000019,,,,Autocuration,8778,,A,,,,,22224
12212,1,Compound was evaluated for the overall absorbance loss at pH of 4,,BAO_0000019,,,,Autocuration,8778,,A,,,,,22224
12213,1,Compound was evaluated for the overall absorbance loss at pH of 7,,BAO_0000019,,,,Autocuration,8778,,A,,,,,22224
12214,1,Compound was evaluated for its absorption in the rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,2249,,A,10116.0,,,,50597
12215,1,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8881,,A,10116.0,,,,50597
12216,1,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8881,,A,10116.0,,,,50597
12217,1,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8881,,A,10116.0,,,,50597
12218,1,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8881,,A,10116.0,,,,50597
12219,1,In vitro percent permeability into rat ileum,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,A,10116.0,,,,50597
12220,1,In vitro percent permeability into rat ileum; Range is 10-17,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,A,10116.0,,,,50597
12221,1,In vitro percent permeability into rat ileum; Range is 10-18,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,A,10116.0,,,,50597
12222,1,In vitro percent permeability into rat ileum; Range is 10-19,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,A,10116.0,,,,50597
12223,1,In vitro percent permeability into rat ileum; Range is 12-15,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,A,10116.0,,,,50597
12224,1,In vitro percent permeability into rat ileum; Range is 13-19,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,A,10116.0,,,,50597
12225,1,In vitro percent permeability into rat ileum; Range is 14-17,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,A,10116.0,,,,50597
12226,1,In vitro percent permeability into rat ileum; Range is 15-18,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,A,10116.0,,,,50597
12227,1,In vitro percent permeability into rat ileum; Range is 2-5,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,A,10116.0,,,,50597
12228,1,In vitro percent permeability into rat ileum; Range is 23-42,Ileum,BAO_0000221,,,,Autocuration,15286,,A,,,,,22224
12229,1,In vitro percent permeability into rat ileum; Range is 28-36,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,A,10116.0,,,,50597
12230,1,In vitro percent permeability into rat ileum; Range is 29-35,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,A,10116.0,,,,50597
12231,1,In vitro percent permeability into rat ileum; Range is 46-66,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,A,10116.0,,,,50597
12232,1,In vitro percent permeability into rat ileum; Range is 50-68,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,A,10116.0,,,,50597
12233,1,In vitro percent permeability into rat ileum; Range is 78-81,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,A,10116.0,,,,50597
12234,1,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,A,10116.0,,,,50597
12235,1,In vitro percent permeability into rat ileum; nd indicates not detected,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,A,10116.0,,,,50597
12236,1,In vitro percent permeability into rat ileum; nt indicates not detected,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,A,10116.0,,,,50597
12237,1,In vitro percent permeability into rat ileum; nt indicates not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,15286,,A,10116.0,,,,50597
12238,1,Compound was tested for oral absorption in bile-duct cannulated rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13770,,A,10116.0,,,,50597
12239,1,Compound was tested for oral absorption in bile-duct cannulated rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13770,,A,10116.0,,,,50597
12240,1,Oral absorption using Caco-2 cell monolayers.,,BAO_0000218,,Homo sapiens,,Intermediate,5202,,A,9606.0,,,,50587
12241,1,Percent of the drug absorbed after administration to humans was determined,,BAO_0000218,,Homo sapiens,,Intermediate,14920,,A,9606.0,,,,50587
12242,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12243,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12244,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12245,1,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12246,1,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12247,1,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13751,In vivo,A,10116.0,,,,50597
12248,1,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",,BAO_0000218,,Rattus norvegicus,,Intermediate,15807,,A,10116.0,,,,50597
12249,1,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,15807,,A,10116.0,,,,50597
12250,1,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,15807,,A,10116.0,,,,50597
12251,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12252,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12253,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12254,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12255,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12256,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12257,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12258,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12259,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12260,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12261,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12262,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12263,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12264,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,Prostate gland,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12265,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,Prostate gland,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12266,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12267,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12268,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12269,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12270,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12271,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12272,1,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12273,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12274,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12275,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12276,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12277,1,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,14950,,A,10116.0,,,,50597
12278,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12279,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12280,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12281,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12282,1,"Concentration of compound in blood of dog 2, after administering intravenously",Blood,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,A,9615.0,,,,50588
12283,1,"Concentration of compound in left ventricle of dog 1, after administering intravenously",,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,A,9615.0,,,,50588
12284,1,"Concentration of compound in left ventricle of dog 2, after administering intravenously",,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,A,9615.0,,,,50588
12285,1,"Concentration of compound in liver of dog 1, after administering intravenously",Liver,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,A,9615.0,,,,50588
12286,1,"Concentration of compound in liver of dog 2, after administering intravenously",Liver,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,A,9615.0,,,,50588
12287,1,"Concentration of compound in lung of dog 1, after administering intravenously",Lung,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,A,9615.0,,,,50588
12288,1,"Concentration of compound in lung of dog 2, after administering intravenously",Lung,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,A,9615.0,,,,50588
12289,1,"Concentration of compound in muscle of dog 1, after administering intravenously",Muscle tissue,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,A,9615.0,,,,50588
12290,1,"Concentration of compound in muscle of dog 2, after administering intravenously",Muscle tissue,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,A,9615.0,,,,50588
12291,1,"Concentration of compound in spleen of dog 1,after administering intravenously",Spleen,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,A,9615.0,,,,50588
12292,1,"Concentration of compound in spleen of dog 2, after administering intravenously",Spleen,BAO_0000218,,Canis lupus familiaris,,Intermediate,9614,,A,9615.0,,,,50588
12293,1,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,,BAO_0000218,,,,Autocuration,10353,,F,,,,,22224
12294,1,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,,BAO_0000218,,,,Autocuration,10353,,F,,,,,22224
12295,1,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,BAO_0000218,,,,Autocuration,10353,,A,,,,,22224
12296,1,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,,BAO_0000218,,,,Autocuration,10353,,F,,,,,22224
12297,1,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,,BAO_0000218,,,,Autocuration,10353,,F,,,,,22224
12298,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12299,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12300,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12301,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12302,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12303,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12304,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12305,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12306,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12307,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12308,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12309,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12310,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12311,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12312,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12313,1,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12314,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12315,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12316,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12317,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12318,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12319,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12320,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12321,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12322,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12323,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12324,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12325,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12326,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12327,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12328,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12329,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12330,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12331,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12332,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12333,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12334,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12335,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12336,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12337,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12338,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12339,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12340,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12341,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12342,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12343,1,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8608,,A,10116.0,,,,50597
12344,1,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,8085,,A,10116.0,,,,50597
12345,1,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,8085,,A,10116.0,,,,50597
12346,1,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,8085,,A,10116.0,,,,50597
12347,1,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8085,,A,10116.0,,,,50597
12348,1,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8085,,A,10116.0,,,,50597
12349,1,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8085,,A,10116.0,,,,50597
12350,1,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8085,,A,10116.0,,,,50597
12351,1,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8085,,A,10116.0,,,,50597
12352,1,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8085,,A,10116.0,,,,50597
12353,1,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,8085,,A,10116.0,,,,50597
12354,1,Distribution coefficient (D %) between octanol and buffer of pH 7.4,,BAO_0000100,,,,Autocuration,7657,,P,,,,,22224
12355,1,Partition coefficient (logD7.4),,BAO_0000218,,Mus musculus,,Intermediate,8935,,A,10090.0,,,,50594
12356,1,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,BAO_0000218,,Mus musculus,,Intermediate,13792,,A,10090.0,,,,50594
12357,1,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",Brain,BAO_0000218,,Mus musculus,,Intermediate,13792,,A,10090.0,,,,50594
12358,1,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,BAO_0000218,,Mus musculus,,Intermediate,13792,,A,10090.0,,,,50594
12359,1,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,Brain,BAO_0000218,,Mus musculus,,Intermediate,13792,,A,10090.0,,,,50594
12360,1,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",,BAO_0000218,,Mus musculus,,Intermediate,13792,,A,10090.0,,,,50594
12361,1,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",Brain,BAO_0000218,,Mus musculus,,Intermediate,13792,,A,10090.0,,,,50594
12362,1,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,,BAO_0000218,,Mus musculus,,Intermediate,13792,,A,10090.0,,,,50594
12363,1,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13792,,A,10116.0,,,,50597
12364,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12365,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12366,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12367,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12368,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12369,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12370,1,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12371,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12372,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12373,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12374,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12375,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12376,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12377,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12378,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12379,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12380,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12381,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12382,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12383,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12384,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12385,1,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14103,,A,10116.0,,,,50597
12386,1,Amount of acetic acid produced by the compound,,BAO_0000019,,,,Autocuration,12904,,A,,,,,22224
12387,1,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,,BAO_0000019,,,,Autocuration,12904,,A,,,,,22224
12388,1,Log of (Cbrain/Cblood) in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,9663,,A,10116.0,,,,50597
12389,1,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),,BAO_0000221,,,,Autocuration,7652,,A,,,,,22224
12390,1,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,BAO_0000221,,,,Autocuration,7652,,A,,,,,22224
12391,1,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),,BAO_0000221,,,,Autocuration,7652,,A,,,,,22224
12392,1,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),,BAO_0000219,,,,Autocuration,7652,,B,,,,,22224
12393,1,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,BAO_0000221,,,,Autocuration,7652,,A,,,,,22224
12394,1,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),,BAO_0000019,,,,Autocuration,7652,,A,,,,,22224
12395,1,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),,BAO_0000019,,,,Autocuration,7652,,A,,,,,22224
12396,1,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),,BAO_0000019,,,,Autocuration,7652,,A,,,,,22224
12397,1,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),,BAO_0000019,,,,Autocuration,7652,,A,,,,,22224
12398,1,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),,BAO_0000019,,,,Autocuration,7652,,A,,,,,22224
12399,1,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),,BAO_0000019,,,,Autocuration,7652,,A,,,,,22224
12400,1,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),,BAO_0000019,,,,Autocuration,7652,,A,,,,,22224
12401,1,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),,BAO_0000019,,,,Autocuration,7652,,A,,,,,22224
12402,1,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),,BAO_0000019,,,,Autocuration,7652,,A,,,,,22224
12403,1,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),,BAO_0000019,,,,Autocuration,7652,,A,,,,,22224
12404,1,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),,BAO_0000019,,,,Autocuration,7652,,A,,,,,22224
12405,1,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,,BAO_0000218,,,,Autocuration,8267,In vivo,F,,,,,22224
12406,1,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8267,,A,9615.0,,,,50588
12407,1,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,,BAO_0000019,,,,Autocuration,14479,,A,,,,,22224
12408,1,Compound was evaluated for total body clearance,,BAO_0000019,,,,Autocuration,17515,,A,,,,,22224
12409,1,Compound was evaluated for volume of distribution at steady state,,BAO_0000019,,,,Autocuration,17515,,A,,,,,22224
12410,1,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,,BAO_0000019,,,,Autocuration,8142,,A,,,,,22224
12411,1,Percentage of the diamine which is monoprotonated at pH 7.4,,BAO_0000019,,,,Autocuration,14849,,A,,,,,22224
12412,1,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,,BAO_0000019,,,,Autocuration,7653,,A,,,,,22224
12413,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12414,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12415,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12416,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12417,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12418,1,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12419,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12420,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12421,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12422,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12423,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12424,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12425,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12426,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12427,1,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12428,1,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12429,1,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12430,1,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12431,1,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12432,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12433,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12434,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12435,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12436,1,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8631,,A,10116.0,,,,50597
12437,1,Maximum biodistribution (Bmax) was determined.,,BAO_0000218,,,,Autocuration,10263,,A,,,,,22224
12438,1,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,,BAO_0000218,,Mus musculus,,Intermediate,12364,,A,10090.0,,,,50594
12439,1,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,,BAO_0000218,,Mus musculus,,Intermediate,12364,,A,10090.0,,,,50594
12440,1,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,,BAO_0000218,,Mus musculus,,Intermediate,12364,,A,10090.0,,,,50594
12441,1,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,,BAO_0000218,,Mus musculus,,Intermediate,12364,,A,10090.0,,,,50594
12442,1,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,,BAO_0000218,,,,Autocuration,14793,,A,,,,,22224
12443,1,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,,BAO_0000218,,,,Autocuration,14793,,A,,,,,22224
12444,1,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,,BAO_0000218,,,,Autocuration,14793,,A,,,,,22224
12445,1,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,,BAO_0000218,,,,Autocuration,14793,,A,,,,,22224
12446,1,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,,BAO_0000218,,,,Autocuration,14793,,A,,,,,22224
12447,1,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,,BAO_0000218,,,,Autocuration,14793,,A,,,,,22224
12448,1,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,,BAO_0000218,,,,Autocuration,14793,,A,,,,,22224
12449,1,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,,BAO_0000218,,,,Autocuration,14793,,A,,,,,22224
12450,1,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,,BAO_0000218,,,,Autocuration,14793,,A,,,,,22224
12451,1,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,,BAO_0000218,,,,Autocuration,14793,,A,,,,,22224
12452,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12453,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12454,1,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12455,1,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12456,1,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12457,1,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12458,1,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12459,1,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12460,1,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12461,1,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12462,1,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12463,1,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12464,1,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12465,1,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12466,1,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12467,1,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12468,1,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12469,1,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12470,1,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12471,1,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12472,1,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12473,1,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12474,1,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12475,1,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12476,1,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12477,1,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12478,1,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12479,1,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12480,1,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12481,1,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12482,1,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12483,1,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12484,1,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12485,1,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12486,1,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12487,1,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12488,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12489,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12490,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12491,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12492,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12493,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12494,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12495,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12496,1,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12023,,A,9615.0,,,,50588
12497,1,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,,BAO_0000218,,Rattus norvegicus,,Intermediate,12023,,A,10116.0,,,,50597
12498,1,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,,BAO_0000218,,Macaca fascicularis,,Intermediate,12023,,A,9541.0,,,,100710
12499,1,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,,BAO_0000100,,,,Autocuration,10580,,P,,,,,22224
12500,1,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,,BAO_0000100,,,,Autocuration,10580,,P,,,,,22224
12501,1,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,,BAO_0000019,,,,Autocuration,16032,,A,,,,,22224
12502,1,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,Urine,BAO_0000019,,,,Autocuration,16032,,A,,,,,22224
12503,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12504,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12505,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12506,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12507,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12508,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12509,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12510,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12511,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12512,1,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12513,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12514,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12515,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12516,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12517,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12518,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12519,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12520,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12521,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12522,1,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12523,1,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12524,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12525,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12526,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12527,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12528,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12529,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12530,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12531,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12532,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12533,1,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12534,1,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12535,1,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12536,1,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12537,1,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),,BAO_0000019,,,,Autocuration,7653,,A,,,,,22224
12538,1,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),,BAO_0000019,,,,Autocuration,7653,,A,,,,,22224
12539,1,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,,BAO_0000019,,,,Autocuration,7653,,A,,,,,22224
12540,1,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,,BAO_0000019,,,,Autocuration,7653,,A,,,,,22224
12541,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",,BAO_0000218,,Rattus norvegicus,,Intermediate,9104,,A,10116.0,,,,50597
12542,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",,BAO_0000218,,Rattus norvegicus,,Intermediate,9104,,A,10116.0,,,,50597
12543,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",,BAO_0000218,,Rattus norvegicus,,Intermediate,9104,,A,10116.0,,,,50597
12544,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",,BAO_0000218,,Rattus norvegicus,,Intermediate,9104,,A,10116.0,,,,50597
12545,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",,BAO_0000218,,Rattus norvegicus,,Intermediate,9104,,A,10116.0,,,,50597
12546,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",,BAO_0000218,,Rattus norvegicus,,Intermediate,9104,,A,10116.0,,,,50597
12547,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",,BAO_0000218,,Rattus norvegicus,,Intermediate,9104,,A,10116.0,,,,50597
12548,1,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",,BAO_0000218,,Rattus norvegicus,,Intermediate,9104,,A,10116.0,,,,50597
12549,1,Free level in rat plasma,,BAO_0000218,,Rattus norvegicus,,Intermediate,12902,,A,10116.0,,,,50597
12550,1,Level reaching in blood plasma of rat or human was determined,,BAO_0000019,,,,Autocuration,6614,,A,,,,,22224
12551,1,Log (Cbrain/Cblood) in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,9663,,A,10116.0,,,,50597
12552,1,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,,BAO_0000019,,,,Autocuration,17658,,A,,,,,22224
12553,1,Mean percentage of compound transport through membrane; expressed as membrane transport,,BAO_0000019,,,,Autocuration,17658,,A,,,,,22224
12554,1,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,,BAO_0000218,,,,Autocuration,14314,,A,,,,,22224
12555,1,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,,BAO_0000019,,,,Autocuration,7385,,A,,,,,22224
12556,1,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",,BAO_0000019,,,,Autocuration,7385,,A,,,,,22224
12557,1,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,,BAO_0000019,,,,Autocuration,7385,,A,,,,,22224
12558,1,Net water uptake by a carrier mediated transport (%cm) mechanism,,BAO_0000019,,,,Autocuration,1329,,A,,,,,22224
12559,1,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,,BAO_0000218,,Simiiformes,,Autocuration,12187,,A,314293.0,,,,22224
12560,1,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,,BAO_0000218,,Mustela putorius furo,,Intermediate,12187,,A,9669.0,,,,50506
12561,1,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",,BAO_0000218,,Mustela putorius furo,,Intermediate,12187,,A,9669.0,,,,50506
12562,1,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,,BAO_0000218,,Simiiformes,,Autocuration,12187,,A,314293.0,,,,22224
12563,1,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",,BAO_0000218,,Simiiformes,,Autocuration,12187,,A,314293.0,,,,22224
12564,1,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12187,,A,10116.0,,,,50597
12565,1,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,BAO_0000218,,Rattus norvegicus,,Intermediate,12187,,A,10116.0,,,,50597
12566,1,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,9278,,A,10116.0,,,,50597
12567,1,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,9278,,A,10116.0,,,,50597
12568,1,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",Plasma,BAO_0000218,,Macaca fascicularis,,Intermediate,9278,,A,9541.0,,,,100710
12569,1,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",Plasma,BAO_0000218,,Homo sapiens,,Intermediate,9278,,A,9606.0,,,,50587
12570,1,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,9278,,A,10116.0,,,,50597
12571,1,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,9278,,A,10116.0,,,,50597
12572,1,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,9278,,A,10116.0,,,,50597
12573,1,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,,BAO_0000218,,Macaca fascicularis,,Intermediate,12186,,A,9541.0,,,,100710
12574,1,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,,BAO_0000218,,Macaca fascicularis,,Intermediate,12186,,A,9541.0,,,,100710
12575,1,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,,BAO_0000218,,,,Autocuration,12186,,A,,,,,22224
12576,1,% metabolized in monkey S-9 after 2 hours (10 ug/mL),,BAO_0000019,,Simiiformes,,Autocuration,12041,,A,314293.0,,,,22224
12577,1,% metabolized in monkey S-9 after 2 hours (1 ug/ml),,BAO_0000019,,Simiiformes,,Autocuration,12041,,A,314293.0,,,,22224
12578,1,% metabolized in monkey S-9 after 2 hours (10 ug/ml),,BAO_0000019,,Simiiformes,,Autocuration,12041,,A,314293.0,,,,22224
12579,1,Permeability in Caco-2 assay at 10E-6,,BAO_0000218,,Homo sapiens,,Intermediate,6737,,A,9606.0,,,,50587
12580,1,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,Brain,BAO_0000218,,,,Autocuration,13758,,A,,,,,22224
12581,1,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,Brain,BAO_0000218,,,,Autocuration,13758,,A,,,,,22224
12582,1,Plasma protein binding was determined,,BAO_0000019,,,,Autocuration,5676,,A,,,,,22224
12583,1,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,,BAO_0000218,,,,Autocuration,14793,,A,,,,,22224
12584,1,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,,BAO_0000218,,,,Autocuration,14793,,A,,,,,22224
12585,1,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,,BAO_0000218,,,,Autocuration,14793,,A,,,,,22224
12586,1,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,,BAO_0000218,,,,Autocuration,14793,,A,,,,,22224
12587,1,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,,BAO_0000218,,,,Autocuration,14793,,A,,,,,22224
12588,1,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,,BAO_0000218,,,,Autocuration,14793,,A,,,,,22224
12589,1,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,,BAO_0000218,,,,Autocuration,14793,,A,,,,,22224
12590,1,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,,BAO_0000218,,,,Autocuration,14793,,A,,,,,22224
12591,1,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,,BAO_0000218,,,,Autocuration,14793,,A,,,,,22224
12592,1,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,,BAO_0000218,,,,Autocuration,14793,,A,,,,,22224
12593,1,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,,BAO_0000019,,,,Autocuration,14000,,A,,,,,22224
12594,1,Partition coefficient (logP),,BAO_0000019,,,,Autocuration,5948,,A,,,,,22224
12595,1,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,BAO_0000100,,,,Autocuration,13824,,P,,,,,22229
12596,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,10778,,P,,,,,22229
12597,1,C max in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17237,In vivo,A,9615.0,,,,50588
12598,1,C max in guinea pig,,BAO_0000218,,Cavia porcellus,,Intermediate,17237,In vivo,A,10141.0,,,,50512
12599,1,C max value was evaluated,,BAO_0000218,,,,Autocuration,2809,In vivo,A,,,,,22224
12600,1,Cmax value after oral dose of 0.1 mg//kg,,BAO_0000218,,,,Autocuration,11954,In vivo,A,,,,,22224
12601,1,Cmax value after oral dose of 0.3 mg/kg,,BAO_0000218,,,,Autocuration,11954,In vivo,A,,,,,22224
12602,1,Cmax value after oral dose of 1 mg/kg,,BAO_0000218,,,,Autocuration,11954,In vivo,A,,,,,22224
12603,1,Cmax value after oral dose of 10 mg/kg,,BAO_0000218,,,,Autocuration,11954,In vivo,A,,,,,22224
12604,1,Cmax value after oral dose of 23.4 mg/kg,,BAO_0000218,,,,Autocuration,11954,In vivo,A,,,,,22224
12605,1,Cmax value after oral dose of 3 mg/kg,,BAO_0000218,,,,Autocuration,11954,In vivo,A,,,,,22224
12606,1,Cmax value after oral dose of 3.87 mg/kg,,BAO_0000218,,,,Autocuration,11954,In vivo,A,,,,,22224
12607,1,Cmax value in female Beagle dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12768,In vivo,A,9615.0,,,,50588
12608,1,Cmax value in male rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,12768,In vivo,A,10116.0,,,,50597
12609,1,Cmax value in rat plasma when administered 20 mg/kg perorally,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,12780,In vivo,A,10116.0,,,,50597
12610,1,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,15592,In vivo,A,9615.0,,,,50588
12611,1,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,15592,In vivo,A,9615.0,,,,50588
12612,1,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17025,,A,9615.0,,,,50588
12613,1,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,,BAO_0000218,,Simiiformes,,Autocuration,17025,,A,314293.0,,,,22224
12614,1,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,17025,,A,9986.0,,,,50592
12615,1,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,,BAO_0000218,,Rattus norvegicus,,Intermediate,17025,,A,10116.0,,,,50597
12616,1,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,Plasma,BAO_0000218,,Macaca mulatta,,Intermediate,4236,,A,9544.0,,,,50797
12617,1,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,15791,,A,10116.0,,,,50597
12618,1,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,,BAO_0000019,,,,Autocuration,11149,,A,,,,,22224
12619,1,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",,BAO_0000218,,Canis lupus familiaris,,Intermediate,15592,,A,9615.0,,,,50588
12620,1,cytotoxicity against HIV protease enzyme.,,BAO_0000218,,Human immunodeficiency virus,,Intermediate,15778,,A,12721.0,,,,50677
12621,1,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,,BAO_0000218,,Mus musculus,,Intermediate,12745,,A,10090.0,,,,50594
12622,1,Apparent clearance in mice after oral administration of 100 mg/kg of dose,,BAO_0000218,,Mus musculus,,Intermediate,12745,,A,10090.0,,,,50594
12623,1,The plasma clearance in dog.,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,13941,In vivo,A,9615.0,,,,50588
12624,1,The plasma clearance in rat.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13941,In vivo,A,10116.0,,,,50597
12625,1,Clearance from plasma in male Sprague-Dawley rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,16449,In vivo,A,10116.0,,,,50597
12626,1,Clearance from plasma in male cynomolgus monkeys,Plasma,BAO_0000218,,Macaca fascicularis,,Intermediate,16449,In vivo,A,9541.0,,,,100710
12627,1,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14224,In vivo,A,9615.0,,,,50588
12628,1,Clearance of compound in dog plasma,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14224,In vivo,A,9615.0,,,,50588
12629,1,Clearance of compound in human plasma,Plasma,BAO_0000218,,Homo sapiens,,Intermediate,14224,In vivo,A,9606.0,,,,50587
12630,1,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14317,In vivo,A,9615.0,,,,50588
12631,1,Clearance of compound when administered intravenously as an individual dose to a single dog.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14317,In vivo,A,9615.0,,,,50588
12632,1,"Clearance (10 mg/kg, intravenously) in dog plasma",Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14224,In vivo,A,9615.0,,,,50588
12633,1,Clearance value in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17237,In vivo,A,9615.0,,,,50588
12634,1,Clearance value in guinea pig,,BAO_0000218,,Cavia porcellus,,Intermediate,17237,In vivo,A,10141.0,,,,50512
12635,1,Clearance values in rats after iv administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,14187,In vivo,A,10116.0,,,,50597
12636,1,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,Plasma,BAO_0000218,,,,Autocuration,4806,In vivo,A,,,,,22224
12637,1,In vivo clearance (5 mg/kg) was determined in rabbits,,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,15025,In vivo,A,9986.0,,,,50592
12638,1,Plasma Clearance rate was determined for the compound in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13197,In vivo,A,10116.0,,,,50597
12639,1,Plasma Clearance rate was determined for the compound in squirrel monkeys,,BAO_0000218,,Saimiri,,Autocuration,13197,In vivo,A,9520.0,,,,22224
12640,1,Plasma clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13960,In vivo,A,10116.0,,,,50597
12641,1,Plasma clearance of the compound,,BAO_0000218,,,,Autocuration,17820,In vivo,A,,,,,22224
12642,1,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,,BAO_0000218,,Cavia porcellus,,Intermediate,14706,In vivo,A,10141.0,,,,50512
12643,1,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,,BAO_0000218,,Cavia porcellus,,Intermediate,14706,In vivo,A,10141.0,,,,50512
12644,1,Plasma clearance was determined,,BAO_0000218,,,,Autocuration,6504,In vivo,A,,,,,22224
12645,1,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14925,In vivo,A,9615.0,,,,50588
12646,1,Plasma clearance rate was determined for the compound in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13197,In vivo,A,10116.0,,,,50597
12647,1,Plasma clearance rate was determined for the compound in squirrel monkeys,,BAO_0000218,,Saimiri,,Autocuration,13197,In vivo,A,9520.0,,,,22224
12648,1,Slow clearance (CL) was determined,,BAO_0000218,,,,Autocuration,3437,In vivo,A,,,,,22224
12649,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12650,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12651,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12652,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12653,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12654,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12655,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12656,1,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12657,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12658,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12659,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12660,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12661,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12662,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12663,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12664,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12665,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12666,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12667,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12668,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12669,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12670,1,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,,BAO_0000218,,,,Autocuration,9196,,A,,,,,22224
12671,1,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12672,1,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8374,,A,10116.0,,,,50597
12673,1,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,A,10116.0,,,,50597
12674,1,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,A,10116.0,,,,50597
12675,1,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,A,10116.0,,,,50597
12676,1,Distribution of compound in mice brain was measured after 1 hr,Brain,BAO_0000218,,Mus musculus,,Intermediate,10009,,A,10090.0,,,,50594
12677,1,Distribution of compound in mice brain was measured after 24 hr r,Brain,BAO_0000218,,Mus musculus,,Intermediate,10009,,A,10090.0,,,,50594
12678,1,Distribution of compound in mice brain was measured after 2 hr,Brain,BAO_0000218,,Mus musculus,,Intermediate,10009,,A,10090.0,,,,50594
12679,1,Distribution of compound in mice brain was measured after 3 hr,Brain,BAO_0000218,,Mus musculus,,Intermediate,10009,,A,10090.0,,,,50594
12680,1,Distribution of compound in mice brain was measured after 6 hr,Brain,BAO_0000218,,Mus musculus,,Intermediate,10009,,A,10090.0,,,,50594
12681,1,Distribution of compound in mice liver was measured after 1 hr,,BAO_0000218,,Mus musculus,,Intermediate,10009,,A,10090.0,,,,50594
12682,1,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,,BAO_0000218,,Mus musculus,,Intermediate,10009,,A,10090.0,,,,50594
12683,1,Distribution of compound in mice liver was measured after 2 hr,,BAO_0000218,,Mus musculus,,Intermediate,10009,,A,10090.0,,,,50594
12684,1,Distribution of compound in mice liver was measured after 3 hr,,BAO_0000218,,Mus musculus,,Intermediate,10009,,A,10090.0,,,,50594
12685,1,Distribution of compound in mice liver was measured after 6 hr,,BAO_0000218,,Mus musculus,,Intermediate,10009,,A,10090.0,,,,50594
12686,1,Distribution in dog adrenal medulla 30 min after administration.,Adrenal medulla,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12687,1,Distribution in dog adrenal medulla 72 hours after administration.,Adrenal medulla,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12688,1,Distribution in female dog Ovary 24 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12689,1,Distribution in female dog Ovary 72 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12690,1,Distribution in female dog adipose 24 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12691,1,Distribution in female dog adipose 72 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12692,1,Distribution in female dog adrenal cortex 72 hours after administration.,Adrenal cortex,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12693,1,Distribution in female dog adrenal cortex 72 hours after administration.,Adrenal cortex,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12694,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12695,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12696,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12697,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12698,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12699,1,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12700,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12701,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12702,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12703,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12704,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12705,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12706,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12707,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12708,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12709,1,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12710,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12711,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12712,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12713,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12714,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12715,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12716,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12717,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12718,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12719,1,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12720,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12721,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12722,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12723,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12724,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12725,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12726,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12727,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12728,1,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12729,1,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12730,1,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12731,1,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12732,1,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12733,1,Rate of acetate production by the compound was determined,,BAO_0000019,,,,Autocuration,12904,,A,,,,,22224
12734,1,Rate of acetate production by the compound was determined; Not determined,,BAO_0000019,,,,Autocuration,12904,,A,,,,,22224
12735,1,Rate of hydrolysis of nitrocefin by compound was evaluated in water,,BAO_0000019,,,,Autocuration,3730,,A,,,,,22224
12736,1,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,,BAO_0000019,,,,Autocuration,3627,,A,,,,,22224
12737,1,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,13799,,A,9986.0,,,,50592
12738,1,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,Plasma,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,13799,,A,9986.0,,,,50592
12739,1,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,,BAO_0000218,,Mus musculus,,Intermediate,13799,,A,10090.0,,,,50594
12740,1,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,13799,,A,10116.0,,,,50597
12741,1,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13799,,A,10116.0,,,,50597
12742,1,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13799,,A,10116.0,,,,50597
12743,1,Solubility after at a pH 1.2,,BAO_0000100,,,,Autocuration,6629,,P,,,,,22229
12744,1,Solubility after at pH 1.2,,BAO_0000100,,,,Autocuration,6629,,P,,,,,22229
12745,1,Solubility after injection of water,,BAO_0000100,,,,Autocuration,6629,,P,,,,,22229
12746,1,Statistical significance of IC 50 values; Expressed as R value,,BAO_0000019,,,,Autocuration,14000,,A,,,,,22224
12747,1,Systemic availability with respect to methyldopa was determined,,BAO_0000019,,,,Autocuration,8267,,A,,,,,22224
12748,1,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,13799,,A,10116.0,,,,50597
12749,1,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,13799,,A,10116.0,,,,50597
12750,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12751,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12752,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12753,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12754,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12755,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12756,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12757,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12758,1,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",Kidney,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12759,1,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12760,1,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12761,1,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12762,1,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12763,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12764,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12765,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12766,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12767,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12768,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12769,1,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12770,1,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",Kidney,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12771,1,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12772,1,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12773,1,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12774,1,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12775,1,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12776,1,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13317,In vivo,A,9615.0,,,,50588
12777,1,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15341,In vivo,A,9615.0,,,,50588
12778,1,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15341,In vivo,A,10116.0,,,,50597
12779,1,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15341,In vivo,A,10116.0,,,,50597
12780,1,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15341,In vivo,A,10116.0,,,,50597
12781,1,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,esophageal tunica muscularis mucosae,BAO_0000218,,Rattus norvegicus,,Intermediate,12801,In vitro,A,10116.0,,,,50597
12782,1,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,esophageal tunica muscularis mucosae,BAO_0000218,,Rattus norvegicus,,Intermediate,12801,In vitro,A,10116.0,,,,50597
12783,1,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14856,In vivo,A,10116.0,,,,50597
12784,1,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14062,In vivo,A,10116.0,,,,50597
12785,1,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14062,In vivo,A,10116.0,,,,50597
12786,1,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14062,In vivo,A,10116.0,,,,50597
12787,1,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14062,In vivo,A,10116.0,,,,50597
12788,1,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14346,In vivo,A,9615.0,,,,50588
12789,1,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,In vivo,A,10116.0,,,,50597
12790,1,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,In vivo,A,10116.0,,,,50597
12791,1,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,In vivo,A,10116.0,,,,50597
12792,1,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,In vivo,A,10116.0,,,,50597
12793,1,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14346,In vivo,A,9615.0,,,,50588
12794,1,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14346,In vivo,A,10116.0,,,,50597
12795,1,plasma clearance in human,Plasma,BAO_0000218,,Homo sapiens,,Intermediate,15711,In vivo,A,9606.0,,,,50587
12796,1,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,14886,In vivo,A,10116.0,,,,50597
12797,1,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,14886,In vivo,A,10116.0,,,,50597
12798,1,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,14886,In vivo,A,10116.0,,,,50597
12799,1,1-Octanol/water partition coefficient measured at 7.4,,BAO_0000100,,,,Autocuration,4115,,P,,,,,22229
12800,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,13733,,P,,,,,22229
12801,1,Partition coefficient (logP),,BAO_0000019,,,,Autocuration,12102,,A,,,,,22224
12802,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,12676,,P,,,,,22229
12803,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,13733,,P,,,,,22229
12804,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,13740,,P,,,,,22229
12805,1,Calculated partition coefficient (clogP) (relative to BAY K 8644),,BAO_0000100,,,,Autocuration,12766,,P,,,,,22229
12806,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,2764,,P,,,,,22229
12807,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,12355,,P,,,,,22229
12808,1,Calculated partition coefficient of the compound,,BAO_0000100,,,,Autocuration,11314,,P,,,,,22229
12809,1,Partition coefficient (logP),,BAO_0000019,,,,Autocuration,12706,,A,,,,,22224
12810,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,12645,,P,,,,,22229
12811,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,13668,,P,,,,,22229
12812,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,12819,,P,,,,,22229
12813,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,13668,,P,,,,,22229
12814,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,13017,,P,,,,,22229
12815,1,Partition coefficient of the compound,,BAO_0000019,,,,Autocuration,2448,,A,,,,,22224
12816,1,Partition coefficient of the compound,,BAO_0000019,,,,Autocuration,11526,,A,,,,,22224
12817,1,Partition coefficient of compound was determined,,BAO_0000019,,,,Autocuration,12426,,A,,,,,22224
12818,1,Partition coefficient was determined,,BAO_0000019,,,,Autocuration,2448,,A,,,,,22224
12819,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,12001,,P,,,,,22229
12820,1,partition coefficient of compound was determined,,BAO_0000100,,,,Autocuration,12426,,P,,,,,22229
12821,1,The total body administered intravenously in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13204,In vivo,A,9615.0,,,,50588
12822,1,The total body administered intravenously in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13204,In vivo,A,10116.0,,,,50597
12823,1,Time taken for the administration to female NIH mice weighing 25-30 g.,,BAO_0000218,,Mus musculus,,Intermediate,13889,,A,10090.0,,,,50594
12824,1,Time taken for the administration,,BAO_0000019,,,,Autocuration,13889,,A,,,,,22224
12825,1,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,17025,In vivo,A,9615.0,,,,50588
12826,1,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,,BAO_0000218,,Simiiformes,,Autocuration,17025,In vivo,A,314293.0,,,,22224
12827,1,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,17025,In vivo,A,9986.0,,,,50592
12828,1,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,,BAO_0000218,,Rattus norvegicus,,Intermediate,17025,In vivo,A,10116.0,,,,50597
12829,1,Plasma clearance for the compound was determined.,,BAO_0000019,,,,Autocuration,15067,,A,,,,,22224
12830,1,CLog P value of the compound,,BAO_0000100,,,,Autocuration,3091,,P,,,,,22224
12831,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,15592,,P,,,,,22229
12832,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,14738,,P,,,,,22229
12833,1,ClogP value of the compound; nd ='no data',,BAO_0000100,,,,Autocuration,14738,,P,,,,,22224
12834,1,ClogP value of the compound; nd ='not determined',,BAO_0000100,,,,Autocuration,14738,,P,,,,,22224
12835,1,CLog P was determined,,BAO_0000100,,,,Autocuration,6076,,P,,,,,22224
12836,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,17840,,P,,,,,22229
12837,1,CLogP was calculated,,BAO_0000019,,,,Autocuration,13589,,A,,,,,22224
12838,1,CLogP value was determined,,BAO_0000019,,,,Autocuration,17655,,A,,,,,22224
12839,1,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,,BAO_0000019,,,,Autocuration,5867,,A,,,,,22224
12840,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,5867,,P,,,,,22229
12841,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,10783,,P,,,,,22229
12842,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,14849,,P,,,,,22229
12843,1,Distribution in female dog adrenal medulla 24 hours after administration.,Adrenal medulla,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12844,1,Distribution in female dog adrenal medulla 72 hours after administration.,Adrenal medulla,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12845,1,Distribution in female dog bile 24 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12846,1,Distribution in female dog bile 72 hr after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12847,1,Distribution in female dog blood 24 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12848,1,Distribution in female dog blood 72 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12849,1,Distribution in female dog heart 24 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12850,1,Distribution in female dog heart 72 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12851,1,Distribution in female dog kidney 24 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12852,1,Distribution in female dog kidney 72 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12853,1,Distribution in female dog large intestine 24 hours after administration.,Intestine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12854,1,Distribution in female dog large intestine 72 hours after administration.,Intestine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12855,1,Distribution in female dog liver 24 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12856,1,Distribution in female dog liver 72 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12857,1,Distribution in female dog lung 24 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12858,1,Distribution in female dog lung 72 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12859,1,Distribution in female dog muscle 24 hours after administration.,Muscle tissue,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12860,1,Distribution in female dog muscle 72 hours after administration.,Muscle tissue,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12861,1,Distribution in female dog pancreas 24 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12862,1,Distribution in female dog pancreas 72 hours after administration.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12863,1,Distribution in female dog small intestine 24 hours after administration.,Intestine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12864,1,Distribution in female dog small intestine 72 hours after administration.,Intestine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12865,1,Distribution in female dog spleen 24 hours after administration.,Spleen,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12866,1,Distribution in female dog spleen 72 hours after administration.,Spleen,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12867,1,Distribution in female dog stomach 24 hours after administration.,Stomach,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12868,1,Distribution in female dog stomach 72 hours after administration.,Stomach,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12869,1,Distribution in female dog thyroid 24 hours after administration.,Thyroid gland,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12870,1,Distribution in female dog thyroid 72 hours after administration.,Thyroid gland,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12871,1,Distribution in female dog urine 24 hours after administration.,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12872,1,Distribution in female dog urine 72 hr after administration.,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8170,,A,9615.0,,,,50588
12873,1,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,Plasma,BAO_0000218,,,,Autocuration,14283,,A,,,,,22224
12874,1,Plasma concentration at 7 hr after intravenous dosing,,BAO_0000019,,,,Autocuration,5623,,A,,,,,22224
12875,1,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,A,10116.0,,,,50597
12876,1,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,A,10116.0,,,,50597
12877,1,Plasma concentration of 3 mg/kg iv after 1 hr in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,A,10116.0,,,,50597
12878,1,Plasma concentration of 3 mg/kg iv after 2 hr in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,A,10116.0,,,,50597
12879,1,Plasma concentration of 3 mg/kg iv after 4 hr in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,A,10116.0,,,,50597
12880,1,Plasma concentration of 3 mg/kg iv after 6 hr in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,A,10116.0,,,,50597
12881,1,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,A,10116.0,,,,50597
12882,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,A,10116.0,,,,50597
12883,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,A,10116.0,,,,50597
12884,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,A,10116.0,,,,50597
12885,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,A,10116.0,,,,50597
12886,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,A,10116.0,,,,50597
12887,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,A,10116.0,,,,50597
12888,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,A,10116.0,,,,50597
12889,1,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,,A,10116.0,,,,50597
12890,1,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,,BAO_0000019,,,,Autocuration,12553,,A,,,,,22224
12891,1,The concentration in plasmat; Not determined,Plasma,BAO_0000019,,,,Autocuration,14548,,A,,,,,22224
12892,1,Tissue level at 10 mg/kg/po in wistar rats in blood,,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,,A,10116.0,,,,50597
12893,1,Tissue level at 10 mg/kg/po in wistar rats in brown fat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,,A,10116.0,,,,50597
12894,1,Tissue level at 10 mg/kg/po in wistar rats in heart,,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,,A,10116.0,,,,50597
12895,1,Tissue level at 10 mg/kg/po in wistar rats in liver,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,,A,10116.0,,,,50597
12896,1,Tissue level at 10 mg/kg/po in wistar rats in plasma,,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,,A,10116.0,,,,50597
12897,1,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,,A,10116.0,,,,50597
12898,1,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,,A,10116.0,,,,50597
12899,1,Water solubility at 37 degree C.,,BAO_0000019,,,,Autocuration,1629,,A,,,,,22224
12900,1,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,BAO_0000100,,,,Autocuration,8194,,P,,,,,22229
12901,1,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,BAO_0000100,,,,Autocuration,8194,,P,,,,,22229
12902,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12903,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12904,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12905,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12906,1,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12907,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12908,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12909,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12910,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12911,1,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12912,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12913,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12914,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12915,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12916,1,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12917,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12918,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12919,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12920,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12921,1,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12922,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12923,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12924,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12925,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12926,1,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12927,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12928,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12929,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12930,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12931,1,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12932,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12933,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12934,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12935,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12936,1,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,,BAO_0000218,,Rattus norvegicus,,Intermediate,8594,,A,10116.0,,,,50597
12937,1,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,,BAO_0000019,,,,Autocuration,8151,,A,,,,,22224
12938,1,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,BAO_0000019,,,,Autocuration,8151,,A,,,,,22224
12939,1,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12940,1,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
12941,1,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),,BAO_0000019,,,,Autocuration,5797,,A,,,,,22224
12942,1,Alkylating activity was determined,,BAO_0000019,,,,Autocuration,7849,,A,,,,,22224
12943,1,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),,BAO_0000251,,,,Autocuration,14220,,A,,,,Microsomes,22224
12944,1,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,8650,,A,9986.0,,,,50592
12945,1,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,8650,,A,9986.0,,,,50592
12946,1,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,8650,,A,9986.0,,,,50592
12947,1,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,8650,,A,9986.0,,,,50592
12948,1,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,8650,,A,9986.0,,,,50592
12949,1,Compound was tested for antidiuretic activity in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,7116,,A,10116.0,,,,50597
12950,1,Compound was tested for inactivation kinetic values,,BAO_0000019,,,,Autocuration,14131,,A,,,,,22224
12951,1,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,,BAO_0000218,,,,Autocuration,7415,In vivo,A,,,,,22224
12952,1,Dissociation rate calculated from the first-order equation using the t1/2 value,,BAO_0000019,,,,Autocuration,13178,,A,,,,,22224
12953,1,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,,BAO_0000100,,,,Autocuration,8815,,P,,,,,22229
12954,1,Aqueous solubility was measured,,BAO_0000100,,,,Autocuration,1450,,P,,,,,22229
12955,1,Aqueous solubility was measured at a pH 4,,BAO_0000100,,,,Autocuration,1450,,P,,,,,22229
12956,1,Aqueous solubility (pH 7),,BAO_0000100,,,,Autocuration,1450,,P,,,,,22229
12957,1,Aqueous solubility was measured at a pH 9,,BAO_0000100,,,,Autocuration,1450,,P,,,,,22229
12958,1,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",,BAO_0000019,,,,Autocuration,12711,,A,,,,,22224
12959,1,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,BAO_0000019,,,,Autocuration,12711,,A,,,,,22224
12960,1,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",,BAO_0000019,,,,Autocuration,12711,,A,,,,,22224
12961,1,Aqueous solubility of the compound,,BAO_0000100,,,,Autocuration,15032,,P,,,,,22229
12962,1,Aqueous solubility at 37 degree Celsius at pH 7.38,,BAO_0000100,,,,Autocuration,9964,,P,,,,,22229
12963,1,Aqueous solubility in pH 7.4 phosphate buffer,,BAO_0000100,,,,Autocuration,14962,,P,,,,,22229
12964,1,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12487,,A,9615.0,,,,50588
12965,1,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12487,,A,9615.0,,,,50588
12966,1,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,,BAO_0000218,,Homo sapiens,,Intermediate,10026,,A,9606.0,,,,50587
12967,1,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,,BAO_0000218,,Homo sapiens,,Intermediate,10026,,A,9606.0,,,,50587
12968,1,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,,BAO_0000218,,Homo sapiens,,Intermediate,10026,,A,9606.0,,,,50587
12969,1,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,,BAO_0000218,,Homo sapiens,,Intermediate,10026,,A,9606.0,,,,50587
12970,1,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,,BAO_0000218,,Homo sapiens,,Intermediate,10026,,A,9606.0,,,,50587
12971,1,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,,BAO_0000019,,,,Autocuration,10026,,A,,,,,22224
12972,1,Compound was evaluated for the average bile flow rat in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,7415,,A,10116.0,,,,50597
12973,1,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,17025,,A,9986.0,,,,50592
12974,1,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,17025,,A,9986.0,,,,50592
12975,1,Average half life period was determined,,BAO_0000019,,,,Autocuration,10184,,A,,,,,22224
12976,1,Average half life period was determined,,BAO_0000019,,,,Autocuration,10184,,A,,,,,22224
12977,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
12978,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
12979,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
12980,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
12981,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
12982,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
12983,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
12984,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
12985,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
12986,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,6030,,P,,,,,22229
12987,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,6147,,P,,,,,22229
12988,1,Calculated partition coefficient (clogP) (MacLogP),,BAO_0000100,,,,Autocuration,14556,,P,,,,,22229
12989,1,Hydrophilicity was determined,,BAO_0000019,,,,Autocuration,768,,A,,,,,22224
12990,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,14452,,P,,,,,22229
12991,1,Increased absorption was determined,,BAO_0000019,,,,Autocuration,5237,,A,,,,,22224
12992,1,Lipophilicity value was evaluated,,BAO_0000100,,,,Autocuration,14378,,P,,,,,22224
12993,1,Log P value of the compound.,,BAO_0000100,,,,Autocuration,14418,,P,,,,,22224
12994,1,Partition coefficient of compound was determined,,BAO_0000019,,,,Autocuration,5249,,A,,,,,22224
12995,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,14621,,P,,,,,22229
12996,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,12542,,P,,,,,22229
12997,1,Partition coefficient was measured by medchem software; Not calculated,,BAO_0000019,,,,Autocuration,12542,,A,,,,,22224
12998,1,Partition coefficient was measured by octanol-water using standard shake-flask method,,BAO_0000100,,,,Autocuration,12542,,P,,,,,22224
12999,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,15462,,P,,,,,22229
13000,1,Partition coefficient (logP),,BAO_0000019,,,,Autocuration,14884,,A,,,,,22224
13001,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,16526,,P,,,,,22229
13002,1,The Octanol/Water partition coefficient CLogP,,BAO_0000100,,,,Autocuration,13693,,P,,,,,22229
13003,1,The pharmacokinetic parameter C Log p was reported,,BAO_0000019,,,,Autocuration,13693,,A,,,,,22224
13004,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,13779,,P,,,,,22229
13005,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,14772,,P,,,,,22229
13006,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,14393,,P,,,,,22229
13007,1,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,In vivo,A,10116.0,,,,50597
13008,1,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,In vivo,A,10116.0,,,,50597
13009,1,Compound was administered intravenously in dog to evaluate plasma clearance values,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,13744,In vivo,A,9615.0,,,,50588
13010,1,Compound was administered intravenously in monkey to evaluate plasma clearance values,Plasma,BAO_0000218,,Simiiformes,,Autocuration,13744,In vivo,A,314293.0,,,,22224
13011,1,Compound was administered intravenously in mouse to evaluate plasma clearance values,Plasma,BAO_0000218,,Mus musculus,,Intermediate,13744,In vivo,A,10090.0,,,,50594
13012,1,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,13207,In vivo,A,9615.0,,,,50588
13013,1,Intrinsic clearance in Rhesus liver microsome,Liver,BAO_0000218,,Macaca mulatta,,Intermediate,5669,In vitro,A,9544.0,,,Microsomes,50797
13014,1,Intrinsic clearance in dog liver microsome,Liver,BAO_0000218,,Canis lupus familiaris,,Intermediate,5669,In vitro,A,9615.0,,,Microsomes,50588
13015,1,Intrinsic clearance in rat liver microsome,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,5669,In vitro,A,10116.0,,,Microsomes,50597
13016,1,Low plasma clearance was calculated in rhesus monkey,Plasma,BAO_0000218,,Macaca mulatta,,Intermediate,4853,In vivo,A,9544.0,,,,50797
13017,1,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,BAO_0000218,,Canis lupus familiaris,,Intermediate,16452,In vivo,A,9615.0,,,,50588
13018,1,Plasma clearance after intravenous dose of 0.3 mg/kg,,BAO_0000218,,,,Autocuration,11954,In vivo,A,,,,,22224
13019,1,Plasma clearance after intravenous dose of 1 mg/kg,,BAO_0000218,,,,Autocuration,11954,In vivo,A,,,,,22224
13020,1,Plasma clearance after intravenous dose of 3 mg/kg,,BAO_0000218,,,,Autocuration,11954,In vivo,A,,,,,22224
13021,1,Plasma clearance after intravenous dose of 3.87 mg/kg,,BAO_0000218,,,,Autocuration,11954,In vivo,A,,,,,22224
13022,1,Plasma clearance after peroral administration at 10 mpk in Rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5669,In vivo,A,10116.0,,,,50597
13023,1,Plasma clearance after peroral administration at 10 mpk in Rhesus,,BAO_0000218,,Macaca mulatta,,Intermediate,5669,In vivo,A,9544.0,,,,50797
13024,1,Plasma clearance after peroral administration at 10 mpk in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5669,In vivo,A,9615.0,,,,50588
13025,1,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13662,In vivo,A,10116.0,,,,50597
13026,1,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),,BAO_0000019,,,,Autocuration,8272,,A,,,,,22224
13027,1,Critical Micellar concentration was determined,,BAO_0000019,,,,Autocuration,13410,,A,,,,,22224
13028,1,Critical Micellar concentration of the compound. was determined,,BAO_0000019,,,,Autocuration,13410,,A,,,,,22224
13029,1,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,,BAO_0000019,,,,Autocuration,12628,,A,,,,,22224
13030,1,Critical micellar concentration was measured in water by the dye solubilization method,,BAO_0000019,,,,Autocuration,9675,,A,,,,,22224
13031,1,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,,BAO_0000019,,,,Autocuration,12628,,B,,,,,22224
13032,1,CMR value (relative to BAY K 8644),,BAO_0000019,,,,Autocuration,12766,,A,,,,,22224
13033,1,Carbamoylating activity was determined,,BAO_0000019,,,,Autocuration,7849,,A,,,,,22224
13034,1,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,,BAO_0000218,,Simiiformes,,Autocuration,12187,,A,314293.0,,,,22224
13035,1,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,,BAO_0000019,,,,Autocuration,2040,,A,,,,,22224
13036,1,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,,BAO_0000019,,,,Autocuration,2040,,A,,,,,22224
13037,1,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,14180,In vivo,A,9615.0,,,,50588
13038,1,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14180,In vivo,A,10116.0,,,,50597
13039,1,"Clearance rate at 0.46 mg/kg, iv, in dogs",,BAO_0000218,,Canis lupus familiaris,,Intermediate,14474,In vivo,A,9615.0,,,,50588
13040,1,"Clearance rate at 5.5 mg/kg, iv, in rat",,BAO_0000218,,Rattus norvegicus,,Intermediate,14474,In vivo,A,10116.0,,,,50597
13041,1,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,,BAO_0000218,,Macaca fascicularis,,Intermediate,14548,In vivo,A,9541.0,,,,100710
13042,1,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,,BAO_0000218,,Macaca fascicularis,,Intermediate,14548,In vivo,A,9541.0,,,,100710
13043,1,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,14548,In vivo,A,9615.0,,,,50588
13044,1,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,14548,In vivo,A,10116.0,,,,50597
13045,1,Clearance rate constant using isolated perfused rat liver (IPRL) assay,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,6125,Ex vivo,A,10116.0,,,,50597
13046,1,Tested for the total clearance of the compound,,BAO_0000218,,,,Autocuration,6874,In vivo,A,,,,,22224
13047,1,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,,BAO_0000218,,Canis lupus familiaris,,Intermediate,15343,In vivo,A,9615.0,,,,50588
13048,1,Total body clearance was determined,,BAO_0000218,,,,Autocuration,6236,In vivo,A,,,,,22224
13049,1,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13050,1,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13051,1,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,BAO_0000100,,,,Autocuration,8194,,P,,,,,22229
13052,1,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,BAO_0000100,,,,Autocuration,8194,,P,,,,,22229
13053,1,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,,BAO_0000100,,,,Autocuration,8194,,P,,,,,22229
13054,1,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,,BAO_0000100,,,,Autocuration,8194,,P,,,,,22229
13055,1,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,,BAO_0000100,,,,Autocuration,8194,,P,,,,,22229
13056,1,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,,BAO_0000100,,,,Autocuration,8194,,P,,,,,22229
13057,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),,BAO_0000218,,Pneumocystis carinii,,Intermediate,13273,,A,4754.0,,,,50339
13058,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,,BAO_0000218,,Pneumocystis carinii,,Intermediate,13273,,A,4754.0,,,,50339
13059,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,,BAO_0000218,,Pneumocystis carinii,,Intermediate,13273,,A,4754.0,,,,50339
13060,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,,BAO_0000218,,Pneumocystis carinii,,Intermediate,13273,,A,4754.0,,,,50339
13061,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,,BAO_0000218,,Pneumocystis carinii,,Intermediate,13273,,A,4754.0,,,,50339
13062,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,,BAO_0000218,,Pneumocystis carinii,,Intermediate,13273,,A,4754.0,,,,50339
13063,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),,BAO_0000218,,Pneumocystis carinii,,Intermediate,13273,,A,4754.0,,,,50339
13064,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),,BAO_0000218,,Pneumocystis carinii,,Intermediate,13273,,A,4754.0,,,,50339
13065,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),,BAO_0000218,,Pneumocystis carinii,,Intermediate,13273,,A,4754.0,,,,50339
13066,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),,BAO_0000218,,Pneumocystis carinii,,Intermediate,13273,,A,4754.0,,,,50339
13067,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),,BAO_0000218,,Pneumocystis carinii,,Intermediate,13273,,A,4754.0,,,,50339
13068,1,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),,BAO_0000218,,Pneumocystis carinii,,Intermediate,13273,,A,4754.0,,,,50339
13069,1,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,,BAO_0000019,,,,Autocuration,13118,,A,,,,,22224
13070,1,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,,BAO_0000019,,,,Autocuration,13118,,A,,,,,22224
13071,1,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,,BAO_0000019,,,,Autocuration,13118,,A,,,,,22224
13072,1,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,,BAO_0000019,,,,Autocuration,13118,,A,,,,,22224
13073,1,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,,BAO_0000019,,,,Autocuration,13118,,A,,,,,22224
13074,1,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,,BAO_0000019,,,,Autocuration,13118,,A,,,,,22224
13075,1,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",,BAO_0000218,,Rattus norvegicus,,Intermediate,10633,,A,10116.0,,,,50597
13076,1,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",,BAO_0000218,,Rattus norvegicus,,Intermediate,10633,,A,10116.0,,,,50597
13077,1,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",,BAO_0000218,,Rattus norvegicus,,Intermediate,10633,,A,10116.0,,,,50597
13078,1,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",,BAO_0000218,,Rattus norvegicus,,Intermediate,10633,,A,10116.0,,,,50597
13079,1,Cp max following ip administration at 1 mg/kg,,BAO_0000218,,,,Autocuration,5767,,A,,,,,22224
13080,1,Maximum concentration in plasma was reported at 0.5 hour,Plasma,BAO_0000218,,,,Autocuration,3302,In vivo,A,,,,,22224
13081,1,Maximum concentration in plasma was reported at 2 hour,Plasma,BAO_0000218,,,,Autocuration,3302,In vivo,A,,,,,22224
13082,1,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,,BAO_0000218,,Mus musculus,,Intermediate,12467,,A,10090.0,,,,50594
13083,1,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),,BAO_0000100,,,,Autocuration,11778,,P,,,,,22229
13084,1,Steady state concentration was evaluated,,BAO_0000019,,,,Autocuration,4321,,A,,,,,22224
13085,1,Partition coefficient (logP),,BAO_0000019,,,,Autocuration,14884,,A,,,,,22224
13086,1,Partition coefficient (logD7.4),,BAO_0000019,,,,Autocuration,15234,,A,,,,,22224
13087,1,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13088,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13089,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13090,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13091,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13092,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13093,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13094,1,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,BAO_0000019,,,,Autocuration,8151,,A,,,,,22224
13095,1,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,BAO_0000019,,,,Autocuration,8151,,A,,,,,22224
13096,1,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,Urine,BAO_0000019,,,,Autocuration,8151,,A,,,,,22224
13097,1,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,Urine,BAO_0000019,,,,Autocuration,8151,,A,,,,,22224
13098,1,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,Urine,BAO_0000019,,,,Autocuration,8151,,A,,,,,22224
13099,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,,BAO_0000218,,Rattus norvegicus,,Intermediate,8151,,A,10116.0,,,,50597
13100,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,8151,,A,10116.0,,,,50597
13101,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,BAO_0000218,,Rattus norvegicus,,Intermediate,8151,,A,10116.0,,,,50597
13102,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,8151,,A,10116.0,,,,50597
13103,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,,BAO_0000218,,Rattus norvegicus,,Intermediate,8151,,A,10116.0,,,,50597
13104,1,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,,BAO_0000218,,Rattus norvegicus,,Intermediate,8151,,A,10116.0,,,,50597
13105,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13106,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13107,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13108,1,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Expert,6996,,F,9615.0,,,,50588
13109,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13110,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13111,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13112,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13113,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13114,1,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13115,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13116,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13117,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13118,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13119,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13120,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13121,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13122,1,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13123,1,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",,BAO_0000218,,,,Autocuration,6996,,B,,,,,22224
13124,1,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13125,1,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",,BAO_0000218,,Rattus norvegicus,,Expert,6996,,F,10116.0,,,,50597
13126,1,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,BAO_0000218,,,,Autocuration,6996,,B,,,,,22224
13127,1,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,BAO_0000218,,Rattus norvegicus,,Expert,6996,,A,10116.0,,,,50597
13128,1,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13129,1,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,,BAO_0000019,,,,Autocuration,7114,,A,,,,,22224
13130,1,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,7114,,A,10116.0,,,,50597
13131,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
13132,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
13133,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
13134,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
13135,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
13136,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
13137,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
13138,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
13139,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
13140,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
13141,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
13142,1,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,,BAO_0000218,,Mus musculus,,Intermediate,8613,,A,10090.0,,,,50594
13143,1,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",,BAO_0000218,,Mustela putorius furo,,Intermediate,11219,,A,9669.0,,,,50506
13144,1,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,BAO_0000218,,Mustela putorius furo,,Intermediate,11219,,A,9669.0,,,,50506
13145,1,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",,BAO_0000218,,Mustela putorius furo,,Intermediate,11219,,A,9669.0,,,,50506
13146,1,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,BAO_0000218,,Mustela putorius furo,,Intermediate,11219,,A,9669.0,,,,50506
13147,1,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,,BAO_0000218,,Mustela putorius furo,,Intermediate,11219,,A,9669.0,,,,50506
13148,1,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,,BAO_0000218,,Mustela putorius furo,,Intermediate,11219,,A,9669.0,,,,50506
13149,1,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,,BAO_0000218,,Mustela putorius furo,,Intermediate,11219,,A,9669.0,,,,50506
13150,1,Pharmacokinetic parameter :drug bound to plasma was reported,,BAO_0000019,,,,Autocuration,14837,,A,,,,,22224
13151,1,compound was evaluated for drug bound in plasma,,BAO_0000019,,,,Autocuration,14837,,A,,,,,22224
13152,1,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,,BAO_0000218,,Rattus norvegicus,,Intermediate,15343,,A,10116.0,,,,50597
13153,1,Bioavailability,,BAO_0000218,,Eutheria,,Autocuration,13761,,A,9347.0,,,,22224
13154,1,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,,BAO_0000218,,Rattus norvegicus,,Intermediate,14810,,A,10116.0,,,,50597
13155,1,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,14810,,A,10116.0,,,,50597
13156,1,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13249,,A,9615.0,,,,50588
13157,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,Bile,BAO_0000218,,Rattus norvegicus,,Intermediate,9267,,A,10116.0,,,,50597
13158,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,Bile,BAO_0000218,,Rattus norvegicus,,Intermediate,9267,,A,10116.0,,,,50597
13159,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,Bile,BAO_0000218,,Rattus norvegicus,,Intermediate,9267,,A,10116.0,,,,50597
13160,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,Bile,BAO_0000218,,Rattus norvegicus,,Intermediate,9267,,A,10116.0,,,,50597
13161,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,Bile,BAO_0000218,,Rattus norvegicus,,Intermediate,9267,,A,10116.0,,,,50597
13162,1,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,Bile,BAO_0000218,,Rattus norvegicus,,Intermediate,9267,,A,10116.0,,,,50597
13163,1,In vitro protein binding in human serum at 5 ug/ml,Serum,BAO_0000218,,Homo sapiens,,Intermediate,15549,,A,9606.0,,,,50587
13164,1,Serum protein binding ability was measured,,BAO_0000019,,,,Autocuration,10929,,A,,,,,22224
13165,1,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,BAO_0000019,,,,Autocuration,15444,,A,,,,,22224
13166,1,Oral bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Autocuration,12860,In vivo,A,9615.0,,,,22224
13167,1,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,BAO_0000218,,Rattus norvegicus,,Intermediate,12170,In vivo,A,10116.0,,,,50597
13168,1,Absolute oral bioavailability at an iv dose of 14 mg/kg,,BAO_0000218,,,,Autocuration,15173,In vivo,A,,,,,22224
13169,1,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,,BAO_0000218,,,,Autocuration,15173,In vivo,A,,,,,22224
13170,1,Oral bioavailability (dose 15 mg/kg i.v.),,BAO_0000218,,Eutheria,,Autocuration,15173,In vivo,A,9347.0,,,,22224
13171,1,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,,BAO_0000218,,,,Autocuration,15173,In vivo,A,,,,,22224
13172,1,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,,BAO_0000218,,,,Autocuration,15173,In vivo,A,,,,,22224
13173,1,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,,BAO_0000218,,,,Autocuration,15173,In vivo,A,,,,,22224
13174,1,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,,BAO_0000218,,,,Autocuration,15173,In vivo,A,,,,,22224
13175,1,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,,BAO_0000218,,Canis lupus familiaris,,Intermediate,11767,In vivo,A,9615.0,,,,50588
13176,1,Bioavailability in ferret,,BAO_0000218,,Mustela putorius furo,,Autocuration,11219,In vivo,A,9669.0,,,,22224
13177,1,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,,BAO_0000218,,Macaca fascicularis,,Intermediate,12186,In vivo,A,9541.0,,,,100710
13178,1,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13179,1,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13180,1,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13181,1,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13182,1,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13183,1,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13184,1,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13185,1,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13186,1,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13187,1,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13188,1,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13189,1,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13190,1,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13191,1,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13192,1,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13193,1,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13194,1,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13195,1,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13196,1,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13197,1,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13198,1,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13199,1,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13200,1,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13201,1,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13202,1,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13203,1,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13204,1,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13205,1,Total body clearance was measured at given dose,,BAO_0000019,,,,Autocuration,7199,,A,,,,,22224
13206,1,Total body clearance was measured at given dose.,,BAO_0000218,,,,Autocuration,7199,,A,,,,,22224
13207,1,Metabolic clearance from the body in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,7095,,A,10116.0,,,,50597
13208,1,Renal clearance from the body,,BAO_0000218,,,,Autocuration,7095,In vivo,A,,,,,22224
13209,1,Renal clearance from the body in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,7095,In vivo,A,10116.0,,,,50597
13210,1,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12528,In vivo,A,10116.0,,,,50597
13211,1,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12528,In vivo,A,9615.0,,,,50588
13212,1,Total clearance from the body in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,7095,,A,10116.0,,,,50597
13213,1,Clearance into cortex from rat plasma or PBS,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14223,In vivo,A,10116.0,,,,50597
13214,1,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,,BAO_0000218,,,,Autocuration,13569,In vivo,A,,,,,22224
13215,1,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,,BAO_0000218,,,,Autocuration,13569,In vivo,A,,,,,22224
13216,1,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,,BAO_0000218,,,,Autocuration,13569,In vivo,A,,,,,22224
13217,1,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,,BAO_0000218,,,,Autocuration,13569,In vivo,A,,,,,22224
13218,1,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,,BAO_0000218,,,,Autocuration,13569,In vivo,A,,,,,22224
13219,1,Clearance was determined,,BAO_0000218,,,,Autocuration,13979,In vivo,A,,,,,22224
13220,1,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,,BAO_0000218,,Mus musculus,,Intermediate,14315,In vivo,A,10090.0,,,,50594
13221,1,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,14315,In vivo,A,9986.0,,,,50592
13222,1,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,,BAO_0000218,,Rattus norvegicus,,Intermediate,14315,In vivo,A,10116.0,,,,50597
13223,1,Clearance in rat after iv dose (100 ug/kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,12174,In vivo,A,10116.0,,,,50597
13224,1,Clearance in guinea pig,,BAO_0000218,,Cavia porcellus,,Autocuration,12797,In vivo,A,10141.0,,,,22224
13225,1,Compound was evaluated for clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12797,In vivo,A,10116.0,,,,50597
13226,1,Compound was evaluated for the clearance in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12797,In vivo,A,9615.0,,,,50588
13227,1,Compound was evaluated for the clearance in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,12797,In vivo,A,10116.0,,,,50597
13228,1,Compound was tested in vivo for clearance after iv administration in the rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,11500,In vivo,A,10116.0,,,,50597
13229,1,IV clearance determined at an iv dose of 14 mg/kg,,BAO_0000218,,,,Autocuration,15173,In vivo,A,,,,,22224
13230,1,IV clearance determined at an iv dose of 15.2 mg/kg,,BAO_0000218,,,,Autocuration,15173,In vivo,A,,,,,22224
13231,1,IV clearance determined at an iv dose of 15 mg/kg,,BAO_0000218,,,,Autocuration,15173,In vivo,A,,,,,22224
13232,1,IV clearance determined at an peroral dose of 30 mg/kg.,,BAO_0000218,,,,Autocuration,15173,In vivo,A,,,,,22224
13233,1,IV clearance determined at an peroral dose of 30.2 mg/kg.,,BAO_0000218,,,,Autocuration,15173,In vivo,A,,,,,22224
13234,1,IV clearance determined at an peroral dose of 30.3 mg/kg.,,BAO_0000218,,,,Autocuration,15173,In vivo,A,,,,,22224
13235,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13236,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13237,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13238,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13239,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13240,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13241,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13242,1,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,Trachea,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13243,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13244,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13245,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13246,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13247,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13248,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13249,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13250,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13251,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13252,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13253,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13254,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13255,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13256,1,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,Trachea,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13257,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13258,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13259,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13260,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13261,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13262,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13263,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13264,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13265,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13266,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13267,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13268,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13269,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13270,1,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,Trachea,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13271,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,Bone,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13272,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13273,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13274,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13275,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13276,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,Intestine,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13277,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13278,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13279,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13280,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13281,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13282,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13283,1,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,Trachea,BAO_0000218,,Rattus norvegicus,,Intermediate,14198,In vivo,A,10116.0,,,,50597
13284,1,Normal diffusion coefficient in water for Escherichia coli,,BAO_0000218,,Escherichia coli,,Intermediate,15599,,A,562.0,,,,50212
13285,1,Average max percent decrease in RVR (renal vascular resistance) was determined,,BAO_0000019,,,,Autocuration,8204,,A,,,,,22224
13286,1,Average max percent decrease in RVR (renal vascular resistance) was determined.,,BAO_0000019,,,,Autocuration,8204,,A,,,,,22224
13287,1,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,,BAO_0000019,,,,Autocuration,6154,,A,,,,,22224
13288,1,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,,BAO_0000019,,,,Autocuration,6154,,A,,,,,22224
13289,1,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,,BAO_0000019,,,,Autocuration,6154,,A,,,,,22224
13290,1,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,,BAO_0000019,,,,Autocuration,6154,,A,,,,,22224
13291,1,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,,BAO_0000019,,,,Autocuration,7114,,A,,,,,22224
13292,1,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,7114,,A,10116.0,,,,50597
13293,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13294,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13295,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13296,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13297,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13298,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13299,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13300,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13301,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13302,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13303,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,A,314293.0,,,,22224
13304,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,A,314293.0,,,,22224
13305,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,A,314293.0,,,,22224
13306,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,A,314293.0,,,,22224
13307,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,A,314293.0,,,,22224
13308,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13309,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13310,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13311,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13312,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13313,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13314,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13315,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13316,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13317,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13318,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13319,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13320,1,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13321,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13322,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13323,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13324,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13325,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13326,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13327,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13328,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13329,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13330,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13331,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,A,314293.0,,,,22224
13332,1,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,BAO_0000218,,Rattus norvegicus,,Autocuration,12170,In vivo,A,10116.0,,,,22224
13333,1,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,,BAO_0000218,,Rattus norvegicus,,Autocuration,12170,In vivo,A,10116.0,,,,22224
13334,1,Bioavailability (dose 20 mg/kg),,BAO_0000218,,Eutheria,,Autocuration,4985,In vivo,A,9347.0,,,,22224
13335,1,Bioavailability in dog,,BAO_0000218,,Canis lupus familiaris,,Autocuration,15145,In vivo,A,9615.0,,,,22224
13336,1,Bioavailability in rat (Sprague-Dawley) (male),,BAO_0000218,,Rattus norvegicus,,Autocuration,14080,In vivo,A,10116.0,,,,22224
13337,1,Bioavailability in monkey (dose 10 mg/kg i.d.),,BAO_0000218,,Primates,,Autocuration,11219,In vivo,A,9443.0,,,,22224
13338,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Autocuration,15145,In vivo,A,10116.0,,,,22224
13339,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Autocuration,15145,In vivo,A,10116.0,,,,22224
13340,1,Bioavailability in dog (dose 3.0 mg/kg p.o.),,BAO_0000218,,Canis lupus familiaris,,Autocuration,1202,In vivo,A,9615.0,,,,22224
13341,1,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,,BAO_0000218,,Canis lupus familiaris,,Autocuration,1202,In vivo,A,9615.0,,,,22224
13342,1,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,,BAO_0000218,,Pan troglodytes,,Intermediate,1202,In vivo,A,9598.0,,,,50505
13343,1,Bioavailability,,BAO_0000218,,Eutheria,,Autocuration,4026,In vivo,A,9347.0,,,,22224
13344,1,Bioavailability in squirrel monkey,,BAO_0000218,,Saimiri,,Autocuration,1492,In vivo,A,9520.0,,,,22224
13345,1,Bioavailability was evaluated in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,12793,In vivo,A,9615.0,,,,50588
13346,1,Bioavailability was evaluated in hamster,,BAO_0000218,,Cricetinae,,Intermediate,12793,In vivo,A,10026.0,,,,100712
13347,1,Bioavailability in rat,,BAO_0000218,,Rattus norvegicus,,Autocuration,12793,In vivo,A,10116.0,,,,22224
13348,1,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,In vivo,A,10116.0,,,,50597
13349,1,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,14793,In vivo,A,10116.0,,,,50597
13350,1,Bioavailability in rat (dose 10 mg/kg p.o.),,BAO_0000218,,Rattus norvegicus,,Autocuration,14793,In vivo,A,10116.0,,,,22224
13351,1,Bioavailability was measured in cynomolgus monkeys.,,BAO_0000218,,Macaca fascicularis,,Intermediate,14731,In vivo,A,9541.0,,,,100710
13352,1,Bioavailability was measured in nude mice.,,BAO_0000218,,Mus musculus,,Intermediate,14731,In vivo,A,10090.0,,,,50594
13353,1,Bioavailability in ferret (dose 10 mg/kg i.d.),,BAO_0000218,,Mustela putorius furo,,Autocuration,12187,In vivo,A,9669.0,,,,22224
13354,1,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),,BAO_0000218,,Simiiformes,,Autocuration,12187,In vivo,A,314293.0,,,,22224
13355,1,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",,BAO_0000218,,Simiiformes,,Autocuration,12187,In vivo,A,314293.0,,,,22224
13356,1,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),,BAO_0000218,,Simiiformes,,Autocuration,12187,In vivo,A,314293.0,,,,22224
13357,1,Bioavailability in rat (dose 10 mg/kg i.d.),,BAO_0000218,,Rattus norvegicus,,Autocuration,12187,In vivo,A,10116.0,,,,22224
13358,1,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",,BAO_0000218,,Rattus norvegicus,,Intermediate,12187,In vivo,A,10116.0,,,,50597
13359,1,Bioavailability was determined; extremely poor,,BAO_0000218,,,,Autocuration,17431,In vivo,A,,,,,22224
13360,1,% bioavailability in mice after oral administration of prodrug,,BAO_0000218,,Mus musculus,,Intermediate,13318,In vivo,A,10090.0,,,,50594
13361,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13362,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13363,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13364,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13365,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13366,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13367,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13368,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13369,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13370,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13371,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13372,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13373,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13374,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13375,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13376,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13377,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13378,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13379,1,IV clearance determined at an peroral dose of 15 mg/kg.,,BAO_0000218,,,,Autocuration,15173,In vivo,A,,,,,22224
13380,1,Mouse oral clearance was measured against Hymenolepiasis nana.,,BAO_0000218,,Hymenolepis nana,,Expert,7732,In vivo,F,102285.0,,,,50064
13381,1,Mouse oral clearance was measured against Nematospiroides dubius,,BAO_0000218,,Heligmosomoides polygyrus,,Expert,7732,In vivo,F,6339.0,,,,50545
13382,1,Mouse oral clearance was measured against N. dubius; NT is Not Tested,,BAO_0000218,,,,Autocuration,7732,In vivo,F,,,,,22224
13383,1,Mouse oral clearance was measured against N. nana; NT is Not Tested,,BAO_0000218,,Mus musculus,,Intermediate,7732,In vivo,A,10090.0,,,,50594
13384,1,Mouse oral clearance was measured against N. nana; NT is Not Tested,,BAO_0000218,,,,Autocuration,7732,In vivo,B,,,,,22224
13385,1,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,,BAO_0000218,,,,Autocuration,8328,In vivo,A,,,,,22224
13386,1,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,,BAO_0000218,,,,Autocuration,8328,In vivo,A,,,,,22224
13387,1,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,,BAO_0000218,,,,Autocuration,8328,In vivo,A,,,,,22224
13388,1,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,,BAO_0000218,,,,Autocuration,8328,In vivo,A,,,,,22224
13389,1,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,,BAO_0000218,,,,Autocuration,8328,In vivo,A,,,,,22224
13390,1,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,,BAO_0000218,,,,Autocuration,8328,In vivo,A,,,,,22224
13391,1,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,,BAO_0000218,,,,Autocuration,8328,In vivo,A,,,,,22224
13392,1,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,,BAO_0000218,,,,Autocuration,8328,In vivo,A,,,,,22224
13393,1,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,,BAO_0000218,,,,Autocuration,8328,In vivo,A,,,,,22224
13394,1,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,,BAO_0000218,,Canis lupus familiaris,,Intermediate,13376,In vivo,A,9615.0,,,,50588
13395,1,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,,BAO_0000218,,Macaca mulatta,,Intermediate,13477,In vivo,A,9544.0,,,,50797
13396,1,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,In vivo,A,10116.0,,,,50597
13397,1,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,13477,In vivo,A,10116.0,,,,50597
13398,1,Plasma clearance was determined for the compound in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,13313,In vivo,A,10116.0,,,,50597
13399,1,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,,BAO_0000218,,Rattus norvegicus,,Intermediate,12504,In vivo,A,10116.0,,,,50597
13400,1,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,,BAO_0000218,,Rattus norvegicus,,Intermediate,12504,In vivo,A,10116.0,,,,50597
13401,1,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,,BAO_0000218,,Rattus norvegicus,,Intermediate,12504,In vivo,A,10116.0,,,,50597
13402,1,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,,BAO_0000218,,Rattus norvegicus,,Intermediate,12504,In vivo,A,10116.0,,,,50597
13403,1,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13129,In vivo,A,10116.0,,,,50597
13404,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,,BAO_0000218,,Heligmosomoides polygyrus,,Intermediate,7732,In vivo,A,6339.0,,,,50545
13405,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,,BAO_0000218,,Heligmosomoides polygyrus,,Intermediate,7732,In vivo,A,6339.0,,,,50545
13406,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,,BAO_0000218,,Heligmosomoides polygyrus,,Intermediate,7732,In vivo,A,6339.0,,,,50545
13407,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,,BAO_0000218,,Heligmosomoides polygyrus,,Intermediate,7732,In vivo,A,6339.0,,,,50545
13408,1,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,,BAO_0000218,,Heligmosomoides polygyrus,,Intermediate,7732,In vivo,A,6339.0,,,,50545
13409,1,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,Urine,BAO_0000218,,Rattus norvegicus,,Autocuration,9278,In vivo,A,10116.0,,,,22224
13410,1,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,,BAO_0000218,,Rattus norvegicus,,Autocuration,9278,In vivo,A,10116.0,,,,22224
13411,1,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,,BAO_0000218,,Rattus norvegicus,,Autocuration,9278,In vivo,A,10116.0,,,,22224
13412,1,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,Urine,BAO_0000218,,Rattus norvegicus,,Autocuration,9278,In vivo,A,10116.0,,,,22224
13413,1,Urinary clearance was determined in rat at 25 mg/kg os dosage,Urine,BAO_0000218,,Rattus norvegicus,,Autocuration,9278,In vivo,A,10116.0,,,,22224
13414,1,Urinary clearance was determined at 100 mg/kg oral dosage in human,Urine,BAO_0000218,,Homo sapiens,,Intermediate,9278,In vivo,A,9606.0,,,,50587
13415,1,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,9278,In vivo,A,9615.0,,,,50588
13416,1,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,5932,In vivo,A,9615.0,,,,50588
13417,1,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,5932,In vivo,A,10116.0,,,,50597
13418,1,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5182,In vivo,A,10116.0,,,,50597
13419,1,Clearance rate in dogs,,BAO_0000218,,Canis lupus familiaris,,Intermediate,10499,In vivo,A,9615.0,,,,50588
13420,1,Compound was measured for intrinsic clearance,,BAO_0000019,,,,Autocuration,6051,In vitro,A,,,,,22224
13421,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,17508,,P,,,,,22229
13422,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,6228,,P,,,,,22229
13423,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,6231,,P,,,,,22229
13424,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,17740,,P,,,,,22229
13425,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,6495,,P,,,,,22229
13426,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,2171,,P,,,,,22229
13427,1,Partition coefficient of the compound,,BAO_0000019,,,,Autocuration,3255,,A,,,,,22224
13428,1,Permeability,,BAO_0000019,,,,Autocuration,6821,,A,,,,,22224
13429,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,2685,,P,,,,,22229
13430,1,Partition coefficient (logD),,BAO_0000019,,,,Autocuration,17584,,A,,,,,22224
13431,1,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,BAO_0000100,,,,Autocuration,13824,,P,,,,,22229
13432,1,Calculated partition coefficient (clogP) (CLOGP3 V3.4),,BAO_0000100,,,,Autocuration,13824,,P,,,,,22229
13433,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,16479,,P,,,,,22229
13434,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,11997,,P,,,,,22229
13435,1,Calculated logarithm of partition coefficient (P) was determined,,BAO_0000100,,,,Autocuration,2988,,P,,,,,22229
13436,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,931,,P,,,,,22229
13437,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,4381,,P,,,,,22229
13438,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,4397,,P,,,,,22229
13439,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,5889,,P,,,,,22229
13440,1,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,,BAO_0000019,,,,Autocuration,6154,,A,,,,,22224
13441,1,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,,BAO_0000019,,,,Autocuration,6154,,A,,,,,22224
13442,1,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,,BAO_0000019,,,,Autocuration,6154,,A,,,,,22224
13443,1,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,,BAO_0000019,,,,Autocuration,6154,,A,,,,,22224
13444,1,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,,BAO_0000019,,,,Autocuration,6154,,A,,,,,22224
13445,1,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,,BAO_0000019,,,,Autocuration,6154,,A,,,,,22224
13446,1,Percent degradation of compound at a pH of 1 over a 18 hr period,,BAO_0000019,,,,Autocuration,6887,,A,,,,,22224
13447,1,Percent degradation of compound at pH of 1 over an 18 hr period,,BAO_0000019,,,,Autocuration,6887,,A,,,,,22224
13448,1,Delta Logarithm of Partition Coefficient value was determined.,,BAO_0000019,,,,Autocuration,14116,,A,,,,,22224
13449,1,Delta logPoct-cyc,,BAO_0000019,,,,Autocuration,11137,,A,,,,,22224
13450,1,Lipophilicity estimated on reversed phase TLC,,BAO_0000100,,,,Autocuration,7230,,P,,,,,22224
13451,1,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,,BAO_0000019,,,,Autocuration,15741,,A,,,,,22224
13452,1,Delta logPoct-cyc,,BAO_0000019,,,,Autocuration,9663,,A,,,,,22224
13453,1,Change in logarithm of partition coefficient of the compound,,BAO_0000100,,,,Autocuration,9663,,P,,,,,22229
13454,1,Delta logD (pH 6.5),,BAO_0000019,,,,Autocuration,13807,,A,,,,,22224
13455,1,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",,BAO_0000100,,,,Autocuration,13807,,P,,,,,22224
13456,1,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,,BAO_0000019,,,,Autocuration,17425,,A,,,,,22224
13457,1,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),,BAO_0000019,,,,Autocuration,12143,,A,,,,,22224
13458,1,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,,BAO_0000219,,,,Autocuration,12608,,A,,,,,22224
13459,1,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,,BAO_0000219,,,,Autocuration,12608,,A,,,,,22224
13460,1,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,,BAO_0000218,,Rattus norvegicus,,Intermediate,8649,,A,10116.0,,,,50597
13461,1,Amount of deuterium retained was reported after normal workup in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,8649,,A,10116.0,,,,50597
13462,1,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,8649,,A,10116.0,,,,50597
13463,1,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,,BAO_0000218,,Rattus norvegicus,,Intermediate,8649,,A,10116.0,,,,50597
13464,1,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,BAO_0000218,,Rattus norvegicus,,Intermediate,8649,,A,10116.0,,,,50597
13465,1,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,,BAO_0000218,,Rattus norvegicus,,Intermediate,8649,,A,10116.0,,,,50597
13466,1,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,,BAO_0000218,,Rattus norvegicus,,Intermediate,8649,,A,10116.0,,,,50597
13467,1,Compound was subjected to electrochemical oxidation,,BAO_0000019,,,,Autocuration,9659,,A,,,,,22224
13468,1,Compound was subjected to photochemical oxidation,,BAO_0000019,,,,Autocuration,9659,,A,,,,,22224
13469,1,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,,BAO_0000019,,,,Autocuration,9659,,A,,,,,22224
13470,1,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,,BAO_0000019,,,,Autocuration,9659,,A,,,,,22224
13471,1,Oxidation of compound by methemoglobin in presence of hydroperoxide,,BAO_0000019,,,,Autocuration,9659,,A,,,,,22224
13472,1,Percent diffusion through fuzzy rat skin after 48 h of incubation,,BAO_0000218,,Rattus norvegicus,,Intermediate,9607,,A,10116.0,,,,50597
13473,1,Dissociation constant (pKa),,BAO_0000100,,,,Autocuration,7057,,P,,,,,22229
13474,1,Dissociation constant value of the compound; ND means not determined.,,BAO_0000100,,,,Autocuration,7057,,P,,,,,22224
13475,1,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,7911,,A,10116.0,,,,50597
13476,1,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,7911,,A,10116.0,,,,50597
13477,1,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,,BAO_0000218,,Rattus norvegicus,,Intermediate,7911,,A,10116.0,,,,50597
13478,1,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,,BAO_0000218,,Rattus norvegicus,,Intermediate,7911,,A,10116.0,,,,50597
13479,1,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,7911,,A,10116.0,,,,50597
13480,1,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,7911,,A,10116.0,,,,50597
13481,1,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,7911,,A,10116.0,,,,50597
13482,1,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,7911,,A,10116.0,,,,50597
13483,1,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,,BAO_0000218,,Rattus norvegicus,,Intermediate,7911,,A,10116.0,,,,50597
13484,1,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,7911,,A,10116.0,,,,50597
13485,1,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,Feces,BAO_0000218,,Rattus norvegicus,,Intermediate,7911,,A,10116.0,,,,50597
13486,1,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,7911,,A,10116.0,,,,50597
13487,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,Cerebellum,BAO_0000218,,Mus musculus,,Intermediate,13792,,A,10090.0,,,,50594
13488,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,Brain,BAO_0000218,,Mus musculus,,Intermediate,13792,,A,10090.0,,,,50594
13489,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,A,314293.0,,,,22224
13490,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,A,314293.0,,,,22224
13491,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,A,314293.0,,,,22224
13492,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,A,314293.0,,,,22224
13493,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13494,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13495,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13496,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13497,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13498,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13499,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13500,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13501,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13502,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13503,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13504,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13505,1,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13506,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13507,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13508,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13509,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13510,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13511,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13512,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13513,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13514,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13515,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,8133,,A,9615.0,,,,50588
13516,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,A,314293.0,,,,22224
13517,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,A,314293.0,,,,22224
13518,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,A,314293.0,,,,22224
13519,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,A,314293.0,,,,22224
13520,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",Urine,BAO_0000218,,Simiiformes,,Autocuration,8133,,A,314293.0,,,,22224
13521,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13522,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13523,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13524,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13525,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13526,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13527,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13528,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13529,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13530,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13531,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13532,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13533,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13534,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13535,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13536,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13537,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13538,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13539,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13540,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13541,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13542,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13543,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13544,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13545,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13546,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13547,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13548,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13549,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13550,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13551,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13552,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13553,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13554,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13555,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13556,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13557,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13558,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13559,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13560,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13561,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,,BAO_0000218,,Rattus norvegicus,,Intermediate,9025,In vivo,A,10116.0,,,,50597
13562,1,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,Artery,BAO_0000218,,Canis lupus familiaris,,Intermediate,9025,In vivo,A,9615.0,,,,50588
13563,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,6448,,P,,,,,22229
13564,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,17221,,P,,,,,22229
13565,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,6545,,P,,,,,22229
13566,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,577,,P,,,,,22229
13567,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,6285,,P,,,,,22229
13568,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,6500,,P,,,,,22229
13569,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,6716,,P,,,,,22229
13570,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,13658,,P,,,,,22229
13571,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,6549,,P,,,,,22229
13572,1,Calculated partition coefficient (clogP) (MacLogP),,BAO_0000100,,,,Autocuration,14685,,P,,,,,22229
13573,1,Partition coefficient (logP),,BAO_0000019,,,,Autocuration,6893,,A,,,,,22224
13574,1,Kinetic parameter was determined,,BAO_0000019,,,,Autocuration,3687,,A,,,,,22224
13575,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,4207,,P,,,,,22229
13576,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,4626,,P,,,,,22229
13577,1,Lipophilicity was determined,,BAO_0000100,,,,Autocuration,1021,,P,,,,,22224
13578,1,Lipophilicity was determined,,BAO_0000100,,,,Autocuration,3777,,P,,,,,22224
13579,1,Lipophilicity was determined,,BAO_0000100,,,,Autocuration,17533,,P,,,,,22224
13580,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,6524,,P,,,,,22229
13581,1,Lipophilicity was determined,,BAO_0000100,,,,Autocuration,17533,,P,,,,,22224
13582,1,Lipophilicity in octanol-water,,BAO_0000100,,,,Autocuration,6480,,P,,,,,22224
13583,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,17606,,P,,,,,22229
13584,1,Octanol-water partition coefficient was determined,,BAO_0000100,,,,Autocuration,6863,,P,,,,,22229
13585,1,Partition coefficient (logP),,BAO_0000019,,,,Autocuration,1356,,A,,,,,22224
13586,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,3326,,P,,,,,22229
13587,1,Partition coefficient was determined; ND means not determined,,BAO_0000019,,,,Autocuration,1356,,A,,,,,22224
13588,1,Calculated partition coefficient (clogP),,BAO_0000100,,,,Autocuration,12984,,P,,,,,22229
13589,1,Partition coefficient of the compound,,BAO_0000019,,,,Autocuration,17363,,A,,,,,22224
13590,1,Permeability was determined,,BAO_0000019,,,,Autocuration,6827,,A,,,,,22224
13591,1,The compound was evaluated for the partition coefficient,,BAO_0000100,,,,Autocuration,261,,P,,,,,22229
13592,1,Partition coefficient (logP),,BAO_0000019,,,,Autocuration,2685,,A,,,,,22224
13593,1,The lipophilicity was reported,,BAO_0000100,,,,Autocuration,414,,P,,,,,22224
13594,1,logarithm of the octanol-water partition coefficient for the compound,,BAO_0000100,,,,Autocuration,15769,,P,,,,,22229
13595,1,Clogp value was determined,,BAO_0000019,,,,Autocuration,17248,,A,,,,,22224
13596,1,Clp at a dose of 1.5 mg/kg,,BAO_0000218,,,,Autocuration,16935,In vivo,A,,,,,22224
13597,1,Clp at a dose of 2.0 mg/kg,,BAO_0000218,,,,Autocuration,16935,In vivo,A,,,,,22224
13598,1,"Clp, plasma clearance at a dose of 10 mg/kg",Plasma,BAO_0000218,,,,Autocuration,14832,In vivo,A,,,,,22224
13599,1,"Clp, plasma clearance at a dose of 50 mg/kg",Plasma,BAO_0000218,,,,Autocuration,14832,In vivo,A,,,,,22224
13600,1,Compound was tested for plasma clearance in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2399,In vivo,A,10116.0,,,,50597
13601,1,Compound was tested for plasma clearance in rat; Not determined,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,2399,In vivo,A,10116.0,,,,50597
13602,1,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,6227,In vivo,A,10116.0,,,,50597
13603,1,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,,BAO_0000218,,Macaca mulatta,,Intermediate,6227,In vivo,A,9544.0,,,,50797
13604,1,Plasma clearance by iv administration at a dose 0.003 ug/mL,,BAO_0000218,,,,Autocuration,5623,In vivo,A,,,,,22224
13605,1,Plasma clearance determined,,BAO_0000218,,,,Autocuration,4854,In vivo,A,,,,,22224
13606,1,Plasma clearance after iv administration at 3 mg/kg in hamster,,BAO_0000218,,Cricetinae,,Intermediate,4493,In vivo,A,10026.0,,,,100712
13607,1,Plasma clearance after iv administration at 4 mg/kg in hamster,,BAO_0000218,,Cricetinae,,Intermediate,4493,In vivo,A,10026.0,,,,100712
13608,1,Rate of clearance in rat was determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,14956,In vivo,A,10116.0,,,,50597
13609,1,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,In vivo,A,10116.0,,,,50597
13610,1,Total plasma clearance after iv dose of 5.10 mg/kg in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,In vivo,A,10116.0,,,,50597
13611,1,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,In vivo,A,10116.0,,,,50597
13612,1,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15372,In vivo,A,10116.0,,,,50597
13613,1,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,Plasma,BAO_0000218,,Simiiformes,,Autocuration,15604,In vivo,A,314293.0,,,,22224
13614,1,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15604,In vivo,A,10116.0,,,,50597
13615,1,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,15604,In vivo,A,9615.0,,,,50588
13616,1,Clpl value in rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,14964,In vivo,A,10116.0,,,,50597
13617,1,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,,BAO_0000218,,Cavia porcellus,,Intermediate,15240,In vivo,A,10141.0,,,,50512
13618,1,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,16449,In vivo,A,10116.0,,,,50597
13619,1,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,,BAO_0000218,,Macaca fascicularis,,Intermediate,16449,In vivo,A,9541.0,,,,100710
13620,1,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,,BAO_0000218,,,,Autocuration,12902,In vivo,A,,,,,22224
13621,1,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,,BAO_0000218,,,,Autocuration,12902,In vivo,A,,,,,22224
13622,1,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,,BAO_0000218,,,,Autocuration,12902,In vivo,A,,,,,22224
13623,1,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,,BAO_0000218,,,,Autocuration,12902,In vivo,A,,,,,22224
13624,1,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,,BAO_0000218,,,,Autocuration,12902,In vivo,A,,,,,22224
13625,1,Cmax in minutes at a po dose of 10.0(pmol/g/h).,,BAO_0000218,,,,Autocuration,12902,In vivo,A,,,,,22224
13626,1,Cmax in minutes at a po dose of 20.0(pmol/g/h).,,BAO_0000218,,,,Autocuration,12902,In vivo,A,,,,,22224
13627,1,Cmax in minutes at a po dose of 40.0(pmol/g/h).,,BAO_0000218,,,,Autocuration,12902,In vivo,A,,,,,22224
13628,1,Cmax was calculated as maximum concentration reached in the blood,Blood,BAO_0000218,,,,Autocuration,11149,In vivo,A,,,,,22224
13629,1,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,Blood,BAO_0000218,,,,Autocuration,11149,In vivo,A,,,,,22224
13630,1,Cmax was determine after peroral administration at 10 mpk in Rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5669,In vivo,A,10116.0,,,,50597
13631,1,Cmax was determine after peroral administration at 10 mpk in Rhesus,,BAO_0000218,,Macaca mulatta,,Intermediate,5669,In vivo,A,9544.0,,,,50797
13632,1,Cmax was determine after peroral administration at 10 mpk in dog,,BAO_0000218,,Canis lupus familiaris,,Intermediate,5669,In vivo,A,9615.0,,,,50588
13633,1,Cmax was determine after peroral administration at 160 mpk in Rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5669,In vivo,A,10116.0,,,,50597
13634,1,Cmax was determine after peroral administration at 20 mpk in Rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5669,In vivo,A,10116.0,,,,50597
13635,1,Cmax was determine after peroral administration at 50 mpk in Rat,,BAO_0000218,,Rattus norvegicus,,Intermediate,5669,In vivo,A,10116.0,,,,50597
13636,1,Cmax was determined,,BAO_0000218,,,,Autocuration,4236,In vivo,A,,,,,22224
13637,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,Brain,BAO_0000218,,Mus musculus,,Intermediate,13792,,A,10090.0,,,,50594
13638,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,Brain,BAO_0000218,,Mus musculus,,Intermediate,13792,,A,10090.0,,,,50594
13639,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,Brain,BAO_0000218,,Mus musculus,,Intermediate,13792,,A,10090.0,,,,50594
13640,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,Brain,BAO_0000218,,Mus musculus,,Intermediate,13792,,A,10090.0,,,,50594
13641,1,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,Striatum,BAO_0000218,,Mus musculus,,Intermediate,13792,,A,10090.0,,,,50594
13642,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13643,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13644,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13645,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13646,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13647,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13648,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13649,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13650,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13651,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13652,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13653,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13654,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13655,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13656,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13657,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13658,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13659,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13660,1,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13661,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13662,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13663,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13664,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13665,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13666,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13667,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13668,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13669,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13670,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13671,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13672,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13673,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13674,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13675,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13676,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13677,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13678,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13679,1,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,,BAO_0000218,,Rattus norvegicus,,Intermediate,8418,,A,10116.0,,,,50597
13680,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13681,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13682,1,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,8133,,A,10116.0,,,,50597
13683,1,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13684,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13685,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13686,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13687,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13688,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13689,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13690,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13691,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13692,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13693,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13694,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13695,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13696,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13697,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13698,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13699,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13700,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13701,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13702,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13703,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13704,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13705,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13706,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13707,1,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),,BAO_0000218,,Rattus norvegicus,,Intermediate,6996,,A,10116.0,,,,50597
13708,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13709,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13710,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13711,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13712,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13713,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13714,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13715,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13716,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13717,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13718,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13719,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13720,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13721,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13722,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13723,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13724,1,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),,BAO_0000218,,Canis lupus familiaris,,Intermediate,6996,,A,9615.0,,,,50588
13725,1,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,A,10090.0,,,,50594
13726,1,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Zone of skin,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,A,10090.0,,,,50594
13727,1,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Spleen,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,A,10090.0,,,,50594
13728,1,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Spleen,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,A,10090.0,,,,50594
13729,1,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Spleen,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,A,10090.0,,,,50594
13730,1,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Spleen,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,A,10090.0,,,,50594
13731,1,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Stomach,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,A,10090.0,,,,50594
13732,1,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Stomach,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,A,10090.0,,,,50594
13733,1,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Stomach,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,A,10090.0,,,,50594
13734,1,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",Stomach,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,A,10090.0,,,,50594
13735,1,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,A,10090.0,,,,50594
13736,1,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,A,10090.0,,,,50594
13737,1,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,A,10090.0,,,,50594
13738,1,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",,BAO_0000218,,Mus musculus,,Intermediate,9716,In vivo,A,10090.0,,,,50594
13739,1,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),Kidney,BAO_0000218,,Mus musculus,,Intermediate,12192,,A,10090.0,,,,50594
13740,1,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,Kidney,BAO_0000218,,Mus musculus,,Intermediate,12192,,A,10090.0,,,,50594
13741,1,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),Kidney,BAO_0000218,,Mus musculus,,Intermediate,12192,,A,10090.0,,,,50594
13742,1,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,,BAO_0000218,,Mus musculus,,Intermediate,12192,,A,10090.0,,,,50594
13743,1,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),,BAO_0000218,,Mus musculus,,Intermediate,12192,,A,10090.0,,,,50594
13744,1,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,,BAO_0000218,,Mus musculus,,Intermediate,12192,,A,10090.0,,,,50594
13745,1,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),,BAO_0000218,,Mus musculus,,Intermediate,12192,,A,10090.0,,,,50594
13746,1,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,,BAO_0000218,,Mus musculus,,Intermediate,12192,,A,10090.0,,,,50594
13747,1,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),,BAO_0000218,,Mus musculus,,Intermediate,12192,,A,10090.0,,,,50594
13748,1,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,,BAO_0000218,,Mus musculus,,Intermediate,12192,,A,10090.0,,,,50594
13749,1,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),,BAO_0000218,,Mus musculus,,Intermediate,12192,,A,10090.0,,,,50594
13750,1,Removal of 238-Plutonium(IV) in feces at 24 h,Feces,BAO_0000019,,,,Autocuration,12192,,A,,,,,22224
13751,1,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),Feces,BAO_0000019,,,,Autocuration,12192,,A,,,,,22224
13752,1,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,,BAO_0000019,,,,Autocuration,12192,,A,,,,,22224
13753,1,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),,BAO_0000019,,,,Autocuration,12192,,A,,,,,22224
13754,1,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),Urine,BAO_0000019,,,,Autocuration,12192,,A,,,,,22224
13755,1,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),Urine,BAO_0000019,,,,Autocuration,12192,,A,,,,,22224
13756,1,Removal of 238-Plutonium(IV) in urine after 0-24 h,Urine,BAO_0000019,,,,Autocuration,12192,,A,,,,,22224
13757,1,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),Urine,BAO_0000019,,,,Autocuration,12192,,A,,,,,22224
13758,1,Removal of 238-Plutonium(IV) in urine after 0-4 h,Urine,BAO_0000019,,,,Autocuration,12192,,A,,,,,22224
13759,1,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),Urine,BAO_0000019,,,,Autocuration,12192,,A,,,,,22224
13760,1,Removal of 238-Plutonium(IV) in urine after 4-24 h,Urine,BAO_0000019,,,,Autocuration,12192,,A,,,,,22224
13761,1,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),Urine,BAO_0000019,,,,Autocuration,12192,,A,,,,,22224
13762,1,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),Urine,BAO_0000019,,,,Autocuration,12192,,A,,,,,22224
13763,1,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),Urine,BAO_0000019,,,,Autocuration,12192,,A,,,,,22224
13764,1,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13765,1,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13766,1,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13767,1,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13768,1,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13769,1,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13770,1,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13771,1,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13772,1,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13773,1,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13774,1,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,A,10116.0,,,,50597
13775,1,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,A,10116.0,,,,50597
13776,1,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,A,10116.0,,,,50597
13777,1,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,A,10116.0,,,,50597
13778,1,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,A,10116.0,,,,50597
13779,1,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,A,10116.0,,,,50597
13780,1,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,A,10116.0,,,,50597
13781,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,A,10116.0,,,,50597
13782,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,A,10116.0,,,,50597
13783,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,A,10116.0,,,,50597
13784,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,A,10116.0,,,,50597
13785,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,A,10116.0,,,,50597
13786,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,A,10116.0,,,,50597
13787,1,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,A,10116.0,,,,50597
13788,1,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,A,10116.0,,,,50597
13789,1,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,11836,,A,10116.0,,,,50597
13790,1,Tested in vitro for intrinsic activity relative to quinpirole,,BAO_0000019,,,,Autocuration,12640,,A,,,,,22224
13791,1,"Relative ion enhancement, determined in pulsed ultrafiltration",,BAO_0000019,,,,Autocuration,14218,,A,,,,,22224
13792,1,% ionization at the pH 7.4 at 37 degree Centigrade,,BAO_0000019,,,,Autocuration,11296,,A,,,,,22224
13793,1,Percentage ionization was measured,,BAO_0000019,,,,Autocuration,10929,,A,,,,,22224
13794,1,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,,BAO_0000218,,Bos taurus,,Intermediate,13841,,A,9913.0,,,,50591
13795,1,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,,BAO_0000019,,,,Autocuration,10431,,A,,,,,22224
13796,1,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,,BAO_0000019,,,,Autocuration,10431,,A,,,,,22224
13797,1,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,,BAO_0000019,,,,Autocuration,10431,,A,,,,,22224
13798,1,Compound was evaluated for the partition coefficient in octanol/water,,BAO_0000100,,,,Autocuration,8826,,P,,,,,22229
13799,1,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),,BAO_0000100,,,,Autocuration,8826,,P,,,,,22229
13800,1,Equilibrium constant measured by the pulse radiolysis at pH 7,,BAO_0000019,,,,Autocuration,9884,,A,,,,,22224
13801,1,In vitro hydrolytic rate constant determined in human blood,,BAO_0000218,,Homo sapiens,,Intermediate,9827,,A,9606.0,,,,50587
13802,1,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,,BAO_0000218,,Homo sapiens,,Intermediate,10009,,A,9606.0,,,,50587
13803,1,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,,BAO_0000019,,,,Autocuration,10009,,A,,,,,22224
13804,1,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,,BAO_0000218,,Mus musculus,,Intermediate,10009,,A,10090.0,,,,50594
13805,1,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,,BAO_0000218,,Mus musculus,,Intermediate,10009,,A,10090.0,,,,50594
13806,1,In vitro oxidation of compound in presence of human plasma,,BAO_0000218,,Homo sapiens,,Intermediate,10009,,A,9606.0,,,,50587
13807,1,In vitro oxidation of compound in presence of hydrogen peroxide,,BAO_0000019,,,,Autocuration,10009,,A,,,,,22224
13808,1,In vitro oxidation of compound in presence of mouse brain homogenate,,BAO_0000218,,Mus musculus,,Intermediate,10009,,A,10090.0,,,,50594
13809,1,In vitro oxidation of compound in presence of mouse liver homogenate,,BAO_0000218,,Mus musculus,,Intermediate,10009,,A,10090.0,,,,50594
13810,1,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13811,1,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13812,1,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13813,1,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13814,1,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13815,1,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13816,1,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13817,1,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13818,1,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13819,1,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13820,1,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13821,1,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13822,1,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13823,1,Biodistribution in rat blood at 240 minutes after dose administration.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13824,1,Biodistribution in rat blood at 30 minutes after dose administration.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13825,1,Biodistribution in rat blood at 360 minutes after dose administration.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13826,1,Biodistribution in rat blood at 3 hr after dose administration.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13827,1,Biodistribution in rat blood at 60 minutes after dose administration.,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13828,1,Biodistribution in rat cerebellum at 120 minutes after dose administration.,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13829,1,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13830,1,Biodistribution in rat cerebellum at 15 minutes after dose administration.,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13831,1,Biodistribution in rat cerebellum at 240 minutes after dose administration.,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13832,1,Biodistribution in rat cerebellum at 30 minutes after dose administration.,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13833,1,Biodistribution in rat cerebellum at 360 minutes after dose administration.,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13834,1,Biodistribution in rat cerebellum at 3 hr after dose administration.,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13835,1,Biodistribution in rat cerebellum at 60 minutes after dose administration.,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13836,1,Biodistribution in rat cortex at 120 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13837,1,Biodistribution in rat cortex at 1440 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13838,1,Biodistribution in rat cortex at 15 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13839,1,Biodistribution in rat cortex at 240 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13840,1,Biodistribution in rat cortex at 30 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13841,1,Biodistribution in rat cortex at 360 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13842,1,Biodistribution in rat cortex at 3 hr after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13843,1,Biodistribution in rat cortex at 60 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13844,1,Biodistribution in rat heart at 120 minutes after dose administration.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13845,1,Biodistribution in rat heart at 15 minutes after dose administration.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13846,1,Biodistribution in rat heart at 240 minutes after dose administration.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13847,1,Biodistribution in rat heart at 30 minutes after dose administration.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13848,1,Biodistribution in rat heart at 360 minutes after dose administration.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13849,1,Biodistribution in rat heart at 3 hr after dose administration.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13850,1,Biodistribution in rat heart at 60 minutes after dose administration.,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13851,1,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13852,1,Biodistribution in rat hippocampus at 240 minutes after dose administration.,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13853,1,Biodistribution in rat hippocampus at 30 minutes after dose administration.,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13854,1,Biodistribution in rat hippocampus at 360 minutes after dose administration.,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13855,1,Biodistribution in rat hippocampus at 15 minutes after dose administration.,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13856,1,Biodistribution in rat kidney at 120 minutes after dose administration.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13857,1,Biodistribution in rat kidney at 1440 minutes after dose administration.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13858,1,Biodistribution in rat kidney at 15 minutes after dose administration.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13859,1,Biodistribution in rat kidney at 240 minutes after dose administration.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13860,1,Biodistribution in rat kidney at 30 minutes after dose administration.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13861,1,Biodistribution in rat kidney at 360 minutes after dose administration.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13862,1,Biodistribution in rat kidney at 60 minutes after dose administration.,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13863,1,Biodistribution in rat liver at 120 minutes after dose administration.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13864,1,Biodistribution in rat liver at 1440 minutes after dose administration.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13865,1,Biodistribution in rat liver at 15 minutes after dose administration.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13866,1,Biodistribution in rat liver at 240 minutes after dose administration.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13867,1,Biodistribution in rat liver at 30 minutes after dose administration.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13868,1,Biodistribution in rat liver at 360 minutes after dose administration.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13869,1,Biodistribution in rat liver at 60 minutes after dose administration.,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13870,1,Biodistribution in rat lung at 120 minutes after dose administration.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13871,1,Biodistribution in rat lung at 1440 minutes after dose administration.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13872,1,Biodistribution in rat lung at 15 minutes after dose administration.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13873,1,Biodistribution in rat lung at 240 minutes after dose administration.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13874,1,Biodistribution in rat lung at 30 minutes after dose administration.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13875,1,Biodistribution in rat lung at 360 minutes after dose administration.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
13876,1,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,Thoracic aorta,BAO_0000218,,Rattus norvegicus,,Intermediate,12361,,A,10116.0,,,,50597
13877,1,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,Thoracic aorta,BAO_0000218,,Rattus norvegicus,,Intermediate,12361,,A,10116.0,,,,50597
13878,1,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,Thoracic aorta,BAO_0000218,,Rattus norvegicus,,Intermediate,12361,,A,10116.0,,,,50597
13879,1,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,Thoracic aorta,BAO_0000218,,Rattus norvegicus,,Intermediate,12361,,A,10116.0,,,,50597
13880,1,Percent of maximal contractile response to compound in rat thoracic aorta strips v,Thoracic aorta,BAO_0000218,,Rattus norvegicus,,Intermediate,12361,,A,10116.0,,,,50597
13881,1,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,Thoracic aorta,BAO_0000218,,Rattus norvegicus,,Intermediate,12361,,A,10116.0,,,,50597
13882,1,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,Thoracic aorta,BAO_0000218,,Rattus norvegicus,,Intermediate,12361,,A,10116.0,,,,50597
13883,1,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12712,,A,10116.0,,,,50597
13884,1,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,Feces,BAO_0000218,,Rattus norvegicus,,Intermediate,7415,,A,10116.0,,,,50597
13885,1,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,7415,,A,10116.0,,,,50597
13886,1,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,7415,,A,10116.0,,,,50597
13887,1,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,7415,,A,10116.0,,,,50597
13888,1,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",Feces,BAO_0000218,,Rattus norvegicus,,Intermediate,7415,,A,10116.0,,,,50597
13889,1,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,7415,,A,10116.0,,,,50597
13890,1,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",,BAO_0000218,,Rattus norvegicus,,Intermediate,7415,,A,10116.0,,,,50597
13891,1,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,,BAO_0000218,,Mus musculus,,Intermediate,8050,,A,10090.0,,,,50594
13892,1,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,,BAO_0000218,,Mus musculus,,Intermediate,8050,,A,10090.0,,,,50594
13893,1,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,,BAO_0000218,,Mus musculus,,Intermediate,8050,,A,10090.0,,,,50594
13894,1,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,,BAO_0000218,,Mus musculus,,Intermediate,8050,,A,10090.0,,,,50594
13895,1,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,Urine,BAO_0000218,,Mus musculus,,Intermediate,8050,,A,10090.0,,,,50594
13896,1,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,Urine,BAO_0000218,,Mus musculus,,Intermediate,8050,,A,10090.0,,,,50594
13897,1,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,Urine,BAO_0000218,,Mus musculus,,Intermediate,8050,,A,10090.0,,,,50594
13898,1,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,Urine,BAO_0000218,,Mus musculus,,Intermediate,8050,,A,10090.0,,,,50594
13899,1,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,Urine,BAO_0000218,,Mus musculus,,Intermediate,8050,,A,10090.0,,,,50594
13900,1,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,Urine,BAO_0000218,,Mus musculus,,Intermediate,8050,,A,10090.0,,,,50594
13901,1,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,Urine,BAO_0000218,,Mus musculus,,Intermediate,8050,,A,10090.0,,,,50594
13902,1,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,Urine,BAO_0000218,,Mus musculus,,Intermediate,8050,,A,10090.0,,,,50594
13903,1,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,Urine,BAO_0000218,,Mus musculus,,Intermediate,8050,,A,10090.0,,,,50594
13904,1,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,Urine,BAO_0000218,,Mus musculus,,Intermediate,8050,,A,10090.0,,,,50594
13905,1,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,Urine,BAO_0000218,,Mus musculus,,Intermediate,8050,,A,10090.0,,,,50594
13906,1,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,Urine,BAO_0000218,,Mus musculus,,Intermediate,8050,,A,10090.0,,,,50594
13907,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
13908,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
13909,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
13910,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
13911,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
13912,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
13913,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
13914,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
13915,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
13916,1,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
13917,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
13918,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
13919,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
13920,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
13921,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
13922,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
13923,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
13924,1,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13925,1,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13926,1,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13927,1,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13928,1,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13929,1,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13930,1,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13931,1,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13932,1,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13933,1,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13934,1,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13935,1,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13936,1,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13937,1,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13938,1,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13939,1,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13940,1,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13941,1,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13942,1,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13943,1,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13944,1,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13945,1,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13946,1,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13947,1,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13948,1,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13949,1,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13950,1,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13951,1,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13952,1,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13953,1,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13954,1,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13955,1,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13956,1,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13957,1,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13958,1,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13959,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13960,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13961,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13962,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13963,1,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13964,1,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
13965,1,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13966,1,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13967,1,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13968,1,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13969,1,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13970,1,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13971,1,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13972,1,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13973,1,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13974,1,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13975,1,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13976,1,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13977,1,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13978,1,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13979,1,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13980,1,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
13981,1,Octanol:water partition coefficient is evaluated,,BAO_0000100,,,,Autocuration,8362,,P,,,,,22229
13982,1,Partition coefficient in 1-octanol/water system,,BAO_0000100,,,,Autocuration,8257,,P,,,,,22224
13983,1,Partition coefficient in 1-octanol/water system measured using radio active compounds,,BAO_0000100,,,,Autocuration,8257,,P,,,,,22224
13984,1,Partition coefficient in octanol/water system was determined,,BAO_0000100,,,,Autocuration,9468,,P,,,,,22224
13985,1,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,,BAO_0000100,,,,Autocuration,9468,,P,,,,,22224
13986,1,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,,BAO_0000019,,,,Autocuration,10568,,A,,,,,22224
13987,1,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",,BAO_0000019,,,,Autocuration,10568,,A,,,,,22224
13988,1,Pseudo-first-order rate constant of the compound,,BAO_0000019,,,,Autocuration,15359,,A,,,,,22224
13989,1,Pseudo-first-order rate constant with 1-min time point,,BAO_0000019,,,,Autocuration,15359,,A,,,,,22224
13990,1,Pseudo-first-order rate constant without 1-min time point,,BAO_0000019,,,,Autocuration,15359,,A,,,,,22224
13991,1,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,,BAO_0000019,,,,Autocuration,10431,,A,,,,,22224
13992,1,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,,BAO_0000019,,,,Autocuration,10431,,A,,,,,22224
13993,1,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,,BAO_0000019,,,,Autocuration,10431,,A,,,,,22224
13994,1,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,,BAO_0000019,,,,Autocuration,15704,,A,,,,,22224
13995,1,The alkaline hydrolysis second order rate constant(K OH) of the compound,,BAO_0000019,,,,Autocuration,15287,,A,,,,,22224
13996,1,The efflux rate constant of the compound,,BAO_0000019,,,,Autocuration,7516,,A,,,,,22224
13997,1,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,BAO_0000019,,,,Autocuration,12973,,A,,,,,22224
13998,1,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,BAO_0000019,,,,Autocuration,12973,,A,,,,,22224
13999,1,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,,BAO_0000019,,,,Autocuration,12973,,F,,,,,22224
14000,1,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,,BAO_0000019,,,,Autocuration,12973,,A,,,,,22224
14001,1,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,,BAO_0000019,,,,Autocuration,8696,,A,,,,,22224
14002,1,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,,BAO_0000019,,,,Autocuration,15052,,A,,,,,22224
14003,1,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,,BAO_0000019,,,,Autocuration,15052,,A,,,,,22224
14004,1,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),,BAO_0000019,,,,Autocuration,10503,,A,,,,,22224
14005,1,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
14006,1,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
14007,1,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
14008,1,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
14009,1,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
14010,1,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,,BAO_0000019,,,,Autocuration,10503,,A,,,,,22224
14011,1,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
14012,1,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
14013,1,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
14014,1,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
14015,1,Biodistribution in rat lung at 60 minutes after dose administration.,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14016,1,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14017,1,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14018,1,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14019,1,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14020,1,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14021,1,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14022,1,Biodistribution in rat striatum at 120 minutes after dose administration.,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14023,1,Biodistribution in rat striatum at 1440 minutes after dose administration.,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14024,1,Biodistribution in rat striatum at 15 minutes after dose administration.,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14025,1,Biodistribution in rat striatum at 240 minutes after dose administration.,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14026,1,Biodistribution in rat striatum at 30 minutes after dose administration.,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14027,1,Biodistribution in rat striatum at 360 minutes after dose administration.,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14028,1,Biodistribution in rat striatum at 3 hr after dose administration.,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14029,1,Biodistribution in rat striatum at 60 minutes after dose administration.,Striatum,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14030,1,Biodistribution in rat thyroid at 120 minutes after dose administration.,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14031,1,Biodistribution in rat thyroid at 1440 minutes after dose administration.,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14032,1,Biodistribution in rat thyroid at 15 minutes after dose administration.,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14033,1,Biodistribution in rat thyroid at 240 minutes after dose administration.,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14034,1,Biodistribution in rat thyroid at 30 minutes after dose administration.,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14035,1,Biodistribution in rat thyroid at 360 minutes after dose administration.,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14036,1,Biodistribution in rat thyroid at 60 minutes after dose administration.,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14037,1,Biodistribution in rest of brain of rat 120 minutes after dose administration.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14038,1,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14039,1,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14040,1,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14041,1,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14042,1,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14043,1,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13100,In vivo,A,10116.0,,,,50597
14044,1,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",,BAO_0000019,,,,Autocuration,13331,,A,,,,,22224
14045,1,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,BAO_0000019,,,,Autocuration,13331,,A,,,,,22224
14046,1,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),,BAO_0000019,,,,Autocuration,13331,,A,,,,,22224
14047,1,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",,BAO_0000019,,,,Autocuration,13331,,A,,,,,22224
14048,1,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",,BAO_0000019,,,,Autocuration,13331,,A,,,,,22224
14049,1,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",,BAO_0000019,,,,Autocuration,13331,,A,,,,,22224
14050,1,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",,BAO_0000019,,,,Autocuration,13331,,A,,,,,22224
14051,1,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",,BAO_0000019,,,,Autocuration,13331,,A,,,,,22224
14052,1,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,10086,,A,10116.0,,,,50597
14053,1,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,Urine,BAO_0000218,,,,Autocuration,10086,,F,,,,,22224
14054,1,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,10086,,A,10116.0,,,,50597
14055,1,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,Urine,BAO_0000218,,,,Autocuration,10086,,F,,,,,22224
14056,1,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,10086,,A,10116.0,,,,50597
14057,1,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,10086,,A,10116.0,,,,50597
14058,1,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,10086,,A,10116.0,,,,50597
14059,1,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,10086,,A,10116.0,,,,50597
14060,1,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,,BAO_0000218,,Rattus norvegicus,,Intermediate,13248,,A,10116.0,,,,50597
14061,1,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,13248,,A,10116.0,,,,50597
14062,1,In vitro metabolism in human liver microsomes,Liver,BAO_0000218,,Homo sapiens,,Intermediate,14527,,A,9606.0,,,,50587
14063,1,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,,BAO_0000218,,Homo sapiens,,Intermediate,3008,,A,9606.0,,,,50587
14064,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14065,1,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14066,1,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14067,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14068,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14069,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14070,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14071,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14072,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14073,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14074,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14075,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14076,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14077,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14078,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14079,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14080,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14081,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14082,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14083,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14084,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14085,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14086,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14087,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14088,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14089,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14090,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14091,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14092,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14093,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14094,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14095,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14096,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14097,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14098,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14099,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14100,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14101,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14102,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14103,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14104,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14105,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14106,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14107,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14108,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14109,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14110,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14111,1,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14112,1,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14113,1,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14114,1,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Uterus,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14115,1,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,14045,In vivo,A,10116.0,,,,50597
14116,1,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,14045,In vivo,A,10116.0,,,,50597
14117,1,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,14045,In vivo,A,10116.0,,,,50597
14118,1,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,14045,In vivo,A,10116.0,,,,50597
14119,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,14045,In vivo,A,10116.0,,,,50597
14120,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,14045,In vivo,A,10116.0,,,,50597
14121,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,14045,In vivo,A,10116.0,,,,50597
14122,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,14045,In vivo,A,10116.0,,,,50597
14123,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),,BAO_0000218,,Rattus norvegicus,,Intermediate,14045,In vivo,A,10116.0,,,,50597
14124,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),,BAO_0000218,,Rattus norvegicus,,Intermediate,14045,In vivo,A,10116.0,,,,50597
14125,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),,BAO_0000218,,Rattus norvegicus,,Intermediate,14045,In vivo,A,10116.0,,,,50597
14126,1,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),,BAO_0000218,,Rattus norvegicus,,Intermediate,14045,In vivo,A,10116.0,,,,50597
14127,1,Biodistribution in mice bladder plus excreted urine was determined,,BAO_0000218,,Mus musculus,,Intermediate,14045,In vivo,A,10090.0,,,,50594
14128,1,"Percentage biodistribution in mouse blood, 10 minutes post injection",,BAO_0000218,,Mus musculus,,Intermediate,14045,,A,10090.0,,,,50594
14129,1,"Percentage biodistribution in mouse blood, 30 minutes post injection",,BAO_0000218,,Mus musculus,,Intermediate,14045,,A,10090.0,,,,50594
14130,1,"Percentage biodistribution in mouse blood, 5 minutes post injection",,BAO_0000218,,Mus musculus,,Intermediate,14045,,A,10090.0,,,,50594
14131,1,"Percentage biodistribution in mouse blood, 60 minutes post injection",,BAO_0000218,,Mus musculus,,Intermediate,14045,,A,10090.0,,,,50594
14132,1,"Percentage biodistribution in mouse brain, 10 minutes post injection",Brain,BAO_0000218,,Mus musculus,,Intermediate,14045,,A,10090.0,,,,50594
14133,1,"Percentage biodistribution in mouse brain, 30 minutes post injection",Brain,BAO_0000218,,Mus musculus,,Intermediate,14045,,A,10090.0,,,,50594
14134,1,"Percentage biodistribution in mouse brain, 5 minutes post injection",Brain,BAO_0000218,,Mus musculus,,Intermediate,14045,,A,10090.0,,,,50594
14135,1,"Percentage biodistribution in mouse brain, 60 minutes post injection",Brain,BAO_0000218,,Mus musculus,,Intermediate,14045,,A,10090.0,,,,50594
14136,1,"Percentage biodistribution in mouse heart, 10 minutes post injection",,BAO_0000218,,Mus musculus,,Intermediate,14045,,A,10090.0,,,,50594
14137,1,"Percentage biodistribution in mouse heart, 30 minutes post injection",,BAO_0000218,,Mus musculus,,Intermediate,14045,,A,10090.0,,,,50594
14138,1,"Percentage biodistribution in mouse heart, 5 minutes post injection",,BAO_0000218,,Mus musculus,,Intermediate,14045,,A,10090.0,,,,50594
14139,1,"Percentage biodistribution in mouse heart, 60 minutes post injection",,BAO_0000218,,Mus musculus,,Intermediate,14045,,A,10090.0,,,,50594
14140,1,"Percentage biodistribution in mouse intestine, 10 minutes post injection",Intestine,BAO_0000218,,Mus musculus,,Intermediate,14045,,A,10090.0,,,,50594
14141,1,"Percentage biodistribution in mouse intestine, 30 minutes post injection",Intestine,BAO_0000218,,Mus musculus,,Intermediate,14045,,A,10090.0,,,,50594
14142,1,"Percentage biodistribution in mouse intestine, 5 minutes post injection",Intestine,BAO_0000218,,Mus musculus,,Intermediate,14045,,A,10090.0,,,,50594
14143,1,"Percentage biodistribution in mouse intestine, 60 minutes post injection",Intestine,BAO_0000218,,Mus musculus,,Intermediate,14045,,A,10090.0,,,,50594
14144,1,"Percentage biodistribution in mouse liver, 10 minutes post injection",Liver,BAO_0000218,,Mus musculus,,Intermediate,14045,,A,10090.0,,,,50594
14145,1,"Percentage biodistribution in mouse liver, 30 minutes of post injection",Liver,BAO_0000218,,Mus musculus,,Intermediate,14045,,A,10090.0,,,,50594
14146,1,"Percentage biodistribution in mouse liver, 5 minutes post injection",Liver,BAO_0000218,,Mus musculus,,Intermediate,14045,,A,10090.0,,,,50594
14147,1,Biodistribution in mice liver at 60 minutes of post injection,Liver,BAO_0000218,,Mus musculus,,Intermediate,14045,In vivo,A,10090.0,,,,50594
14148,1,Biodistribution in mice lungs at 10 min of post injection,Lung,BAO_0000218,,Mus musculus,,Intermediate,14045,In vivo,A,10090.0,,,,50594
14149,1,"Percentage biodistribution in mouse lung, 30 minutes post injection",,BAO_0000218,,Mus musculus,,Intermediate,14045,,A,10090.0,,,,50594
14150,1,"Percentage biodistribution in mousee lung, 5 minutes post injection",,BAO_0000218,,Mus musculus,,Intermediate,14045,,A,10090.0,,,,50594
14151,1,Biodistribution in mice lungs at 60 min of post injection,Lung,BAO_0000218,,Mus musculus,,Intermediate,14045,In vivo,A,10090.0,,,,50594
14152,1,Percentage biodistribution in mouse spleen,Spleen,BAO_0000218,,Mus musculus,,Intermediate,14045,,A,10090.0,,,,50594
14153,1,Percentage biodistribution in mouse stomach,Stomach,BAO_0000218,,Mus musculus,,Intermediate,14045,,A,10090.0,,,,50594
14154,1,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,Urine,BAO_0000218,,Mus musculus,,Intermediate,11745,,A,10090.0,,,,50594
14155,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,Urinary bladder,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14156,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,Blood,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14157,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,Bone element,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14158,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14159,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,Kidney,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14160,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,Liver,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14161,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,Lung,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14162,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14163,1,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
14164,1,Affinity for protein binding expressed as association constant in fresh rat serum,Serum,BAO_0000218,,Rattus norvegicus,,Intermediate,7095,,A,10116.0,,,,50597
14165,1,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,BAO_0000019,,,,Autocuration,12185,,A,,,,,22224
14166,1,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,BAO_0000019,,,,Autocuration,12185,,A,,,,,22224
14167,1,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,,BAO_0000019,,,,Autocuration,12185,,A,,,,,22224
14168,1,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,,BAO_0000019,,,,Autocuration,12185,,A,,,,,22224
14169,1,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,,BAO_0000019,,,,Autocuration,12686,,A,,,,,22224
14170,1,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,BAO_0000019,,,,Autocuration,12686,,A,,,,,22224
14171,1,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,,BAO_0000019,,,,Autocuration,12686,,A,,,,,22224
14172,1,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",,BAO_0000019,,,,Autocuration,12686,,A,,,,,22224
14173,1,Apparent rate constant Koff for inactivation of dTMP synthase.,,BAO_0000019,,,,Autocuration,8057,,A,,,,,22224
14174,1,The irreversible inhibitor activity by second order rate equation.,,BAO_0000019,,,,Autocuration,15778,,A,,,,,22224
14175,1,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,12375,,A,10116.0,,,,50597
14176,1,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,12375,,A,10116.0,,,,50597
14177,1,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,,BAO_0000218,,Rattus norvegicus,,Intermediate,12375,,A,10116.0,,,,50597
14178,1,Dissociation rate calculated from the first-order equation using t1/2 value,,BAO_0000019,,,,Autocuration,13588,,A,,,,,22224
14179,1,The compound was tested for Binding constant against DNA,,BAO_0000019,,,,Autocuration,15039,,A,,,,,22224
14180,1,First order rate constant for cyclization of the compound,,BAO_0000019,,,,Autocuration,9500,,A,,,,,22224
14181,1,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,BAO_0000019,,,,Autocuration,10014,,A,,,,,22224
14182,1,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,BAO_0000019,,,,Autocuration,10014,,A,,,,,22224
14183,1,Hydrolysis rate constant was determined,,BAO_0000019,,,,Autocuration,568,,A,,,,,22224
14184,1,Observed first order rate constant,,BAO_0000019,,,,Autocuration,10026,,A,,,,,22224
14185,1,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,BAO_0000019,,,,Autocuration,10281,,A,,,,,22224
14186,1,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,BAO_0000019,,,,Autocuration,10281,,A,,,,,22224
14187,1,Second-order rate constant for attack on PNPA at 25 degree Centigrade,,BAO_0000019,,,,Autocuration,9680,,A,,,,,22224
14188,1,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14189,1,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14190,1,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14191,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14192,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14193,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14194,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14195,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14196,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14197,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14198,1,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14199,1,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14200,1,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14201,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14202,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14203,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14204,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14205,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14206,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14207,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14208,1,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,,BAO_0000218,,Homo sapiens,,Intermediate,3008,,A,9606.0,,,,50587
14209,1,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,BAO_0000218,,Homo sapiens,,Intermediate,4509,,A,9606.0,,,,50587
14210,1,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,,BAO_0000218,,Homo sapiens,,Intermediate,4509,,A,9606.0,,,,50587
14211,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
14212,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
14213,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
14214,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
14215,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
14216,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
14217,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
14218,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
14219,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
14220,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
14221,1,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,,BAO_0000218,,Human herpesvirus 1,,Intermediate,8613,,A,10298.0,,,,50602
14222,1,Calculated partition coefficient (clogP) (MlogP),,BAO_0000100,,,,Autocuration,6021,,P,,,,,22229
14223,1,Equipotent potent ratio relative to carbachol (nicotinic activity),,BAO_0000019,,,,Autocuration,9348,,A,,,,,22224
14224,1,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",,BAO_0000218,,Canis lupus familiaris,,Intermediate,15592,,A,9615.0,,,,50588
14225,1,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",,BAO_0000218,,Canis lupus familiaris,,Intermediate,15592,,A,9615.0,,,,50588
14226,1,Solubility at pH 7.4 in micro g/mL;NA denotes available,,BAO_0000100,,,,Autocuration,15592,,P,,,,,22229
14227,1,Solubility at pH 7.4 in micro g/mL;NA denotes not available,,BAO_0000100,,,,Autocuration,15592,,P,,,,,22229
14228,1,Solubility at pH 7.4 in ug/mL;NA denotes not available,,BAO_0000100,,,,Autocuration,15592,,P,,,,,22229
14229,1,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,Plasma,BAO_0000218,,Canis lupus familiaris,,Intermediate,15592,In vivo,A,9615.0,,,,50588
14230,1,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,Serum,BAO_0000218,,Rattus norvegicus,,Intermediate,7095,,A,10116.0,,,,50597
14231,1,Area under the MAP curve measured over 5 min; ND means Not determined,,BAO_0000019,,,,Autocuration,16618,,A,,,,,22224
14232,1,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,,BAO_0000100,,,,Autocuration,16835,,P,,,,,22224
14233,1,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,,BAO_0000100,,,,Autocuration,15284,,P,,,,,22229
14234,1,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,,BAO_0000019,,,,Autocuration,15750,,A,,,,,22224
14235,1,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,16618,In vivo,A,10116.0,,,,50597
14236,1,Half life after oral tested,,BAO_0000218,,,,Autocuration,16618,In vivo,A,,,,,22224
14237,1,Half life was determined in plasma of rat; NT indicates not tested,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15812,,A,10116.0,,,,50597
14238,1,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,,BAO_0000218,,Rattus norvegicus,,Intermediate,16618,In vivo,A,10116.0,,,,50597
14239,1,Oral bioavailability after oral tested,,BAO_0000218,,,,Autocuration,16618,In vivo,A,,,,,22224
14240,1,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),,BAO_0000218,,Rattus norvegicus,,Intermediate,13098,,A,10116.0,,,,50597
14241,1,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),,BAO_0000218,,Rattus norvegicus,,Intermediate,13098,,A,10116.0,,,,50597
14242,1,half life was determined in plasma of rat; NT indicates not tested,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15812,,A,10116.0,,,,50597
14243,1,half life was determined in plasma of rat; NT means not tested,Plasma,BAO_0000218,,Rattus norvegicus,,Intermediate,15812,,A,10116.0,,,,50597
14244,1,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14245,1,Mean sodium excretion in rats (Control/Drug treatment value); inactive,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14246,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14247,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14248,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14249,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14250,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14251,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14252,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14253,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14254,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14255,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14256,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14257,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14258,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14259,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14260,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14261,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14262,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14263,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14264,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14265,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14266,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14267,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14268,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14269,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14270,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14271,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14272,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14273,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14274,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14275,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14276,1,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14277,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14278,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14279,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14280,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14281,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14282,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14283,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14284,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14285,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14286,1,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14287,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14288,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14289,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14290,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14291,1,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14292,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14293,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14294,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14295,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14296,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14297,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14298,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14299,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14300,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14301,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14302,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14303,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14304,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14305,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14306,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14307,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14308,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14309,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14310,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14311,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14312,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14313,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14314,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,Spleen,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14315,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,Urinary bladder,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14316,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,Blood,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14317,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,Bone element,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14318,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14319,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,Kidney,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14320,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,Liver,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14321,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,Lung,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14322,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14323,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14324,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14325,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14326,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14327,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14328,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,Spleen,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14329,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14330,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,Urinary bladder,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14331,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,Blood,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14332,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,Bone element,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14333,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14334,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,Kidney,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14335,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,Liver,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14336,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,Lung,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14337,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14338,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14339,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14340,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14341,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14342,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14343,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14344,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,Spleen,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14345,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,Urinary bladder,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14346,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,Blood,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14347,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,Bone element,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14348,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14349,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,Liver,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14350,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,Lung,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14351,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14352,1,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,,BAO_0000019,,,,Autocuration,2193,,A,,,,,22224
14353,1,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,,BAO_0000019,,,,Autocuration,2193,,A,,,,,22224
14354,1,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,,BAO_0000019,,,,Autocuration,2193,,A,,,,,22224
14355,1,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,,BAO_0000019,,,,Autocuration,2193,,A,,,,,22224
14356,1,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,,BAO_0000019,,,,Autocuration,2193,,A,,,,,22224
14357,1,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,,BAO_0000019,,,,Autocuration,2193,,A,,,,,22224
14358,1,Hydrolysis rate constant was determined,,BAO_0000019,,,,Autocuration,568,,A,,,,,22224
14359,1,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",,BAO_0000019,,,,Autocuration,9680,,A,,,,,22224
14360,1,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,BAO_0000019,,,,Autocuration,9680,,A,,,,,22224
14361,1,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,BAO_0000019,,,,Autocuration,9680,,A,,,,,22224
14362,1,Observed second order rate constant,,BAO_0000019,,,,Autocuration,10026,,A,,,,,22224
14363,1,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,,BAO_0000019,,,,Autocuration,10281,,A,,,,,22224
14364,1,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,,BAO_0000019,,,,Autocuration,10014,,A,,,,,22224
14365,1,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,,BAO_0000019,,,,Autocuration,10014,,A,,,,,22224
14366,1,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",,BAO_0000019,,,,Autocuration,9680,,A,,,,,22224
14367,1,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",,BAO_0000019,,,,Autocuration,9680,,A,,,,,22224
14368,1,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14369,1,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14370,1,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14371,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14372,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14373,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14374,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14375,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14376,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14377,1,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,,BAO_0000019,,,,Autocuration,13028,,A,,,,,22224
14378,1,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,,BAO_0000218,,Rattus norvegicus,,Intermediate,10014,,A,10116.0,,,,50597
14379,1,Association constant for compound at 31 degree C was determined,,BAO_0000019,,,,Autocuration,9962,,A,,,,,22224
14380,1,Calculated antagonist equilibrium dissociation constant of the compound,,BAO_0000019,,,,Autocuration,12029,,A,,,,,22224
14381,1,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,,BAO_0000019,,,,Autocuration,12029,,A,,,,,22224
14382,1,Dissociation constants vs LTE4 on guinea pig trachea,Trachea,BAO_0000218,,Cavia porcellus,,Intermediate,10583,,A,10141.0,,,,50512
14383,1,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",,BAO_0000019,,,,Autocuration,568,,A,,,,,22224
14384,1,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",,BAO_0000019,,,,Autocuration,568,,A,,,,,22224
14385,1,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",,BAO_0000019,,,,Autocuration,568,,A,,,,,22224
14386,1,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",,BAO_0000019,,,,Autocuration,568,,A,,,,,22224
14387,1,Affinity constant KD value was derived from TMP,,BAO_0000019,,,,Autocuration,7493,,A,,,,,22224
14388,1,Apparent dissociation (binding) rate constant was evaluated,,BAO_0000019,,,,Autocuration,8371,,A,,,,,22224
14389,1,Dissociation constant (KD) of the compound,,BAO_0000100,,,,Autocuration,13114,,P,,,,,22224
14390,1,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,,BAO_0000100,,,,Autocuration,15515,,P,,,,,22224
14391,1,Dissociation constant from ESR titration experiments,,BAO_0000100,,,,Autocuration,522,,P,,,,,22224
14392,1,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),,BAO_0000019,,,,Autocuration,13888,,,,,,,22224
14393,1,Dissociation constant was evaluated.,,BAO_0000100,,,,Autocuration,2616,,P,,,,,22224
14394,1,Dissociation constant was reported,,BAO_0000100,,,,Autocuration,3798,,P,,,,,22224
14395,1,Dissociation constant was determined in rat pituitary cells.,,BAO_0000218,,Rattus norvegicus,,Intermediate,8731,,A,10116.0,,,,50597
14396,1,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,,BAO_0000019,,,,Autocuration,11892,,A,,,,,22224
14397,1,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,,BAO_0000019,,,,Autocuration,11892,,A,,,,,22224
14398,1,Equilibrium dissociation constant of the compound,,BAO_0000019,,,,Autocuration,2582,,A,,,,,22224
14399,1,Equilibrium dissociation constant was determined,,BAO_0000019,,,,Autocuration,11892,,A,,,,,22224
14400,1,Kinetic constant KD was evaluated,,BAO_0000019,,,,Autocuration,13396,,A,,,,,22224
14401,1,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,,BAO_0000019,,,,Autocuration,603,,A,,,,,22224
14402,1,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,,BAO_0000019,,,,Autocuration,15673,,A,,,,,22224
14403,1,Rate constant for hydrolysis in aqueous acetone.,,BAO_0000019,,,,Autocuration,10368,,A,,,,,22224
14404,1,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,,BAO_0000019,,,,Autocuration,14228,,A,,,,,22224
14405,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14406,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14407,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14408,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14409,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14410,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14411,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14412,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14413,1,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14414,1,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14415,1,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14416,1,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14417,1,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14418,1,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14419,1,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14420,1,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14421,1,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14422,1,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14423,1,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14424,1,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14425,1,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14426,1,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14427,1,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14428,1,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14429,1,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14430,1,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14431,1,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14432,1,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14433,1,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14434,1,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14435,1,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14436,1,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14437,1,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14438,1,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14439,1,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14440,1,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14441,1,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14442,1,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,,BAO_0000218,,Rattus norvegicus,,Intermediate,11510,,A,10116.0,,,,50597
14443,1,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8310,,A,9615.0,,,,50588
14444,1,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8310,,A,9615.0,,,,50588
14445,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,BAO_0000218,,Mus musculus,,Intermediate,8310,,A,10090.0,,,,50594
14446,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,BAO_0000218,,Mus musculus,,Intermediate,8310,,A,10090.0,,,,50594
14447,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,BAO_0000218,,Mus musculus,,Intermediate,8310,,A,10090.0,,,,50594
14448,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,,BAO_0000218,,Mus musculus,,Intermediate,8310,,A,10090.0,,,,50594
14449,1,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,BAO_0000218,,Mus musculus,,Intermediate,8310,,A,10090.0,,,,50594
14450,1,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8310,,A,9615.0,,,,50588
14451,1,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,,BAO_0000218,,Mus musculus,,Intermediate,8310,,A,10090.0,,,,50594
14452,1,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8310,,A,9615.0,,,,50588
14453,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,,BAO_0000218,,Canis lupus familiaris,,Intermediate,8310,,A,9615.0,,,,50588
14454,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,BAO_0000218,,Mus musculus,,Intermediate,8310,,A,10090.0,,,,50594
14455,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,,BAO_0000218,,Mus musculus,,Intermediate,8310,,A,10090.0,,,,50594
14456,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,,BAO_0000218,,Mus musculus,,Intermediate,8310,,A,10090.0,,,,50594
14457,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,,BAO_0000218,,Mus musculus,,Intermediate,8310,,A,10090.0,,,,50594
14458,1,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,,BAO_0000218,,Mus musculus,,Intermediate,8310,,A,10090.0,,,,50594
14459,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14460,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14461,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14462,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14463,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14464,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14465,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14466,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14467,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14468,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14469,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14470,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14471,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14472,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14473,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14474,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14475,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14476,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14477,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14478,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14479,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14480,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14481,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14482,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14483,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14484,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14485,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14486,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14487,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14488,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14489,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14490,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14491,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14492,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14493,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14494,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14495,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14496,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14497,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14498,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14499,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14500,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14501,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14502,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14503,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14504,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14505,1,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14506,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14507,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14508,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14509,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14510,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14511,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,Spleen,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14512,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,Kidney,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14513,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,Urinary bladder,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14514,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,Blood,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14515,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,Bone element,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14516,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14517,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,Kidney,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14518,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,Liver,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14519,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,Lung,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14520,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14521,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14522,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14523,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14524,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14525,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14526,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14527,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,Spleen,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14528,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,Prostate gland,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14529,1,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,Muscle tissue,BAO_0000218,,,,Autocuration,13257,In vivo,A,,,,,22224
14530,1,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14531,1,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14532,1,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14533,1,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14534,1,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14535,1,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14536,1,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,Hypothalamus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14537,1,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,Hypothalamus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14538,1,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14539,1,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14540,1,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14541,1,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,Hypothalamus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14542,1,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14543,1,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14544,1,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14545,1,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,Hypothalamus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14546,1,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14547,1,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14548,1,Biodistribution of the [11C]-radiolabeled compound in rat cortex,,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14549,1,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14550,1,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14551,1,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14552,1,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,Hypothalamus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14553,1,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,Hypothalamus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14554,1,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,Cerebellum,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14555,1,Biodistribution of the [18F]-radiolabeled compound in rat cortex,,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14556,1,Reaction rate parameter value for phosphate with transfer with respect to ATP,,BAO_0000019,,,,Autocuration,12404,,A,,,,,22224
14557,1,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",,BAO_0000019,,,,Autocuration,568,,A,,,,,22224
14558,1,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,BAO_0000019,,,,Autocuration,568,,A,,,,,22224
14559,1,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",,BAO_0000019,,,,Autocuration,568,,A,,,,,22224
14560,1,Reaction rate parameter value for phosphate with transfer with respect to ATP,,BAO_0000019,,,,Autocuration,12404,,A,,,,,22224
14561,1,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,,BAO_0000218,,Escherichia coli,,Intermediate,7624,,A,562.0,,,,50212
14562,1,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",,BAO_0000218,,Rattus norvegicus,,Intermediate,7624,,A,10116.0,,,,50597
14563,1,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",,BAO_0000218,,Rattus norvegicus,,Intermediate,7624,,A,10116.0,,,,50597
14564,1,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",,BAO_0000019,,,,Autocuration,4643,,A,,,,,22224
14565,1,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,,BAO_0000019,,,,Autocuration,11532,,A,,,,,22224
14566,1,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,,BAO_0000019,,,,Autocuration,11018,,A,,,,,22224
14567,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,BAO_0000019,,,,Autocuration,2276,,A,,,,,22224
14568,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",,BAO_0000019,,,,Autocuration,2276,,A,,,,,22224
14569,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",,BAO_0000019,,,,Autocuration,2276,,A,,,,,22224
14570,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",,BAO_0000019,,,,Autocuration,2276,,A,,,,,22224
14571,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",,BAO_0000019,,,,Autocuration,2276,,A,,,,,22224
14572,1,Michaelis constant (KM) was evaluated,,BAO_0000019,,,,Autocuration,8949,,A,,,,,22224
14573,1,Reaction rate parameter value for phosphate with transfer with respect to ATP,,BAO_0000019,,,,Autocuration,12404,,A,,,,,22224
14574,1,Substrate concentration for half maximal velocity was reported for rat hexokinase I,,BAO_0000019,,,,Autocuration,7625,,B,,,,,22224
14575,1,Substrate concentration for half maximal velocity was reported for rat hexokinase II,,BAO_0000019,,,,Autocuration,7625,,B,,,,,22224
14576,1,Substrate concentration for half maximal velocity was reported for rat hexokinase III,,BAO_0000019,,,,Autocuration,7625,,B,,,,,22224
14577,1,Substrate concentration for half maximal velocity was reported for yeast hexokinase,,BAO_0000019,,,,Autocuration,7625,,B,,,,,22224
14578,1,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,,BAO_0000019,,,,Autocuration,12908,,A,,,,,22224
14579,1,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,,BAO_0000019,,,,Autocuration,10368,,A,,,,,22224
14580,1,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,BAO_0000019,,,,Autocuration,13108,,A,,,,,22224
14581,1,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),,BAO_0000019,,,,Autocuration,13108,,A,,,,,22224
14582,1,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,,BAO_0000019,,,,Autocuration,15217,,A,,,,,22224
14583,1,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,,BAO_0000019,,,,Autocuration,15217,,A,,,,,22224
14584,1,Binding constant was determined,,BAO_0000019,,,,Autocuration,10933,,A,,,,,22224
14585,1,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,,BAO_0000019,,,,Autocuration,2363,,A,,,,,22224
14586,1,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,,BAO_0000019,,,,Autocuration,2363,,A,,,,,22224
14587,1,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,,BAO_0000019,,,,Autocuration,2276,,A,,,,,22224
14588,1,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,,BAO_0000100,,,,Autocuration,14915,,P,,,,,22224
14589,1,Catalytic rate constant of the compound,,BAO_0000019,,,,Autocuration,8847,,A,,,,,22224
14590,1,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,,BAO_0000019,,,,Autocuration,15357,,B,,,,,22224
14591,1,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),,BAO_0000019,,,,Autocuration,2869,,A,,,,,22224
14592,1,Catalytic rate constant against phospholipase A2 was determined,,BAO_0000019,,,,Autocuration,3484,,A,,,,,22224
14593,1,"Compound was evaluated for catalytic constant, Kcat",,BAO_0000019,,,,Autocuration,1373,,A,,,,,22224
14594,1,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,,BAO_0000019,,,,Autocuration,8142,,A,,,,,22224
14595,1,Kcat calculated from 0.693/T1/2,,BAO_0000019,,,,Autocuration,14131,,A,,,,,22224
14596,1,Kcat was determined,,BAO_0000019,,,,Autocuration,17269,,A,,,,,22224
14597,1,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,,BAO_0000019,,,,Autocuration,3485,,A,,,,,22224
14598,1,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,,BAO_0000019,,,,Autocuration,3485,,A,,,,,22224
14599,1,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,,BAO_0000019,,,,Autocuration,3485,,A,,,,,22224
14600,1,Kcat value was determined,,BAO_0000019,,,,Autocuration,5962,,A,,,,,22224
14601,1,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,,BAO_0000019,,,,Autocuration,3133,,A,,,,,22224
14602,1,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,,BAO_0000019,,,,Autocuration,3133,,A,,,,,22224
14603,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,BAO_0000019,,,,Autocuration,2276,,A,,,,,22224
14604,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",,BAO_0000019,,,,Autocuration,2276,,A,,,,,22224
14605,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",,BAO_0000019,,,,Autocuration,2276,,A,,,,,22224
14606,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",,BAO_0000019,,,,Autocuration,2276,,A,,,,,22224
14607,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",,BAO_0000019,,,,Autocuration,2276,,A,,,,,22224
14608,1,Kinetic parameter for rate of conversion to PABA was determined,,BAO_0000019,,,,Autocuration,4892,,A,,,,,22224
14609,1,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,BAO_0000019,,,,Autocuration,3133,,A,,,,,22224
14610,1,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",Feces,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
14611,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
14612,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
14613,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
14614,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
14615,1,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
14616,1,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
14617,1,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
14618,1,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
14619,1,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
14620,1,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
14621,1,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
14622,1,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
14623,1,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
14624,1,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
14625,1,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
14626,1,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
14627,1,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
14628,1,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
14629,1,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
14630,1,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
14631,1,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
14632,1,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
14633,1,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,11488,,A,10116.0,,,,50597
14634,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
14635,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
14636,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
14637,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
14638,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
14639,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
14640,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
14641,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
14642,1,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
14643,1,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
14644,1,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
14645,1,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
14646,1,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",Feces,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
14647,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
14648,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
14649,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
14650,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
14651,1,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",Urine,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,7132,,A,9986.0,,,,50592
14652,1,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,A,10116.0,,,,50597
14653,1,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,A,10116.0,,,,50597
14654,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14655,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14656,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14657,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14658,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14659,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14660,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14661,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14662,1,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14663,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14664,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14665,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14666,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14667,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14668,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14669,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14670,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14671,1,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,Urine,BAO_0000218,,Canis lupus familiaris,,Intermediate,12582,,A,9615.0,,,,50588
14672,1,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14673,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14674,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14675,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14676,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14677,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14678,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14679,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14680,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14681,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14682,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14683,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14684,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14685,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14686,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14687,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14688,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14689,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14690,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14691,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14692,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14693,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14694,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14695,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14696,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14697,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14698,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14699,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14700,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14701,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14702,1,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,Hippocampus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14703,1,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,Hypothalamus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14704,1,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,Hypothalamus,BAO_0000218,,Rattus norvegicus,,Intermediate,15413,In vivo,A,10116.0,,,,50597
14705,1,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14706,1,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14707,1,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14708,1,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14709,1,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14710,1,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14711,1,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14712,1,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14713,1,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14714,1,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14715,1,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14716,1,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14717,1,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14718,1,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14719,1,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14720,1,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14721,1,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14722,1,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14723,1,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14724,1,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14725,1,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14726,1,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14727,1,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14728,1,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14729,1,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14730,1,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14731,1,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14732,1,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14733,1,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14734,1,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14735,1,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14736,1,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14737,1,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14738,1,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14739,1,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14740,1,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14741,1,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14742,1,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14743,1,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14744,1,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14745,1,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14746,1,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,,BAO_0000019,,,,Autocuration,3133,,A,,,,,22224
14747,1,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,,BAO_0000019,,,,Autocuration,2742,,A,,,,,22224
14748,1,Compound was tested for amidase rate in the presence of N62C screen enzyme,,BAO_0000019,,,,Autocuration,2742,,A,,,,,22224
14749,1,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,,BAO_0000019,,,,Autocuration,2742,,A,,,,,22224
14750,1,Compound was tested for amidase rate in the presence of S166C screen enzyme,,BAO_0000019,,,,Autocuration,2742,,A,,,,,22224
14751,1,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,,BAO_0000019,,,,Autocuration,2742,,A,,,,,22224
14752,1,Compound was tested for esterase rate in the presence of N62C screen enzyme,,BAO_0000019,,,,Autocuration,2742,,A,,,,,22224
14753,1,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,,BAO_0000019,,,,Autocuration,2742,,A,,,,,22224
14754,1,Compound was tested for esterase rate in the presence of S166C screen enzyme,,BAO_0000019,,,,Autocuration,2742,,A,,,,,22224
14755,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,BAO_0000019,,,,Autocuration,2276,,A,,,,,22224
14756,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,BAO_0000019,,,,Autocuration,2276,,A,,,,,22224
14757,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",,BAO_0000019,,,,Autocuration,2276,,A,,,,,22224
14758,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,BAO_0000019,,,,Autocuration,2276,,A,,,,,22224
14759,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",,BAO_0000019,,,,Autocuration,2276,,A,,,,,22224
14760,1,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",,BAO_0000019,,,,Autocuration,2276,,A,,,,,22224
14761,1,Ratio of Kcat to that of Km was determined,,BAO_0000019,,,,Autocuration,17269,,A,,,,,22224
14762,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,BAO_0000019,,,,Autocuration,2276,,A,,,,,22224
14763,1,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",,BAO_0000019,,,,Autocuration,2276,,A,,,,,22224
14764,1,"Compound was evaluated for constant, Kd",,BAO_0000019,,,,Autocuration,15917,,A,,,,,22224
14765,1,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,,BAO_0000019,,,,Autocuration,10933,,A,,,,,22224
14766,1,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,,BAO_0000019,,,,Autocuration,10933,,A,,,,,22224
14767,1,Dissociation Constant of compound determined,,BAO_0000019,,,,Autocuration,14293,,A,,,,,22224
14768,1,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,,BAO_0000019,,,,Autocuration,6698,,B,,,,,22224
14769,1,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,,BAO_0000019,,,,Autocuration,6698,,B,,,,,22224
14770,1,Dissociation constant of compound with Fructose was determined,,BAO_0000100,,,,Autocuration,4318,,P,,,,,22224
14771,1,Dissociation constant of compound with Fructose was determined; Not determined,,BAO_0000100,,,,Autocuration,4318,,P,,,,,22224
14772,1,Dissociation constant of compound with Lactulose was determined,,BAO_0000100,,,,Autocuration,4318,,P,,,,,22224
14773,1,Dissociation constant of compound with Lactulose was determined; Not determined,,BAO_0000100,,,,Autocuration,4318,,P,,,,,22224
14774,1,Dissociation constant of the Compound,,BAO_0000100,,,,Autocuration,14959,,P,,,,,22224
14775,1,Dissociation constant by non-linear regression analysis,,BAO_0000100,,,,Autocuration,5913,,P,,,,,22224
14776,1,Dissociation constant was determined,,BAO_0000100,,,,Autocuration,14218,,P,,,,,22224
14777,1,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,,BAO_0000100,,,,Autocuration,10689,,P,,,,,22224
14778,1,Dissociation constant was determined,,BAO_0000100,,,,Autocuration,13925,,P,,,,,22224
14779,1,Dissociation constant was determined,,BAO_0000100,,,,Autocuration,16359,,P,,,,,22224
14780,1,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,10944,,A,10116.0,,,,50597
14781,1,The dissociation constant determined by fluorescence displacement assay,,BAO_0000019,,,,Autocuration,11080,,A,,,,,22224
14782,1,kd value surface plasmon resonance (SPR) method,,BAO_0000019,,,,Autocuration,17805,,A,,,,,22224
14783,1,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,10944,,A,10116.0,,,,50597
14784,1,First dissociation constant of the binding of compound to V30M TTR,,BAO_0000019,,,,Autocuration,16645,,F,,,,,22224
14785,1,Second dissociation constant of the binding of compound to V30M TTR,,BAO_0000019,,,,Autocuration,16645,,F,,,,,22224
14786,1,"Compound was evaluated for equilibrium constant, Ke",,BAO_0000019,,,,Autocuration,7793,,A,,,,,22224
14787,1,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,Hypothalamus,BAO_0000019,,,,Autocuration,12199,,A,,,,,22224
14788,1,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,Hypothalamus,BAO_0000019,,,,Autocuration,12199,,A,,,,,22224
14789,1,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,,BAO_0000019,,,,Autocuration,9680,,A,,,,,22224
14790,1,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,BAO_0000019,,,,Autocuration,9680,,A,,,,,22224
14791,1,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,,BAO_0000019,,,,Autocuration,9680,,A,,,,,22224
14792,1,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,BAO_0000218,,Mus musculus,,Intermediate,13758,,A,10090.0,,,,50594
14793,1,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,BAO_0000218,,Mus musculus,,Intermediate,13758,,A,10090.0,,,,50594
14794,1,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,BAO_0000218,,Mus musculus,,Intermediate,13758,,A,10090.0,,,,50594
14795,1,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,BAO_0000218,,Mus musculus,,Intermediate,13758,,A,10090.0,,,,50594
14796,1,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,,BAO_0000218,,Mus musculus,,Intermediate,13758,,A,10090.0,,,,50594
14797,1,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,,BAO_0000218,,Mus musculus,,Intermediate,13758,,A,10090.0,,,,50594
14798,1,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,,BAO_0000218,,Mus musculus,,Intermediate,13758,,A,10090.0,,,,50594
14799,1,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,,BAO_0000218,,Mus musculus,,Intermediate,13758,,A,10090.0,,,,50594
14800,1,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,,A,10116.0,,,,50597
14801,1,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,,BAO_0000218,,Rattus norvegicus,,Intermediate,14393,,A,10116.0,,,,50597
14802,1,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",,BAO_0000218,,Rattus norvegicus,,Intermediate,15078,,A,10116.0,,,,50597
14803,1,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,A,10116.0,,,,50597
14804,1,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,A,10116.0,,,,50597
14805,1,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,A,10116.0,,,,50597
14806,1,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,A,10116.0,,,,50597
14807,1,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,A,10116.0,,,,50597
14808,1,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Kidney,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,A,10116.0,,,,50597
14809,1,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,A,10116.0,,,,50597
14810,1,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,A,10116.0,,,,50597
14811,1,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,A,10116.0,,,,50597
14812,1,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,A,10116.0,,,,50597
14813,1,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,A,10116.0,,,,50597
14814,1,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,A,10116.0,,,,50597
14815,1,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,A,10116.0,,,,50597
14816,1,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Zone of skin,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,A,10116.0,,,,50597
14817,1,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,A,10116.0,,,,50597
14818,1,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,In vivo,A,10116.0,,,,50597
14819,1,Biodistribution of Compound in rat blood after 15 minutes of administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9712,In vivo,A,10116.0,,,,50597
14820,1,Biodistribution of Compound in rat blood after 2 minutes of administration,Blood,BAO_0000218,,Rattus norvegicus,,Intermediate,9712,In vivo,A,10116.0,,,,50597
14821,1,Biodistribution of Compound in rat brain after 15 minutes of administration,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,9712,In vivo,A,10116.0,,,,50597
14822,1,Biodistribution of Compound in rat brain after 2 minutes of administration,Brain,BAO_0000218,,Rattus norvegicus,,Intermediate,9712,In vivo,A,10116.0,,,,50597
14823,1,Biodistribution of Compound in rat heart after 15 minutes of administration,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9712,In vivo,A,10116.0,,,,50597
14824,1,Biodistribution of Compound in rat heart after 2 minutes of administration,Heart,BAO_0000218,,Rattus norvegicus,,Intermediate,9712,In vivo,A,10116.0,,,,50597
14825,1,Biodistribution of Compound in rat liver after 15 minutes of administration,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9712,In vivo,A,10116.0,,,,50597
14826,1,Biodistribution of Compound in rat liver after 2 minutes of administration,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,9712,In vivo,A,10116.0,,,,50597
14827,1,Biodistribution of Compound in rat lung after 15 minutes of administration,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,9712,In vivo,A,10116.0,,,,50597
14828,1,Biodistribution of Compound in rat lung after 2 minutes of administration,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,9712,In vivo,A,10116.0,,,,50597
14829,1,Biodistribution of Compound in rat muscle after 15 minutes of administration,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9712,In vivo,A,10116.0,,,,50597
14830,1,Biodistribution of Compound in rat muscle after 2 minutes of administration,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,9712,In vivo,A,10116.0,,,,50597
14831,1,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,,A,10116.0,,,,50597
14832,1,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,,A,10116.0,,,,50597
14833,1,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,,BAO_0000218,,Rattus norvegicus,,Intermediate,13925,,A,10116.0,,,,50597
14834,1,Organ distribution in rat blood 2 minutes after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,A,10116.0,,,,50597
14835,1,Organ distribution in rat blood 2 hr after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,A,10116.0,,,,50597
14836,1,Organ distribution in rat blood 30 minutes after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,A,10116.0,,,,50597
14837,1,Organ distribution in rat blood 30 min after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,A,10116.0,,,,50597
14838,1,Organ distribution in rat brain 2 minutes after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,A,10116.0,,,,50597
14839,1,Organ distribution in rat brain 2 hr after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,A,10116.0,,,,50597
14840,1,Organ distribution in rat brain 30 minutes after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,A,10116.0,,,,50597
14841,1,Organ distribution in rat heart 2 minutes after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,A,10116.0,,,,50597
14842,1,Organ distribution in rat heart 2 hr after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,A,10116.0,,,,50597
14843,1,Organ distribution in rat heart 30 minutes after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,A,10116.0,,,,50597
14844,1,Organ distribution in rat kidney 2 minutes after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,A,10116.0,,,,50597
14845,1,Organ distribution in rat kidney 2 hr after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,A,10116.0,,,,50597
14846,1,Organ distribution in rat kidney 30 minutes after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,A,10116.0,,,,50597
14847,1,Organ distribution in rat liver 2 minutes after intravenous injection,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,A,10116.0,,,,50597
14848,1,Organ distribution in rat liver 2 hr after intravenous injection,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,A,10116.0,,,,50597
14849,1,Organ distribution in rat liver 30 minutes after intravenous injection,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,A,10116.0,,,,50597
14850,1,Organ distribution in rat lung 2 minutes after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,A,10116.0,,,,50597
14851,1,Organ distribution in rat lung 2 hr after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,A,10116.0,,,,50597
14852,1,Organ distribution in rat lung 30 minutes after intravenous injection,,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,A,10116.0,,,,50597
14853,1,Organ distribution in rat muscle 2 minutes after intravenous injection,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,A,10116.0,,,,50597
14854,1,Organ distribution in rat muscle 2 hr after intravenous injection,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,A,10116.0,,,,50597
14855,1,Organ distribution in rat muscle 30 minutes after intravenous injection,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,6941,,A,10116.0,,,,50597
14856,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,A,10090.0,,,,50594
14857,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,A,10090.0,,,,50594
14858,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,A,10090.0,,,,50594
14859,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14860,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14861,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14862,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14863,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14864,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14865,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14866,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14867,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14868,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14869,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14870,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14871,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14872,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14873,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14874,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14875,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14876,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14877,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14878,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14879,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14880,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14881,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14882,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14883,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14884,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14885,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14886,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14887,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14888,1,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,Urine,BAO_0000218,,Rattus norvegicus,,Intermediate,12582,,A,10116.0,,,,50597
14889,1,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",,BAO_0000218,,Rattus norvegicus,,Intermediate,7415,,A,10116.0,,,,50597
14890,1,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,,BAO_0000019,,,,Autocuration,7313,,A,,,,,22224
14891,1,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,,BAO_0000019,,,,Autocuration,7313,,A,,,,,22224
14892,1,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,,BAO_0000019,,,,Autocuration,7313,,A,,,,,22224
14893,1,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,Adrenal cortex,BAO_0000019,,,,Autocuration,7570,,A,,,,,22224
14894,1,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,Adrenal cortex,BAO_0000019,,,,Autocuration,7570,,A,,,,,22224
14895,1,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,,BAO_0000019,,,,Autocuration,7570,,A,,,,,22224
14896,1,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,,BAO_0000019,,,,Autocuration,7570,,A,,,,,22224
14897,1,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,Adrenal cortex,BAO_0000019,,,,Autocuration,7570,,A,,,,,22224
14898,1,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,Adrenal cortex,BAO_0000019,,,,Autocuration,7570,,A,,,,,22224
14899,1,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,,BAO_0000019,,,,Autocuration,7570,,A,,,,,22224
14900,1,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,,BAO_0000019,,,,Autocuration,7570,,A,,,,,22224
14901,1,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,,BAO_0000019,,,,Autocuration,7570,,A,,,,,22224
14902,1,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,,BAO_0000019,,,,Autocuration,7570,,A,,,,,22224
14903,1,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,Adrenal cortex,BAO_0000019,,,,Autocuration,7570,,A,,,,,22224
14904,1,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,,BAO_0000019,,,,Autocuration,7570,,A,,,,,22224
14905,1,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,,BAO_0000019,,,,Autocuration,7570,,A,,,,,22224
14906,1,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,Adrenal cortex,BAO_0000019,,,,Autocuration,7570,,A,,,,,22224
14907,1,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,,BAO_0000019,,,,Autocuration,7570,,A,,,,,22224
14908,1,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,,BAO_0000019,,,,Autocuration,7570,,A,,,,,22224
14909,1,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",,BAO_0000218,,Canis lupus familiaris,,Autocuration,14122,In vivo,A,9615.0,,,,22224
14910,1,Absolute bioavailability in male cynomolgus monkeys,,BAO_0000218,,Macaca fascicularis,,Autocuration,16449,In vivo,A,9541.0,,,,22224
14911,1,Absolute bioavailability in maleSprague-Dawley rats,,BAO_0000218,,Rattus norvegicus,,Autocuration,16449,In vivo,A,10116.0,,,,22224
14912,1,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14913,1,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14914,1,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Liver,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14915,1,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14916,1,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14917,1,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14918,1,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14919,1,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14920,1,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14921,1,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14922,1,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14923,1,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14924,1,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Lung,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14925,1,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14926,1,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14927,1,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14928,1,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14929,1,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14930,1,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14931,1,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14932,1,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14933,1,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14934,1,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Muscle tissue,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14935,1,Biodistribution in normal mice blood after 120 hr,Blood,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,A,10090.0,,,,50594
14936,1,Biodistribution in normal mice blood after 24 hr,Blood,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,A,10090.0,,,,50594
14937,1,Biodistribution in normal mice blood after 4 hr,Blood,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,A,10090.0,,,,50594
14938,1,Biodistribution in normal mice bone after 120 hr,Bone,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,A,10090.0,,,,50594
14939,1,Biodistribution in normal mice bone after 24 hr,Bone,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,A,10090.0,,,,50594
14940,1,Biodistribution in normal mice bone after 4 hr,Bone,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,A,10090.0,,,,50594
14941,1,Biodistribution in normal mice heart after 120 hr,Heart,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,A,10090.0,,,,50594
14942,1,Biodistribution in normal mice heart after 24 hr,Heart,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,A,10090.0,,,,50594
14943,1,Biodistribution in normal mice heart after 4 hr,Heart,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,A,10090.0,,,,50594
14944,1,Biodistribution in normal mice kidney after 120 hr,Kidney,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,A,10090.0,,,,50594
14945,1,Biodistribution in normal mice kidney after 24 hr,Kidney,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,A,10090.0,,,,50594
14946,1,Biodistribution in normal mice kidney after 4 hr,Kidney,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,A,10090.0,,,,50594
14947,1,Biodistribution in normal mice liver after 120 hr,Liver,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,A,10090.0,,,,50594
14948,1,Biodistribution in normal mice liver after 24 hr,Liver,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,A,10090.0,,,,50594
14949,1,Biodistribution in normal mice liver after 4 hr,Liver,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,A,10090.0,,,,50594
14950,1,Biodistribution in normal mice spleen after 120 hr,Spleen,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,A,10090.0,,,,50594
14951,1,Biodistribution in normal mice spleen after 24 hr,Spleen,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,A,10090.0,,,,50594
14952,1,Biodistribution in normal mice spleen after 4 hr,Spleen,BAO_0000218,,Mus musculus,,Intermediate,15045,In vivo,A,10090.0,,,,50594
14953,1,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14954,1,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14955,1,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14956,1,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14957,1,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14958,1,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14959,1,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14960,1,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14961,1,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14962,1,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Spleen,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14963,1,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,Thyroid gland,BAO_0000218,,Rattus norvegicus,,Intermediate,12017,In vivo,A,10116.0,,,,50597
14964,1,The Kel values in female wistar rats.,,BAO_0000218,,Rattus norvegicus,,Intermediate,14941,,A,10116.0,,,,50597
14965,1,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,,BAO_0000019,,,,Autocuration,4646,,A,,,,,22224
14966,1,Hydrolysis rate constant of the compound,,BAO_0000019,,,,Autocuration,8847,,A,,,,,22224
14967,1,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,,BAO_0000100,,,,Autocuration,11778,,P,,,,,22229
14968,1,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",,BAO_0000019,,,,Autocuration,2363,,A,,,,,22224
14969,1,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",,BAO_0000019,,,,Autocuration,2363,,A,,,,,22224
14970,1,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",,BAO_0000019,,,,Autocuration,2363,,A,,,,,22224
14971,1,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",,BAO_0000019,,,,Autocuration,2363,,A,,,,,22224
14972,1,Apparent inactivation rate constant was evaluated,,BAO_0000019,,,,Autocuration,8371,,A,,,,,22224
14973,1,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,,BAO_0000019,,,,Autocuration,14883,,A,,,,,22224
14974,1,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,,BAO_0000019,,,,Autocuration,14883,,A,,,,,22224
14975,1,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,,BAO_0000019,,,,Autocuration,4643,,A,,,,,22224
14976,1,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,,BAO_0000019,,,,Autocuration,3519,,A,,,,,22224
14977,1,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,,BAO_0000019,,,,Autocuration,10600,,A,,,,,22224
14978,1,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,,BAO_0000019,,,,Autocuration,8501,,F,,,,,22224
14979,1,Dissociation constant was determined,,BAO_0000100,,,,Autocuration,8505,,P,,,,,22224
14980,1,Dissociation constant was determined,,BAO_0000100,,,,Autocuration,9778,,P,,,,,22224
14981,1,Dissociation constant at pH 7.4,,BAO_0000100,,,,Autocuration,9778,,P,,,,,22224
14982,1,Dissociation constant in presence of 1 mM dithiothreitol,,BAO_0000100,,,,Autocuration,9778,,P,,,,,22224
14983,1,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,BAO_0000019,,,,Autocuration,13007,,A,,,,,22224
14984,1,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,,BAO_0000019,,,,Autocuration,13007,,A,,,,,22224
14985,1,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,BAO_0000019,,,,Autocuration,13007,,A,,,,,22224
14986,1,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,,BAO_0000019,,,,Autocuration,13007,,A,,,,,22224
14987,1,Kinetic constant for aromatization of androstenedione,,BAO_0000019,,,,Autocuration,11482,,A,,,,,22224
14988,1,Kinetic constant for aromatization of testosterone,,BAO_0000019,,,,Autocuration,11482,,A,,,,,22224
14989,1,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,,BAO_0000019,,,,Autocuration,2303,,A,,,,,22224
14990,1,Local inhibition constant was determined,,BAO_0000019,,,,Autocuration,11964,,A,,,,,22224
14991,1,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,,BAO_0000218,,Saccharomyces cerevisiae,,Intermediate,3140,,A,4932.0,,,,50347
14992,1,Dissociation constant value of the compound,,BAO_0000100,,,,Autocuration,10650,,P,,,,,22224
14993,1,In vitro permeability through cornea without epithelium,Cornea,BAO_0000019,,,,Autocuration,4667,,A,,,,,22224
14994,1,In vitro permeability through intact cornea,Cornea,BAO_0000019,,,,Autocuration,4667,,A,,,,,22224
14995,1,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,Cornea,BAO_0000218,,Oryctolagus cuniculus,,Intermediate,9199,,A,9986.0,,,,50592
14996,1,Rate of enzyme inactivation for the compound was determined,,BAO_0000019,,,,Autocuration,11966,,A,,,,,22224
14997,1,In vitro permeability through cornea without epithelium,Cornea,BAO_0000019,,,,Autocuration,4667,,A,,,,,22224
14998,1,In vitro permeability through intact cornea,Cornea,BAO_0000019,,,,Autocuration,4667,,A,,,,,22224
14999,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
15000,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
15001,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
15002,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
15003,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
15004,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
15005,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
15006,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
15007,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
15008,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
15009,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
15010,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
15011,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
15012,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
15013,1,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",,BAO_0000019,,,,Autocuration,8354,,A,,,,,22224
15014,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,A,10090.0,,,,50594
15015,1,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,,BAO_0000218,,Homo sapiens,,Intermediate,14439,In vivo,A,9606.0,,,,50587
15016,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,A,10090.0,,,,50594
15017,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,A,10090.0,,,,50594
15018,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,A,10090.0,,,,50594
15019,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,A,10090.0,,,,50594
15020,1,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,A,10090.0,,,,50594
15021,1,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,A,10090.0,,,,50594
15022,1,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,A,10090.0,,,,50594
15023,1,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,A,10090.0,,,,50594
15024,1,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),,BAO_0000218,,Mus musculus,,Intermediate,14439,In vivo,A,10090.0,,,,50594
